,datetime,title,source,link,sentiment_class,sentiment_score
0,9/6/2005 1:07:00 PM,"Burden of ADHD Greater than Asthma, According to New Study",PR Newswire,/news/stocks/burden-of-adhd-greater-than-asthma-according-to-new-study-588983,positive,0.6297904849052429
1,1/20/2006 1:37:00 PM,Lilly ICOS LLC Reports First Full-Year Profit in its History,PR Newswire,/news/stocks/lilly-icos-llc-reports-first-full-year-profit-in-its-history-1004417673,negative,0.8315368890762329
2,2/7/2006 2:22:00 PM,Lilly Launches Humalog(R) Mix50/50(TM) Insulin in United States,PR Newswire,/news/stocks/lilly-launches-humalogr-mix50-50tm-insulin-in-united-states-405092,positive,0.7082609534263611
3,3/14/2006 8:02:00 PM,Study Shows More Potent and More Reliable Platelet Inhibition with Prasugrel Compared to Clopidogrel Even in Patients With More Reactive Platelets,PR Newswire,/news/stocks/study-shows-more-potent-and-more-reliable-platelet-inhibition-with-prasugrel-compared-to-clopidogrel-even-in-patients-with-more-reactive-platelets-1005660628,negative,0.9492109417915344
4,11/15/2007 12:30:00 PM,Eli Lilly and Company to Receive Honor from National Urban League,PR Newswire,/news/stocks/eli-lilly-and-company-to-receive-honor-from-national-urban-league-1024085798,negative,0.7869887351989746
5,5/9/2008 2:42:00 PM,"Seven Summits Research Releases Comments on XOM, NVDA, ICE, LLY, and ATVI",PR Newswire,/news/stocks/seven-summits-research-releases-comments-on-xom-nvda-ice-lly-and-atvi-1027513098,positive,0.9465052485466003
6,5/9/2014 8:50:07 PM,Eli Lilly and Italian firm fined $450 million for poisoning in Brazil,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/jyvEcP3twVI/story01.htm,neutral,0.9120906591415405
7,9/26/2016 6:10:23 PM,BRIEF-Cerecor announces acquisition of TARP-8-AMPA receptor antagonist (CERC-611) from Lilly (LLY),Reuters,/news/stocks/brief-cerecor-announces-acquisition-of-tarp-8-ampa-receptor-antagonist-cerc-611-from-lilly-lly-1001418592,positive,0.5665112137794495
8,10/3/2016 12:10:22 PM,"Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001431817,neutral,0.6420669555664062
9,10/3/2016 2:20:21 PM,"RPT-Big Pharma vs Big Pharma in court battles over biosimilar drugs (SAN, SHP, BIIB, JNJ, MRK, LLY, PFE, AMGN)",Reuters,/news/stocks/rpt-big-pharma-vs-big-pharma-in-court-battles-over-biosimilar-drugs-san-shp-biib-jnj-mrk-lly-pfe-amgn-1001432682,neutral,0.5524706840515137
10,10/5/2016 2:40:20 PM,"BRIEF-Elanco Animal Health enters agreement to acquire Boehringer Ingelheim Vetmedica's U.S. feline, canine and rabies vaccines portfolio (LLY)",Reuters,/news/stocks/brief-elanco-animal-health-enters-agreement-to-acquire-boehringer-ingelheim-vetmedicas-u-s-feline-canine-and-rabies-vaccines-portfolio-lly-1001437877,negative,0.6076149344444275
11,10/5/2016 2:50:23 PM,Eli Lilly to buy Boehringer Ingelheim's U.S. pet vaccines unit (LLY),Reuters,/news/stocks/eli-lilly-to-buy-boehringer-ingelheims-u-s-pet-vaccines-unit-lly-1001437874,positive,0.9055872559547424
12,10/5/2016 3:30:21 PM,"UPDATE 1-Lilly to buy Boehringer's U.S. pet vaccines unit (SAN, LLY)",Reuters,/news/stocks/update-1-lilly-to-buy-boehringers-u-s-pet-vaccines-unit-san-lly-1001438067,positive,0.7242138385772705
13,10/5/2016 4:40:27 PM,BRIEF-Lilly highlights advancements in its oncology portfolio (LLY),Reuters,/news/stocks/brief-lilly-highlights-advancements-in-its-oncology-portfolio-lly-1001438169,negative,0.7704199552536011
14,10/10/2016 7:10:21 AM,"Novartis challenges Pfizer with strong breast cancer drug data (LLY, PFE)",Reuters,/news/stocks/novartis-challenges-pfizer-with-strong-breast-cancer-drug-data-lly-pfe-1001444918,negative,0.9462957382202148
15,10/10/2016 8:00:22 AM,"UPDATE 1-Novartis challenges Pfizer with strong breast cancer drug data (LLY, PFE)",Reuters,/news/stocks/update-1-novartis-challenges-pfizer-with-strong-breast-cancer-drug-data-lly-pfe-1001445007,negative,0.9516933560371399
16,10/19/2016 10:40:20 PM,Lilly's soft tissue sarcoma treatment gets U.S. approval (LLY),Reuters,http://www.businessinsider.com/r-lillys-soft-tissue-sarcoma-treatment-gets-us-approval-2016-10,negative,0.9472679495811462
17,10/19/2016 10:40:20 PM,BRIEF-U.S. FDA grants approval to Lilly's treatment for advanced soft tissue sarcoma (LLY),Reuters,http://www.businessinsider.com/r-brief-us-fda-grants-approval-to-lillys-treatment-for-advanced-soft-tissue-sarcoma-2016-10,negative,0.9187652468681335
18,10/19/2016 11:00:36 PM,UPDATE 1-FDA grants accelerated approval to Lilly's soft tissue sarcoma drug (LLY),Reuters,http://www.businessinsider.com/r-update-1-fda-grants-accelerated-approval-to-lillys-soft-tissue-sarcoma-drug-2016-10,negative,0.9304419755935669
19,10/25/2016 12:40:18 PM,Lilly third-quarter revenue rises 4.7 percent (LLY),Reuters,http://www.businessinsider.com/r-lilly-third-quarter-revenue-rises-47-percent-2016-10,negative,0.9406341314315796
20,10/25/2016 12:40:19 PM,BRIEF-Lilly reports third-quarter 2016 results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-third-quarter-2016-results-2016-10,positive,0.9174395203590393
21,10/25/2016 1:02:21 PM,UPDATE 1-Lilly third-quarter results miss estimates (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-third-quarter-results-miss-estimates-2016-10,neutral,0.9313660264015198
22,10/25/2016 4:50:19 PM,BRIEF-Lilly says likely to boost funding of other Alzheimer's drugs if solanezumab succeeds (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-likely-to-boost-funding-of-other-alzheimers-drugs-if-solanezumab-succeeds-2016-10,negative,0.9341660141944885
23,10/25/2016 9:10:19 PM,U.S. FDA adds abuse warning to prescription testosterone (LLY),Reuters,http://www.businessinsider.com/r-us-fda-adds-abuse-warning-to-prescription-testosterone-2016-10,neutral,0.4863133132457733
24,10/27/2016 10:20:20 PM,BRIEF-Bank of America declares quarterly dividend of $0.075/share (BAC),Reuters,http://www.businessinsider.com/r-brief-bank-of-america-declares-quarterly-dividend-of-0075/share-2016-10,positive,0.6821951866149902
25,10/27/2016 11:06:30 PM,"Biotech's election-year political cloud threatens to linger (VRX, LLY, BMY, ARIA, VRX)",Reuters,http://www.businessinsider.com/r-biotechs-election-year-political-cloud-threatens-to-linger-2016-10,positive,0.541508138179779
26,11/2/2016 5:48:50 AM,"Bernie Sanders is going after insulin makers over price hikes (LLY, NVO, SNY)",Business Insider,http://www.businessinsider.com/bernie-sanders-criticizes-insulin-price-hikes-2016-11,positive,0.8901512026786804
27,11/4/2016 5:52:18 AM,"U.S. lawmakers call for probe of possible insulin price collusion (SAN, LLY, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-us-lawmakers-call-for-probe-of-possible-insulin-price-collusion-2016-11,positive,0.8774906396865845
28,11/8/2016 2:46:21 PM,"BRIEF-Becton Dickinson launches syringe for use with Humulin R U-500 insulin (BDX, LLY)",Reuters,http://www.businessinsider.com/r-brief-becton-dickinson-launches-syringe-for-use-with-humulin-r-u-500-insulin-2016-11,positive,0.8458430767059326
29,11/14/2016 1:04:20 PM,"Richter's generic osteoporosis drug gets EU recommendation (RICHTER, LLY)",Reuters,http://www.businessinsider.com/r-richters-generic-osteoporosis-drug-gets-eu-recommendation-2016-11,negative,0.9231276512145996
30,11/14/2016 6:56:18 PM,"BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-incyte-says-baricitinib-treatment-show-improvements-in-rheumatoid-arthritis-symptoms-in-phase-3-2016-11,negative,0.9534701108932495
31,11/14/2016 7:00:18 PM,"BRIEF-Baricitinib demonstrates early response compared to placebo (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-baricitinib-demonstrates-early-response-compared-to-placebo-2016-11,negative,0.9413467049598694
32,11/14/2016 10:14:20 PM,BRIEF-U.S. FDA approves Itrafungol for treating ringworm in cats (LLY),Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-itrafungol-for-treating-ringworm-in-cats-2016-11,negative,0.8917545080184937
33,11/15/2016 2:36:18 AM,"BRIEF-Paulson & Co cuts share stake in Pfizer, raises share stake in Facebook (PFE, LLY)",Reuters,http://www.businessinsider.com/r-brief-paulson--co-cuts-share-stake-in-pfizer-raises-share-stake-in-facebook-2016-11,positive,0.5948380827903748
34,11/17/2016 1:04:18 PM,"UPDATE 1-Amgen, Novartis aim for big, crowded migraine market after new drug data (AGN, LLY, TEVA, AMGN)",Reuters,http://www.businessinsider.com/r-update-1-amgen-novartis-aim-for-big-crowded-migraine-market-after-new-drug-data-2016-11,negative,0.6455399394035339
35,11/18/2016 4:54:18 PM,BRIEF-Athenex and Lilly enter clinical collaboration agreement (LLY),Reuters,http://www.businessinsider.com/r-brief-athenex-and-lilly-enter-clinical-collaboration-agreement-2016-11,negative,0.8371766805648804
36,11/21/2016 3:22:18 PM,"BRIEF-Intelgenx secures a license for tadalafil erectile dysfunction dosing patent (IGX, LLY)",Reuters,http://www.businessinsider.com/r-brief-intelgenx-secures-a-license-for-tadalafil-erectile-dysfunction-dosing-patent-2016-11,negative,0.9374762773513794
37,11/23/2016 2:44:20 PM,"Lilly Alzheimer's drug fails to slow memory loss in big study (LLY, BIIB)",Reuters,http://www.businessinsider.com/r-lilly-alzheimers-drug-fails-to-slow-memory-loss-in-big-study-2016-11,negative,0.4760325849056244
38,11/23/2016 2:46:20 PM,BRIEF-Lilly to abandon Alzheimer's drug after late-stage failure (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-to-abandon-alzheimers-drug-after-late-stage-failure-2016-11,positive,0.6437722444534302
39,11/23/2016 2:58:20 PM,BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-incoming-ceo-david-ricks-on-cnbc---amyloid-hypothesis-should-be-continued-to-be-studied-in-reference-to-its-alzheimers-drug-2016-11,positive,0.8944713473320007
40,11/23/2016 3:50:06 PM,A major Alzheimer's drug just failed a key trial (LLY),Business Insider,http://www.businessinsider.com/solanezumab-alzheimers-disease-drug-fails-phase-3-trial-2016-11,neutral,0.8668869137763977
41,11/23/2016 6:42:20 PM,"Lilly failure a blow for Alzheimer's research, not end of road (LLY, BIIB, AZN)",Reuters,http://www.businessinsider.com/r-lilly-failure-a-blow-for-alzheimers-research-not-end-of-road-2016-11,positive,0.9176262617111206
42,11/23/2016 11:28:18 PM,"Roche confident in Alzheimer's programmes, despite Lilly flop (LLY)",Reuters,http://www.businessinsider.com/r-roche-confident-in-alzheimers-programmes-despite-lilly-flop-2016-11,negative,0.877241313457489
43,12/1/2016 12:04:06 PM,"BRIEF-Lupin Ltd and Eli Lilly expand partnership in India (LUPIN, LLY)",Reuters,http://www.businessinsider.com/r-brief-lupin-ltd-and-eli-lilly-expand-partnership-in-india-2016-12,negative,0.8259616494178772
44,12/2/2016 10:30:03 PM,BRIEF-FDA approves jardiance to reduce cardiovascular death in adults with Type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-approves-jardiance-to-reduce-cardiovascular-death-in-adults-with-type-2-diabetes-2016-12,negative,0.9108496308326721
45,12/2/2016 10:42:03 PM,Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA,Reuters,http://www.businessinsider.com/r-lillys-diabetes-drug-jardiance-cuts-risk-of-cardiovascular-death-fda-2016-12,positive,0.6425725221633911
46,12/2/2016 11:20:03 PM,UPDATE 1-FDA allows use of diabetes drug Jardiance to reduce heart risk (LLY),Reuters,http://www.businessinsider.com/r-update-1-fda-allows-use-of-diabetes-drug-jardiance-to-reduce-heart-risk-2016-12,negative,0.7718449234962463
47,12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.8780308961868286
48,12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,neutral,0.9314919114112854
49,12/8/2016 4:16:09 PM,BRIEF-Lilly says neoMONARCH phase 2 trial met primary endpoint of reducing expression of KI67 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-neomonarch-phase-2-trial-met-primary-endpoint-of-reducing-expression-of-ki67-2016-12,negative,0.7136996388435364
50,12/9/2016 2:46:03 PM,BRIEF-Eli lilly says Solanezumab did not meet primary endpoint in expedition3 clinical trial (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-solanezumab-did-not-meet-primary-endpoint-in-expedition3-clinical-trial-2016-12,neutral,0.9191890954971313
51,12/9/2016 3:14:03 PM,"BRIEF-Lilly, Astrazeneca to develop potentially disease-modifying Alzheimer's treatment (LLY, AZN)",Reuters,http://www.businessinsider.com/r-brief-lilly-astrazeneca-to-develop-potentially-disease-modifying-alzheimers-treatment-2016-12,negative,0.7453447580337524
52,12/9/2016 3:55:11 PM,"We just got some of the most promising Alzheimer's drug data of the year (BIIB, LLY)",Reuters,http://www.businessinsider.com/r-update-1-further-promising-data-seen-with-biogen-alzheimers-drug-study-2016-12,negative,0.7639119029045105
53,12/9/2016 4:00:08 PM,"Astra, Lilly stick with Alzheimer's approach despite setback (BIIB, LLY, AZN)",Reuters,http://www.businessinsider.com/r-astra-lilly-stick-with-alzheimers-approach-despite-setback-2016-12,positive,0.5094075798988342
54,12/9/2016 11:36:03 PM,"New diabetes guidelines imminent, Jardiance sales may surge",Reuters,http://www.businessinsider.com/r-new-diabetes-guidelines-imminent-jardiance-sales-may-surge-2016-12,positive,0.6802309155464172
55,12/12/2016 11:14:05 PM,BRIEF-FDA approves Synjardy XR tablets for adults with type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-approves-synjardy-xr-tablets-for-adults-with-type-2-diabetes-2016-12,negative,0.8688706159591675
56,12/13/2016 7:06:05 AM,BRIEF-Lilly reports dividend increase (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-dividend-increase-2016-12,negative,0.8942506909370422
57,12/13/2016 2:16:04 PM,"BRIEF-Eli Lilly announces program to provide Insulin at discounted prices (ESRX, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-program-to-provide-insulin-at-discounted-prices-2016-12,positive,0.7252360582351685
58,12/13/2016 2:54:09 PM,Lilly to offer insulin at discounted prices,Reuters,http://www.businessinsider.com/r-lilly-to-offer-insulin-at-discounted-prices-2016-12,positive,0.862928569316864
59,12/13/2016 4:15:23 PM,"Some people spend as much on insulin as their mortgage - and drugmakers are taking note (NVO, LLY)",Business Insider,http://www.businessinsider.com/lilly-express-scripts-blink-health-insulin-discounts-2016-12,positive,0.9360153675079346
60,12/13/2016 4:40:06 PM,"UPDATE 1-Lilly to offer insulin at discounted prices to certain patients (LLY, CVS, TGT, ESRX)",Reuters,http://www.businessinsider.com/r-update-1-lilly-to-offer-insulin-at-discounted-prices-to-certain-patients-2016-12,positive,0.8381107449531555
61,12/15/2016 12:50:03 PM,BRIEF-Eli Lilly provides 2017 financial forecast and 2016 update (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-provides-2017-financial-forecast-and-2016-update-2016-12,positive,0.9385153651237488
62,12/15/2016 1:06:03 PM,"Lilly forecasts 2017 revenue, profit above estimates (LLY)",Reuters,http://www.businessinsider.com/r-lilly-forecasts-2017-revenue-profit-above-estimates-2016-12,positive,0.7441138029098511
63,12/15/2016 1:46:03 PM,"UPDATE 1-Lilly forecasts 2017 revenue, profit above estimates (LLY)",Reuters,http://www.businessinsider.com/r-update-1-lilly-forecasts-2017-revenue-profit-above-estimates-2016-12,positive,0.6839408874511719
64,12/15/2016 4:59:53 PM,"A cheaper version of the lifesaving diabetes medication just launched in the US (NVO, LLY, SNY)",Business Insider,http://www.businessinsider.com/insulin-cheaper-generic-2016-12,positive,0.49736371636390686
65,12/15/2016 5:20:05 PM,BRIEF-Eli Lilly sees potential launch of 20 new drugs through 2023 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sees-potential-launch-of-20-new-drugs-through-2023-2016-12,negative,0.5000212788581848
66,12/16/2016 2:00:07 PM,BRIEF-EMA recommends approving new Eli Lilly rheumatoid arthritis drug (LLY),Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approving-new-eli-lilly-rheumatoid-arthritis-drug-2016-12,positive,0.7881578207015991
67,12/16/2016 7:06:03 PM,BRIEF-Adocia and Lilly announce successful completion of an insulin pump study with BioChaperone Lispro in people with type 1 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-and-lilly-announce-successful-completion-of-an-insulin-pump-study-with-biochaperone-lispro-in-people-with-type-1-diabetes-2016-12,negative,0.9261752367019653
68,12/16/2016 10:44:02 PM,"BRIEF-Incyte Corp , Eli Lilly amended license, development and commercialization agreement, entered into as of December 18, 2009 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-corp--eli-lilly-amended-license-development-and-commercialization-agreement-entered-into-as-of-december-18-2009-2016-12,positive,0.9028259515762329
69,12/23/2016 8:42:05 PM,Migraine drugs may repeat rheumatoid arthritis success,Reuters,http://www.businessinsider.com/r-migraine-drugs-may-repeat-rheumatoid-arthritis-success-2016-12,neutral,0.720610499382019
70,12/27/2016 6:26:03 PM,Sanofi sues Novo Nordisk over diabetes drugs in the U.S.,Reuters,http://www.businessinsider.com/r-sanofi-sues-novo-nordisk-over-diabetes-drugs-in-the-us-2016-12,neutral,0.9522473812103271
71,12/28/2016 11:24:03 PM,"UPDATE 1-U.S. FTC requires divestitures in $13.53 bln Boehringer-Sanofi deal (SAN, BAYN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-ftc-requires-divestitures-in-1353-bln-boehringer-sanofi-deal-2016-12,positive,0.9021737575531006
72,1/23/2017 2:08:04 PM,BRIEF-Inovalon announces agreement with Boehringer Ingelheim to support outcome-based contracting (LLY),Reuters,http://www.businessinsider.com/r-brief-inovalon-announces-agreement-with-boehringer-ingelheim-to-support-outcome-based-contracting-2017-1,negative,0.9196880459785461
73,1/24/2017 10:50:06 PM,BRIEF-Galliprant now available for canine osteoarthritis (LLY),Reuters,http://www.businessinsider.com/r-brief-galliprant-now-available-for-canine-osteoarthritis-2017-1,positive,0.8585896492004395
74,1/25/2017 8:52:06 AM,"UPDATE 2-Novartis considers Alcon spin-off, launches share buyback (LLY)",Reuters,http://www.businessinsider.com/r-update-2-novartis-considers-alcon-spin-off-launches-share-buyback-2017-1,positive,0.9107950329780579
75,1/27/2017 8:16:10 AM,BRIEF-Adocia says Eli Lilly terminates collaboration biochaperone Lispro (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-says-eli-lilly-terminates-collaboration-biochaperone-lispro-2017-1,positive,0.9362091422080994
76,1/27/2017 2:04:05 PM,"BRIEF-EMA recommends approval of two biosimilars from Amgen (AMGN, LLY, GSK)",Reuters,http://www.businessinsider.com/r-brief-ema-recommends-approval-of-two-biosimilars-from-amgen-2017-1,positive,0.5977601408958435
77,1/30/2017 9:46:06 PM,"Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit",Reuters,http://www.businessinsider.com/r-sanofi-novo-nordisk-and-lilly-named-in-patients-price-fixing-suit-2017-1,neutral,0.6988139748573303
78,1/30/2017 10:06:06 PM,"UPDATE 1-Sanofi, Novo Nordisk and Lilly named in patients' price fixing suit (SAN, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-novo-nordisk-and-lilly-named-in-patients-price-fixing-suit-2017-1,positive,0.777275562286377
79,1/31/2017 7:34:07 AM,"PRESS DIGEST- New York Times business news - Jan 31 (AMZN, EXPE, DBK, SAN, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-press-digest--new-york-times-business-news---jan-31-2017-1,positive,0.9470707178115845
80,1/31/2017 12:56:06 PM,Lilly revenue rises 7.2 pct on higher demand for new drugs (LLY),Reuters,http://www.businessinsider.com/r-lilly-revenue-rises-72-pct-on-higher-demand-for-new-drugs-2017-1,negative,0.9511407613754272
81,1/31/2017 1:00:52 PM,10 things you need to know today,Business Insider,http://www.businessinsider.com/opening-bell-january-31-2017-2017-1,positive,0.9297025203704834
82,1/31/2017 1:02:07 PM,BRIEF-Lilly reports Q4 EPS $0.73 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-q4-eps-073-2017-1,positive,0.7460445165634155
83,1/31/2017 2:30:32 PM,"10 things you need to know before the opening bell (SPY, SPX, QQQ, DIA, DB, LLY)",Business Insider,http://markets.businessinsider.com/news/stocks/opening-bell-january-31-2017-2017-1-1001708230,positive,0.9464765191078186
84,1/31/2017 4:10:07 PM,"Trump meets with drugmakers, seeks lower prices, U.S. production (MRK, JNJ, CELG, LLY, AMGN)",Reuters,http://www.businessinsider.com/r-trump-meets-with-drugmakers-seeks-lower-prices-us-production-2017-1,positive,0.6421660780906677
85,1/31/2017 7:06:07 PM,"UPDATE 3-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-3-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1,negative,0.909467875957489
86,1/31/2017 7:44:07 PM,BRIEF-Lilly CEO says prepared for all scenarios in case of ACA repeal (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-ceo-says-prepared-for-all-scenarios-in-case-of-aca-repeal-2017-1,positive,0.9338161945343018
87,1/31/2017 7:51:41 PM,Trump Calls For Increased Competition To Reduce Drug Prices ,RTTNews,/news/stocks/trump-calls-for-increased-competition-to-reduce-drug-prices-1001710287,negative,0.7998009324073792
88,1/31/2017 9:30:07 PM,"UPDATE 4-Trump pushes drugmakers for lower prices, more U.S. production (JNJ, MRK, LLY, AMGN, CELG)",Reuters,http://www.businessinsider.com/r-update-4-trump-pushes-drugmakers-for-lower-prices-more-us-production-2017-1,negative,0.9122521281242371
89,2/2/2017 3:34:08 PM,BRIEF-Japan high court rules in Lilly's favor on Alimta patents (LLY),Reuters,http://www.businessinsider.com/r-brief-japan-high-court-rules-in-lillys-favor-on-alimta-patents-2017-2,positive,0.7520418167114258
90,2/2/2017 11:16:08 PM,"GE, Boeing, Oracle form coalition to support Republican border tax",Reuters,http://www.businessinsider.com/r-ge-boeing-oracle-form-coalition-to-support-republican-border-tax-2017-2,negative,0.492760568857193
91,2/8/2017 12:55:01 PM,Lilly's Trulicity Label Updated On Basal Insulin ,RTTNews,/news/stocks/lilly-s-trulicity-label-updated-on-basal-insulin-1001732734,positive,0.9412593841552734
92,2/8/2017 1:10:09 PM,BRIEF-Lilly announces label update for its diabetes drug Trulicity (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-label-update-for-its-diabetes-drug-trulicity-2017-2,positive,0.834754467010498
93,2/9/2017 1:30:06 PM,BRIEF-Carolyn Bertozzi elected to Lilly board of directors (LLY),Reuters,http://www.businessinsider.com/r-brief-carolyn-bertozzi-elected-to-lilly-board-of-directors-2017-2,positive,0.9379135966300964
94,2/13/2017 10:56:10 PM,"BRIEF-European Commission approves once-daily olumiant tablets for treatment of rheumatoid arthritis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-once-daily-olumiant-tablets-for-treatment-of-rheumatoid-arthritis-2017-2,negative,0.7532097101211548
95,2/14/2017 6:46:10 PM,BRIEF-Adocia 2016 revenue down at 22.4 million euros (LLY),Reuters,http://www.businessinsider.com/r-brief-adocia-2016-revenue-down-at-224-million-euros-2017-2,neutral,0.9679372906684875
96,2/15/2017 12:22:10 AM,Merck to halt study of mild to moderate Alzheimer's drug,Reuters,http://www.businessinsider.com/r-merck-to-halt-study-of-mild-to-moderate-alzheimers-drug-2017-2,neutral,0.5677351355552673
97,2/15/2017 1:08:10 AM,"UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-stopping-late-stage-study-as-another-alzheimers-drug-fails-2017-2,neutral,0.851006805896759
98,2/16/2017 12:12:11 AM,"BRIEF-Eli Lilly says additional results from pivotal ra-beam study published in New England Journal of Medicine (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-additional-results-from-pivotal-ra-beam-study-published-in-new-england-journal-of-medicine-2017-2,positive,0.902260959148407
99,2/21/2017 1:50:12 PM,"Export companies tell U.S. Congress to push tax code rewrite (BA, CAT, GE, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-export-companies-tell-us-congress-to-push-tax-code-rewrite-2017-2,positive,0.8782085180282593
100,2/21/2017 5:56:12 PM,"UPDATE 1-CEOs of 16 U.S. companies urge Congress to pass border tax (BA, CAT, GE, AAPL, IBM, INTC, DOW, CE, CELG, LLY, RTN, MRK, UTX, PFE, VAR)",Reuters,http://www.businessinsider.com/r-update-1-ceos-of-16-us-companies-urge-congress-to-pass-border-tax-2017-2,positive,0.8676490187644958
101,2/21/2017 10:16:12 PM,BRIEF-Lilly says provisions included in legislation to repeal Affordable Care Act could adversely affect results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-provisions-included-in-legislation-to-repeal-affordable-care-act-could-adversely-affect-results-2017-2,neutral,0.9136071801185608
102,2/24/2017 8:22:12 PM,"BRIEF-FTC approves final order settling charges for Boehringer Ingelheim’s asset swap with Sanofi (SAN, BAYN, LLY)",Reuters,http://www.businessinsider.com/r-brief-ftc-approves-final-order-settling-charges-for-boehringer-ingelheims-asset-swap-with-sanofi-2017-2,negative,0.7393410801887512
103,2/28/2017 3:00:00 PM,Lilly to Present New Data for Taltz® (ixekizumab) in Psoriasis and Psoriatic Arthritis at the American Academy of Dermatology (AAD) Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-new-data-for-taltz-ixekizumab-in-psoriasis-and-psoriatic-arthritis-at-the-american-academy-of-dermatology-aad-annual-meeting-1001790430,positive,0.8499405384063721
104,2/28/2017 3:20:41 PM,"The quest to find new drugs to treat Alzheimer's just suffered another blow (MRK, LLY, BIIB, AMGN)",Reuters,http://www.businessinsider.com/r-acceras-alzheimers-trial-fails-in-yet-another-setback-for-disease-2017-2,negative,0.5512112379074097
105,3/1/2017 2:45:00 PM,Lilly Completes Acquisition of CoLucid Pharmaceuticals,PR Newswire,/news/stocks/lilly-completes-acquisition-of-colucid-pharmaceuticals-1001794873,positive,0.8291995525360107
106,3/1/2017 3:10:19 PM,BRIEF-Perrigo announces FDA final approval for the generic version of Axiron topical solution (LLY),Reuters,http://www.businessinsider.com/r-brief-perrigo-announces-fda-final-approval-for-the-generic-version-of-axiron-topical-solution-2017-3,negative,0.7642824053764343
107,3/2/2017 12:45:00 PM,Lilly Announces Changes in Senior Management,PR Newswire,/news/stocks/lilly-announces-changes-in-senior-management-1001798603,positive,0.5369921326637268
108,3/3/2017 8:45:00 PM,Lilly Diabetes Becomes 'Official Diabetes Health Partner of NASCAR®',PR Newswire,/news/stocks/lilly-diabetes-becomes-official-diabetes-health-partner-of-nascar-1001804016,negative,0.6652315258979797
109,3/4/2017 3:20:00 PM,New Head-to-Head Data Shows Significantly Higher Response Rates for Lilly's Taltz® (ixekizumab) Compared to Stelara® (ustekinumab) in Patients with Moderate-to-Severe Plaque Psoriasis,PR Newswire,/news/stocks/new-head-to-head-data-shows-significantly-higher-response-rates-for-lilly-s-taltz-ixekizumab-compared-to-stelara-ustekinumab-in-patients-with-moderate-to-severe-plaque-psoriasis-1001804620,negative,0.9282079935073853
110,3/5/2017 5:55:17 AM,Lilly: Taltz Shows Superior Efficacy Compared To Stelara In Plaque Psoriasis ,RTTNews,/news/stocks/lilly-taltz-shows-superior-efficacy-compared-to-stelara-in-plaque-psoriasis-1001804733,negative,0.955485463142395
111,3/8/2017 5:42:22 PM,"INSIGHT-'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks (JNJ, MRK, LLY, CELG, AMGN, GM, F, CPB, TGT, LUV, UAL, DAL)",Reuters,http://www.businessinsider.com/r-insight-its-like-kumbaya-trumps-genial-private-meetings-with-ceos-jar-with-public-attacks-2017-3,positive,0.8371442556381226
112,3/13/2017 1:00:00 PM,OilPrice.com: The Next Big Biotech Breakthrough Could Just be on the Horizon,PR Newswire,/news/stocks/oilprice-com-the-next-big-biotech-breakthrough-could-just-be-on-the-horizon-1001828875,positive,0.7319250702857971
113,3/17/2017 12:10:00 PM,"Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/technical-reports-on-drug-makers-stocks-bristol-myers-squibb-astrazeneca-eli-lilly-and-immune-pharma-1001845502,positive,0.9368956089019775
114,3/17/2017 1:00:00 PM,First dedicated outcome trials of empagliflozin in chronic heart failure initiated,PR Newswire,/news/stocks/first-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated-1001845706,positive,0.6986518502235413
115,3/17/2017 2:04:43 PM,BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated (LLY),Reuters,http://www.businessinsider.com/r-brief-first-dedicated-outcome-trials-of-empagliflozin-in-chronic-heart-failure-initiated-2017-3,negative,0.6393217444419861
116,3/19/2017 9:12:46 PM,Newer type 2 diabetes drugs show heart protective quality in study,Reuters,http://www.businessinsider.com/r-newer-type-2-diabetes-drugs-show-heart-protective-quality-in-study-2017-3,negative,0.7342519760131836
117,3/20/2017 11:45:00 AM,Lilly Announces Phase 3 MONARCH 2 Breast Cancer Study of Abemaciclib Met Primary Endpoint of Progression-Free Survival,PR Newswire,/news/stocks/lilly-announces-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-of-progression-free-survival-1001849408,negative,0.7024067044258118
118,3/20/2017 12:10:07 PM,Lilly: Phase 3 MONARCH 2 Breast Cancer Study Of Abemaciclib Met Primary Endpoint ,RTTNews,/news/stocks/lilly-phase-3-monarch-2-breast-cancer-study-of-abemaciclib-met-primary-endpoint-1001849493,negative,0.5647680163383484
119,3/20/2017 12:24:44 PM,"UPDATE 1-Lilly's breast cancer drug combination succeeds key study (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-lillys-breast-cancer-drug-combination-succeeds-key-study-2017-3,negative,0.7935267686843872
120,3/20/2017 3:34:46 PM,BRIEF-Eli Lilly and Co says CEO John Lechleiter's 2016 total compensation was $18.4 mln (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-says-ceo-john-lechleiters-2016-total-compensation-was-184-mln-2017-3,positive,0.6687998175621033
121,3/23/2017 5:00:00 PM,Lilly and the William Sansum Diabetes Center announce a five-year research collaboration,PR Newswire,/news/stocks/lilly-and-the-william-sansum-diabetes-center-announce-a-five-year-research-collaboration-1001863095,positive,0.8344830274581909
122,3/23/2017 9:50:47 PM,BRIEF-Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-ignyta-to-explore-strategic-options-for-taladegib-through-amendment-of-taladegib-license-agreement-with-lilly-2017-3,negative,0.6984206438064575
123,3/24/2017 11:33:55 AM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1001865270,positive,0.7716754078865051
124,3/24/2017 1:00:00 PM,Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017,PR Newswire,/news/stocks/lilly-announces-850-million-investment-in-u-s-capital-projects-in-2017-1001865606,positive,0.7096723318099976
125,3/24/2017 1:12:49 PM,Eli Lilly Plans $850 Mln Investments In U.S. Operations In FY17 - Quick Facts ,RTTNews,/news/stocks/eli-lilly-plans-850-mln-investments-in-u-s-operations-in-fy17-quick-facts-1001865658,positive,0.871044933795929
126,3/24/2017 1:30:48 PM,BRIEF-Eli Lilly announces $850 mln investment in U.S. capital projects in 2017 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-850-mln-investment-in-us-capital-projects-in-2017-2017-3,positive,0.8630527853965759
127,3/24/2017 1:30:48 PM,Drugmaker Lilly to invest $850 mln in U.S. operations in 2017 (LLY),Reuters,http://www.businessinsider.com/r-drugmaker-lilly-to-invest-850-mln-in-us-operations-in-2017-2017-3,positive,0.8420568108558655
128,3/24/2017 2:14:46 PM,UPDATE 1-Drugmaker Lilly to invest $850 mln in U.S. operations in 2017 (LLY),Reuters,http://www.businessinsider.com/r-update-1-drugmaker-lilly-to-invest-850-mln-in-us-operations-in-2017-2017-3,positive,0.7445011138916016
129,3/24/2017 4:42:45 PM,"LPC: Top US firms raise loans on tax reform hopes (LLY, BMY, CSCO)",Reuters,http://www.businessinsider.com/r-lpc-top-us-firms-raise-loans-on-tax-reform-hopes-2017-3,negative,0.9026652574539185
130,3/28/2017 2:28:49 PM,"BRIEF-Intelgenx Technologies says Eli Lilly granted Versafilm exclusive license for tadalafil film product under erectile dysfunction dosing patent (IGX, LLY)",Reuters,http://www.businessinsider.com/r-brief-intelgenx-technologies-says-eli-lilly-granted-versafilm-exclusive-license-for-tadalafil-film-product-under-erectile-dysfunction-dosing-patent-2017-3,negative,0.8673747181892395
131,3/31/2017 6:24:48 PM,"BRIEF-Eli Lilly says Lilly Endowment Inc reports open market sale of 210,000 of stock (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-lilly-endowment-inc-reports-open-market-sale-of-210000-of-stock-2017-3,positive,0.9417386651039124
132,4/4/2017 7:00:00 PM,Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students,PR Newswire,/news/stocks/lilly-and-ohio-university-heritage-college-of-osteopathic-medicine-partner-on-rotation-program-for-medical-students-1001895732,positive,0.8100031614303589
133,4/5/2017 11:00:52 AM,"Boehringer eyes marked sales gain, boosted by animal health (SAN, LLY)",Reuters,http://www.businessinsider.com/r-boehringer-eyes-marked-sales-gain-boosted-by-animal-health-2017-4,negative,0.9557393193244934
134,4/7/2017 4:00:00 PM,"Life with Type 1 Diabetes Made a Little Easier through Lilly Diabetes Scholarship Donations for Camps, College and Conferences",PR Newswire,/news/stocks/life-with-type-1-diabetes-made-a-little-easier-through-lilly-diabetes-scholarship-donations-for-camps-college-and-conferences-1001907024,positive,0.8404471278190613
135,4/11/2017 8:13:02 AM,"PRESS DIGEST - Wall Street Journal - April 11 (WFM, WFC, BARC, UAL, TSLA, LLY, 2354, 6502)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---april-11-2017-4,positive,0.9426089525222778
136,4/11/2017 5:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2017-financial-results-announcement-1001914519,positive,0.9402515292167664
137,4/14/2017 3:00:00 PM,U.S. FDA Issues Complete Response Letter for Baricitinib,PR Newswire,/news/stocks/u-s-fda-issues-complete-response-letter-for-baricitinib-1001922584,positive,0.854012668132782
138,4/14/2017 3:10:34 PM,Eli Lilly And Incyte Say FDA Issues CRL For Baricitinib ,RTTNews,/news/stocks/eli-lilly-and-incyte-say-fda-issues-crl-for-baricitinib-1001922595,neutral,0.48892974853515625
139,4/14/2017 3:59:02 PM,"BRIEF-U.S. FDA issues CRL for baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-us-fda-issues-crl-for-baricitinib-2017-4,positive,0.8069430589675903
140,4/14/2017 6:05:04 PM,"U.S. FDA declines to approve Eli Lilly and Incyte arthritis drug Olumiant (LLY, INCY, PFE)",Reuters,http://www.businessinsider.com/r-us-fda-declines-to-approve-eli-lilly-and-incyte-arthritis-drug-olumiant-2017-4,neutral,0.7621970176696777
141,4/17/2017 6:24:50 AM,"FDA Says No To INCY, ZTS Snaps Up NVET, MDXG On The Move ",RTTNews,/news/stocks/fda-says-no-to-incy-zts-snaps-up-nvet-mdxg-on-the-move-1001923443,positive,0.8315284848213196
142,4/17/2017 1:59:03 PM,"US STOCKS-Futures dip on soft U.S. data, geopolitical risks (NFLX, UAL, INCY, LLY, PFE)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-dip-on-soft-us-data-geopolitical-risks-2017-4,neutral,0.9683301448822021
143,4/17/2017 2:50:35 PM,"The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling (INCY, LLY)",Business Insider,http://www.businessinsider.com/fda-rejects-lilly-and-incytes-baricitinib-2017-4,neutral,0.6186674237251282
144,4/17/2017 3:13:03 PM,"US STOCKS-Wall Street looks set to open slightly higher (NFLX, UAL, INCY, LLY, PFE, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-street-looks-set-to-open-slightly-higher-2017-4,negative,0.939262330532074
145,4/17/2017 4:55:07 PM,"US STOCKS-Wall St edges higher as tech, financials gain (NFLX, UAL, INCY, LLY, ALR, ABT)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-edges-higher-as-tech-financials-gain-2017-4,negative,0.9337784647941589
146,4/17/2017 10:45:05 PM,"US STOCKS-Wall St rallies in low volume led by banks, tech (NFLX, AMZN, BA, INCY, LLY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-rallies-in-low-volume-led-by-banks-tech-2017-4,negative,0.4718031883239746
147,4/19/2017 5:41:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-eli-lilly-and-company-lly-1001931509,positive,0.7513298392295837
148,4/20/2017 5:35:00 PM,Lilly to Present Data for Galcanezumab for the Prevention of Migraine at the American Academy of Neurology (AAN) Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-data-for-galcanezumab-for-the-prevention-of-migraine-at-the-american-academy-of-neurology-aan-annual-meeting-1001935489,positive,0.8188774585723877
149,4/21/2017 3:15:05 PM,"UPDATE 1-Valeant prices psoriasis treatment at $3,500 per month (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-update-1-valeant-prices-psoriasis-treatment-at-3500-per-month-2017-4,positive,0.928935170173645
150,4/21/2017 9:51:09 PM,"EMA panel recommends nod for Sanofi, Regeneron's arthritis drug (SAN, REGN, JNJ, LLY, INCY)",Reuters,http://www.businessinsider.com/r-ema-panel-recommends-nod-for-sanofi-regenerons-arthritis-drug-2017-4,positive,0.6911615133285522
151,4/24/2017 12:25:00 PM,"Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-bristol-myers-astrazeneca-eli-lilly-and-immune-pharma-1001941450,positive,0.6895372867584229
152,4/24/2017 12:45:00 PM,Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaciclib Demonstrated Superior Progression-Free Survival at Interim Analysis,PR Newswire,/news/stocks/lilly-announces-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-demonstrated-superior-progression-free-survival-at-interim-analysis-1001941508,negative,0.953628659248352
153,4/24/2017 12:53:03 PM,Lilly :Phase 3 MONARCH 3 Breast Cancer Study Of Abemaciclib Shows Superior PFS ,RTTNews,/news/stocks/lilly-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-shows-superior-pfs-1001941530,negative,0.9470701813697815
154,4/24/2017 1:25:10 PM,BRIEF-Lilly says phase 3 MONARCH 3 breast cancer study of Abemaciclib demonstrated superior progression-free survival at interim analysis (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-phase-3-monarch-3-breast-cancer-study-of-abemaciclib-demonstrated-superior-progression-free-survival-at-interim-analysis-2017-4,negative,0.954008936882019
155,4/24/2017 7:01:12 PM,"Lilly reports positive interim data on breast cancer combo drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-lilly-reports-positive-interim-data-on-breast-cancer-combo-drug-2017-4,negative,0.8465091586112976
156,4/25/2017 8:33:08 AM,"BRIEF-Novartis CEO says takeover prices have risen, focusing on early-stage targets (LLY)",Reuters,http://www.businessinsider.com/r-brief-novartis-ceo-says-takeover-prices-have-risen-focusing-on-early-stage-targets-2017-4,negative,0.9249567985534668
157,4/25/2017 12:05:10 PM,"UPDATE 2-Novartis sets sights on return to growth in 2018 (GSK, LLY)",Reuters,http://www.businessinsider.com/r-update-2-novartis-sets-sights-on-return-to-growth-in-2018-2017-4,negative,0.9092616438865662
158,4/25/2017 12:25:00 PM,Lilly Reports First-Quarter 2017 Results,PR Newswire,/news/stocks/lilly-reports-first-quarter-2017-results-1001945666,positive,0.9085061550140381
159,4/25/2017 12:32:28 PM,Eli Lilly And Co. Announces 18% Increase In Q1 Profit,RTTNews,/news/stocks/eli-lilly-and-co-announces-18-increase-in-q1-profit-1001945700,negative,0.9429376125335693
160,4/25/2017 12:49:08 PM,BRIEF-Lilly Q1 non-GAAP earnings per share $0.98 (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-q1-non-gaap-earnings-per-share-098-2017-4,positive,0.837551474571228
161,4/25/2017 12:58:20 PM,Lilly Q1 Results Top Estimates; Cuts 2017 EPS View ,RTTNews,/news/stocks/lilly-q1-results-top-estimates-cuts-2017-eps-view-1001945794,neutral,0.9344818592071533
162,4/25/2017 1:11:08 PM,"UPDATE 1-Eli Lilly's profit beats on demand for newer drugs (LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-eli-lillys-profit-beats-on-demand-for-newer-drugs-2017-4,negative,0.63278728723526
163,4/25/2017 2:25:00 PM,Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders,PR Newswire,/news/stocks/autism-awareness-puts-spotlight-on-development-of-innovative-therapies-and-treatments-for-youth-mental-disorders-1001946378,negative,0.7258084416389465
164,4/25/2017 2:25:00 PM,Autism Awareness Puts Spotlight on Development of Innovative Therapies and Treatments for Youth Mental Disorders,PR Newswire,/news/stocks/autism-awareness-puts-spotlight-on-development-of-innovative-therapies-and-treatments-for-youth-mental-disorders-1001946377,negative,0.7258084416389465
165,4/26/2017 4:00:00 PM,The global car rental industry is expected to reach $99.6 billion by 2022,PR Newswire,/news/stocks/the-global-car-rental-industry-is-expected-to-reach-$99-6-billion-by-2022-1001611911,negative,0.7520802021026611
166,4/28/2017 12:49:07 PM,"CORRECTED-UPDATE 2-Valeant prices psoriasis treatment at $3,500 per month (April 21) (VRX, LLY, AMGN, JNJ)",Reuters,http://www.businessinsider.com/r-corrected-update-2-valeant-prices-psoriasis-treatment-at-3500-per-month-april-21-2017-4,positive,0.9364179372787476
167,5/1/2017 6:58:05 PM,BRIEF-Eli Lilly says got civil investigative demand from Washington AG's office about pricing of insulin products (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-got-civil-investigative-demand-from-washington-ags-office-about-pricing-of-insulin-products-2017-5,positive,0.8039060235023499
168,5/1/2017 8:45:00 PM,Lilly Declares Second-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2017-dividend-1001966540,positive,0.7535759806632996
169,5/1/2017 9:32:02 PM,BRIEF-Eli Lilly and Co sets Q2 2017 dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-sets-q2-2017-dividend-of-052-per-share-2017-5,positive,0.9097601175308228
170,5/2/2017 9:30:00 PM,Lilly Announces Webcast to Discuss Oncology Pipeline,PR Newswire,/news/stocks/lilly-announces-webcast-to-discuss-oncology-pipeline-1001639351,positive,0.9201152324676514
171,5/3/2017 11:24:05 AM,"UPDATE 1-Drugmaker Novo Nordisk nudges up full-year profit outlook after Q1 beat (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-drugmaker-novo-nordisk-nudges-up-full-year-profit-outlook-after-q1-beat-2017-5,negative,0.9383900165557861
172,5/3/2017 7:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-1001975846,positive,0.9201810359954834
173,5/4/2017 1:44:02 PM,"BRIEF-Incyte Q1 loss per share $0.96 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-q1-loss-per-share-096-2017-5,neutral,0.925426721572876
174,5/4/2017 2:50:03 PM,BRIEF-Eli Lilly and Co files for potential three-part notes offering (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-files-for-potential-three-part-notes-offering-2017-5,positive,0.9317617416381836
175,5/10/2017 2:00:00 PM,Leigh Ann Pusey Joins Lilly as Senior Vice President of Corporate Affairs and Communications,PR Newswire,/news/stocks/leigh-ann-pusey-joins-lilly-as-senior-vice-president-of-corporate-affairs-and-communications-1001998994,positive,0.9373534917831421
176,5/10/2017 7:00:00 PM,Lilly to Participate in Bernstein Strategic Decisions Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bernstein-strategic-decisions-conference-1002000451,positive,0.8582611680030823
177,5/11/2017 12:00:05 AM,"UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK, LLY, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5,negative,0.8430594205856323
178,5/12/2017 12:45:00 PM,Lilly Announces Positive Results for Three Phase 3 Studies of Galcanezumab for the Prevention of Episodic and Chronic Migraine,PR Newswire,/news/stocks/lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-for-the-prevention-of-episodic-and-chronic-migraine-1002007829,negative,0.9417768716812134
179,5/12/2017 12:57:09 PM,Lilly: Galcanezumab For Migraine Met Primary Endpoint In Three Phase 3 Trials ,RTTNews,/news/stocks/lilly-galcanezumab-for-migraine-met-primary-endpoint-in-three-phase-3-trials-1002007862,negative,0.8291045427322388
180,5/12/2017 1:02:03 PM,BRIEF-Lilly announces positive results for three phase 3 studies of galcanezumab (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-positive-results-for-three-phase-3-studies-of-galcanezumab-2017-5,negative,0.9392446279525757
181,5/12/2017 1:12:02 PM,Lilly migraine treatment meets main goal in late-stage studies (LLY),Reuters,http://www.businessinsider.com/r-lilly-migraine-treatment-meets-main-goal-in-late-stage-studies-2017-5,positive,0.7293023467063904
182,5/12/2017 4:29:13 PM,An experimental treatment for migraines just passed a critical study (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-migraine-treatment-meets-main-goal-in-late-stage-studies-2017-5,negative,0.7878748178482056
183,5/16/2017 12:00:04 AM,"BRIEF-Soros Fund Management dissolves share stake in Ebay Inc (EBAY, LLY)",Reuters,http://www.businessinsider.com/r-brief-soros-fund-management-dissolves-share-stake-in-ebay-inc-2017-5,positive,0.8134583830833435
184,5/16/2017 12:44:03 PM,"BRIEF-Lupin and Lilly expand partnership in India (LUPIN, LLY)",Reuters,http://www.businessinsider.com/r-brief-lupin-and-lilly-expand-partnership-in-india-2017-5,negative,0.7996332049369812
185,5/16/2017 1:30:00 PM,Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk -- in honor of her mom,PR Newswire,/news/stocks/actress-angela-bassett-joins-for-your-sweetheart-to-urge-people-with-diabetes-to-know-their-heart-disease-risk-in-honor-of-her-mom-1002016569,positive,0.8617801070213318
186,5/16/2017 2:08:04 PM,BRIEF-3Sbio Inc enters distribution and promotion agreement with two subsidiaries of Eli Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-3sbio-inc-enters-distribution-and-promotion-agreement-with-two-subsidiaries-of-eli-lilly-2017-5,negative,0.9161373376846313
187,5/17/2017 1:26:03 AM,"U.S. FDA warns of foot, leg amputations with J&J diabetes drug (JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-us-fda-warns-of-foot-leg-amputations-with-jj-diabetes-drug-2017-5,neutral,0.8133893609046936
188,5/18/2017 12:26:05 PM,"BRIEF-United Therapeutics says it entered into first amendment to license agreement with Eli Lilly and company (UTHR, LLY)",Reuters,http://www.businessinsider.com/r-brief-united-therapeutics-says-it-entered-into-first-amendment-to-license-agreement-with-eli-lilly-and-company-2017-5,negative,0.8555063009262085
189,5/20/2017 9:22:05 AM,"U.S., China accelerate beef talks; deal possible by early June (TSN, JBSS3, LLY)",Reuters,http://www.businessinsider.com/r-us-china-accelerate-beef-talks-deal-possible-by-early-june-2017-5,positive,0.8615724444389343
190,5/22/2017 12:38:07 PM,"RPT-U.S., China accelerate beef talks; deal possible by early June (TSN, JBSS3, LLY)",Reuters,http://www.businessinsider.com/r-rpt-us-china-accelerate-beef-talks-deal-possible-by-early-june-2017-5,positive,0.7594865560531616
191,5/30/2017 7:26:03 PM,"U.S. top court restricts patent owners' right to block resale of goods (002180, PFE, LLY, INTC)",Reuters,http://www.businessinsider.com/r-us-top-court-restricts-patent-owners-right-to-block-resale-of-goods-2017-5,positive,0.7187386155128479
192,5/30/2017 8:46:04 PM,"UPDATE 1-U.S. top court restricts patent owners' right to block resale of goods (002180, PFE, LLY, INTC)",Reuters,http://www.businessinsider.com/r-update-1-us-top-court-restricts-patent-owners-right-to-block-resale-of-goods-2017-5,neutral,0.6092459559440613
193,5/30/2017 10:54:03 PM,BRIEF-Canadian pork processor Olymel says shipped tainted pork to China (LLY),Reuters,http://www.businessinsider.com/r-brief-canadian-pork-processor-olymel-says-shipped-tainted-pork-to-china-2017-5,neutral,0.742544949054718
194,5/31/2017 7:24:05 AM,"Swiss biotech NLS Pharma's ADHD drug succeeds in mid-stage study (SHP, LLY)",Reuters,http://www.businessinsider.com/r-swiss-biotech-nls-pharmas-adhd-drug-succeeds-in-mid-stage-study-2017-5,negative,0.9304858446121216
195,5/31/2017 8:14:00 AM,"ALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD ",RTTNews,/news/stocks/albo-spikes-glyc-abuzz-fda-approves-1st-generic-strattera-for-adhd-1002052929,negative,0.8213559985160828
196,5/31/2017 12:45:00 PM,"Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA® (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival",PR Newswire,/news/stocks/lilly-announces-phase-3-range-urothelial-cancer-trial-of-cyramza-ramucirumab-met-primary-endpoint-improving-progression-free-survival-1002053990,negative,0.9505085945129395
197,5/31/2017 12:59:34 PM,Lilly Says Phase 3 RANGE Urothelial Cancer Trial Of CYRAMZA Met Primary Endpoint ,RTTNews,/news/stocks/lilly-says-phase-3-range-urothelial-cancer-trial-of-cyramza-met-primary-endpoint-1002054014,negative,0.8195981383323669
198,5/31/2017 1:04:03 PM,BRIEF-Eli Lilly announces phase 3 RANGE Urothelial cancer trial of CYRAMZA met primary endpoint (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-phase-3-range-urothelial-cancer-trial-of-cyramza-met-primary-endpoint-2017-5,positive,0.699036180973053
199,5/31/2017 8:30:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1002056191,positive,0.892741322517395
200,6/1/2017 12:20:00 PM,"Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-astrazeneca-bristol-myers-squibb-eli-lilly-and-sanofi-1002058233,positive,0.912547767162323
201,6/1/2017 12:45:00 PM,Derica Rice to Retire as Lilly Chief Financial Officer,PR Newswire,/news/stocks/derica-rice-to-retire-as-lilly-chief-financial-officer-1002058356,positive,0.7648385763168335
202,6/1/2017 1:00:09 PM,BRIEF-Eli Lilly says Derica Rice to retire as CFO (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-derica-rice-to-retire-as-cfo-2017-6,positive,0.8873233795166016
203,6/1/2017 1:03:27 PM,Eli Lilly CFO Derica Rice To Retire By End Of 2017  - Quick Facts ,RTTNews,/news/stocks/eli-lilly-cfo-derica-rice-to-retire-by-end-of-2017-quick-facts-1002058456,positive,0.7964140176773071
204,6/1/2017 1:04:03 PM,Lilly CFO to retire by the end of this year (LLY),Reuters,http://www.businessinsider.com/r-lilly-cfo-to-retire-by-the-end-of-this-year-2017-6,positive,0.804705798625946
205,6/1/2017 2:30:00 PM,Boehringer Ingelheim and Lilly Diabetes Alliance to Present 33 Abstracts at the American Diabetes Association's 77th Scientific Sessions®,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-diabetes-alliance-to-present-33-abstracts-at-the-american-diabetes-association-s-77th-scientific-sessions-1002059036,positive,0.9294722676277161
206,6/2/2017 5:18:08 PM,"Novo Nordisk looks to shore up European market share (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisk-looks-to-shore-up-european-market-share-2017-6,negative,0.8873603940010071
207,6/3/2017 8:15:00 PM,Lilly Builds Upon Body of Data for Abemaciclib with Phase 3 MONARCH 2 Data Demonstrating Superior Progression-Free Survival in Advanced Breast Cancer,PR Newswire,/news/stocks/lilly-builds-upon-body-of-data-for-abemaciclib-with-phase-3-monarch-2-data-demonstrating-superior-progression-free-survival-in-advanced-breast-cancer-1002065390,negative,0.9453155398368835
208,6/5/2017 7:26:03 AM,"RPT-INSIGHT-Canada beats US in pork sales to China - feet, elbows and all (SEB, LLY, TSN, HRL, 288)",Reuters,http://www.businessinsider.com/r-rpt-insight-canada-beats-us-in-pork-sales-to-china---feet-elbows-and-all-2017-6,negative,0.8294244408607483
209,6/5/2017 7:26:04 AM,"INSIGHT-Canada beats US in pork sales to China - feet, elbows and all (SEB, LLY, TSN, HRL, 288)",Reuters,http://www.businessinsider.com/r-insight-canada-beats-us-in-pork-sales-to-china---feet-elbows-and-all-2017-6,negative,0.8680251240730286
210,6/7/2017 2:00:00 PM,Blink Health Commits To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,PR Newswire,/news/stocks/blink-health-commits-to-give-away-10-million-worth-of-free-diabetes-medications-to-help-people-afford-treatment-1002074089,negative,0.5731944441795349
211,6/7/2017 2:52:06 PM,"UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage trial (AMGN, PFE, LLY, INCY)",Reuters,http://www.businessinsider.com/r-update-1-abbvies-rheumatoid-arthritis-drug-succeeds-in-late-stage-trial-2017-6,negative,0.9333683848381042
212,6/7/2017 6:23:00 PM,News Alert: Blink Health To Give Away $10 Million Worth Of Free Diabetes Medications To Help People Afford Treatment,PR Newswire,/news/stocks/news-alert-blink-health-to-give-away-10-million-worth-of-free-diabetes-medications-to-help-people-afford-treatment-1002075532,positive,0.6612555980682373
213,6/8/2017 12:30:00 PM,Lilly Announces Strategic Collaboration with KeyBioscience AG,PR Newswire,/news/stocks/lilly-announces-strategic-collaboration-with-keybioscience-ag-1002077714,positive,0.5377771258354187
214,6/8/2017 12:46:04 PM,BRIEF-Lilly announces strategic collaboration with Keybioscience (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-strategic-collaboration-with-keybioscience-2017-6,positive,0.5488111972808838
215,6/8/2017 9:00:00 PM,Lilly Announces Webcast to Discuss Pain Management Portfolio,PR Newswire,/news/stocks/lilly-announces-webcast-to-discuss-pain-management-portfolio-1002079693,positive,0.9107609987258911
216,6/8/2017 9:25:00 PM,Lilly to Present Late-Breaking Data for Galcanezumab and Lasmiditan at the American Headache Society Annual Scientific Meeting,PR Newswire,/news/stocks/lilly-to-present-late-breaking-data-for-galcanezumab-and-lasmiditan-at-the-american-headache-society-annual-scientific-meeting-1002079732,positive,0.8605038523674011
217,6/9/2017 12:30:00 PM,"IDF, in partnership with Lilly, announces second phase of BRIDGES programme funding for translational research in diabetes with focus on secondary prevention",PR Newswire,/news/stocks/idf-in-partnership-with-lilly-announces-second-phase-of-bridges-programme-funding-for-translational-research-in-diabetes-with-focus-on-secondary-prevention-1002081464,negative,0.7218462824821472
218,6/9/2017 12:50:05 PM,"BRIEF-IDF, Eli Lilly announce second phase of BRIDGES programme funding (LLY)",Reuters,http://www.businessinsider.com/r-brief-idf-eli-lilly-announce-second-phase-of-bridges-programme-funding-2017-6,positive,0.8412913084030151
219,6/10/2017 4:00:00 PM,Lilly's Galcanezumab Significantly Reduces Number of Migraine Headache Days for Patients with Migraine: New Results Presented at AHS,PR Newswire,/news/stocks/lilly-s-galcanezumab-significantly-reduces-number-of-migraine-headache-days-for-patients-with-migraine-new-results-presented-at-ahs-1002083346,negative,0.5549250841140747
220,6/12/2017 9:54:03 AM,"Chi-Med steps closer to Chinese pharma first with drug filing (HCM, 1, LLY)",Reuters,http://www.businessinsider.com/r-chi-med-steps-closer-to-chinese-pharma-first-with-drug-filing-2017-6,negative,0.806499183177948
221,6/12/2017 1:28:08 PM,"BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development (LLY)",Reuters,http://www.businessinsider.com/r-brief-zymeworks-two-bispecific-immuno-oncology-drug-candidates-have-been-nominated-by-eli-lilly-for-late-stage-preclinical-development-2017-6,negative,0.8676466941833496
222,6/12/2017 1:28:08 PM,"BRIEF-Zymeworks' two bispecific immuno-oncology drug candidates have been nominated by Eli Lilly for late-stage, preclinical development (LLY)",Reuters,http://www.businessinsider.com/r-brief-zymeworks-two-bispecific-immuno-oncology-drug-candidates-have-been-nominated-by-eli-lilly-for-late-stage-preclinical-development-2017-6,negative,0.8676466941833496
223,6/12/2017 2:00:00 PM,Jardiance® (empagliflozin) tablets to be studied in chronic kidney disease,PR Newswire,/news/stocks/jardiance-empagliflozin-tablets-to-be-studied-in-chronic-kidney-disease-1002085320,positive,0.668727457523346
224,6/12/2017 2:12:08 PM,BRIEF-Lilly says Jardiance tablets to be studied in chronic kidney disease (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-says-jardiance-tablets-to-be-studied-in-chronic-kidney-disease-2017-6,positive,0.7477654814720154
225,6/12/2017 2:12:54 PM,"Boehringer, Eli Lilly To Conduct New Trial Investigating Jardiance Tablets ",RTTNews,/news/stocks/boehringer-eli-lilly-to-conduct-new-trial-investigating-jardiance-tablets-1002085383,positive,0.8437866568565369
226,6/12/2017 9:00:00 PM,Elanco Releases First-Ever Corporate Social Responsibility Impact Report,PR Newswire,/news/stocks/elanco-releases-first-ever-corporate-social-responsibility-impact-report-1002086742,positive,0.9119068384170532
227,6/12/2017 10:30:06 PM,"There’s a race to treat a condition that affects 38 million Americans — here’s what you need to know (AMGN, TEVA, LLY, ALDR)",Business Insider,http://www.businessinsider.com/new-migraine-prevention-treatments-2017-6,positive,0.9345234632492065
228,6/12/2017 11:22:08 PM,U.S. finalizes talks to resume beef exports to China after ban (LLY),Reuters,http://www.businessinsider.com/r-us-finalizes-talks-to-resume-beef-exports-to-china-after-ban-2017-6,negative,0.8145841360092163
229,6/13/2017 12:30:07 AM,"J&J diabetes drug shows heart benefit in large safety study (JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-jj-diabetes-drug-shows-heart-benefit-in-large-safety-study-2017-6,negative,0.911771297454834
230,6/13/2017 2:34:06 PM,"BRIEF-Pfizer and Lilly receive FDA fast track designation for Tanezumab (PFE, LLY)",Reuters,http://www.businessinsider.com/r-brief-pfizer-and-lilly-receive-fda-fast-track-designation-for-tanezumab-2017-6,negative,0.8465412259101868
231,6/13/2017 8:00:00 PM,Jardiance® (empagliflozin) analysis reinforces established safety profile,PR Newswire,/news/stocks/jardiance-empagliflozin-analysis-reinforces-established-safety-profile-1002090306,negative,0.9088422060012817
232,6/13/2017 8:18:05 PM,BRIEF-Eli Lilly updates on study data on Jardiance (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-updates-on-study-data-on-jardiance-2017-6,positive,0.9201222062110901
233,6/14/2017 12:01:00 AM,Lilly to Present New Data on Olumiant® (baricitinib) in Rheumatoid Arthritis and Taltz® (ixekizumab) in Psoriatic Arthritis at the Annual European Congress of Rheumatology (EULAR 2017),PR Newswire,/news/stocks/lilly-to-present-new-data-on-olumiant-baricitinib-in-rheumatoid-arthritis-and-taltz-ixekizumab-in-psoriatic-arthritis-at-the-annual-european-congress-of-rheumatology-eular-2017-1002090752,positive,0.7774092555046082
234,6/14/2017 7:18:05 AM,"PRESS DIGEST - Wall Street Journal - June 14 (IBM, VOW3, LLY, VZ, YHOO)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---june-14-2017-6,positive,0.9463484883308411
235,6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092780,positive,0.5165343284606934
236,6/14/2017 2:45:00 PM,Patented Biotechnology Formulations Resulting in New Generation of Animal Healthcare Medications and Treatments,PR Newswire,/news/stocks/patented-biotechnology-formulations-resulting-in-new-generation-of-animal-healthcare-medications-and-treatments-1002092769,positive,0.5165343284606934
237,6/15/2017 4:35:00 PM,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated Significant Improvements in Disease Signs and Symptoms at 24 Weeks Among Patients with Active Psoriatic Arthritis Who Had Prior Inadequate...,PR Newswire,/news/stocks/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-significant-improvements-in-disease-signs-and-symptoms-at-24-weeks-among-patients-with-active-psoriatic-arthritis-who-had-prior-inadequate-1002096764,negative,0.9538742899894714
238,6/15/2017 5:09:55 PM,Lilly's Taltz Shows Improvements In Disease Signs And Symptoms In PsA ,RTTNews,/news/stocks/lilly-s-taltz-shows-improvements-in-disease-signs-and-symptoms-in-psa-1002096914,negative,0.9501631855964661
239,6/15/2017 6:22:05 PM,BRIEF-Eli Lilly files supplemental biologics license application with FDA for Taltz (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-files-supplemental-biologics-license-application-with-fda-for-taltz-2017-6,positive,0.8517336249351501
240,6/16/2017 4:23:42 AM,"ADMP Soars On FDA Nod, It Is Advantage OXFD, LLY In Good Spirits ",RTTNews,/news/stocks/admp-soars-on-fda-nod-it-is-advantage-oxfd-lly-in-good-spirits-1002098096,negative,0.9112159013748169
241,6/16/2017 7:00:00 AM,"Eli Lilly and Company: RA Matters Survey Uncovers What Matters Most to Over 5,000 People Living With Rheumatoid Arthritis",PR Newswire,/news/stocks/eli-lilly-and-company-ra-matters-survey-uncovers-what-matters-most-to-over-5-000-people-living-with-rheumatoid-arthritis-1002098212,positive,0.8620198965072632
242,6/16/2017 10:15:00 AM,New Safety and Long-Term Efficacy Data from Baricitinib Clinical Trials in Patients with Moderate-to-Severe Rheumatoid Arthritis Presented at EULAR 2017,PR Newswire,/news/stocks/new-safety-and-long-term-efficacy-data-from-baricitinib-clinical-trials-in-patients-with-moderate-to-severe-rheumatoid-arthritis-presented-at-eular-2017-1002098713,positive,0.768063485622406
243,6/16/2017 11:10:00 AM,EULAR 2017: Lilly's Taltz® (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks,PR Newswire,/news/stocks/eular-2017-lilly-s-taltz-ixekizumab-demonstrated-no-progression-or-minimal-progression-of-radiographic-disease-in-patients-with-psoriatic-arthritis-through-52-weeks-1002098847,negative,0.8698924779891968
244,6/16/2017 11:51:38 AM,Eli Lilly Reports Results From Extension Period Of SPIRIT-P1 Trial ,RTTNews,/news/stocks/eli-lilly-reports-results-from-extension-period-of-spirit-p1-trial-1002098956,positive,0.829589307308197
245,6/16/2017 11:51:57 AM,"Eli Lilly, Incyte Announce Positive Results From Pooled Analysis Of Baricitinib ",RTTNews,/news/stocks/eli-lilly-incyte-announce-positive-results-from-pooled-analysis-of-baricitinib-1002098955,negative,0.9320670366287231
246,6/19/2017 2:11:00 PM,Lilly and NRAS Launch New Film for RA Awareness Week to Reveal the True Impact of RA,PR Newswire,/news/stocks/lilly-and-nras-launch-new-film-for-ra-awareness-week-to-reveal-the-true-impact-of-ra-1002103419,positive,0.9153136610984802
247,6/19/2017 7:05:00 PM,Lilly Declares Third-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2017-dividend-1002104701,positive,0.8180514574050903
248,6/19/2017 7:12:03 PM,BRIEF-Eli Lilly and Co sets quarterly dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-sets-quarterly-dividend-of-052-per-share-2017-6,positive,0.8901100158691406
249,6/21/2017 5:00:00 PM,Eli Lilly and Company Unveils Expanded Biotechnology Center in San Diego,PR Newswire,/news/stocks/eli-lilly-and-company-unveils-expanded-biotechnology-center-in-san-diego-1002112722,negative,0.5018261075019836
250,6/21/2017 5:38:05 PM,BRIEF-Eli Lilly unveils expanded biotech center in San Diego (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-unveils-expanded-biotech-center-in-san-diego-2017-6,positive,0.5409709811210632
251,6/27/2017 2:00:00 PM,Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launch of Annual Camp Care Package Speaker Tour,PR Newswire,/news/stocks/lilly-diabetes-brings-an-extra-splash-of-summertime-fun-and-inspiration-to-diabetes-camps-with-launch-of-annual-camp-care-package-speaker-tour-1002127158,positive,0.721946656703949
252,6/27/2017 3:12:00 PM,Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications,PR Newswire,/news/stocks/blink-health-giving-away-10-million-worth-of-free-diabetes-medications-1002127694,positive,0.8321623802185059
253,6/28/2017 3:12:00 PM,Blink Health Giving Away $10 Million Worth Of Free Diabetes Medications,PR Newswire,/news/stocks/blink-health-giving-away-10-million-worth-of-free-diabetes-medications-1002131451,positive,0.8321623802185059
254,7/3/2017 2:00:00 PM,"Japan Ministry of Health, Labor and Welfare (MHLW) Grants Marketing Approval For Olumiant® (baricitinib) for the Treatment of Rheumatoid Arthritis",PR Newswire,/news/stocks/japan-ministry-of-health-labor-and-welfare-mhlw-grants-marketing-approval-for-olumiant-baricitinib-for-the-treatment-of-rheumatoid-arthritis-1002143353,negative,0.9354477524757385
255,7/3/2017 2:06:59 PM,Eli Lilly Reports Japan Marketing Approval For Olumiant - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-japan-marketing-approval-for-olumiant-quick-facts-1002143389,negative,0.8129168748855591
256,7/3/2017 2:16:04 PM,"BRIEF-Incyte says Japan Ministry of Health, Labor And Welfare grants marketing approval for Olumiant (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-japan-ministry-of-health-labor-and-welfare-grants-marketing-approval-for-olumiant-2017-7,negative,0.7859511971473694
257,7/5/2017 7:02:05 PM,"New cancer treatments that are programmed to treat a person's specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)",Reuters,http://www.businessinsider.com/r-personalised-vaccines-hold-cancer-at-bay-in-two-early-trials-2017-7,positive,0.640192449092865
258,7/6/2017 2:11:39 PM,"Lilly, Purdue University Announce Strategic Research Collaboration - Quick Facts ",RTTNews,/news/stocks/lilly-purdue-university-announce-strategic-research-collaboration-quick-facts-1002152422,positive,0.8920261859893799
259,7/6/2017 2:32:03 PM,BRIEF-Lilly and Purdue University announce strategic research collaboration (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-and-purdue-university-announce-strategic-research-collaboration-2017-7,positive,0.7199954390525818
260,7/6/2017 6:22:09 PM,"UPDATE 1-Celgene signs deal with BeiGene for tumor cancer treatment (CELG, AZN, HCM, LLY)",Reuters,http://www.businessinsider.com/r-update-1-celgene-signs-deal-with-beigene-for-tumor-cancer-treatment-2017-7,negative,0.8679231405258179
261,7/7/2017 1:59:10 PM,UK Supreme Court Rules In Favor Of Lilly On Alimta Vitamin Regimen Patents ,RTTNews,/news/stocks/uk-supreme-court-rules-in-favor-of-lilly-on-alimta-vitamin-regimen-patents-1002155906,positive,0.6771533489227295
262,7/7/2017 2:00:10 PM,BRIEF-UK Supreme Court rules in Lilly's favor on Alimta vitamin regimen patents (LLY),Reuters,http://www.businessinsider.com/r-brief-uk-supreme-court-rules-in-lillys-favor-on-alimta-vitamin-regimen-patents-2017-7,positive,0.744457483291626
263,7/7/2017 2:52:08 PM,"UK Supreme Court rules in favor of Lilly's Alimta patents (LLY, AGN)",Reuters,http://www.businessinsider.com/r-uk-supreme-court-rules-in-favor-of-lillys-alimta-patents-2017-7,positive,0.8517665863037109
264,7/7/2017 3:52:03 PM,"UPDATE 1-UK Supreme Court rules in favor of Lilly's Alimta patents (LLY, TEVA, AGN)",Reuters,http://www.businessinsider.com/r-update-1-uk-supreme-court-rules-in-favor-of-lillys-alimta-patents-2017-7,positive,0.8059655427932739
265,7/10/2017 1:06:11 PM,Lilly: FDA Files NDA For Abemaciclib For Treatment Of Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-fda-files-nda-for-abemaciclib-for-treatment-of-advanced-breast-cancer-1002159665,negative,0.7220050096511841
266,7/10/2017 1:38:06 PM,BRIEF-FDA grants priority review for Lilly's abemaciclib (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-lillys-abemaciclib-2017-7,negative,0.5102941989898682
267,7/12/2017 4:08:03 PM,BRIEF-Eli lilly reaches settlement agreement in U.S. Cialis patent litigation (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-reaches-settlement-agreement-in-us-cialis-patent-litigation-2017-7,negative,0.8981173038482666
268,7/12/2017 4:16:25 PM,Lilly Reaches Settlement Deal In US Cialis Patent Litigation ,RTTNews,/news/stocks/lilly-reaches-settlement-deal-in-us-cialis-patent-litigation-1002167646,negative,0.7362338304519653
269,7/14/2017 1:48:03 PM,"Novartis stocks drug cabinet with ""Big-3"" arthritis blockbusters (AMGN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-novartis-stocks-drug-cabinet-with-big-3-arthritis-blockbusters-2017-7,positive,0.8232624530792236
270,7/18/2017 3:20:08 PM,BRIEF-Adimab says entered into agreement to transfer adimab platform to Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-adimab-says-entered-into-agreement-to-transfer-adimab-platform-to-lilly-2017-7,negative,0.8438771367073059
271,7/20/2017 6:58:08 PM,"FDA tentatively approves Merck's copycat of Sanofi's Lantus (MRK, SAN, LLY, CVS)",Reuters,http://www.businessinsider.com/r-fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-2017-7,negative,0.6010927557945251
272,7/24/2017 1:30:00 PM,"Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy",PR Newswire,/news/stocks/lilly-and-nektar-therapeutics-announce-alliance-to-develop-and-commercialize-nktr-358-a-novel-autoimmune-therapy-1002198244,negative,0.8653672337532043
273,7/24/2017 1:48:34 PM,Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358 ,RTTNews,/news/stocks/eli-lilly-agrees-with-nektar-to-co-develop-nktr-358-1002198315,negative,0.8611847162246704
274,7/24/2017 3:02:06 PM,"BRIEF-Eli Lilly and Nektar Therapeutics to develop, commercialize NKTR-358 (LLY, NKTR)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-nektar-therapeutics-to-develop-commercialize-nktr-358-2017-7,positive,0.8310455679893494
275,7/25/2017 12:15:00 PM,Lilly and Incyte Provide Update on Baricitinib,PR Newswire,/news/stocks/lilly-and-incyte-provide-update-on-baricitinib-1002201262,positive,0.9393396377563477
276,7/25/2017 12:25:00 PM,Lilly Reports Second-Quarter Results,PR Newswire,/news/stocks/lilly-reports-second-quarter-results-1002201298,positive,0.8420024514198303
277,7/25/2017 12:28:12 PM,Eli Lilly & Incyte Issue Update On Resubmission Of NDA For Baricitinib ,RTTNews,/news/stocks/eli-lilly-incyte-issue-update-on-resubmission-of-nda-for-baricitinib-1002201296,positive,0.9104512333869934
278,7/25/2017 12:28:25 PM,Eli Lilly And Co. Reports 30% Advance In Q2 Profit,RTTNews,/news/stocks/eli-lilly-and-co-reports-30-advance-in-q2-profit-1002201295,negative,0.9369744062423706
279,7/25/2017 12:36:07 PM,"BRIEF-Lilly and Incyte provide update on baricitinib (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-and-incyte-provide-update-on-baricitinib-2017-7,positive,0.9436993598937988
280,7/25/2017 12:39:28 PM,Eli Lilly Raises 2017 Non-GAAP EPS Guidance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-raises-2017-non-gaap-eps-guidance-quick-facts-1002201353,positive,0.8708354234695435
281,7/25/2017 12:50:05 PM,BRIEF-Lilly reports second-quarter results (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-second-quarter-results-2017-7,positive,0.8586272597312927
282,7/25/2017 12:50:06 PM,Drugmaker Lilly's profit jumps 35 percent (LLY),Reuters,http://www.businessinsider.com/r-drugmaker-lillys-profit-jumps-35-percent-2017-7,negative,0.9377220273017883
283,7/25/2017 2:58:03 PM,"US STOCKS-Caterpillar, McDonald's to lift S&P, Dow at open (CAT, MCD, AMZN, AAPL, T, CMG, CB, BIIB, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-caterpillar-mcdonalds-to-lift-sp-dow-at-open-2017-7,negative,0.6481931209564209
284,7/25/2017 3:58:03 PM,"US STOCKS-McDonald's, Caterpillar power S&P to record (MCD, CAT, AMZN, AAPL, T, CMG, CB, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-mcdonalds-caterpillar-power-sp-to-record-2017-7,negative,0.4987177550792694
285,7/25/2017 4:52:06 PM,BRIEF-Eli lilly says seeks external early cancer assets (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-seeks-external-early-cancer-assets-2017-7,positive,0.9219643473625183
286,7/25/2017 5:22:05 PM,"US STOCKS-Strong earnings boost S&P, Dow; Alphabet drags Nasdaq (MCD, CAT, AMZN, AAPL, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-strong-earnings-boost-sp-dow-alphabet-drags-nasdaq-2017-7,neutral,0.6697109341621399
287,7/25/2017 6:58:05 PM,"US STOCKS-S&P hits record on strong earnings; Alphabet drags Nasdaq (MCD, CAT, AMZN, AAPL, DD, LLY, MMM)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-hits-record-on-strong-earnings-alphabet-drags-nasdaq-2017-7,neutral,0.5566036701202393
288,7/25/2017 8:58:05 PM,"US STOCKS-S&P 500 jumps to record high on busy earnings day (MCD, CAT, C, MMM, LLY, FCX)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-500-jumps-to-record-high-on-busy-earnings-day-2017-7,negative,0.8991402387619019
289,7/25/2017 10:32:06 PM,"US STOCKS-Earnings, bank shares propel S&P 500 to record high (MCD, CAT, C, MMM, LLY, FCX)",Reuters,http://www.businessinsider.com/r-us-stocks-earnings-bank-shares-propel-sp-500-to-record-high-2017-7,negative,0.9253700375556946
290,7/26/2017 8:55:22 AM,"Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX ",RTTNews,/news/stocks/positive-data-ignites-ttph-mdco-makes-a-good-tango-wait-continues-for-egrx-1002204619,negative,0.6598851680755615
291,7/28/2017 6:08:11 PM,"BRIEF-Lilly gets civil investigative demand from Minnesota AG for insulin product pricing‍​ (LLY, 8086)",Reuters,http://www.businessinsider.com/r-brief-lilly-gets-civil-investigative-demand-from-minnesota-ag-for-insulin-product-pricing-2017-7,positive,0.7826346755027771
292,8/2/2017 10:52:04 AM,"Two biggest U.S. drug purchasers keep key Novo Nordisk drugs on 2018 list (CVS, NOVO , LLY)",Reuters,http://www.businessinsider.com/r-two-biggest-us-drug-purchasers-keep-key-novo-nordisk-drugs-on-2018-list-2017-8,positive,0.8329435586929321
293,8/4/2017 12:45:00 PM,Lilly Announces Positive Results for Second Phase 3 Study of Lasmiditan for the Acute Treatment of Migraine,PR Newswire,/news/stocks/lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-the-acute-treatment-of-migraine-1002233546,negative,0.94012850522995
294,8/4/2017 12:52:03 PM,BRIEF-Eli Lilly announces positive results for second phase 3 study of Lasmiditan for treatment of Migraine (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-announces-positive-results-for-second-phase-3-study-of-lasmiditan-for-treatment-of-migraine-2017-8,negative,0.9434513449668884
295,8/4/2017 12:52:03 PM,Lilly's acute migraine drug succeeds in late-stage study (LLY),Reuters,http://www.businessinsider.com/r-lillys-acute-migraine-drug-succeeds-in-late-stage-study-2017-8,negative,0.9371262788772583
296,8/4/2017 12:59:00 PM,Eli Lilly: Lasmiditan Meets Primary Endpoint In Second Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-lasmiditan-meets-primary-endpoint-in-second-phase-3-study-1002233573,negative,0.5388268232345581
297,8/4/2017 1:27:07 PM,"UPDATE 1-Lilly's acute migraine drug succeeds in late-stage study (LLY, AMGN, TEVA)",Reuters,http://www.businessinsider.com/r-update-1-lillys-acute-migraine-drug-succeeds-in-late-stage-study-2017-8,negative,0.9306519031524658
298,8/9/2017 7:07:03 PM,"UPDATE 1-Mexico watchdog finds big pharma faces no competition on some drugs (GSK, PFE, MRK, ABT, LLY, SAN, AZN)",Reuters,http://www.businessinsider.com/r-update-1-mexico-watchdog-finds-big-pharma-faces-no-competition-on-some-drugs-2017-8,negative,0.8694553971290588
299,8/16/2017 11:37:17 PM,"Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8,negative,0.9154216051101685
300,8/17/2017 12:42:07 AM,"UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8,negative,0.9371985197067261
301,8/17/2017 7:02:03 AM,"RPT-UPDATE 1-Novo Nordisk's diabetes drug succeeds in key trial (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-rpt-update-1-novo-nordisks-diabetes-drug-succeeds-in-key-trial-2017-8,negative,0.9318801164627075
302,8/17/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- Pfizer, Eli Lilly, Merck, and Sanofi",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-pfizer-eli-lilly-merck-and-sanofi-1002264947,positive,0.9307227730751038
303,8/18/2017 7:52:14 PM,"BRIEF-Teva announces exclusive launch of generic Axiron® in United States (TEVA, LLY)",Reuters,http://www.businessinsider.com/r-brief-teva-announces-exclusive-launch-of-generic-axiron-in-united-states-2017-8,negative,0.8234730362892151
304,8/25/2017 11:37:18 PM,"BRIEF-Nektar Therapeutics and Eli Lilly got notice of early termination of waiting period related to license agreement (NKTR, LLY)",Reuters,http://www.businessinsider.com/r-brief-nektar-therapeutics-and-eli-lilly-got-notice-of-early-termination-of-waiting-period-related-to-license-agreement-2017-8,neutral,0.8297459483146667
305,8/28/2017 8:00:00 PM,Lilly to Participate in Morgan Stanley Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-global-healthcare-conference-1002289223,positive,0.8802716135978699
306,8/29/2017 9:07:04 AM,"Merck cholesterol drug cuts heart risk by 9 pct in study (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-cholesterol-drug-cuts-heart-risk-by-9-pct-in-study-2017-8,negative,0.8817371129989624
307,8/29/2017 12:45:00 PM,New Phase 3 Data for Abemaciclib and Ramucirumab Presented at ESMO 2017 Congress,PR Newswire,/news/stocks/new-phase-3-data-for-abemaciclib-and-ramucirumab-presented-at-esmo-2017-congress-1002290925,positive,0.911247968673706
308,8/29/2017 1:14:50 PM,"Eli Lilly To Present Data From Phase 3 Studies Of Abemaciclib, Ramucirumab ",RTTNews,/news/stocks/eli-lilly-to-present-data-from-phase-3-studies-of-abemaciclib-ramucirumab-1002291015,positive,0.8479776382446289
309,8/30/2017 12:45:00 PM,Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018,PR Newswire,/news/stocks/lilly-to-file-baricitinib-resubmission-to-u-s-fda-before-end-of-january-2018-1002294227,positive,0.8667067289352417
310,8/30/2017 12:57:05 PM,"BRIEF-Lilly to file baricitinib resubmission to U.S. FDA before end of January 2018 (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-to-file-baricitinib-resubmission-to-us-fda-before-end-of-january-2018-2017-8,positive,0.9152293801307678
311,8/30/2017 1:02:01 PM,Lilly To Resubmit NDA For Baricitinib To FDA Before End Of January 2018 ,RTTNews,/news/stocks/lilly-to-resubmit-nda-for-baricitinib-to-fda-before-end-of-january-2018-1002294296,positive,0.8328335881233215
312,8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8,negative,0.9372472763061523
313,9/6/2017 3:17:04 AM,"BRIEF-Acrux says co and Eli Lilly and Co agreed to terminate licensing agreement for Axiron (ACR, LLY)",Reuters,http://www.businessinsider.com/r-brief-acrux-says-co-and-eli-lilly-and-co-agreed-to-terminate-licensing-agreement-for-axiron-2017-9,neutral,0.917357325553894
314,9/6/2017 12:45:00 PM,Lilly to Present New Data for Galcanezumab and Lasmiditan at the 18th Congress of the International Headache Society (IHC),PR Newswire,/news/stocks/lilly-to-present-new-data-for-galcanezumab-and-lasmiditan-at-the-18th-congress-of-the-international-headache-society-ihc-1002344737,positive,0.9098039269447327
315,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345383,positive,0.7913914918899536
316,9/6/2017 2:30:00 PM,Landmark M&A Deals Continue to Shape Big Pharma,PR Newswire,/news/stocks/landmark-m-a-deals-continue-to-shape-big-pharma-1002345356,positive,0.7913914918899536
317,9/7/2017 3:15:00 PM,"Lilly Takes Steps to Streamline Business, Invest in New Medicines and Drive Growth",PR Newswire,/news/stocks/lilly-takes-steps-to-streamline-business-invest-in-new-medicines-and-drive-growth-1002350156,negative,0.8307044506072998
318,9/7/2017 3:32:03 PM,"Lilly to cut 8 pct jobs, focus on developing new medicines (LLY)",Reuters,http://www.businessinsider.com/r-lilly-to-cut-8-pct-jobs-focus-on-developing-new-medicines-2017-9,negative,0.8150993585586548
319,9/7/2017 3:37:03 PM,"BRIEF-Eli Lilly to cuts jobs, focus on developing new medicines (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-to-cuts-jobs-focus-on-developing-new-medicines-2017-9,neutral,0.4515800476074219
320,9/7/2017 3:51:44 PM,"Lilly Plans To Cut About 3,500 Jobs Globally ",RTTNews,/news/stocks/lilly-plans-to-cut-about-3-500-jobs-globally-1002350308,neutral,0.9650757312774658
321,9/7/2017 3:57:06 PM,UPDATE 1-Lilly to cut 8 pct jobs as it works to reduce costs (LLY),Reuters,http://www.businessinsider.com/r-update-1-lilly-to-cut-8-pct-jobs-as-it-works-to-reduce-costs-2017-9,neutral,0.878445029258728
322,9/7/2017 9:12:18 PM,"US STOCKS-Wall St slips as media stocks, Hurricane Irma weigh (MSFT, AMZN, GILD, CMCSA, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-as-media-stocks-hurricane-irma-weigh-2017-9,neutral,0.9605973958969116
323,9/7/2017 10:32:09 PM,"US STOCKS-Wall St ends flat as media stocks slump, healthcare gains (CMCSA, BMY, MSFT, AMZN, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ends-flat-as-media-stocks-slump-healthcare-gains-2017-9,neutral,0.958350658416748
324,9/8/2017 7:02:05 AM,"PRESS DIGEST - Wall Street Journal - Sept 8 (AMZN, EFX, PFE, LLY)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---sept-8-2017-9,positive,0.9445129632949829
325,9/8/2017 12:45:00 PM,IHC 2017: Lilly's Galcanezumab Demonstrates Positive Long-Term Safety Results for up to 12 Months in Patients with Migraine,PR Newswire,/news/stocks/ihc-2017-lilly-s-galcanezumab-demonstrates-positive-long-term-safety-results-for-up-to-12-months-in-patients-with-migraine-1002353219,negative,0.9510101079940796
326,9/8/2017 12:56:40 PM,Eli Lilly: Galcanezumab Shows Positive Safety Results In 12-month Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-galcanezumab-shows-positive-safety-results-in-12-month-phase-3-study-1002353243,negative,0.9524142742156982
327,9/8/2017 1:22:05 PM,BRIEF-Eli Lilly says galcanezumab demonstrates positive long-term safety results for up to 12 months in patients with migraine (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-galcanezumab-demonstrates-positive-long-term-safety-results-for-up-to-12-months-in-patients-with-migraine-2017-9,negative,0.9506039023399353
328,9/9/2017 2:00:00 PM,IHC 2017: Lilly's Lasmiditan Significantly Reduces Pain in Patients with Migraine,PR Newswire,/news/stocks/ihc-2017-lilly-s-lasmiditan-significantly-reduces-pain-in-patients-with-migraine-1002355527,negative,0.9482253193855286
329,9/10/2017 12:12:11 AM,"Lilly drug cuts risk of advanced breast cancer progression -study (LLY, PFE)",Reuters,http://www.businessinsider.com/r-lilly-drug-cuts-risk-of-advanced-breast-cancer-progression--study-2017-9,positive,0.8484269976615906
330,9/10/2017 8:26:00 AM,Lilly Builds Upon Body of Clinical Evidence for CYRAMZA® (ramucirumab) with Phase 3 RANGE Data Demonstrating Superior Progression-Free Survival in Advanced or Metastatic Urothelial Cancer,PR Newswire,/news/stocks/lilly-builds-upon-body-of-clinical-evidence-for-cyramza-ramucirumab-with-phase-3-range-data-demonstrating-superior-progression-free-survival-in-advanced-or-metastatic-urothelial-cancer-1001656476,negative,0.9502990245819092
331,9/10/2017 11:12:03 AM,"UPDATE 1-Lilly takes on Pfizer, Novartis with new breast cancer drug data (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-lilly-takes-on-pfizer-novartis-with-new-breast-cancer-drug-data-2017-9,positive,0.8266234397888184
332,9/11/2017 3:00:00 PM,Lilly to Present New Data for Olumiant® (baricitinib) and Taltz® (ixekizumab) at the European Academy of Dermatology and Venereology (EADV) Annual Congress,PR Newswire,/news/stocks/lilly-to-present-new-data-for-olumiant-baricitinib-and-taltz-ixekizumab-at-the-european-academy-of-dermatology-and-venereology-eadv-annual-congress-1002358235,positive,0.8154897093772888
333,9/12/2017 12:59:00 PM,Jardiance® (empagliflozin) tablets reduced risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease independent of background blood sugar control,PR Newswire,/news/stocks/jardiance-empagliflozin-tablets-reduced-risk-of-cardiovascular-death-in-people-with-type-2-diabetes-and-established-cardiovascular-disease-independent-of-background-blood-sugar-control-1002361308,negative,0.9078952670097351
334,9/12/2017 1:31:40 PM,Lilly: Jardiance Tablets Reduces Cardiovascular Death Risks In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-jardiance-tablets-reduces-cardiovascular-death-risks-in-type-2-diabetes-1002361542,negative,0.8889655470848083
335,9/13/2017 2:30:00 PM,Biosynthesis Technology Could Transform Cannabinoid Production,PR Newswire,/news/stocks/biosynthesis-technology-could-transform-cannabinoid-production-1002365968,positive,0.7866100668907166
336,9/13/2017 2:30:00 PM,Biosynthesis Technology Could Transform Cannabinoid Production,PR Newswire,/news/stocks/biosynthesis-technology-could-transform-cannabinoid-production-1002365995,positive,0.7866100668907166
337,9/14/2017 10:02:03 AM,"Astra's Farxiga results may open up type 1 diabetes opportunity (AZN, LLY, JNJ)",Reuters,http://www.businessinsider.com/r-astras-farxiga-results-may-open-up-type-1-diabetes-opportunity-2017-9,negative,0.7758440375328064
338,9/14/2017 3:00:00 PM,Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis,PR Newswire,/news/stocks/baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-1002370452,negative,0.9003221988677979
339,9/14/2017 3:02:03 PM,"Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,positive,0.5306563377380371
340,9/14/2017 3:12:05 PM,"BRIEF-Incyte's baricitinib meets primary endpoint in phase 2 study of patients with moderate-to-severe atopic dermatitis (INCY, LLY)",Reuters,http://www.businessinsider.com/r-brief-incytes-baricitinib-meets-primary-endpoint-in-phase-2-study-of-patients-with-moderate-to-severe-atopic-dermatitis-2017-9,negative,0.9352310299873352
341,9/14/2017 3:13:25 PM,Lilly Announces New Safety And Efficacy Data From Phase 2 Study Of Baricitinib ,RTTNews,/news/stocks/lilly-announces-new-safety-and-efficacy-data-from-phase-2-study-of-baricitinib-1002370600,positive,0.5726248621940613
342,9/14/2017 8:52:15 PM,"UPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial (LLY, INCY, REGN, SAN)",Reuters,http://www.businessinsider.com/r-update-1-lilly-incyte-pill-beats-placebo-in-mid-stage-eczema-trial-2017-9,negative,0.9154360294342041
343,9/22/2017 11:02:07 PM,"UPDATE 1-U.S. FDA declines to approve J&J arthritis drug (JNJ, SAN, REGN, LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-declines-to-approve-jj-arthritis-drug-2017-9,neutral,0.8860206604003906
344,9/25/2017 2:30:00 PM,"Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications,...",PR Newswire,/news/stocks/geisinger-and-boehringer-ingelheim-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-at-greatest-risk-of-serious-long-term-complications-1002519082,negative,0.640264630317688
345,9/25/2017 2:43:15 PM,"Geisinger, Boehringer Ingelheim Announce Collaboration - Quick Facts ",RTTNews,/news/stocks/geisinger-boehringer-ingelheim-announce-collaboration-quick-facts-1002519436,positive,0.8831182718276978
346,9/25/2017 3:17:03 PM,BRIEF-Boehringer Ingelheim and Eli Lilly collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes (LLY),Reuters,http://www.businessinsider.com/r-brief-boehringer-ingelheim-and-eli-lilly-collaborate-to-create-a-predictive-model-to-help-improve-health-outcomes-for-people-with-type-2-diabetes-2017-9,negative,0.8362363576889038
347,9/28/2017 2:05:00 PM,Elanco Celebrates 10 Years of Volunteerism During Global Day of Service,PR Newswire,/news/stocks/elanco-celebrates-10-years-of-volunteerism-during-global-day-of-service-1002732913,negative,0.8288668990135193
348,9/28/2017 8:17:07 PM,"Eli Lilly wins U.S. approval for breast cancer drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-eli-lilly-wins-us-approval-for-breast-cancer-drug-2017-9,negative,0.9235324859619141
349,9/28/2017 8:42:12 PM,"UPDATE 1-Eli Lilly wins U.S. approval for breast cancer drug (LLY, PFE)",Reuters,http://www.businessinsider.com/r-update-1-eli-lilly-wins-us-approval-for-breast-cancer-drug-2017-9,negative,0.9041095972061157
350,9/28/2017 10:27:16 PM,"BRIEF-Eli Lilly sets list price of new breast cancer drug at $10,948/month (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sets-list-price-of-new-breast-cancer-drug-at-10948-month-2017-9,positive,0.9246872067451477
351,9/29/2017 3:26:19 AM,FDA Okays Lilly's Breast Cancer Drug Verzenio ,RTTNews,/news/stocks/fda-okays-lilly-s-breast-cancer-drug-verzenio-1002795433,positive,0.651533305644989
352,9/29/2017 12:45:00 PM,"Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing",PR Newswire,/news/stocks/lilly-announces-senior-leadership-appointments-for-finance-research-development-and-manufacturing-1002840402,positive,0.927800714969635
353,9/29/2017 12:59:22 PM,Lilly Promotes Josh Smiley To SVP And CFO ,RTTNews,/news/stocks/lilly-promotes-josh-smiley-to-svp-and-cfo-1002840425,positive,0.905690610408783
354,9/29/2017 4:32:03 PM,"Lilly names new CFO, replaces head of R&D in management shakeup (LLY)",Reuters,http://www.businessinsider.com/r-lilly-names-new-cfo-replaces-head-of-rd-in-management-shakeup-2017-9,positive,0.7047938704490662
355,9/29/2017 5:22:03 PM,"U.S. FDA approves Novo Nordisk fast-acting insulin Fiasp (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-novo-nordisk-fast-acting-insulin-fiasp-2017-9,positive,0.7889273762702942
356,9/29/2017 5:27:05 PM,"Puerto Rico power outage set to hurt global reinsurers (MAP, QBE, AIG, BMY, LLY, PFE, AMGN, AZN, MMC)",Reuters,http://www.businessinsider.com/r-puerto-rico-power-outage-set-to-hurt-global-reinsurers-2017-9,neutral,0.960808515548706
357,10/2/2017 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2017-financial-results-announcement-1002916339,positive,0.9381588101387024
358,10/2/2017 5:08:00 PM,"NAFTA, retail innovation, brand resilience and entrepreneurial retailer leadership examined on Oct 12 at Retail West 2017",PR Newswire,/news/stocks/nafta-retail-innovation-brand-resilience-and-entrepreneurial-retailer-leadership-examined-on-oct-12-at-retail-west-2017-1001597388,positive,0.8651238083839417
359,10/4/2017 3:00:00 PM,Humalog® Junior KwikPen® Now Available in the U.S. for People with Diabetes,PR Newswire,/news/stocks/humalog-junior-kwikpen-now-available-in-the-u-s-for-people-with-diabetes-1002996757,positive,0.7151340842247009
360,10/5/2017 2:54:00 PM,"MDA Completes Acquisition of DigitalGlobe, Creates Industry Leader in Satellite Systems, Earth Imagery, Geospatial Solutions and Analytics",PR Newswire,/news/stocks/mda-completes-acquisition-of-digitalglobe-creates-industry-leader-in-satellite-systems-earth-imagery-geospatial-solutions-and-analytics-1001610444,negative,0.808399498462677
361,10/5/2017 9:12:19 PM,"BRIEF-Eli lilly says Lilly Endowment Inc reports open market sale of 205,000 shares of co's common stock on Oct. 4 (LLY)",Reuters,http://www.businessinsider.com/r-brief-eli-lilly-says-lilly-endowment-inc-reports-open-market-sale-of-205000-shares-of-cos-common-stock-on-oct-4-2017-10,positive,0.9455647468566895
362,10/5/2017 9:48:00 PM,Additional Delivery of Insulin Ready for Distribution in Puerto Rico,PR Newswire,/news/stocks/additional-delivery-of-insulin-ready-for-distribution-in-puerto-rico-1003104398,positive,0.6398575305938721
363,10/5/2017 10:13:00 PM,U.S. Patent and Trademark Office Rules In Lilly's Favor On Alimta Vitamin Regimen Patent,PR Newswire,/news/stocks/u-s-patent-and-trademark-office-rules-in-lilly-s-favor-on-alimta-vitamin-regimen-patent-1003106521,positive,0.8615423440933228
364,10/5/2017 10:32:54 PM,BRIEF-U.S. PTO rules in Eli Lilly's favor on Alimta (LLY),Reuters,http://www.businessinsider.com/r-brief-us-pto-rules-in-eli-lillys-favor-on-alimta-2017-10,positive,0.7090088725090027
365,10/5/2017 10:42:16 PM,Eli Lilly defeats challenge to Alimta cancer drug patent (LLY),Reuters,http://www.businessinsider.com/r-eli-lilly-defeats-challenge-to-alimta-cancer-drug-patent-2017-10,negative,0.8349789977073669
366,10/5/2017 10:47:14 PM,Lilly wins Alimta patent dispute in US (LLY),Reuters,http://www.businessinsider.com/r-lilly-wins-alimta-patent-dispute-in-us-2017-10,negative,0.35354340076446533
367,10/6/2017 6:56:00 AM,SK Planet Japan to Launch Geo-Targeted Crypto-Currencies to Attract Booming Chinese Tourists,PR Newswire,/news/stocks/sk-planet-japan-to-launch-geo-targeted-crypto-currencies-to-attract-booming-chinese-tourists-452684,negative,0.8494634628295898
368,10/6/2017 7:00:00 PM,Lilly MONARCH 3 Study Published in Journal of Clinical Oncology Demonstrates Benefit of Verzenio™ (abemaciclib) Plus NSAI in Advanced Breast Cancer,PR Newswire,/news/stocks/lilly-monarch-3-study-published-in-journal-of-clinical-oncology-demonstrates-benefit-of-verzenio-abemaciclib-plus-nsai-in-advanced-breast-cancer-1003196213,negative,0.9161379337310791
369,10/8/2017 3:03:03 PM,"It has been a brutal year in the search for a treatment for Alzheimer’s — here’s where researchers are looking now (BIIB, VTVT, MRK, LLY, ROG, AZN)",Business Insider,http://www.businessinsider.com/what-alzheimers-disease-drugs-are-in-development-next-trial-2017-10,positive,0.9026668667793274
370,10/9/2017 11:48:57 AM,New Drugs Approved In September ,RTTNews,/news/stocks/new-drugs-approved-in-september-1003503219,positive,0.6164653897285461
371,10/10/2017 12:00:00 PM,InMed Appoints Dr. Mauro Maccarrone to its Scientific Advisory Board,PR Newswire,/news/stocks/inmed-appoints-dr-mauro-maccarrone-to-its-scientific-advisory-board-479404,positive,0.9356477856636047
372,10/10/2017 12:45:00 PM,"Lilly Reports Topline Results from Phase 3 JUNIPER Trial Evaluating Verzenio™ (abemaciclib) in KRAS-Mutated, Advanced Non-Small Cell Lung Cancer",PR Newswire,/news/stocks/lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verzenio-abemaciclib-in-kras-mutated-advanced-non-small-cell-lung-cancer-1003649489,negative,0.7750111818313599
373,10/10/2017 12:57:05 PM,BRIEF-Lilly reports topline results from Phase 3 JUNIPER trial evaluating Verzenio (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-reports-topline-results-from-phase-3-juniper-trial-evaluating-verzenio-2017-10,positive,0.7762479186058044
374,10/10/2017 1:02:03 PM,Lilly's lung cancer drug fails late-stage study (LLY),Reuters,http://www.businessinsider.com/r-lillys-lung-cancer-drug-fails-late-stage-study-2017-10,positive,0.7437427043914795
375,10/10/2017 1:27:03 PM,"US STOCKS-Futures higher as earnings take focus (BLK, DAL, JPM, C, GE, AIG, PG, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-higher-as-earnings-take-focus-2017-10,negative,0.9281554818153381
376,10/10/2017 3:02:03 PM,"US STOCKS-Wall St set to open higher as earnings take focus (BLK, DAL, JPM, C, GE, WMT, PFE, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-as-earnings-take-focus-2017-10,negative,0.9330078363418579
377,10/10/2017 4:07:03 PM,"US STOCKS-Wall St scales new records on gains in Wal-Mart, energy stocks (WMT, BLK, DAL, JPM, C, NVDA, LLY, HON)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-scales-new-records-on-gains-in-wal-mart-energy-stocks-2017-10,negative,0.8933858275413513
378,10/10/2017 5:27:05 PM,"US STOCKS-Wall St scales new records, helped by Wal-Mart, energy stocks (WMT, PG, AMZN, NVDA, LLY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-scales-new-records-helped-by-wal-mart-energy-stocks-2017-10,negative,0.9226226806640625
379,10/11/2017 7:42:28 AM,"CRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes, RNN Awaits DATA In Q4 ",RTTNews,/news/stocks/cry-opens-wallet-lly-s-juniper-flops-mdxg-catches-eyes-rnn-awaits-data-in-q4-1003777417,positive,0.5235242247581482
380,10/11/2017 5:47:03 PM,"BRIEF-‍BIOLOGICS SAYS SELECTED BY ELI LILLY TO BE IN LIMITED DISTRIBUTION NETWORK FOR VERZENIO​ (LLY, MCK)",Reuters,http://www.businessinsider.com/r-brief-biologics-says-selected-by-eli-lilly-to-be-in-limited-distribution-network-for-verzenio-2017-10,positive,0.8628303408622742
381,10/11/2017 11:17:08 PM,"Merck says will not seek approval of cholesterol treatment (MRK, PFE, LLY)",Reuters,http://www.businessinsider.com/r-merck-says-will-not-seek-approval-of-cholesterol-treatment-2017-10,positive,0.9214851260185242
382,10/12/2017 12:45:00 PM,FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer,PR Newswire,/news/stocks/fda-grants-priority-review-for-potential-new-indication-for-lilly-s-verzenio-abemaciclib-as-initial-treatment-of-advanced-breast-cancer-1003968302,negative,0.8698647022247314
383,10/12/2017 12:56:50 PM,Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-s-verzenio-gets-fda-priority-review-designation-for-advanced-breast-cancer-1003968320,negative,0.8771522045135498
384,10/12/2017 1:07:04 PM,BRIEF-FDA grants priority review for Lilly's verzenio (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-grants-priority-review-for-lillys-verzenio-2017-10,positive,0.6633631587028503
385,10/14/2017 3:00:00 AM,"Indigenous groups, science community, marine industry, and government partners make progress in protecting endangered killer whale population",PR Newswire,/news/stocks/indigenous-groups-science-community-marine-industry-and-government-partners-make-progress-in-protecting-endangered-killer-whale-population-487896,negative,0.8135910630226135
386,10/16/2017 12:45:00 PM,Rapidly Progressing Advanced Non-Small Cell Lung Cancer Patients Shown to Benefit in New CYRAMZA® (ramucirumab) Phase 3 Subgroup Analysis,PR Newswire,/news/stocks/rapidly-progressing-advanced-non-small-cell-lung-cancer-patients-shown-to-benefit-in-new-cyramza-ramucirumab-phase-3-subgroup-analysis-1004476575,negative,0.9337615966796875
387,10/16/2017 1:04:21 PM,Eli Lilly: REVEL Data Show Efficacy Of Ramucirumab Plus Docetaxel - Quick Factsz ,RTTNews,/news/stocks/eli-lilly-revel-data-show-efficacy-of-ramucirumab-plus-docetaxel-quick-factsz-1004477469,negative,0.7360755205154419
388,10/16/2017 2:42:11 PM,"UPDATE 1-Novo Nordisk diabetes drug effective, preliminary FDA review finds (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisk-diabetes-drug-effective-preliminary-fda-review-finds-2017-10,positive,0.8445964455604553
389,10/16/2017 8:45:00 PM,Lilly Declares Fourth-Quarter 2017 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2017-dividend-1004519947,positive,0.8079231381416321
390,10/16/2017 9:02:14 PM,BRIEF-Eli Lilly sets quarterly dividend of $0.52 per share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-sets-quarterly-dividend-of-052-per-share-2017-10,positive,0.8872985243797302
391,10/16/2017 9:37:50 PM,BRIEF-Eli Lilly ‍declares Q4 dividend of $0.52/share (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-declares-q4-dividend-of-052-share-2017-10,positive,0.6069977283477783
392,10/17/2017 9:32:03 PM,Trump favors ex-pharma executive Azar for health secretary -Politico (LLY),Reuters,http://www.businessinsider.com/r-trump-favors-ex-pharma-executive-azar-for-health-secretary--politico-2017-10,positive,0.8836904168128967
393,10/18/2017 12:32:03 AM,UPDATE 1-Trump favors ex-pharma executive Azar for health secretary -Politico (LLY),Reuters,http://www.businessinsider.com/r-update-1-trump-favors-ex-pharma-executive-azar-for-health-secretary--politico-2017-10,positive,0.8592621684074402
394,10/18/2017 12:45:00 PM,Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines,PR Newswire,/news/stocks/lilly-and-curevac-announce-global-collaboration-to-develop-mrna-cancer-vaccines-1004756424,negative,0.8169519305229187
395,10/18/2017 10:42:09 PM,"UPDATE 1-U.S. FDA panel backs approval of Novo Nordisk diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-panel-backs-approval-of-novo-nordisk-diabetes-drug-2017-10,neutral,0.5859568119049072
396,10/19/2017 8:27:14 AM,"INSIGHT-China biotech's 'coming out party' masks long road ahead (HCM, AZN, PFE, LLY, CELG, GSK, SAN)",Reuters,http://www.businessinsider.com/r-insight-china-biotechs-coming-out-party-masks-long-road-ahead-2017-10,positive,0.7154397368431091
397,10/20/2017 6:12:03 PM,"Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-merck-to-cut-1800-us-sales-jobs-add-960-jobs-in-chronic-care-2017-10,neutral,0.9515475034713745
398,10/20/2017 6:42:11 PM,"UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care (MRK, LLY)",Reuters,http://www.businessinsider.com/r-update-1-merck-to-cut-1800-us-sales-jobs-add-960-in-chronic-care-2017-10,neutral,0.9298647046089172
399,10/23/2017 12:45:00 PM,Lilly announces $72 million investment in diabetes manufacturing in Indianapolis,PR Newswire,/news/stocks/lilly-announces-72-million-investment-in-diabetes-manufacturing-in-indianapolis-1005324110,positive,0.7040948271751404
400,10/23/2017 1:02:06 PM,BRIEF-Lilly announces $72 million investment in diabetes manufacturing in Indianapolis (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-72-million-investment-in-diabetes-manufacturing-in-indianapolis-2017-10,positive,0.6935823559761047
401,10/23/2017 1:21:22 PM,Eli Lilly Plans To Invest $72 Mln In Insulin Manufacturing Project - Quick Facts ,RTTNews,/news/stocks/eli-lilly-plans-to-invest-72-mln-in-insulin-manufacturing-project-quick-facts-1005326357,positive,0.8024632930755615
402,10/24/2017 12:25:00 PM,"Lilly Reports Third-Quarter Results, Announces Strategic Review of Elanco Animal Health",PR Newswire,/news/stocks/lilly-reports-third-quarter-results-announces-strategic-review-of-elanco-animal-health-1005434556,positive,0.8601331114768982
403,10/24/2017 12:30:51 PM,Eli Lilly And Co. Q3 Earnings Rise 19%,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-rise-19-1005433730,negative,0.9235382676124573
404,10/24/2017 12:52:12 PM,BRIEF-Eli Lilly reports Q3 EPS $0.53 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-reports-q3-eps-053-2017-10,positive,0.7755740284919739
405,10/24/2017 1:02:14 PM,"UPDATE 1-Lilly beats profit estimates, mulls sale of animal health business (LLY, MON)",Reuters,http://www.businessinsider.com/r-update-1-lilly-beats-profit-estimates-mulls-sale-of-animal-health-business-2017-10,neutral,0.46647655963897705
406,10/24/2017 1:18:31 PM,Lilly Lifts FY17 View As Q3 Results Top Estimates; Mulls IPO Or Sale Of Elanco ,RTTNews,/news/stocks/lilly-lifts-fy17-view-as-q3-results-top-estimates-mulls-ipo-or-sale-of-elanco-1005438151,neutral,0.49320024251937866
407,10/24/2017 4:37:03 PM,"BRIEF-Lilly ""very optimistic"" on U.S. prospect for arthritis drug (LLY)",Reuters,http://www.businessinsider.com/r-brief-lilly-very-optimistic-on-us-prospect-for-arthritis-drug-2017-10,negative,0.8713927865028381
408,10/24/2017 9:57:00 PM,Eli Lilly and Company -- Moody's: Lilly's animal health separation would reduce diversity and earnings,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-animal-health-separation-would-reduce-diversity-and-earnings-1005486217,neutral,0.9031568169593811
409,10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10,negative,0.8058122396469116
410,10/25/2017 4:00:00 PM,Lilly To Participate In Credit Suisse 26th Annual Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-credit-suisse-26th-annual-healthcare-conference-1005581041,positive,0.8249992728233337
411,10/25/2017 4:29:00 PM,5 Tenets for Successful Robotic Process Automation Deployment,PR Newswire,/news/stocks/5-tenets-for-successful-robotic-process-automation-deployment-641645,positive,0.8173618912696838
412,10/25/2017 7:12:15 PM,"Teva accuses Lilly in U.S. court of infringing migraine drug patents (TEVA, LLY)",Reuters,http://www.businessinsider.com/r-teva-accuses-lilly-in-us-court-of-infringing-migraine-drug-patents-2017-10,neutral,0.8038415908813477
413,10/27/2017 9:17:03 PM,FDA tentatively approves Eagle Pharma's cancer drug (LLY),Reuters,http://www.businessinsider.com/r-fda-tentatively-approves-eagle-pharmas-cancer-drug-2017-10,negative,0.7555778622627258
414,10/27/2017 10:47:21 PM,UPDATE 1-Eagle Pharma gets tentative FDA approval for Lilly's Alimta version (LLY),Reuters,http://www.businessinsider.com/r-update-1-eagle-pharma-gets-tentative-fda-approval-for-lillys-alimta-version-2017-10,negative,0.9157810807228088
415,10/30/2017 12:22:25 PM,"BRIEF-‍Kymera Therapeutics announces $30 mln series A financing round​ (AMGN, LLY)",Reuters,http://www.businessinsider.com/r-brief-kymera-therapeutics-announces-30-mln-series-a-financing-round-2017-10,positive,0.8481873273849487
416,10/30/2017 2:00:00 PM,Lilly to Present New Data on Immunology Portfolio at ACR/ARHP Annual Meeting,PR Newswire,/news/stocks/lilly-to-present-new-data-on-immunology-portfolio-at-acr-arhp-annual-meeting-1006175661,positive,0.9324414730072021
417,10/30/2017 2:00:00 PM,"BMO Blue Book: Provinces in Central Canada See Strengthening Growth, Led by Ontario",PR Newswire,/news/stocks/bmo-blue-book-provinces-in-central-canada-see-strengthening-growth-led-by-ontario-491818,negative,0.9530032277107239
418,11/1/2017 11:07:12 AM,"UPDATE 2-Drugmaker Novo Nordisk warns of U.S. legislation, cautious on 2018 (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-2-drugmaker-novo-nordisk-warns-of-us-legislation-cautious-on-2018-2017-11,neutral,0.8323338627815247
419,11/2/2017 9:07:04 AM,"UPDATE 1-Sanofi refines expectations on drop in sales at diabetes arm (SAN, CVS, UNH, LLY)",Reuters,http://www.businessinsider.com/r-update-1-sanofi-refines-expectations-on-drop-in-sales-at-diabetes-arm-2017-11,neutral,0.9705420136451721
420,11/3/2017 12:00:00 PM,Boyd Group Income Fund Announces Completion of Redemption of Convertible Debentures,PR Newswire,/news/stocks/boyd-group-income-fund-announces-completion-of-redemption-of-convertible-debentures-492517,positive,0.835394024848938
421,11/5/2017 3:00:00 PM,ACR/ARHP 2017: New Analysis Shows Rheumatoid Arthritis Patients Treated with Baricitinib Reported Greater Improvements in Pain Compared to Adalimumab or Placebo,PR Newswire,/news/stocks/acr-arhp-2017-new-analysis-shows-rheumatoid-arthritis-patients-treated-with-baricitinib-reported-greater-improvements-in-pain-compared-to-adalimumab-or-placebo-1006960473,negative,0.9226011633872986
422,11/6/2017 5:38:55 AM,"Lilly, Incyte: Baricitinib Shows Greater Improvements In Pain Control In RA ",RTTNews,/news/stocks/lilly-incyte-baricitinib-shows-greater-improvements-in-pain-control-in-ra-1007018255,negative,0.9568936228752136
423,11/8/2017 11:02:05 AM,"UPDATE 1-Novartis takes fight to Pfizer's Ibrance with new Kisqali data (PFE, LLY)",Reuters,http://www.businessinsider.com/r-update-1-novartis-takes-fight-to-pfizers-ibrance-with-new-kisqali-data-2017-11,positive,0.7923449873924255
424,11/8/2017 1:22:20 PM,BRIEF-Eagle Pharmaceuticals Q3 earnings per share $0.98 (LLY),Reuters,http://www.businessinsider.com/r-brief-eagle-pharmaceuticals-q3-earnings-per-share-098-2017-11,positive,0.8183147311210632
425,11/8/2017 3:00:00 PM,ACR/ARHP 2017: Long-Term Use of Lilly's Taltz® (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors,PR Newswire,/news/stocks/acr-arhp-2017-long-term-use-of-lilly-s-taltz-ixekizumab-shows-efficacy-improvements-in-psoriatic-arthritis-for-patients-with-prior-inadequate-response-or-intolerance-to-tnf-inhibitors-1007295077,negative,0.9544405937194824
426,11/8/2017 8:07:03 PM,Ex-pharma exec Azar is top choice to run U.S. health agency -sources (LLY),Reuters,http://www.businessinsider.com/r-ex-pharma-exec-azar-is-top-choice-to-run-us-health-agency--sources-2017-11,positive,0.9007884860038757
427,11/10/2017 12:30:00 AM,New Data on FORTEO® (teriparatide [rDNA origin] injection) Showed Reduced Risk for New Vertebral and Clinical Fractures in Postmenopausal Women with Severe Osteoporosis,PR Newswire,/news/stocks/new-data-on-forteo-teriparatide-rdna-origin-injection-showed-reduced-risk-for-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-severe-osteoporosis-1007481715,negative,0.9033374190330505
428,11/10/2017 2:17:04 AM,BRIEF-New data on Forteo showed reduced risk for new vertebral and clinical fractures in postmenopausal women with severe osteoporosis (LLY),Reuters,http://www.businessinsider.com/r-brief-new-data-on-forteo-showed-reduced-risk-for-new-vertebral-and-clinical-fractures-in-postmenopausal-women-with-severe-osteoporosis-2017-11,negative,0.8798061609268188
429,11/10/2017 5:31:00 PM,"Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe",PR Newswire,/news/stocks/elanco-aratana-announce-positive-opinion-on-galliprant-grapiprant-tablets-in-europe-1007570282,negative,0.8903902769088745
430,11/10/2017 5:42:17 PM,"BRIEF-ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE (LLY)",Reuters,http://www.businessinsider.com/r-brief-elanco-aratana-announce-positive-opinion-on-galliprant-in-europe-2017-11,negative,0.8673669695854187
431,11/13/2017 5:07:03 PM,UPDATE 1-Trump to tap ex-pharma executive Azar as U.S. health secretary (LLY),Reuters,http://www.businessinsider.com/r-update-1-trump-to-tap-ex-pharma-executive-azar-as-us-health-secretary-2017-11,positive,0.8992801308631897
432,11/13/2017 8:00:00 PM,Lilly Appoints Philip Johnson to Senior Vice President and Treasurer,PR Newswire,/news/stocks/lilly-appoints-philip-johnson-to-senior-vice-president-and-treasurer-1007901662,positive,0.9236862063407898
433,11/14/2017 12:02:03 AM,"Cost of diabetes epidemic reaches $850 billion a year (NOVO , SAN, LLY)",Reuters,http://www.businessinsider.com/r-cost-of-diabetes-epidemic-reaches-850-billion-a-year-2017-11,positive,0.8780144453048706
434,11/14/2017 12:45:00 AM,Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease,PR Newswire,/news/stocks/jardiance-reduced-risk-of-cardiovascular-death-in-adults-with-type-2-diabetes-and-peripheral-artery-disease-1007925692,negative,0.8450582027435303
435,11/14/2017 2:46:23 AM,Lilly: Jardiance Reduces Risk Of Cardiovascular Death In Type 2 Diabetes And PAD ,RTTNews,/news/stocks/lilly-jardiance-reduces-risk-of-cardiovascular-death-in-type-2-diabetes-and-pad-1007934701,negative,0.8699309825897217
436,11/14/2017 7:02:03 AM,"PRESS DIGEST-New York Times business news - Nov 14 (GE, LLY)",Reuters,http://www.businessinsider.com/r-press-digest-new-york-times-business-news---nov-14-2017-11,positive,0.9364675879478455
437,11/14/2017 8:34:47 AM,"FDA Nod For AGN, ZYME Strikes A Deal With Janssen Biotech, TCON Abuzz ",RTTNews,/news/stocks/fda-nod-for-agn-zyme-strikes-a-deal-with-janssen-biotech-tcon-abuzz-1007962961,negative,0.8916678428649902
438,11/15/2017 1:22:04 PM,BRIEF-Leap Therapeutics announces $18 million private placement offering (LLY),Reuters,http://www.businessinsider.com/r-brief-leap-therapeutics-announces-18-million-private-placement-offering-2017-11,positive,0.8926666378974915
439,11/17/2017 9:45:00 PM,Lilly to Participate in Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-2017-biopharma-catalyst-deep-dive-conference-1008473720,positive,0.8791024088859558
440,11/20/2017 4:30:00 PM,Lilly Confirms Date and Conference Call for 2018 Financial Guidance Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-2018-financial-guidance-announcement-1008808514,positive,0.9440568685531616
441,11/21/2017 12:32:03 PM,"UPDATE 1-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs (NOVO , 4523, OREX, LLY, VVUS)",Reuters,http://www.businessinsider.com/r-update-1-under-pressure-in-diabetes-novo-nordisk-steps-up-focus-on-obesity-drugs-2017-11,negative,0.7707492113113403
442,11/21/2017 3:30:00 PM,Ontario Nurses' Association Welcomes New Members,PR Newswire,/news/stocks/ontario-nurses-association-welcomes-new-members-633054,positive,0.8577997088432312
443,11/21/2017 4:42:06 PM,"BRIEF-Dexcom announces development agreement with Lilly (DXCM, LLY)",Reuters,http://www.businessinsider.com/r-brief-dexcom-announces-development-agreement-with-lilly-2017-11,negative,0.5262478590011597
444,11/22/2017 10:32:03 PM,BRIEF-Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14 (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-and-co-reports-175-pct-passive-stake-in-leap-therapeutics-as-of-nov-14-2017-11,positive,0.9477589726448059
445,11/29/2017 4:27:08 PM,HHS nominee Azar says drug pricing a top priority (LLY),Reuters,http://www.businessinsider.com/r-hhs-nominee-azar-says-drug-pricing-a-top-priority-2017-11,positive,0.8710816502571106
446,11/29/2017 5:12:04 PM,"UPDATE 1-Health secretary nominee Azar says drug pricing a top priority (LLY, SAN, MRK, NOVO )",Reuters,http://www.businessinsider.com/r-update-1-health-secretary-nominee-azar-says-drug-pricing-a-top-priority-2017-11,positive,0.8332783579826355
447,11/29/2017 6:54:03 PM,One topic dominated a Senate hearing for Trump's top healthcare pick (LLY),Business Insider,http://www.businessinsider.com/hhs-alex-azar-hearing-drug-pricing-comments-2017-11,positive,0.8869689106941223
448,12/1/2017 11:01:00 PM,Lilly's Taltz® (ixekizumab) Receives U.S. FDA Approval for the Treatment of Active Psoriatic Arthritis,PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-receives-u-s-fda-approval-for-the-treatment-of-active-psoriatic-arthritis-1010234717,negative,0.9340447187423706
449,12/1/2017 11:17:04 PM,BRIEF-Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Active Psoriatic Arthritis (LLY),Reuters,http://www.businessinsider.com/r-brief-lillys-taltz-ixekizumab-receives-us-fda-approval-for-the-treatment-of-active-psoriatic-arthritis-2017-12,negative,0.9371563196182251
450,12/5/2017 3:00:00 PM,Lilly Initiates Clinical Trial to Evaluate the Functionality and Safety of its Automated Insulin Delivery System,PR Newswire,/news/stocks/lilly-initiates-clinical-trial-to-evaluate-the-functionality-and-safety-of-its-automated-insulin-delivery-system-1010351813,negative,0.589077353477478
451,12/5/2017 3:17:03 PM,BRIEF-Eli Lilly initiates clinical trial to evaluate its automated insulin delivery system (LLY),Reuters,http://www.businessinsider.com/r-brief-eli-lilly-initiates-clinical-trial-to-evaluate-its-automated-insulin-delivery-system-2017-12,positive,0.49969667196273804
452,12/5/2017 7:07:03 PM,"U.S. FDA approves Novo Nordisk diabetes drug Ozempic (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-novo-nordisk-diabetes-drug-ozempic-2017-12,positive,0.5377041697502136
453,12/5/2017 7:22:04 PM,"UPDATE 1-U.S. FDA approves Novo Nordisk diabetes drug Ozempic (NOVO , LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-novo-nordisk-diabetes-drug-ozempic-2017-12,negative,0.7453942894935608
454,12/6/2017 12:42:03 PM,"BRIEF-Novo Nordisk expects to launch new diabetes drug in Japan during H1 2018 (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-brief-novo-nordisk-expects-to-launch-new-diabetes-drug-in-japan-during-h1-2018-2017-12,positive,0.8329271674156189
455,12/6/2017 3:17:04 PM,"BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center (LLY)",Reuters,http://www.businessinsider.com/r-brief-juno-therapeutics-signs-licensing-agreements-with-lilly-oncotracker-and-fred-hutchinson-cancer-research-center-2017-12,negative,0.8281762599945068
456,12/8/2017 11:00:00 PM,Lilly Reports Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 Study in First-Line Advanced Gastric Cancer,PR Newswire,/news/stocks/lilly-reports-top-line-results-from-cyramza-ramucirumab-phase-3-study-in-first-line-advanced-gastric-cancer-1010637173,negative,0.8254284262657166
457,12/8/2017 11:37:04 PM,Lilly's Cyramza meets main goal in gastric cancer study (LLY),Reuters,http://www.businessinsider.com/r-lillys-cyramza-meets-main-goal-in-gastric-cancer-study-2017-12,positive,0.7925565838813782
458,12/8/2017 11:42:03 PM,BRIEF-Lilly's Cyramza meets Primary Endpoint in gastric cancer study (LLY),Reuters,http://www.businessinsider.com/r-brief-lillys-cyramza-meets-primary-endpoint-in-gastric-cancer-study-2017-12,negative,0.7275242805480957
459,12/9/2017 12:32:03 AM,"UPDATE 1-Lilly's stomach cancer drug meets main goal, but fails to improve survival rate (LLY, BMY)",Reuters,http://www.businessinsider.com/r-update-1-lillys-stomach-cancer-drug-meets-main-goal-but-fails-to-improve-survival-rate-2017-12,negative,0.8356025218963623
460,12/11/2017 12:30:00 PM,"Kimberly Blackwell, M.D., to become Vice President of Early Phase Development and Immuno-oncology at Lilly Oncology",PR Newswire,/news/stocks/kimberly-blackwell-m-d-to-become-vice-president-of-early-phase-development-and-immuno-oncology-at-lilly-oncology-1010931086,positive,0.9376163482666016
461,12/11/2017 12:45:00 PM,FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults,PR Newswire,/news/stocks/fda-accepts-biologics-license-application-bla-to-review-galcanezumab-for-the-prevention-of-migraine-in-adults-1010932888,negative,0.763866662979126
462,12/11/2017 12:57:04 PM,BRIEF-Kimberly Blackwell To Become Vice President Of Early Phase Development And Immuno-Oncology At Lilly Oncology (LLY),Reuters,http://www.businessinsider.com/r-brief-kimberly-blackwell-to-become-vice-president-of-early-phase-development-and-immuno-oncology-at-lilly-oncology-2017-12,positive,0.9307000637054443
463,12/11/2017 1:00:03 PM,Eli Lily: FDA Accepts BLA To Review Galcanezumab For Prevention Of Migraine ,RTTNews,/news/stocks/eli-lily-fda-accepts-bla-to-review-galcanezumab-for-prevention-of-migraine-1010932913,negative,0.908622682094574
464,12/11/2017 1:07:04 PM,BRIEF-FDA Accepts Biologics License Application (BLA) To Review Galcanezumab For The Prevention Of Migraine In Adults (LLY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-biologics-license-application-bla-to-review-galcanezumab-for-the-prevention-of-migraine-in-adults-2017-12,negative,0.7582120299339294
465,12/11/2017 7:17:03 PM,"FDA clears Sanofi's follow-on diabetes biologic of Lilly's Humalog (SAN, LLY)",Reuters,http://www.businessinsider.com/r-fda-clears-sanofis-follow-on-diabetes-biologic-of-lillys-humalog-2017-12,positive,0.5985020995140076
466,12/11/2017 8:07:03 PM,"UPDATE 1-FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog (SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-fda-oks-sanofis-follow-on-biologic-of-lillys-diabetes-drug-humalog-2017-12,positive,0.5132423043251038
467,12/11/2017 9:30:00 PM,Lilly Announces 8 Percent Dividend Increase,PR Newswire,/news/stocks/lilly-announces-8-percent-dividend-increase-1010982620,positive,0.7701420783996582
468,12/11/2017 9:42:07 PM,BRIEF-Lilly Announces 8 Percent Dividend Increase (LLY),Reuters,http://www.businessinsider.com/r-brief-lilly-announces-8-percent-dividend-increase-2017-12,negative,0.9289199709892273
469,12/13/2017 12:45:00 PM,Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020,PR Newswire,/news/stocks/lilly-announces-2018-financial-guidance-and-enhances-outlook-through-2020-1011229095,negative,0.844791829586029
470,12/13/2017 1:08:03 PM,Lilly Cuts 2017 EPS View; Announces Outlook Through 2020 ,RTTNews,/news/stocks/lilly-cuts-2017-eps-view-announces-outlook-through-2020-1011230227,neutral,0.8654022812843323
471,12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12,neutral,0.7240303158760071
472,12/14/2017 5:57:08 PM,BRIEF-NSAV Subsidiary Signs Agreement With Eli Lilly (LLY),Reuters,http://www.businessinsider.com/r-brief-nsav-subsidiary-signs-agreement-with-eli-lilly-2017-12,negative,0.7664897441864014
473,12/14/2017 6:30:00 PM,Rimidi and Lilly Collaborate to Personalize Solutions for People Using Insulin,PR Newswire,/news/stocks/rimidi-and-lilly-collaborate-to-personalize-solutions-for-people-using-insulin-1011419613,positive,0.5022001266479492
474,12/15/2017 11:37:04 AM,"UPDATE 1-Boehringer CFO Menne quits in differences over strategy (LHA, SAN, LLY)",Reuters,http://www.businessinsider.com/r-update-1-boehringer-cfo-menne-quits-in-differences-over-strategy-2017-12,neutral,0.870087742805481
475,12/15/2017 1:17:04 PM,"Novo Nordisk wins EU panel's backing for key diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-novo-nordisk-wins-eu-panels-backing-for-key-diabetes-drug-2017-12,negative,0.9421855807304382
476,12/15/2017 1:47:03 PM,"UPDATE 1-Novo Nordisk wins EU panel's backing for key diabetes drug (NOVO , LLY)",Reuters,http://www.businessinsider.com/r-update-1-novo-nordisk-wins-eu-panels-backing-for-key-diabetes-drug-2017-12,negative,0.9455022215843201
477,12/18/2017 3:30:00 PM,Lilly to Participate in Goldman Sachs Healthcare CEOs Unscripted Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-healthcare-ceos-unscripted-conference-1011618202,positive,0.9418261051177979
478,12/19/2017 9:07:04 AM,"BRIEF-Puretech Says Lilly To Invest $5M In PureTech's Entrega (PDC, LLY)",Reuters,http://www.businessinsider.com/r-brief-puretech-says-lilly-to-invest-5m-in-puretechs-entrega-2017-12,positive,0.8435354232788086
479,12/20/2017 10:17:04 PM,"BRIEF-U.S. Fda Approves New Diabetes Drug From Merck And Pfizer (MRK, PFE, JNJ, LLY, AZN)",Reuters,http://www.businessinsider.com/r-brief-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,negative,0.7861426472663879
480,12/20/2017 10:27:06 PM,"U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,negative,0.8601289391517639
481,12/20/2017 10:42:03 PM,"UPDATE 1-U.S. FDA approves new diabetes drug from Merck and Pfizer (MRK, PFE, AZN, JNJ, LLY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-new-diabetes-drug-from-merck-and-pfizer-2017-12,negative,0.8735406398773193
482,12/22/2017 11:17:03 PM,"UPDATE 2-U.S. judge tosses verdict against AbbVie in AndroGel case (LLY, ENDP)",Reuters,http://www.businessinsider.com/r-update-2-us-judge-tosses-verdict-against-abbvie-in-androgel-case-2017-12,positive,0.6632838249206543
483,1/2/2018 6:00:00 PM,Vancouver Island 2018 Property Assessment Notices in the Mail,PR Newswire,/news/stocks/vancouver-island-2018-property-assessment-notices-in-the-mail-1001658057,positive,0.8823054432868958
484,1/5/2018 3:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter 2017 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-2017-financial-results-announcement-1012522652,positive,0.9381837844848633
485,1/8/2018 3:00:00 PM,Livongo and Lilly Collaborate on Real-World Diabetes Research,PR Newswire,/news/stocks/livongo-and-lilly-collaborate-on-real-world-diabetes-research-1012665767,positive,0.8331595659255981
486,1/9/2018 3:11:00 PM,Moody's: US pharmaceutical companies' cash holdings set to decline under new tax law,Moodys,/news/bonds/moody-s-us-pharmaceutical-companies-cash-holdings-set-to-decline-under-new-tax-law-1012731176,neutral,0.9666052460670471
487,1/11/2018 2:20:00 PM,"Elanco, Aratana Announce Marketing Authorization of GALLIPRANT® (grapiprant tablets) in Europe",PR Newswire,/news/stocks/elanco-aratana-announce-marketing-authorization-of-galliprant-grapiprant-tablets-in-europe-1001662149,negative,0.8565695285797119
488,1/11/2018 10:30:00 PM,Elanco Announces Addition of New North America and Global Strategy Senior Executive,PR Newswire,/news/stocks/elanco-announces-addition-of-new-north-america-and-global-strategy-senior-executive-1012956084,positive,0.9098206162452698
489,1/15/2018 9:00:00 PM,Federal-Mogul Motorparts' Abex® Brand Introduces New Brake Rotors for Commercial Vehicle Market,PR Newswire,/news/stocks/federal-mogul-motorparts-abex-brand-introduces-new-brake-rotors-for-commercial-vehicle-market-668085,negative,0.6624818444252014
490,1/18/2018 2:00:00 PM,GALLIPRANT® (grapiprant tablets) Named Best Companion Animal Product for 2017,PR Newswire,/news/stocks/galliprant-grapiprant-tablets-named-best-companion-animal-product-for-2017-677514,negative,0.8961595296859741
491,1/18/2018 6:02:00 PM,Elanco Innovations Named Best Products for 2017,PR Newswire,/news/stocks/elanco-innovations-named-best-products-for-2017-1013235455,negative,0.8442107439041138
492,1/22/2018 8:58:59 AM,Some Branded Drugs Going Generic In 2018 ,RTTNews,/news/stocks/some-branded-drugs-going-generic-in-2018-1013567302,positive,0.897983968257904
493,1/22/2018 2:00:00 PM,Elanco Animal Health Announces U.S. Food and Drug Administration (FDA) Approval of Credelio® (lotilaner) to Treat and Protect Against Ticks and Fleas,PR Newswire,/news/stocks/elanco-animal-health-announces-u-s-food-and-drug-administration-fda-approval-of-credelio-lotilaner-to-treat-and-protect-against-ticks-and-fleas-1013590548,negative,0.776339590549469
494,1/22/2018 2:18:20 PM,Eli Lilly Animal Health Unit Announces FDA Approval Of Credelio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-animal-health-unit-announces-fda-approval-of-credelio-quick-facts-1013591458,positive,0.8334542512893677
495,1/26/2018 12:27:00 AM,Elanco Announces Global Agreement with Ab E Discovery for New Technology,PR Newswire,/news/stocks/elanco-announces-global-agreement-with-ab-e-discovery-for-new-technology-1014052394,negative,0.8718016743659973
496,1/26/2018 2:45:00 PM,Lilly To Present At Leerink Partners Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-present-at-leerink-partners-global-healthcare-conference-1014129587,positive,0.939577579498291
497,1/31/2018 12:25:00 PM,"Lilly Reports Strong Fourth-Quarter and Full-Year 2017 Revenue Growth, Increases 2018 EPS Guidance",PR Newswire,/news/stocks/lilly-reports-strong-fourth-quarter-and-full-year-2017-revenue-growth-increases-2018-eps-guidance-1014670122,negative,0.9528952240943909
498,1/31/2018 12:28:50 PM,Eli Lilly And Co. Profit Rises In Q4,RTTNews,/news/stocks/eli-lilly-and-co-profit-rises-in-q4-1014669352,negative,0.918949544429779
499,1/31/2018 12:48:41 PM,Lilly Lifts 2018 Profit View; Backs Revenue Outlook ,RTTNews,/news/stocks/lilly-lifts-2018-profit-view-backs-revenue-outlook-1014670972,negative,0.5678561329841614
500,2/13/2018 12:45:00 PM,Lilly Announces Positive Top-Line Phase 3 Results for Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis),PR Newswire,/news/stocks/lilly-announces-positive-top-line-phase-3-results-for-taltz-ixekizumab-in-ankylosing-spondylitis-radiographic-axial-spondyloarthritis-1015625005,negative,0.9448611736297607
501,2/13/2018 1:02:17 PM,Eli Lilly: Taltz Phase 3 Study Meets Endpoints To Treat Ankylosing Spondylitis ,RTTNews,/news/stocks/eli-lilly-taltz-phase-3-study-meets-endpoints-to-treat-ankylosing-spondylitis-1015625982,negative,0.6197891235351562
502,2/14/2018 7:17:00 PM,Lilly to Showcase New Data for Taltz® (ixekizumab) and Other Products Across Immunology Pipeline at AAD Annual Meeting,PR Newswire,/news/stocks/lilly-to-showcase-new-data-for-taltz-ixekizumab-and-other-products-across-immunology-pipeline-at-aad-annual-meeting-1015793140,positive,0.6856403946876526
503,2/19/2018 12:45:00 PM,AAD 2018: Treatment with Lilly's Taltz® (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity,PR Newswire,/news/stocks/aad-2018-treatment-with-lilly-s-taltz-ixekizumab-resulted-in-improvement-in-impact-of-genital-psoriasis-on-sexual-activity-1016320495,negative,0.9520179629325867
504,2/19/2018 1:18:26 PM,Eli Lilly: Taltz Improves Sexual Health Of Genital Psoriasis Patients ,RTTNews,/news/stocks/eli-lilly-taltz-improves-sexual-health-of-genital-psoriasis-patients-1016321992,negative,0.9240726828575134
505,2/20/2018 1:00:00 PM,Survey Reveals Many People with Migraine Live with Pain Nearly Half of Every Month,PR Newswire,/news/stocks/survey-reveals-many-people-with-migraine-live-with-pain-nearly-half-of-every-month-1016433555,neutral,0.8120743036270142
506,2/20/2018 9:30:00 PM,Lilly to Participate in Cowen Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-health-care-conference-1016483072,positive,0.8665114641189575
507,2/21/2018 6:30:00 PM,Lilly to Participate in Barclays Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-barclays-global-healthcare-conference-1016600550,positive,0.91036456823349
508,2/26/2018 12:45:00 PM,New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes,PR Newswire,/news/stocks/new-data-show-lilly-s-trulicity-dulaglutide-in-combination-with-an-sglt-2-inhibitor-improves-blood-sugar-control-in-people-with-type-2-diabetes-1017168573,negative,0.9314545392990112
509,2/26/2018 1:03:27 PM,Eli Lilly Reports New Data From Trulicity Phase 3b Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-new-data-from-trulicity-phase-3b-study-quick-facts-1017169447,positive,0.8782950043678284
510,2/26/2018 10:16:00 PM,"Lilly Receives Additional FDA Approval for VerzenioTM (abemaciclib), as Initial Treatment for Advanced Breast Cancer",PR Newswire,/news/stocks/lilly-receives-additional-fda-approval-for-verzeniotm-abemaciclib-as-initial-treatment-for-advanced-breast-cancer-1017216252,negative,0.9384156465530396
511,2/26/2018 10:25:48 PM,Eli Lilly Announces Additional FDA Approval For Verzenio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-additional-fda-approval-for-verzenio-quick-facts-1017216273,negative,0.6307780146598816
512,3/6/2018 2:00:00 PM,Boehringer Ingelheim and Lilly expand heart failure program for Jardiance® with new exercise capacity trials,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-expand-heart-failure-program-for-jardiance-with-new-exercise-capacity-trials-1018128182,negative,0.8293488621711731
513,3/8/2018 12:30:00 PM,"EFSD, JDRF and Lilly Extend Collaboration Supporting Type 1 Diabetes Research",PR Newswire,/news/stocks/efsd-jdrf-and-lilly-extend-collaboration-supporting-type-1-diabetes-research-1018393644,negative,0.9137725234031677
514,3/8/2018 12:39:58 PM,"EFSD, JDRF, Lilly Extend Collaboration Supporting Type 1 Diabetes Research ",RTTNews,/news/stocks/efsd-jdrf-lilly-extend-collaboration-supporting-type-1-diabetes-research-1018393686,negative,0.5911152958869934
515,3/9/2018 2:59:00 PM,"Maura Dickler, M.D., to become Vice President of Late Phase Development at Lilly Oncology",PR Newswire,/news/stocks/maura-dickler-m-d-to-become-vice-president-of-late-phase-development-at-lilly-oncology-1018548952,positive,0.9428407549858093
516,3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162,positive,0.7716754078865051
517,4/3/2018 1:54:24 PM,Will These Drugs Reach Blockbuster Status? ,RTTNews,/news/stocks/will-these-drugs-reach-blockbuster-status-1020339832,positive,0.7288854122161865
518,4/3/2018 4:05:00 PM,Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes,PR Newswire,/news/stocks/improving-cardiology-care-biotronik-us-to-distribute-aziyo-ecm-envelopes-541488,negative,0.7493953704833984
519,4/4/2018 12:45:00 PM,Lilly Announces CYRAMZA® (ramucirumab) Phase 3 REACH-2 Study in Second-Line Hepatocellular Carcinoma Patients Met Overall Survival Endpoint,PR Newswire,/news/stocks/lilly-announces-cyramza-ramucirumab-phase-3-reach-2-study-in-second-line-hepatocellular-carcinoma-patients-met-overall-survival-endpoint-1020452409,negative,0.949155867099762
520,4/4/2018 12:53:36 PM,Eli Lilly: CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-cyramza-phase-3-reach-2-study-meets-primary-endpoint-quick-facts-1020452419,negative,0.7264457941055298
521,4/4/2018 1:00:00 PM,Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes,PR Newswire,/news/stocks/lilly-and-sigilon-therapeutics-announce-strategic-collaboration-to-develop-encapsulated-cell-therapies-for-the-treatment-of-type-1-diabetes-541863,negative,0.8918259739875793
522,4/4/2018 1:15:11 PM,"Eli Lilly, Sigilon Announce Global Collaboration - Quick Facts ",RTTNews,/news/stocks/eli-lilly-sigilon-announce-global-collaboration-quick-facts-1020454022,positive,0.8400558829307556
523,4/4/2018 10:49:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2018 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2018-financial-results-announcement-1020501857,positive,0.9414342045783997
524,4/5/2018 6:33:03 AM,"CNAT Disappoints, EBIO To Report VISTA Data In May, PRTK To Face FDA In Oct. ",RTTNews,/news/stocks/cnat-disappoints-ebio-to-report-vista-data-in-may-prtk-to-face-fda-in-oct-1020539894,positive,0.7869491577148438
525,4/15/2018 2:30:00 PM,St. Baldrick's Foundation Commits $8 million to Support Pediatric Cancer Dream Team with Stand Up To Cancer,PR Newswire,/news/stocks/st-baldrick-s-foundation-commits-8-million-to-support-pediatric-cancer-dream-team-with-stand-up-to-cancer-1001935114,negative,0.5924278497695923
526,4/16/2018 2:00:00 PM,Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease,PR Newswire,/news/stocks/boehringer-ingelheim-and-lilly-announce-an-academic-collaboration-with-university-of-oxford-to-investigate-the-effects-of-jardiance-in-adults-with-chronic-kidney-disease-1021397180,negative,0.7851428985595703
527,4/19/2018 10:26:00 AM,"Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising",Moodys,/news/bonds/moody-s-stable-outlook-for-global-pharmaceuticals-m-a-event-risk-is-rising-1021562771,negative,0.6777340173721313
528,4/20/2018 4:14:00 PM,"Lilly to Present Phase 3 Data at AAN 2018 Reinforcing Commitment to New, Innovative Therapies in Migraine",PR Newswire,/news/stocks/lilly-to-present-phase-3-data-at-aan-2018-reinforcing-commitment-to-new-innovative-therapies-in-migraine-1021688075,negative,0.9228730797767639
529,4/20/2018 8:50:00 PM,Lilly Reports Additional Top-Line Results from CYRAMZA® (ramucirumab) Phase 3 RANGE Study in Advanced or Metastatic Urothelial Cancer,PR Newswire,/news/stocks/lilly-reports-additional-top-line-results-from-cyramza-ramucirumab-phase-3-range-study-in-advanced-or-metastatic-urothelial-cancer-1021708657,positive,0.5796981453895569
530,4/21/2018 3:23:59 AM,"An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-10-stocks-to-watch-bhvn-lly-toca-aldr-1021738099,positive,0.9135176539421082
531,4/23/2018 1:30:00 PM,Elanco Announces Addition of Chief Financial Officer,PR Newswire,/news/stocks/elanco-announces-addition-of-chief-financial-officer-1021990678,positive,0.9144657254219055
532,4/24/2018 2:11:00 AM,"FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis",PR Newswire,/news/stocks/fda-advisory-committee-recommends-the-approval-of-baricitinib-2mg-but-not-4mg-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis-1022051417,negative,0.5407771468162537
533,4/24/2018 2:58:55 AM,"FDA Panel Backs Lower Dose Of Lilly-Incyte Arthritis Drug, But Not Higher Dose ",RTTNews,/news/stocks/fda-panel-backs-lower-dose-of-lilly-incyte-arthritis-drug-but-not-higher-dose-1022054657,negative,0.48646464943885803
534,4/24/2018 8:46:50 AM,"PRTA Jolted, FDA Strikes Down PFE's Herceptin Biosimilar, No Relief Yet For KMDA ",RTTNews,/news/stocks/prta-jolted-fda-strikes-down-pfe-s-herceptin-biosimilar-no-relief-yet-for-kmda-1022084035,neutral,0.8953303694725037
535,4/24/2018 12:00:00 PM,AAN 2018: Lilly's Galcanezumab Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed to Respond to Multiple Preventive Therapies,PR Newswire,/news/stocks/aan-2018-lillys-galcanezumab-significantly-reduced-monthly-migraine-headache-days-in-patients-with-migraine-who-previously-failed-to-respond-to-multiple-preventive-therapies-611371,negative,0.9432709813117981
536,4/24/2018 12:25:00 PM,"Lilly Reports Strong First-Quarter 2018 Results, Raises EPS Guidance",PR Newswire,/news/stocks/lilly-reports-strong-first-quarter-2018-results-raises-eps-guidance-1001618899,negative,0.9427055716514587
537,4/24/2018 12:29:36 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1022103401,negative,0.9003615379333496
538,4/24/2018 1:24:18 PM,Lilly Q1 Results Beat Estimates; Raises 2018 Outlook ,RTTNews,/news/stocks/lilly-q1-results-beat-estimates-raises-2018-outlook-1022108942,negative,0.9398773908615112
539,4/25/2018 12:45:00 PM,Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease,PR Newswire,/news/stocks/lilly-and-china-s-nccd-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease-1022247073,negative,0.9006130695343018
540,4/27/2018 9:53:00 PM,Lilly to Participate in Bank of America Merrill Lynch Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bank-of-america-merrill-lynch-health-care-conference-1022585365,positive,0.8901779651641846
541,4/30/2018 12:45:00 PM,"Leena Gandhi, M.D., Ph.D., to Lead Lilly Oncology Immuno-Oncology Medical Development",PR Newswire,/news/stocks/leena-gandhi-m-d-ph-d-to-lead-lilly-oncology-immuno-oncology-medical-development-1022880135,positive,0.8942209482192993
542,5/1/2018 3:52:00 PM,Lilly and Local Partners Launch Diabetes Prevention and Management Pilot in Three Underserved Neighborhoods in Indianapolis,PR Newswire,/news/stocks/lilly-and-local-partners-launch-diabetes-prevention-and-management-pilot-in-three-underserved-neighborhoods-in-indianapolis-1023017542,negative,0.641509473323822
543,5/7/2018 9:15:00 PM,Lilly Declares Second-Quarter 2018 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2018-dividend-1023678242,positive,0.852789580821991
544,5/10/2018 1:30:00 PM,Lilly Announces Agreement To Acquire ARMO BioSciences,PR Newswire,/news/stocks/lilly-announces-agreement-to-acquire-armo-biosciences-1023991146,positive,0.8292984962463379
545,5/10/2018 1:30:00 PM,Elanco Animal Health Announces Addition of General Counsel,PR Newswire,/news/stocks/elanco-animal-health-announces-addition-of-general-counsel-1023991147,positive,0.9156569242477417
546,5/10/2018 1:41:44 PM,Eli Lilly To Acquire ARMO BioSciences For Approx. $1.6 Bln - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-armo-biosciences-for-approx-1-6-bln-quick-facts-1023992084,positive,0.9194812774658203
547,5/11/2018 7:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-1024148444,positive,0.9201810359954834
548,5/12/2018 5:44:25 AM,"An Ear To The Pharma: 8 Stocks To Watch (VYGR, BOLD, RXII, CYAD…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-8-stocks-to-watch-vygr-bold-rxii-cyad-1024202578,positive,0.9059410095214844
549,5/14/2018 1:44:00 PM,Lilly to Acquire AurKa Pharma,PR Newswire,/news/stocks/lilly-to-acquire-aurka-pharma-1024436961,positive,0.9345867037773132
550,5/14/2018 1:55:23 PM,Lilly To Buy AurKa Pharma ,RTTNews,/news/stocks/lilly-to-buy-aurka-pharma-1024436976,positive,0.9291946887969971
551,5/14/2018 5:38:00 PM,WeissLaw LLP: ARMO BioSciences Inc. Acquisition May Not Be In The Best Interests of ARMO shareholders,PR Newswire,/news/stocks/weisslaw-llp-armo-biosciences-inc-acquisition-may-not-be-in-the-best-interests-of-armo-shareholders-1024456187,positive,0.6674194931983948
552,5/15/2018 12:45:00 PM,Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache,PR Newswire,/news/stocks/lilly-s-galcanezumab-meets-primary-endpoint-in-phase-3-study-evaluating-galcanezumab-for-the-prevention-of-episodic-cluster-headache-1024553454,negative,0.5831174254417419
553,5/15/2018 12:56:11 PM,Eli Lilly: Galcanezumab Meets Primary Endpoint In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-galcanezumab-meets-primary-endpoint-in-phase-3-study-quick-facts-1024553486,negative,0.8406283855438232
554,5/16/2018 8:48:18 AM,"LLY Gets Headache Relief, XENE Abuzz, 3rd Time's A Charm For PFE's Epogen Biosim ",RTTNews,/news/stocks/lly-gets-headache-relief-xene-abuzz-3rd-time-s-a-charm-for-pfe-s-epogen-biosim-1024665378,positive,0.7174733877182007
555,5/16/2018 11:00:00 PM,Lilly Data at ASCO Illustrate Patient-Driven Advances in Cancer Care,PR Newswire,/news/stocks/lilly-data-at-asco-illustrate-patient-driven-advances-in-cancer-care-1024752450,negative,0.6480158567428589
556,5/18/2018 3:13:00 PM,AAM to Present at the 2018 Barclays High Yield Bond and Syndicated Loan Conference on May 22,PR Newswire,/news/stocks/aam-to-present-at-the-2018-barclays-high-yield-bond-and-syndicated-loan-conference-on-may-22-1001708162,positive,0.9467983841896057
557,5/22/2018 2:30:00 PM,Lilly's Taltz® (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area,PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-receives-the-first-u-s-fda-approval-for-label-update-to-include-data-for-psoriasis-involving-the-genital-area-1025087539,negative,0.8049776554107666
558,5/22/2018 2:39:30 PM,Eli Lilly: FDA Approves Label Update For Taltz - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-approves-label-update-for-taltz-quick-facts-1025087624,negative,0.5383195281028748
559,5/23/2018 4:02:00 PM,"Elanco, Heifer International 10-Year Effort Breaks the Cycle of Hunger for 160,000 Families",PR Newswire,/news/stocks/elanco-heifer-international-10-year-effort-breaks-the-cycle-of-hunger-for-160-000-families-1025140337,positive,0.5457601547241211
560,5/23/2018 8:00:00 PM,Sue Mahony to Retire as President of Lilly Oncology,PR Newswire,/news/stocks/sue-mahony-to-retire-as-president-of-lilly-oncology-1025150757,positive,0.8899989724159241
561,5/30/2018 11:21:00 PM,Lilly to Participate in Jefferies Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-jefferies-global-healthcare-conference-1025896236,positive,0.8886672258377075
562,5/31/2018 11:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1026027094,positive,0.892741322517395
563,6/1/2018 12:45:00 PM,Lilly to Showcase New Data at Digestive Disease Week 2018 for Mirikizumab in Moderate-to-Severe Ulcerative Colitis,PR Newswire,/news/stocks/lilly-to-showcase-new-data-at-digestive-disease-week-2018-for-mirikizumab-in-moderate-to-severe-ulcerative-colitis-1026103392,positive,0.8890845775604248
564,6/1/2018 6:04:00 PM,FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis,PR Newswire,/news/stocks/fda-approves-olumiant-baricitinib-2-mg-tablets-for-the-treatment-of-adults-with-moderately-to-severely-active-rheumatoid-arthritis-1026133279,negative,0.9166295528411865
565,6/4/2018 6:46:25 AM,"FDA Nod For LLY/INCY RA Drug, JAZZ Hits Right Tones, SLS' Study Stopped Early ",RTTNews,/news/stocks/fda-nod-for-lly-incy-ra-drug-jazz-hits-right-tones-sls-study-stopped-early-1026406603,positive,0.7329449653625488
566,6/5/2018 12:45:00 PM,"FDA Expands Lilly's ALIMTA® (pemetrexed) Label to Include Combination with KEYTRUDA® (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer,...",PR Newswire,/news/stocks/fda-expands-lilly-s-alimta-pemetrexed-label-to-include-combination-with-keytruda-pembrolizumab-and-carboplatin-as-first-line-treatment-for-metastatic-nonsquamous-non-small-cell-lung-cancer-1026553603,negative,0.9050644636154175
567,6/5/2018 12:51:56 PM,Eli Lilly: FDA Expands ALIMTA Label To Include Combination With KEYTRUD ,RTTNews,/news/stocks/eli-lilly-fda-expands-alimta-label-to-include-combination-with-keytrud-1026553625,negative,0.8763241767883301
568,6/5/2018 4:15:00 PM,DDW 2018: Patients with Moderate-to-Severe Ulcerative Colitis Achieved Clinical and Endoscopic Remission with Mirikizumab in Phase 2 Trial,PR Newswire,/news/stocks/ddw-2018-patients-with-moderate-to-severe-ulcerative-colitis-achieved-clinical-and-endoscopic-remission-with-mirikizumab-in-phase-2-trial-1026573276,negative,0.9330452084541321
569,6/5/2018 8:53:00 PM,Lilly Recommends Shareholders Reject Below-Market Mini-Tender Offer by TRC Capital Corp.,PR Newswire,/news/stocks/lilly-recommends-shareholders-reject-below-market-mini-tender-offer-by-trc-capital-corp-1026600910,positive,0.6383914947509766
570,6/11/2018 12:45:00 PM,"Lilly to Unveil New Data at the Annual European Congress of Rheumatology, Furthering Commitment to Scientific Discovery in Immunology",PR Newswire,/news/stocks/lilly-to-unveil-new-data-at-the-annual-european-congress-of-rheumatology-furthering-commitment-to-scientific-discovery-in-immunology-1026834212,negative,0.882249116897583
571,6/11/2018 12:53:06 PM,Eli Lilly To Present New Data From Its Immunology Portfolio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-present-new-data-from-its-immunology-portfolio-quick-facts-1026834226,positive,0.8506288528442383
572,6/11/2018 1:00:00 PM,Elanco Animal Health Introduces New Respiratory PRRS Vaccine,PR Newswire,/news/stocks/elanco-animal-health-introduces-new-respiratory-prrs-vaccine-1026834355,positive,0.60894775390625
573,6/12/2018 8:00:00 AM,Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease,PR Newswire,/news/stocks/update-on-phase-3-clinical-trials-of-lanabecestat-for-alzheimer-s-disease-1026857734,positive,0.9046880602836609
574,6/12/2018 8:16:31 AM,"AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's ",RTTNews,/news/stocks/astrazeneca-eli-lilly-to-discontinue-lanabecestat-trials-in-alzheimer-s-1026858002,positive,0.5488573908805847
575,6/13/2018 7:45:47 AM,"CAH Closer To FDA Approval, Another Alzheimer's Disease Drug Fails, VTVT Tanks ",RTTNews,/news/stocks/cah-closer-to-fda-approval-another-alzheimer-s-disease-drug-fails-vtvt-tanks-1026908489,negative,0.6741431951522827
576,6/18/2018 10:27:00 PM,Lilly Declares Third-Quarter 2018 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2018-dividend-1027177119,positive,0.8834538459777832
577,6/23/2018 3:58:14 PM,Eli Lilly: Trulicity Phase 2 Data Shows Efficacy In People With Type 2 Diabetes ,RTTNews,/news/stocks/eli-lilly-trulicity-phase-2-data-shows-efficacy-in-people-with-type-2-diabetes-1027312332,negative,0.9285315275192261
578,6/23/2018 8:20:16 PM,Eli Lilly: Lispro Shows Improved Blood Sugar Control In Phase 1b Studies ,RTTNews,/news/stocks/eli-lilly-lispro-shows-improved-blood-sugar-control-in-phase-1b-studies-1027312415,negative,0.9537867903709412
579,6/23/2018 9:19:19 PM,Eli Lilly: Jardiance Reduces Risk Of Kidney Disease Progression In Diabetes ,RTTNews,/news/stocks/eli-lilly-jardiance-reduces-risk-of-kidney-disease-progression-in-diabetes-1027312421,negative,0.8158531785011292
580,6/25/2018 5:21:12 AM,"LLY Scores Win In Alimta Patent Suit, LXRX For The Long Haul, MNKD Breathes Easy ",RTTNews,/news/stocks/lly-scores-win-in-alimta-patent-suit-lxrx-for-the-long-haul-mnkd-breathes-easy-1027312812,negative,0.8831096291542053
581,6/25/2018 12:59:54 PM,"Eli Lilly To Present Phase 3 Data For Galcanezumab, Lasmiditan - Quick Facts ",RTTNews,/news/stocks/eli-lilly-to-present-phase-3-data-for-galcanezumab-lasmiditan-quick-facts-1027314032,positive,0.8317787051200867
582,6/25/2018 2:19:15 PM,Boehringer Ingelheim & Eli Lilly: Empagliflozin Trials Meet Primary Endpoint ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-empagliflozin-trials-meet-primary-endpoint-1027314563,negative,0.5704441666603088
583,6/25/2018 2:51:33 PM,Eli Lilly: Humulin R U-500 Administered In Insulin Pump Shows Improved A1C ,RTTNews,/news/stocks/eli-lilly-humulin-r-u-500-administered-in-insulin-pump-shows-improved-a1c-1027314738,negative,0.9560748338699341
584,6/28/2018 8:03:05 AM,"ACRX Gets EC Nod, AQXP Tanks As LEADERSHIP 301 Fails, ZSAN Catches Eye ",RTTNews,/news/stocks/acrx-gets-ec-nod-aqxp-tanks-as-leadership-301-fails-zsan-catches-eye-1027324885,neutral,0.6022970080375671
585,7/18/2018 12:55:49 PM,Pfizer And Lilly Announce Positive Results From Phase 3 Trial Of Tanezumab ,RTTNews,/news/stocks/pfizer-and-lilly-announce-positive-results-from-phase-3-trial-of-tanezumab-1027377487,negative,0.87937992811203
586,7/19/2018 2:14:55 PM,Lilly: Tradjenta's CARMELINA Cardiovascular Outcome Trial Meets Primary Endpoint ,RTTNews,/news/stocks/lilly-tradjenta-s-carmelina-cardiovascular-outcome-trial-meets-primary-endpoint-1027382111,negative,0.7587738037109375
587,7/23/2018 3:01:43 PM,Eli Lilly and is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1027389862,positive,0.9341102242469788
588,7/24/2018 12:31:50 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1027393216,negative,0.8854392170906067
589,7/24/2018 12:47:34 PM,Eli Lilly Revises Guidance; To Pursue IPO Of Elanco - Quick Facts ,RTTNews,/news/stocks/eli-lilly-revises-guidance-to-pursue-ipo-of-elanco-quick-facts-1027393284,positive,0.8231827020645142
590,7/24/2018 4:52:00 PM,Eli Lilly and Company -- Moody's: Lilly's planned separation of Elanco is credit negative,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-planned-separation-of-elanco-is-credit-negative-1027395121,positive,0.8420889377593994
591,8/2/2018 11:54:40 PM,Elanco Animal Health Files Registration Statement For IPO - Quick Facts ,RTTNews,/news/stocks/elanco-animal-health-files-registration-statement-for-ipo-quick-facts-1027428046,positive,0.9423864483833313
592,8/31/2018 12:05:59 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1027499929,positive,0.6874357461929321
593,9/20/2018 3:00:11 AM,Lilly's Elanco Animal Health Prices IPO Of 62.9 Mln Shares At $24.00/shr ,RTTNews,/news/stocks/lilly-s-elanco-animal-health-prices-ipo-of-62-9-mln-shares-at-24-00-shr-1027549293,positive,0.9327084422111511
594,9/21/2018 1:59:57 PM,Lilly' Emgality Gets Positive CHMP Opinion For Prophylaxis Of Migraine In Adults ,RTTNews,/news/stocks/lilly-emgality-gets-positive-chmp-opinion-for-prophylaxis-of-migraine-in-adults-1027554576,negative,0.951697587966919
595,9/28/2018 2:52:53 AM,FDA Approves Lilly's Emgality For Preventive Treatment Of Migraine In Adults ,RTTNews,/news/stocks/fda-approves-lilly-s-emgality-for-preventive-treatment-of-migraine-in-adults-1027572913,negative,0.7519612908363342
596,9/28/2018 3:45:03 AM,A new medication that's changing the way we treat a condition that affects 38 million Americans just got approved (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-migraine-drug-emgality-approved-by-fda-2018-9,positive,0.7473967671394348
597,10/2/2018 12:58:43 PM,Eli Lilly: Phase 3 Studies Show URLi Meets Primary Efficacy Endpoint ,RTTNews,/news/stocks/eli-lilly-phase-3-studies-show-urli-meets-primary-efficacy-endpoint-1027582521,negative,0.911189079284668
598,10/4/2018 12:51:16 PM,Boehringer Ingelheim & Eli Lilly: Empagliflozin Meets Primary Efficacy Endpoint ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-empagliflozin-meets-primary-efficacy-endpoint-1027589821,negative,0.8620214462280273
599,10/4/2018 8:00:05 PM,Eli Lilly stock gets bump after results for its mid-stage diabetes drug trial show positive results (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-stock-gets-bump-after-drug-trial-positive-results-2018-10,negative,0.9178339838981628
600,10/22/2018 4:25:03 AM,Lilly And Incyte Update Safety Analysis Of OLUMIANT ,RTTNews,/news/stocks/lilly-and-incyte-update-safety-analysis-of-olumiant-1027636343,positive,0.9261642098426819
601,10/24/2018 7:39:15 AM,"CMTA Fast Tracks NDA Filing, USNA In Good Health, DERM To Report Data In Apr. ",RTTNews,/news/stocks/cmta-fast-tracks-nda-filing-usna-in-good-health-derm-to-report-data-in-apr-1027647548,positive,0.47431284189224243
602,10/29/2018 1:11:21 PM,Dicerna Stock Surges On RNAi Deal With Lilly ,RTTNews,/news/stocks/dicerna-stock-surges-on-rnai-deal-with-lilly-1027665366,neutral,0.7060533165931702
603,10/31/2018 9:23:57 AM,"Dr. Reddy's Launches Atomoxetine Capsules, Generic Version Of Strattera, In U.S. ",RTTNews,/news/stocks/dr-reddy-s-launches-atomoxetine-capsules-generic-version-of-strattera-in-u-s-1027674796,positive,0.6489608883857727
604,11/5/2018 1:09:27 PM,Eli Lilly: REWIND Trial Demonstrates MACE Reduction By Trulicity - Quick Facts ,RTTNews,/news/stocks/eli-lilly-rewind-trial-demonstrates-mace-reduction-by-trulicity-quick-facts-1027690457,negative,0.816718578338623
605,11/5/2018 3:02:36 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q3-quarterly-earnings-preview-1027691145,positive,0.9387240409851074
606,11/6/2018 1:04:14 PM,Eli Lilly Q3 Results Beat View; Lifts FY18 Outlook ,RTTNews,/news/stocks/eli-lilly-q3-results-beat-view-lifts-fy18-outlook-1027695886,negative,0.9358175992965698
607,12/12/2018 12:13:14 PM,Lilly And AC Immune Enter Into License And Collaboration Agreement ,RTTNews,/news/stocks/lilly-and-ac-immune-enter-into-license-and-collaboration-agreement-1027801850,negative,0.7403958439826965
608,12/13/2018 12:58:22 PM,Eli Lilly : FDA Grants Fast Track Designation To Baricitinib Development Program ,RTTNews,/news/stocks/eli-lilly-fda-grants-fast-track-designation-to-baricitinib-development-program-1027806092,negative,0.9070156812667847
609,12/17/2018 1:00:38 PM,Eli Lilly: Taltz Meets Primary And Secondary Endpoints In Spirit-H2H Study ,RTTNews,/news/stocks/eli-lilly-taltz-meets-primary-and-secondary-endpoints-in-spirit-h2h-study-1027813489,negative,0.8287187814712524
610,12/19/2018 1:02:49 PM,Lilly Sees FY19 Results Above View; Hikes Dividend ,RTTNews,/news/stocks/lilly-sees-fy19-results-above-view-hikes-dividend-1027821066,negative,0.5221154689788818
611,12/19/2018 6:48:58 PM,Eli Lilly Pulls Back Off Best Levels But Remains Firmly Positive ,RTTNews,/news/stocks/eli-lilly-pulls-back-off-best-levels-but-remains-firmly-positive-1027822751,negative,0.8991411924362183
612,12/27/2018 8:47:47 AM,"Innovent, Lilly Co-developed Tyvyt Gets China's NMPA Approval For CHL ",RTTNews,/news/stocks/innovent-lilly-co-developed-tyvyt-gets-china-s-nmpa-approval-for-chl-1027833166,negative,0.9062929749488831
613,1/7/2019 12:52:33 PM,Lilly To Buy Loxo Oncology In $8.0 Bln Deal ,RTTNews,/news/stocks/lilly-to-buy-loxo-oncology-in-8-0-bln-deal-1027847015,positive,0.8948747515678406
614,1/7/2019 7:53:00 PM,Eli Lilly and Company -- Moody's affirms Eli Lilly's A2/P-1 ratings; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-affirms-eli-lilly-s-a2-p-1-ratings-stable-outlook-1027848947,negative,0.8957984447479248
615,1/18/2019 5:15:09 AM,"FDA Turns Down IMMU's Breast Cancer Drug, MGNX/LLY Deal Progresses, ZFGN Abuzz ",RTTNews,/news/stocks/fda-turns-down-immu-s-breast-cancer-drug-mgnx-lly-deal-progresses-zfgn-abuzz-1027878304,neutral,0.731471061706543
616,1/18/2019 1:27:40 PM,Lilly : Phase 3 Soft Tissue Sarcoma Study Fails Not Meet Primary Endpoints ,RTTNews,/news/stocks/lilly-phase-3-soft-tissue-sarcoma-study-fails-not-meet-primary-endpoints-1027879277,neutral,0.9612579941749573
617,1/29/2019 12:39:19 PM,"Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain ",RTTNews,/news/stocks/pfizer-lilly-announce-results-from-phase-3-study-of-tanezumab-in-oa-pain-1027904214,negative,0.5303031802177429
618,2/1/2019 1:00:44 PM,"Eli Lilly, Loxo Oncology Report Expiration Of HSR Act Waiting Period ",RTTNews,/news/stocks/eli-lilly-loxo-oncology-report-expiration-of-hsr-act-waiting-period-1027916192,positive,0.5037455558776855
619,2/4/2019 12:52:11 PM,Lilly : Baricitinib Meets Primary Endpoint In BREEZE-AD1 And BREEZE-AD2 ,RTTNews,/news/stocks/lilly-baricitinib-meets-primary-endpoint-in-breeze-ad1-and-breeze-ad2-1027920368,negative,0.8698106408119202
620,2/4/2019 3:02:00 PM,What Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q4-quarterly-earnings-preview-1027920992,positive,0.9346717596054077
621,2/6/2019 12:28:49 PM,Eli Lilly And Co. Q4 adjusted earnings Miss Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-miss-estimates-1027928952,neutral,0.9573677182197571
622,2/6/2019 12:48:46 PM,Eli Lilly Lowers FY19 Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-lowers-fy19-outlook-quick-facts-1027929033,neutral,0.9214228987693787
623,2/8/2019 1:17:44 PM,Eli Lilly To Divest Remaining Stake In Elanco Animal Health Via Exchange Offer ,RTTNews,/news/stocks/eli-lilly-to-divest-remaining-stake-in-elanco-animal-health-via-exchange-offer-1027936747,positive,0.9504658579826355
624,2/8/2019 2:00:22 PM,Elanco Animal Health To File Registration Statement On Lilly Divestiture ,RTTNews,/news/stocks/elanco-animal-health-to-file-registration-statement-on-lilly-divestiture-1027936863,positive,0.9327926635742188
625,2/8/2019 7:28:00 PM,Eli Lilly and Company -- Moody's: Lilly's animal health divestiture will reduce scale and diversity,Moodys,/news/bonds/eli-lilly-and-company-moody-s-lilly-s-animal-health-divestiture-will-reduce-scale-and-diversity-1027937747,neutral,0.6300684213638306
626,2/15/2019 10:09:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1027957884,positive,0.8798279762268066
627,2/15/2019 10:20:00 PM,Elanco Animal Health Incorporated -- Moody's announces completion of a periodic review of ratings of Elanco Animal Health Incorporated,Moodys,/news/bonds/elanco-animal-health-incorporated-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-elanco-animal-health-incorporated-1027957917,positive,0.8829481601715088
628,2/19/2019 12:55:51 PM,Eli Lilly: Tanezumab 10 Mg Meets Primary Endpoint In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-tanezumab-10-mg-meets-primary-endpoint-in-phase-3-study-quick-facts-1027963149,negative,0.6266610026359558
629,2/20/2019 4:12:00 PM,Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's notes; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-assigns-a2-rating-to-eli-lilly-s-notes-stable-outlook-1027968672,negative,0.7222816944122314
630,3/1/2019 1:07:07 PM,"Lilly To Present Data For Taltz, Mirikizumab At AAD Annual Meeting ",RTTNews,/news/stocks/lilly-to-present-data-for-taltz-mirikizumab-at-aad-annual-meeting-1027996687,positive,0.93385910987854
631,3/4/2019 12:41:36 PM,Eli Lilly To Introduce Lower-priced Version Of Insulin Humalog - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-introduce-lower-priced-version-of-insulin-humalog-quick-facts-1028000383,positive,0.8016512989997864
632,3/4/2019 4:21:03 PM,A drugmaker just released a half-price version of a life-saving diabetes medication in a bet that a lower price tag will help it escape the political crosshairs (LLY),Business Insider,https://www.businessinsider.com/eli-lilly-cuts-price-of-humalog-insulin-by-50-through-authorized-generic-2019-3,negative,0.93804532289505
633,3/4/2019 11:12:06 PM,"A drugmaker just slashed the price of its life-saving medication by 50%, but people are worried the $137 price tag is still unaffordable (LLY)",Business Insider,https://www.businessinsider.com/lillys-50-price-cut-to-insulin-humalog-is-still-unaffordable-2019-3,neutral,0.9199522137641907
634,3/5/2019 1:00:51 PM,Lilly Gets FDA Priority Review Designation For Emgality Injection - Quick Facts ,RTTNews,/news/stocks/lilly-gets-fda-priority-review-designation-for-emgality-injection-quick-facts-1028004391,negative,0.7302911877632141
635,3/11/2019 12:10:20 PM,Eli Lilly: Elanco Exchange Offer Oversubscribed - Quick Facts ,RTTNews,/news/stocks/eli-lilly-elanco-exchange-offer-oversubscribed-quick-facts-1028018614,positive,0.8378238081932068
636,3/12/2019 12:05:54 PM,Eli Lilly: Phase 3 RELAY Study With CYRAMZA Meets Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-phase-3-relay-study-with-cyramza-meets-primary-endpoint-quick-facts-1028022486,positive,0.7602878212928772
637,3/13/2019 11:56:12 AM,Elanco Appoints Four Members To Board ,RTTNews,/news/stocks/elanco-appoints-four-members-to-board-1028026375,positive,0.9449424147605896
638,3/26/2019 10:30:16 PM,"Lilly, ImmuNext Sign Licensing And Research Agreement ",RTTNews,/news/stocks/lilly-immunext-sign-licensing-and-research-agreement-1028060919,negative,0.615807294845581
639,3/27/2019 9:59:02 AM,"Dr. Reddy's Labs Launches Tadalafil Tablets, Generic Version Of Cialis, In U.S. ",RTTNews,/news/stocks/dr-reddy-s-labs-launches-tadalafil-tablets-generic-version-of-cialis-in-u-s-1028061852,negative,0.5371807217597961
640,4/1/2019 11:35:32 AM,Royalty Pharma Buys Royalty Of Eli Lilly's Emgality From Arteaus For $260 Mln ,RTTNews,/news/stocks/royalty-pharma-buys-royalty-of-eli-lilly-s-emgality-from-arteaus-for-260-mln-1028073761,positive,0.9183142781257629
641,4/1/2019 2:58:21 PM,Merck Announces Post-hoc Analysis From KEYNOTE-189 Trial - Quick Facts ,RTTNews,/news/stocks/merck-announces-post-hoc-analysis-from-keynote-189-trial-quick-facts-1028074699,positive,0.9402921795845032
642,4/22/2019 1:00:29 PM,"Eli Lilly, Avidity Collaborate To Develop New Medicines In Immunology ",RTTNews,/news/stocks/eli-lilly-avidity-collaborate-to-develop-new-medicines-in-immunology-1028125831,positive,0.5563275218009949
643,4/22/2019 1:46:54 PM,Eli Lilly Reports Positive Top-line Results From Phase 3 Study Of Taltz ,RTTNews,/news/stocks/eli-lilly-reports-positive-top-line-results-from-phase-3-study-of-taltz-1028125955,negative,0.9510924816131592
644,4/29/2019 3:02:37 PM,Eli Lilly and earnings preview: what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-q1-earnings-preview-1028148484,positive,0.936410129070282
645,4/30/2019 12:29:04 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1028152591,negative,0.9003615379333496
646,4/30/2019 12:51:54 PM,Eli Lilly Updates 2019 Guidance To Reflect Elanco Disposition - Quick Facts ,RTTNews,/news/stocks/eli-lilly-updates-2019-guidance-to-reflect-elanco-disposition-quick-facts-1028152679,positive,0.925647497177124
647,4/30/2019 2:07:16 PM,Incyte To No Longer Participate In Co-funding Of Development Of Baricitinib ,RTTNews,/news/stocks/incyte-to-no-longer-participate-in-co-funding-of-development-of-baricitinib-1028153188,positive,0.9280421137809753
648,5/13/2019 1:10:07 PM,Eli Lilly Announces FDA Approval Of CYRAMZA For New Indication - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-fda-approval-of-cyramza-for-new-indication-quick-facts-1028194198,positive,0.7214550971984863
649,5/28/2019 2:11:11 PM,Eli Lilly To Acquire Global Rights For Non-Opioid Pain Asset From Centrexion ,RTTNews,/news/stocks/eli-lilly-to-acquire-global-rights-for-non-opioid-pain-asset-from-centrexion-1028235024,positive,0.5547998547554016
650,5/28/2019 2:18:35 PM,Eli Lilly Licenses Early-phase Molecule From Centrexion To Treat Chronic Pain ,RTTNews,/news/stocks/eli-lilly-licenses-early-phase-molecule-from-centrexion-to-treat-chronic-pain-1028235053,negative,0.643551230430603
651,6/4/2019 1:41:24 PM,FDA Accepts NDA For Triple Combination Tablet For Adults With Type 2 Diabetes ,RTTNews,/news/stocks/fda-accepts-nda-for-triple-combination-tablet-for-adults-with-type-2-diabetes-1028252127,negative,0.5163441896438599
652,6/5/2019 3:25:07 AM,Lilly : FDA Approves Emgality To Treat Episodic Cluster Headache In Adults ,RTTNews,/news/stocks/lilly-fda-approves-emgality-to-treat-episodic-cluster-headache-in-adults-1028254538,negative,0.9069287180900574
653,6/11/2019 9:18:35 AM,Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts ,RTTNews,/news/stocks/lilly-reports-positive-results-from-taltz-5-yr-study-quick-facts-1028268598,negative,0.9491420984268188
654,6/14/2019 1:17:22 PM,Eli Lilly Reports Positive Results From Phase 3b/4 Study Of Taltz - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-phase-3b-4-study-of-taltz-quick-facts-1028280046,negative,0.9487969279289246
655,6/26/2019 12:20:00 PM,Eli Lilly: FDA Grants Fast Track Designation To Empagliflozin - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-grants-fast-track-designation-to-empagliflozin-quick-facts-1028308830,negative,0.8754526972770691
656,6/26/2019 1:09:19 PM,Eli Lilly: Trulicity AWARD-11 Trial Meets Endpoints - Quick Facts ,RTTNews,/news/stocks/eli-lilly-trulicity-award-11-trial-meets-endpoints-quick-facts-1028309097,positive,0.862087607383728
657,6/27/2019 12:34:54 PM,"3 Big Stock Charts for Thursday: H & R Block, Boeing and Eli Lilly",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-lly-ba-hrb-1028315917,positive,0.9039901494979858
658,7/9/2019 1:05:35 PM,"3 Big Stock Charts for Tuesday: Eli Lilly, SYSCO and Interpublic Group",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-eli-lilly-sysco-and-interpublic-group-1028340756,positive,0.9173672795295715
659,7/11/2019 7:00:51 PM,4 Drug Stocks Getting Smashed,InvestorPlace,/news/stocks/4-drug-stocks-getting-smashed-1028347976,negative,0.3786204159259796
660,7/12/2019 1:33:44 PM,Eli Lilly To Present Post-hoc Analyses On Emgality Compared To Placebo ,RTTNews,/news/stocks/eli-lilly-to-present-post-hoc-analyses-on-emgality-compared-to-placebo-1028348887,positive,0.6696959137916565
661,7/25/2019 9:27:18 AM,First Needle-free Treatment For Severe Hypoglycemia Gets FDA Nod ,RTTNews,/news/stocks/first-needle-free-treatment-for-severe-hypoglycemia-gets-fda-nod-1028383560,positive,0.7175700068473816
662,7/25/2019 12:10:53 PM,"GEMP Gets Facelift, Castle Bio To Debut Today, What's The Buzz About Baqsimi? ",RTTNews,/news/stocks/gemp-gets-facelift-castle-bio-to-debut-today-what-s-the-buzz-about-baqsimi-1028384130,positive,0.9065386056900024
663,7/26/2019 3:53:32 PM,"Notable Earnings To Watch Next Week - LLY, AAPL, PG, MRK, PFE, CVX ",RTTNews,/news/stocks/notable-earnings-to-watch-next-week-lly-aapl-pg-mrk-pfe-cvx-1028388673,positive,0.7602753639221191
664,7/29/2019 3:02:47 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1028393689,positive,0.9291529059410095
665,7/30/2019 12:30:29 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1028397681,negative,0.8854392170906067
666,7/30/2019 12:39:19 PM,Eli Lilly Raises FY19 Earnings Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-raises-fy19-earnings-outlook-quick-facts-1028397734,positive,0.6839452385902405
667,8/5/2019 1:03:12 PM,Eli Lilly: Emgality Meets Endpoints In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-emgality-meets-endpoints-in-phase-3-study-quick-facts-1028416801,negative,0.5951659679412842
668,8/7/2019 1:03:07 PM,Eli Lilly Announces Several Leadership Changes - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-several-leadership-changes-quick-facts-1028425928,positive,0.8975715041160583
669,8/8/2019 3:17:33 PM,Lilly Says Emgality Meets Primary And Secondary Outcomes In CONQUER Study ,RTTNews,/news/stocks/lilly-says-emgality-meets-primary-and-secondary-outcomes-in-conquer-study-1028431201,positive,0.6120874881744385
670,8/13/2019 1:17:45 PM,Eli Lilly: Taltz Shows Efficacy In Phase 4 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-taltz-shows-efficacy-in-phase-4-study-quick-facts-1028441379,negative,0.8821551203727722
671,8/23/2019 6:37:40 PM,Will Lawsuits Sink Johnson & Johnson Stock?,InvestorPlace,/news/stocks/lawsuits-jnj-stock-probably-not-1028470702,neutral,0.6193097829818726
672,8/26/2019 12:55:02 PM,Lilly : FDA Approves Taltz To Treat Active Ankylosing Spondylitis ,RTTNews,/news/stocks/lilly-fda-approves-taltz-to-treat-active-ankylosing-spondylitis-1028472709,negative,0.9042730331420898
673,9/9/2019 9:43:20 AM,Eli Lilly Reports Positive Results From Selpercatinib Trial - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-selpercatinib-trial-quick-facts-1028507827,negative,0.944675624370575
674,9/10/2019 2:55:17 PM,10 Healthcare Stocks to Buy Despite the Headlines,InvestorPlace,/news/stocks/10-healthcare-stocks-to-buy-despite-the-headlines-1028514931,positive,0.49671414494514465
675,9/20/2019 1:26:11 PM,Lilly : CHMP Issues Positive Opinion To Expand Trulicity Label ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-to-expand-trulicity-label-1028540642,negative,0.9508929252624512
676,9/23/2019 1:12:08 PM,Lilly To Present Data Across Its Oncology Product Portfolio ,RTTNews,/news/stocks/lilly-to-present-data-across-its-oncology-product-portfolio-1028544292,positive,0.7987229228019714
677,10/3/2019 1:05:34 PM,Eli Lilly: Taltz Shows Superiority At Week 12 Of Phase 4 IXORA-R Study ,RTTNews,/news/stocks/eli-lilly-taltz-shows-superiority-at-week-12-of-phase-4-ixora-r-study-1028573567,negative,0.9443488121032715
678,10/3/2019 3:41:34 PM,Eli Lilly Shares To Be Delisted From Euronext Paris On Oct. 31 - Quick Facts ,RTTNews,/news/stocks/eli-lilly-shares-to-be-delisted-from-euronext-paris-on-oct-31-quick-facts-1028574388,positive,0.9213414192199707
679,10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887,positive,0.9226393103599548
680,10/9/2019 11:15:46 AM,"3 Big Stock Charts for Wednesday: General Mills, Eli Lilly and Hartford Financial Services",InvestorPlace,/news/stocks/3-big-stock-charts-for-wednesday-general-mills-eli-lilly-and-hartford-financial-services-1028588734,positive,0.9361486434936523
681,10/14/2019 3:13:21 PM,FDA Approves Reyvow Tablets To Treat Migraine ,RTTNews,/news/stocks/fda-approves-reyvow-tablets-to-treat-migraine-1028596616,negative,0.7882925271987915
682,10/16/2019 1:11:06 PM,Lilly Says Phase 3 SEQUOIA Study Did Not Meet Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/lilly-says-phase-3-sequoia-study-did-not-meet-primary-endpoint-quick-facts-1028603135,neutral,0.8250056505203247
683,10/22/2019 3:01:31 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-stock-1028618955,positive,0.9319095611572266
684,10/22/2019 5:23:57 PM,5 Healthcare Stocks to Buy,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-2-1028620498,positive,0.8994204998016357
685,10/23/2019 12:31:10 PM,Eli Lilly And Co. Q3 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q3-adjusted-earnings-beat-estimates-1028622377,negative,0.888725221157074
686,10/23/2019 12:32:14 PM,Eli Lilly Boosts FY19 Earnings Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-boosts-fy19-earnings-outlook-quick-facts-1028622376,negative,0.9266737699508667
687,10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304,positive,0.905576229095459
688,10/29/2019 10:48:00 AM,Eli Lilly and Company -- Moody's assigns A2 rating to Eli Lilly's euro notes; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-assigns-a2-rating-to-eli-lilly-s-euro-notes-stable-outlook-1028638218,negative,0.8011042475700378
689,10/31/2019 11:27:44 AM,"3 Big Stock Charts for Thursday: Merck, Anheuser-Busch InBev, and PPG Industries",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-merck-anheuser-busch-inbev-ppg-industries-1028648405,positive,0.916330873966217
690,11/1/2019 6:16:10 PM,"The Good, Bad, and Ugly for Biogen Stock",InvestorPlace,/news/stocks/the-good-bad-and-ugly-for-biogen-stock-1028652569,positive,0.5726682543754578
691,11/1/2019 8:24:18 PM,WeWork IPO was a Failure – These 2 IPO Stocks are Surging,InvestorPlace,/news/stocks/wework-ipo-was-a-failure-these-2-ipo-stocks-are-surging-1028652783,neutral,0.949650228023529
692,11/4/2019 3:23:09 PM,Boehringer Ingelheim - Lilly Alliance To Focus Full Expertise On Jardiance ,RTTNews,/news/stocks/boehringer-ingelheim-lilly-alliance-to-focus-full-expertise-on-jardiance-1028655365,positive,0.6457117795944214
693,11/12/2019 12:56:11 PM,Lilly Says Phase 3 Study Of Taltz Meets Primary & All Major Secondary Endpoints ,RTTNews,/news/stocks/lilly-says-phase-3-study-of-taltz-meets-primary-all-major-secondary-endpoints-1028680102,negative,0.639778196811676
694,11/17/2019 7:27:06 PM,Lilly Announces Interim Analysis From EMPRISE Real-world Study ,RTTNews,/news/stocks/lilly-announces-interim-analysis-from-emprise-real-world-study-1028694769,positive,0.9026693105697632
695,11/20/2019 12:40:13 PM,Lilly Plans To Invest $400 Mln In Manufacturing Facilities In Indianapolis ,RTTNews,/news/stocks/lilly-plans-to-invest-400-mln-in-manufacturing-facilities-in-indianapolis-1028703519,positive,0.8084639310836792
696,11/25/2019 11:37:00 AM,Moody's  - Novo Nordisk cements its position in the big league after FDA approves new diabetes drug,Moodys,/news/bonds/moody-s-novo-nordisk-cements-its-position-in-the-big-league-after-fda-approves-new-diabetes-drug-1028714115,negative,0.9515080451965332
697,12/5/2019 12:42:19 PM,Lilly Announces New Leadership In Oncology R&D ,RTTNews,/news/stocks/lilly-announces-new-leadership-in-oncology-r-d-1028740135,positive,0.5850476622581482
698,12/9/2019 3:39:38 AM,Lilly Presents Interim Data From Trial In B-Cell Leukemias And Lymphomas ,RTTNews,/news/stocks/lilly-presents-interim-data-from-trial-in-b-cell-leukemias-and-lymphomas-1028745937,positive,0.912886917591095
699,12/13/2019 12:56:48 PM,What to Do with Karuna Stock After It Soared and Then Plunged,InvestorPlace,/news/stocks/karuna-stock-soared-and-plunged-1028762057,positive,0.9301010370254517
700,12/13/2019 1:04:57 PM,Lilly : CHMP Issues Positive Opinion To Expand Cyramza Label ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-to-expand-cyramza-label-1028761852,negative,0.939216673374176
701,12/13/2019 2:22:39 PM,Lilly Updates On Jardiance Exercise Ability Studies In Chronic Heart Failure ,RTTNews,/news/stocks/lilly-updates-on-jardiance-exercise-ability-studies-in-chronic-heart-failure-1028762101,positive,0.8737440705299377
702,12/16/2019 1:00:57 PM,Lilly To Include Dexcom's Technology Into Its Diabetes Management System ,RTTNews,/news/stocks/lilly-to-include-dexcom-s-technology-into-its-diabetes-management-system-1028765048,positive,0.6634654998779297
703,12/17/2019 12:34:22 PM,Drugs That Missed Key Goals In Phase III Trials ,RTTNews,/news/stocks/drugs-that-missed-key-goals-in-phase-iii-trials-1028768208,positive,0.49023494124412537
704,12/17/2019 12:49:13 PM,"Eli Lilly Reaffirms FY19 Adj. EPS, Revenue Outlook - Quick Facts ",RTTNews,/news/stocks/eli-lilly-reaffirms-fy19-adj-eps-revenue-outlook-quick-facts-1028768250,positive,0.8650804162025452
705,12/17/2019 2:27:25 PM,Collect on the Pharmaceutical Boom With Eli Lilly,InvestorPlace,/news/stocks/collect-pharmaceutical-boom-eli-lilly-lly-1028769423,positive,0.910460889339447
706,12/17/2019 9:25:49 PM,Stock Market Today: Roku’s CFO Stepping Down; Buy Microsoft?,InvestorPlace,/news/stocks/stock-market-today-roku-cfo-buy-microsoft-stock-1028770587,positive,0.6185455918312073
707,12/18/2019 1:00:02 PM,Lilly Launches Real-World Evidence Study Of Emgality On Migraine ,RTTNews,/news/stocks/lilly-launches-real-world-evidence-study-of-emgality-on-migraine-1028771779,positive,0.7769995927810669
708,1/10/2020 12:45:03 PM,Lilly To Acquire Dermira In $1.1 Bln Deal - Quick Facts ,RTTNews,/news/stocks/lilly-to-acquire-dermira-in-1-1-bln-deal-quick-facts-1028808907,positive,0.8964062929153442
709,1/14/2020 7:03:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1028817192,positive,0.8798279762268066
710,1/15/2020 4:37:07 PM,Pfizer Stock Offers Good Value to Patient Investors,InvestorPlace,/news/stocks/pfizer-stock-offers-good-value-investors-1028820483,negative,0.7911884784698486
711,1/16/2020 1:27:17 PM,"Beyond the Growing Dividend, Abbvie Stock Is a Good Buy Here",InvestorPlace,/news/stocks/growing-dividend-abbvie-stock-good-buy-1028823662,negative,0.8297058343887329
712,1/27/2020 12:57:19 PM,Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028846153,negative,0.914971113204956
713,1/28/2020 2:12:13 AM,FDA Oks Triple-combination Tablet With Jardiance For Adults With Type 2 Diabetes ,RTTNews,/news/stocks/fda-oks-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes-1028848360,negative,0.5496453642845154
714,1/28/2020 3:41:09 AM,"XLRN Soars, FDA Approves Triple Combo Pill For Type 2 Diabetes, MGEN On Watch ",RTTNews,/news/stocks/xlrn-soars-fda-approves-triple-combo-pill-for-type-2-diabetes-mgen-on-watch-1028848386,negative,0.8125909566879272
715,1/29/2020 11:00:56 AM,Why Teva Stock Could Be the Next General Electric Stock,InvestorPlace,/news/stocks/teva-stock-next-general-electric-1028854259,positive,0.9428749084472656
716,1/29/2020 3:02:11 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-q4-earnings-preview-stock-1028855403,positive,0.9245331287384033
717,1/30/2020 3:44:30 AM,"CABA Hits New High, IMMP On Watch, SBPH Drops CATALYST ",RTTNews,/news/stocks/caba-hits-new-high-immp-on-watch-sbph-drops-catalyst-1028857403,neutral,0.5361455082893372
718,1/30/2020 12:32:02 PM,Eli Lilly And Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-beat-estimates-1028858989,negative,0.9041681289672852
719,1/30/2020 12:41:58 PM,Eli Lilly FY20 Non-GAAP Earnings Outlook Unchanged - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fy20-non-gaap-earnings-outlook-unchanged-quick-facts-1028859032,positive,0.7509714365005493
720,1/30/2020 12:47:34 PM,"Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study ",RTTNews,/news/stocks/eli-lilly-incyte-baricitinib-meets-primary-endpoint-in-breeze-ad5-study-1028859050,negative,0.9164578318595886
721,1/31/2020 12:27:53 PM,Lilly Receives Positive CHMP Opinion For New Mealtime Insulin ,RTTNews,/news/stocks/lilly-receives-positive-chmp-opinion-for-new-mealtime-insulin-1028862918,negative,0.9358147382736206
722,2/3/2020 2:15:36 PM,There Are Better Pharmaceutical Names Than Teva Stock,InvestorPlace,/news/stocks/teva-stock-has-rebounded-off-its-lows-but-its-not-a-buy-right-now-1028868411,positive,0.774203360080719
723,2/4/2020 4:40:51 PM,Teva Pharmaceutical Just Got a Little Migraine Relief ,InvestorPlace,/news/stocks/teva-stock-just-got-a-little-migraine-relief-1028873202,neutral,0.9239121079444885
724,2/10/2020 7:20:36 AM,Eli Lilly: DIAN-TU Study With Solanezumab Fails To Meet Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-dian-tu-study-with-solanezumab-fails-to-meet-endpoint-quick-facts-1028887627,neutral,0.932953417301178
725,2/10/2020 3:36:10 PM,Eagle Pharma nabs final FDA nod for Pemfexy,Seeking Alpha,https://seekingalpha.com/news/3540074-eagle-pharma-nabs-final-fda-nod-for-pemfexy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7108278274536133
726,2/10/2020 3:54:36 PM,Stock Alert: Eli Lilly Drops As Alzheimer's Drug Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/stock-alert-eli-lilly-drops-as-alzheimer-s-drug-fails-to-meet-primary-endpoint-1028889581,neutral,0.967850923538208
727,2/11/2020 12:19:34 PM,Lilly's Taltz OK'd in Canada for arthritis of the spine,Seeking Alpha,https://seekingalpha.com/news/3540423-lillys-taltz-okd-in-canada-for-arthritis-of-spine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6260377764701843
728,2/12/2020 3:42:23 AM,Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation ,RTTNews,/news/stocks/lilly-s-study-meets-primary-endpoint-of-75-improvement-of-skin-inflammation-1028895966,negative,0.8651469945907593
729,2/19/2020 2:28:44 PM,FDA Ad Com in April for Lilly imaging agent,Seeking Alpha,https://seekingalpha.com/news/3543254-fda-ad-com-in-april-for-lilly-imaging-agent?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8123184442520142
730,2/20/2020 3:58:47 PM,FDA implements new rule aimed at boosting competition in insulin,Seeking Alpha,https://seekingalpha.com/news/3544009-fda-implements-new-rule-aimed-boosting-competition-in-insulin?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8966698050498962
731,2/21/2020 12:30:11 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3544390-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9446426630020142
732,2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9021157026290894
733,2/24/2020 12:14:25 PM,Eli Lilly's Trulicity approved for new indication,Seeking Alpha,https://seekingalpha.com/news/3544724-eli-lillys-trulicity-approved-for-new-indication?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8503916263580322
734,2/27/2020 2:20:58 AM,FDA Panels Backs Lilly's Cyramza As Treatment For Metastatic EGFR-Mutated NSCLC ,RTTNews,/news/stocks/fda-panels-backs-lilly-s-cyramza-as-treatment-for-metastatic-egfr-mutated-nsclc-1028943503,negative,0.6722171306610107
735,3/2/2020 1:03:08 PM,Pfizer & Eli Lilly: FDA To Review BLA For Tanezumab - Quick Facts ,RTTNews,/news/stocks/pfizer-eli-lilly-fda-to-review-bla-for-tanezumab-quick-facts-1028954544,positive,0.786250114440918
736,3/2/2020 2:56:53 PM,FDA accepts Pfizer application for novel pain med,Seeking Alpha,https://seekingalpha.com/news/3547448-fda-accepts-pfizer-application-for-novel-pain-med?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8187137842178345
737,3/3/2020 12:22:57 PM,Coronavirus outbreak to not affect supply of medicines - Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3547921-coronavirus-outbreak-to-not-affect-supply-of-medicines-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9061515927314758
738,3/3/2020 1:15:05 PM,Eli Lilly Anticipates No Shortages Of Products Due To Coronavirus Impact ,RTTNews,/news/stocks/eli-lilly-anticipates-no-shortages-of-products-due-to-coronavirus-impact-1028958877,positive,0.6209592223167419
739,3/11/2020 4:59:50 PM,Lilly to participate in new Medicare model lowering out-of-pocket insulin costs,Seeking Alpha,https://seekingalpha.com/news/3550626-lilly-to-participate-in-new-medicare-model-lowering-out-of-pocket-insulin-costs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5817734003067017
740,3/12/2020 1:19:54 PM,Boehringer Ingelheim & Eli Lilly: Jardiance Granted FDA Fast Track Designation ,RTTNews,/news/stocks/boehringer-ingelheim-eli-lilly-jardiance-granted-fda-fast-track-designation-1028989427,negative,0.6658742427825928
741,3/13/2020 10:39:42 AM,Lilly in the mix of coronavirus therapy developers,Seeking Alpha,https://seekingalpha.com/news/3551442-lilly-in-mix-of-coronavirus-therapy-developers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8854641318321228
742,3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6742608547210693
743,3/16/2020 11:10:24 AM,FDA grants BTD tag to baricitinib for alopecia areata,Seeking Alpha,https://seekingalpha.com/news/3551919-fda-grants-btd-tag-to-baricitinib-for-alopecia-areata?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7808043360710144
744,3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9542070627212524
745,3/20/2020 8:46:00 PM,FDA rejects Lilly's Jardiance for type 1 diabetes,Seeking Alpha,https://seekingalpha.com/news/3553964-fda-rejects-lillys-jardiance-for-type-1-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4901692867279053
746,3/23/2020 4:00:40 AM,Lilly Offers Free Coronavirus Tests To Indianapolis Health Care Workers ,RTTNews,/news/stocks/lilly-offers-free-coronavirus-tests-to-indianapolis-health-care-workers-1029020877,positive,0.7532588243484497
747,3/23/2020 10:21:55 AM,Companies continue to step up during Covid-19 outbreak,Seeking Alpha,https://seekingalpha.com/news/3554085-companies-continue-to-step-up-during-covidminus-19-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6610246896743774
748,3/23/2020 10:40:29 AM,Lilly pauses enrollment in clinical trials amid coronavirus outbreak,Seeking Alpha,https://seekingalpha.com/news/3554088-lilly-pauses-enrollment-in-clinical-trials-amid-coronavirus-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9496996998786926
749,3/23/2020 11:41:26 AM,Eli Lilly To Delay Most New Study Starts - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-delay-most-new-study-starts-quick-facts-1029021992,neutral,0.5874810814857483
750,3/23/2020 6:12:19 PM,FDA enacts abbreviated approval pathway for insulin biosimilars,Seeking Alpha,https://seekingalpha.com/news/3554323-fda-enacts-abbreviated-approval-pathway-for-insulin-biosimilars?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9039352536201477
751,3/24/2020 1:25:21 PM,Eli Lilly Issues Updates On Insulin Supply - Quick Facts ,RTTNews,/news/stocks/eli-lilly-issues-updates-on-insulin-supply-quick-facts-1029026506,positive,0.9273455142974854
752,3/30/2020 12:54:16 PM,Eli Lilly: Taltz Receives FDA Approval For Treatment Of Pediatric Patients ,RTTNews,/news/stocks/eli-lilly-taltz-receives-fda-approval-for-treatment-of-pediatric-patients-1029043917,negative,0.9271901249885559
753,3/30/2020 8:16:47 PM,Stock Market Today: Healthcare Stocks Leads the Way; Buy Zoom?,InvestorPlace,/news/stocks/stock-market-today-healthcare-stocks-leads-the-way-buy-zoom-1029046564,positive,0.8414232134819031
754,3/31/2020 12:50:18 PM,"Eli Lilly, Sitryx Announce Global Licensing & Research Collaboration ",RTTNews,/news/stocks/eli-lilly-sitryx-announce-global-licensing-research-collaboration-1029048200,positive,0.6855255961418152
755,3/31/2020 3:18:40 PM,Teva prevails in migraine patent dispute; shares up 9%,Seeking Alpha,https://seekingalpha.com/news/3556858-teva-prevails-in-migraine-patent-dispute-shares-up-9?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9183056950569153
756,3/31/2020 4:19:54 PM,Is iBio Stock Worth the Risk as Coronavirus Continues to Spread?,InvestorPlace,/news/stocks/is-ibio-stock-worth-the-risk-as-coronavirus-continues-to-spread-1029050739,positive,0.9000698924064636
757,4/5/2020 6:55:44 PM,Incyte details late-stage data on ruxolitinib cream for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3558456-incyte-details-late-stage-data-on-ruxolitinib-cream-for-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8612488508224487
758,4/7/2020 1:23:31 PM,Lilly Says New $35 Co-Pay Available Through Lilly Insulin Value Program ,RTTNews,/news/stocks/lilly-says-new-35-co-pay-available-through-lilly-insulin-value-program-1029071176,positive,0.7588480114936829
759,4/8/2020 10:47:18 PM,FDA OKs Pfizer's Braftovi combo for certain type of colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3559539-fda-oks-pfizers-braftovi-combo-for-certain-type-of-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.830585777759552
760,4/9/2020 11:32:59 AM,Evercore bearish on medical device makers in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3559606-evercore-bearish-on-medical-device-makers-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9429272413253784
761,4/11/2020 1:35:01 AM,Eli Lilly launches clinical testing of potential coronavirus treatment,Seeking Alpha,https://seekingalpha.com/news/3559950-eli-lilly-launches-clinical-testing-of-potential-coronavirus-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7946590185165405
762,4/15/2020 9:37:44 AM,Stock Alert: Eli Lilly Continues Its Uptrend ,RTTNews,/news/stocks/stock-alert-eli-lilly-continues-its-uptrend-1029092856,negative,0.602066159248352
763,4/15/2020 3:13:45 PM,RemeGen candidate Fast Track'd for lupus,Seeking Alpha,https://seekingalpha.com/news/3560931-remegen-candidate-fast-trackd-for-lupus?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7099936008453369
764,4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790,negative,0.5579317212104797
765,4/21/2020 4:33:49 PM,10 S&P 500 Stocks That Are Still Overvalued By Discounted Cash Flow,InvestorPlace,/news/stocks/10-sp-500-stocks-that-are-still-overvalued-by-discounted-cash-flow-1029113970,neutral,0.7640334963798523
766,4/22/2020 3:01:37 PM,Here's what to expect from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q1-earnings-preview-1029117737,positive,0.9407582879066467
767,4/23/2020 12:29:47 PM,Eli Lilly And Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-beat-estimates-1029121783,negative,0.9003615379333496
768,4/23/2020 1:22:56 PM,Eli Lilly Q1 Results Top Estimates; Lifts 2020 Profit View ,RTTNews,/news/stocks/eli-lilly-q1-results-top-estimates-lifts-2020-profit-view-1029122063,positive,0.5285084843635559
769,4/23/2020 6:51:18 PM,Eli Lilly Earnings: LLY Stock Leaps 2% on Q1 Beat,InvestorPlace,/news/stocks/eli-lilly-earnings-boost-lly-stock-up-1029124611,negative,0.8080660700798035
770,4/23/2020 9:05:42 PM,"5 Top Stock Trades for Friday: GILD, INO, LVS, DPZ, LLY",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-gild-ino-lvs-dpz-lly-1029124957,positive,0.9255844354629517
771,4/24/2020 4:02:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1029127334,negative,0.7757176160812378
772,4/30/2020 3:20:25 PM,Why Investors Should Avoid Inovio Pharmaceuticals,InvestorPlace,/news/stocks/why-investors-should-avoid-inovio-pharmaceuticals-1029151438,positive,0.9054948091506958
773,5/1/2020 2:48:55 PM,3 Bullish Coronavirus Stocks to Trade Into Weakness,InvestorPlace,/news/stocks/3-bullish-coronavirus-stocks-to-trade-into-weakness-1029155697,positive,0.8526918292045593
774,5/4/2020 2:38:58 PM,"Junshi, Eli Lilly Agree To Co-develop JS016 Antibodies Against COVID-19 ",RTTNews,/news/stocks/junshi-eli-lilly-agree-to-co-develop-js016-antibodies-against-covid-19-1029160111,negative,0.7872077822685242
775,5/5/2020 6:18:48 PM,3 Healthcare Stocks Popping Off Support,InvestorPlace,/news/stocks/3-healthcare-stocks-popping-off-support-1029167820,neutral,0.9234455227851868
776,5/7/2020 4:55:34 AM,Innovent:phase 3 Study On Advanced Lung Cancer Meets Predefined Primary Endpoint ,RTTNews,/news/stocks/innovent-phase-3-study-on-advanced-lung-cancer-meets-predefined-primary-endpoint-1029173381,positive,0.7041735053062439
777,5/8/2020 12:25:16 PM,"3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-bristol-myers-squibb-eli-lilly-and-glaxosmithkline-1029182410,positive,0.8863689303398132
778,5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.901307225227356
779,5/8/2020 10:57:18 PM,FDA approves Eli Lilly drug to treat three types of tumors,Seeking Alpha,https://seekingalpha.com/news/3572368-fda-approves-eli-lilly-drug-to-treat-three-types-of-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6944090723991394
780,5/19/2020 3:24:21 PM,Eli Lilly Reports Results Of GERAS-US Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-results-of-geras-us-study-quick-facts-1029215497,positive,0.9148815870285034
781,5/26/2020 1:36:09 PM,Lilly and BI team up with Duke in study of Jardiance following heart attack,Seeking Alpha,https://seekingalpha.com/news/3577514-lilly-and-bi-team-up-duke-in-study-of-jardiance-following-heart-attack?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5142310261726379
782,5/26/2020 3:45:27 PM,Lilly partner Junshi Biosciences advances COVID-19 antibody candidate,Seeking Alpha,https://seekingalpha.com/news/3577565-lilly-partner-junshi-biosciences-advances-covidminus-19-antibody-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7193387746810913
783,5/27/2020 12:50:26 PM,7 Cheap Stocks to Buy With Great Potential,InvestorPlace,/news/stocks/7-cheap-stocks-buy-great-potential-now-1029238272,negative,0.5561124086380005
784,5/29/2020 2:36:45 AM,FDA approves Eli Lilly Alzheimer's diagnosis drug,Seeking Alpha,https://seekingalpha.com/news/3578522-fda-approves-eli-lilly-alzheimers-diagnosis-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8748782873153687
785,5/29/2020 3:18:05 AM,FDA Oks Lilly's Drug To Image Tau Pathology In Patients Being Evaluated For Alzheimer's Disease ,RTTNews,/news/stocks/fda-oks-lilly-s-drug-to-image-tau-pathology-in-patients-being-evaluated-for-alzheimer-s-disease-1029261468,positive,0.6347458362579346
786,5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9381866455078125
787,5/30/2020 5:08:49 AM,FDA Approves Lilly's Cyramza To Treat Metastatic EGFR-Mutated Non-Small Cell Lung Cancer ,RTTNews,/news/stocks/fda-approves-lilly-s-cyramza-to-treat-metastatic-egfr-mutated-non-small-cell-lung-cancer-1029265038,negative,0.7974278330802917
788,6/1/2020 5:32:10 AM,Innovent Announces Results Of TYVYT In Treatment Of Locally Advanced Or Metastatic ESCC ,RTTNews,/news/stocks/innovent-announces-results-of-tyvyt-in-treatment-of-locally-advanced-or-metastatic-escc-1029267350,negative,0.5989055037498474
789,6/3/2020 9:16:46 AM,Abbvie Stock is Offering Investors an Oil Yield Without Oil’s Risk,InvestorPlace,/news/stocks/abbv-stock-an-oil-yield-without-oil-1029275806,positive,0.8119696378707886
790,6/3/2020 1:10:28 PM,Eli Lilly: Taltz Shows Consistent Efficacy In Psoriatic Arthritis - Quick Facts ,RTTNews,/news/stocks/eli-lilly-taltz-shows-consistent-efficacy-in-psoriatic-arthritis-quick-facts-1029276056,negative,0.9436804056167603
791,6/6/2020 1:18:27 PM,"The Week That Was In COVID: Russia Approves 1st COVID-19 Drug, INO Sues Vaccine Supplier... ",RTTNews,/news/stocks/the-week-that-was-in-covid-russia-approves-1st-covid-19-drug-ino-sues-vaccine-supplier-1029286233,negative,0.7855429649353027
792,6/7/2020 5:55:53 PM,Early-stage study underway in China for Junshi SARS-CoV-2 antibody,Seeking Alpha,https://seekingalpha.com/news/3580971-early-stage-study-underway-in-china-for-junshi-sars-covminus-2-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4986559748649597
793,6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865,negative,0.7292519211769104
794,6/10/2020 7:59:09 PM,Lilly's baricitinib shows sustained benefit in rheumatoid arthritis study,Seeking Alpha,https://seekingalpha.com/news/3582063-lillys-baricitinib-shows-sustained-benefit-in-rheumatoid-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9501987099647522
795,6/12/2020 8:09:14 PM,Lilly's lebrikizumab shows encouraging action in dermatitis study,Seeking Alpha,https://seekingalpha.com/news/3582761-lillys-lebrikizumab-shows-encouraging-action-in-dermatitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9477152824401855
796,6/15/2020 11:45:59 AM,Lilly launches late-stage study of baricitinib in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3582916-lilly-launches-late-stage-study-of-baricitinib-in-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.630946159362793
797,6/15/2020 12:34:51 PM,Eli Lilly Is a Big Pharma Play With Big Potential,InvestorPlace,/news/stocks/eli-lilly-lly-stock-big-pharma-coronavirus-potential-1029308833,positive,0.803265392780304
798,6/15/2020 1:00:05 PM,Lilly Starts Phase 3 Clinical Trial With Baricitinib For Hospitalized COVID-19 Patients ,RTTNews,/news/stocks/lilly-starts-phase-3-clinical-trial-with-baricitinib-for-hospitalized-covid-19-patients-1029307552,negative,0.5815112590789795
799,6/16/2020 5:02:26 AM,FDA Approves Lilly's New Rapid-acting Insulin Lyumjev ,RTTNews,/news/stocks/fda-approves-lilly-s-new-rapid-acting-insulin-lyumjev-1029310459,positive,0.5313396453857422
800,6/16/2020 12:59:01 PM,Eli Lilly Reports Positive Results From Interim Analysis Of Phase 3 MonarchE Study ,RTTNews,/news/stocks/eli-lilly-reports-positive-results-from-interim-analysis-of-phase-3-monarche-study-1029311906,negative,0.9485092163085938
801,6/16/2020 5:49:43 PM,Pfizer and Merck's diabetes med Steglatro shows mixed results in cardiovascular outcomes study,Seeking Alpha,https://seekingalpha.com/news/3583523-pfizer-and-mercks-diabetes-med-steglatro-shows-mixed-results-in-cardiovascular-outcomes-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9532431364059448
802,6/16/2020 6:54:03 PM,"Eli Lilly soars 15% after its breast cancer drug shows efficacy where a treatment from Pfizer failed (LLY, PFE)",Business Insider,https://markets.businessinsider.com/news/stocks/eli-lilly-stock-price-after-successful-drug-trial-breast-cancer-2020-6-1029314306,negative,0.9232605695724487
803,6/16/2020 7:06:23 PM,Eli Lilly News: LLY Stock Soars 15% on Successful Breast Cancer Drug Trial,InvestorPlace,/news/stocks/eli-lilly-breast-cancer-news-boosts-lly-stock-1029314839,negative,0.9413955211639404
804,6/17/2020 7:25:36 AM,"AMRN Makes Peace With Apotex, IDYA Cuts Deal With GSK, SLRX On Watch, NBIX, TAK Ink $2Bln Pact ",RTTNews,/news/stocks/amrn-makes-peace-with-apotex-idya-cuts-deal-with-gsk-slrx-on-watch-nbix-tak-ink-2bln-pact-1029315680,positive,0.4364316761493683
805,6/18/2020 2:31:38 PM,Lilly Begins Phase 3 Study To Evaluate Baricitinib In Hospitalized Adults With COVID-19 ,RTTNews,/news/stocks/lilly-begins-phase-3-study-to-evaluate-baricitinib-in-hospitalized-adults-with-covid-19-1029321737,negative,0.7327050566673279
806,7/14/2020 3:37:23 PM,The 7 Best Pharmaceutical Stocks That Go Beyond the Covid-19 Chase,InvestorPlace,/news/stocks/the-7-best-pharmaceutical-stocks-that-go-beyond-the-covid-19-chase-1029393527,positive,0.8562304377555847
807,7/15/2020 11:36:51 AM,Novavax Stock Has Probably Topped Out Until Successful Clinical Trials,InvestorPlace,/news/stocks/nvax-stock-topped-out-clinical-trials-1029397795,negative,0.8751546740531921
808,7/17/2020 1:02:22 PM,Eli Lilly Says Mirikizumab Superior To Cosentyx In Phase 3 Study - Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-mirikizumab-superior-to-cosentyx-in-phase-3-study-quick-facts-1029404743,negative,0.9459535479545593
809,7/27/2020 6:12:59 PM,Science Is the Reason to Invest in Neurotez Stock,InvestorPlace,/news/stocks/science-is-the-reason-to-invest-in-neurotez-stock-1029435254,positive,0.9033043384552002
810,7/29/2020 3:03:03 PM,Eli Lilly and earnings: here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q2-earnings-preview-1029445764,positive,0.9447187185287476
811,7/30/2020 12:29:22 PM,Eli Lilly And Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-beat-estimates-1029449986,negative,0.8854392170906067
812,7/30/2020 12:42:52 PM,Eli Lilly Boost FY20 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-boost-fy20-adj-eps-outlook-quick-facts-1029450071,positive,0.6583291888237
813,7/30/2020 1:23:44 PM,Eli Lilly Announces Positive Top-line Results From EMPEROR-Reduced Phase III Trial ,RTTNews,/news/stocks/eli-lilly-announces-positive-top-line-results-from-emperor-reduced-phase-iii-trial-1029450334,negative,0.9491285681724548
814,8/3/2020 1:36:54 PM,Lilly Initiates Phase 3 COVID-19 Trial Of LY-CoV555 At Long-Term Care Facilities ,RTTNews,/news/stocks/lilly-initiates-phase-3-covid-19-trial-of-ly-cov555-at-long-term-care-facilities-1029461133,positive,0.5464618802070618
815,8/5/2020 1:59:32 PM,Novavax Stock Needs Solid Results Beyond Headlines,InvestorPlace,/news/stocks/nvax-stock-needs-solid-results-beyond-headlines-1029473742,negative,0.9414753913879395
816,8/5/2020 3:09:42 PM,Lilly : Empagliflozin Reduces Risk Of Cardiovascular Death Or Hospitalization For Heart Failure ,RTTNews,/news/stocks/lilly-empagliflozin-reduces-risk-of-cardiovascular-death-or-hospitalization-for-heart-failure-1029473363,negative,0.8849620223045349
817,8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490,positive,0.9439411759376526
818,8/8/2020 9:44:59 PM,Lilly's sintilimab shows treatment benefit in first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3603108-lillys-sintilimab-shows-treatment-benefit-in-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9091399312019348
819,8/18/2020 12:57:51 PM,Lilly Obtains License For TYVYT From Innovent For Geographies Outside Of China ,RTTNews,/news/stocks/lilly-obtains-license-for-tyvyt-from-innovent-for-geographies-outside-of-china-1029511945,positive,0.6360357999801636
820,8/18/2020 5:17:26 PM,Hold Eli Lilly as Mobile Covid-19 Labs Address Critical Needs,InvestorPlace,/news/stocks/hold-lly-stock-as-mobile-covid-19-labs-address-critical-needs-1029514261,positive,0.8549660444259644
821,8/20/2020 4:37:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1029521357,negative,0.7757176160812378
822,8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567,negative,0.805871844291687
823,9/8/2020 5:54:15 PM,6 of the Best Pharmaceutical Stocks to Buy Today,InvestorPlace,/news/stocks/6-of-the-best-pharmaceutical-stocks-to-buy-today-1029571607,positive,0.7528263330459595
824,9/9/2020 12:45:05 PM,Eli Lilly Promotes Ilya Yuffa To SVP & President Of Lilly Bio-Medicines ,RTTNews,/news/stocks/eli-lilly-promotes-ilya-yuffa-to-svp-president-of-lilly-bio-medicines-1029572815,positive,0.9000411629676819
825,9/10/2020 12:58:59 PM,Eli Lilly To Present Clinically Meaningful Results From MonarchE Phase 3 Study At ESMO ,RTTNews,/news/stocks/eli-lilly-to-present-clinically-meaningful-results-from-monarche-phase-3-study-at-esmo-1029577187,negative,0.7233050465583801
826,9/11/2020 1:27:54 PM,Eli Lilly: REYVOW Meets All 18 Gated Endpoints In New Phase 3 Study ,RTTNews,/news/stocks/eli-lilly-reyvow-meets-all-18-gated-endpoints-in-new-phase-3-study-1029581535,positive,0.5856569409370422
827,9/14/2020 1:19:20 PM,"Lilly, Incyte Announce Initial Data From Adaptive COVID-19 Treatment Trial - Quick Facts ",RTTNews,/news/stocks/lilly-incyte-announce-initial-data-from-adaptive-covid-19-treatment-trial-quick-facts-1029585401,positive,0.9289562702178955
828,9/15/2020 2:50:18 PM,"Eli Lilly, Boehringer Ingelheim: FDA Grants Fast Track Designation To Jardiance ",RTTNews,/news/stocks/eli-lilly-boehringer-ingelheim-fda-grants-fast-track-designation-to-jardiance-1029590187,negative,0.8710629343986511
829,9/16/2020 1:38:25 PM,Lilly: BLAZE-1 Interim Data Show LY-CoV555 Antibody Reduces COVID-related Hospitalizations ,RTTNews,/news/stocks/lilly-blaze-1-interim-data-show-ly-cov555-antibody-reduces-covid-related-hospitalizations-1029594017,negative,0.7412548661231995
830,9/16/2020 5:35:56 PM,Eli Lilly Stock Looks Hot on New Antibody Drug Evidence,InvestorPlace,/news/stocks/eli-lilly-stock-looks-hot-on-new-antibody-drug-evidence-1029596051,negative,0.5884913206100464
831,9/16/2020 10:56:34 PM,Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting,GlobeNewswire,/news/stocks/lilly-announces-proof-of-concept-data-for-neutralizing-antibody-ly-cov555-in-the-covid-19-outpatient-setting-1029596519,negative,0.871965229511261
832,9/17/2020 12:56:42 PM,"Eli Lilly, Amgen Ink Antibody Manufacturing Deal To Boost Supply For COVID-19 Therapies ",RTTNews,/news/stocks/eli-lilly-amgen-ink-antibody-manufacturing-deal-to-boost-supply-for-covid-19-therapies-1029597997,negative,0.9506921172142029
833,9/17/2020 1:35:51 PM,SRNE Stock: Sorrento Therapeutics Pops on Plans to Launch Drug Trials,InvestorPlace,/news/stocks/srne-stock-sorrento-therapeutics-pops-on-plans-to-launch-drug-trials-1029599296,positive,0.809693455696106
834,9/17/2020 7:41:53 PM,Baricitinib in Combination with Remdesivir Reduces Time to Recovery in Hospitalized Patients with COVID-19 in NIAID-Sponsored ACTT-2 Trial,GlobeNewswire,/news/stocks/baricitinib-in-combination-with-remdesivir-reduces-time-to-recovery-in-hospitalized-patients-with-covid-19-in-niaid-sponsored-actt-2-trial-1029600273,negative,0.7799350619316101
835,9/18/2020 2:04:17 PM,"Lilly, Incyte: CHMP Adopts Positive Opinion For Baricitinib In Treatment Of Atopic Dermatitis ",RTTNews,/news/stocks/lilly-incyte-chmp-adopts-positive-opinion-for-baricitinib-in-treatment-of-atopic-dermatitis-1029602319,negative,0.9471803307533264
836,9/21/2020 1:10:04 PM,Buy JetBlue Stock at These Levels and Sock It Away for the Recovery,InvestorPlace,/news/stocks/buy-jblu-stock-sock-it-away-recovery-1029607469,positive,0.9290062785148621
837,9/21/2020 5:10:56 PM,"Tread Carefully, But Sorrento Stock Could Continue to Bounce Back",InvestorPlace,/news/stocks/tread-carefully-buy-srne-stock-continue-bounce-back-1029608339,neutral,0.4507673382759094
838,9/22/2020 3:29:36 PM,"Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have...",GlobeNewswire,/news/stocks/trulicity-dulaglutide-is-now-indicated-as-an-adjunct-to-diet-exercise-and-standard-of-care-therapy-to-reduce-the-risk-of-non-fatal-stroke-in-adults-with-type-2-diabetes-mellitus-who-have-1029611364,negative,0.7829935550689697
839,9/23/2020 12:05:31 PM,There Simply Isn’t Enough Good News for iBio,InvestorPlace,/news/stocks/simply-not-enough-good-news-ibio-stock-1029615057,positive,0.6294528245925903
840,10/6/2020 1:14:28 PM,Eli Lilly: REYVOW Shows Superiority Over Placebo In Migraine Pain Relief At 2 Hours ,RTTNews,/news/stocks/eli-lilly-reyvow-shows-superiority-over-placebo-in-migraine-pain-relief-at-2-hours-1029651591,negative,0.9352256059646606
841,10/7/2020 4:38:23 AM,Innovent Bio's expanded collaboration with Lilly for Tyvyt now effective,Seeking Alpha,https://seekingalpha.com/news/3620325-innovent-bios-expanded-collaboration-lilly-for-tyvyt-now-effective?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8532602787017822
842,10/7/2020 10:54:16 AM,Lilly teams up with DexCom for diabetes management,Seeking Alpha,https://seekingalpha.com/news/3620364-lilly-teams-up-dexcom-for-diabetes-management?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5892696380615234
843,10/7/2020 1:01:10 PM,Lilly files for emergency use authorization in U.S. for COVID-19 antibody,Seeking Alpha,https://seekingalpha.com/news/3620445-lilly-files-for-emergency-use-authorization-in-u-s-for-covidminus-19-antibody?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5428430438041687
844,10/7/2020 3:15:56 PM,Eli Lilly Submits Initial Request For Emergency Use Authorization To Treat COVID-19 ,RTTNews,/news/stocks/eli-lilly-submits-initial-request-for-emergency-use-authorization-to-treat-covid-19-1029657413,negative,0.7458852529525757
845,10/7/2020 10:06:46 PM,Regeneron +2.3% after Trump praises drug in new video,Seeking Alpha,https://seekingalpha.com/news/3620637-regeneronplus-2_3-after-trump-praises-drug-in-new-video?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8205900192260742
846,10/8/2020 9:01:29 AM,"CDNA, OCUL Soar On Prelim Q3 Revenue, Lilly Seeks EUA For LY-CoV555 In COVID-19, ALKS On Watch ",RTTNews,/news/stocks/cdna-ocul-soar-on-prelim-q3-revenue-lilly-seeks-eua-for-ly-cov555-in-covid-19-alks-on-watch-1029660015,negative,0.8723205924034119
847,10/8/2020 11:10:58 AM,Lilly signs deal to supply COVID-19 antibody treatment to developing countries,Seeking Alpha,https://seekingalpha.com/news/3620710-lilly-signs-deal-to-supply-covidminus-19-antibody-treatment-to-developing-countries?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9202080368995667
848,10/8/2020 12:22:49 PM,Regeneron and Lilly to get emergency approval for antibody treatments - Trump,Seeking Alpha,https://seekingalpha.com/news/3620753-regeneron-and-lilly-to-get-emergency-approval-for-antibody-treatments-trump?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5635969638824463
849,10/8/2020 1:11:54 PM,"Lilly, Gates Foundation To Supply Potential COVID-19 Therapy For Low, Middle Income Countries ",RTTNews,/news/stocks/lilly-gates-foundation-to-supply-potential-covid-19-therapy-for-low-middle-income-countries-1029660842,negative,0.7611315846443176
850,10/8/2020 1:56:34 PM,REGN Stock: Regeneron Pops on Trump’s Antibody Support,InvestorPlace,/news/stocks/regn-stock-regeneron-pops-on-trumps-antibody-support-1029662216,positive,0.7643977403640747
851,10/8/2020 3:19:14 PM,Lilly doublet therapy for COVID-19 reduced hospitalizations in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3620846-lilly-doublet-therapy-for-covidminus-19-reduced-hospitalizations-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9276494979858398
852,10/8/2020 4:20:17 PM,Lilly's baricitinib shows incremental benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3620863-lillys-baricitinib-shows-incremental-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9489912390708923
853,10/9/2020 11:40:19 AM,Lilly/Innovent rituximab injection OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3621048-lilly-innovent-rituximab-injection-okd-in-china?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6740302443504333
854,10/9/2020 1:16:37 PM,Eli Lilly: Nearly 4 Out Of 5 People In OVERCOME Survey Report Improvement In Migraine ,RTTNews,/news/stocks/eli-lilly-nearly-4-out-of-5-people-in-overcome-survey-report-improvement-in-migraine-1029665353,negative,0.8886613845825195
855,10/9/2020 1:29:30 PM,"Innovent, Eli Lilly Announce Approval Of HALPRYZA In China - Quick Facts ",RTTNews,/news/stocks/innovent-eli-lilly-announce-approval-of-halpryza-in-china-quick-facts-1029665370,positive,0.7069453001022339
856,10/9/2020 4:37:25 PM,Covid-19 Therapeutics May Push Novavax Out of the Spotlight,InvestorPlace,/news/stocks/covid-19-therapeutics-may-push-nvax-stock-out-of-the-spotlight-cseo-1029666747,neutral,0.9274026155471802
857,10/9/2020 8:25:25 PM,COVID-19 drug developer Atea Pharmaceuticals files for IPO,Seeking Alpha,https://seekingalpha.com/news/3621228-covidminus-19-drug-developer-atea-pharmaceuticals-files-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9147786498069763
858,10/12/2020 12:12:15 PM,Lilly's mirikizumab shows sustained benefit in mid-stage Crohn's study,Seeking Alpha,https://seekingalpha.com/news/3621322-lillys-mirikizumab-shows-sustained-benefit-in-mid-stage-crohns-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9517876505851746
859,10/12/2020 1:02:47 PM,Eli Lilly Reports Data From Phase 2 SERENITY Study Evaluating Mirikizumab ,RTTNews,/news/stocks/eli-lilly-reports-data-from-phase-2-serenity-study-evaluating-mirikizumab-1029669444,positive,0.7156968116760254
860,10/12/2020 3:33:55 PM,7 Elections Stocks You Definitely Want To Avoid Leading up To the Big Vote,InvestorPlace,/news/stocks/7-election-stocks-you-definitely-want-to-avoid-leading-up-to-the-election-1029670817,positive,0.8887040615081787
861,10/12/2020 8:58:31 PM,7 Highly Rated Pharmaceutical Stocks for Q4,InvestorPlace,/news/stocks/7-highly-rated-pharmaceutical-stocks-for-q4-1029679826,positive,0.8309608697891235
862,10/13/2020 6:46:50 PM,Eli Lilly's Covid-19 antibody trial paused over safety concerns,Seeking Alpha,https://seekingalpha.com/news/3621824-eli-lillys-covidminus-19-antibody-trial-paused-over-safety-concerns?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9175911545753479
863,10/13/2020 6:54:32 PM,7 Pet Stocks to Adopt Today ,InvestorPlace,/news/stocks/7-pet-stocks-to-adopt-today-1029676172,positive,0.8865429759025574
864,10/14/2020 7:06:20 AM,Quality control lapses at plant making Eli Lilly COVID drug,Seeking Alpha,https://seekingalpha.com/news/3621925-quality-control-lapses-plant-making-eli-lilly-covid-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9548757076263428
865,10/14/2020 8:31:39 AM,"LLY Pauses COVID-19 Antibody Trial, JNJ Boosts Annual Outlook, Double Whammy For GOSS ",RTTNews,/news/stocks/lly-pauses-covid-19-antibody-trial-jnj-boosts-annual-outlook-double-whammy-for-goss-1029677498,negative,0.9347585439682007
866,10/14/2020 1:03:22 PM,Health care holding up despite COVID setbacks: At the Open,Seeking Alpha,https://seekingalpha.com/news/3622071-health-care-holding-up-despite-covid-setbacks-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7862377762794495
867,10/14/2020 7:23:24 PM,Eli Lilly says other COVID-19 antibody drug trials ongoing after study halted for safety concern - Reuters,Seeking Alpha,https://seekingalpha.com/news/3622224-eli-lilly-says-covidminus-19-antibody-drug-trials-ongoing-after-study-halted-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7537630796432495
868,10/14/2020 7:35:36 PM,Don’t Give Up on Sorrento Therapeutics Stock Just Yet,InvestorPlace,/news/stocks/dont-give-up-on-sorrento-srne-stock-just-yet-1029681139,positive,0.9235071539878845
869,10/15/2020 12:37:15 PM,"Carnival Stock Is Far from Recovered, But the Worst Is Behind",InvestorPlace,/news/stocks/carnival-stock-is-far-from-recovered-but-the-worst-is-behind-1029684755,neutral,0.8601924777030945
870,10/15/2020 1:53:03 PM,Eli Lilly scoops up Disarm Therapeutics for $135M upfront,Seeking Alpha,https://seekingalpha.com/news/3622494-eli-lilly-scoops-up-disarm-therapeutics-for-135m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8790954947471619
871,10/15/2020 3:51:22 PM,Lilly To Buy Disarm Therapeutics For Upfront Payment Of $135.0 Mln ,RTTNews,/news/stocks/lilly-to-buy-disarm-therapeutics-for-upfront-payment-of-135-0-mln-1029684606,positive,0.8840798139572144
872,10/16/2020 8:37:24 AM,"SNY/TBIO Move COVID-19 Vaccine Into Clinic, AVXL's PDD Study Promising, EIGR On Watch ",RTTNews,/news/stocks/sny-tbio-move-covid-19-vaccine-into-clinic-avxl-s-pdd-study-promising-eigr-on-watch-1029687214,positive,0.7386726140975952
873,10/16/2020 11:58:35 AM,Biden Town Hall: 4 Key Investing Takeaways,InvestorPlace,/news/stocks/biden-town-hall-4-key-investing-takeaways-1029688135,positive,0.9202543497085571
874,10/16/2020 1:03:00 PM,7 Short-Term Stocks to Make a Quick Buck,InvestorPlace,/news/stocks/7-short-term-stocks-to-buy-for-quick-buck-1029688757,positive,0.8304802775382996
875,10/16/2020 5:53:26 PM,Can Cytonics Pivot Successfully to Covid-19 Therapeutics?,InvestorPlace,/news/stocks/cytonics-stock-pivot-coronavirus-therapeutics-1029689508,positive,0.7348707318305969
876,10/16/2020 5:53:36 PM,Novavax Stock Looks Volatile As Vaccine Enthusiasm Wanes,InvestorPlace,/news/stocks/nvax-stock-looks-volatile-as-vaccine-enthusiasm-wanes-1029689507,neutral,0.9606714248657227
877,10/16/2020 7:30:50 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3622976-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
878,10/16/2020 8:03:31 PM,Lilly/Incyte's baricitinib shows additional benefit in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3623006-lilly-incytes-baricitinib-shows-additional-benefit-in-hospitalized-covidminus-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.952124834060669
879,10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6425066590309143
880,10/19/2020 12:28:44 PM,Lilly's Taltz OK'd in Canada for arthritis of the spine,Seeking Alpha,https://seekingalpha.com/news/3623179-lillys-taltz-okd-in-canada-for-arthritis-of-spine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6260377764701843
881,10/19/2020 4:24:41 PM,Eli Lilly declares $0.74 dividend,Seeking Alpha,https://seekingalpha.com/news/3623314-eli-lilly-declares-0_74-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9263155460357666
882,10/19/2020 5:25:37 PM,Why the FDA’s Inquiry of Inovio Is More Critical Than You Think,InvestorPlace,/news/stocks/why-fda-inquiry-very-critical-ino-stock-1029694935,positive,0.9059134125709534
883,10/19/2020 5:50:56 PM,The Low-Hanging Fruit for Covid-19 Vaccines Is Gone for iBio,InvestorPlace,/news/stocks/ibio-stock-no-more-low-hanging-fruit-1029694932,positive,0.8469913005828857
884,10/21/2020 9:48:02 AM,Lilly taps outside advisor for problems at COVID drug plant,Seeking Alpha,https://seekingalpha.com/news/3624057-lilly-taps-outside-advisor-for-problems-covid-drug-plant?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8388985395431519
885,10/21/2020 7:50:43 PM,Sorrento Therapeutics Is a Vaccine Movie That Investors Have Already Seen,InvestorPlace,/news/stocks/lack-of-covid-19-focus-could-hinder-srne-stock-1029706960,positive,0.8901838064193726
886,10/22/2020 5:31:38 PM,Is It Too Late for Novavax to Profit From a Covid-19 Vaccine?,InvestorPlace,/news/stocks/is-it-too-late-for-novavax-to-profit-from-a-covid-19-vaccine-1029712056,positive,0.827395498752594
887,10/22/2020 9:37:48 PM,GILD News: Gilead Stock Pops as FDA Approves Remdesivir Treatment,InvestorPlace,/news/stocks/gild-news-gilead-stock-pops-as-fda-approves-remdesivir-treatment-1029712808,negative,0.48570021986961365
888,10/24/2020 4:30:00 AM,Gilead solidifies leadership in COVID-19 treatments with FDA remdesivir nod,Seeking Alpha,https://seekingalpha.com/news/3625261-gilead-solidifies-leadership-in-covidminus-19-treatments-fda-remdesivir-nod?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9483959674835205
889,10/26/2020 1:33:08 PM,10 Robinhood Stocks to Buy From the Top 100,InvestorPlace,/news/stocks/10-robinhood-stocks-to-buy-from-top-100-1029721869,positive,0.8937418460845947
890,10/26/2020 3:01:39 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-stock-1029721393,positive,0.9291529059410095
891,10/26/2020 4:13:39 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3625836-notable-earnings-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
892,10/26/2020 6:17:42 PM,Eli Lilly Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3625964-eli-lilly-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8271541595458984
893,10/27/2020 4:04:29 AM,Eli Lilly Ends Late-stage Covid-19 Antibody Trial In U.S. Due To Insufficient Data ,RTTNews,/news/stocks/eli-lilly-ends-late-stage-covid-19-antibody-trial-in-u-s-due-to-insufficient-data-1029723434,neutral,0.9657176733016968
894,10/27/2020 6:48:04 AM,Lilly ends COVID-19 antibody trial after lack of improvement,Seeking Alpha,https://seekingalpha.com/news/3626170-lilly-ends-covidminus-19-antibody-trial-after-lack-of-improvement?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9469443559646606
895,10/27/2020 10:32:15 AM,"Eli Lilly EPS misses by $0.17, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3626213-eli-lilly-eps-misses-0_17-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8482317924499512
896,10/27/2020 11:00:07 AM,"Lilly slips 5% on Q3 miss, GAAP EPS  guidance lowered",Seeking Alpha,https://seekingalpha.com/news/3626249-lilly-slips-5-on-q3-miss-gaap-eps-guidance-lowered?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9422228336334229
897,10/27/2020 11:05:34 AM,Lilly COVID-19 antibody treatment comes up empty in NIAID study,Seeking Alpha,https://seekingalpha.com/news/3626261-lilly-covidminus-19-antibody-treatment-comes-up-empty-in-niaid-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.739362359046936
898,10/27/2020 11:42:27 AM,Eli Lilly And Co. Q3 adjusted earnings Miss Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q3-adjusted-earnings-miss-estimates-1029725667,neutral,0.958758533000946
899,10/27/2020 12:10:27 PM,Eli Lilly Q3 Profit Misses Estimates; Revenue Up 5% ,RTTNews,/news/stocks/eli-lilly-q3-profit-misses-estimates-revenue-up-5-1029725848,negative,0.9475628137588501
900,10/28/2020 10:59:13 AM,Lilly inks U.S. deal to supply 300K vials of LY-CoV555 for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3627067-lilly-inks-u-s-deal-to-supply-300k-vials-of-ly-cov555-for-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9004683494567871
901,10/28/2020 12:14:31 PM,"Lilly In Deal To Supply 300,000 Vials Of COVID-19 Drug Bamlanivimab To U.S. Govt For $375 Mln ",RTTNews,/news/stocks/lilly-in-deal-to-supply-300-000-vials-of-covid-19-drug-bamlanivimab-to-u-s-govt-for-375-mln-1029733057,negative,0.7200305461883545
902,10/28/2020 11:00:20 PM,Eli Lilly's Bamlanivimab Phase 2 Study Data Shows Treatment May Be Effective Against COVID-19 ,RTTNews,/news/stocks/eli-lilly-s-bamlanivimab-phase-2-study-data-shows-treatment-may-be-effective-against-covid-19-1029737260,negative,0.9152852892875671
903,10/29/2020 10:37:34 PM,Eli Lilly secures $312.5M U.S. Army contract for LY-CoV555 procurement,Seeking Alpha,https://seekingalpha.com/news/3628859-eli-lilly-secures-312_5m-u-s-army-contract-for-ly-cov555-procurement?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9329670667648315
904,10/30/2020 12:26:12 PM,"Lilly, Incyte Report Positive New Data For Baricitinib In Adult Patients With Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-report-positive-new-data-for-baricitinib-in-adult-patients-with-alopecia-areata-1029745907,negative,0.9473748207092285
905,11/2/2020 1:14:27 PM,A Lot of News Isn’t Necessarily Good News for Sorrento Therapeutics,InvestorPlace,/news/stocks/lot-news-good-news-srne-stock-1029754095,positive,0.8521668910980225
906,11/3/2020 1:04:10 PM,Sorrento Therapeutics Is Charming But Read the Label,InvestorPlace,/news/stocks/srne-stock-charming-but-read-label-1029758584,positive,0.8833617568016052
907,11/4/2020 7:50:27 AM,Lilly updates on FDA surveillance inspections,Seeking Alpha,https://seekingalpha.com/news/3630908-lilly-updates-on-fda-surveillance-inspections?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9357237219810486
908,11/4/2020 5:12:44 PM,Healthcare rallies as Presidential vote count continues,Seeking Alpha,https://seekingalpha.com/news/3631239-healthcare-rallies-presidential-vote-count-continues?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5205023288726807
909,11/5/2020 8:06:56 PM,Cytonics: Invest In A Startup That’s Targeting Osteoarthritis,InvestorPlace,/news/stocks/cytonics-invest-in-a-startup-thats-targeting-osteoarthritis-1029772608,positive,0.8583500385284424
910,11/7/2020 5:30:00 AM,Biogen's long and winding road in Alzheimer's hits wall,Seeking Alpha,https://seekingalpha.com/news/3633230-biogens-long-and-winding-road-in-alzheimers-hits-wall?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5482168793678284
911,11/9/2020 4:55:35 PM,COVID-19 treatment developers under pressure on positive COVID-19 vaccine data,Seeking Alpha,https://seekingalpha.com/news/3633767-covidminus-19-treatment-developers-under-pressure-on-positive-covidminus-19-vaccine-data?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6168063282966614
912,11/9/2020 11:42:39 PM,Eli Lilly gets emergency OK for COVID-19 treatment bamlanivimab; shares +4.7%,Seeking Alpha,https://seekingalpha.com/news/3634128-eli-lilly-gets-emergency-ok-for-covidminus-19-treatment-bamlanivimab-sharesplus-4_7?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6645992398262024
913,11/10/2020 4:38:24 AM,Lilly's COVID-19 Antibody Drug Gets FDA Emergency Use Authorization For Non-hospitalized Patients ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-drug-gets-fda-emergency-use-authorization-for-non-hospitalized-patients-1029783969,negative,0.9249613881111145
914,11/10/2020 8:35:00 AM,"ARNA Falls Short Of ADVICE, PFE's COVID-19 Vaccine Shows 90% Efficacy, SUPN Hit By Double Whammy ",RTTNews,/news/stocks/arna-falls-short-of-advice-pfe-s-covid-19-vaccine-shows-90-efficacy-supn-hit-by-double-whammy-1029784994,negative,0.807870090007782
915,11/10/2020 1:52:47 PM,Lilly chief defends need for antibody treatment despite availability of vaccine,Seeking Alpha,https://seekingalpha.com/news/3634346-lilly-chief-defends-need-for-antibody-treatment-despite-availability-of-vaccine?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.42634060978889465
916,11/10/2020 10:32:33 PM,Market Insight: What’s Behind Monday’s Huge Rally,InvestorPlace,/news/stocks/market-insight-whats-behind-mondays-huge-rally-1029789442,positive,0.8550593852996826
917,11/11/2020 4:50:34 PM,7 Biotech Penny Stocks Worth a Gamble,InvestorPlace,/news/stocks/7-biotech-stocks-to-gamble-with-1029793010,positive,0.7899965047836304
918,11/11/2020 9:46:42 PM,Lilly webcast on late-stage tirzepatide program in T2D November 20,Seeking Alpha,https://seekingalpha.com/news/3635197-lilly-webcast-on-late-stage-tirzepatide-program-in-t2d-november-20?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9453646540641785
919,11/12/2020 9:31:59 PM,"With Pfizer Winning the Vaccine Race, Novavax Is a Strong Sell",InvestorPlace,/news/stocks/with-pfizer-winning-the-vaccine-race-nvax-stock-is-a-strong-sell-1029799195,negative,0.9159317016601562
920,11/13/2020 12:13:55 PM,Beyond Spring teams up with Lilly to develop protein degraders,Seeking Alpha,https://seekingalpha.com/news/3636038-beyond-spring-teams-up-lilly-to-develop-protein-degraders?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6841576099395752
921,11/13/2020 8:00:17 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3636251-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
922,11/13/2020 9:25:41 PM,3 Oil Stocks To Buy And Bull Trade For Big Gains,InvestorPlace,/news/stocks/3-oil-stocks-to-buy-and-bull-trade-for-big-gains-1029802756,positive,0.5944176912307739
923,11/16/2020 4:31:37 PM,Dicerna earns $10M in milestone from Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3636624-dicerna-earns-10m-in-milestone-from-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7352747917175293
924,11/17/2020 2:28:04 PM,Samsung BioLogics mass producing Eli Lilly's COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3637101-samsung-biologics-mass-producing-eli-lillys-covidminus-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7586166262626648
925,11/18/2020 1:46:16 PM,Lilly's Jardiance reduced risk of cardiovascular events in adults with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3637472-lillys-jardiance-reduced-risk-of-cardiovascular-events-in-adults-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8717901706695557
926,11/18/2020 2:22:38 PM,Eli Lilly : Jardiance Reduces Risk Of First Plus Recurrent Cardiovascular Events ,RTTNews,/news/stocks/eli-lilly-jardiance-reduces-risk-of-first-plus-recurrent-cardiovascular-events-1029815923,negative,0.9092251658439636
927,11/19/2020 12:11:11 PM,Lilly and Ypsomed collaborate to advance automated insulin delivery system in diabetes,Seeking Alpha,https://seekingalpha.com/news/3637853-lilly-and-ypsomed-collaborate-to-advance-automated-insulin-delivery-system-in-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7123021483421326
928,11/19/2020 1:04:42 PM,Lilly Partners Ypsomed To Offer Automated Insulin Delivery System For Diabetes Patients ,RTTNews,/news/stocks/lilly-partners-ypsomed-to-offer-automated-insulin-delivery-system-for-diabetes-patients-1029819956,negative,0.8113201856613159
929,11/20/2020 2:57:39 AM,Eli Lilly arthritis drug gets FDA OK for emergency use to treat COVID-19,Seeking Alpha,https://seekingalpha.com/news/3638211-eli-lilly-arthritis-drug-gets-fda-ok-for-emergency-use-to-treat-covidminus-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8861280083656311
930,11/20/2020 5:04:01 AM,FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-approval-to-lilly-s-arthritis-drug-with-remdesivir-for-covid-19-treatment-1029823536,neutral,0.5320243239402771
931,11/20/2020 7:46:37 AM,"AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B ",RTTNews,/news/stocks/azn-s-covid-jab-immunosenescence-pfe-bntx-to-seek-emergency-nod-for-vaccine-qure-aces-hope-b-1029823800,positive,0.6857633590698242
932,11/20/2020 12:17:09 PM,Precision BioSciences up more than 20% after gene therapy pact with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3638267-precision-biosciences-up-20-after-gene-therapy-pact-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9494326710700989
933,11/20/2020 1:26:01 PM,"Lilly, Precision BioSciences Reach Genome Editing Research Collaboration And License Deal ",RTTNews,/news/stocks/lilly-precision-biosciences-reach-genome-editing-research-collaboration-and-license-deal-1029824716,negative,0.5330902338027954
934,11/20/2020 1:50:00 PM,Oil fighting $42 and still responding better to vaccine news: At the Open,Seeking Alpha,https://seekingalpha.com/news/3638317-oil-fighting-42-and-still-responding-better-to-vaccine-news-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6397237777709961
935,11/22/2020 2:53:22 AM,FDA grants emergency clearance for Regeneron's COVID-19 threapy,Seeking Alpha,https://seekingalpha.com/news/3638520-fda-grants-emergency-clearance-for-regenerons-covidminus-19-threapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8491759896278381
936,11/23/2020 3:52:03 PM,REGN Stock: 11 Things for Investors to Know About Regeneron Approval,InvestorPlace,/news/stocks/regn-stock-11-things-for-investors-to-know-about-regeneron-approval-1029830793,positive,0.9467133283615112
937,12/1/2020 6:01:43 PM,4 Pharmaceutical Stocks That Aren’t Worth Their Outsized 2020 Gains,InvestorPlace,/news/stocks/4-pharmaceutical-stocks-ino-regn-abbv-nvax-that-arent-worth-their-2020-gains-1029854808,positive,0.752234935760498
938,12/2/2020 5:30:54 PM,CVS picked to administer Eli Lilly Covid-19 treatment in nursing homes and long-term care facilities,Seeking Alpha,https://seekingalpha.com/news/3640922-cvs-picked-to-administer-eli-lilly-covidminus-19-treatment-in-nursing-homes-and-long-term?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7578672766685486
939,12/2/2020 9:44:17 PM,Feds buy another 650K doses of Lilly COVID-19 med bamlanivimab,Seeking Alpha,https://seekingalpha.com/news/3641135-feds-buy-another-650k-doses-of-lilly-covidminus-19-med-bamlanivimab?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7285361289978027
940,12/4/2020 1:54:36 PM,"Lilly, UnitedHealth to study antibody treatment in high-risk COVID patients",Seeking Alpha,https://seekingalpha.com/news/3641704-lilly-unitedhealth-to-study-antibody-treatment-in-high-risk-covid-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7496023774147034
941,12/4/2020 1:57:53 PM,Lilly partners with UnitedHealth on real-world study of COVID-19 med in diverse high-risk population,Seeking Alpha,https://seekingalpha.com/news/3641707-lilly-partners-unitedhealth-on-real-world-study-of-covidminus-19-med-in-diverse-high-risk?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7038686275482178
942,12/4/2020 2:12:12 PM,"Lilly, UnitedHealth Partner On Pragmatic Study Of Bamlanivimab For COVID-19 ",RTTNews,/news/stocks/lilly-unitedhealth-partner-on-pragmatic-study-of-bamlanivimab-for-covid-19-1029865109,positive,0.709759533405304
943,12/7/2020 10:52:00 AM,Moody's - Outlook for global pharmaceutical industry revised to positive as COVID-19 vaccines and treatments boost earnings,Moodys,/news/bonds/moody-s-outlook-for-global-pharmaceutical-industry-revised-to-positive-as-covid-19-vaccines-and-treatments-boost-earnings-1029868484,negative,0.9331789612770081
944,12/7/2020 5:27:58 PM,Loxo Oncology Announces Data From The Phase 1/2 Trial For LOXO-305 In Chronic Lymphocytic Leukemia ,RTTNews,/news/stocks/loxo-oncology-announces-data-from-the-phase-1-2-trial-for-loxo-305-in-chronic-lymphocytic-leukemia-1029870137,positive,0.6228836178779602
945,12/9/2020 12:36:32 PM,Lilly's tirzepatide shows impressive A1C and weight reductions for people with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3642823-lillys-tirzepatide-shows-impressive-a1c-and-weight-reductions-for-people-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9486953616142273
946,12/9/2020 1:30:22 PM,Lilly's Tirzepatide Significantly Reduces A1C And Body Weight In People With Type 2 Diabetes ,RTTNews,/news/stocks/lilly-s-tirzepatide-significantly-reduces-a1c-and-body-weight-in-people-with-type-2-diabetes-1029876920,negative,0.7210196256637573
947,12/9/2020 3:39:55 PM,Lilly’s verzenio data shows decrease in breast cancer recurrence,Seeking Alpha,https://seekingalpha.com/news/3642951-lilly-s-verzenio-data-shows-decrease-in-breast-cancer-recurrence?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.695961058139801
948,12/9/2020 4:12:09 PM,Lilly : Verzenio - Standard Endocrine Therapy Combination Reduces Breast Cancer Recurrence Risk ,RTTNews,/news/stocks/lilly-verzenio-standard-endocrine-therapy-combination-reduces-breast-cancer-recurrence-risk-1029878034,negative,0.9194850325584412
949,12/10/2020 11:01:11 AM,Government and Institutional Support Are Positives for Sorrento Stock,InvestorPlace,/news/stocks/government-institutional-support-sorrento-snre-stock-1029880666,negative,0.946810781955719
950,12/11/2020 7:02:40 AM,COVID-19 antibody therapy developer AbCellera Bio prices IPO above range at $20,Seeking Alpha,https://seekingalpha.com/news/3643591-covidminus-19-antibody-therapy-developer-abcellera-bio-prices-ipo-above-range-20?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8786646723747253
951,12/11/2020 7:45:03 PM,Eli Lilly/Incyte announce peer-reviewed publication of Baricitinib/remdesivir trial data,Seeking Alpha,https://seekingalpha.com/news/3643811-eli-lilly-incyte-announce-peer-reviewed-publication-of-baricitinib-remdesivir-trial-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8726758360862732
952,12/11/2020 8:30:29 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3643803-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
953,12/14/2020 10:31:06 AM,The 7 Best Dow Jones Stocks to Buy Now As You Ready for the Coming Year,InvestorPlace,/news/stocks/7-best-dow-jones-stocks-to-buy-now-ibm-hd-mmm-aapl-msft-wmt-amgn-1029889146,positive,0.8910359740257263
954,12/14/2020 9:07:39 PM,Eli Lilly increases dividend by ~15% to $0.85,Seeking Alpha,https://seekingalpha.com/news/3644202-eli-lilly-increases-dividend-15-to-0_85?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9406476020812988
955,12/15/2020 11:41:13 AM,Prevail Therapeutics rockets 85% on being acquired by Lilly for ~$1.04B,Seeking Alpha,https://seekingalpha.com/news/3644314-prevail-therapeutics-rockets-85-on-being-acquired-lilly-for-1_04b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.853044867515564
956,12/15/2020 12:09:39 PM,"Lilly lifts 2020 guidance, sets 2021 outlook ahead of consensus; shares rise premarket",Seeking Alpha,https://seekingalpha.com/news/3644332-lilly-lifts-2020-guidance-sets-2021-outlook-ahead-of-consensus-shares-rise-premarket?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8820358514785767
957,12/15/2020 12:24:14 PM,Eli Lilly To Acquire Prevail Therapeutics - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-prevail-therapeutics-quick-facts-1029893140,positive,0.9279285073280334
958,12/15/2020 1:01:04 PM,Lilly Raises 2020 Outlook; Sees 2021 In Line With View - Quick Facts ,RTTNews,/news/stocks/lilly-raises-2020-outlook-sees-2021-in-line-with-view-quick-facts-1029893271,negative,0.9294794797897339
959,12/15/2020 2:51:14 PM,Prevail Therapeutics surges 86% on news of a $1 billion buyout by Eli Lilly,Business Insider,https://www.businessinsider.com/prevail-therapeutics-stock-price-eli-lilly-buyout-deal-billion-prvl-2020-12,negative,0.9174201488494873
960,12/15/2020 3:18:48 PM,PRVL Stock: Why Gene Therapy Play Prevail Therapeutics Is Rocketing Higher Tuesday,InvestorPlace,/news/stocks/prvl-stock-rises-on-prevail-therapeutics-lly-deal-1029895198,negative,0.9041007161140442
961,12/15/2020 3:52:00 PM,Eli Lilly and Company -- Moody's announces completion of a periodic review of ratings of Eli Lilly and Company,Moodys,/news/bonds/eli-lilly-and-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-eli-lilly-and-company-1029894439,positive,0.8798279762268066
962,12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4526408910751343
963,12/16/2020 3:42:52 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644938-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6051305532455444
964,12/16/2020 3:43:17 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644940-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6051305532455444
965,12/16/2020 3:43:50 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644941-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6051305532455444
966,12/16/2020 3:43:59 PM,Eli Lilly set to outperform on catalysts and growth prospects: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3644942-eli-lilly-set-to-outperform-on-catalysts-and-growth-prospects-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6051305532455444
967,12/18/2020 7:41:39 PM,Vir Biotech’s COVID-19 agents could be ‘NPV negative’: Baird,Seeking Alpha,https://seekingalpha.com/news/3645867-vir-biotech-s-covidminus-19-agents-be-npv-negative-baird?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8025674819946289
968,12/20/2020 4:02:46 PM,"The Week Ahead In Biotech: Light Calendar In Abbreviated Week Features 1 IPO, 1 FDA Decision",Benzinga,/news/stocks/the-week-ahead-in-biotech-light-calendar-in-abbreviated-week-features-1-ipo-1-fda-decision-1029909484,positive,0.9442067742347717
969,12/21/2020 7:57:25 AM,Lilly to launch bamlanivimab study for COVID-19 in New Mexico,Seeking Alpha,https://seekingalpha.com/news/3646049-lilly-to-launch-bamlanivimab-study-for-covidminus-19-in-new-mexico?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6061428189277649
970,12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9501712918281555
971,12/28/2020 11:35:55 AM,"As Vaccine Excitement Fades, Buy the Pullback in Pfizer",InvestorPlace,/news/stocks/vaccine-excitement-fades-buy-pullback-pfizer-pfe-stock-1029921274,positive,0.8600408434867859
972,12/29/2020 8:03:33 AM,Amphastar Pharma gains 10% on FDA approval of generic glucagon in low blood sugar,Seeking Alpha,https://seekingalpha.com/news/3647627-amphastar-pharma-gains-10-on-fda-approval-of-generic-glucagon-in-low-blood-sugar?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9476807117462158
973,12/29/2020 8:08:08 PM,COVID-19 antibody therapies left unused; developers carry on regardless,Seeking Alpha,https://seekingalpha.com/news/3647775-covidminus-19-antibody-therapies-left-unused-developers-carry-on-regardless?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.822996973991394
974,1/5/2021 11:37:37 PM,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",Seeking Alpha,https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9218689203262329
975,1/7/2021 12:41:34 PM,Precision Bio closes gene therapy deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3649546-precision-bio-closes-gene-therapy-deal-eli-lilly?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7577039003372192
976,1/8/2021 1:43:26 PM,Eli Lilly collaborates with Blacksmith Medicines in a deal worth $300M,Seeking Alpha,https://seekingalpha.com/news/3649921-eli-lilly-collaborates-blacksmith-medicines-in-deal-worth-300m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7004776000976562
977,1/11/2021 12:38:39 PM,Eli Lilly up 20% after Donanemab shows phase 2 positive result for Alzheimer's disease,Seeking Alpha,https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-phase-2-positive-result-for-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.932597815990448
978,1/11/2021 12:45:09 PM,Lilly's Donanemab Slows Clinical Decline Of Alzheimer's Disease In Phase 2 Trial ,RTTNews,/news/stocks/lilly-s-donanemab-slows-clinical-decline-of-alzheimer-s-disease-in-phase-2-trial-1029946907,negative,0.8017780780792236
979,1/11/2021 1:28:59 PM,"LLY, GME, NIO and BNGO among notable premarket gainers",Seeking Alpha,https://seekingalpha.com/news/3650232-lly-gme-nio-and-bngo-among-notable-premarket-gainers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6558292508125305
980,1/11/2021 2:24:01 PM,Eli Lilly: FDA Accepts Supplemental New Drug Application For Jardiance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-fda-accepts-supplemental-new-drug-application-for-jardiance-quick-facts-1029955272,negative,0.7132741808891296
981,1/11/2021 2:33:36 PM,Alzheimer’s Drug News: Why Eli Lilly (LLY) Stock Is Soaring Today,InvestorPlace,/news/stocks/alzheimers-drug-news-why-eli-lilly-lly-stock-is-soaring-today-1029955967,negative,0.92094886302948
982,1/11/2021 4:19:50 PM,Stocks That Hit 52-Week Highs On Monday,Benzinga,/news/stocks/stocks-that-hit-52-week-highs-on-monday-1029956096,positive,0.6719298958778381
983,1/11/2021 4:21:28 PM,Stock Alert: Eli Lilly And Company Jumps 11% ,RTTNews,/news/stocks/stock-alert-eli-lilly-and-company-jumps-11-1029956099,negative,0.6726352572441101
984,1/11/2021 5:32:08 PM,Alzheimer's peers jump after Eli Lilly's donanemab study meets endpoint,Seeking Alpha,https://seekingalpha.com/news/3650395-alzheimers-peers-jump-after-eli-lillys-donanemab-study-meets-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8135956525802612
985,1/11/2021 6:05:51 PM,63 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/63-stocks-moving-in-monday-s-mid-day-session-1029956505,neutral,0.5569143295288086
986,1/11/2021 8:30:04 PM,Eli Lilly rockets 14% after experimental Alzheimer's drug slows rate of decline in trial,Business Insider,https://www.businessinsider.com/eli-lilly-stock-price-alzheimers-drug-trial-results-positive-lly-2021-1,negative,0.7560379505157471
987,1/11/2021 10:21:46 PM,"4 Top Stock Trades for Tuesday: LLY, GME, F, UPWK",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-lly-gme-f-upwk-1029957365,positive,0.8273886442184448
988,1/12/2021 6:24:05 AM,Lilly and Innovent Bio's application for Tyvyt  as second-line therapy for lung cancer OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3650563-lilly-and-innovent-bios-application-for-tyvyt-second-line-therapy-for-lung-cancer-okd-in?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7889876365661621
989,1/12/2021 7:32:37 AM,"BGNE Teams Up With NVS, Editas Slumps Over 15%, LLY's Drug Shines In TRAILBLAZER-ALZ, MESO On Watch ",RTTNews,/news/stocks/bgne-teams-up-with-nvs-editas-slumps-over-15-lly-s-drug-shines-in-trailblazer-alz-meso-on-watch-1029958073,negative,0.8734846115112305
990,1/12/2021 11:00:12 AM,84 Biggest Movers From Yesterday,Benzinga,/news/stocks/84-biggest-movers-from-yesterday-1029958576,positive,0.8005322813987732
991,1/12/2021 2:15:54 PM,"The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue",Benzinga,/news/stocks/the-daily-biotech-pulse-gsk-vir-to-start-covid-19-antibody-study-novartis-in-licenses-beigene-s-cancer-drug-earnings-preannouncements-continue-1029959657,positive,0.9257159233093262
992,1/12/2021 3:28:18 PM,Covid-19 South African variant could evade our medicines: Eli Lilly CEO,Seeking Alpha,https://seekingalpha.com/news/3650751-covidminus-19-south-african-variant-evade-medicines-eli-lilly-ceo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8843564391136169
993,1/13/2021 8:42:34 PM,Lilly and Innovent Bio's application for Tyvyt combo as first-line therapy for liver cancer OK'd in China,Seeking Alpha,https://seekingalpha.com/news/3651248-lilly-and-innovent-bios-application-for-tyvyt-combo-first-line-therapy-for-liver-cancer-okd?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7082937955856323
994,1/15/2021 12:55:23 PM,Eli Lilly Invests In Unseen Capital Health Fund As Part Of Racial Justice Efforts ,RTTNews,/news/stocks/eli-lilly-invests-in-unseen-capital-health-fund-as-part-of-racial-justice-efforts-1029972387,positive,0.8654543161392212
995,1/15/2021 2:40:13 PM,Lilly invests $30M in Unseen Capital Health Fund,Seeking Alpha,https://seekingalpha.com/news/3651837-lilly-invests-30m-in-unseen-capital-health-fund?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8573040962219238
996,1/18/2021 9:38:34 AM,New drugs and injections to overcome challenges in COVID-19 antibody therapies - WSJ,Seeking Alpha,https://seekingalpha.com/news/3652061-new-drugs-and-injections-to-overcome-challenges-in-covidminus-19-antibody-therapies-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8107872605323792
997,1/19/2021 12:47:46 PM,"Lilly, Merus Collaborate To Discover T-Cell Re-Directing Bispecific Antibodies ",RTTNews,/news/stocks/lilly-merus-collaborate-to-discover-t-cell-re-directing-bispecific-antibodies-1029980302,negative,0.5807878971099854
998,1/19/2021 1:32:22 PM,Lilly teams up with Merus to discover T-cell re-directing antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3652204-?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6291022300720215
999,1/19/2021 4:04:22 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-19-2021-1029982130,neutral,0.6533176898956299
1000,1/19/2021 4:50:45 PM,"Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today",Benzinga,/news/stocks/why-aclaris-tenax-gritstone-merus-minerva-and-celyad-are-rallying-today-1029982313,negative,0.6973766088485718
1001,1/19/2021 8:42:32 PM,"Lilly Awash In Catalysts, Pipeline Updates, Mizuho Says In Upgrade",Benzinga,/news/stocks/lilly-awash-in-catalysts-pipeline-updates-mizuho-says-in-upgrade-1029983120,negative,0.7608827948570251
1002,1/19/2021 8:44:04 PM,Eli Lilly upgraded to buy at Mizuho on positive donanemab data,Seeking Alpha,https://seekingalpha.com/news/3652410-eli-lilly-upgraded-to-buy-on-positive-donanemab-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9095020294189453
1003,1/20/2021 1:32:35 PM,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-greenlights-merck-s-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study-1029985849,positive,0.48656928539276123
1004,1/20/2021 3:24:21 PM,The 7 Best Healthcare Stocks to Buy for 2021,InvestorPlace,/news/stocks/the-7-best-healthcare-stocks-to-buy-for-2021-1029987247,positive,0.817572295665741
1005,1/21/2021 1:30:41 PM,Eli Lilly's bamlanivimab effective in reducing COVID-19 risk in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3653068-?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9297394752502441
1006,1/21/2021 2:05:24 PM,"The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-addex-jumps-on-positive-data-for-out-licensed-drug-covid-19-vaccine-developer-inovio-announces-150m-follow-on-offering-boston-scientific-goes-shopping-1029990203,negative,0.7720292210578918
1007,1/21/2021 2:25:22 PM,Eli Lilly: Bamlanivimab Reduced Risk Of Contracting COVID-19 At Nursing Homes By Up To 80% ,RTTNews,/news/stocks/eli-lilly-bamlanivimab-reduced-risk-of-contracting-covid-19-at-nursing-homes-by-up-to-80-1029990290,negative,0.9515336155891418
1008,1/21/2021 4:25:23 PM,Biden Stocks: 16 Stocks to Watch for a Defense Production Act Boost,InvestorPlace,/news/stocks/biden-stocks-16-stocks-to-watch-for-a-defense-production-act-boost-1029991455,positive,0.895939290523529
1009,1/22/2021 6:43:01 AM,"ADMP's Symjepi Hits Walgreen's Shelves, LLY's Antibody Cuts COVID-19 Risk By 80%, FLDM On Watch ",RTTNews,/news/stocks/admp-s-symjepi-hits-walgreen-s-shelves-lly-s-antibody-cuts-covid-19-risk-by-80-fldm-on-watch-1029992967,negative,0.902843713760376
1010,1/22/2021 1:22:34 PM,"The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa",Benzinga,/news/stocks/the-daily-biotech-pulse-fluidigm-s-saliva-based-covid-test-approved-in-europe-china-backs-amarin-s-vascepa-1029993832,positive,0.8599371910095215
1011,1/22/2021 2:06:53 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1029993983,positive,0.7916322350502014
1012,1/22/2021 3:05:53 PM,Lilly Closes Acquisition Of Prevail Therapeutics ,RTTNews,/news/stocks/lilly-closes-acquisition-of-prevail-therapeutics-1029994268,positive,0.9249433279037476
1013,1/23/2021 3:14:04 PM,"The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-24-30-j-j-lilly-to-kickstart-big-pharma-earnings-amgen-fda-decision-and-more-1029996049,negative,0.6939177513122559
1014,1/25/2021 3:46:00 PM,Eli Lilly shares up as it completes Prevail Therapeutics deal,Seeking Alpha,https://seekingalpha.com/news/3653940-eli-lilly-shares-up-as-it-completes-prevail-therapeutics-deal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6238163709640503
1015,1/25/2021 6:04:14 PM,Adocia announces positive results from BioChaperone Lispro Diabetes study,Seeking Alpha,https://seekingalpha.com/news/3653986-adocia-announces-positive-results-from-biochaperone-bc-lispro-diabetes-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.942814290523529
1016,1/25/2021 10:29:05 PM,Germany to become first in EU to use COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3654167-germany-to-become-first-in-eu-to-use-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6590954661369324
1017,1/26/2021 1:51:34 PM,Eli Lilly: Phase 3 BLAZE-1 Trial Meets Primary And Secondary Endpoints ,RTTNews,/news/stocks/eli-lilly-phase-3-blaze-1-trial-meets-primary-and-secondary-endpoints-1030003776,positive,0.8729931116104126
1018,1/26/2021 2:07:40 PM,"The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-misses-j-j-beats-in-big-pharma-earnings-vaccine-developer-curevac-taps-equity-market-1030004007,negative,0.7611163854598999
1019,1/26/2021 2:42:06 PM,"Lilly bamlanivimab combo therapy lowers COVID-19 hospitalizations, death by 70%",Seeking Alpha,https://seekingalpha.com/news/3654378-lilly-combo-therapy-reduced-covid-hospitalizations-death-by-70?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7522633075714111
1020,1/27/2021 12:07:25 PM,Lilly teams up with Vir Bio/GSK to evaluate bamlanivimab with VIR-7831 in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3654808-lilly-teams-up-with-vir-biogsk-to-evaluate-bamlanivimab-with-vir-7831-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7772610187530518
1021,1/27/2021 12:40:52 PM,Regeneron’s antibody cocktail neutralizes new COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3654838-regenerons-antibody-cocktail-neutralizes-new-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.49047961831092834
1022,1/27/2021 1:03:05 PM,"Lilly, Vir Biotechnology, GSK Say First Patient Dosed In Expanded BLAZE-4 Trial - Quick Facts ",RTTNews,/news/stocks/lilly-vir-biotechnology-gsk-say-first-patient-dosed-in-expanded-blaze-4-trial-quick-facts-1030009053,positive,0.8319900631904602
1023,1/27/2021 1:35:59 PM,"The Daily Biotech Pulse: Sorrento, Immutep Surge On COVID-19 Study Data, T2 Biosystems Sinks On Preannouncement",Benzinga,/news/stocks/the-daily-biotech-pulse-sorrento-immutep-surge-on-covid-19-study-data-t2-biosystems-sinks-on-preannouncement-1030009241,positive,0.8347625136375427
1024,1/27/2021 3:02:36 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q4-1030010033,positive,0.9319095611572266
1025,1/27/2021 8:30:44 PM,Pfizer’s setback can hurt others with JAK inhibitors,Seeking Alpha,https://seekingalpha.com/news/3655131-pfizers-setback-can-hurt-others-with-jak-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9525027871131897
1026,1/27/2021 10:23:39 PM,Eli Lilly secures $625M Army contract modification for 50K doses of LY-CoV555,Seeking Alpha,https://seekingalpha.com/news/3655282-eli-lilly-secures-625m-army-contract-modification-for-50k-doses-of-ly-cov555?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.940802276134491
1027,1/28/2021 8:49:22 AM,"AGTC Sheds Light On Achromatopsia Trials, LLY, VIR And GSK Team Up, CVM Turns Head As It Awaits Data ",RTTNews,/news/stocks/agtc-sheds-light-on-achromatopsia-trials-lly-vir-and-gsk-team-up-cvm-turns-head-as-it-awaits-data-1030013470,positive,0.49416959285736084
1028,1/28/2021 12:16:55 PM,"Eli Lilly, Asahi Kasei Pharma inks licensing pact for chronic pain drug candidate",Seeking Alpha,https://seekingalpha.com/news/3655445-eli-lilly-asahi-kasei-pharma-inks-licensing-pact-for-chronic-pain-drug-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9193081855773926
1029,1/28/2021 12:51:57 PM,Lilly To Buy Exclusive Rights For Chronic Pain Drug Candidate From Asahi Kasei Pharma ,RTTNews,/news/stocks/lilly-to-buy-exclusive-rights-for-chronic-pain-drug-candidate-from-asahi-kasei-pharma-1030014281,negative,0.5921609997749329
1030,1/28/2021 2:03:49 PM,"The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-decision-day-for-amgen-zymeworks-sinks-on-data-ortho-clinical-diagnostics-ipo-1030014922,positive,0.9371458292007446
1031,1/28/2021 4:59:28 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3655663-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8830810189247131
1032,1/28/2021 6:15:24 PM,Eli Lilly Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3655696-eli-lilly-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8449435234069824
1033,1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.795691967010498
1034,1/29/2021 11:21:57 AM,"Eli Lilly EPS beats by $0.36, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3656047-eli-lilly-eps-beats-0_36-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5639787316322327
1035,1/29/2021 11:58:10 AM,"Lilly tops Q4 forecast, Trulicity sales up 24%, GAAP EPS guidance lowered",Seeking Alpha,https://seekingalpha.com/news/3656066-lilly-tops-q4-forecast-trulicity-sales-up-24-gaap-eps-guidance-lowered?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9514915943145752
1036,1/29/2021 12:33:15 PM,Eli Lilly And Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/eli-lilly-and-co-q4-adjusted-earnings-beat-estimates-1030019303,negative,0.9041681289672852
1037,1/29/2021 1:00:55 PM,Eli Lilly Q4 Results Top Estimates; Backs FY21 Outlook ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-backs-fy21-outlook-1030019411,positive,0.6828452944755554
1038,1/29/2021 1:45:44 PM,"The Daily Biotech Pulse: Novavax Vaccine Readout, Clinical Hold On Bellicum Study Lifted, Lilly Earnings, NLS Pharma IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-readout-clinical-hold-on-bellicum-study-lifted-lilly-earnings-nls-pharma-ipo-1030019600,positive,0.9045888781547546
1039,1/29/2021 7:19:02 PM,Biogen’s FDA review extension: ‘a positive for Lilly’s Alzheimer perception' – MS,Seeking Alpha,https://seekingalpha.com/news/3656321-biogens-fda-review-extension-a-positive-for-lillys-alzheimer-perception-ms?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7267768383026123
1040,1/30/2021 7:19:15 PM,"The Week Ahead In Biotech: Merck, Pfizer In Earnings Mix, Plus Adamas, Mallinckrodt FDA Decisions, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-merck-pfizer-in-earnings-mix-plus-adamas-mallinckrodt-fda-decisions-ipos-and-more-1030022250,positive,0.8783656358718872
1041,1/31/2021 3:35:05 PM,3 Recent Earnings Stocks Worth Buying Today,InvestorPlace,/news/stocks/3-recent-earnings-stocks-worth-buying-today-1030023479,positive,0.8960018754005432
1042,2/2/2021 2:30:28 PM,Cassava surges after favorable trial data for simufilam in Alzheimer’s disease,Seeking Alpha,https://seekingalpha.com/news/3657220-cassava-surges-after-favorable-results-for-simufilam-in-alzheimers-disease?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9413415193557739
1043,2/3/2021 5:33:40 AM,"Lilly, Innovent Bio's Tyvyt + chemotherapy OK'd in China for lung cancer",Seeking Alpha,https://seekingalpha.com/news/3657589-lilly-innovent-bios-tyvyt-chemotherapy-okd-in-china-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5170992612838745
1044,2/4/2021 3:00:00 PM,10 Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-thursday-1030043861,positive,0.7969076037406921
1045,2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6293289065361023
1046,2/9/2021 1:19:15 PM,Eli Lilly Appoints Anat Ashkenazi To Succeed Josh Smiley As CFO - Quick Facts ,RTTNews,/news/stocks/eli-lilly-appoints-anat-ashkenazi-to-succeed-josh-smiley-as-cfo-quick-facts-1030059967,positive,0.934157133102417
1047,2/9/2021 2:58:26 PM,Lilly taps Anat Ashkenazi as new CFO,Seeking Alpha,https://seekingalpha.com/news/3659911-lilly-picks-internal-candidate-for-cfo-position?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9331649541854858
1048,2/10/2021 2:20:40 AM,Lilly's COVID-19 Antibody Combination Receives Emergency Use Authorization In U.S. ,RTTNews,/news/stocks/lilly-s-covid-19-antibody-combination-receives-emergency-use-authorization-in-u-s-1030063212,negative,0.8536990880966187
1049,2/10/2021 4:59:02 AM,FDA grants EUA for Lilly COVID-19 monoclonal antibody combo,Seeking Alpha,https://seekingalpha.com/news/3660349-fda-grants-emergency-use-authorization-lilly-covid-19-monoclonal-antibody-combo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.810177743434906
1050,2/10/2021 8:53:35 AM,"GMDA On Track, GNFT Soars, HTBX Sparkles, LLY's Neutralizing Antibody Therapies Get FDA  Nod ",RTTNews,/news/stocks/gmda-on-track-gnft-soars-htbx-sparkles-lly-s-neutralizing-antibody-therapies-get-fda-nod-1030065055,negative,0.8798632025718689
1051,2/10/2021 1:34:43 PM,"The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-covid-19-antibody-cocktail-approved-for-emergency-use-gamida-genfit-jump-on-data-2-ipos-1030066164,positive,0.6823869347572327
1052,2/10/2021 1:51:54 PM,AbCellera shares jump after bamlanivimab combo nabs FDA's EUA for COVID-19 treatment,Seeking Alpha,https://seekingalpha.com/news/3660525-abcellera-shares-jump-after-bamlanivimab-combo-nabs-fdas-eua-for-covid-19-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.36324360966682434
1053,2/11/2021 3:14:41 PM,ACIU Stock: Why AC Immune Shares Are Rocketing Higher Today,InvestorPlace,/news/stocks/aciu-stock-why-ac-immune-shares-are-rocketing-higher-today-1030073976,negative,0.8638250231742859
1054,2/13/2021 9:00:00 PM,"Pharmas engaged in Alzheimer's, the 'holy grail' of drug development",Seeking Alpha,https://seekingalpha.com/news/3661766-pharmas-engaged-in-alzheimers-the-holy-grail-of-drug-development?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8926677107810974
1055,2/17/2021 1:04:31 PM,Eli Lilly: Tirzepatide Significantly Reduced A1C And Body Weight In Two Phase 3 SURPASS Trials ,RTTNews,/news/stocks/eli-lilly-tirzepatide-significantly-reduced-a1c-and-body-weight-in-two-phase-3-surpass-trials-1030091441,negative,0.5448886156082153
1056,2/17/2021 2:40:46 PM,Lilly’s Tirzepatide studies achieve primary and secondary endpoints,Seeking Alpha,https://seekingalpha.com/news/3662856-lillys-tirzepatide-studies-achieve-primary-and-secondary-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.619914174079895
1057,2/18/2021 11:47:33 AM,Rigel shares surge 41% on RIPK1 inhibitors deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3663357-eli-lilly-rigel-team-up-to-develop-ripk1-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9009903073310852
1058,2/18/2021 12:53:14 PM,"Lilly, Rigel To Develop RIPK1 Inhibitors For Treatment Of Immunological & Neurodegenerative Diseases ",RTTNews,/news/stocks/lilly-rigel-to-develop-ripk1-inhibitors-for-treatment-of-immunological-neurodegenerative-diseases-1030096390,positive,0.6856825947761536
1059,2/18/2021 2:14:38 PM,"The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-lily-rigel-licensing-deal-vtv-starts-early-stage-psoriasis-study-immunic-data-readout-1030097072,positive,0.9154621958732605
1060,2/18/2021 4:47:21 PM,"Lilly Strikes Licensing Deal With Rigel In Push Toward Neurological, Immunological Therapies",Benzinga,/news/stocks/lilly-strikes-licensing-deal-with-rigel-in-push-toward-neurological-immunological-therapies-1030098049,negative,0.9064223766326904
1061,2/18/2021 7:48:55 PM,RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today,InvestorPlace,/news/stocks/rigl-stock-why-rigel-pharmaceuticals-is-climbing-today-1030099041,negative,0.8389608860015869
1062,2/19/2021 7:02:13 AM,"FLXN On Track, IMNM Discovers Antibodies To Fight S. African Variant, RIGL In Deal With LLY ",RTTNews,/news/stocks/flxn-on-track-imnm-discovers-antibodies-to-fight-s-african-variant-rigl-in-deal-with-lly-1030100306,negative,0.922179102897644
1063,2/19/2021 1:25:51 PM,"The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-supply-deal-orphan-drug-designation-for-travere-covid-19-boost-for-quidel-opko-1030101326,positive,0.7778980731964111
1064,2/19/2021 2:32:59 PM,"Precision Bio's ARCUS Gene Editing Platform Is Safe, Durable; Long-Term Animal Study Shows",Benzinga,/news/stocks/precision-bio-s-arcus-gene-editing-platform-is-safe-durable-long-term-animal-study-shows-1030101589,negative,0.8003303408622742
1065,2/19/2021 8:30:27 PM,Avidity Biosciences shares soar 18% in afternoon trading,Seeking Alpha,https://seekingalpha.com/news/3664079-avidity-biosciences-shares-soar-18-in-afternoon-trading?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9040855169296265
1066,2/22/2021 2:07:58 PM,Six stocks hedge funds and mutual funds love (and 20 they don't): At the Open,Seeking Alpha,https://seekingalpha.com/news/3664311-six-stocks-hedge-funds-and-mutual-funds-love?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9283661842346191
1067,2/23/2021 5:21:45 PM,Veru Files US Application For TADFIN Combo For Prostate Enlargement,Benzinga,/news/stocks/veru-files-us-application-for-tadfin-combo-for-prostate-enlargement-1030114252,positive,0.7021368741989136
1068,2/24/2021 1:17:19 PM,RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today,InvestorPlace,/news/stocks/rlftf-why-little-known-relief-therapeutics-is-climbing-today-brpa-stock-1030119085,negative,0.6067991852760315
1069,2/24/2021 10:57:00 PM,"Alvogen Pharma US, Inc. -- Moody's affirms Alvogen's ratings; outlook revised to negative",Moodys,/news/bonds/alvogen-pharma-us-inc-moody-s-affirms-alvogen-s-ratings-outlook-revised-to-negative-1030120543,neutral,0.6485306620597839
1070,2/25/2021 7:50:23 PM,Lilly's migraine med approved in Canada for episodic cluster headache,Seeking Alpha,https://seekingalpha.com/news/3666622-lillys-migraine-med-approved-in-canada-for-episodic-cluster-headache?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5736086368560791
1071,2/26/2021 12:15:26 PM,U.S. to buy 100K doses of Lilly's bamlanivimab combo for COVID-19,Seeking Alpha,https://seekingalpha.com/news/3667055-us-to-buy-100k-doses-of-lillys-bamlanivimab-combo-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6771022081375122
1072,2/26/2021 1:14:22 PM,"Eli Lilly: U.S. Govt. To Buy Min. 100K Doses Of Bamlanivimab 700 Mg, Etesevimab 1400 Mg Together ",RTTNews,/news/stocks/eli-lilly-u-s-govt-to-buy-min-100k-doses-of-bamlanivimab-700-mg-etesevimab-1400-mg-together-1030129089,negative,0.5141299366950989
1073,2/26/2021 2:16:52 PM,"The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-test-awaits-j-j-s-covid-19-vaccine-lilly-to-supply-additional-antibody-therapy-doses-to-us-regulatory-setback-for-tricida-1030129439,neutral,0.9285117387771606
1074,2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296,positive,0.9465387463569641
1075,3/1/2021 8:40:13 PM,Eli Lilly secures $2.52B Army contract for LY-CoV555 and LY-CoV016,Seeking Alpha,https://seekingalpha.com/news/3667860-eli-lilly-secures-252b-army-contract-for-ly-cov555-and-ly-cov016?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9248424768447876
1076,3/3/2021 12:04:43 PM,"Lilly, Incyte's baricitinib shows hair regrowth in late-stage alopecia areata study",Seeking Alpha,https://seekingalpha.com/news/3668631-lilly-incytes-baricitinib-successful-in-alopecia-areata-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5546414256095886
1077,3/3/2021 1:04:01 PM,Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth ,RTTNews,/news/stocks/lilly-phase-3-study-on-baricitinib-meets-primary-endpoint-of-hair-regrowth-1030144664,negative,0.7628650665283203
1078,3/3/2021 1:34:53 PM,"Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment- Quick Facts ",RTTNews,/news/stocks/eli-lilly-incyte-report-positive-results-for-baricitinib-in-alopecia-areata-treatment-quick-facts-1030144848,negative,0.9428061246871948
1079,3/4/2021 12:28:41 PM,Lilly's tirzepatide improves blood glucose and weight loss vs. semaglutide in diabetes,Seeking Alpha,https://seekingalpha.com/news/3669286-lillys-tirzepatide-shows-superiority-over-semaglutide-in-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9360838532447815
1080,3/4/2021 2:04:33 PM,Eli Lilly Announces Positive Topline Results From Late-stage Study Of Tirzepatide- Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-positive-topline-results-from-late-stage-study-of-tirzepatide-quick-facts-1030150027,negative,0.925592303276062
1081,3/4/2021 2:12:10 PM,"The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-pfizer-kiniksa-rises-on-commercialization-pact-with-regeneron-bio-techne-to-buy-diagnostic-company-1030150188,negative,0.9189565181732178
1082,3/4/2021 5:06:51 PM,9 Cheap Stocks That Look Like a Bargain,InvestorPlace,/news/stocks/9-cheap-stocks-look-like-bargain-1030151715,positive,0.8964874744415283
1083,3/5/2021 5:15:16 PM,Eli Lilly’s antibody combo wins positive opinion in Europe against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3669986-eli-lillys-antibody-combo-wins-positive-opinion-in-europe-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9497390389442444
1084,3/5/2021 8:45:57 PM,AbCellera's bamlanivimab wins EMA's positive recommendation,Seeking Alpha,https://seekingalpha.com/news/3670026-abcelleras-bamlanivimab-wins-emas-positive-recommendation?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9448854327201843
1085,3/8/2021 1:13:12 PM,Struggling defensive sectors losing even more appeal ahead of more stimulus: At the Open,Seeking Alpha,https://seekingalpha.com/news/3670158-struggling-defensive-sectors-losing-even-more-appeal?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.882236659526825
1086,3/8/2021 10:20:04 PM,Lilly to collaborate with Biolojic Design to develop diabetes antibody therapies,Seeking Alpha,https://seekingalpha.com/news/3670507-lilly-to-collaborate-with-biolojic-design-to-develop-diabetes-antibody-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.508934497833252
1087,3/9/2021 12:53:49 PM,Eli Lilly: Myles O'Neill And Melissa Barnes To Retire - Quick Facts ,RTTNews,/news/stocks/eli-lilly-myles-o-neill-and-melissa-barnes-to-retire-quick-facts-1030163056,positive,0.9315310716629028
1088,3/9/2021 2:08:24 PM,"The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data",Benzinga,/news/stocks/the-daily-biotech-pulse-regulatory-setback-for-acadia-lilly-forges-diabetes-antibody-treatment-collaboration-aytu-s-positive-covid-19-data-1030163477,positive,0.44644373655319214
1089,3/10/2021 1:22:28 PM,Lilly's (LLY) COVID-19 antibody combo reduced hospitalization and death by 87%,Seeking Alpha,https://seekingalpha.com/news/3671153-lillys-covid-19-combo-therapy-reduced-covid-hospitalizationby-87?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9428842067718506
1090,3/10/2021 1:25:59 PM,"The Daily Biotech Pulse: MediciNova Bags BARDA Contract, Lilly's COVID-19 Antibody Cocktail Data, Bluebird Bio Refutes Blood Cancer Link",Benzinga,/news/stocks/the-daily-biotech-pulse-medicinova-bags-barda-contract-lilly-s-covid-19-antibody-cocktail-data-bluebird-bio-refutes-blood-cancer-link-1030168202,positive,0.9139814972877502
1091,3/10/2021 1:27:12 PM,Lilly' Bamlanivimab & Etesevimab Reduce Hospitalizations & Death In Phase 3 Trial For Early COVID-19 ,RTTNews,/news/stocks/lilly-bamlanivimab-etesevimab-reduce-hospitalizations-death-in-phase-3-trial-for-early-covid-19-1030168188,positive,0.6802834868431091
1092,3/10/2021 4:37:41 PM,AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3671258-abcellera-discovered-bamlanivimab-combo-shows-promise-in-late-stage-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9282432198524475
1093,3/10/2021 4:54:25 PM,8 Biotech Penny Stocks for Investors to Watch,InvestorPlace,/news/stocks/eight-biotech-penny-stocks-investors-to-watch-1030169900,positive,0.9360546469688416
1094,3/10/2021 5:30:16 PM,Adocia initiates mid-stage M1pram diabetes trial,Seeking Alpha,https://seekingalpha.com/news/3671288-adocia-initiates-mid-stage-m1pram-diabetes-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8973620533943176
1095,3/11/2021 9:44:40 PM,What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.,InvestorPlace,/news/stocks/what-did-the-stock-market-do-today-3-big-stories-cpng-stock-ocgn-stock-stimulus-1030175736,positive,0.9254742860794067
1096,3/12/2021 8:30:12 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3672347-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
1097,3/13/2021 2:20:32 PM,Full phase 2 data of Lilly's donanemab for Alzheimer's offers mixed bag,Seeking Alpha,https://seekingalpha.com/news/3672430-full-phase-2-data-of-lilly-donanemab-for-alzheimers-offers-mixed-bag?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9169200658798218
1098,3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6729742884635925
1099,3/14/2021 1:14:58 PM,"Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations",Benzinga,/news/stocks/week-ahead-in-biotech-march-14-20-update-on-fibrogen-astrazeneca-s-anemia-drug-earnings-and-presentations-1030194424,positive,0.9395514130592346
1100,3/15/2021 12:23:11 PM,"Eli Lilly, Magnite leads the premarket losers' pack",Seeking Alpha,https://seekingalpha.com/news/3672572-eli-lilly-magnite-leads-the-premarket-losers-pack?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8879707455635071
1101,3/15/2021 12:49:00 PM,Eli Lilly viewed with interest at Citi despite ‘zero’ chance of approval for donanemab,Seeking Alpha,https://seekingalpha.com/news/3672599-eli-lilly-viewed-with-interest-at-citi-despite-donanemab-results?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8796790242195129
1102,3/15/2021 4:35:15 PM,Lilly charts course for second donanemab pivotal trial in Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3672720-lilly-charts-course-for-second-donanemab-pivotal-trial-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5574560761451721
1103,3/15/2021 4:55:51 PM,Lilly's bamlanivimab combo cuts hospitalizations and death in phase 3 early COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3672747-lillys-bamlanivimab-combo-cuts-hospitalizations-and-death-in-phase-3-early-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5426474809646606
1104,3/15/2021 5:04:34 PM,Mid-Day Market Update: Intec Pharma Jumps Following Merger News; HighPoint Resources Shares Plunge,Benzinga,/news/stocks/mid-day-market-update-intec-pharma-jumps-following-merger-news-highpoint-resources-shares-plunge-1030206136,neutral,0.643177330493927
1105,3/15/2021 5:36:28 PM,42 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/42-stocks-moving-in-monday-s-mid-day-session-1030206348,neutral,0.5072711110115051
1106,3/15/2021 6:06:24 PM,Biogen nears session lows as Jefferies holds call on Alzheimer's drugs,Seeking Alpha,https://seekingalpha.com/news/3672776-biogen-nears-session-lows-as-jefferies-holds-call-on-alzheimers-drugs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9045403599739075
1107,3/16/2021 11:29:14 AM,65 Biggest Movers From Yesterday,Benzinga,/news/stocks/65-biggest-movers-from-yesterday-1030213887,positive,0.5446376800537109
1108,3/16/2021 12:35:22 PM,Lilly's mirikizumab meets endpoints in late-stage ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3673072-lillys-mirikizumab-meets-endpoints-in-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8652240633964539
1109,3/17/2021 7:18:58 AM,"CELC Inks Breast Cancer Trial Collaboration, CANF Soars On Deal With Ewopharma, MRUS On Watch ",RTTNews,/news/stocks/celc-inks-breast-cancer-trial-collaboration-canf-soars-on-deal-with-ewopharma-mrus-on-watch-1030217968,negative,0.5795764327049255
1110,3/17/2021 12:00:17 PM,FTC moves to hinder cross-border pharma mergers; CVS cut to neutral at Guggenheim and more in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3673529-ftc-moves-to-hinder-cross-border-pharma-mergers-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8739835023880005
1111,3/17/2021 12:02:41 PM,Lilly Reports Patient-Reported Outcomes From Phase 3 MonarchE Trial For Verzenio ,RTTNews,/news/stocks/lilly-reports-patient-reported-outcomes-from-phase-3-monarche-trial-for-verzenio-1030218745,positive,0.5911619663238525
1112,3/17/2021 12:22:17 PM,Lilly presents favorable patient reported outcomes in late-stage trial for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3673543-lilly-presents-favorable-patient-reported-outcomes-in-late-stage-trial-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9507423639297485
1113,3/20/2021 2:52:32 PM,"FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings",Benzinga,/news/stocks/fda-decisions-for-pfizer-eli-lilly-and-bluebird-bio-bristol-meyers-squibb-plus-new-data-and-earnings-1030229632,positive,0.9303885102272034
1114,3/21/2021 4:18:05 PM,"Barron's Latest Picks And Pans: Space Race Picks, Eli Lilly, GameStop, Splunk And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-space-race-picks-eli-lilly-gamestop-splunk-and-more-1030230109,positive,0.9424091577529907
1115,3/22/2021 2:23:40 PM,FDA briefing documents released ahead of AdCom meeting on Pfizer’s BLA for tanezumab,Seeking Alpha,https://seekingalpha.com/news/3674809-fda-briefing-documents-released-ahead-of-adcom-meeting-on-pfizers-tanezumab?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9152623414993286
1116,3/23/2021 6:31:22 AM,"AZN's COVID-19 Jab Shows 79% Efficacy, ZEAL Wins FDA Approval, AdComm To Review Osteoarthritis Drug ",RTTNews,/news/stocks/azn-s-covid-19-jab-shows-79-efficacy-zeal-wins-fda-approval-adcomm-to-review-osteoarthritis-drug-1030234460,negative,0.9112752676010132
1117,3/24/2021 1:59:18 PM,"The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-dynavax-clover-start-phase-2-3-vaccine-study-brainstorm-reports-positive-ms-readout-neogenomics-goes-shopping-1030241020,negative,0.6489724516868591
1118,3/25/2021 12:58:24 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-s-skin-cancer-readout-cellect-strikes-reverse-merger-deal-lava-therapeutics-makes-nasdaq-debut-1030245316,positive,0.8989565968513489
1119,3/25/2021 4:30:01 PM,Pfizer’s tanezumab in osteoarthritis turned down by FDA expert panel (updated),Seeking Alpha,https://seekingalpha.com/news/3676348-pfizers-marketing-application-on-tanezumab-fails-in-adcom-vote?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.528425931930542
1120,3/26/2021 9:38:09 AM,"5 Stocks To Watch For March 26, 2021",Benzinga,/news/stocks/5-stocks-to-watch-for-march-26-2021-1030249063,positive,0.9011488556861877
1121,3/26/2021 10:57:30 AM,A Peek Into The Markets: US Stock Futures Gain Ahead Of Economic Reports,Benzinga,/news/stocks/a-peek-into-the-markets-us-stock-futures-gain-ahead-of-economic-reports-1030249240,negative,0.8521950244903564
1122,3/26/2021 12:20:54 PM,Aspira extends gains as analysts weigh in; Flexion to benefit from Pfizer’s failure in osteoarthritis drug and more in today’s analyst action,Seeking Alpha,https://seekingalpha.com/news/3676731-aspira-extends-gains-as-analysts-weigh-in-flexion-to-benefit-from-pfizers-failure?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9457762837409973
1123,3/29/2021 12:50:46 PM,"Lilly, Vir Bio, GSK's cocktail antibody shows positive action in COVID-19",Seeking Alpha,https://seekingalpha.com/news/3677146-lilly-vir-bio-gsks-cocktail-antibody-shows-positive-action-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8984183669090271
1124,3/29/2021 2:58:45 PM,"Lilly, Vir And GSK Announce Positive Data From Phase 2 BLAZE-4 Trial On COVID-19 ",RTTNews,/news/stocks/lilly-vir-and-gsk-announce-positive-data-from-phase-2-blaze-4-trial-on-covid-19-1030254696,negative,0.9051219820976257
1125,3/30/2021 2:06:26 PM,"The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-wave-life-sciences-pulls-plug-on-2-assets-amarin-s-vascepa-snags-european-approval-biocept-jumps-on-earnings-1030258478,negative,0.7632596492767334
1126,4/1/2021 3:02:28 PM,Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition,Benzinga,/news/stocks/fortress-biotech-s-partner-firm-expands-footprint-in-dermatology-with-qbrexza-acquisition-1030269030,negative,0.7961474657058716
1127,4/1/2021 7:40:39 PM,Eli Lilly subsidiary to divest Qbrexza to Journey Medical,Seeking Alpha,https://seekingalpha.com/news/3678822-eli-lilly-subsidiary-to-divest-qbrexza-to-journey-medical?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9461510181427002
1128,4/3/2021 3:11:24 PM,"The Week Ahead In Biotech: Regeneron, Supernus FDA Decisions, Cancer Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-regeneron-supernus-fda-decisions-cancer-conference-presentations-in-the-spotlight-1030272481,positive,0.9472838640213013
1129,4/5/2021 6:42:13 AM,Health Canada approves Lilly's Taltz for plaque psoriasis in pediatric patients,Seeking Alpha,https://seekingalpha.com/news/3679018-health-canada-approves-lillys-taltz-for-plaque-psoriasis-in-pediatric-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6620964407920837
1130,4/6/2021 2:29:11 PM,JP Morgan physician survey finds support for Lilly's donanemab in Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/3679541-jp-morgan-physician-survey-finds-support-for-lilly-donanemab-in-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9133780002593994
1131,4/6/2021 2:55:42 PM,Is Silicon Valley Replacing Big Pharma In Neuroscience?,Benzinga,/news/stocks/is-silicon-valley-replacing-big-pharma-in-neuroscience-1030277135,positive,0.8876467347145081
1132,4/6/2021 8:39:09 PM,"FDA extends review period for Eli Lilly, Incyte's baricitinib atopic dermatitis sNDA",Seeking Alpha,https://seekingalpha.com/news/3679664-fda-extends-review-period-for-eli-lilly-incytes-baricitinib-atopic-dermatitis-snda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4313618242740631
1133,4/7/2021 1:57:58 PM,"The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award",Benzinga,/news/stocks/the-daily-biotech-pulse-fibrogen-fudges-safety-data-novartis-strikes-cancer-drug-collaboration-immutep-gains-on-patent-award-1030280866,negative,0.6349209547042847
1134,4/8/2021 11:23:22 AM,"Lilly, Incyte's COV-BARRIER study fails to meet primary endpoint in COVID-19",Seeking Alpha,https://seekingalpha.com/news/3680241-lilly-incytes-cov-barrier-study-fails-to-meet-primary-endpoint-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.939039409160614
1135,4/8/2021 1:26:43 PM,"Lilly woes provide buying opportunity, Danaher a buy with likely earnings beat, and more in today's analyst action",Seeking Alpha,https://seekingalpha.com/news/3680280-lilly-woes-provide-buying-opportunity-danaher-a-buy-with-likely-earnings-beat-and-more-in-todays-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7149387001991272
1136,4/8/2021 1:41:24 PM,Eli Lilly Says Late-stage Study Of Baricitinib In Hospitalized Covid Patients Didn't Meet Main Goal ,RTTNews,/news/stocks/eli-lilly-says-late-stage-study-of-baricitinib-in-hospitalized-covid-patients-didn-t-meet-main-goal-1030285100,neutral,0.7557854056358337
1137,4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466,positive,0.8932459950447083
1138,4/9/2021 12:30:56 PM,Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes,Benzinga,/news/stocks/provention-bio-stock-craters-after-fda-flags-deficiencies-in-pk-profiles-from-teplizumab-trials-for-diabetes-1030288688,neutral,0.8574405312538147
1139,4/9/2021 1:26:03 PM,"The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-negative-regulatory-tidings-for-provention-bio-celcuity-soars-on-in-licensing-deal-2-ipos-1030288848,neutral,0.9328569769859314
1140,4/10/2021 3:20:43 PM,The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight,Benzinga,/news/stocks/the-week-ahead-in-biotech-april-11-17-avenue-therapeutics-fda-decision-and-conference-presentations-in-the-spotlight-1030290858,positive,0.9432237148284912
1141,4/11/2021 3:38:21 PM,Healthcare momentum struggling with UnitedHealth set to report: Sector Watch,Seeking Alpha,https://seekingalpha.com/news/3680852-healthcare-stocks-momentum-stalling?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.954887330532074
1142,4/12/2021 9:06:47 AM,Lilly's retevmo shows antitumor activity in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3680871-lillys-retevmo-shows-antitumor-activity-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5441265106201172
1143,4/12/2021 11:21:17 AM,Eli Lilly and U.S. government amend supply agreement for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3680902-eli-lilly-and-us-government-amend-supply-agreement-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7592058777809143
1144,4/12/2021 12:58:46 PM,"Eli Lilly, U.S. Government Amend Purchase Agreements For Neutralizing Antibody Therapies ",RTTNews,/news/stocks/eli-lilly-u-s-government-amend-purchase-agreements-for-neutralizing-antibody-therapies-1030293179,negative,0.5018901824951172
1145,4/13/2021 3:51:18 AM,Lilly : Phase 3 Study Shows Sintilimab Improves OS For Squamous Non-small Cell Lung Cancer Patients ,RTTNews,/news/stocks/lilly-phase-3-study-shows-sintilimab-improves-os-for-squamous-non-small-cell-lung-cancer-patients-1030295802,negative,0.9145209193229675
1146,4/13/2021 6:53:37 AM,Lilly's Tyvyt 'significantly improves' overall survival as a second-line treatment for lung cancer,Seeking Alpha,https://seekingalpha.com/news/3681219-lillys-tyvyt-significantly-improves-overall-survival-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.954315185546875
1147,4/13/2021 12:43:44 PM,Eli Lilly Appoints Diogo Rau To Head Information Technology And Digital Capabilities ,RTTNews,/news/stocks/eli-lilly-appoints-diogo-rau-to-head-information-technology-and-digital-capabilities-1030297649,positive,0.9291257262229919
1148,4/13/2021 2:16:36 PM,"The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-leadership-transition-at-amarin-vaccine-setback-for-j-j-fda-nod-for-label-expansion-of-roche-s-asthma-drug-1030298345,negative,0.5212363004684448
1149,4/14/2021 11:35:37 AM,Eli Lilly and SciNeuro Pharmaceuticals ink exclusive license agreement,Seeking Alpha,https://seekingalpha.com/news/3681646-eli-lilly-and-scineuro-pharmaceuticals-ink-exclusive-license-agreement?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.701579213142395
1150,4/14/2021 1:51:00 PM,"The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-cfo-departs-zai-lab-inks-cancer-drug-collaboration-fda-nod-for-gilead-1030303096,positive,0.9114657044410706
1151,4/15/2021 5:39:05 PM,Merck hurt by another setback in its battle against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682287-merck-hurt-by-another-setback-in-its-battle-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9712752103805542
1152,4/16/2021 10:52:08 AM,Lilly requests withdrawal of emergency use nod of bamlanivimab alone in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3682491-lilly-requests-withdrawal-of-emergency-use-nod-of-bamlanivimab-alone-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5598994493484497
1153,4/16/2021 12:50:40 PM,Eli Lilly Requests FDA Revoke EUA For Bamlanivimab 700 Mg Alone - Quick Facts ,RTTNews,/news/stocks/eli-lilly-requests-fda-revoke-eua-for-bamlanivimab-700-mg-alone-quick-facts-1030312052,positive,0.5891981720924377
1154,4/16/2021 2:00:59 PM,"The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-precision-biosciences-regains-rights-to-car-t-candidates-cfo-changes-2-ipos-1030312278,positive,0.8637768626213074
1155,4/16/2021 8:47:11 PM,Lilly and Incyte's baricitinib fails to meet main goal in late-stage COVID-19 trial,Seeking Alpha,https://seekingalpha.com/news/3682728-lilly-and-incytes-baricitinib-fails-to-meet-main-goal-in-late-stage-covid-19-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9349154233932495
1156,4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6620304584503174
1157,4/19/2021 4:58:40 PM,Large NIH-funded study to explore repurposed drugs for mild-to-moderate COVID-19,Seeking Alpha,https://seekingalpha.com/news/3683056-large-nih-funded-study-to-explore-repurposed-drugs-for-mild-to-moderate-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4961980879306793
1158,4/20/2021 11:11:34 AM,"Lilly, Incyte's second baricitinib study shows improvement in hair regrowth in alopecia areata patients",Seeking Alpha,https://seekingalpha.com/news/3683289-lilly-incytes-second-baricitinib-study-shows-improvement-in-hair-regrowth-in-alopecia-areata-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9484562277793884
1159,4/20/2021 1:51:46 PM,Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-2nd-late-stage-study-of-baricitinib-achieved-main-goal-quick-facts-1030322410,negative,0.8178072571754456
1160,4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640,positive,0.7906168103218079
1161,4/21/2021 1:31:27 PM,"The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-to-supply-variant-specific-vaccine-to-israel-roche-s-diagnostics-business-comes-to-rescue-1030327873,positive,0.6515435576438904
1162,4/23/2021 3:52:51 PM,Incyte presents more data from positive late-stage studies for ruxolitinib in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/3685158-incyte-presents-more-data-from-late-stage-studies-for-ruxolitinib-in-atopic-dermatitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5830709338188171
1163,4/23/2021 4:44:02 PM,Incyte : Olumiant Shows Improvements In Severity And Extent Of Atopic Dermatitis ,RTTNews,/news/stocks/incyte-olumiant-shows-improvements-in-severity-and-extent-of-atopic-dermatitis-1030339129,negative,0.9510595798492432
1164,4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692,positive,0.9154146313667297
1165,4/25/2021 3:01:40 PM,Eli Lilly and is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-q1-quarterly-earnings-preview-1030341714,positive,0.9350223541259766
1166,4/26/2021 4:36:08 PM,Eli Lilly Q1 2021 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3685577-eli-lilly-q1-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7261270880699158
1167,4/26/2021 4:42:37 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3685586-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
1168,4/27/2021 10:26:27 AM,"Eli Lilly EPS misses by $0.23, misses on revenue",Seeking Alpha,https://seekingalpha.com/news/3685930-eli-lilly-eps-misses-0_23-misses-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.849587619304657
1169,4/27/2021 11:08:52 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday Morning,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-morning-3-1030351233,neutral,0.5035114288330078
1170,4/27/2021 11:17:05 AM,Lilly slips 4% as Q4 trails estimates; Guidance lags consensus; COVID-19 antibody revenues of $810M,Seeking Alpha,https://seekingalpha.com/news/3685967-lilly-slips-4-as-q4-trails-estimates-and-guidance-lags-consensus-covid-19-antibody-revenues-of-810m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9727076888084412
1171,4/27/2021 12:30:23 PM,Eli Lilly And Co. Q1 adjusted earnings of $1.87 per share,RTTNews,/news/stocks/eli-lilly-and-co-q1-adjusted-earnings-of-1-87-per-share-1030350476,positive,0.7998855113983154
1172,4/27/2021 1:05:22 PM,24 Stocks Moving in Tuesday's Pre-Market Session,Benzinga,/news/stocks/24-stocks-moving-in-tuesday-s-pre-market-session-1030350694,positive,0.7560313940048218
1173,4/27/2021 1:25:45 PM,Lilly Q1 Profit Down; Cuts FY Profit View ,RTTNews,/news/stocks/lilly-q1-profit-down-cuts-fy-profit-view-1030350841,neutral,0.968636155128479
1174,4/28/2021 1:51:14 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030357518,positive,0.8142690658569336
1175,4/29/2021 2:39:08 PM,Lilly’s Olumiant undergoes European review for hospitalized  COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3687965-lillys-olumiant-undergoes-european-review-for-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.582008957862854
1176,5/1/2021 5:43:35 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1030373547,positive,0.9478530883789062
1177,5/1/2021 7:19:25 PM,"Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge",Benzinga,/news/stocks/week-ahead-in-biotech-may-2-8-chemocentryx-adcom-ophthalmology-conference-presentations-earnings-deluge-1030373608,positive,0.8418352007865906
1178,5/4/2021 1:28:54 PM,"Lilly donates 400,000 baricitinib tablets to India for use as COVID-19 therapy",Seeking Alpha,https://seekingalpha.com/news/3690156-lilly-donates-400000-baricitinib-tablets-to-india-for-use-as-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4968743324279785
1179,5/4/2021 1:38:50 PM,Lilly To Donate COVID-19 Treatment Baricitinib To India - Quick Facts ,RTTNews,/news/stocks/lilly-to-donate-covid-19-treatment-baricitinib-to-india-quick-facts-1030383661,positive,0.6993637681007385
1180,5/4/2021 2:19:15 PM,Lilly-AbCellera collaboration develops new antibody that can neutralize COVID-19 variants,Seeking Alpha,https://seekingalpha.com/news/3690194-lilly-abcellera-collaboration-develops-new-antibody-that-can-neutralize-covid-19-variants?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7320814728736877
1181,5/4/2021 2:34:49 PM,Lilly Outlines Plans To Strengthen ESG Commitments ,RTTNews,/news/stocks/lilly-outlines-plans-to-strengthen-esg-commitments-1030384194,negative,0.821785569190979
1182,5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6773343086242676
1183,5/5/2021 5:22:43 PM,Lilly implicated in production lapses at two of its plants,Seeking Alpha,https://seekingalpha.com/news/3691282-lilly-implicated-in-production-lapses-at-two-of-its-plants?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9651216864585876
1184,5/7/2021 7:30:30 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3693377-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8980498313903809
1185,5/8/2021 6:10:15 PM,"The Past Week's Notable Insider Buys: Amphenol, Aldeyra, Werewolf Therapeutics And More",Benzinga,/news/stocks/the-past-week-s-notable-insider-buys-amphenol-aldeyra-werewolf-therapeutics-and-more-1030404834,positive,0.7857415080070496
1186,5/11/2021 11:02:42 AM,"Lilly, MiNA Therapeutics ink saRNA research collaboration",Seeking Alpha,https://seekingalpha.com/news/3694429-lilly-mina-therapeutics-ink-sarna-research-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9376315474510193
1187,5/11/2021 1:03:18 PM,"Eli Lilly, MiNA Therapeutics To Collaborate On Research Using MiNA's SaRNA Technology - Quick Facts ",RTTNews,/news/stocks/eli-lilly-mina-therapeutics-to-collaborate-on-research-using-mina-s-sarna-technology-quick-facts-1030413814,positive,0.729781985282898
1188,5/11/2021 1:54:31 PM,"The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-pfizer-biontech-covid-19-vaccine-for-adolescents-lilly-strikes-r-d-collaboration-vaccine-stocks-novavax-inovio-sink-on-earnings-1030414147,positive,0.846595048904419
1189,5/11/2021 5:50:08 PM,Dr Reddy's strikes licensing deal with Lilly for Baricitinib,Seeking Alpha,https://seekingalpha.com/news/3694741-dr-reddys-strikes-licensing-deal-with-lilly-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7995362281799316
1190,5/18/2021 4:32:53 AM,"FDA accepts Lilly, Innovent's sintilimab + chemotherapy application in lung cancer",Seeking Alpha,https://seekingalpha.com/news/3697564-fda-accepts-lilly-innovents-sintilimab-chemotherapy-application-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8080570101737976
1191,5/18/2021 1:44:45 PM,"The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO",Benzinga,/news/stocks/the-daily-biotech-pulse-spero-secures-niaid-funding-glaxosmithkline-releases-covid-19-data-biontech-gets-new-cfo-1030440714,positive,0.7303595542907715
1192,5/18/2021 3:16:29 PM,Hershey To Buy Lily's Confectionery Brand - Quick Facts ,RTTNews,/news/stocks/hershey-to-buy-lily-s-confectionery-brand-quick-facts-1030441609,positive,0.8445928692817688
1193,5/18/2021 7:54:31 PM,Why Zomedica Doesn’t Need Reddit,InvestorPlace,/news/stocks/zom-stock-why-zomedica-doesnt-need-reddit-1030443399,positive,0.9341819286346436
1194,5/19/2021 9:01:32 AM,7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage,InvestorPlace,/news/stocks/7-best-biotech-stocks-to-buy-in-2021-as-innovation-takes-center-stage-1030445426,negative,0.6162664890289307
1195,5/20/2021 11:37:10 AM,Lilly’s Tirzepatide reaches endpoints in open label study for patients with type 2 diabetes,Seeking Alpha,https://seekingalpha.com/news/3698580-lillys-tirzepatide-reaches-endpoints-in-open-label-study-for-patients-with-type-2-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8910667300224304
1196,5/20/2021 1:49:56 PM,Lilly's Diabetes Drug Candidate Tirzepatide Meets Primary Study Outcome In Surpass-4 Trial ,RTTNews,/news/stocks/lilly-s-diabetes-drug-candidate-tirzepatide-meets-primary-study-outcome-in-surpass-4-trial-1030450418,negative,0.8861271142959595
1197,5/20/2021 2:27:03 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-order-flow-abounds-voyager-ceo-cmo-to-depart-decision-day-for-bristol-myers-squibb-asco-abstracts-move-stocks-1030450798,positive,0.6443605422973633
1198,5/21/2021 6:37:07 PM,FDA approves J&J's Rybrevant as targeted therapy for NSCLC patient subset,Seeking Alpha,https://seekingalpha.com/news/3699217-fda-approves-johnson-johnson-rybrevant-as-targeted-therapy-for-nsclc-patient-subset?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.799612283706665
1199,5/23/2021 4:05:56 PM,"The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-23-29-eton-lantheus-fda-decisions-adcom-test-for-provention-chiasma-data-presentation-1030457244,positive,0.9378595948219299
1200,5/24/2021 6:31:26 PM,3 Healthcare Stocks to Buy as the Sector Breaks Out,InvestorPlace,/news/stocks/3-healthcare-stocks-to-buy-as-the-sector-breaks-out-1030459870,positive,0.7721390128135681
1201,5/25/2021 1:53:39 PM,"The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-in-vaccine-supply-talks-with-india-provention-in-focus-ahead-of-briefing-doc-neurorx-to-list-via-spac-deal-1030461990,positive,0.8795015215873718
1202,5/27/2021 3:12:17 AM,GSK/Vir COVID-19 biologic wins FDA Emergency Use Authorization; Vir up 9%,Seeking Alpha,https://seekingalpha.com/news/3700603-gsk-vir-covid-19-biologic-wins-fda-emergency-use-authorization-vir-up-9?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9460386633872986
1203,5/27/2021 11:37:19 AM,FDA accepts Lilly and Dicerna's cardiometabolic diseases IND,Seeking Alpha,https://seekingalpha.com/news/3700702-fda-accepts-lilly-and-dicernas-cardiometabolic-diseases-ind?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8487316966056824
1204,5/27/2021 3:17:34 PM,Eli Lilly Reveals Receipt Of Subpoena From DoJ On Branchburg Manufacturing Facility - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reveals-receipt-of-subpoena-from-doj-on-branchburg-manufacturing-facility-quick-facts-1030471647,neutral,0.46652963757514954
1205,5/27/2021 4:45:07 PM,Eli Lilly under probe over alleged manufacturing lapses at New Jersey plant: Reuters,Seeking Alpha,https://seekingalpha.com/news/3700900-eli-lilly-under-probe-over-alleged-manufacturing-lapses-at-new-jersey-plant-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.91075199842453
1206,5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.850368320941925
1207,6/2/2021 2:20:24 PM,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-novartis-irhythm-ceo-quits-abruptly-moderna-inks-vaccine-supply-agreements-1030486987,positive,0.7045097351074219
1208,6/3/2021 9:13:31 AM,"Lilly, Innovent Bio's Tyvyt combo OK'd in China for lung cancer",Seeking Alpha,https://seekingalpha.com/news/3702755-lilly-innovent-bios-tyvyt-combo-okd-in-china-for-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5225493311882019
1209,6/4/2021 9:37:08 PM,Merus Reveals New Data From Zeno Program in NRG1 Fusion Cancers,Benzinga,/news/stocks/merus-reveals-new-data-from-zeno-program-in-nrg1-fusion-cancers-1030496448,positive,0.8860421776771545
1210,6/7/2021 6:34:19 PM,Eli Lilly hits 52-week high after Biogen wins FDA approval for Alzheimer’s therapy,Seeking Alpha,https://seekingalpha.com/news/3703836-eli-lilly-hits-52-week-high-after-biogen-won-fda-approval-for-alzheimers-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7779040336608887
1211,6/7/2021 7:21:42 PM,Biogen CEO: committed to gathering new data on FDA-approved Alzheimer's drug,Seeking Alpha,https://seekingalpha.com/news/3703844-biogen-ceo-committed-to-gathering-new-data-on-fda-approved-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.749740719795227
1212,6/8/2021 3:17:38 PM,"The Daily Biotech Pulse: Hookipa, PDS Biotech Report Positive Data, Ironwood CFO To Depart, Decision Day For Vertex",Benzinga,/news/stocks/the-daily-biotech-pulse-hookipa-pds-biotech-report-positive-data-ironwood-cfo-to-depart-decision-day-for-vertex-1030503836,positive,0.9079675674438477
1213,6/8/2021 3:18:10 PM,"Could Lilly's donanemab, others for Alzheimer's get a boost from Biogen approval?",Seeking Alpha,https://seekingalpha.com/news/3704152-could-lilly-donanemab-others-for-alzheimers-get-a-boost-from-biogen-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6547841429710388
1214,6/8/2021 4:09:35 PM,"Biogen, Eisai and other Alzheimer's players cool off in afternoon trading",Seeking Alpha,https://seekingalpha.com/news/3704216-biogen-eisai-and-other-alzheimers-players-cool-off-in-afternoon-trading?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6041277647018433
1215,6/8/2021 6:51:45 PM,"5 Biogen Analysts On FDA Approval Of Alzheimer's Drug Aduhelm, Broad Label, Pricing",Benzinga,/news/stocks/5-biogen-analysts-on-fda-approval-of-alzheimer-s-drug-aduhelm-broad-label-pricing-1030504841,positive,0.8534533977508545
1216,6/10/2021 11:05:59 AM,"Lilly, ALX Oncology collaborate in gastric or gastroesophageal cancer",Seeking Alpha,https://seekingalpha.com/news/3704911-lilly-alx-oncology-collaborate-in-gastric-or-gastroesophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9088579416275024
1217,6/10/2021 1:30:22 PM,ALX Oncology Inks Clinical Trial Collaboration Supply Deal With Eli Lilly For ALX148 Combination ,RTTNews,/news/stocks/alx-oncology-inks-clinical-trial-collaboration-supply-deal-with-eli-lilly-for-alx148-combination-1030511170,negative,0.7585814595222473
1218,6/10/2021 2:13:41 PM,"The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-us-to-procure-500m-pfizer-biontech-vaccine-doses-for-donation-verona-out-licenses-copd-drug-nautilus-lists-through-spac-deal-1030511571,positive,0.745228111743927
1219,6/10/2021 2:49:41 PM,Biogen Gets an Unearned Rip on an Unproven Drug,InvestorPlace,/news/stocks/biib-stock-an-unearned-rip-on-an-unproven-drug-1030512916,neutral,0.8146692514419556
1220,6/10/2021 4:43:14 PM,UBS sees $13B in peak Biogen Aduhelm sales for Alzheimer's based on doc checks,Seeking Alpha,https://seekingalpha.com/news/3705125-ubs-sees-13b-in-peak-biogen-aduhelm-sales-for-alzheimers-based-on-doc-checks?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7501081824302673
1221,6/11/2021 2:05:19 PM,"The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-shelves-mid-stage-study-precigen-novan-jump-on-data-hematology-conference-janux-debuts-1030515558,positive,0.8261427283287048
1222,6/11/2021 7:00:00 PM,Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-diabetes-portfolio-update-at-ada-1030516583,positive,0.923477053642273
1223,6/12/2021 8:00:43 PM,The road -- and obstacles -- ahead for Biogen's Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3705833-the-road-and-obstacles-ahead-for-biogens-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8098733425140381
1224,6/14/2021 4:00:00 PM,Lilly to Participate in Guggenheim Biopharma Strategy Series,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-biopharma-strategy-series-1030520135,positive,0.8311465978622437
1225,6/15/2021 9:59:16 AM,AstraZeneca’s STORM CHASER trial in COVID-19 misses primary endpoint of preventing COVID-19,Seeking Alpha,https://seekingalpha.com/news/3706281-astrazenecas-storm-chaser-trial-in-covid-19-misses-primary-endpoint-of-preventing-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7501548528671265
1226,6/15/2021 11:20:12 AM,Eli Lilly to start head-to-head study comparing two approved migraine therapies,Seeking Alpha,https://seekingalpha.com/news/3706320-eli-lilly-to-start-head-to-head-study-comparing-two-approved-migraine-therapies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6815512776374817
1227,6/15/2021 12:45:00 PM,Lilly Announces Head-to-Head Study Comparing Once-Monthly Emgality® with Every-Other-Day Nurtec® ODT for the Preventive Treatment of Migraine,PR Newswire,/news/stocks/lilly-announces-head-to-head-study-comparing-once-monthly-emgality-with-every-other-day-nurtec-odt-for-the-preventive-treatment-of-migraine-1030522796,negative,0.8786134719848633
1228,6/15/2021 1:07:41 PM,Eli Lilly To Launch Head-to-head Study Comparing Once-monthly Injectable Emgality With Nurtec ODT ,RTTNews,/news/stocks/eli-lilly-to-launch-head-to-head-study-comparing-once-monthly-injectable-emgality-with-nurtec-odt-1030522928,positive,0.5564526319503784
1229,6/15/2021 3:36:14 PM,Alzheimer's-focused Anavex takes a breather day after gaining 35%,Seeking Alpha,https://seekingalpha.com/news/3706529-alzheimers-focused-anavex-takes-a-breather-day-after-gaining-35?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.42907005548477173
1230,6/15/2021 4:10:47 PM,10 Biggest Price Target Changes For Tuesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-tuesday-1030524490,positive,0.8152946829795837
1231,6/15/2021 7:05:41 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030525266,positive,0.9322600364685059
1232,6/16/2021 2:02:10 PM,"Cramer Shares His Thoughts On Vertex Pharma, Snap And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-vertex-pharma-snap-and-more-1030527592,positive,0.932751476764679
1233,6/16/2021 2:06:24 PM,"Eli Lilly, Sanofi, and Novo Nordisk sued over insulin prices",Seeking Alpha,https://seekingalpha.com/news/3706905-eli-lilly-sanofi-and-novo-nordisk-sued-over-insulin-prices?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9124127626419067
1234,6/17/2021 2:00:00 PM,Lilly Launches Think Talk Treat Migraine™ to Help Improve Diagnosis and Treatment of Migraine,PR Newswire,/news/stocks/lilly-launches-think-talk-treat-migraine-to-help-improve-diagnosis-and-treatment-of-migraine-1030531801,negative,0.5268535614013672
1235,6/18/2021 2:55:08 PM,Biohaven gains on takeover speculation following board appointment,Seeking Alpha,https://seekingalpha.com/news/3707709-biohaven-gains-on-takeover-speculation-following-board-appointment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6574825644493103
1236,6/18/2021 6:00:30 PM,"4 Top Stock Trades for Monday: MSFT, TWLO, LLY, GE",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-msft-twlo-lly-ge-1030536281,positive,0.9386783838272095
1237,6/21/2021 7:35:35 PM,3 Top Stock Trades of the Week,InvestorPlace,/news/stocks/3-top-stock-trades-of-the-week-1030540695,positive,0.8558505177497864
1238,6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8699349761009216
1239,6/24/2021 7:42:17 AM,Biotech Stocks Facing FDA Decision In July 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-july-2021-1030549382,positive,0.818015456199646
1240,6/24/2021 10:59:56 AM,Eli Lilly to file marketing application for Alzheimer’s therapy this year,Seeking Alpha,https://seekingalpha.com/news/3709448-eli-lilly-says-it-plans-to-file-marketing-application-for-alzheimers-therapy-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.745063841342926
1241,6/24/2021 12:26:43 PM,"FSLR, LLY, SNDL and BBBY among premarket gainers",Seeking Alpha,https://seekingalpha.com/news/3709505-fslr-lly-sndl-and-bbby-among-premarket-gainers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8768869042396545
1242,6/24/2021 12:45:00 PM,Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease,PR Newswire,/news/stocks/lilly-s-donanemab-receives-u-s-fda-s-breakthrough-therapy-designation-for-treatment-of-alzheimer-s-disease-1030550392,negative,0.9317339658737183
1243,6/24/2021 1:38:12 PM,Lilly's Donanemab For Alzheimer's Disease Gets Breakthrough Therapy Designation ,RTTNews,/news/stocks/lilly-s-donanemab-for-alzheimer-s-disease-gets-breakthrough-therapy-designation-1030550648,negative,0.7858726978302002
1244,6/24/2021 2:00:00 PM,Lilly announces call for Leonard Award nominations as part of global initiative celebrating 100 years of insulin,PR Newswire,/news/stocks/lilly-announces-call-for-leonard-award-nominations-as-part-of-global-initiative-celebrating-100-years-of-insulin-1030550851,positive,0.6989043354988098
1245,6/24/2021 2:12:04 PM,"The Daily Biotech Pulse: Lilly Spikes On Alzheimer's Drug Regulatory Filing Plan, Applied Genetics, Arcus Issue Data Readouts, Adcom Test Awaits Incyte, Monte Rosa Prices IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-spikes-on-alzheimer-s-drug-regulatory-filing-plan-applied-genetics-arcus-issue-data-readouts-adcom-test-awaits-incyte-monte-rosa-prices-ipo-1030550889,positive,0.93064284324646
1246,6/24/2021 2:59:27 PM,LLY Stock: The Alzheimer’s Drug News Sending Eli Lilly Higher Today,InvestorPlace,/news/stocks/lly-stock-the-alzheimers-drug-news-sending-eli-lilly-higher-today-1030551951,negative,0.9066019058227539
1247,6/24/2021 3:18:48 PM,ENFA Stock: 10 Things Potential Investors Should Know About the BuzzFeed SPAC Merger,InvestorPlace,/news/stocks/enfa-stock-10-things-potential-investors-should-know-about-the-buzzfeed-spac-merger-1030552091,positive,0.9345970153808594
1248,6/24/2021 3:42:34 PM,LAZR Stock: The Volvo News That Has Luminar Technologies Investors Smiling Today,InvestorPlace,/news/stocks/lazr-stock-the-volvo-news-that-has-luminar-technologies-investors-smiling-today-1030552154,positive,0.5945194959640503
1249,6/24/2021 4:00:54 PM,Midday Market Update: 10 Biggest Stocks Gainers Today,InvestorPlace,/news/stocks/midday-market-update-10-biggest-stocks-gainers-today-1030552204,negative,0.5918791890144348
1250,6/24/2021 4:58:13 PM,PreMarket Prep Recap: The 4 Stocks Dennis Dick Bought Yesterday,Benzinga,/news/stocks/premarket-prep-recap-the-4-stocks-dennis-dick-bought-yesterday-1030551973,positive,0.9400940537452698
1251,6/24/2021 6:04:24 PM,Mizuho enthusiasm for Eli Lilly tempered after talk with company,Seeking Alpha,https://seekingalpha.com/news/3709766-mizuho-enthusiasm-for-eli-lilly-alzheimers-drug-tempered-after-talk-with-company?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9339338541030884
1252,6/24/2021 6:10:26 PM,36 Stocks Moving In Thursday's Mid-Day Session,Benzinga,/news/stocks/36-stocks-moving-in-thursday-s-mid-day-session-1030552259,neutral,0.5422112941741943
1253,6/24/2021 9:22:04 PM,"Biogen shares hit by Lilly donanemab Breakthrough Therapy designation, filing plans",Seeking Alpha,https://seekingalpha.com/news/3709984-biogen-shares-hit-by-lilly-donanemab-breakthrough-therapy-designation-filing-plans?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9538450241088867
1254,6/25/2021 11:20:52 AM,45 Biggest Movers From Yesterday,Benzinga,/news/stocks/45-biggest-movers-from-yesterday-1030554190,positive,0.7124632000923157
1255,6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577,negative,0.7482125759124756
1256,6/25/2021 5:30:00 PM,Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type ...,PR Newswire,/news/stocks/lilly-s-surpass-2-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-superior-a1c-and-body-weight-reductions-compared-to-injectable-semaglutide-in-adults-with-type-1030555443,negative,0.9499629735946655
1257,6/25/2021 6:39:42 PM,Eli Lilly COVID-19 antibody shipments halted in the U.S. citing prevalence of variants,Seeking Alpha,https://seekingalpha.com/news/3710240-eli-lilly-covid-19-antibody-shipments-halted-in-the-us-citing-prevalence-of-variants?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9594301581382751
1258,6/26/2021 10:15:00 PM,Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes,PR Newswire,/news/stocks/lilly-s-surpass-1-results-published-in-the-lancet-show-tirzepatide-s-superior-a1c-and-body-weight-reductions-versus-placebo-in-adults-with-type-2-diabetes-1030556609,negative,0.947365939617157
1259,6/27/2021 6:02:12 AM,"Eli Lilly, BioMarin and Seagen among top large-cap biopharma names at BofA",Seeking Alpha,https://seekingalpha.com/news/3710326-eli-lilly-biomarin-and-seagen-among-top-large-cap-biopharma-names-at-bofa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6189488768577576
1260,6/27/2021 6:55:52 PM,"The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus",Benzinga,/news/stocks/the-week-ahead-in-biotech-mediwound-provention-fda-decisions-ipos-pending-clinical-readouts-in-focus-1030556958,positive,0.940535843372345
1261,6/28/2021 7:39:58 AM,Lilly's tirzepatide shows superior A1C and body weight reductions in late-stage diabetes study,Seeking Alpha,https://seekingalpha.com/news/3710338-lillys-tirzepatide-shows-superior-a1c-and-body-weight-reductions-in-late-stage-type-2-diabetes-study?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9504790902137756
1262,6/28/2021 8:51:40 AM,"Lilly's tirzepatide showed superior blood glucose, weight reductions compared to semaglutide in SURPASS-2 trial",Seeking Alpha,https://seekingalpha.com/news/3710340-lillys-tirzepatide-showed-superior-blood-glucose-and-weight-reductions-compared-to-semaglutide-in-surpass-2-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9511363506317139
1263,6/28/2021 10:41:55 AM,"Pre-market Movers: NTLA, ABUS, ATOS, GTEC... ",RTTNews,/news/stocks/pre-market-movers-ntla-abus-atos-gtec-1030557805,positive,0.945693850517273
1264,6/29/2021 3:54:15 PM,Lilly and Regeneron monoclonal antibodies among preferred therapies in EU against COVID-19,Seeking Alpha,https://seekingalpha.com/news/3711042-lilly-and-regeneron-monoclonal-antibodies-among-preferred-therapies-in-eu-against-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5084574222564697
1265,6/29/2021 4:20:34 PM,3 Better Alzheimer’s Drug Stocks to Buy Instead of Biogen,InvestorPlace,/news/stocks/3-better-alzheimers-drug-stocks-to-buy-instead-of-biogen-1030564044,positive,0.704683780670166
1266,6/29/2021 6:02:16 PM,Walmart looks for healthcare advantage with insulin push,Seeking Alpha,https://seekingalpha.com/news/3711072-walmart-looks-for-healthcare-advantage-with-insulin-push?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6235102415084839
1267,6/29/2021 10:27:00 PM,Lilly Declares Third-Quarter 2021 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2021-dividend-1030564583,positive,0.8541672825813293
1268,7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8283566832542419
1269,7/1/2021 11:07:05 PM,Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-july-pdufa-dates-1030573631,positive,0.9455710649490356
1270,7/2/2021 4:27:11 PM,10 Biggest Price Target Changes For Friday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-friday-1030575765,positive,0.7916322350502014
1271,7/2/2021 7:06:16 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030576232,positive,0.9322600364685059
1272,7/4/2021 2:00:00 PM,"Pharmas, payers to meet at Duke to hash out how to pay for Alzheimer's drugs - Endpoints",Seeking Alpha,https://seekingalpha.com/news/3712734-pharmas-payers-to-meet-at-duke-to-hash-out-how-to-pay-for-alzheimers-drugs-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9124140739440918
1273,7/6/2021 11:20:35 AM,Lilly's Jardiance successful in late-stage EMPEROR-Preserved trial for cardiovascular diseaase,Seeking Alpha,https://seekingalpha.com/news/3712811-lillys-jardiance-successful-in-late-stage-emperor-preserved-trial-for-cardiovascular-diseaase?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.884530782699585
1274,7/6/2021 12:25:00 PM,Breakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction,PR Newswire,/news/stocks/breakthrough-results-for-jardiance-empagliflozin-confirm-emperor-preserved-as-first-and-only-successful-trial-for-heart-failure-with-preserved-ejection-fraction-1030581158,negative,0.9090167880058289
1275,7/6/2021 12:55:24 PM,Eli Lilly Says EMPEROR-Preserved Phase III Trial Of Jardiance Met Primary Endpoint - Quick Facts ,RTTNews,/news/stocks/eli-lilly-says-emperor-preserved-phase-iii-trial-of-jardiance-met-primary-endpoint-quick-facts-1030581226,negative,0.7129114866256714
1276,7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6112593412399292
1277,7/7/2021 8:05:41 PM,Big pharma outperforms smaller rivals to lead second quarter gains: Evaluate,Seeking Alpha,https://seekingalpha.com/news/3713436-big-pharma-outperforms-smaller-rivals-to-lead-second-quarter-gains-evaluate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9427438378334045
1278,7/8/2021 11:20:05 AM,Eli Lilly in pact with Verge Genomics for treatments in amyotrophic lateral sclerosis,Seeking Alpha,https://seekingalpha.com/news/3713541-eli-lilly-in-pact-with-verge-genomics-for-treatments-in-amyotrophic-lateral-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7510129809379578
1279,7/8/2021 1:45:17 PM,"The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test",Benzinga,/news/stocks/the-daily-biotech-pulse-priority-review-for-amgen-s-asthma-treatment-evaxion-reports-positive-skin-cancer-readout-quidel-recalls-lyra-covid-19-test-1030589266,positive,0.5796154737472534
1280,7/8/2021 7:38:27 PM,"House Oversight report says pharmas spend more on buybacks, dividends than R&D",Seeking Alpha,https://seekingalpha.com/news/3713778-house-oversight-report-says-pharmas-spend-more-on-buybacks-dividends-than-research-development?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8492424488067627
1281,7/9/2021 11:16:57 AM,Lilly's mirikizumab up-regulates genes related with mucosal healing in UC for up to one year,Seeking Alpha,https://seekingalpha.com/news/3713912-lillys-mirikizumab-up-regulates-genes-related-with-mucosal-healing-in-uc-for-up-to-one-year?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.623569905757904
1282,7/9/2021 12:31:00 PM,Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study,PR Newswire,/news/stocks/mirikizumab-up-regulates-genes-associated-with-mucosal-healing-in-ulcerative-colitis-for-up-to-one-year-in-phase-2-study-1030592567,negative,0.6972841024398804
1283,7/9/2021 1:24:08 PM,Lilly: Mirikizumab In Trial Up-Regulates Genes Associated With Mucosal Healing In UC For Upto 1 Year ,RTTNews,/news/stocks/lilly-mirikizumab-in-trial-up-regulates-genes-associated-with-mucosal-healing-in-uc-for-upto-1-year-1030592704,negative,0.6170077323913574
1284,7/9/2021 1:36:16 PM,"The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-morphic-s-positive-data-at-ecco-humanigen-s-covid-treatment-gets-expedited-review-in-uk-transcode-ipo-1030592766,positive,0.6329361796379089
1285,7/9/2021 6:39:01 PM,"Biogen FDA probe on Alzheimer's drug unlikely to have `tangible' impact, analyst says",Seeking Alpha,https://seekingalpha.com/news/3714076-biogen-fda-probe-on-alzheimers-drug-unlikely-to-have-tangible-impact-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6848843097686768
1286,7/14/2021 10:57:55 AM,Lilly acquires Protomer Technologies for potential deal value of more than $1B,Seeking Alpha,https://seekingalpha.com/news/3715004-lilly-acquires-protomer-technologies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.602350115776062
1287,7/14/2021 12:45:00 PM,Lilly Announces Acquisition of Protomer Technologies,PR Newswire,/news/stocks/lilly-announces-acquisition-of-protomer-technologies-1030605671,positive,0.9172881245613098
1288,7/14/2021 1:37:11 PM,Eli Lilly Buys Protomer Technologies For Value That Could Be Above $1 Bln ,RTTNews,/news/stocks/eli-lilly-buys-protomer-technologies-for-value-that-could-be-above-1-bln-1030605961,positive,0.6381763219833374
1289,7/14/2021 1:48:12 PM,"The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues",Benzinga,/news/stocks/the-daily-biotech-pulse-scpharma-s-positive-data-lilly-goes-shopping-lemaitre-pre-announces-q2-revenues-1030605990,positive,0.8019024729728699
1290,7/15/2021 2:22:54 PM,Eli Lilly in pact with Banner Alzheimer's Institute for donanemab late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3715574-eli-lilly-in-pact-with-banner-alzheimers-institute-for-donanemab-late-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6825140714645386
1291,7/15/2021 2:38:54 PM,"FDA, Alzheimer's stakeholders look at expediting post-marketing confirmatory trials",Seeking Alpha,https://seekingalpha.com/news/3715573-fda-alzheimers-stakeholders-look-at-expediting-post-marketing-confirmatory-trials?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.896777868270874
1292,7/15/2021 4:00:00 PM,Lilly and Banner Alzheimer's Institute collaborate on planned Phase 3 prevention trial of donanemab,PR Newswire,/news/stocks/lilly-and-banner-alzheimer-s-institute-collaborate-on-planned-phase-3-prevention-trial-of-donanemab-1030611798,negative,0.6150068640708923
1293,7/15/2021 4:28:56 PM,"Lilly, Banner Alzheimer's Institute Collaborate On Phase 3 Trial Of Donanemab On Alzheimer's Disease ",RTTNews,/news/stocks/lilly-banner-alzheimer-s-institute-collaborate-on-phase-3-trial-of-donanemab-on-alzheimer-s-disease-1030611987,negative,0.7044606804847717
1294,7/16/2021 2:09:18 PM,Lilly and Incyte provide update on FDA regulatory timeline for baricitinib,Seeking Alpha,https://seekingalpha.com/news/3715993-lilly-and-incyte-provide-update-on-fda-regulatory-timeline-for-baricitinib?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9406559467315674
1295,7/16/2021 4:00:00 PM,Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis,PR Newswire,/news/stocks/lilly-and-incyte-provide-update-on-supplemental-new-drug-application-for-baricitinib-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-1030615435,positive,0.8242168426513672
1296,7/16/2021 4:33:50 PM,Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis ,RTTNews,/news/stocks/lilly-fda-delays-review-of-baricitinib-snda-on-atopic-dermatitis-1030615528,neutral,0.9322182536125183
1297,7/18/2021 4:25:56 PM,"The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-earnings-kickstart-with-j-j-and-biogen-albireo-awaits-fda-decisions-more-ipos-1030617574,negative,0.5948063731193542
1298,7/20/2021 3:09:13 AM,Common cholesterol drugs may lower death risk from COVID-19,Seeking Alpha,https://seekingalpha.com/news/3716662-common-cholesterol-drugs-statins-may-lower-death-risk-from-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9076204895973206
1299,7/22/2021 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2021-financial-results-announcement-1030635625,positive,0.9357712268829346
1300,7/23/2021 1:45:07 PM,"The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-acorda-spikes-on-distribution-deal-alzamend-soars-on-data-pfizer-biontech-to-supply-more-vaccine-doses-3-ipos-1030638740,negative,0.9013098478317261
1301,7/27/2021 1:48:33 PM,"The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-obseva-surges-on-out-licensing-deal-eyegate-appoints-new-ceo-2-positive-catalysts-for-merck-candel-therapeutics-debuts-1030649705,negative,0.7360387444496155
1302,7/29/2021 12:45:00 PM,Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses,PR Newswire,/news/stocks/lilly-and-kumquat-biosciences-announce-collaboration-to-discover-and-develop-novel-small-molecules-that-stimulate-tumor-specific-immune-responses-1030661500,negative,0.8515236377716064
1303,7/29/2021 1:28:19 PM,"Eli Lilly, Kumquat in immuno-oncology collaboration potentially worth more than $2B",Seeking Alpha,https://seekingalpha.com/news/3721524-eli-lilly-kumquat-in-immuno-oncology-collaboration-potentially-worth-more-than-2b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7485273480415344
1304,7/29/2021 1:55:42 PM,"Lilly, Kumquat To Develop Novel Small Molecules That Stimulate Tumor-Specific Immune Responses ",RTTNews,/news/stocks/lilly-kumquat-to-develop-novel-small-molecules-that-stimulate-tumor-specific-immune-responses-1030661995,negative,0.5587591528892517
1305,7/29/2021 1:59:04 PM,"FDA broadens EUA for Lilly, Incyte's baricitinib for COVID-19",Seeking Alpha,https://seekingalpha.com/news/3721602-fda-broadens-eua-for-lilly-incytes-baricitinib-olumiant-for-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8792058825492859
1306,7/29/2021 3:26:00 PM,FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen,PR Newswire,/news/stocks/fda-broadens-existing-emergency-use-of-lilly-and-incyte-s-baricitinib-in-patients-hospitalized-with-covid-19-requiring-oxygen-1030662816,negative,0.8493576645851135
1307,7/29/2021 3:45:21 PM,Lilly : FDA Broadens Emergency Use Of Baricitinib In Patients Hospitalized With COVID-19 ,RTTNews,/news/stocks/lilly-fda-broadens-emergency-use-of-baricitinib-in-patients-hospitalized-with-covid-19-1030662943,negative,0.8980918526649475
1308,7/29/2021 7:35:13 PM,Eli Lilly releases data showing potential of donanemab in lowering Alzheimer’s pathology,Seeking Alpha,https://seekingalpha.com/news/3721791-eli-lilly-releases-data-showing-potential-of-donanemab-in-lowering-alzheimers-pathology?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6422052979469299
1309,7/29/2021 9:00:00 PM,Lilly releases donanemab data that demonstrated relationship between reduction of amyloid plaque and slowing of cognitive decline,PR Newswire,/news/stocks/lilly-releases-donanemab-data-that-demonstrated-relationship-between-reduction-of-amyloid-plaque-and-slowing-of-cognitive-decline-1030664072,negative,0.6668915152549744
1310,7/30/2021 5:21:53 PM,Biogen: Does Aduhelm Make it the Next Dendreon?,InvestorPlace,/news/stocks/biib-stock-does-aduhelm-make-it-the-next-dendreon-1030669123,positive,0.9347943663597107
1311,8/1/2021 3:01:51 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q2-1030671386,positive,0.9387240409851074
1312,8/2/2021 10:00:07 AM,Investors Should Avoid High-Risk Atossa Therapeutics,InvestorPlace,/news/stocks/investors-should-avoid-high-risk-atos-stock-1030675492,positive,0.9028822779655457
1313,8/2/2021 2:02:49 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3722982-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
1314,8/3/2021 10:31:12 AM,"Eli Lilly EPS misses by $0.02, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3723637-eli-lilly-eps-misses-0_02-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4903144836425781
1315,8/3/2021 10:53:35 AM,"Eli Lilly posts Q2 topline beat on Trulicity, Humalog strength; updates FY forecast",Seeking Alpha,https://seekingalpha.com/news/3723669-eli-lilly-posts-q2-topline-beat-on-trulicity-humalog-strength-updates-fy-forecast?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9182580709457397
1316,8/3/2021 10:55:42 AM,"Lilly, Incyte's baricitinib reduces deaths among COVID-19 patients on mechanical ventilation",Seeking Alpha,https://seekingalpha.com/news/3723668-lilly-incytes-baricitinib-reduces-deaths-among-covid-19-patients-on-mechanical-ventilation?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8990769982337952
1317,8/3/2021 12:00:00 PM,Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation,PR Newswire,/news/stocks/lilly-and-incyte-s-baricitinib-reduced-deaths-among-patients-with-covid-19-receiving-invasive-mechanical-ventilation-1030681949,negative,0.9076222777366638
1318,8/3/2021 12:25:00 PM,"Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance",PR Newswire,/news/stocks/lilly-delivers-strong-second-quarter-2021-financial-results-updates-2021-financial-guidance-1030682047,negative,0.9345687627792358
1319,8/3/2021 12:28:52 PM,Eli Lilly And Co. Q2 adjusted earnings of $1.87 per share,RTTNews,/news/stocks/eli-lilly-and-co-q2-adjusted-earnings-of-1-87-per-share-1030682051,positive,0.7908283472061157
1320,8/3/2021 12:36:53 PM,"Lilly, Incyte: Baricitinib Reduced Deaths In COVID-19 Patients Under Invasive Mechanical Ventilation ",RTTNews,/news/stocks/lilly-incyte-baricitinib-reduced-deaths-in-covid-19-patients-under-invasive-mechanical-ventilation-1030682109,negative,0.9218716621398926
1321,8/3/2021 1:19:34 PM,"Lilly Q2 Profit Down; Cuts FY21 EPS, Margin View; Backs Adj. Earnings Forecast ",RTTNews,/news/stocks/lilly-q2-profit-down-cuts-fy21-eps-margin-view-backs-adj-earnings-forecast-1030682446,neutral,0.9569262862205505
1322,8/3/2021 1:55:12 PM,"The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-buys-translate-bio-in-3-2b-deal-lilly-s-q2-earnings-disappoint-bausch-to-spin-off-medical-aesthetics-business-1030682672,positive,0.7302430868148804
1323,8/3/2021 8:07:45 PM,"4 Top Stock Trades for Wednesday: Ethereum, Bitcoin, LLY, HOOD",InvestorPlace,/news/stocks/4-top-stock-trades-for-wednesday-ethereum-bitcoin-lly-hood-1030685426,positive,0.9266069531440735
1324,8/4/2021 1:52:10 PM,"The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-s-positive-readout-nrx-strikes-r-d-collaboration-with-mannkind-cerus-invitae-jump-on-earnings-1030688766,negative,0.7550449371337891
1325,8/4/2021 4:40:12 PM,"Eisai, Biogen will push for fast approval of another Alzheimer's candidate, lecanemab",Seeking Alpha,https://seekingalpha.com/news/3725115-eisai-biogen-will-push-for-fast-approval-of-another-alzheimers-candidate-lecanemab?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8218269348144531
1326,8/5/2021 2:07:56 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-readout-moderna-slips-despite-q2-beat-bayer-to-buy-vividion-for-up-to-2b-glycomimetics-gets-new-ceo-1030695873,negative,0.8679100871086121
1327,8/5/2021 4:07:30 PM,"Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-august-5-2021-1030696756,neutral,0.5251516699790955
1328,8/5/2021 6:19:51 PM,Analyst Ratings For Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1030697230,positive,0.9140509963035583
1329,8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.935555636882782
1330,8/10/2021 1:55:36 PM,"The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-arcturus-soars-on-covid-19-vaccine-updates-merck-s-keytruda-on-track-for-more-label-expansions-eliem-debuts-1030712978,negative,0.8045278787612915
1331,8/13/2021 3:31:47 PM,AbCellera rises over 15% most since March despite revenue miss,Seeking Alpha,https://seekingalpha.com/news/3730374-abcellera-rises-over-15-most-since-march-despite-revenue-miss?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9349340796470642
1332,8/16/2021 8:00:00 AM,Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials,PR Newswire,/news/stocks/lilly-s-lebrikizumab-significantly-improved-skin-clearance-and-itch-in-people-with-moderate-to-severe-atopic-dermatitis-in-two-phase-3-trials-1030733039,negative,0.951166570186615
1333,8/16/2021 8:31:10 AM,"Lilly: Lebrikizumab Meets Primary, Secondary Goals In ADvocate 1, ADvocate 2 Phase 3 Trials ",RTTNews,/news/stocks/lilly-lebrikizumab-meets-primary-secondary-goals-in-advocate-1-advocate-2-phase-3-trials-1030733102,negative,0.7525894641876221
1334,8/16/2021 1:00:00 PM,FDA approves Lyumjev® (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps,PR Newswire,/news/stocks/fda-approves-lyumjev-insulin-lispro-aabc-injection-100-units-ml-for-use-in-insulin-pumps-1030733732,negative,0.6762892603874207
1335,8/16/2021 1:21:46 PM,FDA Approves Pump Use For Lilly's Insulin ,RTTNews,/news/stocks/fda-approves-pump-use-for-lilly-s-insulin-1030733801,positive,0.8350648283958435
1336,8/17/2021 12:30:00 PM,Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units,PR Newswire,/news/stocks/lilly-announces-leadership-changes-and-formation-of-neuroscience-and-immunology-business-units-1030737422,positive,0.8863329887390137
1337,8/17/2021 1:09:38 PM,Eli Lilly Creates Separate Divisions For Neuroscience And Immunology - Quick Facts ,RTTNews,/news/stocks/eli-lilly-creates-separate-divisions-for-neuroscience-and-immunology-quick-facts-1030737607,positive,0.9326313734054565
1338,8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023,positive,0.9126444458961487
1339,8/18/2021 1:37:56 PM,"The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline",Benzinga,/news/stocks/the-daily-biotech-pulse-azurrx-jumps-on-data-agios-regulatory-application-for-mitapivat-accepted-for-priority-review-fda-nod-for-glaxosmithkline-1030741574,negative,0.5053824782371521
1340,8/18/2021 7:30:00 PM,US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-to-treat-adults-living-with-heart-failure-with-reduced-ejection-fraction-1030743128,negative,0.8609145283699036
1341,8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7850372195243835
1342,8/20/2021 12:12:31 PM,Spotify To Buy Back Up To $1.0 Bln Of Stock ,RTTNews,/news/stocks/spotify-to-buy-back-up-to-1-0-bln-of-stock-1030748433,negative,0.6360981464385986
1343,8/22/2021 3:01:25 PM,"The Week Ahead In Biotech: Cara FDA Decision, Ascendis Earnings, Aileron Data Presentation And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-cara-fda-decision-ascendis-earnings-aileron-data-presentation-and-more-1030750711,positive,0.9420926570892334
1344,8/23/2021 1:27:52 PM,COVID-19 vaccinations pick up as some states face with a ‘tsunami of patients’,Seeking Alpha,https://seekingalpha.com/news/3733039-covid-19-vaccinations-pick-up-as-some-states-face-with-a-tsunami-of-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.791989803314209
1345,8/23/2021 2:15:21 PM,Medigen Vaccine Biologics Announces Rollout Of COVID-19 Vaccine In Taiwan ,RTTNews,/news/stocks/medigen-vaccine-biologics-announces-rollout-of-covid-19-vaccine-in-taiwan-1030752207,negative,0.5450382828712463
1346,8/25/2021 12:45:00 PM,Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders,PR Newswire,/news/stocks/lilly-and-lycia-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-novel-lysosomal-targeting-chimera-lytac-degraders-1030757201,negative,0.8000094890594482
1347,8/25/2021 12:45:00 PM,Lilly Announces that Professor Carolyn Bertozzi has Resigned from its Board of Directors,PR Newswire,/news/stocks/lilly-announces-that-professor-carolyn-bertozzi-has-resigned-from-its-board-of-directors-1030757200,neutral,0.8361917734146118
1348,8/25/2021 12:58:14 PM,Lilly Says Carolyn Bertozzi Resigns From Board - Quick Facts ,RTTNews,/news/stocks/lilly-says-carolyn-bertozzi-resigns-from-board-quick-facts-1030757231,neutral,0.8115514516830444
1349,8/25/2021 1:07:21 PM,Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas ,RTTNews,/news/stocks/eli-lilly-to-utilize-lycia-s-lytac-platform-to-treat-challenging-disease-areas-1030757293,negative,0.7852018475532532
1350,8/25/2021 1:30:14 PM,"The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-strikes-1-6b-r-d-collaboration-fsd-pulls-plug-on-covid-19-program-cassava-sinks-on-questions-about-alzheimer-s-drug-1030757345,neutral,0.8795362114906311
1351,8/27/2021 1:06:42 PM,"CBO: Drug pricing bill could stymie pharma, biotech R&D",Seeking Alpha,https://seekingalpha.com/news/3734838-cbo-drug-pricing-bill-could-stymie-pharma-biotech-research-development?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9226203560829163
1352,8/27/2021 5:25:00 PM,Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction,PR Newswire,/news/stocks/landmark-trial-demonstrates-jardiance-empagliflozin-is-the-first-therapy-to-show-statistically-significant-improvement-in-heart-failure-outcomes-in-adults-with-preserved-ejection-fraction-1030763952,negative,0.9441831111907959
1353,8/30/2021 12:22:55 PM,"A Peek Into The Markets: US Stock Futures Edge Higher After S&P 500, Nasdaq Hit Record Highs",Benzinga,/news/stocks/a-peek-into-the-markets-us-stock-futures-edge-higher-after-s-p-500-nasdaq-hit-record-highs-1030766402,negative,0.9193388223648071
1354,8/30/2021 7:06:05 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030767628,positive,0.9322600364685059
1355,8/31/2021 8:00:00 PM,Lilly to Participate in Citi's 16th Annual BioPharma Virtual Conference,PR Newswire,/news/stocks/lilly-to-participate-in-citi-s-16th-annual-biopharma-virtual-conference-1030770980,positive,0.8248777985572815
1356,9/1/2021 2:21:43 PM,Avidity Biosciences drops over 10% on resignation of chief medical officer,Seeking Alpha,https://seekingalpha.com/news/3736123-avidity-biosciences-drops-over-10-on-resignation-of-chief-medical-officer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9687713980674744
1357,9/1/2021 3:50:24 PM,Healthcare groups ask Democrats to back drug pricing reforms in reconciliation package,Seeking Alpha,https://seekingalpha.com/news/3736163-healthcare-groups-ask-democrats-to-back-drug-pricing-reforms-in-reconciliation-package?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7003874778747559
1358,9/3/2021 4:00:00 PM,Lilly to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-morgan-stanley-19th-annual-global-healthcare-conference-1030779892,positive,0.8191019296646118
1359,9/3/2021 4:17:20 PM,AbCellera Biologics gains as COVID-19 antibody shipments resume,Seeking Alpha,https://seekingalpha.com/news/3737227-abcellera-biologics-gains-as-covid-19-antibody-shipments-resume?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9280555844306946
1360,9/3/2021 6:50:43 PM,Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal,Benzinga,/news/stocks/wall-street-crime-and-punishment-martha-stewart-s-perfectly-ridiculous-stock-scandal-1030780207,positive,0.7803280353546143
1361,9/7/2021 12:00:00 PM,Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,PR Newswire,/news/stocks/lilly-announces-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-1030783374,negative,0.5926609039306641
1362,9/7/2021 12:16:34 PM,Eli Lilly Begins Cash Tender Offer Of Specified Series Of Outstanding Debt Securities ,RTTNews,/news/stocks/eli-lilly-begins-cash-tender-offer-of-specified-series-of-outstanding-debt-securities-1030783447,positive,0.9249613881111145
1363,9/7/2021 3:00:00 PM,"Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to ""Type 1 Diabetes Camps Initiative""",PR Newswire,/news/stocks/lilly-diabetes-joins-the-leona-m-and-harry-b-helmsley-charitable-trust-to-pledge-significant-funding-to-type-1-diabetes-camps-initiative-1030784208,negative,0.744086742401123
1364,9/8/2021 12:07:00 PM,Eli Lilly and Company -- Moody's rates Eli Lilly's notes A2; stable outlook,Moodys,/news/bonds/eli-lilly-and-company-moody-s-rates-eli-lilly-s-notes-a2-stable-outlook-1030786393,negative,0.7757176160812378
1365,9/8/2021 8:09:21 PM,ProQR Therapeutics teams up with Eli Lilly in potential $1.25B research collaboration,Seeking Alpha,https://seekingalpha.com/news/3738081-proqr-therapeutics-teams-up-with-eli-lilly-in-potential-125b-research-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8658348321914673
1366,9/8/2021 9:13:32 PM,BeyondSpring gains as Baird sees FDA approval for its lead asset,Seeking Alpha,https://seekingalpha.com/news/3738143-beyondspring-gains-as-baird-sees-fda-approval-for-its-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8236712217330933
1367,9/9/2021 11:24:06 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-sept-9-1030789643,neutral,0.48035502433776855
1368,9/9/2021 12:58:03 PM,"Eli Lilly Inks Another RNA Collab, This Time With ProQR",Benzinga,/news/stocks/eli-lilly-inks-another-rna-collab-this-time-with-proqr-1030789543,positive,0.9069600105285645
1369,9/9/2021 2:00:00 PM,FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction,PR Newswire,/news/stocks/fda-grants-jardiance-breakthrough-therapy-designation-for-heart-failure-with-preserved-ejection-fraction-1030789842,negative,0.9119890928268433
1370,9/9/2021 2:17:07 PM,"The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization",Benzinga,/news/stocks/the-daily-biotech-pulse-proqr-lilly-r-d-partnership-sanofi-s-pemphigus-trial-disappointment-humanigen-s-covid-19-drug-denied-emergency-use-authorization-1030789942,positive,0.9088907241821289
1371,9/9/2021 2:46:51 PM,Eli Lilly Reports Breakthrough Therapy Designation For Jardiance - Quick Facts ,RTTNews,/news/stocks/eli-lilly-reports-breakthrough-therapy-designation-for-jardiance-quick-facts-1030790074,negative,0.6188307404518127
1372,9/9/2021 8:00:00 PM,Lilly Prices First Sustainability Bond to Advance Global ESG Strategy,PR Newswire,/news/stocks/lilly-prices-first-sustainability-bond-to-advance-global-esg-strategy-1030791057,negative,0.6069852113723755
1373,9/10/2021 12:08:22 AM,Baird Initiates BeyondSpring With Outperform On Plinabulin Potential,Benzinga,/news/stocks/baird-initiates-beyondspring-with-outperform-on-plinabulin-potential-1030791416,neutral,0.6525954008102417
1374,9/13/2021 2:00:00 PM,Lilly to Present New Data from Oncology Portfolio at ESMO Congress,PR Newswire,/news/stocks/lilly-to-present-new-data-from-oncology-portfolio-at-esmo-congress-1030795660,positive,0.9207786917686462
1375,9/13/2021 4:00:00 PM,Lilly to Participate in the 2021 Cantor Virtual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-2021-cantor-virtual-global-healthcare-conference-1030796058,positive,0.7934136390686035
1376,9/15/2021 12:45:00 PM,"Lilly to supply 388,000 doses of etesevimab to U.S. government for treatment of COVID-19",PR Newswire,/news/stocks/lilly-to-supply-388-000-doses-of-etesevimab-to-u-s-government-for-treatment-of-covid-19-1030801008,negative,0.7518258094787598
1377,9/15/2021 1:04:48 PM,"Lilly To Supply 388,000 Doses Of Etesevimab To U.S. For Treatment Of COVID-19 ",RTTNews,/news/stocks/lilly-to-supply-388-000-doses-of-etesevimab-to-u-s-for-treatment-of-covid-19-1030801074,negative,0.7714139223098755
1378,9/15/2021 1:38:39 PM,"The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-regeneron-ink-covid-19-drug-deal-with-us-regulatory-setback-for-calliditas-theravance-to-cut-75-jobs-4-ipos-1030801226,neutral,0.9463478326797485
1379,9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6811553239822388
1380,9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5973886251449585
1381,9/16/2021 9:56:00 PM,Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19,PR Newswire,/news/stocks/emergency-use-authorization-for-lilly-s-bamlanivimab-and-etesevimab-administered-together-expanded-to-include-post-exposure-prophylaxis-for-covid-19-1030805731,negative,0.7233108878135681
1382,9/16/2021 11:26:24 PM,"FDA Expands EUA For Lilly's Bamlanivimab, Etesevimab To Include Post-exposure Prophylaxis For COVID ",RTTNews,/news/stocks/fda-expands-eua-for-lilly-s-bamlanivimab-etesevimab-to-include-post-exposure-prophylaxis-for-covid-1030805886,negative,0.7770383358001709
1383,9/17/2021 1:36:08 PM,"The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold",Benzinga,/news/stocks/the-daily-biotech-pulse-adcom-tryst-for-pfizer-biontech-booster-shot-abcellera-s-covid-antibody-treatment-gets-expanded-use-protagonist-slapped-with-clinical-hold-1030806977,negative,0.6039010882377625
1384,9/17/2021 5:18:04 PM,"Powell, two Fed presidents owned securities the Fed was buying last year - CNBC",Seeking Alpha,https://seekingalpha.com/news/3740916-powell-two-fed-presidents-owned-securities-the-fed-was-buying-last-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9310913681983948
1385,9/21/2021 1:00:00 PM,Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of the Note Caps...,PR Newswire,/news/stocks/lilly-announces-the-early-tender-results-of-its-pending-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-and-removal-of-the-note-caps-1030812258,positive,0.5353097915649414
1386,9/21/2021 7:37:00 PM,Lilly announces procurement agreement with European Commission to supply bamlanivimab and etesevimab together for the treatment of confirmed COVID-19,PR Newswire,/news/stocks/lilly-announces-procurement-agreement-with-european-commission-to-supply-bamlanivimab-and-etesevimab-together-for-the-treatment-of-confirmed-covid-19-1030813862,negative,0.9242534041404724
1387,9/21/2021 10:15:00 PM,Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities,PR Newswire,/news/stocks/lilly-announces-the-pricing-terms-of-its-cash-tender-offer-for-up-to-1-5-billion-combined-aggregate-principal-amount-of-its-outstanding-debt-securities-1030814168,positive,0.8874704837799072
1388,9/25/2021 2:04:00 AM,Eli Lilly and Company Issues Voluntary Nationwide Recall of One Lot of GLUCAGON® Emergency Kit Due to Loss of Potency,PR Newswire,/news/stocks/eli-lilly-and-company-issues-voluntary-nationwide-recall-of-one-lot-of-glucagon-emergency-kit-due-to-loss-of-potency-1030822884,neutral,0.9573409557342529
1389,9/27/2021 8:07:55 AM,Lilly Recalls One Lot Of GLUCAGON Emergency Kit ,RTTNews,/news/stocks/lilly-recalls-one-lot-of-glucagon-emergency-kit-1030824532,neutral,0.5747854709625244
1390,9/27/2021 2:00:00 PM,New Data from Verzenio® (abemaciclib) monarchE Study to Be Featured in ESMO Virtual Plenary,PR Newswire,/news/stocks/new-data-from-verzenio-abemaciclib-monarche-study-to-be-featured-in-esmo-virtual-plenary-1030825427,positive,0.8877429366111755
1391,9/28/2021 12:30:00 PM,Lilly again reduces list price of Insulin Lispro Injection as latest change to affordability options,PR Newswire,/news/stocks/lilly-again-reduces-list-price-of-insulin-lispro-injection-as-latest-change-to-affordability-options-1030827465,positive,0.632688045501709
1392,9/28/2021 12:59:27 PM,"Lilly Cuts List Price Of Insulin Lispro Injection In U.S. Again, Effective Jan. 1 ",RTTNews,/news/stocks/lilly-cuts-list-price-of-insulin-lispro-injection-in-u-s-again-effective-jan-1-1030827509,neutral,0.5086489915847778
1393,9/28/2021 7:30:23 PM,7 Biotech Stocks Entering the Golden Boom Phase,InvestorPlace,/news/stocks/7-biotech-stocks-entering-the-golden-boom-phase-1030829968,positive,0.7444129586219788
1394,9/28/2021 11:45:00 PM,FDA Expands Lilly's ERBITUX® (cetuximab) Label with Combination of BRAFTOVI® (encorafenib) for the Treatment of BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) after Prior Therapy,PR Newswire,/news/stocks/fda-expands-lilly-s-erbitux-cetuximab-label-with-combination-of-braftovi-encorafenib-for-the-treatment-of-braf-v600e-mutation-positive-metastatic-colorectal-cancer-crc-after-prior-therapy-1030829222,negative,0.9376215934753418
1395,9/29/2021 4:27:13 AM,FDA Expands Lilly's Erbitux Label With Braftovi For Treatment Of Metastatic Colorectal Cancer ,RTTNews,/news/stocks/fda-expands-lilly-s-erbitux-label-with-braftovi-for-treatment-of-metastatic-colorectal-cancer-1030829333,negative,0.8986799120903015
1396,9/29/2021 1:36:38 PM,10 Biggest Price Target Changes For Wednesday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-wednesday-1030830738,positive,0.8142690658569336
1397,9/29/2021 2:13:41 PM,"The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-abbvie-s-migraine-drug-ok-d-by-fda-amicus-spins-off-gene-therapy-business-geovax-in-licenses-cancer-drug-1030831016,positive,0.9129316210746765
1398,9/29/2021 4:00:00 PM,Lilly and Susan G. Komen® Partner to Address Disparities in Breast Cancer Outcomes Experienced By Black Women,PR Newswire,/news/stocks/lilly-and-susan-g-komen-partner-to-address-disparities-in-breast-cancer-outcomes-experienced-by-black-women-1030831411,negative,0.6318040490150452
1399,9/29/2021 4:11:58 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-29-2021-1030831447,neutral,0.545376718044281
1400,9/29/2021 9:09:33 PM,Why Eli Lilly Shares Are Moving Higher Today,Benzinga,/news/stocks/why-eli-lilly-shares-are-moving-higher-today-1030832108,negative,0.5483311414718628
1401,9/29/2021 10:30:09 PM,Citi Upgrades This Big Pharma Stock On Positive Alzheimer's Expectations,Benzinga,/news/stocks/citi-upgrades-this-big-pharma-stock-on-positive-alzheimer-s-expectations-1030832239,negative,0.9104568362236023
1402,9/30/2021 10:30:00 AM,Lilly's tirzepatide led to greater time in range compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 CGM sub-study,PR Newswire,/news/stocks/lilly-s-tirzepatide-led-to-greater-time-in-range-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-surpass-3-cgm-sub-study-1030833217,negative,0.9380805492401123
1403,9/30/2021 10:40:00 AM,Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study,PR Newswire,/news/stocks/lilly-s-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-surpass-3-mri-sub-study-1030833229,negative,0.9526036977767944
1404,9/30/2021 11:37:54 AM,Lilly Reports Positive Results From Two SURPASS-3 Sub-studies Of Tirzepatide In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-reports-positive-results-from-two-surpass-3-sub-studies-of-tirzepatide-in-type-2-diabetes-1030833366,negative,0.9368146061897278
1405,9/30/2021 11:56:00 AM,OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata,PR Newswire,/news/stocks/olumiant-significantly-improved-hair-regrowth-to-at-least-80-scalp-coverage-as-early-as-24-weeks-across-first-completed-phase-3-studies-for-alopecia-areata-1030833394,negative,0.9547622799873352
1406,9/30/2021 12:40:08 PM,"Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata ",RTTNews,/news/stocks/lilly-incyte-present-detailed-results-from-olumiant-brave-aa1-brave-aa2-trials-in-alopecia-areata-1030833516,positive,0.9086092114448547
1407,9/30/2021 1:43:13 PM,"The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-confirms-acceleron-purchase-regeneron-touts-covid-19-antibody-cocktail-data-takeda-in-licenses-huntington-s-disease-drug-1030833761,positive,0.8744046688079834
1408,9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5914813876152039
1409,10/1/2021 3:00:00 PM,"At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study",PR Newswire,/news/stocks/at-week-104-75-of-patients-with-ulcerative-colitis-taking-mirikizumab-maintained-symptomatic-remission-in-phase-2-study-1030837268,negative,0.6060194373130798
1410,10/4/2021 3:00:00 PM,Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals,PR Newswire,/news/stocks/ready-for-the-challenge-boehringer-ingelheim-and-eli-lilly-and-company-launch-first-ever-online-game-on-cardio-renal-metabolic-conditions-for-healthcare-professionals-1030840780,positive,0.8042923808097839
1411,10/7/2021 1:36:16 PM,Sonoco To Implement Price Increase For Uncoated Recycled Paperboard ,RTTNews,/news/stocks/sonoco-to-implement-price-increase-for-uncoated-recycled-paperboard-1030849920,negative,0.8247303366661072
1412,10/7/2021 3:00:00 PM,Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-details-of-presentations-at-2021-aacr-nci-eortc-virtual-international-conference-on-molecular-targets-and-cancer-therapeutics-1030850358,positive,0.9390292167663574
1413,10/11/2021 1:35:40 PM,10 Biggest Price Target Changes For Monday,Benzinga,/news/stocks/10-biggest-price-target-changes-for-monday-1030855838,positive,0.7998325824737549
1414,10/11/2021 4:51:48 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-11-2021-1030856429,neutral,0.5863182544708252
1415,10/11/2021 7:03:01 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1030856715,positive,0.9322600364685059
1416,10/12/2021 3:30:41 PM,COVAX Exercises Option To Purchase 176.5 Mln Addl Doses Of Moderna COVID-19 Vaccine In H1 2022 ,RTTNews,/news/stocks/covax-exercises-option-to-purchase-176-5-mln-addl-doses-of-moderna-covid-19-vaccine-in-h1-2022-1030859372,positive,0.7418822646141052
1417,10/12/2021 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2021-financial-results-announcement-1030859524,positive,0.9370685815811157
1418,10/13/2021 12:45:00 PM,FDA Approves Verzenio® (abemaciclib) as the First and Only CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer,PR Newswire,/news/stocks/fda-approves-verzenio-abemaciclib-as-the-first-and-only-cdk4-6-inhibitor-for-certain-people-with-hr-her2-high-risk-early-breast-cancer-1030862350,negative,0.8594917058944702
1419,10/13/2021 1:01:36 PM,Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer ,RTTNews,/news/stocks/eli-lilly-fda-approves-verzenio-in-adjuvant-treatment-of-hr-her2-early-breast-cancer-1030862398,negative,0.9200511574745178
1420,10/13/2021 1:46:14 PM,"The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-lilly-regulus-slumps-on-study-discontinuation-obseva-strikes-linzagolix-commercialization-deal-1030862589,neutral,0.7553718090057373
1421,10/13/2021 8:24:22 PM,Agilent gets FDA companion diagnostic approval for Ki-67 IHC MIB-1 pharmDx,Seeking Alpha,https://seekingalpha.com/news/3752596-agilent-gets-fda-companion-diagnostic-approval-for-ki-67-ihc-mib-1-pharmdx?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9311447143554688
1422,10/14/2021 5:15:16 PM,White House eyeing former FDA commissioner Robert Califf for FDA top spot -- WaPo,Seeking Alpha,https://seekingalpha.com/news/3752938-white-house-eyeing-former-commissioner-robert-califf-for-fda-top-spot-wapo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9065146446228027
1423,10/14/2021 7:30:00 PM,Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology,PR Newswire,/news/stocks/lilly-announces-updated-verzenio-abemaciclib-phase-3-monarche-trial-data-presented-at-esmo-virtual-plenary-and-simultaneously-published-in-the-annals-of-oncology-1030867519,positive,0.9119027256965637
1424,10/16/2021 10:15:09 PM,"Barron's Latest Picks And Pans: Amazon, Apple, Chevron, Citigroup, Dell And More",Benzinga,/news/stocks/barron-s-latest-picks-and-pans-amazon-apple-chevron-citigroup-dell-and-more-1030870768,positive,0.9446086287498474
1425,10/18/2021 2:47:35 PM,Quest to provide companion diagnostic for Lilly's breast cancer drug Verzenio,Seeking Alpha,https://seekingalpha.com/news/3754112-quest-to-provide-companion-diagnostic-for-lillys-breast-cancer-drug-verzenio?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7319744229316711
1426,10/18/2021 8:52:00 PM,Lilly Declares Fourth-Quarter 2021 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2021-dividend-1030874735,positive,0.8603151440620422
1427,10/19/2021 12:45:00 PM,Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk,PR Newswire,/news/stocks/tirzepatide-results-published-in-the-lancet-show-superior-a1c-and-body-weight-reductions-compared-to-insulin-glargine-in-adults-with-type-2-diabetes-with-increased-cardiovascular-risk-1030876763,negative,0.9201543927192688
1428,10/19/2021 1:00:51 PM,Lilly : Phase 3 Tirzepatide Results Show Superior A1C And Body Weight Reductions In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-phase-3-tirzepatide-results-show-superior-a1c-and-body-weight-reductions-in-type-2-diabetes-1030876853,negative,0.9473423957824707
1429,10/19/2021 6:10:09 PM,Abbott Laboratories Q3 earnings preview and review,Seeking Alpha,https://seekingalpha.com/news/3755153-abbott-laboratories-q3-earnings-preview-and-review?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8984233736991882
1430,10/19/2021 9:10:23 PM,3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat,Benzinga,/news/stocks/3-biopharma-stocks-to-watch-following-johnson-johnson-s-earnings-beat-1030878749,positive,0.8914384841918945
1431,10/20/2021 12:45:09 PM,"28 Stocks To Benefit From Inflation, According To Jim Cramer",Benzinga,/news/stocks/28-stocks-to-benefit-from-inflation-according-to-jim-cramer-1030881145,negative,0.9265294075012207
1432,10/24/2021 3:01:33 PM,What Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-q3-quarterly-earnings-preview-stock-1030891515,positive,0.9346717596054077
1433,10/24/2021 3:02:41 PM,Eli Lilly hosts conference call for investors,Markets Insider Automation,/news/stocks/eli_lilly_conference-1029887223,positive,0.9353128671646118
1434,10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741,positive,0.9414970874786377
1435,10/25/2021 3:00:12 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3757513-notable-earnings-before-tuesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8660826683044434
1436,10/26/2021 12:25:00 PM,Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthens Future Growth Potential,PR Newswire,/news/stocks/lilly-reports-robust-third-quarter-2021-financial-results-as-pipeline-success-strengthens-future-growth-potential-1030898889,negative,0.9546700119972229
1437,10/26/2021 12:29:31 PM,Eli Lilly And Co. Profit Drops In Q3,RTTNews,/news/stocks/eli-lilly-and-co-profit-drops-in-q3-1030898896,neutral,0.9733676314353943
1438,10/26/2021 1:08:46 PM,"Lilly Lifts FY21 Adj. EPS, Revenue View Above Market - Quick Facts ",RTTNews,/news/stocks/lilly-lifts-fy21-adj-eps-revenue-view-above-market-quick-facts-1030899109,negative,0.9425260424613953
1439,10/26/2021 2:30:47 PM,"The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-gains-on-vaccine-news-novartis-reports-q3-beat-adcom-reviews-authorization-of-pfizer-biontech-s-vaccine-for-children-1030899570,negative,0.6003707051277161
1440,10/26/2021 4:13:44 PM,Teva Pharmaceutical falls 6% on eve of Q3 earnings show,Seeking Alpha,https://seekingalpha.com/news/3758203-teva-pharmaceutical-q3-2021-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9715293645858765
1441,10/28/2021 1:15:01 PM,"Inventiva Plans To Start Lanifibranor Combo Study In NASH, Diabetes In 2022",Benzinga,/news/stocks/inventiva-plans-to-start-lanifibranor-combo-study-in-nash-diabetes-in-2022-1030909822,positive,0.8292226791381836
1442,10/28/2021 10:00:00 PM,Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology,PR Newswire,/news/stocks/additional-verzenio-abemaciclib-phase-3-monarche-trial-data-published-in-the-annals-of-oncology-1030911942,positive,0.9175266027450562
1443,10/30/2021 8:00:00 PM,"BioNTech, GSK top pharma performers in October; Bristol, Amgen biggest laggards",Seeking Alpha,https://seekingalpha.com/news/3761145-biontech-gsk-top-pharma-performers-in-october-bristol-amgen-biggest-laggards?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8818862438201904
1444,11/1/2021 5:00:00 PM,Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bernstein-s-second-annual-operational-decisions-conference-1030922462,positive,0.8938631415367126
1445,11/2/2021 11:28:40 AM,Eli Lilly gets additional U.S. government order for bamlanivimab/etesevimab combo,Seeking Alpha,https://seekingalpha.com/news/3762716-eli-lilly-gets-additional-us-government-order-for-bamlanivimabetesevimab-combo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.874174177646637
1446,11/2/2021 11:45:00 AM,"Lilly to supply 614,000 additional doses of bamlanivimab and etesevimab to the U.S. Government for the treatment or post-exposure prevention of COVID-19",PR Newswire,/news/stocks/lilly-to-supply-614-000-additional-doses-of-bamlanivimab-and-etesevimab-to-the-u-s-government-for-the-treatment-or-post-exposure-prevention-of-covid-19-1030925254,negative,0.8040209412574768
1447,11/2/2021 12:52:53 PM,"The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-solid-q3-earnings-regulatory-setback-for-legend-lilly-to-supply-additional-covid-19-antibody-cocktails-to-us-1030925781,negative,0.9155561327934265
1448,11/2/2021 1:23:24 PM,Lilly To Supply 614K Additional Doses Of Bamlanivimab And Etesevimab To The US ,RTTNews,/news/stocks/lilly-to-supply-614k-additional-doses-of-bamlanivimab-and-etesevimab-to-the-us-1030926030,negative,0.79848313331604
1449,11/2/2021 5:42:57 PM,Eli Lilly pulls rolling submission seeking EU nod for COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3763177-eli-lilly-pulls-rolling-submission-seeking-eu-nod-for-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5564444661140442
1450,11/3/2021 12:14:31 PM,Democrats finally hammer out prescription drug pricing plan,Seeking Alpha,https://seekingalpha.com/news/3763812-democrats-finally-hammer-out-prescription-drug-pricing-plan?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8670295476913452
1451,11/4/2021 2:00:00 PM,Loxo Oncology at Lilly Announces Details of Presentations at the 2021 American Society of Hematology (ASH) Annual Meeting,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-details-of-presentations-at-the-2021-american-society-of-hematology-ash-annual-meeting-1030937395,positive,0.9453234076499939
1452,11/5/2021 8:00:00 PM,Jardiance® shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40% regardless of chronic kidney disease status,PR Newswire,/news/stocks/jardiance-shows-consistent-cardio-renal-benefits-in-adults-with-heart-failure-with-left-ventricular-ejection-fraction-over-40-regardless-of-chronic-kidney-disease-status-1030943568,negative,0.9456208348274231
1453,11/9/2021 2:30:00 PM,"OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis",PR Newswire,/news/stocks/olumiant-long-term-safety-profile-established-up-to-9-3-years-in-integrated-analysis-of-more-than-3-700-patients-with-rheumatoid-arthritis-1030953796,negative,0.8902518153190613
1454,11/9/2021 8:00:00 PM,Lilly to Participate in Wolfe Research Virtual Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-wolfe-research-virtual-healthcare-conference-1030955245,positive,0.8482686281204224
1455,11/11/2021 2:30:00 PM,"Lilly announces winners of inaugural Leonard Award, a global program celebrating 100 years of innovation in diabetes care",PR Newswire,/news/stocks/lilly-announces-winners-of-inaugural-leonard-award-a-global-program-celebrating-100-years-of-innovation-in-diabetes-care-1030965166,positive,0.5666762590408325
1456,11/11/2021 7:30:00 PM,US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-and-grants-priority-review-for-jardiance-for-adults-with-heart-failure-independent-of-left-ventricular-ejection-fraction-1030966505,negative,0.8161298632621765
1457,11/11/2021 8:01:30 PM,Eli Lilly - Boehringer Ingelheim granted FDA’s priority review for heart failure drug,Seeking Alpha,https://seekingalpha.com/news/3769661-eli-lilly-boehringer-ingelheim-granted-fdas-priority-review-for-heart-failure-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7927128672599792
1458,11/16/2021 2:04:33 PM,Pfizer moves to allow cheaper COVID-19 pills sending shares of rivals lower,Seeking Alpha,https://seekingalpha.com/news/3771400-pfizer-moves-to-allow-cheaper-covid-19-pills-sending-shares-of-rivals-lower?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9393699169158936
1459,11/17/2021 1:24:59 PM,Jim Cramer Likes This Stock Over Cassava Sciences And Biogen,Benzinga,/news/stocks/jim-cramer-likes-this-stock-over-cassava-sciences-and-biogen-1030983909,positive,0.912594199180603
1460,11/17/2021 4:00:00 PM,Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-fourth-annual-evercore-isi-healthconx-conference-1030984856,positive,0.7835982441902161
1461,11/18/2021 1:43:31 PM,Enrollment underway in Eli Lilly' Emgality vs. Nurtec ODT trial in migraine,Seeking Alpha,https://seekingalpha.com/news/3772399-enrollment-underway-in-eli-lilly-emgality-vs-nurtec-odt-trial-in-migraine?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.802159309387207
1462,11/18/2021 2:00:00 PM,Emgality® Versus Nurtec® ODT Head-to-Head Migraine Preventive Treatment Study Now Enrolling Patients,PR Newswire,/news/stocks/emgality-versus-nurtec-odt-head-to-head-migraine-preventive-treatment-study-now-enrolling-patients-1030987910,positive,0.7684139013290405
1463,11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825,neutral,0.6235842108726501
1464,11/23/2021 7:18:02 PM,"Jim Cramer Weighs In On Cano Health, Moderna And More",Benzinga,/news/stocks/jim-cramer-weighs-in-on-cano-health-moderna-and-more-1030998921,positive,0.9249311089515686
1465,11/23/2021 10:28:21 PM,Eli Lilly and Company bags $525M US Army contract for combination therapeutic doses,Seeking Alpha,https://seekingalpha.com/news/3774061-eli-lilly-and-company-bags-535m-us-army-contract-for-combination-therapeutic-doses?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9020496606826782
1466,11/29/2021 12:58:31 PM,Tetra Announces Positive Initial Data From Phase 2 Trials Of QIXLEEF For Cancer Pain ,RTTNews,/news/stocks/tetra-announces-positive-initial-data-from-phase-2-trials-of-qixleef-for-cancer-pain-1031008379,negative,0.9063855409622192
1467,11/29/2021 2:21:46 PM,"Moderna, Pfizer, and Adagio likely to benefit from Omicron variant - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3774880-moderna-pfizer-and-adagio-likely-to-benefit-from-omicron-covid-variant-morgan-stanley?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8247672319412231
1468,11/29/2021 6:58:45 PM,3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries,Benzinga,/news/stocks/3-pharma-stocks-morgan-stanley-says-will-be-omicron-variant-beneficiaries-1031009763,positive,0.9128556847572327
1469,11/29/2021 9:57:43 PM,ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential,InvestorPlace,/news/stocks/adgi-stock-soars-as-analysts-lock-on-to-its-omicron-fighting-potential-1031010138,neutral,0.6825145483016968
1470,11/30/2021 12:17:53 PM,Moderna CEO warns “material drop” in vaccine efficacy against new COVID-19 variant,Seeking Alpha,https://seekingalpha.com/news/3775258-moderna-ceo-warns-material-drop-in-vaccine-efficacy-against-new-covid-19-variant?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9687873721122742
1471,12/1/2021 4:00:00 PM,Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment Community Meeting,PR Newswire,/news/stocks/lilly-to-announce-initial-2022-financial-guidance-provide-r-d-overview-at-investment-community-meeting-1031016499,positive,0.9102950096130371
1472,12/3/2021 1:40:11 PM,"The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-pulls-plug-on-phase-1-asset-xenon-aces-mid-stage-epilepsy-study-esperion-prices-offering-1031022833,positive,0.8068130016326904
1473,12/3/2021 7:02:42 PM,House Oversight Committee schedules Dec. 9 hearing on prescription drug prices,Seeking Alpha,https://seekingalpha.com/news/3777032-house-oversight-committee-schedules-dec-9-hearing-on-prescription-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8558977246284485
1474,12/3/2021 7:59:59 PM,Eli Lilly COVID-19 antibody cocktail is now FDA authorized for use in newborns,Seeking Alpha,https://seekingalpha.com/news/3777059-eli-lilly-covid-19-antibody-cocktail-is-now-fda-authorized-for-use-in-newborns?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8748354315757751
1475,12/3/2021 8:51:00 PM,Lilly's bamlanivimab with etesevimab authorized as the first and only neutralizing antibody therapy for emergency use in COVID-19 patients under the age of 12,PR Newswire,/news/stocks/lilly-s-bamlanivimab-with-etesevimab-authorized-as-the-first-and-only-neutralizing-antibody-therapy-for-emergency-use-in-covid-19-patients-under-the-age-of-12-1031023920,negative,0.570867121219635
1476,12/3/2021 9:40:58 PM,AbCellera rises 9% after hours as beneficiary of COVID antibody cocktail EUA expansion,Seeking Alpha,https://seekingalpha.com/news/3777091-abcellera-rises-9-after-hours-as-beneficiary-of-covid-antibody-cocktail-eua-expansion?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9410256147384644
1477,12/3/2021 9:43:36 PM,AbbVie updates U.S. labeling info for RINVOQ in rheumatoid arthritis,Seeking Alpha,https://seekingalpha.com/news/3777094-abbvie-updates-us-labeling-info-for-rinvoq-in-rheumatoid-arthritis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9334484338760376
1478,12/6/2021 3:16:26 AM,FDA Expands Authorization For Lilly's COVID-19 Antibody Therapy To Include Young Children & Infants ,RTTNews,/news/stocks/fda-expands-authorization-for-lilly-s-covid-19-antibody-therapy-to-include-young-children-infants-1031024713,negative,0.8475132584571838
1479,12/6/2021 8:50:20 PM,Biden calls on Senate to pass legislation to tackle 'outrageously expensive' drug prices,Seeking Alpha,https://seekingalpha.com/news/3777526-biden-call-on-senate-to-pass-legislation-to-tackle-outrageously-expensive-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6551856398582458
1480,12/9/2021 1:38:59 PM,"AbbVie is Wells Fargo's top pick in large biotech, pharma sectors; sees 35% upside",Seeking Alpha,https://seekingalpha.com/news/3778670-abbvie-is-wells-fargo-top-pick-in-large-biotech-pharma-sectors-sees-35-upside?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8829697966575623
1481,12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,neutral,0.5978407859802246
1482,12/9/2021 4:29:00 PM,New Lilly Study Reveals Underappreciation of Bowel Urgency as a Symptom of Ulcerative Colitis and Highlights Communication Gap Between Healthcare Providers and Patients,PR Newswire,/news/stocks/new-lilly-study-reveals-underappreciation-of-bowel-urgency-as-a-symptom-of-ulcerative-colitis-and-highlights-communication-gap-between-healthcare-providers-and-patients-1031036142,neutral,0.9578803181648254
1483,12/10/2021 11:57:48 AM,Lilly collaborates with Regor Therapeutics to develop therapies for metabolic disorders,Seeking Alpha,https://seekingalpha.com/news/3779072-lilly-collaborates-with-regor-therapeutics-to-develop-therapies-for-metabolic-disorders?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5255199074745178
1484,12/10/2021 12:30:00 PM,Lilly and Regor Therapeutics Group Enter into Strategic Collaboration to Discover and Develop Novel Therapies for Metabolic Disorders,PR Newswire,/news/stocks/lilly-and-regor-therapeutics-group-enter-into-strategic-collaboration-to-discover-and-develop-novel-therapies-for-metabolic-disorders-1031038298,negative,0.8499124646186829
1485,12/10/2021 12:38:59 PM,"Lilly, Regor Collaborates To Discover & Develop Novel Therapies For Metabolic Disorders ",RTTNews,/news/stocks/lilly-regor-collaborates-to-discover-develop-novel-therapies-for-metabolic-disorders-1031038320,positive,0.6795867681503296
1486,12/10/2021 1:50:11 PM,"The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-sings-metabolic-disorder-drug-pact-moderna-reports-positive-flu-vaccine-data-halozyme-to-buy-back-shares-1031038565,positive,0.6495084166526794
1487,12/10/2021 8:00:40 PM,"Catalyst watch for next week: FOMC drama, events for Lowe's and Delta Air Lines, Rivian earnings",Seeking Alpha,https://seekingalpha.com/news/3779254-catalyst-watch-for-next-week-fomc-drama-events-for-lowes-and-delta-air-lines-rivian-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9469307065010071
1488,12/12/2021 3:30:00 PM,Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for Pirtobrutinib at the American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-oncology-at-lilly-announces-updated-data-from-the-phase-1-2-bruin-clinical-trial-for-pirtobrutinib-at-the-american-society-of-hematology-annual-meeting-1031040264,positive,0.8994220495223999
1489,12/13/2021 8:48:32 AM,Lilly unit Loxo Oncology reports updated pirtobrutinib data from Phase 1/2 BRUIN trial at ASH2021,Seeking Alpha,https://seekingalpha.com/news/3779376-lilly-unit-loxo-oncology-reports-updated-pirtobrutinib-data-from-phase-12-bruin-trial-at-ash2021?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.936312198638916
1490,12/13/2021 11:44:13 AM,Foghorn jumps 36% after collaborating with Lilly in oncology medicines,Seeking Alpha,https://seekingalpha.com/news/3779408-foghorn-jumps-36-after-collaborating-with-lilly-in-oncology-medicines?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8833639025688171
1491,12/13/2021 12:00:00 PM,Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform,PR Newswire,/news/stocks/lilly-and-foghorn-announce-strategic-collaboration-for-novel-oncology-targets-using-foghorn-s-proprietary-gene-traffic-control-platform-1031045742,negative,0.7776232957839966
1492,12/13/2021 12:19:21 PM,Why Foghorn Therapeutics Is Rising In Pre-market? ,RTTNews,/news/stocks/why-foghorn-therapeutics-is-rising-in-pre-market-1031041276,positive,0.7957040667533875
1493,12/13/2021 12:31:03 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-december-13-1031041442,positive,0.497906357049942
1494,12/13/2021 2:57:32 PM,Foghorn Therapeutics Stock Surges After $1.5B Cancer Pact With Eli Lilly,Benzinga,/news/stocks/foghorn-therapeutics-stock-surges-after-1-5b-cancer-pact-with-eli-lilly-1031041669,negative,0.6812402606010437
1495,12/13/2021 4:02:55 PM,Mid-Morning Market Update: Markets Open Lower; Pfizer To Acquire Arena Pharmaceuticals,Benzinga,/news/stocks/mid-morning-market-update-markets-open-lower-pfizer-to-acquire-arena-pharmaceuticals-1031041800,neutral,0.9335423707962036
1496,12/13/2021 7:08:16 PM,40 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/40-stocks-moving-in-monday-s-mid-day-session-1031042190,neutral,0.48610568046569824
1497,12/13/2021 7:08:33 PM,Mid-Day Market Update: Nasdaq Drops Over 100 Points;  Foghorn Therapeutics Shares Surge,Benzinga,/news/stocks/mid-day-market-update-nasdaq-drops-over-100-points-foghorn-therapeutics-shares-surge-1031042189,neutral,0.9411525130271912
1498,12/13/2021 8:36:34 PM,Mid-Afternoon Market Update: Dow Tumbles Over 200 Points; BELLUS Health Shares Spike Higher,Benzinga,/news/stocks/mid-afternoon-market-update-dow-tumbles-over-200-points-bellus-health-shares-spike-higher-1031042273,negative,0.6639701128005981
1499,12/13/2021 8:39:59 PM,Eli Lilly raises dividend by 15% to $0.98,Seeking Alpha,https://seekingalpha.com/news/3779650-eli-lilly-raises-dividend-by-15-to-098?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.885791003704071
1500,12/13/2021 8:41:07 PM,How Eli Lilly's potential ~$1.7B partnership with Foghorn bolsters its oncology portfolio,Seeking Alpha,https://seekingalpha.com/news/3779440-how-eli-lillys-17b-partnership-with-foghorn-bolsters-its-oncology-portfolio?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9405802488327026
1501,12/13/2021 8:45:54 PM,FHTX Stock Alert: 7 Things to Know About the Partnership Lifting Foghorn Today,InvestorPlace,/news/stocks/fhtx-stock-alert-7-things-to-know-about-the-partnership-lifting-foghorn-today-1031042345,positive,0.9329181909561157
1502,12/13/2021 9:35:00 PM,"Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend",PR Newswire,/news/stocks/lilly-announces-15-percent-dividend-increase-first-quarter-2022-dividend-1031046031,negative,0.8738941550254822
1503,12/14/2021 11:15:51 AM,59 Biggest Movers From Yesterday,Benzinga,/news/stocks/58-biggest-movers-from-yesterday-1031043167,positive,0.8069567084312439
1504,12/14/2021 12:35:38 PM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-dec-14-1031043500,neutral,0.5084244012832642
1505,12/14/2021 4:27:45 PM,"Eli Lilly, Regeneron COVID-19 antibody therapies lose effectiveness against Omicron - study",Seeking Alpha,https://seekingalpha.com/news/3780004-eli-lilly-regeneron-covid-19-antibody-therapies-lose-effectiveness-against-omicron-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9235165119171143
1506,12/14/2021 10:36:19 PM,Eli Lilly's mirikizumab meets primary endpoint in late-stage ulcerative colitis trial,Seeking Alpha,https://seekingalpha.com/news/3780169-eli-lilly-mirikizumab-meets-primary-endpoint-in-late-stage-ulcerative-colitis-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5832057595252991
1507,12/14/2021 11:00:00 PM,"Mirikizumab Demonstrates Superiority over Placebo in Phase 3 Maintenance Study in Ulcerative Colitis, Supporting Regulatory Submissions in 2022",PR Newswire,/news/stocks/mirikizumab-demonstrates-superiority-over-placebo-in-phase-3-maintenance-study-in-ulcerative-colitis-supporting-regulatory-submissions-in-2022-1031046538,negative,0.9532919526100159
1508,12/15/2021 12:12:15 PM,Lilly gains 5% after providing financial guidance above consensus; raised 2021 outlook,Seeking Alpha,https://seekingalpha.com/news/3780258-lilly-gains-5-after-providing-financial-guidance-above-consensus-raised-2021-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.943250834941864
1509,12/15/2021 12:45:00 PM,Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting,PR Newswire,/news/stocks/lilly-highlights-innovation-based-growth-strategy-and-pipeline-developments-announces-2022-financial-guidance-at-investment-community-meeting-1031046703,negative,0.5826118588447571
1510,12/15/2021 1:15:13 PM,Eli Lilly Increases 2021 Adj. Earnings Guidance; Announces 2022 Outlook - Quick Facts ,RTTNews,/news/stocks/eli-lilly-increases-2021-adj-earnings-guidance-announces-2022-outlook-quick-facts-1031046822,negative,0.8182931542396545
1511,12/15/2021 3:44:01 PM,Nektar Announces Positive Phase 1b Data For NKTR-358 In Patients With Atopic Dermatitis ,RTTNews,/news/stocks/nektar-announces-positive-phase-1b-data-for-nktr-358-in-patients-with-atopic-dermatitis-1031047588,negative,0.9504151940345764
1512,12/15/2021 6:40:47 PM,36 Stocks Moving In Wednesday's Mid-Day Session,Benzinga,/news/stocks/36-stocks-moving-in-wednesday-s-mid-day-session-1031048166,neutral,0.49296703934669495
1513,12/16/2021 10:42:57 AM,46 Biggest Movers From Yesterday,Benzinga,/news/stocks/46-biggest-movers-from-yesterday-1031049509,positive,0.8463758826255798
1514,12/16/2021 1:32:45 PM,Eli Lilly price target upped at Cantor following new closing high; sees 22% upside,Seeking Alpha,https://seekingalpha.com/news/3780737-eli-lilly-price-target-upped-at-cantor-following-new-closing-high-sees-22-upside?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9425253868103027
1515,12/16/2021 8:22:33 PM,Cantor raises Pfizer price target ahead of company event highlighting COVID treatments,Seeking Alpha,https://seekingalpha.com/news/3781034-cantor-raises-pfizer-price-target-ahead-of-company-event-highlighting-covid-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9030519127845764
1516,12/17/2021 3:37:09 PM,What 5 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-eli-lilly-1031053521,positive,0.9394197463989258
1517,12/17/2021 4:17:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-17-2021-1031053650,neutral,0.5951845049858093
1518,12/20/2021 12:50:30 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031055900,positive,0.8907203078269958
1519,12/21/2021 6:01:00 AM,Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study,PR Newswire,/news/stocks/lilly-s-lebrikizumab-demonstrated-significant-skin-improvement-and-itch-relief-when-combined-with-topical-corticosteroids-in-people-with-atopic-dermatitis-in-third-phase-3-study-1031057941,negative,0.9456897974014282
1520,12/21/2021 7:15:30 AM,Lilly's Phase 3 Study Of Lebrikizumab In Atopic Dermatitis Meets All Goals ,RTTNews,/news/stocks/lilly-s-phase-3-study-of-lebrikizumab-in-atopic-dermatitis-meets-all-goals-1031058037,positive,0.853609025478363
1521,12/21/2021 9:33:37 AM,Lilly's late-stage lebrikizumab study in atopic dermatitis met all endpoints,Seeking Alpha,https://seekingalpha.com/news/3782200-lillys-late-stage-lebrikizumab-study-in-atopic-dermatitis-met-all-endpoints?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8298954367637634
1522,12/23/2021 1:23:04 PM,Biogen price target cut at BofA on Japan refusing to approve Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3782992-biogen-price-target-cut-at-bofa-on-japan-refusing-to-approve-aduhelm-alzheimers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9293254017829895
1523,12/24/2021 11:06:44 AM,Innovent Biologics : China Accepts SNDA Of TYVYT On Lung-cancer ,RTTNews,/news/stocks/innovent-biologics-china-accepts-snda-of-tyvyt-on-lung-cancer-1031065384,negative,0.6817498207092285
1524,12/29/2021 11:00:41 AM,Stock Market Crash Coming? 7 Wall Street Pros Make Their Predictions,InvestorPlace,/news/stocks/stock-market-crash-coming-7-wall-street-pros-make-their-predictions-1031069368,positive,0.8285650610923767
1525,1/4/2022 1:18:53 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031075865,positive,0.8907203078269958
1526,1/4/2022 7:12:11 PM,Califf FDA commissioner nomination to go before Senate Health Committee Jan. 12,Seeking Alpha,https://seekingalpha.com/news/3785167-califf-fda-commissioner-nomination-to-go-before-senate-health-committee-jan-12?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8831196427345276
1527,1/6/2022 12:13:18 PM,Lilly collaborates with Entos Pharma to develop therapies in multiple neurologic indications,Seeking Alpha,https://seekingalpha.com/news/3785729-lilly-collaborates-with-entos-pharma-to-develop-therapies-in-multiple-neurologic-indications?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5470309257507324
1528,1/6/2022 12:45:00 PM,Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications,PR Newswire,/news/stocks/lilly-and-entos-pharmaceuticals-enter-into-research-and-collaboration-agreement-to-support-the-development-of-innovative-therapies-in-multiple-neurologic-indications-1031081137,negative,0.9158408045768738
1529,1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342,positive,0.9103521108627319
1530,1/6/2022 1:36:56 PM,Lilly Buys Exclusive Rights Of Entos' Fusogenix Nucleic Acid Technology ,RTTNews,/news/stocks/lilly-buys-exclusive-rights-of-entos-fusogenix-nucleic-acid-technology-1031081273,positive,0.8278109431266785
1531,1/6/2022 2:24:12 PM,"The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-strikes-neurological-r-d-collaboration-valneva-confirms-vaccine-timelines-biohaven-gains-on-strong-migraine-drug-sales-1031081477,negative,0.9267310500144958
1532,1/6/2022 8:00:00 PM,Lilly to Participate in the J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-1031082374,positive,0.805112361907959
1533,1/7/2022 6:17:06 PM,Biden administration to ask Congress for more COVID funding - WaPo,Seeking Alpha,https://seekingalpha.com/news/3786338-biden-administration-to-ask-congress-for-more-covid-funding?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7112752199172974
1534,1/11/2022 4:43:14 PM,Two Lilly candidates make Clarivate 'drugs to watch'; total sales of $9B in 2026,Seeking Alpha,https://seekingalpha.com/news/3787184-two-lilly-candidates-make-clarivate-drugs-to-watch-total-sales-of-9b-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.740022599697113
1535,1/11/2022 4:43:14 PM,Three Lilly candidates make Clarivate 'drugs to watch'; total sales of $10.75B in 2026,Seeking Alpha,https://seekingalpha.com/news/3787184-three-lilly-candidates-make-clarivate-drugs-to-watch-total-sales-of-1075b-2022?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7533605694770813
1536,1/11/2022 9:34:29 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-cms-severely-limits-coverage-for-biogens-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9214109182357788
1537,1/11/2022 9:52:04 PM,Medicare limits coverage for Biogen's controversial Alzheimer's drug Aduhelm; shares fall,Seeking Alpha,https://seekingalpha.com/news/3787286-medicare-severely-limits-coverage-for-biogen-controversial-alzheimers-drug-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9214109182357788
1538,1/12/2022 11:00:23 AM,The 10 Best Performing Stocks in the S&P 500 for 2021,InvestorPlace,/news/stocks/the-10-best-performing-stocks-in-the-sp-500-for-2021-1031096258,positive,0.6121297478675842
1539,1/12/2022 12:25:56 PM,Biogen extends losses as Wall Street weighs in on Medicare decision on Aduhelm,Seeking Alpha,https://seekingalpha.com/news/3787408-biogen-extends-losses-as-wall-street-weighs-in-on-medicare-decision-on-aduhelm?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9269967675209045
1540,1/12/2022 8:20:01 PM,Vir extends gains as Needham lifts sales outlook for COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3787638-vir-extends-gains-as-needham-lifts-sales-outlook-for-covid-19-antibody-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9440396428108215
1541,1/13/2022 8:52:18 AM,Calls grow to treat COVID like an 'endemic' illness,Seeking Alpha,https://seekingalpha.com/news/3787737-calls-grow-to-treat-covid-like-an-endemic-illness?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5648321509361267
1542,1/13/2022 2:52:59 PM,Why Jim Cramer Prefers This Mining Stock Over Vale,Benzinga,/news/stocks/why-jim-cramer-prefers-this-mining-stock-over-vale-1031100220,positive,0.9281270503997803
1543,1/13/2022 8:28:29 PM,Lilly's diabetes therapy Baqsimi gets coverage in all federal benefit programs in Canada,Seeking Alpha,https://seekingalpha.com/news/3788056-lillys-diabetes-therapy-baqsimi-gets-coverage-in-all-federal-benefit-programs-in-canada?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7592683434486389
1544,1/14/2022 11:51:18 AM,Eli Lilly and GlaxoSmithKline/Vir COVID-19 therapies get WHO backing,Seeking Alpha,https://seekingalpha.com/news/3788201-eli-lilly-and-glaxosmithklinevir-covid-19-therapies-get-who-backing?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8087514638900757
1545,1/14/2022 1:26:21 PM,Pieris Pharmaceuticals begins dosing in phase 2 gastric cancer study,Seeking Alpha,https://seekingalpha.com/news/3788254-pieris-pharmaceuticals-begins-dosing-in-phase-2-gastric-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5663272738456726
1546,1/18/2022 7:52:12 AM,Evotec Enters Research Partnership With Lilly - Quick Facts ,RTTNews,/news/stocks/evotec-enters-research-partnership-with-lilly-quick-facts-1031107647,negative,0.5377863645553589
1547,1/18/2022 12:02:56 PM,Eli Lilly signs drug discovery collaboration with Evotec in a deal valued up to $5B,Seeking Alpha,https://seekingalpha.com/news/3788584-eli-lilly-signs-drug-discovery-collaboration-with-evotec-in-a-deal-valued-up-to-5b?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8097826242446899
1548,1/18/2022 7:27:13 PM,7 of the Top-Rated Pharmaceutical Stocks for Q1,InvestorPlace,/news/stocks/7-of-the-top-rated-pharmaceutical-stocks-for-q1-1031110217,positive,0.8801546692848206
1549,1/20/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter and Full-Year 2021 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2021-financial-results-announcement-1031116590,positive,0.9399124979972839
1550,1/21/2022 4:04:17 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 21, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-21-2022-1031119319,neutral,0.5361481308937073
1551,1/21/2022 6:01:35 PM,Expert Ratings For Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031119590,positive,0.8414194583892822
1552,1/21/2022 7:09:36 PM,GlaxoSmithKline and Vir to boost U.S. output of COVID-19 antibody - Reuters,Seeking Alpha,https://seekingalpha.com/news/3790412-glaxosmithkline-and-vir-to-boost-us-output-of-covid-19-antibody-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9439486265182495
1553,1/24/2022 10:52:04 AM,"Innovent, Lilly report final results of Phase ib study of Tyvyt + bevacizumab biosimilar in liver cancer",Seeking Alpha,https://seekingalpha.com/news/3790540-innovent-lilly-report-final-results-of-phase-ib-study-of-tyvyt-bevacizumab-biosimilar-in-liver-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8170230984687805
1554,1/25/2022 6:17:15 PM,"CBO report finds skyrocketing price increases for brand Rx drugs for Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/3791432-cbo-report-finds-skyrocketing-price-increases-for-brand-rx-drugs-for-medicare-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5263792276382446
1555,1/27/2022 1:47:08 PM,Health Canada authorizes Lilly's Verzenio for HR+ HER2- early breast cancer patients,Seeking Alpha,https://seekingalpha.com/news/3792441-health-canada-authorizes-lillys-verzenio-for-hr-her2-early-breast-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8365492224693298
1556,1/27/2022 6:50:00 PM,ALX Oncology gastric cancer candidate granted Orphan Drug Designation,Seeking Alpha,https://seekingalpha.com/news/3792646-alx-oncology-gastric-cancer-candidate-granted-orphan-drug-designation?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5769140124320984
1557,1/28/2022 2:00:00 PM,Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis,PR Newswire,/news/stocks/updates-on-olumiant-baricitinib-phase-3-lupus-program-and-fda-review-for-atopic-dermatitis-1031139169,positive,0.8766374588012695
1558,1/28/2022 2:16:35 PM,Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts ,RTTNews,/news/stocks/lilly-to-discontinue-phase-3-development-program-for-olumiant-in-lupus-quick-facts-1031139271,positive,0.8179276585578918
1559,1/28/2022 5:24:38 PM,Eli Lilly to invest $1B to set up manufacturing site in North Carolina,Seeking Alpha,https://seekingalpha.com/news/3793173-eli-lilly-to-invest-1b-to-set-up-manufacturing-site-in-north-carolina?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6366198658943176
1560,1/28/2022 6:15:00 PM,Lilly announces $1 billion investment in new manufacturing facility in North Carolina,PR Newswire,/news/stocks/lilly-announces-1-billion-investment-in-new-manufacturing-facility-in-north-carolina-1031140038,negative,0.6690519452095032
1561,1/29/2022 12:37:14 AM,Eli Lilly To Invest $1 Bln To Build New Plant In Concord ,RTTNews,/news/stocks/eli-lilly-to-invest-1-bln-to-build-new-plant-in-concord-1031140494,negative,0.5679590702056885
1562,1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7369604706764221
1563,1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,positive,0.9110234379768372
1564,2/1/2022 3:22:51 PM,Attention Biotech Investors: Mark Your Calendar For These Key February PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-key-february-pdufa-dates-1031149588,positive,0.946699321269989
1565,2/1/2022 8:00:00 PM,Lilly to Participate in Guggenheim Oncology Conference,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-oncology-conference-1031150571,positive,0.8337247967720032
1566,2/2/2022 12:11:22 PM,What's in store for Eli Lilly's Q4 earnings?,Seeking Alpha,https://seekingalpha.com/news/3794751-whats-in-store-for-eli-lillys-q4-earnings?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9116352796554565
1567,2/2/2022 3:00:35 PM,Novo Nordisk challenges House report it collaborated with competitors on insulin prices,Seeking Alpha,https://seekingalpha.com/news/3794874-novo-nordisk-challenges-house-report-it-collaborated-with-competitors-on-insulin-prices?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7927260994911194
1568,2/2/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q4-1031154281,positive,0.9245331287384033
1569,2/2/2022 3:47:17 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3794923-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
1570,2/2/2022 4:00:00 PM,UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents,PR Newswire,/news/stocks/unicef-and-lilly-collaborate-to-help-improve-health-outcomes-for-10-million-children-and-adolescents-1031154595,negative,0.8118799328804016
1571,2/3/2022 11:27:13 AM,"Eli Lilly Non-GAAP EPS of $2.49 misses by $0.02, revenue of $8B beats by $110M",Seeking Alpha,https://seekingalpha.com/news/3795356-eli-lilly-non-gaap-eps-of-2_49-misses-0_02-revenue-of-8b-beats-110m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5118884444236755
1572,2/3/2022 12:25:00 PM,"Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients",PR Newswire,/news/stocks/lilly-reports-solid-fourth-quarter-and-full-year-2021-financial-results-recent-late-stage-pipeline-successes-set-up-next-wave-of-innovative-medicines-for-patients-1031158104,negative,0.9289697408676147
1573,2/3/2022 12:27:39 PM,Eli Lilly tops Q4 revenue estimates as sales of COVID-19 antibodies exceed $1B,Seeking Alpha,https://seekingalpha.com/news/3795434-eli-lilly-tops-q4-revenue-estimates-as-sales-of-covid-19-antibodies-exceed-1b?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9490503072738647
1574,2/3/2022 12:28:37 PM,Eli Lilly And Co. Profit Declines In Q4,RTTNews,/news/stocks/eli-lilly-and-co-profit-declines-in-q4-1031158111,neutral,0.9723398089408875
1575,2/3/2022 12:58:21 PM,Eli Lilly Q4 Results Top Estimates; Reaffirms FY22 Outlook ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-reaffirms-fy22-outlook-1031158235,negative,0.6482353806495667
1576,2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702,neutral,0.9289477467536926
1577,2/3/2022 6:10:08 PM,Eli Lilly pushes back regulatory submissions for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3795666-eli-lilly-pushes-back-regulatory-submissions-for-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9197622537612915
1578,2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083,positive,0.7185425758361816
1579,2/8/2022 8:58:39 PM,"Eli Lilly, Innovent draw negative FDA comments for cancer drug ahead of AdCom meeting",Seeking Alpha,https://seekingalpha.com/news/3797458-eli-lilly-innovent-draw-negative-fda-comments-for-cancer-drug-ahead-of-adcom-meeting?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7973679900169373
1580,2/10/2022 2:29:52 PM,"The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly",Benzinga,/news/stocks/the-daily-biotech-pulse-astrazeneca-q4-gets-covid-boost-seagen-plunges-on-earnings-adcom-test-awaits-lilly-1031182008,neutral,0.7779287695884705
1581,2/10/2022 7:58:22 PM,Eli Lilly/ Innovent cancer drug rebuked at FDA AdCom meeting (updated),Seeking Alpha,https://seekingalpha.com/news/3798772-eli-lilly-innovent-cancer-drug-rebuked-at-fda-adcom-meeting?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8159738183021545
1582,2/10/2022 11:01:00 PM,"Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",PR Newswire,/news/stocks/lilly-will-supply-up-to-600-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options-1031183803,negative,0.8019724488258362
1583,2/11/2022 2:55:23 AM,"Lilly Reaches Deal With U.S. To Supply Up To 600,000 Doses Of Bebtelovimab For COVID-19 Treatment ",RTTNews,/news/stocks/lilly-reaches-deal-with-u-s-to-supply-up-to-600-000-doses-of-bebtelovimab-for-covid-19-treatment-1031184003,negative,0.8966246843338013
1584,2/11/2022 11:00:03 AM,Lilly inks deal to supply 600K doses of COVID drug bebtelovimab to US for $720M,Seeking Alpha,https://seekingalpha.com/news/3799043-lilly-inks-deal-to-supply-600k-doses-of-covid-drug-bebtelovimab-to-us-for-720m?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8240616321563721
1585,2/11/2022 1:22:42 PM,FDA Panel Votes Against Lilly's Lung Cancer Drug For China-only Trial ,RTTNews,/news/stocks/fda-panel-votes-against-lilly-s-lung-cancer-drug-for-china-only-trial-1031186334,positive,0.4311072528362274
1586,2/11/2022 2:08:16 PM,Journey Medical to get $2.5M as Rapifort gets approval in Japan,Seeking Alpha,https://seekingalpha.com/news/3799171-journey-medical-to-get-25m-as-rapifort-gets-approval-in-japan?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9172477722167969
1587,2/11/2022 7:53:41 PM,Eli Lilly granted FDA nod for new COVID-19 antibody therapy with efficacy against Omicron,Seeking Alpha,https://seekingalpha.com/news/3799324-eli-lilly-granted-fda-nod-for-new-covid-19-antibody-therapy-with-efficacy-against-omicron?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9320455193519592
1588,2/11/2022 9:08:00 PM,Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19,PR Newswire,/news/stocks/lilly-s-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19-1031187477,negative,0.9293518662452698
1589,2/11/2022 11:02:34 PM,FDA Issues Emergency Use Authorization For Eli Lilly's Covid-19 Treatment ,RTTNews,/news/stocks/fda-issues-emergency-use-authorization-for-eli-lilly-s-covid-19-treatment-1031187655,positive,0.8298859000205994
1590,2/12/2022 9:00:00 PM,Cassava Sciences citizen petition saga shines light on alleged abuse of FDA program,Seeking Alpha,https://seekingalpha.com/news/3799281-cassava-sciences-citizen-petition-saga-shines-light-on-alleged-abuse-of-fda-program?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7945619225502014
1591,2/15/2022 12:21:20 PM,ImmunoGen gains on pact with Eli Lilly for antibody-drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3799985-immunogen-gains-on-pact-with-eli-lilly-for-antibody-drug-conjugates?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.942370593547821
1592,2/15/2022 5:19:07 PM,Lilly Unites With ImmunoGen In ADC Deal Worth Up To $1.7B,Benzinga,/news/stocks/lilly-unites-with-immunogen-in-adc-deal-worth-up-to-1-7b-1031196711,negative,0.7743508219718933
1593,2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8565000891685486
1594,2/16/2022 2:21:33 PM,"Eli Lilly diabetes drug tirzepatide isn't better than other meds, ICER says",Seeking Alpha,https://seekingalpha.com/news/3800715-eli-lilly-diabetes-drug-tirzepatide-isnt-better-than-other-meds-icer-says?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.47470730543136597
1595,2/16/2022 3:00:00 PM,Lilly and Breast Cancer Advocacy Organizations Collaborate to Drive Awareness of the Complexities of Early Breast Cancer and the Risk of Recurrence,PR Newswire,/news/stocks/lilly-and-breast-cancer-advocacy-organizations-collaborate-to-drive-awareness-of-the-complexities-of-early-breast-cancer-and-the-risk-of-recurrence-1031200904,positive,0.8073012828826904
1596,2/17/2022 9:47:49 PM,NexImmune promotes chief operating officer to lead the company as CEO departs,Seeking Alpha,https://seekingalpha.com/news/3801729-neximmune-promotes-chief-operating-officer-to-lead-the-company-as-ceo-departs?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8967829346656799
1597,2/18/2022 4:45:00 PM,Nearly Two-Thirds of Patients Respond to Mirikizumab Treatment at 12 Weeks in Lilly's First-in-Class Ulcerative Colitis Phase 3 LUCENT-1 Study,PR Newswire,/news/stocks/nearly-two-thirds-of-patients-respond-to-mirikizumab-treatment-at-12-weeks-in-lilly-s-first-in-class-ulcerative-colitis-phase-3-lucent-1-study-1031208982,positive,0.6155534386634827
1598,2/22/2022 12:45:00 PM,Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site,PR Newswire,/news/stocks/lilly-announces-the-institute-for-genetic-medicine-and-700-million-investment-in-boston-seaport-site-1031215311,positive,0.8240318298339844
1599,2/22/2022 1:24:52 PM,Lilly Launches Institute For Genetic Medicine; Invests $700 Mln ,RTTNews,/news/stocks/lilly-launches-institute-for-genetic-medicine-invests-700-mln-1031215534,positive,0.6293913722038269
1600,2/22/2022 1:29:32 PM,Lilly launches Institute for Genetic Medicine; $700M for new facility at Boston Seaport,Seeking Alpha,https://seekingalpha.com/news/3802420-lilly-launches-institute-for-genetic-medicine-700m-for-new-facility-at-boston-seaport?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7118241786956787
1601,2/24/2022 8:24:04 PM,Lilly-Boehringer Ingelheim's Jardiance granted expanded indication in heart failure,Seeking Alpha,https://seekingalpha.com/news/3805360-lilly-boehringer-ingelheims-jardiance-granted-expanded-indication-in-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7764662504196167
1602,2/24/2022 10:15:00 PM,US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-to-treat-adults-with-heart-failure-regardless-of-left-ventricular-ejection-fraction-1031228735,negative,0.8771427273750305
1603,2/25/2022 11:31:07 AM,FDA Approves Jardiance To Treat Adults With Heart Failure ,RTTNews,/news/stocks/fda-approves-jardiance-to-treat-adults-with-heart-failure-1031231393,negative,0.6758896112442017
1604,2/25/2022 2:02:25 PM,"The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-s-jardiance-gets-nod-for-heart-failure-pulmatrix-announces-reverse-split-reata-awaits-fda-decision-1031231988,positive,0.890190601348877
1605,2/25/2022 4:46:48 PM,Healthcare leads a rally in S&P 500 amid hopes of Russia - Ukraine talks,Seeking Alpha,https://seekingalpha.com/news/3806014-healthcare-leads-a-rally-in-sp-500-amid-hopes-of-russia-ukraine-talks?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7153167128562927
1606,2/27/2022 3:26:47 PM,"The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-27-march-5-earnings-multiple-regulatory-decisions-take-the-spotlight-1031235310,positive,0.818364143371582
1607,2/28/2022 7:41:42 AM,Biotech Stocks Facing FDA Decision In March 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2022-1031236842,positive,0.9167487025260925
1608,2/28/2022 8:00:00 PM,Lilly to Participate in Cowen Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-health-care-conference-1031239581,positive,0.8665114641189575
1609,2/28/2022 8:34:39 PM,Why did Vir Biotechnology stock drop today?,Seeking Alpha,https://seekingalpha.com/news/3807154-why-did-vir-stock-drop-today-falling-covid-19-cases?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9167329668998718
1610,3/1/2022 4:06:00 PM,Jardiance® provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE phase III trial,PR Newswire,/news/stocks/jardiance-provided-a-significant-clinical-benefit-in-adults-stabilized-in-hospital-following-acute-heart-failure-in-empulse-phase-iii-trial-1031243500,negative,0.9430065155029297
1611,3/1/2022 5:07:10 PM,Eli Lilly's Jardiance provides benefit for acute heart failure patients,Seeking Alpha,https://seekingalpha.com/news/3807867-eli-lilly-jardiance-provides-benefit-for-acute-heart-failure-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7605757713317871
1612,3/1/2022 9:05:19 PM,Eli Lilly Says Jardiance Provides Significant Benefit In Adults Following Acute Heart Failure ,RTTNews,/news/stocks/eli-lilly-says-jardiance-provides-significant-benefit-in-adults-following-acute-heart-failure-1031244507,negative,0.9344347715377808
1613,3/2/2022 1:00:40 PM,ALX Oncology begins dosing in phase 2/3 trial of evorpacept in gastric cancer,Seeking Alpha,https://seekingalpha.com/news/3808374-alx-oncology-begins-dosing-in-phase-23-trial-of-evorpacept-in-gastric-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7067335247993469
1614,3/2/2022 1:35:33 PM,"Biden pushes for insulin price cap, Medicare drug negotiations in SOTU",Seeking Alpha,https://seekingalpha.com/news/3808400-biden-pushes-for-insulin-price-cap-medicare-drug-negotiations-in-sotu?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6005553603172302
1615,3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946,positive,0.8909978270530701
1616,3/3/2022 3:57:17 PM,U.S. to share government-backed COVID-19 tech with WHO - Washington Post,Seeking Alpha,https://seekingalpha.com/news/3809199-us-to-share-government-backed-covid-19-tech-with-who-washington-post?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.697287917137146
1617,3/3/2022 8:00:00 PM,Lilly to Participate in Barclays Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-barclays-global-healthcare-conference-1031252743,positive,0.91036456823349
1618,3/4/2022 9:48:01 AM,Lilly/Incyte's baricitinib reduces risk of death in COVID patients in UK study- Reuters,Seeking Alpha,https://seekingalpha.com/news/3809478-lillyincytes-baricitinib-reduces-risk-of-death-in-covid-patients-in-uk-study-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9268586039543152
1619,3/6/2022 12:16:50 PM,Johnson & Johnson is in talks for biotech deals in China - FT,Seeking Alpha,https://seekingalpha.com/news/3809928-johnson-johnson-is-in-talks-for-biotech-deals-in-china-ft?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6490351557731628
1620,3/8/2022 10:42:21 AM,"Lilly, Boehringer Ingelheim's Jardiance gets EU approval for expanded use in heart failure",Seeking Alpha,https://seekingalpha.com/news/3810496-lilly-boehringer-ingelheims-jardiance-gets-eu-approval-for-expanded-use-in-heart-failure?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9155697226524353
1621,3/8/2022 10:30:00 PM,Lilly Announces Details of Presentations at 2022 American Association for Cancer Research (AACR),PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-american-association-for-cancer-research-aacr-1031264187,positive,0.9434910416603088
1622,3/9/2022 1:47:19 PM,Push to curb insulin costs reemerges for Senate action,Seeking Alpha,https://seekingalpha.com/news/3811093-push-to-curb-insulin-costs-reemerges-for-senate-action?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6749652028083801
1623,3/10/2022 2:25:03 PM,"Eli Lilly, Erasca ink clinical trial/supply agreement",Seeking Alpha,https://seekingalpha.com/news/3812163-eli-lilly-erasca-ink-clinical-trialsupply-agreement?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9148085713386536
1624,3/11/2022 4:56:36 PM,"Foghorn Therapeutics buoyed by 2021 annual report, 2022 outlook",Seeking Alpha,https://seekingalpha.com/news/3812790-foghorn-therapeutics-buoyed-by-earnings-2022-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.895919680595398
1625,3/12/2022 7:20:14 PM,Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict,Seeking Alpha,https://seekingalpha.com/news/3812903-drugmakers-face-clinical-trial-disruptions-amid-russia-ukraine-conflict?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9664651155471802
1626,3/13/2022 2:24:45 PM,Biogen awaits Medicare decision on Alzheimer’s drug amid public pressure for coverage,Seeking Alpha,https://seekingalpha.com/news/3812913-biogen-awaits-medicare-decision-on-alzheimers-drug-amid-public-pressure-for-coverage?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7791392207145691
1627,3/14/2022 3:22:48 PM,Boeing : Arajet Orders 20 737 MAX Aircraft ,RTTNews,/news/stocks/boeing-arajet-orders-20-737-max-aircraft-1031278248,positive,0.4887166917324066
1628,3/15/2022 12:51:10 PM,Executives Sell More Than $25M Of 4 Stocks,Benzinga,/news/stocks/executives-sell-more-than-25m-of-4-stocks-1031280885,positive,0.9050988554954529
1629,3/15/2022 2:49:24 PM,Eli Lilly to halt exporting “non-essential” medicines to Russia,Seeking Alpha,https://seekingalpha.com/news/3813665-eli-lilly-to-halt-exporting-non-essential-medicines-to-russia-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5850395560264587
1630,3/15/2022 5:19:52 PM,U.S. faces a shortage of COVID-19 antibody therapies without more funds - White House,Seeking Alpha,https://seekingalpha.com/news/3813747-us-risks-shortage-of-covid-19-antibody-therapies-without-more-funds?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4740936756134033
1631,3/16/2022 1:00:00 PM,Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease,PR Newswire,/news/stocks/jardiance-phase-iii-empa-kidney-trial-will-stop-early-due-to-clear-positive-efficacy-in-people-with-chronic-kidney-disease-1031284743,negative,0.6352353692054749
1632,3/16/2022 1:47:00 PM,Eli Lilly: EMPA-KIDNEY Trial Shows Efficacy For Jardiance At Early Stage; Trial To Stop ,RTTNews,/news/stocks/eli-lilly-empa-kidney-trial-shows-efficacy-for-jardiance-at-early-stage-trial-to-stop-1031285003,negative,0.9005649089813232
1633,3/17/2022 8:53:55 AM,"Lilly, Boehringer to stop Jardiance's kidney disease trial early due to 'clear efficacy'",Seeking Alpha,https://seekingalpha.com/news/3814437-lilly-boehringer-to-stop-jardiances-kidney-disease-trial-early-due-to-clear-efficacy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7935139536857605
1634,3/17/2022 3:03:13 PM,Eli Lilly extends gains as BofA raises target citing prospects in weight loss space,Seeking Alpha,https://seekingalpha.com/news/3814645-eli-lilly-extends-gains-as-bofa-raises-target-citing-prospects-in-weight-loss?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8189259171485901
1635,3/24/2022 11:00:13 AM,Eli Lilly says lung cancer drug rejected by FDA citing need for a diverse trial,Seeking Alpha,https://seekingalpha.com/news/3816811-eli-lilly-says-lung-cancer-drug-rejected-by-fda-citing-need-for-a-diverse-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7013117074966431
1636,3/24/2022 11:45:00 AM,Lilly Announces Complete Response Letter for Sintilimab in Combination with Pemetrexed and Platinum Chemotherapy for the First-Line Treatment of People with Nonsquamous Non-Small Cell Lung Cancer,PR Newswire,/news/stocks/lilly-announces-complete-response-letter-for-sintilimab-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the-first-line-treatment-of-people-with-nonsquamous-non-small-cell-lung-cancer-1031304269,negative,0.88970947265625
1637,3/24/2022 11:55:44 AM,Eli Lilly: FDA Issues CRL For BLA For Sintilimab; Unable To Approve Application In Its Current Form ,RTTNews,/news/stocks/eli-lilly-fda-issues-crl-for-bla-for-sintilimab-unable-to-approve-application-in-its-current-form-1031304295,neutral,0.7826648950576782
1638,3/24/2022 1:10:16 PM,"The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL",Benzinga,/news/stocks/the-daily-biotech-pulse-novartis-prostate-cancer-drug-lands-fda-approval-ligand-announces-spac-deal-to-spin-off-antibody-business-lilly-s-lung-cancer-therapy-hit-with-crl-1031304689,positive,0.8169834613800049
1639,3/26/2022 2:20:00 PM,Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies,PR Newswire,/news/stocks/majority-of-patients-treated-with-lebrikizumab-achieved-skin-clearance-in-lilly-s-pivotal-phase-3-atopic-dermatitis-studies-1031309481,negative,0.6654060482978821
1640,3/26/2022 4:20:00 PM,Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies,PR Newswire,/news/stocks/nearly-40-of-adults-with-alopecia-areata-taking-olumiant-4-mg-saw-at-least-80-scalp-hair-coverage-at-52-weeks-in-lilly-s-pivotal-phase-3-studies-1031309584,negative,0.8868787884712219
1641,3/28/2022 2:00:00 AM,Innovent and Lilly Expand Strategic Partnership in Oncology,PR Newswire,/news/stocks/innovent-and-lilly-expand-strategic-partnership-in-oncology-1031310210,negative,0.928623378276825
1642,3/28/2022 3:44:01 AM,"Innovent Biologics, Lilly Expand Partnership In Oncology ",RTTNews,/news/stocks/innovent-biologics-lilly-expand-partnership-in-oncology-1031310225,negative,0.6218974590301514
1643,3/28/2022 9:51:19 AM,"Lilly, Biologics expand collaboration over cancer drugs in China",Seeking Alpha,https://seekingalpha.com/news/3817853-lilly-biologics-expand-collaboration-over-cancer-drugs-in-china?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.889133870601654
1644,3/28/2022 10:51:53 AM,"Eli Lilly, Incyte present late-stage 52-week data for hair loss therapy",Seeking Alpha,https://seekingalpha.com/news/3817874-eli-lilly-incy-present-late-stage-52-week-data-for-hair-loss-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8569996953010559
1645,3/29/2022 8:47:27 AM,"US agency pauses distribution of GSK, Vir's COVID-19 therapy sotrovimab in certain states",Seeking Alpha,https://seekingalpha.com/news/3818262-us-agency-pauses-distribution-of-gsk-virs-covid-19-antibody-therapy-in-certain-states?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8007267713546753
1646,3/29/2022 2:53:29 PM,J&J to suspend supply of personal care products in Russia,Seeking Alpha,https://seekingalpha.com/news/3818471-jj-to-suspend-supply-of-personal-care-products-in-russia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8334856629371643
1647,4/1/2022 12:01:26 PM,Lilly reports new data from phase 1/2 trial of Retevmo in advanced lung cancer,Seeking Alpha,https://seekingalpha.com/news/3819786-lilly-reports-new-data-from-phase-12-trial-of-retevmo-in-advanced-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7126660346984863
1648,4/1/2022 12:45:00 PM,Lilly Presents Updated Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer (NSCLC) at the 2022 European Lung Cancer Congress,PR Newswire,/news/stocks/lilly-presents-updated-data-on-retevmo-selpercatinib-in-advanced-ret-fusion-positive-non-small-cell-lung-cancer-nsclc-at-the-2022-european-lung-cancer-congress-1031325951,positive,0.8361642360687256
1649,4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374,positive,0.9468021392822266
1650,4/1/2022 10:56:45 PM,4 Stocks Reporting Earnings the Week of April 4,InvestorPlace,/news/stocks/4-stocks-reporting-earnings-the-week-of-april-4-1031327553,positive,0.6486364603042603
1651,4/4/2022 9:00:38 PM,Lawmakers agree on $10 billion additional funding for U.S. COVID response (Updated),Seeking Alpha,https://seekingalpha.com/news/3820489-lawmakers-set-to-announce-10-billion-additional-funding-for-us-covid-response?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6900182366371155
1652,4/6/2022 1:33:41 AM,"GlaxoSmithKline, Vir COVID-19 therapy is no longer authorized in U.S. - FDA",Seeking Alpha,https://seekingalpha.com/news/3820993-glaxosmithkline-vir-covid-19-therapy-is-no-longer-authorized-in-us-fda?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9018964171409607
1653,4/6/2022 2:33:34 PM,Eli Lilly price target raised at Morgan Stanley on robust product outlook,Seeking Alpha,https://seekingalpha.com/news/3821186-eli-lilly-price-target-raised-at-morgan-stanley-on-robust-product-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6701922416687012
1654,4/6/2022 5:05:03 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1031337266,positive,0.9322600364685059
1655,4/7/2022 7:43:39 PM,"House, Senate Democrats introduce bills targeting 'abusive' pharma business practices",Seeking Alpha,https://seekingalpha.com/news/3821821-house-senate-democrats-introduce-bills-targeting-abusive-pharma-business-practices?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6520105004310608
1656,4/8/2022 2:01:42 PM,Why Is Biogen (BIIB) Stock in the Spotlight Today?,InvestorPlace,/news/stocks/why-is-biogen-biib-stock-in-the-spotlight-today-1031343182,positive,0.8517704606056213
1657,4/9/2022 4:00:14 PM,Healthcare stocks outperform as investors look for safety,Seeking Alpha,https://seekingalpha.com/news/3822171-healthcare-stocks-outperform-as-investors-look-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9504939317703247
1658,4/10/2022 10:42:49 PM,"The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-10-april-16-regeneron-fda-decision-cancer-conference-presentations-and-more-1031344759,positive,0.9415993690490723
1659,4/11/2022 4:15:00 PM,Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis,PR Newswire,/news/stocks/lilly-s-lebrikizumab-combined-with-topical-corticosteroids-showed-significant-improvements-in-disease-severity-for-atopic-dermatitis-1031346782,negative,0.9467454552650452
1660,4/11/2022 4:45:23 PM,Lilly atopic dermatitis candidate lebrikizumab shows improvement in disease severity,Seeking Alpha,https://seekingalpha.com/news/3822353-lilly-atopic-dermatitis-candidate-lebrikizumab-shows-improvement-in-disease-severity?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9534206986427307
1661,4/11/2022 4:47:41 PM,Lilly's Lebrikizumab - Corticosteroids Show Improvements In Disease Severity For Atopic Dermatitis ,RTTNews,/news/stocks/lilly-s-lebrikizumab-corticosteroids-show-improvements-in-disease-severity-for-atopic-dermatitis-1031346873,negative,0.9487952589988708
1662,4/15/2022 11:03:38 AM,3 Mutual Funds to Buy for April,InvestorPlace,/news/stocks/3-mutual-funds-to-buy-for-april-1031358654,positive,0.9319861531257629
1663,4/18/2022 11:59:23 AM,Eli Lilly expects $165 million in charges related to in-process R&D projects,Seeking Alpha,https://seekingalpha.com/news/3823792-eli-lilly-to-recognize-165-million-in-charges-related-to-in-process-rd-projects?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9416850805282593
1664,4/19/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2022-financial-results-announcement-1031364440,positive,0.9414366483688354
1665,4/20/2022 3:00:00 PM,Tackling Health Disparities and Inequities for Women with Heart Failure: New Program Encourages Black and Latina Women to Demand More From Their Care,PR Newswire,/news/stocks/tackling-health-disparities-and-inequities-for-women-with-heart-failure-new-program-encourages-black-and-latina-women-to-demand-more-from-their-care-1031368129,negative,0.858415961265564
1666,4/21/2022 12:10:33 PM,7 Potential Biotech Stocks Buyout Targets in 2022,InvestorPlace,/news/stocks/7-potential-biotech-stocks-targets-in-2022-1031371733,positive,0.8115262389183044
1667,4/22/2022 4:32:49 PM,EMA panel recommends extending indication for Lilly's cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3825852-ema-panel-recommends-extending-indication-for-lillys-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8228102922439575
1668,4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9413689374923706
1669,4/25/2022 7:48:12 PM,Pfizer and Gilead earn preferred status for COVID-19 antivirals in new CDC advisory,Seeking Alpha,https://seekingalpha.com/news/3826382-pfe-gild-stocks-up-on-preferred-status-for-covid-19-antivirals-in-cdc-advisory?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7187272906303406
1670,4/25/2022 9:26:09 PM,"Nektar Therapeutics unveils restructuring plan, laying off 70% of its workforce",Seeking Alpha,https://seekingalpha.com/news/3826475-nektar-therapeutics-unveils-restructuring-plan-laying-off-70-of-its-workforce?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9647687077522278
1671,4/27/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q1-earnings-preview-1031391569,positive,0.938167929649353
1672,4/27/2022 3:25:48 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3827680-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8825733065605164
1673,4/27/2022 5:22:22 PM,"Eli Lilly Q1 result to focus on COVID-19 therapies sales, comments on Alzheimer's drug",Seeking Alpha,https://seekingalpha.com/news/3827833-eli-lilly-q1-result-to-focus-on-covid-19-therapies-sales-comments-on-alzheimers-drug?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9300889372825623
1674,4/28/2022 10:26:24 AM,"Eli Lilly Non-GAAP EPS of $2.62 beats by $0.32, revenue of $7.81B beats by $520M",Seeking Alpha,https://seekingalpha.com/news/3828363-eli-lilly-non-gaap-eps-of-2_62-beats-0_32-revenue-of-7_81b-beats-520m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.49302956461906433
1675,4/28/2022 11:55:30 AM,"Lilly Q1 revenue soars on COVID antibodies, Trulicity; raises FY22 revenue outlook, cuts EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3828506-lilly-q1-revenue-soars-on-covid-antibodies-trulicity-raises-fy22-revenue-outlook-cuts-eps-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5696375370025635
1676,4/28/2022 12:15:00 PM,Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1,PR Newswire,/news/stocks/lilly-s-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-surmount-1-1031396399,negative,0.9296858906745911
1677,4/28/2022 12:25:00 PM,Solid First-Quarter Financial Results Reflect Lilly's Continued Momentum into 2022,PR Newswire,/news/stocks/solid-first-quarter-financial-results-reflect-lilly-s-continued-momentum-into-2022-1031396440,negative,0.9519197344779968
1678,4/28/2022 12:30:18 PM,Eli Lilly And Co. Reveals Increase In Q1 Profit,RTTNews,/news/stocks/eli-lilly-and-co-reveals-increase-in-q1-profit-1031396489,negative,0.9405080080032349
1679,4/28/2022 12:52:39 PM,Eli Lilly Q1 Results Top Estimates; Boosts FY22 Revenue Outlook ,RTTNews,/news/stocks/eli-lilly-q1-results-top-estimates-boosts-fy22-revenue-outlook-1031396555,negative,0.9314490556716919
1680,4/28/2022 1:28:07 PM,Lilly's tirzepatide shows weight loss benefit in adults without diabetes,Seeking Alpha,https://seekingalpha.com/news/3828625-eli-lilly-tirzepatide-shows-weight-loss-benefit-in-adults-without-diabetes?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9183995127677917
1681,4/28/2022 2:04:49 PM,Lilly: Tirzepatide In SURMOUNT-1 Trial Delivers Superior Weight Loss In Adults ,RTTNews,/news/stocks/lilly-tirzepatide-in-surmount-1-trial-delivers-superior-weight-loss-in-adults-1031397022,negative,0.9520041942596436
1682,4/28/2022 2:52:43 PM,"The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-seeks-fda-approval-for-covid-19-shot-for-children-2-6-tax-disclosure-for-amgen-fast-track-tags-for-sqz-biotech-timber-pharma-candidates-1031397312,positive,0.7427427768707275
1683,4/29/2022 5:02:56 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031403053,positive,0.9140509963035583
1684,4/30/2022 8:00:00 PM,U.S. pharmaceutical sector fails to spring higher amid lackluster April performance,Seeking Alpha,https://seekingalpha.com/news/3829651-us-pharmaceutical-sector-fails-to-spring-higher-amid-lackluster-april-performance?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6144396066665649
1685,5/2/2022 10:15:00 AM,Morgan Stanley issues list of 45 highest conviction stock picks,Seeking Alpha,https://seekingalpha.com/news/3829447-morgan-stanley-issues-list-of-45-highest-conviction-stock-picks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8834772706031799
1686,5/2/2022 7:01:26 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3830361-eli-lilly-and-company-declares-0_98-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9216097593307495
1687,5/2/2022 8:26:00 PM,Lilly Declares Second-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2022-dividend-1031410053,positive,0.8947626352310181
1688,5/3/2022 3:07:41 PM,Lilly partners with AI-focused Genesis Therapeutics in up to $670M deal,Seeking Alpha,https://seekingalpha.com/news/3831062-lilly-partners-with-ai-artifical-intelligence-focused-genesis-therapeutics-in-up-to-670m-deal?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7286641001701355
1689,5/3/2022 8:00:00 PM,Lilly to Participate in Bank of America Securities 2022 Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-bank-of-america-securities-2022-healthcare-conference-1031415107,positive,0.908056914806366
1690,5/4/2022 10:39:59 AM,"Starbucks, Meta, Exxon among many stocks dropping off BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3831217-starbucks-meta-exxon-among-many-stocks-dropping-off-bofas-alpa-surprise-screen?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.948421835899353
1691,5/5/2022 7:32:41 PM,Biogen spat with SEC over accounting impacting other pharmas' quarterly reports - MarketWatch,Seeking Alpha,https://seekingalpha.com/news/3833608-biogen-spat-with-sec-over-accounting-impacting-other-pharmas-quarterly-reports-marketwatch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9378116726875305
1692,5/6/2022 8:00:00 PM,Mary Lynne Hedley Elected to Lilly Board of Directors,PR Newswire,/news/stocks/mary-lynne-hedley-elected-to-lilly-board-of-directors-1031431727,positive,0.9262236952781677
1693,5/9/2022 9:15:08 AM,Adocia to get $5M as Chinese partner Tonghua begins dosing of insulin BioChaperone in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3834787-adocia-to-get-5m-as-chinese-partner-tonghua-begins-dosing-of-insulin-biochaperone-in-phase-3-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8263086676597595
1694,5/11/2022 10:35:43 AM,7 Biotech Stocks With Key Catalysts for May,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-for-may-1031447419,positive,0.7446258068084717
1695,5/11/2022 11:16:47 AM,"Lilly, Incyte get FDA approval of Olumiant to treat certain hospitalized COVID-19 patients",Seeking Alpha,https://seekingalpha.com/news/3836682-lilly-incyte-get-fda-approval-of-olumiant-to-treat-certain-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9326473474502563
1696,5/11/2022 12:45:00 PM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-for-the-treatment-of-certain-hospitalized-patients-with-covid-19-1031447417,negative,0.8625271916389465
1697,5/11/2022 1:04:22 PM,"Eli Lilly, Incyte Announce FDA Approval Of OLUMIANT For Hospitalized Patients With COVID-19 ",RTTNews,/news/stocks/eli-lilly-incyte-announce-fda-approval-of-olumiant-for-hospitalized-patients-with-covid-19-1031447512,negative,0.8166871070861816
1698,5/11/2022 3:37:50 PM,"The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine",Benzinga,/news/stocks/the-daily-biotech-pulse-veru-shares-up-on-covid-candidate-update-fda-approves-lilly-s-covid-treatment-latest-on-sanofi-astrazeneca-rsv-vaccine-1031448828,negative,0.6131426095962524
1699,5/12/2022 2:14:54 PM,Federal flags to fly at half-staff to mark one million COVID deaths,Seeking Alpha,https://seekingalpha.com/news/3837849-federal-flags-to-fly-at-half-staff-to-mark-one-million-covid-deaths?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9106363654136658
1700,5/13/2022 5:55:52 PM,"Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas",Benzinga,/news/stocks/amid-slowing-sales-at-home-innovent-biologics-stumbles-overseas-1031459391,neutral,0.9719640016555786
1701,5/13/2022 7:44:06 PM,Eli Lilly's dual-receptor diabetes drug tirzepatide granted FDA approval,Seeking Alpha,https://seekingalpha.com/news/3838811-eli-lilly-dual-receptor-diabetes-drug-tirzepatide-mounjaro-granted-fda-approval?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9467118978500366
1702,5/13/2022 11:54:00 PM,"FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes",PR Newswire,/news/stocks/fda-approves-lilly-s-mounjaro-tirzepatide-injection-the-first-and-only-gip-and-glp-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes-1031459853,negative,0.861160933971405
1703,5/14/2022 3:58:03 AM,FDA Approves Lilly's Mounjaro Injection For Type 2 Diabetes Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-mounjaro-injection-for-type-2-diabetes-treatment-1031459884,negative,0.5365328788757324
1704,5/14/2022 8:00:00 PM,Why the approval of Eli Lilly's tirzepatide for diabetes will lead to blockbuster sales,Seeking Alpha,https://seekingalpha.com/news/3838865-why-the-approval-of-eli-lilly-tirzepatide-mounjaro-for-diabetes-will-lead-to-blockbuster-sales?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9098069071769714
1705,5/16/2022 6:04:27 PM,FDA rejects old antidepressant Luvox as COVID treatment citing lack of evidence,Seeking Alpha,https://seekingalpha.com/news/3839377-fda-rejects-old-antidepressant-luvox-fluvoxamine-as-covid-treatment-citing-lack-of-evidence?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4814581573009491
1706,5/16/2022 8:00:00 PM,Lilly to Participate in UBS Global Healthcare Conference 2022,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-global-healthcare-conference-2022-1031465541,positive,0.9102637767791748
1707,5/18/2022 6:37:57 PM,Eli Lilly says COVID therapy bebtelovimab effective against dominant U.S. COVID strain,Seeking Alpha,https://seekingalpha.com/news/3840595-eli-lilly-says-covid-therapy-bebtelovimab-effective-against-dominant-us-covid-strain?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9460289478302002
1708,5/19/2022 12:44:29 PM,PepsiCo And 3 Other Stocks Insiders Are Selling,Benzinga,/news/stocks/pepsico-and-3-other-stocks-insiders-are-selling-1031475155,positive,0.9041250944137573
1709,5/19/2022 6:49:20 PM,Eli Lilly oncologic selpercatinib granted Orphan Drug status for solid tumors,Seeking Alpha,https://seekingalpha.com/news/3841094-eli-lilly-oncologic-selpercatinib-retevmo-granted-orphan-drug-status-for-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9287541508674622
1710,5/20/2022 2:11:00 PM,CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA),PR Newswire,/news/stocks/chmp-recommends-approval-of-lilly-and-incyte-s-olumiant-baricitinib-as-the-first-and-only-centrally-authorized-treatment-for-adults-with-severe-alopecia-areata-aa-1031478443,negative,0.823082447052002
1711,5/20/2022 2:29:07 PM,Lilly : CHMP Issues Positive Opinion For Olumiant For Severe Alopecia Areata Treatment ,RTTNews,/news/stocks/lilly-chmp-issues-positive-opinion-for-olumiant-for-severe-alopecia-areata-treatment-1031478481,negative,0.9450750350952148
1712,5/20/2022 8:19:36 PM,Eli Lilly's new diabetes drug Mounjaro priced below Novo Nordisk's Wegovy,Seeking Alpha,https://seekingalpha.com/news/3841486-eli-lilly-new-diabetes-drug-mounjaro-tirzepatidepriced-below-novo-nordisk-wegovy-semaglutide?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7816492915153503
1713,5/23/2022 2:18:39 PM,"AstraZeneca, Eli Lilly in focus as U.S. panel weighs routine kidney disease screening",Seeking Alpha,https://seekingalpha.com/news/3841740-lly-azn-stocks-in-focus-as-us-panel-weighs-kidney-disease-screening?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6932756304740906
1714,5/23/2022 4:33:42 PM,"Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-may-23-2022-1031482320,positive,0.527824878692627
1715,5/23/2022 8:08:01 PM,What 7 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-eli-lilly-1031482764,positive,0.9413512945175171
1716,5/23/2022 8:44:09 PM,The Analyst Says 'Impressive Phase 3 Data Highlight Best-In-Class Opportunity' For Concert Pharma,Benzinga,/news/stocks/the-analyst-says-impressive-phase-3-data-highlight-best-in-class-opportunity-for-concert-pharma-1031482839,negative,0.9539371728897095
1717,5/23/2022 11:00:00 PM,Lilly Announces Webcast to Provide Diabetes and Obesity Portfolio Update at ADA,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-diabetes-and-obesity-portfolio-update-at-ada-1031483078,positive,0.9218766093254089
1718,5/24/2022 9:01:00 AM,Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study,PR Newswire,/news/stocks/fifty-percent-of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lilly-s-pivotal-phase-3-study-1031483807,negative,0.8152573704719543
1719,5/24/2022 9:38:02 AM,Lilly mirikizumab helps reduce ulcerative colitis symptoms in 50% patients at 1 year in trial,Seeking Alpha,https://seekingalpha.com/news/3842076-lilly-mirikizumab-helps-reduce-ulcerative-colitis-symptoms-in-50-patients-at-1-year-in-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8495863080024719
1720,5/24/2022 10:20:00 AM,Lilly: One-half Of Mirikizumab Patients Achieves Clinical Remission At One Year In Phase 3 Study ,RTTNews,/news/stocks/lilly-one-half-of-mirikizumab-patients-achieves-clinical-remission-at-one-year-in-phase-3-study-1031483947,negative,0.7928492426872253
1721,5/24/2022 1:29:05 PM,COVID-19 sales boom for vaccine and drug makers might be over - analysts,Seeking Alpha,https://seekingalpha.com/news/3842211-covid-19-sales-boom-for-vaccine-and-drug-makers-might-be-over?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.39463990926742554
1722,5/25/2022 2:10:21 PM,Executives Sell Around $207M Of 5 Stocks,Benzinga,/news/stocks/executives-sell-around-207m-of-5-stocks-1031488093,positive,0.9301442503929138
1723,5/25/2022 4:58:45 PM,AbbVie trails Lilly despite a 30% bigger ex-Humira business - Wells Fargo,Seeking Alpha,https://seekingalpha.com/news/3842736-abbvie-stock-gains-as-wells-fargo-backs-ex-humira-business?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5263083577156067
1724,5/25/2022 5:52:58 PM,Eli Lilly allocates $2.1 billion to expand production footprint in Indiana,Seeking Alpha,https://seekingalpha.com/news/3842765-eli-lilly-allocates-21-billion-to-expand-production-footprint-in-indiana?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9233389496803284
1725,5/25/2022 7:15:00 PM,Lilly plans to invest $2.1 billion in new manufacturing sites in Indiana,PR Newswire,/news/stocks/lilly-plans-to-invest-2-1-billion-in-new-manufacturing-sites-in-indiana-1031489204,positive,0.6240642070770264
1726,5/26/2022 3:23:32 AM,Lilly To Invest $2.1 Bln In New Manufacturing Sites In Indiana ,RTTNews,/news/stocks/lilly-to-invest-2-1-bln-in-new-manufacturing-sites-in-indiana-1031489755,negative,0.7843693494796753
1727,5/26/2022 2:45:54 PM,"The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review",Benzinga,/news/stocks/the-daily-biotech-pulse-setback-for-nrx-pharma-s-covid-study-fast-track-tag-for-pfizer-s-nash-combo-therapy-reata-s-ataxia-drug-in-fda-review-1031490976,negative,0.6595115065574646
1728,5/26/2022 3:41:44 PM,Pfizer's Paxlovid by far the most administered COVID-19 therapy,Seeking Alpha,https://seekingalpha.com/news/3843162-pfizer-paxlovid-by-far-the-most-administered-covid-19-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4997808039188385
1729,5/26/2022 7:30:04 PM,Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness,Benzinga,/news/stocks/mizuho-sees-compelling-risk-reward-for-this-schizophrenia-stock-despite-recent-weakness-1031491666,negative,0.9201868176460266
1730,5/26/2022 11:00:00 PM,Lilly Announces Details of Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-american-society-of-clinical-oncology-asco-annual-meeting-1031491995,positive,0.9398189783096313
1731,5/30/2022 12:52:39 PM,Sanofi trial for over-the-counter Cialis put on hold by FDA,Seeking Alpha,https://seekingalpha.com/news/3843681-sanofi-trial-for-over-the-counter-cialis-put-on-hold-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5811018347740173
1732,5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9459705948829651
1733,6/1/2022 2:44:41 PM,Executives Sell Over $100M Of 4 Stocks,Benzinga,/news/stocks/executives-sell-over-100m-of-4-stocks-1031501797,positive,0.8883760571479797
1734,6/3/2022 4:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1031508671,positive,0.892741322517395
1735,6/4/2022 4:02:00 PM,Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight,PR Newswire,/news/stocks/lilly-s-surmount-1-results-published-in-the-new-england-journal-of-medicine-show-tirzepatide-achieved-between-16-0-and-22-5-weight-loss-in-adults-with-obesity-or-overweight-1031509535,negative,0.9164233803749084
1736,6/4/2022 5:00:00 PM,Lilly's AWARD-PEDS trial investigating use of Trulicity® (dulaglutide) in youth and adolescents with type 2 diabetes showed superiority in A1C reduction vs placebo,PR Newswire,/news/stocks/lilly-s-award-peds-trial-investigating-use-of-trulicity-dulaglutide-in-youth-and-adolescents-with-type-2-diabetes-showed-superiority-in-a1c-reduction-vs-placebo-1031509542,negative,0.9395977258682251
1737,6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946,positive,0.804358184337616
1738,6/5/2022 10:30:00 PM,Jardiance® decreased relative risk of hospitalization for heart failure by 50% versus DPP-4 inhibitors and by 30% versus GLP-1 receptor agonists in adults with type 2 diabetes in real-world eviden...,PR Newswire,/news/stocks/jardiance-decreased-relative-risk-of-hospitalization-for-heart-failure-by-50-versus-dpp-4-inhibitors-and-by-30-versus-glp-1-receptor-agonists-in-adults-with-type-2-diabetes-in-real-world-eviden-1031509950,negative,0.9453573822975159
1739,6/6/2022 5:19:22 AM,Lilly : Jardiance Decreases Risk Of Hospitalization For Heart Failure By 50% In Type 2 Diabetes ,RTTNews,/news/stocks/lilly-jardiance-decreases-risk-of-hospitalization-for-heart-failure-by-50-in-type-2-diabetes-1031509998,negative,0.940382719039917
1740,6/6/2022 10:45:52 AM,Lilly/Boehringer Jardiance cuts risk of heart failure hospitalization for diabetes patients in 5-year data,Seeking Alpha,https://seekingalpha.com/news/3845812-lillyboehringer-jardiance-cuts-risk-of-heart-failure-hospitalization-for-diabetes-patients-in-5-year-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8208136558532715
1741,6/6/2022 6:31:15 PM,Eli Lilly rebounds as analysts cheer newly published data for weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/3846046-lly-stock-rebounds-as-analysts-cheer-newly-published-weight-loss-therapy-data?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7233931422233582
1742,6/7/2022 1:00:00 AM,New analyses of Mounjaro™ (tirzepatide) injection for the treatment of adults with type 2 diabetes presented at the American Diabetes Association's® 82nd Scientific Sessions®,PR Newswire,/news/stocks/new-analyses-of-mounjaro-tirzepatide-injection-for-the-treatment-of-adults-with-type-2-diabetes-presented-at-the-american-diabetes-association-s-82nd-scientific-sessions-1031511962,positive,0.8432268500328064
1743,6/7/2022 6:01:00 AM,Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials,PR Newswire,/news/stocks/eight-out-of-ten-patients-maintained-skin-clearance-at-one-year-in-lilly-s-lebrikizumab-atopic-dermatitis-monotherapy-trials-1031512139,positive,0.8378658890724182
1744,6/7/2022 7:14:10 AM,Lilly Reports Positive Data From Lebrikizumab Atopic Dermatitis Monotherapy Trials ,RTTNews,/news/stocks/lilly-reports-positive-data-from-lebrikizumab-atopic-dermatitis-monotherapy-trials-1031512313,negative,0.9430842399597168
1745,6/7/2022 10:13:51 AM,Lilly/Almirall drug maintains clearer skin in eczema patients in trials; Lilly plans FDA filing,Seeking Alpha,https://seekingalpha.com/news/3846159-lillyalmirall-drug-maintains-clearer-skin-in-eczema-patients-in-trials-lilly-plans-fda-filing?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5128700733184814
1746,6/9/2022 6:49:28 PM,Amphastar crashes 22% as FDA rejects generic for osteoporosis drug,Seeking Alpha,https://seekingalpha.com/news/3847440-amph-stock-crashes-as-fda-rejects-generic-for-osteoporosis-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.959395706653595
1747,6/10/2022 2:57:48 PM,7 Great ETFs to Buy Now for Momentum in Q2,InvestorPlace,/news/stocks/7-great-etfs-to-buy-now-for-momentum-in-q2-1031522477,negative,0.6736835837364197
1748,6/10/2022 9:53:38 PM,Goldman Sachs comes under SEC civil probe over ESG funds - WSJ,Seeking Alpha,https://seekingalpha.com/news/3847829-goldman-sachs-comes-under-sec-probe-on-esg-funds-wsj?utm_source=businessinsider&utm_medium=referral,neutral,0.9274108409881592
1749,6/13/2022 7:31:49 PM,Eli Lilly wins FDA label expansion for Olumiant in hair-loss disorder,Seeking Alpha,https://seekingalpha.com/news/3848167-eli-lilly-wins-fda-label-expansion-for-olumiant-in-hair-loss-disorder?utm_source=businessinsider&utm_medium=referral,negative,0.9257203936576843
1750,6/14/2022 3:50:00 AM,FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata,PR Newswire,/news/stocks/fda-approves-lilly-and-incyte-s-olumiant-baricitinib-as-first-and-only-systemic-medicine-for-adults-with-severe-alopecia-areata-1031526339,negative,0.8151333332061768
1751,6/14/2022 7:47:24 AM,FDA Approves Lilly's Olumiant As First Systemic Treatment For Alopecia ,RTTNews,/news/stocks/fda-approves-lilly-s-olumiant-as-first-systemic-treatment-for-alopecia-1031526677,negative,0.7089864015579224
1752,6/14/2022 9:39:14 AM,FDA Approves First Medicine Ever For Alopecia Areata ,RTTNews,/news/stocks/fda-approves-first-medicine-ever-for-alopecia-areata-1031526865,positive,0.5018296241760254
1753,6/14/2022 2:37:49 PM,"Morning Brief: Top Financial Stories Dominating on Tuesday, June 14",Benzinga,/news/stocks/morning-brief-top-financial-stories-dominating-on-tuesday-june-14-1031527745,positive,0.9107048511505127
1754,6/14/2022 8:09:00 PM,Approval Of Baricitinib For Patchy Baldness Validates Clinical Patch For This Small-Cap Stock,Benzinga,/news/stocks/approval-of-baricitinib-for-patchy-baldness-validates-clinical-patch-for-this-small-cap-stock-1031528830,negative,0.9399095177650452
1755,6/16/2022 2:32:22 PM,Jim Cramer Says This Company Is A Great One,Benzinga,/news/stocks/jim-cramer-says-this-company-is-a-great-one-1031533078,negative,0.697556734085083
1756,6/16/2022 5:26:53 PM,Lilly partnering with Sidekick Health for breast cancer digital therapeutic app,Seeking Alpha,https://seekingalpha.com/news/3849343-lilly-partnering-with-sidekick-health-for-breast-cancer-digital-therapeutic-app?utm_source=businessinsider&utm_medium=referral,positive,0.5343196392059326
1757,6/17/2022 3:03:44 AM,FTC votes unanimously to increase scrutiny over pharmacy agent fees,Seeking Alpha,https://seekingalpha.com/news/3849443-ftc-votes-unanimously-to-increase-scrutiny-over-rebates-paid-to-pbms?utm_source=businessinsider&utm_medium=referral,negative,0.6849480271339417
1758,6/17/2022 6:30:21 PM,BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock,Benzinga,/news/stocks/bmo-sees-differentiated-gene-editing-platform-for-this-small-cap-stock-1031536035,negative,0.6232393980026245
1759,6/21/2022 3:25:07 AM,Innovent : China Approves TYVYT Combination As Treatment For Esophageal Squamous Cell Carcinoma ,RTTNews,/news/stocks/innovent-china-approves-tyvyt-combination-as-treatment-for-esophageal-squamous-cell-carcinoma-1031538652,negative,0.846867024898529
1760,6/21/2022 10:35:05 AM,Lilly/Innovent Tyvyt gets approval in China for expanded use in esophagus cancer,Seeking Alpha,https://seekingalpha.com/news/3849948-lillyinnovent-tyvyt-gets-approval-in-china-for-expanded-use-in-esophagus-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.9259209036827087
1761,6/21/2022 12:12:02 PM,Top stocks insulated from risk with recession not fully priced in - Morgan Stanley,Seeking Alpha,https://seekingalpha.com/news/3849977-top-stocks-insulated-from-risk-with-recession-not-fully-priced-in-morgan-stanley?utm_source=businessinsider&utm_medium=referral,positive,0.8133299946784973
1762,6/22/2022 1:34:57 PM,AVEO Oncology partners with Eli Lilly to develop and supply head and neck cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/3850765-aveo-oncology-partners-with-eli-lilly-to-develop-and-supply-head-and-neck-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.6185252666473389
1763,6/24/2022 12:43:55 PM,Lilly's migraine therapy Rayvow gets EMA panel nod for EU approval,Seeking Alpha,https://seekingalpha.com/news/3851498-lillys-migraine-therapy-rayvow-gets-ema-panel-nod-for-eu-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8577622175216675
1764,6/27/2022 3:09:10 AM,Lilly : China Approves TYVYT Combination For Treatment Of Gastric Cancer ,RTTNews,/news/stocks/lilly-china-approves-tyvyt-combination-for-treatment-of-gastric-cancer-1031550439,negative,0.8904908299446106
1765,6/27/2022 5:37:12 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3852172-eli-lilly-and-company-declares-0_98-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9216097593307495
1766,6/27/2022 7:26:00 PM,Lilly Declares Third-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2022-dividend-1031552633,positive,0.9107850193977356
1767,6/27/2022 10:04:34 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/defensive-stocks-to-buy-for-a-bear-market-1031557948,positive,0.9065269827842712
1768,6/27/2022 10:04:38 PM,7 Defensive Stocks to Buy for a Bear Market,InvestorPlace,/news/stocks/7-defensive-stocks-to-buy-for-a-bear-market-1031552985,positive,0.9065269827842712
1769,6/29/2022 11:10:12 AM,Lilly to supply additional 150K doses of COVID-19 antibody therapy to U.S.,Seeking Alpha,https://seekingalpha.com/news/3852750-lly-stock-on-watch-after-deal-to-supply-covid-19-antibody-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8380051851272583
1770,6/29/2022 12:45:00 PM,"Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options",PR Newswire,/news/stocks/lilly-will-supply-an-additional-150-000-doses-of-bebtelovimab-to-u-s-government-in-ongoing-effort-to-provide-covid-19-treatment-options-1031556993,negative,0.8529200553894043
1771,6/29/2022 12:57:33 PM,Lilly To Supply Addl. 150K Doses Of Bebtelovimab To U.S. Government For About $275 Mln ,RTTNews,/news/stocks/lilly-to-supply-addl-150k-doses-of-bebtelovimab-to-u-s-government-for-about-275-mln-1031557022,positive,0.5972912311553955
1772,6/29/2022 3:50:08 PM,5 S&P 500 Stocks Ready to Break Out,InvestorPlace,/news/stocks/sp-500-stocks-ready-to-break-out-1031558401,positive,0.7080057859420776
1773,6/29/2022 6:06:23 PM,"The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-eli-lilly-modifies-covid-19-treatment-pact-oyster-point-outlines-restructuring-plan-icosavax-posts-interim-rsv-vaccine-data-1031558382,positive,0.9134541153907776
1774,7/2/2022 6:00:00 PM,"As amyloid-targeting therapies for Alzheimer's fail, where might success lie?",Seeking Alpha,https://seekingalpha.com/news/3853361-as-amyloid-targeting-therapies-for-alzheimers-fail-where-might-success-lie?utm_source=businessinsider&utm_medium=referral,positive,0.8673624992370605
1775,7/6/2022 3:00:44 PM,Eli Lilly hits new all-time high buoyed by recent drug approvals; up 21% YTD,Seeking Alpha,https://seekingalpha.com/news/3854637-eli-lilly-hits-new-all-time-high-buoyed-by-recent-drug-approvals-up-21-ytd?utm_source=businessinsider&utm_medium=referral,negative,0.9452106952667236
1776,7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral,negative,0.7087149620056152
1777,7/7/2022 1:53:40 PM,This Analyst Cuts Price Target On Microsoft; Here's The Biggest Price Target Changes For Thursday,Benzinga,/news/stocks/this-analyst-cuts-price-target-on-microsoft-here-s-the-biggest-price-target-changes-for-thursday-1031572813,positive,0.9334458112716675
1778,7/7/2022 10:27:17 PM,What 8 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-8-analyst-ratings-have-to-say-about-eli-lilly-1031574128,positive,0.9419816136360168
1779,7/11/2022 3:29:42 PM,Goldman screens stocks most and least vulnerable to recession margin pressure,Seeking Alpha,https://seekingalpha.com/news/3855643-goldman-screens-stocks-most-ane-least-vulnerable-to-recession-margin-pressure?utm_source=businessinsider&utm_medium=referral,neutral,0.8081632852554321
1780,7/12/2022 7:33:16 PM,Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?,Benzinga,/news/stocks/incyte-incy-outperforms-industry-ytd-what-lies-ahead-1031582179,positive,0.7776051163673401
1781,7/15/2022 9:41:21 PM,Eli Lilly (again) hits a new 52-week high; up 22% YTD,Seeking Alpha,https://seekingalpha.com/news/3857334-eli-lilly-again-hits-a-new-52-week-high-up-22-ytd?utm_source=businessinsider&utm_medium=referral,negative,0.9453327655792236
1782,7/17/2022 4:00:59 PM,"Novo, Eli Lilly to dominate >$50B obesity market - Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3857375-lly-nvo-stocks-in-focus-as-morgan-stanley-projects-over-50b-obesity-market?utm_source=businessinsider&utm_medium=referral,positive,0.8719704151153564
1783,7/18/2022 1:18:25 PM,"Erasca, Eli Lilly to collaborate on trial to evaluate combo treatment for two cancers",Seeking Alpha,https://seekingalpha.com/news/3857560-erasca-eli-lilly-to-collaborate-on-trial-to-evaluate-combo-treatment-for-two-cancers?utm_source=businessinsider&utm_medium=referral,negative,0.639413595199585
1784,7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral,negative,0.9346281290054321
1785,7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627,positive,0.8794339299201965
1786,7/21/2022 3:49:50 PM,AstraZeneca COVID-19 therapy less effective against new Omicron strains: study,Seeking Alpha,https://seekingalpha.com/news/3859171-astrazeneca-covid-19-therapy-less-protection-against-new-omicron-strains?utm_source=businessinsider&utm_medium=referral,neutral,0.845219612121582
1787,7/21/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2022-financial-results-announcement-1031605059,positive,0.9390143752098083
1788,7/21/2022 7:03:18 PM,"New Indication Approval For Incyte ""To Usher New Growth Avenue""",Benzinga,/news/stocks/new-indication-approval-for-incyte-to-usher-new-growth-avenue-1031605581,negative,0.8550176620483398
1789,7/21/2022 9:05:24 PM,Scientist casts doubt on amyloid theory for Alzheimer's; sees issues with Cassava images,Seeking Alpha,https://seekingalpha.com/news/3859403-scientist-casts-doubt-on-amyloid-theory-for-alzheimers-sees-issues-with-cassava-images?utm_source=businessinsider&utm_medium=referral,neutral,0.6803063750267029
1790,7/22/2022 1:13:06 PM,"EMA panel recommends approval of Lilly drug Mounjaro, extension of indication for Retsevmo",Seeking Alpha,https://seekingalpha.com/news/3859615-ema-panel-recommends-approval-of-lilly-drug-mounjaro-extension-of-indication-for-retsevmo?utm_source=businessinsider&utm_medium=referral,negative,0.8792368769645691
1791,7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,positive,0.8448383808135986
1792,7/26/2022 10:37:23 AM,"China clears HIV pill for COVID-19, marking 1st home-made pill against coronavirus",Seeking Alpha,https://seekingalpha.com/news/3860382-china-clears-hiv-pill-for-covid-19-marking-1st-home-made-pill-against-coronavirus?utm_source=businessinsider&utm_medium=referral,negative,0.672778844833374
1793,7/26/2022 8:16:10 PM,Surge in use of Pfizer's COVID antiviral Paxlovid since May,Seeking Alpha,https://seekingalpha.com/news/3860833-nearly-28m-courses-of-pfizer-covid-antiviral-paxlovid-administered-so-far?utm_source=businessinsider&utm_medium=referral,negative,0.9445315003395081
1794,7/28/2022 8:20:28 PM,Senate Democrats propose $21B funding for next phase of COVID-19 response,Seeking Alpha,https://seekingalpha.com/news/3862718-senate-democrats-propose-21b-funding-for-next-phase-of-covid-19-response?utm_source=businessinsider&utm_medium=referral,negative,0.6786968111991882
1795,7/29/2022 4:41:48 PM,"Earnings Week Ahead: Starbucks, Caterpillar, AMD, Uber, Moderna, JetBlue, and more",Seeking Alpha,https://seekingalpha.com/news/3863301-earnings-week-ahead-starbucks-caterpillar-amd-uber-moderna-jetblue-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9190043210983276
1796,8/1/2022 10:16:04 AM,Innate stock slumps 16% as AstraZeneca pulls plug on monalizumab in head/neck cancer after trial failure,Seeking Alpha,https://seekingalpha.com/news/3863571-innate-stock-slumps-16-as-astrazeneca-pulls-plug-on-monalizumab-in-headneck-cancer-after-trial-failure?utm_source=businessinsider&utm_medium=referral,neutral,0.9690659642219543
1797,8/3/2022 2:45:21 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3865794-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8825733065605164
1798,8/3/2022 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q2-earnings-preview-1031645714,positive,0.9245331287384033
1799,8/3/2022 5:43:40 PM,What to expect from Eli Lilly Q2 2022 earnings?,Seeking Alpha,https://seekingalpha.com/news/3866097-what-to-expect-from-eli-lilly-q2-2022-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.9153544306755066
1800,8/4/2022 10:26:56 AM,"Eli Lilly Non-GAAP EPS of $1.71 in-line, revenue of $6.48B misses by $370M, cuts FY22 EPS guidance",Seeking Alpha,https://seekingalpha.com/news/3866905-eli-lilly-non-gaap-eps-of-1_71-in-line-revenue-of-6_48b-misses-370m?utm_source=businessinsider&utm_medium=referral,neutral,0.8595412969589233
1801,8/4/2022 11:10:11 AM,Eli Lilly slips as quarterly revenue declines for the first time in two years,Seeking Alpha,https://seekingalpha.com/news/3866996-lly-stock-slips-as-quarterly-revenue-declines-for-the-first-time-in-two-years?utm_source=businessinsider&utm_medium=referral,neutral,0.973044753074646
1802,8/4/2022 12:25:00 PM,"Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements",PR Newswire,/news/stocks/lilly-reports-second-quarter-financial-results-highlights-momentum-of-new-medicines-and-pipeline-advancements-1031650013,negative,0.8996227383613586
1803,8/4/2022 12:30:33 PM,Eli Lilly And Co. Profit Declines In Q2,RTTNews,/news/stocks/eli-lilly-and-co-profit-declines-in-q2-1031650064,neutral,0.9720865488052368
1804,8/4/2022 12:58:11 PM,Eli Lilly Reduces FY22 Earnings Guidance; Revenue Outlook Remains Unchanged ,RTTNews,/news/stocks/eli-lilly-reduces-fy22-earnings-guidance-revenue-outlook-remains-unchanged-1031650211,neutral,0.8660551309585571
1805,8/4/2022 3:06:29 PM,"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",Benzinga,/news/stocks/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazeneca-s-lynparza-in-early-stage-breast-cancer-decision-day-for-alzheimer-s-associated-hallucinations-candidate-1031651306,positive,0.8657047748565674
1806,8/4/2022 3:52:00 PM,Lilly Updates Conference Call Start Time for Second-Quarter 2022 Financial Results,PR Newswire,/news/stocks/lilly-updates-conference-call-start-time-for-second-quarter-2022-financial-results-1031651514,positive,0.9157080054283142
1807,8/4/2022 5:18:38 PM,Eli Lilly ordered to pay $183M in whistleblower Medicaid fraud case - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3867381-eli-lilly-ordered-to-pay-183m-in-whistleblower-medicaid-fraud-case-bloomberg?utm_source=businessinsider&utm_medium=referral,neutral,0.8791701197624207
1808,8/7/2022 8:39:37 PM,The 7 Best Fidelity Funds for Retirees,InvestorPlace,/news/stocks/best-fidelity-funds-for-retirees-1031657952,positive,0.8513666987419128
1809,8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral,positive,0.5326845645904541
1810,8/8/2022 7:35:46 AM,HUTCHMED Stock Up As Fruquintinib Global Phase III FRESCO-2 Study In CRC Meets Primary Goal ,RTTNews,/news/stocks/hutchmed-stock-up-as-fruquintinib-global-phase-iii-fresco-2-study-in-crc-meets-primary-goal-1031660134,negative,0.9298799633979797
1811,8/8/2022 9:38:29 AM,What companies are most exposed to the Inflation Reduction Act?,Seeking Alpha,https://seekingalpha.com/news/3868607-what-companies-are-most-exposed-to-the-inflation-reduction-act?utm_source=businessinsider&utm_medium=referral,positive,0.8536490797996521
1812,8/8/2022 9:55:13 AM,"Hutchmed fruquintinib improves survival, meets main goal of colorectal cancer study",Seeking Alpha,https://seekingalpha.com/news/3868609-hutchmed-fruquintinib-improves-survival-meets-main-goal-of-colorectal-cancer-study?utm_source=businessinsider&utm_medium=referral,negative,0.8957234025001526
1813,8/8/2022 11:31:00 AM,Lilly arthritis/psoriasis drug Taltz's citrate-free formulation becomes available in US,Seeking Alpha,https://seekingalpha.com/news/3868675-lilly-arthritispsoriasis-drug-taltzs-citrate-free-formulation-becomes-available-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.6780219078063965
1814,8/8/2022 12:45:00 PM,"Lilly's Taltz® (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience",PR Newswire,/news/stocks/lilly-s-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-site-pain-for-improved-patient-experience-1031660650,negative,0.9147680997848511
1815,8/8/2022 1:51:11 PM,Eli Lilly Says New Formulation Of Taltz Injection Available Across US ,RTTNews,/news/stocks/eli-lilly-says-new-formulation-of-taltz-injection-available-across-us-1031660874,negative,0.7870239615440369
1816,8/8/2022 3:44:30 PM,Nektar downgraded at JPMorgan citing setup after end to anti-cancer program,Seeking Alpha,https://seekingalpha.com/news/3868851-nektar-downgraded-at-jpmorgan-citing-setup-after-end-to-anti-cancer-program?utm_source=businessinsider&utm_medium=referral,neutral,0.657801628112793
1817,8/9/2022 1:38:04 AM,The 3 Best Vanguard Funds to Buy in August,InvestorPlace,/news/stocks/best-vanguard-funds-1031663161,positive,0.8945893049240112
1818,8/9/2022 3:26:35 PM,Lilly picks AmerisourceBergen for U.S. commercial rollout of COVID-19 antibody therapy,Seeking Alpha,https://seekingalpha.com/news/3869877-lilly-picks-amerisourcebergen-for-commercial-rollout-of-covid-antibody-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.5025681257247925
1819,8/10/2022 5:48:21 PM,AbCellera stock rises ~17% as continued strength from COVID royalties overshadows Q2 miss,Seeking Alpha,https://seekingalpha.com/news/3870902-abcellera-stock-rises-17-as-continued-strength-from-covid-royalties-overshadows-q2-miss?utm_source=businessinsider&utm_medium=referral,negative,0.9477035999298096
1820,8/11/2022 2:30:00 PM,Lilly Announces Leadership Transition in Human Resources and New Chief Commercial Officer for Loxo@Lilly,PR Newswire,/news/stocks/lilly-announces-leadership-transition-in-human-resources-and-new-chief-commercial-officer-for-loxo-lilly-1031675758,positive,0.8713284134864807
1821,8/11/2022 4:52:13 PM,ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off,Benzinga,/news/stocks/alx-oncology-shares-climb-as-mid-stage-triple-combination-colorectal-cancer-study-kicks-off-1031676485,negative,0.911541759967804
1822,8/11/2022 7:26:06 PM,CDC eases COVID guidance for unvaccinated people,Seeking Alpha,https://seekingalpha.com/news/3871779-cdc-eases-covid-guidance-for-unvaccinated-people?utm_source=businessinsider&utm_medium=referral,neutral,0.8480912446975708
1823,8/12/2022 12:07:01 AM,Recap Of Thursday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-thursday-s-biotech-catalysts---end-of-the-day-summary-1031677667,positive,0.9353505373001099
1824,8/12/2022 8:05:42 PM,Raymond James Bullish On This Penny Stock's Reprioritized Pipeline,Benzinga,/news/stocks/raymond-james-bullish-on-this-penny-stock-s-reprioritized-pipeline-1031680579,positive,0.7169521450996399
1825,8/13/2022 1:13:36 AM,"House clears bill on climate change, drug prices",Seeking Alpha,https://seekingalpha.com/news/3872584-house-clears-bill-on-climate-change-drug-prices?utm_source=businessinsider&utm_medium=referral,positive,0.9000400304794312
1826,8/17/2022 10:54:23 AM,"U.S. govt. to stop buying COVID-19 vaccines, therapies, tests from this fall – Jha",Seeking Alpha,https://seekingalpha.com/news/3874012-us-govt-to-stop-buying-covid-19-vaccines-therapies-tests-from-this-fall-jha?utm_source=businessinsider&utm_medium=referral,positive,0.7759352922439575
1827,8/17/2022 5:10:23 PM,CDC seeks reforms to correct COVID missteps,Seeking Alpha,https://seekingalpha.com/news/3874241-cdc-to-implement-reforms-to-correct-covid-missteps?utm_source=businessinsider&utm_medium=referral,negative,0.785580039024353
1828,8/18/2022 3:13:59 PM,"Alnylam discovery of genetic mutations could lead to therapies for diabetes, obesity",Seeking Alpha,https://seekingalpha.com/news/3874688-alnylam-discovery-of-genetic-mutations-could-lead-to-therapies-for-diabetes-obesity?utm_source=businessinsider&utm_medium=referral,positive,0.751090407371521
1829,8/19/2022 12:31:52 PM,"HHS sets Aug. 30 meeting as costs for COVID products to shift to payors, individuals – WSJ",Seeking Alpha,https://seekingalpha.com/news/3875015-hhs-sets-aug-meeting-as-covid-products-head-for-commercialization-wsj?utm_source=businessinsider&utm_medium=referral,positive,0.9202150106430054
1830,8/19/2022 6:44:30 PM,10 Best Fidelity Funds to Buy Now,InvestorPlace,/news/stocks/best-fidelity-funds-1031695976,positive,0.8979091048240662
1831,8/25/2022 1:03:42 PM,"Aclaris, Lilly ink patent license deal for Olumiant to treat alopecia areata",Seeking Alpha,https://seekingalpha.com/news/3876632-aclaris-lilly-ink-patent-license-deal-for-olumiant-to-treat-alopecia-areata?utm_source=businessinsider&utm_medium=referral,negative,0.818631112575531
1832,8/25/2022 2:40:47 PM,Jim Cramer Says He's Passing On This $10 Social Media Stock As It's 'Losing Money',Benzinga,/news/stocks/jim-cramer-says-he-s-passing-on-this-10-social-media-stock-as-it-s-losing-money-1031705774,neutral,0.5715369582176208
1833,8/25/2022 2:40:57 PM,Citi bullish on Eli Lilly as it significantly boosts price target; sees 16% upside,Seeking Alpha,https://seekingalpha.com/news/3876692-citi-bullish-on-eli-lilly-as-it-significantly-boosts-price-target-sees-16-upside?utm_source=businessinsider&utm_medium=referral,negative,0.9430423974990845
1834,8/25/2022 4:00:00 PM,Lilly to Participate in Citi's 17th Annual BioPharma Conference,PR Newswire,/news/stocks/lilly-to-participate-in-citi-s-17th-annual-biopharma-conference-1031706171,positive,0.8402643203735352
1835,8/25/2022 8:45:32 PM,Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate,Benzinga,/news/stocks/citi-is-bullish-on-this-large-pharma-stock-on-upcoming-data-readout-from-diabetes-candidate-1031706767,negative,0.7031033039093018
1836,8/31/2022 2:27:50 PM,"U.S. outlines plans to move COVID-19 drugs, vaccines to commercial market",Seeking Alpha,https://seekingalpha.com/news/3878943-us-outlines-plans-to-move-covid-19-drugs-vaccines-to-commercial-market?utm_source=businessinsider&utm_medium=referral,negative,0.5740588307380676
1837,8/31/2022 4:00:00 PM,Lilly to Participate in Morgan Stanley 20th Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-20th-annual-global-healthcare-conference-1031716507,positive,0.8076958656311035
1838,9/2/2022 10:00:00 PM,"Micron, Intel among new ideas in BofA's Alpha Surprise screen",Seeking Alpha,https://seekingalpha.com/news/3879926-micron-intel-among-new-ideas-in-bofas-alpha-surprise-screen?utm_source=businessinsider&utm_medium=referral,positive,0.7787503004074097
1839,9/6/2022 2:16:31 PM,"This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%",Benzinga,/news/stocks/this-analyst-predicts-396-for-eli-lilly-plus-raymond-james-slashes-pt-on-this-stock-by-over-73-1031726123,neutral,0.8357675671577454
1840,9/6/2022 5:24:31 PM,Why Eli Lilly Stock Is Rising Today,Benzinga,/news/stocks/why-eli-lilly-stock-is-rising-today-1031726838,negative,0.5506150722503662
1841,9/7/2022 8:06:21 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031730199,positive,0.8414194583892822
1842,9/7/2022 10:05:54 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031730392,positive,0.9140509963035583
1843,9/8/2022 12:05:00 AM,Lilly Announces Details of Presentations at ESMO Congress 2022,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-esmo-congress-2022-1031730623,positive,0.948250412940979
1844,9/8/2022 2:15:00 PM,Lebrikizumab Dosed Every Four Weeks Maintained Durable Skin Clearance in Lilly's Phase 3 Monotherapy Atopic Dermatitis Trials,PR Newswire,/news/stocks/lebrikizumab-dosed-every-four-weeks-maintained-durable-skin-clearance-in-lilly-s-phase-3-monotherapy-atopic-dermatitis-trials-1031731845,negative,0.8044053316116333
1845,9/8/2022 3:40:48 PM,Eli Lilly: Late-breaking Lebrikizumab Data Shows Long-lasting Results In Atopic Dermatitis ,RTTNews,/news/stocks/eli-lilly-late-breaking-lebrikizumab-data-shows-long-lasting-results-in-atopic-dermatitis-1031732361,negative,0.9408199787139893
1846,9/9/2022 12:17:21 AM,"Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary",Benzinga,/news/stocks/important-biotech-catalysts-for-september-8-2022---end-of-the-day-summary-1031733508,positive,0.943282961845398
1847,9/9/2022 1:14:39 PM,Tesla Fame's Robot-Run ETF Sold Its Entire Apple Stake In August — Here's What It Bought,Benzinga,/news/etf/tesla-fame-s-robot-run-etf-sold-its-entire-apple-stake-in-august-—-here-s-what-it-bought-1031734407,positive,0.9398238062858582
1848,9/12/2022 8:49:32 PM,Biotech Stocks Stand to Benefit as Biden Announces Support for Industry,InvestorPlace,/news/stocks/biotech-stocks-stand-to-benefit-as-biden-announces-support-for-industry-1031738367,negative,0.9459112882614136
1849,9/14/2022 2:18:38 PM,"End in sight for COVID-19 pandemic, WHO chief says",Seeking Alpha,https://seekingalpha.com/news/3882728-end-in-sight-for-covid-19-pandemic-who-chief-says?utm_source=businessinsider&utm_medium=referral,positive,0.8521955013275146
1850,9/14/2022 3:02:28 PM,Piper Sandler sees Altimmune liver/obesity drug competitive despite weight loss data,Seeking Alpha,https://seekingalpha.com/news/3882751-piper-sandler-sees-altimmune-liverobesity-drug-as-competitive-despite-weight-loss-data?utm_source=businessinsider&utm_medium=referral,negative,0.8696615099906921
1851,9/17/2022 8:14:23 PM,7 Blue-Chip Stocks to Buy for Safety in This Volatile Market,InvestorPlace,/news/stocks/7-blue-chip-stocks-to-buy-for-safety-in-this-volatile-market-1031749158,positive,0.849772036075592
1852,9/20/2022 8:18:52 PM,3 Stocks That Could Rocket on Biden’s Cancer Moonshot,InvestorPlace,/news/stocks/3-stocks-that-could-rocket-on-bidens-cancer-moonshot-1031754919,positive,0.813847541809082
1853,9/22/2022 1:12:00 AM,"FDA Approves Lilly's Retevmo® (selpercatinib), the First and Only RET Inhibitor for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type",PR Newswire,/news/stocks/fda-approves-lilly-s-retevmo-selpercatinib-the-first-and-only-ret-inhibitor-for-adults-with-advanced-or-metastatic-solid-tumors-with-a-ret-gene-fusion-regardless-of-type-1031757905,negative,0.8696590065956116
1854,9/22/2022 2:47:16 AM,Lilly : FDA Approves Retevmo For Adult Patients With Locally Advanced Or Metastatic Solid Tumors ,RTTNews,/news/stocks/lilly-fda-approves-retevmo-for-adult-patients-with-locally-advanced-or-metastatic-solid-tumors-1031757926,negative,0.7036322355270386
1855,9/22/2022 10:58:30 AM,Eli Lilly wins FDA approval for solid tumor therapy,Seeking Alpha,https://seekingalpha.com/news/3885170-lly-stock-gains-after-fda-approval-for-solid-tumor-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8889502286911011
1856,9/22/2022 1:35:19 PM,Eli Lilly raised to Buy at UBS; named top large cap pick,Seeking Alpha,https://seekingalpha.com/news/3885286-lly-stock-raised-to-buy-at-ubs-named-top-large-cap-pick?utm_source=businessinsider&utm_medium=referral,negative,0.5208812355995178
1857,9/22/2022 3:55:15 PM,"WHO chief reiterates belief that COVID-19 pandemic end near, says work still needed",Seeking Alpha,https://seekingalpha.com/news/3885339-who-chief-reiterates-belief-that-covid-19-pandemic-end-near-says-work-still-needed?utm_source=businessinsider&utm_medium=referral,positive,0.5798600316047668
1858,9/22/2022 4:38:31 PM,Why Eli Lilly Is This Analyst's 'New Top Large Cap Pick',Benzinga,/news/stocks/why-eli-lilly-is-this-analyst-s-new-top-large-cap-pick-1031759769,positive,0.8833720684051514
1859,9/22/2022 7:25:05 PM,Healthcare outperforms S&P 500 as large cap pharma rebounds,Seeking Alpha,https://seekingalpha.com/news/3885399-healthcare-outperforms-sp-500-as-large-cap-pharma-rebounds?utm_source=businessinsider&utm_medium=referral,negative,0.6939451098442078
1860,9/22/2022 8:55:50 PM,7 Stocks to Buy That Can Soar in Good Times or in Bad,InvestorPlace,/news/stocks/7-stocks-to-buy-that-can-soar-in-good-times-or-in-bad-1031760580,positive,0.882334291934967
1861,9/23/2022 6:48:02 PM,BlackRock Says Buy High-Quality Healthcare Stocks to Weather a Recession; Here Are 2 Names That Analysts Like,TipRanks,/news/stocks/blackrock-says-buy-high-quality-healthcare-stocks-to-weather-a-recession-here-are-2-names-that-analysts-like-1031762647,positive,0.9104045629501343
1862,9/26/2022 1:50:20 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbCellera Biologics (ABCL)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-abcellera-biologics-abcl-1031764942,positive,0.6856526732444763
1863,9/26/2022 10:29:08 PM,"EEOC sues Lilly USA, alleging nationwide age discrimination",Seeking Alpha,https://seekingalpha.com/news/3886177-eeoc-sues-lilly-usa-alleging-nationwide-age-discrimination?utm_source=businessinsider&utm_medium=referral,neutral,0.9501233696937561
1864,9/27/2022 9:04:58 PM,Thermo Fisher wins FDA OK of Oncomine Dx Target test to aid in cancer therapy selection,Seeking Alpha,https://seekingalpha.com/news/3886564-thermo-fisher-wins-fda-ok-of-oncomine-dx-target-test-to-aid-in-cancer-therapy-selection?utm_source=businessinsider&utm_medium=referral,negative,0.7208126783370972
1865,9/28/2022 10:43:14 AM,"Biogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trial",Seeking Alpha,https://seekingalpha.com/news/3886651-biogen-eisai-spark-rally-in-alzheimers-stocks-on-late-stage-lecanemab-data?utm_source=businessinsider&utm_medium=referral,negative,0.8227694034576416
1866,9/28/2022 12:09:47 PM,2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data,Benzinga,/news/stocks/2-sympathy-plays-to-watch-for-in-the-wake-of-biogen-s-positive-alzheimer-s-drug-data-1031769371,negative,0.5770570039749146
1867,9/28/2022 12:13:38 PM,"Biogen, Eli Lilly And Some Other Big Stocks Moving Higher In Today's Pre-Market Session",Benzinga,/news/stocks/biogen-eli-lilly-and-some-other-big-stocks-moving-higher-in-today-s-pre-market-session-1031769388,negative,0.9157373905181885
1868,9/28/2022 12:53:05 PM,"Pre-market Movers: SILO, PRTA, BIIB, NXPL, ABOS… ",RTTNews,/news/stocks/pre-market-movers-silo-prta-biib-nxpl-abos-1031769509,positive,0.9539187550544739
1869,9/28/2022 1:17:23 PM,Why MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket,Benzinga,/news/stocks/why-mindmed-is-trading-lower-by-around-35-here-are-31-stocks-moving-premarket-1031769653,neutral,0.7719113826751709
1870,9/28/2022 2:22:32 PM,Prothena climbs 80% as Bofa upgrades after rivals’ Alzheimer’s data,Seeking Alpha,https://seekingalpha.com/news/3886766-prothena-climbs-80-as-bofa-upgrades-after-rivals-alzheimers-data?utm_source=businessinsider&utm_medium=referral,negative,0.8883492350578308
1871,9/28/2022 3:02:10 PM,Why Is Cassava Sciences (SAVA) Stock Heating Up Today?,InvestorPlace,/news/stocks/why-is-cassava-sciences-sava-stock-heating-up-today-1031770608,positive,0.8180983662605286
1872,9/28/2022 3:54:55 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogens-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9412573575973511
1873,9/28/2022 4:04:37 PM,"Eisai, Biogen's lecanemab cognitive improvement bodes well for Alzheimer's approval",Seeking Alpha,https://seekingalpha.com/news/3886771-eisai-biogen-lecanemab-cognitive-improvement-bodes-well-for-alzheimers-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9412573575973511
1874,9/28/2022 5:39:12 PM,"Biotech Stocks LLY, ESALY Gain on Biogen’s Positive Trial Results",InvestorPlace,/news/stocks/biotech-stocks-lly-esaly-biib-gain-on-biogen-positive-trial-results-1031771015,negative,0.9171364903450012
1875,9/28/2022 6:30:05 PM,This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval,Benzinga,/news/stocks/this-analyst-believes-biogen-s-lecanemab-data-not-slam-dunk-for-complete-cms-approval-1031770867,positive,0.7880455851554871
1876,9/28/2022 6:40:47 PM,"Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session",Benzinga,/news/stocks/why-prothena-corporation-shares-are-trading-higher-by-76-here-are-53-stocks-moving-in-wednesday-s-mid-day-session-1031770887,positive,0.8901486992835999
1877,9/28/2022 10:01:13 PM,"Many Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai data",Seeking Alpha,https://seekingalpha.com/news/3886925-many-alzheimers-drug-developers-close-significantly-higher-thanks-to-biogen-eisai-data?utm_source=businessinsider&utm_medium=referral,negative,0.9467376470565796
1878,9/28/2022 10:17:23 PM,These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win,Benzinga,/news/stocks/these-stocks-are-on-the-radar-after-biogen-eisai-s-surprising-alzheimer-s-trial-win-1031771238,positive,0.5415467619895935
1879,9/29/2022 12:43:06 AM,7 Growth Stocks to Buy to Tap Into a Hidden Bull Market,InvestorPlace,/news/stocks/7-growth-stocks-to-buy-to-tap-into-a-hidden-bull-market-1031771484,positive,0.8190701007843018
1880,9/29/2022 9:45:49 AM,"Netflix, Biogen And Other Big Gainers From Wednesday",Benzinga,/news/stocks/netflix-biogen-and-other-big-gainers-from-wednesday-1031771992,negative,0.8002164363861084
1881,9/29/2022 11:09:35 AM,Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-nls-pharmaceutics-shares-tumbled-over-66-here-are-68-biggest-movers-from-yesterday-1031772129,positive,0.6120434999465942
1882,9/29/2022 6:07:42 PM,"Biogen, Eisai cool off after massive run-up following lecanemab Alzheimer's data",Seeking Alpha,https://seekingalpha.com/news/3887223-biogen-eisai-cool-off-after-massive-run-up-following-lecanemab-alzheimers-data?utm_source=businessinsider&utm_medium=referral,neutral,0.8865597248077393
1883,10/2/2022 4:00:31 PM,COVID stocks lag U.S. biopharma in Q3; Alzheimer’s theme regains focus,Seeking Alpha,https://seekingalpha.com/news/3887740-covid-stocks-lag-us-biopharma-in-q3-alzheimers-theme-regains-focus?utm_source=businessinsider&utm_medium=referral,neutral,0.8604695200920105
1884,10/3/2022 2:10:59 PM,Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-and-alnylam-pharma-alny-1031779181,neutral,0.48980721831321716
1885,10/3/2022 7:23:24 PM,AstraZeneca COVID-19 antibodies unlikely to protect against new Omicron subvariant,Seeking Alpha,https://seekingalpha.com/news/3888160-astrazeneca-covid-19-antibody-unlikely-to-act-against-new-omicron-subvariant?utm_source=businessinsider&utm_medium=referral,negative,0.8156739473342896
1886,10/4/2022 4:30:31 AM,"LLY, ISRG, or BMY: Which Healthcare Stock Could Yield Better Returns?",TipRanks,/news/stocks/lly-isrg-or-bmy-which-healthcare-stock-could-yield-better-returns-1031780497,positive,0.8583230972290039
1887,10/5/2022 12:15:30 PM,"Use short-term rallies to boost high-momentum stock exposure, Wells Fargo says",Seeking Alpha,https://seekingalpha.com/news/3888434-use-short-term-rallies-to-bost-high-momentum-stock-exposure?utm_source=businessinsider&utm_medium=referral,negative,0.7352736592292786
1888,10/6/2022 9:51:10 AM,Adocia M1Pram shows weight loss benefit vs Lilly's Humalog in obese diabetic patients in trial,Seeking Alpha,https://seekingalpha.com/news/3889114-adocia-m1pram-shows-weight-loss-benefit-vs-lillys-humalog-in-obese-diabetic-patients-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9436827301979065
1889,10/6/2022 11:10:06 AM,Lilly's tirzepatide gets FDA fast track status to treat obesity,Seeking Alpha,https://seekingalpha.com/news/3889141-lillys-tirzepatide-gets-fda-fast-track-status-to-treat-obesity?utm_source=businessinsider&utm_medium=referral,negative,0.8591820597648621
1890,10/6/2022 12:35:11 PM,FDA agrees to single phase 3 trial by Entera for bone disorder drug EB613 to support approval,Seeking Alpha,https://seekingalpha.com/news/3889191-fda-agrees-to-single-phase-3-trial-by-entera-for-bone-disorder-drug-eb613-to-support-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8790311217308044
1891,10/6/2022 12:45:00 PM,"Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities",PR Newswire,/news/stocks/lilly-receives-u-s-fda-fast-track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity-or-overweight-with-weight-related-comorbidities-1031786861,negative,0.9359771609306335
1892,10/6/2022 1:21:43 PM,Eli Lilly Gets Fast Track Status For Its Tirzepatide To Treat Obesity ,RTTNews,/news/stocks/eli-lilly-gets-fast-track-status-for-its-tirzepatide-to-treat-obesity-1031786970,negative,0.9082910418510437
1893,10/6/2022 2:58:18 PM,Bipartisan bill aims to get CMS to cover Alzheimer's antibody treatments,Seeking Alpha,https://seekingalpha.com/news/3889267-bipartisan-bill-aims-to-gets-cms-to-cover-alzheimers-antibody-treatments?utm_source=businessinsider&utm_medium=referral,negative,0.7279573082923889
1894,10/10/2022 3:11:37 AM,Innovent Biologics: China Oks Selpercatinib NDA For Treatment Of RET-driven Lung And Thyroid Cancers ,RTTNews,/news/stocks/innovent-biologics-china-oks-selpercatinib-nda-for-treatment-of-ret-driven-lung-and-thyroid-cancers-1031791613,positive,0.7694805264472961
1895,10/10/2022 3:18:05 AM,Innovent Biologics : China Approves SNDA For CYRAMZA For Hepatocellular Carcinoma Treatment ,RTTNews,/news/stocks/innovent-biologics-china-approves-snda-for-cyramza-for-hepatocellular-carcinoma-treatment-1031791615,negative,0.81062251329422
1896,10/10/2022 8:34:09 AM,"Lilly, Innovent's Cyramza gets approval in China to treat liver cancer",Seeking Alpha,https://seekingalpha.com/news/3889903-lilly-innovents-cyramza-gets-approval-in-china-to-treat-liver-cancer?utm_source=businessinsider&utm_medium=referral,negative,0.8923497796058655
1897,10/10/2022 10:15:48 AM,These 7 Biotech Stocks Are Set to Boom in 2023,InvestorPlace,/news/stocks/7-biotech-stocks-set-to-boom-2023-1031792647,negative,0.8603333234786987
1898,10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral,positive,0.5134317874908447
1899,10/11/2022 9:01:54 AM,"Analysts Are Bullish on Top Healthcare Stocks: Avenue Therapeutics (ATXI), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-avenue-therapeutics-atxi-eli-lilly-co-lly-1031795182,positive,0.6784286499023438
1900,10/11/2022 4:08:51 PM,"Amgen up 6%, leading S&P 500, following bullish call from Morgan Stanley",Seeking Alpha,https://seekingalpha.com/news/3890404-amgen-up-6-leading-sp-500-following-bullish-call-from-morgan-stanley?utm_source=businessinsider&utm_medium=referral,negative,0.9221031069755554
1901,10/11/2022 7:18:00 PM,Lilly in license agreement with Nimbus Therapeutics for metabollc disease treatments,Seeking Alpha,https://seekingalpha.com/news/3890460-lilly-in-license-agreement-with-nimbus-therapeutics-for-metabollc-disease-treatments?utm_source=businessinsider&utm_medium=referral,negative,0.6964021325111389
1902,10/12/2022 8:23:13 PM,What 4 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-4-analyst-ratings-have-to-say-about-eli-lilly-1031800702,positive,0.9393445253372192
1903,10/12/2022 8:47:17 PM,Lilly Q3 results will be impacted by 6-cent charge to GAAP and adjusted EPS,Seeking Alpha,https://seekingalpha.com/news/3890851-eli-lilly-q3-results-will-be-impacted-by-6-cent-charge-to-gaap-and-adjusted-eps?utm_source=businessinsider&utm_medium=referral,neutral,0.8975078463554382
1904,10/13/2022 3:27:17 PM,Biogen upgraded to buy at Stifel on lecanemab Alzheimer's treatment,Seeking Alpha,https://seekingalpha.com/news/3891135-biogen-upgraded-to-buy-at-stifel-on-lecanemab-alzheimers-treatment?utm_source=businessinsider&utm_medium=referral,negative,0.7770352363586426
1905,10/13/2022 7:45:04 PM,"Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts",Benzinga,/news/stocks/analyst-upgrades-biogen-citing-upcoming-conference-competitive-readouts-1031804196,positive,0.8114140629768372
1906,10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral,negative,0.8669121861457825
1907,10/14/2022 1:28:20 PM,Lilly's Lyumjev gets EMA panel backing for use in children with diabetes,Seeking Alpha,https://seekingalpha.com/news/3891425-lillys-lyumjev-gets-ema-panel-backing-for-use-in-children-with-diabetes?utm_source=businessinsider&utm_medium=referral,negative,0.865410566329956
1908,10/14/2022 4:45:44 PM,CDC data shows that cases of new COVID 'escape variants' on the rise,Seeking Alpha,https://seekingalpha.com/news/3891468-cdc-data-shows-that-cases-of-new-covid-escape-variants-on-the-rise?utm_source=businessinsider&utm_medium=referral,neutral,0.621448814868927
1909,10/15/2022 12:15:27 PM,Eli Lilly & Co (LLY) Gets a Buy from J.P. Morgan,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-j-p-morgan-1031807379,negative,0.7561423182487488
1910,10/17/2022 4:09:15 PM,Eli Lilly declares $0.98 dividend,Seeking Alpha,https://seekingalpha.com/news/3891896-eli-lilly-and-company-declares-0_98-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9216097593307495
1911,10/17/2022 6:04:00 PM,Lilly Declares Fourth-Quarter 2022 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2022-dividend-1031810669,positive,0.9062821865081787
1912,10/18/2022 11:25:10 AM,Akouos soars 87% as Lilly nabs hearing loss gene therapy developer,Seeking Alpha,https://seekingalpha.com/news/3892121-akouos-soars-87-as-lilly-nabs-hearing-loss-gene-therapy-developer?utm_source=businessinsider&utm_medium=referral,negative,0.9051903486251831
1913,10/18/2022 12:50:00 PM,Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss,PR Newswire,/news/stocks/lilly-to-acquire-akouos-to-discover-and-develop-treatments-for-hearing-loss-1031812818,positive,0.5687199831008911
1914,10/18/2022 1:20:23 PM,Eli Lilly To Buy Akouos For Up To $610 Mln ,RTTNews,/news/stocks/eli-lilly-to-buy-akouos-for-up-to-610-mln-1031812953,positive,0.8431450724601746
1915,10/18/2022 2:46:47 PM,Why Is Akouos (AKUS) Stock Up 85% Today?,InvestorPlace,/news/stocks/why-is-akouos-akus-stock-up-85-today-1031814104,negative,0.7335121035575867
1916,10/18/2022 3:30:49 PM,Decibel Therapeutics hears it may be a takeout target after Lilly acquisition of Akouos,Seeking Alpha,https://seekingalpha.com/news/3892281-decibel-therapeutics-hears-it-may-be-a-takeou-ttarget-after-eli-lilly-acquisition-of-akouos?utm_source=businessinsider&utm_medium=referral,positive,0.4988768398761749
1917,10/18/2022 4:14:25 PM,US Stocks Extend Monday's Gains; Dow Jumps Over 500 Points,Benzinga,/news/stocks/us-stocks-extend-monday-s-gains-dow-jumps-over-500-points-1031813982,negative,0.7643325924873352
1918,10/18/2022 6:43:40 PM,Why Akouos Shares Are Trading Sharply Higher? Here Are 36 Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-akouos-shares-are-trading-sharply-higher-here-are-36-stocks-moving-in-tuesday-s-mid-day-session-1031814418,positive,0.8889509439468384
1919,10/18/2022 6:54:57 PM,Nasdaq Rises Over 100 Points; Goldman Sachs Tops Q3 Views,Benzinga,/news/stocks/nasdaq-rises-over-100-points-goldman-sachs-tops-q3-views-1031814476,negative,0.8238531351089478
1920,10/18/2022 8:43:41 PM,Crude Oil Drops Over 2%; Akouos Shares Spike Higher,Benzinga,/news/stocks/crude-oil-drops-over-2-akouos-shares-spike-higher-1031814653,negative,0.8842865228652954
1921,10/19/2022 10:18:19 AM,"Carnival, Amazon, Iamgold And Other Big Gainers From Tuesday",Benzinga,/news/stocks/carnival-amazon-iamgold-and-other-big-gainers-from-tuesday-1031816461,negative,0.7686089873313904
1922,10/19/2022 11:10:26 AM,Why Quoin Pharmaceuticals Shares Jumped By More Than 44%; Here Are 57 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-quoin-pharmaceuticals-shares-jumped-by-more-than-44-here-are-57-biggest-movers-from-yesterday-1031816546,positive,0.9068009853363037
1923,10/19/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2022-financial-results-announcement-1031817838,positive,0.9390432834625244
1924,10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral,positive,0.7574050426483154
1925,10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral,positive,0.6700782775878906
1926,10/26/2022 12:10:43 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Masimo (MASI) and Teleflex (TFX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-masimo-masi-and-teleflex-tfx-1031837891,positive,0.9180166721343994
1927,10/26/2022 2:39:42 PM,Biogen raised to Buy at Goldman Sachs as Alzheimer’s prospects return,Seeking Alpha,https://seekingalpha.com/news/3895547-biib-stock-gains-as-goldman-sachs-upgrades-on-alzheimers-prospects?utm_source=businessinsider&utm_medium=referral,negative,0.42891964316368103
1928,10/27/2022 4:00:00 PM,Lilly commits $92.5 million to Purdue to establish an innovative pharmaceutical manufacturing scholarship program and to extend research collaboration,PR Newswire,/news/stocks/lilly-commits-92-5-million-to-purdue-to-establish-an-innovative-pharmaceutical-manufacturing-scholarship-program-and-to-extend-research-collaboration-1031844055,negative,0.8226892948150635
1929,10/28/2022 5:30:56 PM,"Earnings week ahead: Uber, Pfizer, Peloton, Paramount Global, BP and more",Seeking Alpha,https://seekingalpha.com/news/3897313-earnings-week-ahead-uber-pfizer-peloton-paramount-global-bp-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.923667848110199
1930,10/28/2022 6:30:28 PM,"Catalyst watch: FOMC jitters, Starbucks and Pfizer earnings, Boeing and AMD events",Seeking Alpha,https://seekingalpha.com/news/3897337-catalyst-watch-fomc-jitters-starbucks-and-pfizer-earnings-boeing-and-amd-events?utm_source=businessinsider&utm_medium=referral,positive,0.9197320342063904
1931,10/31/2022 1:21:04 PM,Amgen downgraded at Barclays citing rally fueled by weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/3897732-amgn-stock-downgraded-at-barclays-citing-rally-fueled-by-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.9647801518440247
1932,10/31/2022 2:12:40 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), AbbVie (ABBV)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-abbvie-abbv-1031854099,positive,0.5588529706001282
1933,10/31/2022 2:38:59 PM,What to expect from Eli Lilly Q3 2022 Earnings,Seeking Alpha,https://seekingalpha.com/news/3897794-what-to-expect-from-eli-lilly-q3-2022-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.9405311942100525
1934,10/31/2022 3:01:13 PM,Eli Lilly and is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-quarter-earnings-preview-q3-1031853955,positive,0.9341102242469788
1935,10/31/2022 3:21:29 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3897806-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
1936,11/1/2022 10:27:00 AM,"Eli Lilly Non-GAAP EPS of $2.04 beats by $0.11, revenue of $6.94B beats by $30M, cuts FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3898329-eli-lilly-non-gaap-eps-of-204-beats-by-011-revenue-of-694b-beats-by-30m-cuts-fy22-outlook?utm_source=businessinsider&utm_medium=referral,neutral,0.8133589625358582
1937,11/1/2022 11:19:39 AM,"Lilly falls as FY22 outlook cut on forex impact, Trulicity drives Q3 sales",Seeking Alpha,https://seekingalpha.com/news/3898399-lilly-falls-as-fy22-outlook-cut-on-forex-impact-trulicity-drives-q3-sales?utm_source=businessinsider&utm_medium=referral,neutral,0.9592770338058472
1938,11/1/2022 11:25:00 AM,Lilly Reports Solid Third-Quarter 2022 Financial Results and Continued Pipeline Progress,PR Newswire,/news/stocks/lilly-reports-solid-third-quarter-2022-financial-results-and-continued-pipeline-progress-1031857552,negative,0.9545201063156128
1939,11/1/2022 11:34:21 AM,Eli Lilly And Co. Q3 Income Rises,RTTNews,/news/stocks/eli-lilly-and-co-q3-income-rises-1031857587,negative,0.74349445104599
1940,11/1/2022 12:00:42 PM,Lilly Cuts FY22 Earnings Outlook Again - Update ,RTTNews,/news/stocks/lilly-cuts-fy22-earnings-outlook-again-update-1031857729,neutral,0.9240671992301941
1941,11/1/2022 4:30:59 PM,AnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonists,Seeking Alpha,https://seekingalpha.com/news/3898656-anab-stock-raised-to-buy-at-guggenheim-on-checkpoint-agonists?utm_source=businessinsider&utm_medium=referral,negative,0.9374743700027466
1942,11/1/2022 7:57:55 PM,Nasdaq Down 60 Points; Eli Lilly Lowers Earnings Forecast,Benzinga,/news/stocks/nasdaq-down-60-points-eli-lilly-lowers-earnings-forecast-1031859928,neutral,0.9704110026359558
1943,11/2/2022 4:45:52 AM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031860929,positive,0.6265906095504761
1944,11/2/2022 12:43:36 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Idexx Laboratories (IDXX) and Waters (WAT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-idexx-laboratories-idxx-and-waters-wat-1031863998,positive,0.9213647842407227
1945,11/2/2022 1:53:58 PM,Jim Cramer Says These 2 ‘Strong Buy’ Stocks Could Be Among the New Market Leaders,TipRanks,/news/stocks/jim-cramer-says-these-2-strong-buy-stocks-could-be-among-the-new-market-leaders-1031864877,negative,0.5240828394889832
1946,11/2/2022 7:07:52 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031865815,positive,0.8414194583892822
1947,11/3/2022 2:00:00 PM,Loxo@Lilly Announces Details of Presentations at the 2022 American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-announces-details-of-presentations-at-the-2022-american-society-of-hematology-annual-meeting-1031870510,positive,0.948702335357666
1948,11/4/2022 3:30:00 PM,Landmark EMPA-KIDNEY trial showed significant benefit of Jardiance® in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people with chronic kidney disease,PR Newswire,/news/stocks/landmark-empa-kidney-trial-showed-significant-benefit-of-jardiance-in-reducing-kidney-disease-progression-or-cardiovascular-death-by-28-vs-placebo-in-people-with-chronic-kidney-disease-1031876269,negative,0.9362043142318726
1949,11/4/2022 3:31:28 PM,Eli Lilly COVID-19 therapy unlikely to neutralize new Omicron subvariants - FDA,Seeking Alpha,https://seekingalpha.com/news/3902025-eli-lilly-covid-19-therapy-unlikely-to-neutralize-new-omicron-subvariants?utm_source=businessinsider&utm_medium=referral,negative,0.7704504728317261
1950,11/4/2022 4:12:00 PM,Lilly : Phase III Trial Shows Benefit Of Jardiance In Reducing Kidney Disease Progression In CKD ,RTTNews,/news/stocks/lilly-phase-iii-trial-shows-benefit-of-jardiance-in-reducing-kidney-disease-progression-in-ckd-1031876429,negative,0.9195740222930908
1951,11/4/2022 5:26:53 PM,Eli Lilly heart disease therapy meets main goal in Phase 3 kidney disease trial,Seeking Alpha,https://seekingalpha.com/news/3902191-eli-lilly-heart-disease-therapy-meets-main-goal-in-phase-3-kidney-disease-trial?utm_source=businessinsider&utm_medium=referral,negative,0.5278940796852112
1952,11/6/2022 5:00:24 PM,"Off-patent drugs make up 91% of prescriptions, but only 18% of spending - report",Seeking Alpha,https://seekingalpha.com/news/3902378-off-patent-drugs-make-up-91-of-prescriptions-18-of-spending?utm_source=businessinsider&utm_medium=referral,positive,0.8645551800727844
1953,11/7/2022 2:50:55 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), ImmunoGen (IMGN) and Bausch Health Companies (BHC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-immunogen-imgn-and-bausch-health-companies-bhc-1031881979,neutral,0.6375505924224854
1954,11/7/2022 5:30:00 PM,Lilly to begin rollout of Tempo® Personalized Diabetes Management Platform,PR Newswire,/news/stocks/lilly-to-begin-rollout-of-tempo-personalized-diabetes-management-platform-1031882320,positive,0.6319058537483215
1955,11/8/2022 7:04:04 PM,The 7 Best Pharma Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-best-pharma-stocks-to-buy-now-1031893081,positive,0.8310678601264954
1956,11/8/2022 7:47:03 PM,"Eli Lilly, Merck reach new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3903867-eli-lilly-merck-reach-new-52-week-highs?utm_source=businessinsider&utm_medium=referral,negative,0.6138051152229309
1957,11/10/2022 10:23:43 AM,Boston jury orders Lilly to pay $176.5M to Teva in migraine drug patent suit,Seeking Alpha,https://seekingalpha.com/news/3905343-boston-jury-orders-lilly-to-pay-1765m-to-teva-in-migraine-drug-patent-suit?utm_source=businessinsider&utm_medium=referral,neutral,0.94134122133255
1958,11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral,neutral,0.8541243672370911
1959,11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660,neutral,0.944724440574646
1960,11/12/2022 9:00:00 PM,"Novo Nordisk expected to maintain lead in diabetes market over Eli Lilly, report finds",Seeking Alpha,https://seekingalpha.com/news/3906692-novo-nordisk-expected-to-maintain-lead-in-diabetes-market-over-eli-lilly-report-finds?utm_source=businessinsider&utm_medium=referral,negative,0.8325029611587524
1961,11/13/2022 1:17:33 AM,Fake tweets from ‘verified’ Twitter accounts spur real losses for Lilly and Lockheed stock,Seeking Alpha,https://seekingalpha.com/news/3906751-fake-tweets-from-verified-twitter-accounts-spur-real-losses-for-lilly-and-lockheed-stock?utm_source=businessinsider&utm_medium=referral,neutral,0.9652352929115295
1962,11/13/2022 1:59:54 AM,U.S. COVID health emergency to stay in place,Seeking Alpha,https://seekingalpha.com/news/3906753-us-covid-health-emergency-to-stay-in-place?utm_source=businessinsider&utm_medium=referral,neutral,0.6932175159454346
1963,11/14/2022 2:11:59 AM,HUTCHMED Reports Mixed Results In Fruquintinib PhaseIII Study In Second-Line Gastric Cancer In China ,RTTNews,/news/stocks/hutchmed-reports-mixed-results-in-fruquintinib-phaseiii-study-in-second-line-gastric-cancer-in-china-1031907090,neutral,0.9642734527587891
1964,11/14/2022 11:47:20 AM,Hutchmed stock rises 15% as fruquintinib meets one main goal in gastric cancer trial,Seeking Alpha,https://seekingalpha.com/news/3906919-hutchmed-stock-rises-15-as-fruquintinib-meets-one-main-goal-in-gastric-cancer-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9296244978904724
1965,11/14/2022 1:17:31 PM,"Nasdaq, S&P 500 Futures Pullback At Start Of New Trading Week As Rate Fears Return To Haunt; AMD, Tesla, Biogen, Eli Lilly, JD In Focus",Benzinga,/news/stocks/nasdaq-s-p-500-futures-pullback-at-start-of-new-trading-week-as-rate-fears-return-to-haunt-amd-tesla-biogen-eli-lilly-jd-in-focus-1031909736,neutral,0.7648295164108276
1966,11/14/2022 1:40:23 PM,Hutchmed-Lilly Partnered Gastric Cancer Drug Shows Mixed Results In Phase 3 Study,Benzinga,/news/stocks/hutchmed-lilly-partnered-gastric-cancer-drug-shows-mixed-results-in-phase-3-study-1031909859,neutral,0.9548247456550598
1967,11/14/2022 2:51:28 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1031910665,positive,0.9151490926742554
1968,11/14/2022 4:59:20 PM,"Cassava, Biogen lead Alzheimer's stocks higher following Roche's gantenerumab setback",Seeking Alpha,https://seekingalpha.com/news/3907250-cassava-biogen-lead-alzheimers-stocks-higher-following-roches-gantenerumab-setback?utm_source=businessinsider&utm_medium=referral,negative,0.9394575357437134
1969,11/14/2022 9:02:09 PM,"Druckenmiller's Duquesne adds Amazon, exits Westlake, lowers Microsoft stake",Seeking Alpha,https://seekingalpha.com/news/3907390-druckenmillers-duquesne-adds-amazon-exits-westlake-lowers-microsoft-stake?utm_source=businessinsider&utm_medium=referral,positive,0.644759476184845
1970,11/14/2022 9:08:32 PM,Fake free insulin Tweet leads Eli Lilly to pull advertising from Twitter - WaPo,Seeking Alpha,https://seekingalpha.com/news/3907399-fake-free-insulin-tweet-leads-eli-lilly-to-pull-advertising-from-twitter-wapo?utm_source=businessinsider&utm_medium=referral,neutral,0.9345202445983887
1971,11/15/2022 11:04:32 PM,Successful Alzheimer's Data Would Have Placed Roche At Two-Year Competitive Advantage,Benzinga,/news/stocks/successful-alzheimer-s-data-would-have-placed-roche-at-two-year-competitive-advantage-1031916589,negative,0.8776633739471436
1972,11/16/2022 7:51:07 AM,"Analysts’ Top Healthcare Picks: Lineage Cell Therapeutics (LCTX), Compugen (CGEN)",TipRanks,/news/stocks/analysts-top-healthcare-picks-lineage-cell-therapeutics-lctx-compugen-cgen-1031917474,negative,0.6683369874954224
1973,11/16/2022 4:00:00 PM,Lilly to Participate in Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-healthconx-conference-1031919113,positive,0.8830476999282837
1974,11/16/2022 5:17:42 PM,"Pfizer, Roche, Lilly COVID treatments get draft recommendation from UK NHS advisors",Seeking Alpha,https://seekingalpha.com/news/3908715-pfizer-roche-lilly-covid-treatments-get-draft-recommendation-from-uk-nhs-advisors?utm_source=businessinsider&utm_medium=referral,positive,0.8119016885757446
1975,11/17/2022 4:40:49 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Gossamer Bio (GOSS) and Alcon (ALC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-gossamer-bio-goss-and-alcon-alc-1031924296,positive,0.9214606285095215
1976,11/18/2022 2:03:01 PM,Where Eli Lilly Stands With Analysts,Benzinga,/news/stocks/where-eli-lilly-stands-with-analysts-1031925085,positive,0.9322600364685059
1977,11/18/2022 3:03:49 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031925440,positive,0.8414194583892822
1978,11/18/2022 4:03:30 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1031925614,positive,0.9140509963035583
1979,11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925,neutral,0.5206902027130127
1980,11/18/2022 8:22:36 PM,"Eli Lilly Is Best-In-Class Growth, Says Analyst While Initiating Coverage",Benzinga,/news/stocks/eli-lilly-is-best-in-class-growth-says-analyst-while-initiating-coverage-1031926179,negative,0.8654052019119263
1981,11/21/2022 3:00:00 PM,Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2022-san-antonio-breast-cancer-symposium-1031928665,positive,0.9412591457366943
1982,11/23/2022 3:35:18 AM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031932748,positive,0.6265906095504761
1983,11/25/2022 11:00:46 AM,3 Reasons to Turn Any LLY Stock Skeptic Into a Believer,InvestorPlace,/news/stocks/3-reasons-to-turn-any-lly-stock-skeptic-into-a-believer-1031937458,positive,0.8878430128097534
1984,11/28/2022 3:00:48 PM,"Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), Spectrum Pharmaceuticals (SPPI) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arcus-biosciences-rcus-spectrum-pharmaceuticals-sppi-and-eli-lilly-co-lly-1031940203,positive,0.9145106077194214
1985,11/28/2022 5:23:11 PM,7 Beaten-Down Stocks That Can Make You a Millionaire by 2030,InvestorPlace,/news/stocks/7-beaten-down-stocks-that-can-make-you-a-millionaire-by-2030-1031942973,positive,0.8710116744041443
1986,11/28/2022 10:28:43 PM,Wall Street Loves These 4 “Strong Buy” Stocks Right Now,TipRanks,/news/stocks/wall-street-loves-these-4-strong-buy-stocks-right-now-1031940806,positive,0.7561403512954712
1987,11/29/2022 4:00:00 PM,Lilly Confirms Date and Conference Call for 2023 Financial Guidance Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-2023-financial-guidance-announcement-1031942466,positive,0.94536292552948
1988,11/30/2022 12:50:00 PM,Lilly and Akouos Announce Expiration of Akouos Tender Offer,PR Newswire,/news/stocks/lilly-and-akouos-announce-expiration-of-akouos-tender-offer-1031944475,positive,0.8456414937973022
1989,12/1/2022 12:00:00 AM,Lilly Shares Positive Donanemab Data in First Active Comparator Study in Early Symptomatic Alzheimer's Disease,PR Newswire,/news/stocks/lilly-shares-positive-donanemab-data-in-first-active-comparator-study-in-early-symptomatic-alzheimer-s-disease-1031946402,negative,0.924656867980957
1990,12/1/2022 2:20:39 AM,FDA Pulls Emergency Use Authorization For Lilly's COVID-19 Antibody Drug ,RTTNews,/news/stocks/fda-pulls-emergency-use-authorization-for-lilly-s-covid-19-antibody-drug-1031946501,neutral,0.876496434211731
1991,12/1/2022 2:32:41 AM,Lilly Reports Positive Donanemab Data In Comparator Study In Early Symptomatic Alzheimer's Disease ,RTTNews,/news/stocks/lilly-reports-positive-donanemab-data-in-comparator-study-in-early-symptomatic-alzheimer-s-disease-1031946506,negative,0.9459328055381775
1992,12/1/2022 2:41:00 PM,Lilly Completes Acquisition of Akouos Expanding Efforts to Help People with Genetic Diseases,PR Newswire,/news/stocks/lilly-completes-acquisition-of-akouos-expanding-efforts-to-help-people-with-genetic-diseases-1031947790,negative,0.8994879126548767
1993,12/2/2022 3:10:33 AM,"Analysts Are Bullish on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-1031949326,positive,0.7992329001426697
1994,12/2/2022 2:20:00 PM,3 Analyst-Loved Healthcare Stocks for a Recession,TipRanks,/news/stocks/3-analyst-loved-healthcare-stocks-for-a-recession-1031950786,neutral,0.6958721280097961
1995,12/2/2022 2:50:09 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Rigel (RIGL)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-rigel-rigl-1031950666,positive,0.5731444954872131
1996,12/5/2022 11:15:30 AM,"Even After This Year’s Melt-Up, Runway Remains for LLY Stock",InvestorPlace,/news/stocks/even-after-this-years-melt-up-runway-remains-for-lly-stock-1031952582,negative,0.7969921231269836
1997,12/5/2022 6:06:27 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1031953622,positive,0.8414194583892822
1998,12/5/2022 8:04:55 PM,What 12 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-12-analyst-ratings-have-to-say-about-eli-lilly-1031953824,positive,0.9426296949386597
1999,12/5/2022 10:02:23 PM,12 Analysts Have This to Say About Eli Lilly,Benzinga,/news/stocks/12-analysts-have-this-to-say-about-eli-lilly-1031953925,positive,0.9377140402793884
2000,12/6/2022 2:44:39 PM,Eli Lilly sees “unprecedented” demand for its diabetes drugs,Seeking Alpha,https://seekingalpha.com/news/3914335-lly-stock-company-sees-unprecedented-demand-for-diabetes-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.8751673102378845
2001,12/6/2022 4:30:59 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AbbVie (ABBV) and Mirati Therapeutics (MRTX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-abbvie-abbv-and-mirati-therapeutics-mrtx-1031956241,positive,0.9200422167778015
2002,12/6/2022 9:00:00 PM,Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology,PR Newswire,/news/stocks/lilly-announces-updated-data-from-the-verzenio-abemaciclib-phase-3-monarche-trial-presented-at-sabcs-and-simultaneously-published-in-the-lancet-oncology-1031956359,positive,0.9230512976646423
2003,12/7/2022 1:48:23 PM,"Lilly, Boehringer diabetes drug meets main goal in patients aged 10-17",Seeking Alpha,https://seekingalpha.com/news/3914862-lly-stock-on-watch-as-diabetes-drug-meets-main-goal-in-young-patients?utm_source=businessinsider&utm_medium=referral,negative,0.8385599851608276
2004,12/7/2022 2:00:00 PM,Phase III trial demonstrated Jardiance® is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes,PR Newswire,/news/stocks/phase-iii-trial-demonstrated-jardiance-is-the-first-sglt2-inhibitor-to-show-statistically-significant-reduction-in-blood-sugar-levels-in-children-and-adolescents-with-type-2-diabetes-1031957696,negative,0.8686772584915161
2005,12/7/2022 2:31:23 PM,Eli Lilly: Jardiance Improves Overall Blood Sugar Control In Children With Type 2 Diabetes ,RTTNews,/news/stocks/eli-lilly-jardiance-improves-overall-blood-sugar-control-in-children-with-type-2-diabetes-1031957845,negative,0.9520676136016846
2006,12/7/2022 9:38:11 PM,"These 2 Stocks Can Easily Survive a Recession, Analysts Believe",TipRanks,/news/stocks/these-2-stocks-can-easily-survive-a-recession-analysts-believe-1031959029,negative,0.8983575105667114
2007,12/8/2022 2:40:55 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1031960877,positive,0.9151490926742554
2008,12/9/2022 10:27:28 AM,Innovent's drug shows promise in advanced lung cancer patients in early-stage trial,Seeking Alpha,https://seekingalpha.com/news/3915620-innovent-drug-shows-promise-in-advanced-lung-cancer-patients-in-early-stage-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9273059368133545
2009,12/9/2022 7:30:48 PM,"Catalyst Watch: FOMC, CPI print and spotlight on Yum Brands",Seeking Alpha,https://seekingalpha.com/news/3915821-stocks-to-watch-fomc-cpi-print-and-spotlight-on-yum-brands?utm_source=businessinsider&utm_medium=referral,positive,0.9273848533630371
2010,12/11/2022 5:00:50 PM,"Lilly, Novo dominance in weight loss market intact despite Amgen entry – BofA",Seeking Alpha,https://seekingalpha.com/news/3915950-lly-stock-novo-nordisk-to-dominate-obesity-despite-amgen-entry?utm_source=businessinsider&utm_medium=referral,negative,0.6963549852371216
2011,12/12/2022 11:15:21 AM,Eli Lilly Stock Is a Mega-Blockbuster Buy,InvestorPlace,/news/stocks/lly-stock-is-a-mega-blockbuster-buy-1031964937,positive,0.9184119701385498
2012,12/12/2022 8:57:53 PM,Eli Lilly raises dividend by 15% to $1.13,Seeking Alpha,https://seekingalpha.com/news/3916279-eli-lilly-raises-dividend-by-15-to-113?utm_source=businessinsider&utm_medium=referral,negative,0.9209580421447754
2013,12/12/2022 9:26:00 PM,"Lilly Announces 15% Dividend Increase, First-Quarter 2023 Dividend",PR Newswire,/news/stocks/lilly-announces-15-dividend-increase-first-quarter-2023-dividend-1031967641,negative,0.9083152413368225
2014,12/12/2022 11:30:00 PM,Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-presents-updated-pirtobrutinib-data-from-the-phase-1-2-bruin-clinical-trial-at-the-2022-american-society-of-hematology-annual-meeting-1031967801,positive,0.9278122186660767
2015,12/13/2022 12:45:00 PM,"Lilly Announces 2023 Financial Guidance, Plans to Launch up to Four New Medicines",PR Newswire,/news/stocks/lilly-announces-2023-financial-guidance-plans-to-launch-up-to-four-new-medicines-1031968733,positive,0.5024220943450928
2016,12/13/2022 12:57:25 PM,Eli Lilly dips after issuing underwhelming 2023 guidance,Seeking Alpha,https://seekingalpha.com/news/3916459-lly-stock-dips-after-issuing-underwhelming-2023-guidance-?utm_source=businessinsider&utm_medium=referral,neutral,0.962017834186554
2017,12/13/2022 1:11:29 PM,Eli Lilly Issues FY23 Guidance; Reaffirms FY22 Outlook ,RTTNews,/news/stocks/eli-lilly-issues-fy23-guidance-reaffirms-fy22-outlook-1031968824,negative,0.4763127565383911
2018,12/13/2022 7:04:10 PM,"mRNA cancer vaccines could be in greater focus after Moderna, Merck candidate shines",Seeking Alpha,https://seekingalpha.com/news/3916642-mrna-cancer-vaccines-could-be-in-greater-focus-after-moderna-merck-candidate-shines?utm_source=businessinsider&utm_medium=referral,positive,0.6820481419563293
2019,12/13/2022 7:53:12 PM,Our Top 10 Stock Picks for 2023,InvestorPlace,/news/stocks/our-top-10-stock-picks-for-2023-1031970169,positive,0.9293897747993469
2020,12/14/2022 3:55:31 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1031970545,positive,0.90191650390625
2021,12/14/2022 10:15:00 AM,Lilly and EVA Pharma Announce Collaboration to Enhance Sustainable Access to Affordable Insulin in Africa,PR Newswire,/news/stocks/lilly-and-eva-pharma-announce-collaboration-to-enhance-sustainable-access-to-affordable-insulin-in-africa-1031971102,negative,0.9041632413864136
2022,12/14/2022 10:27:01 AM,Lilly teams up with Eva to make and provide affordable insulin in Africa,Seeking Alpha,https://seekingalpha.com/news/3916824-lilly-teams-up-with-eva-to-make-and-provide-affordable-insulin-in-africa?utm_source=businessinsider&utm_medium=referral,negative,0.7925227880477905
2023,12/14/2022 12:10:29 PM,"Analysts Offer Insights on Healthcare Companies: Conmed (CNMD), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-conmed-cnmd-eli-lilly-co-lly-and-irhythm-technologies-irtc-1031971458,positive,0.9255250096321106
2024,12/14/2022 2:40:39 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Ligand Pharma (LGND),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-ligand-pharma-lgnd-1031971993,positive,0.9111519455909729
2025,12/14/2022 4:25:25 PM,Morgan Stanley Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1031972299,positive,0.7820586562156677
2026,12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral,positive,0.7342972755432129
2027,12/15/2022 2:05:56 PM,Carnival To Rally Over 36%? Here Are 10 Other Price Target Changes For Thursday,Benzinga,/news/stocks/carnival-to-rally-over-36-here-are-10-other-price-target-changes-for-thursday-1031974554,positive,0.9162083864212036
2028,12/16/2022 9:34:17 AM,"Sosei to get $37M upfront from Lilly in pact to discover drugs for diabetes, metabolic diseases",Seeking Alpha,https://seekingalpha.com/news/3917900-sosei-to-get-37m-upfront-from-lilly-in-pact-to-discover-drugs-for-diabetes-metabolic-diseases?utm_source=businessinsider&utm_medium=referral,negative,0.7930293083190918
2029,12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937,positive,0.8808764219284058
2030,12/16/2022 12:30:27 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), HCA Healthcare (HCA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-hca-healthcare-hca-1031977178,positive,0.7001062035560608
2031,12/16/2022 1:27:21 PM,Lilly withdraws Olumiant filing in EU for COVID; gets EMA panel nod for Adcirca's use in kids,Seeking Alpha,https://seekingalpha.com/news/3917969-lilly-withdraws-olumiant-filing-in-eu-for-covid-gets-ema-panel-nod-for-adcircas-use-in-kids?utm_source=businessinsider&utm_medium=referral,positive,0.6003168821334839
2032,12/16/2022 5:36:44 PM,Eli Lilly diabetes drugs in shortage due to rising demand,Seeking Alpha,https://seekingalpha.com/news/3918115-eli-lilly-diabetes-drugs-in-shortage-due-to-rising-demand?utm_source=businessinsider&utm_medium=referral,neutral,0.9605182409286499
2033,12/18/2022 2:04:41 PM,The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond,InvestorPlace,/news/stocks/the-7-hottest-healthcare-stocks-to-own-for-2023-and-beyond-1031978729,positive,0.8950048089027405
2034,12/18/2022 9:34:20 PM,The 7 Best Retirement Stocks to Buy Now,InvestorPlace,/news/stocks/best-retirement-stocks-1031562793,positive,0.8736042380332947
2035,12/20/2022 2:35:26 PM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1031982614,positive,0.9430696964263916
2036,12/20/2022 5:00:22 PM,The 7 Best Bear Market Stocks to Buy Now,InvestorPlace,/news/stocks/best-bear-market-stocks-1031573318,positive,0.8821819424629211
2037,12/20/2022 9:00:54 PM,"Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says",Benzinga,/news/stocks/top-m-a-target-madrigal-pharmaceuticals-could-be-next-after-successful-nash-data-analyst-says-1031983372,negative,0.7063286304473877
2038,12/21/2022 5:21:22 PM,Halozyme Therapeutics overweight at Morgan Stanley on Enhanze subcutaneous technology,Seeking Alpha,https://seekingalpha.com/news/3919530-halozyme-therapeutics-overweight-at-morgan-stanley-on-enhanze-subcutaneous-technology?utm_source=businessinsider&utm_medium=referral,positive,0.7923977375030518
2039,12/22/2022 11:42:33 AM,Eli Lilly sends ProQR 35% higher after expanding RNA editing deal,Seeking Alpha,https://seekingalpha.com/news/3919739-prqr-stock-surges-as-eli-lilly-expands-rna-editing-deal?utm_source=businessinsider&utm_medium=referral,negative,0.9486555457115173
2040,12/22/2022 12:00:00 PM,Lilly and ProQR to Expand RNA Editing Collaboration,PR Newswire,/news/stocks/lilly-and-proqr-to-expand-rna-editing-collaboration-1031986680,negative,0.6003817915916443
2041,12/22/2022 12:20:36 PM,"Lilly, ProQR To Expand Licensing And Collaboration Deal For New Genetic Medicines ",RTTNews,/news/stocks/lilly-proqr-to-expand-licensing-and-collaboration-deal-for-new-genetic-medicines-1031986721,negative,0.8561233282089233
2042,12/22/2022 5:48:44 PM,"Biogen, Lilly potential Alzheimer's drugs given lukewarm review by drug evaluation group",Seeking Alpha,https://seekingalpha.com/news/3919908-biogen-lilly-potential-alzheimers-drugs-given-lukewarm-review-by-drug-evaluation-group?utm_source=businessinsider&utm_medium=referral,negative,0.7613864541053772
2043,12/22/2022 5:51:29 PM,Why Is ProQR (PRQR) Stock Up 83% Today?,InvestorPlace,/news/stocks/why-is-proqr-prqr-stock-up-83-today-1031987573,negative,0.797468364238739
2044,12/22/2022 6:18:16 PM,ProQR adds 75% as Cantor upgrades on expanded deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3919928-prqr-stock-climbs-cantor-upgrades-expanded-eli-lilly-deal?utm_source=businessinsider&utm_medium=referral,negative,0.910769522190094
2045,12/23/2022 4:51:10 PM,Immune-evasive Omicron subvariant XBB rapidly gaining ground in U.S.,Seeking Alpha,https://seekingalpha.com/news/3920398-immune-evasive-omicron-subvariant-xbb-rapidly-gaining-ground-in-us?utm_source=businessinsider&utm_medium=referral,negative,0.9495846629142761
2046,12/25/2022 5:00:44 PM,Goldman Sachs highlights key healthcare themes for 2023,Seeking Alpha,https://seekingalpha.com/news/3920634-goldman-sachs-micro-over-macro-healthcare-themes-2023?utm_source=businessinsider&utm_medium=referral,positive,0.7464402914047241
2047,12/26/2022 11:15:34 AM,Why Eli Lilly Stock Will Stay Strong in 2023,InvestorPlace,/news/stocks/why-lly-stock-will-stay-strong-in-2023-1031990189,positive,0.7337775826454163
2048,12/27/2022 2:12:49 PM,PeptiDream signs licensing deal with Lilly for peptide drug conjugates,Seeking Alpha,https://seekingalpha.com/news/3920726-peptidream-signs-licensing-deal-with-lilly-for-peptide-drug-conjugates?utm_source=businessinsider&utm_medium=referral,negative,0.8612983226776123
2049,12/29/2022 10:14:33 AM,"Adocia, Tonghua's BioChaperone Lispro insulin shows promise in phase 1 trial",Seeking Alpha,https://seekingalpha.com/news/3921073-adocia-tonghuas-biochaperone-lispro-insulin-shows-promise-in-phase-1-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9266999959945679
2050,12/30/2022 12:28:33 PM,7 Cheap Large-Cap Stocks to Buy Before They Surge Higher,InvestorPlace,/news/stocks/cheap-large-cap-stocks-1031607723,positive,0.8062047362327576
2051,12/30/2022 5:11:21 PM,Diabetes rates in children set to skyrocket by 2060 - study,Seeking Alpha,https://seekingalpha.com/news/3921303-diabetes-rates-in-children-set-to-skyrocket-by-2060-study?utm_source=businessinsider&utm_medium=referral,positive,0.8470563888549805
2052,12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral,negative,0.9400242567062378
2053,12/31/2022 2:37:49 PM,The 7 Best Retirement Stocks for Investors Over 50,InvestorPlace,/news/stocks/best-retirement-stocks-for-investors-over-50-1031581892,positive,0.8301514387130737
2054,1/2/2023 12:00:59 PM,Why LLY Stock Could Meet (or Beat!) 2022’s Stellar Performance,InvestorPlace,/news/stocks/lly-stock-could-meet-or-beat-2022-stellar-performance-1031996431,negative,0.8433679938316345
2055,1/3/2023 7:53:16 PM,10 Best Stock Traders In Congress In 2022 (Spoiler: Nancy Pelosi Isn't No. 1),Benzinga,/news/stocks/10-best-stock-traders-in-congress-in-2022-spoiler-nancy-pelosi-isn-t-no-1-1031998484,positive,0.8845786452293396
2056,1/4/2023 4:00:00 PM,Lilly to Participate in the J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-the-j-p-morgan-healthcare-conference-1032000138,positive,0.805112361907959
2057,1/4/2023 5:30:15 PM,The 10 Best Dividend Stocks of All Time ,InvestorPlace,/news/stocks/best-dividend-stocks-of-all-time-1031596593,positive,0.7762686014175415
2058,1/5/2023 4:35:57 PM,Jim Cramer Says Avoid This Stock: 'Too Expensive',Benzinga,/news/stocks/jim-cramer-says-avoid-this-stock-too-expensive-1032002488,neutral,0.5342662334442139
2059,1/6/2023 8:19:28 PM,"Lilly, Anavex, other Alzheimer's drug developers rise modestly on Biogen lecanemab approval",Seeking Alpha,https://seekingalpha.com/news/3922771-lilly-roche-other-alzheimers-drug-developer-rise-modestly-on-biogen-lecanemab-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9446359276771545
2060,1/6/2023 8:47:34 PM,"SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday",Benzinga,/news/stocks/sava-lly-ibb-why-these-alzheimer-s-related-stocks-are-volatile-on-friday-1032005036,positive,0.7991046905517578
2061,1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182,positive,0.8010979890823364
2062,1/9/2023 3:00:58 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY) and G1 Therapeutics (GTHX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-alnylam-pharma-alny-and-g1-therapeutics-gthx-1032007403,neutral,0.7420678734779358
2063,1/10/2023 12:29:26 PM,7 Long-Term Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/long-term-stocks-to-buy-and-hold-1031656398,positive,0.9400481581687927
2064,1/11/2023 12:22:40 AM,Lilly could launch tirzepatide as obesity treatment by end of the year,Seeking Alpha,https://seekingalpha.com/news/3923535-lilly-could-launch-tirzepatide-as-obesity-treatment-by-end-of-the-year?utm_source=businessinsider&utm_medium=referral,positive,0.7708166241645813
2065,1/11/2023 6:06:37 PM,7 Hot Healthcare Stocks to Watch in 2023,InvestorPlace,/news/stocks/7-hot-healthcare-stocks-to-watch-in-2023-1032013193,positive,0.8813204169273376
2066,1/11/2023 9:55:36 PM,"Eli Lilly says Q4 results will be impacted by $240M in IPR&D, development milestone charges",Seeking Alpha,https://seekingalpha.com/news/3923934-eli-lilly-says-q4-results-will-be-impacted-by-240m-in-iprd-development-milestone-charges?utm_source=businessinsider&utm_medium=referral,neutral,0.9493566155433655
2067,1/12/2023 4:19:04 PM,"Medications appropriate for obese teens, new guideline says",Seeking Alpha,https://seekingalpha.com/news/3924214-medications-appropriate-for-obese-teens-new-guideline-says?utm_source=businessinsider&utm_medium=referral,positive,0.8191192746162415
2068,1/12/2023 7:44:45 PM,"Eli Lilly, Novo, Sanofi and leading PBMs accused in California over insulin prices",Seeking Alpha,https://seekingalpha.com/news/3924281-eli-lilly-novo-sanofi-leading-pbms-accused-in-california-over-insulin-prices?utm_source=businessinsider&utm_medium=referral,neutral,0.9355102181434631
2069,1/14/2023 7:54:32 PM,Gamechanging Weight Loss Drug Could Send LLY Stock Soaring,InvestorPlace,/news/stocks/lly-stock-recent-sideways-movement-belies-mounjaro-progress-1032018570,neutral,0.963817834854126
2070,1/14/2023 9:00:00 PM,"Type 2 diabetes market to surpass $136B in 2029 from new therapies, increased diagnoses",Seeking Alpha,https://seekingalpha.com/news/3924584-type-2-diabetes-market-to-surpass-136b-in-2029-from-new-therapies-increased-diagnoses?utm_source=businessinsider&utm_medium=referral,negative,0.8843289017677307
2071,1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral,negative,0.8843089938163757
2072,1/16/2023 12:15:26 PM,AbbVie and Lilly leave U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3924704-abbvie-and-lilly-leave-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral,neutral,0.6320776343345642
2073,1/16/2023 2:55:12 PM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1032020613,positive,0.9430696964263916
2074,1/17/2023 6:36:59 PM,Bristol-Myers earns bullish views at Cantor on breakout potential,Seeking Alpha,https://seekingalpha.com/news/3925135-bmy-stock-earns-bullish-views-cantor-breakout-potential?utm_source=businessinsider&utm_medium=referral,negative,0.8574527502059937
2075,1/19/2023 1:10:49 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), Roche Holding AG (OtherRHHVF) and Avidity Biosciences (RNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-roche-holding-ag-otherrhhvf-and-avidity-biosciences-rna-1032028292,neutral,0.931168794631958
2076,1/19/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Fourth-Quarter 2022 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-fourth-quarter-2022-financial-results-announcement-1032028718,positive,0.9393976926803589
2077,1/19/2023 6:19:18 PM,Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide,Benzinga,/news/stocks/analyst-views-novo-nordisk-s-upcoming-obesity-drug-data-to-lay-grounds-for-eli-lilly-s-tirzepatide-1032029171,positive,0.7001729011535645
2078,1/19/2023 11:12:42 PM,Eli Lilly shares fall 3% after hours as FDA rejects submission for Alzheimer's treatment,Seeking Alpha,https://seekingalpha.com/news/3926184-eli-lilly-shares-fall-3-after-hours-as-fda-rejects-submission-for-alzheimers-treatment?utm_source=businessinsider&utm_medium=referral,neutral,0.9652923941612244
2079,1/20/2023 12:00:00 AM,U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-accelerated-approval-of-donanemab-1032029712,positive,0.7091593742370605
2080,1/20/2023 2:03:10 AM,FDA Declines To Grant Accelerated Approval To Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-declines-to-grant-accelerated-approval-to-lilly-s-alzheimer-s-drug-1032029741,neutral,0.6685226559638977
2081,1/20/2023 3:00:00 PM,US FDA accepts supplemental New Drug Application for Jardiance® for adults with chronic kidney disease,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-adults-with-chronic-kidney-disease-1032030902,negative,0.8330084085464478
2082,1/20/2023 3:02:47 PM,Lilly's diabetes drug Jardiance to get FDA review for chronic kidney disease indication,Seeking Alpha,https://seekingalpha.com/news/3926360-lillys-diabetes-drug-jardiance-to-get-fda-review-for-chronic-kidney-disease-indication?utm_source=businessinsider&utm_medium=referral,negative,0.7699634432792664
2083,1/20/2023 3:24:40 PM,Eli Lilly Announces FDA Acceptance Of SNDA For Jardiance For Chronic Kidney Disease ,RTTNews,/news/stocks/eli-lilly-announces-fda-acceptance-of-snda-for-jardiance-for-chronic-kidney-disease-1032030968,negative,0.7927075624465942
2084,1/20/2023 3:49:19 PM,Eli Lilly slips while Street defends FDA setback for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/3926378-lly-stock-slips-as-street-defends-alzheimers-setback?utm_source=businessinsider&utm_medium=referral,neutral,0.8872591853141785
2085,1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.9066245555877686
2086,1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,negative,0.8150349855422974
2087,1/23/2023 9:49:07 AM,Takeda to acquire rights to Hutchmed's cancer drug fruquintinib for $400M upfront,Seeking Alpha,https://seekingalpha.com/news/3926597-takeda-to-acquire-rights-to-hutchmeds-cancer-drug-fruquintinib-for-400m-upfront?utm_source=businessinsider&utm_medium=referral,positive,0.7648897171020508
2088,1/23/2023 2:35:16 PM,Eli Lilly & Co (LLY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bmo-capital-1032034183,negative,0.49973437190055847
2089,1/23/2023 3:03:07 PM,3 Drug Stocks With Promising Pipelines for 2023,InvestorPlace,/news/stocks/3-drug-stocks-with-promising-pipelines-for-2023-1032034241,negative,0.8955257534980774
2090,1/24/2023 12:27:58 PM,Lilly to invest $450M to expand production of diabetes meds,Seeking Alpha,https://seekingalpha.com/news/3927076-lly-stock-amid-plans-expand-production-diabetes-meds?utm_source=businessinsider&utm_medium=referral,negative,0.8726360201835632
2091,1/24/2023 12:30:00 PM,Lilly Plans to Invest Additional $450 million at Manufacturing Site in Research Triangle Park,PR Newswire,/news/stocks/lilly-plans-to-invest-additional-450-million-at-manufacturing-site-in-research-triangle-park-1032036356,positive,0.7640884518623352
2092,1/24/2023 12:40:39 PM,Lilly To Expand Manufacturing Facility In North Carolina ,RTTNews,/news/stocks/lilly-to-expand-manufacturing-facility-in-north-carolina-1032036401,negative,0.8644159436225891
2093,1/24/2023 6:22:14 PM,Cassava Sciences Shares Fall On Phase 2 Alzheimer's Trial Results,Benzinga,/news/stocks/cassava-sciences-shares-fall-as-alzheimer-s-candidate-worsens-patients-with-moderate-disease-1032037660,neutral,0.9622421860694885
2094,1/26/2023 4:00:00 PM,Lilly Supports Direct Relief's Efforts to Expand Access to Medicines by Improving Cold Chain Capacity,PR Newswire,/news/stocks/lilly-supports-direct-relief-s-efforts-to-expand-access-to-medicines-by-improving-cold-chain-capacity-1032044178,negative,0.8509485125541687
2095,1/26/2023 11:06:46 PM,The 3 Best Biotech Stocks Under $1 to Buy for January,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-under-1-to-buy-for-january-1032045234,positive,0.7229993939399719
2096,1/27/2023 11:00:21 AM,"Good News, LLY Stock Invetors! Eli Lilly Is Poised for a Promising 2023.",InvestorPlace,/news/stocks/lly-stock-is-poised-for-a-promising-2023-1032046341,negative,0.9217123985290527
2097,1/27/2023 12:14:02 PM,Lilly's diabetes drug Trulicity gets EMA committee nod for use in adolescents,Seeking Alpha,https://seekingalpha.com/news/3928883-lillys-diabetes-drug-trulicity-gets-ema-committee-nod-for-use-in-adolescents?utm_source=businessinsider&utm_medium=referral,negative,0.7178521752357483
2098,1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.936018705368042
2099,1/27/2023 7:15:05 PM,"Catalyst watch: Eyes on tech earnings, Chinese EV stocks, Peloton and Church & Dwight",Seeking Alpha,https://seekingalpha.com/news/3929095-catalyst-watch-eyes-on-tech-earnings-chinese-ev-stocks-peloton-and-church-dwight?utm_source=businessinsider&utm_medium=referral,positive,0.9359208345413208
2100,1/27/2023 7:42:05 PM,Eli Lilly wins FDA accelerated approval for lymphoma therapy,Seeking Alpha,https://seekingalpha.com/news/3929112-lly-stock-wins-fda-accelerated-approval-lymphoma-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.9196877479553223
2101,1/27/2023 8:07:00 PM,"U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Line...",PR Newswire,/news/stocks/u-s-fda-approves-jaypirca-pirtobrutinib-the-first-and-only-non-covalent-reversible-btk-inhibitor-for-adult-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-after-at-least-two-line-1032047471,negative,0.8848387002944946
2102,1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678,positive,0.745915949344635
2103,1/30/2023 12:00:56 PM,WHO maintains public health emergency on COVID but sees pandemic at 'transition point',Seeking Alpha,https://seekingalpha.com/news/3929274-who-maintains-public-health-emergency-on-covid-with-3-years-into-pandemic?utm_source=businessinsider&utm_medium=referral,positive,0.743737518787384
2104,1/31/2023 3:06:19 PM,7 Healthcare Stocks That Will Be Big Winners in 2023,InvestorPlace,/news/stocks/7-healthcare-stocks-that-will-be-big-winners-in-2023-1032054711,negative,0.49766457080841064
2105,1/31/2023 4:35:10 PM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032055024,negative,0.595212996006012
2106,1/31/2023 8:33:01 PM,"February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More",Benzinga,/news/stocks/february-pdufa-catalysts-biotech-investors-must-know-sanofi-s-bleeding-disorder-drug-regeneron-s-twin-eylea-label-expansions-3-delayed-approvals-and-more-1032055559,positive,0.8971438407897949
2107,1/31/2023 11:22:27 PM,Diabetes drug developer Structure Therapeutics sets terms for $125M US IPO,Seeking Alpha,https://seekingalpha.com/news/3930220-diabetes-drug-developer-structure-therapeutics-sets-terms-for-125m-us-ipo?utm_source=businessinsider&utm_medium=referral,positive,0.931587815284729
2108,2/1/2023 1:47:08 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), HCA Healthcare (HCA) and Spectrum Pharmaceuticals (SPPI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-hca-healthcare-hca-and-spectrum-pharmaceuticals-sppi-1032058779,positive,0.9263390898704529
2109,2/1/2023 3:01:13 PM,Here's what to expect from Eli Lilly and's earnings,Markets Insider Automation,/news/stocks/eli_lilly-stock-quarter-earnings-preview-q4-1032058988,positive,0.9407582879066467
2110,2/1/2023 3:44:59 PM,"Eli Lilly to report Q4 earnings amid forex headwinds, loss of COVID-19 antibody revenue",Seeking Alpha,https://seekingalpha.com/news/3930493-eli-lilly-to-report-q4-earnings-amid-forex-headwinds-loss-of-covid-19-antibody-revenue?utm_source=businessinsider&utm_medium=referral,neutral,0.9511139392852783
2111,2/1/2023 3:55:38 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3930495-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8825733065605164
2112,2/2/2023 11:49:05 AM,"Eli Lilly Non-GAAP EPS of $2.09 beats by $0.24, revenue of $7.3B misses by $90M",Seeking Alpha,https://seekingalpha.com/news/3931105-eli-lilly-non-gaap-eps-of-2_09-beats-0_24-revenue-of-7_3b-misses-90m?utm_source=businessinsider&utm_medium=referral,positive,0.507034420967102
2113,2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305,positive,0.7443466782569885
2114,2/2/2023 12:41:59 PM,Eli Lilly slips as falling demand for COVID therapy hurts topline,Seeking Alpha,https://seekingalpha.com/news/3931176-lly-stock-slips-falling-demand-covid-therapy-hurts-topline?utm_source=businessinsider&utm_medium=referral,neutral,0.9700133800506592
2115,2/2/2023 12:45:00 PM,"Lilly Reports Fourth-Quarter 2022 Financial Results, Core Business Growth and Pipeline Advancements Support Strong Long-Term Outlook",PR Newswire,/news/stocks/lilly-reports-fourth-quarter-2022-financial-results-core-business-growth-and-pipeline-advancements-support-strong-long-term-outlook-1032062351,negative,0.9537460803985596
2116,2/2/2023 12:48:23 PM,Eli Lilly And Co. Reveals Rise In Q4 Bottom Line,RTTNews,/news/stocks/eli-lilly-and-co-reveals-rise-in-q4-bottom-line-1032062364,negative,0.930219292640686
2117,2/2/2023 1:07:35 PM,Lilly Lifts FY23 Earnings View Above Market On Updated Tax Rate - Update ,RTTNews,/news/stocks/lilly-lifts-fy23-earnings-view-above-market-on-updated-tax-rate-update-1032062448,negative,0.5728535056114197
2118,2/2/2023 6:49:16 PM,Lilly's quarterly results impacted by less than expected growth in diabetes drug Mounjaro,Seeking Alpha,https://seekingalpha.com/news/3931468-lillys-quarterly-results-impacted-by-less-than-expected-growth-in-diabetes-drug-mounjaro?utm_source=businessinsider&utm_medium=referral,neutral,0.9527752995491028
2119,2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,neutral,0.9276774525642395
2120,2/2/2023 8:20:04 PM,"Nasdaq, S&P off session highs but on track to extend post-Fed rally; Dow in the red",Seeking Alpha,https://seekingalpha.com/news/3931346-sp500-nasdaq-dow-jones-stock-market-meta-earnings-post-fed-rally?utm_source=businessinsider&utm_medium=referral,negative,0.7363039255142212
2121,2/3/2023 11:10:26 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-humana-hum-1032065666,positive,0.7804961800575256
2122,2/3/2023 12:30:25 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-merck-company-mrk-1032066009,positive,0.9203616976737976
2123,2/3/2023 4:00:00 PM,Lilly to Participate in Guggenheim Oncology Conference,PR Newswire,/news/stocks/lilly-to-participate-in-guggenheim-oncology-conference-1032066381,positive,0.8337247967720032
2124,2/3/2023 4:58:11 PM,Erasca rises as Morgan Stanley upgrades on newly added asset,Seeking Alpha,https://seekingalpha.com/news/3931908-eras-stock-rises-as-morgan-stanley-upgrades-on-newly-added-asset?utm_source=businessinsider&utm_medium=referral,negative,0.8934355974197388
2125,2/3/2023 9:14:45 PM,Diabetes drug developer Structure Therapeutics stock soars 73% in debut (update),Seeking Alpha,https://seekingalpha.com/news/3932013-diabetes-drug-developer-structure-therapeutics-stock-soars-72-in-market-debut?utm_source=businessinsider&utm_medium=referral,positive,0.5223464965820312
2126,2/3/2023 10:00:31 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1032067123,positive,0.9140509963035583
2127,2/6/2023 9:30:23 AM,"Analysts Conflicted on These Healthcare Names: Mednax (MD), Aclaris Therapeutics (ACRS) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-mednax-md-aclaris-therapeutics-acrs-and-eli-lilly-co-lly-1032069702,neutral,0.7108811736106873
2128,2/6/2023 4:31:12 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-regeneron-regn-and-seagen-sgen-1032070948,positive,0.9220420122146606
2129,2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral,positive,0.6935389041900635
2130,2/7/2023 11:30:10 AM,7 A-Rated Stocks to Buy for February 2023,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-for-february-2023-1032073457,positive,0.9190111756324768
2131,2/7/2023 12:16:26 PM,Ten top growth stocks and 10 top value stocks from BofA's screens,Seeking Alpha,https://seekingalpha.com/news/3932604-ten-top-growth-stocks-and-10-top-value-stocks-from-bofas-screens?utm_source=businessinsider&utm_medium=referral,positive,0.8979679942131042
2132,2/7/2023 4:00:00 PM,Lilly to Participate in SVB Securities Global Biopharma Conference,PR Newswire,/news/stocks/lilly-to-participate-in-svb-securities-global-biopharma-conference-1032074441,positive,0.9036015272140503
2133,2/8/2023 3:54:52 PM,The 7 Best Dividend Stocks to Buy for February 2023,InvestorPlace,/news/stocks/the-7-best-dividend-stocks-to-buy-for-february-2023-1032079245,positive,0.9203088879585266
2134,2/10/2023 11:00:07 AM,Ignore the Worrywarts! Snap Up Eli Lilly Stock on Sale,InvestorPlace,/news/stocks/ignore-the-worrywarts-snap-up-lly-stock-on-sale-1032085942,positive,0.9264987707138062
2135,2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,positive,0.5336910486221313
2136,2/12/2023 3:56:18 PM,7 A-Rated Healthcare Stocks to Buy for the Future of Medicine,InvestorPlace,/news/stocks/7-a-rated-healthcare-stocks-to-buy-for-the-future-of-medicine-1032088046,positive,0.8510341644287109
2137,2/13/2023 11:15:28 AM,"Lilly, IABL team up to provide affordable insulin in Bangladesh",Seeking Alpha,https://seekingalpha.com/news/3935095-lilly-iabl-team-up-to-provide-affordable-insulin-in-bangladesh?utm_source=businessinsider&utm_medium=referral,negative,0.7629144787788391
2138,2/13/2023 11:40:05 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), IQVIA Holdings (IQV) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-iqvia-holdings-iqv-and-viatris-vtrs-1032090836,positive,0.9209754467010498
2139,2/13/2023 12:00:00 PM,Lilly and IABL Collaborate to Ensure Patient Access to High-Quality Affordable Insulin in Bangladesh,PR Newswire,/news/stocks/lilly-and-iabl-collaborate-to-ensure-patient-access-to-high-quality-affordable-insulin-in-bangladesh-1032090726,negative,0.8011587262153625
2140,2/14/2023 11:00:30 AM,7 Great Growth Stocks to Buy in February,InvestorPlace,/news/stocks/ceg-csgp-hal-lly-meli-tmus-uri-7-great-growth-stocks-to-buy-in-february-1032094204,positive,0.8712149262428284
2141,2/14/2023 9:05:22 PM,Which Healthcare Stock Is a Better Pick in 2023?,InvestorPlace,/news/stocks/which-healthcare-stock-is-a-better-pick-in-2023-1032095959,positive,0.9094558358192444
2142,2/14/2023 9:54:34 PM,"Druckenmiller's Duquesne adds Nvidia, AMD, exits Amazon, Microsoft",Seeking Alpha,https://seekingalpha.com/news/3936047-druckenmillers-duquesne-adds-nvidia-amd-exits-amazon-microsoft?utm_source=businessinsider&utm_medium=referral,positive,0.9357320070266724
2143,2/15/2023 4:09:25 PM,Entera Bio up 9% after FDA agrees to review design for phase 3 osteoporosis candidate,Seeking Alpha,https://seekingalpha.com/news/3936418-entera-bio-up-9-after-fda-agrees-to-review-design-for-phase-3-osteoporosis-candidate?utm_source=businessinsider&utm_medium=referral,negative,0.9335383772850037
2144,2/15/2023 6:14:14 PM,Eli Lilly downgraded to sell at Societe Generale on lack of potential upside,Seeking Alpha,https://seekingalpha.com/news/3936538-eli-lilly-downgraded-to-sell-at-societe-generale-on-lack-of-potential-upside?utm_source=businessinsider&utm_medium=referral,neutral,0.9191156029701233
2145,2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,positive,0.4218192398548126
2146,2/15/2023 6:54:20 PM,Concert retains breakthrough status for hair loss therapy despite rival entry,Seeking Alpha,https://seekingalpha.com/news/3936569-concert-retains-breakthrough-status-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8489053845405579
2147,2/15/2023 7:11:38 PM,7 Hot Healthcare Stocks With the Potential to Outperform,InvestorPlace,/news/stocks/7-hot-healthcare-stocks-with-the-potential-to-outperform-1032103825,negative,0.9004144668579102
2148,2/16/2023 1:34:25 AM,Eli Lilly’s (NYSE:LLY) Growth Slowdown Doesn’t Take Away from Its Bull Case,TipRanks,/news/stocks/eli-lilly-s-nyse-lly-growth-slowdown-doesn-t-take-away-from-its-bull-case-1032100627,positive,0.6344327926635742
2149,2/16/2023 12:30:46 PM,"US Stocks' Resilience Faces Test As Traders Await Flurry Of Economic Data: Fed May 'Surprise To The Upside' On Rates Again In 2023, Says Analyst",Benzinga,/news/stocks/us-stocks-resilience-faces-test-as-traders-await-flurry-of-economic-data-fed-may-surprise-to-the-upside-on-rates-again-in-2023-says-analyst-1032102212,neutral,0.6953021883964539
2150,2/17/2023 5:54:00 PM,Senators urge swift action to expand Medicare coverage for Alzheimer’s therapies,Seeking Alpha,https://seekingalpha.com/news/3937793-senators-urge-expand-medicare-coverage-for-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral,negative,0.9097914099693298
2151,2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,negative,0.9136704802513123
2152,2/21/2023 8:31:09 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Phibro Animal Health (PAHC) and Elanco Animal Health (ELAN)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-phibro-animal-health-pahc-and-elanco-animal-health-elan-1032110756,positive,0.9293184280395508
2153,2/21/2023 12:40:57 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Teladoc (TDOC) and Apellis Pharmaceuticals (APLS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-teladoc-tdoc-and-apellis-pharmaceuticals-apls-1032111359,positive,0.9156094789505005
2154,2/21/2023 4:00:00 PM,Lilly to Participate in Cowen's 43rd Annual Health Care Conference,PR Newswire,/news/stocks/lilly-to-participate-in-cowen-s-43rd-annual-health-care-conference-1032112115,positive,0.8593372702598572
2155,2/23/2023 11:53:25 AM,Medicare says coverage limits on Alzheimer’s drugs is not under review,Seeking Alpha,https://seekingalpha.com/news/3939776-medicare-says-coverage-limits-on-alzheimers-drugs-is-not-under-review?utm_source=businessinsider&utm_medium=referral,positive,0.8763622045516968
2156,2/24/2023 1:11:22 AM,Nektar Therapeutics plunges 29% after hours on mid-stage lupus treatment failure,Seeking Alpha,https://seekingalpha.com/news/3940432-nektar-therapeutics-plunges-29-after-hours-on-mid-stage-lupus-treatment-failure?utm_source=businessinsider&utm_medium=referral,neutral,0.9649159908294678
2157,2/24/2023 12:10:54 PM,US Stocks Stare At More Losses In a Lackluster Week: Can Inflation Data Salvage Year's Rally?,Benzinga,/news/stocks/us-stocks-stare-at-more-losses-in-a-lackluster-week-can-inflation-data-salvage-year-s-rally-1032123114,neutral,0.5344229936599731
2158,2/24/2023 2:23:12 PM,Why Nektar Therapeutics Stock Is Plunging Today,Benzinga,/news/stocks/why-nektar-therapeutics-stock-is-plunging-today-1032123579,neutral,0.9471486806869507
2159,2/24/2023 5:03:36 PM,Nektar sheds 45% as trial setback prompts Jefferies downgrade,Seeking Alpha,https://seekingalpha.com/news/3940735-nktr-stock-plunges-as-trial-setback-prompts-jefferies-downgrade?utm_source=businessinsider&utm_medium=referral,neutral,0.965013325214386
2160,2/24/2023 5:46:09 PM,7 Dynamite Dividend Stocks for Income and Growth in 2023,InvestorPlace,/news/stocks/7-dynamite-dividend-stocks-for-income-and-growth-in-2023-1032124388,positive,0.9167734384536743
2161,2/24/2023 6:29:49 PM,3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End,InvestorPlace,/news/stocks/lly-nams-sava-3-drug-stocks-to-watch-as-alzheimers-disease-drugs-clinical-trials-end-1032124474,positive,0.8502106070518494
2162,2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral,positive,0.6739813089370728
2163,2/26/2023 2:45:56 PM,7 Mega-Cap Stocks to Buy for the Long Haul,InvestorPlace,/news/stocks/7-mega-cap-stocks-to-buy-for-the-long-haul-1032125500,positive,0.8480883240699768
2164,2/27/2023 10:50:27 AM,Analysts Conflicted on These Healthcare Names: Personalis (PSNL) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-personalis-psnl-and-eli-lilly-co-lly-1032127148,neutral,0.5860928297042847
2165,2/28/2023 11:30:12 AM,Stocks most and least liked by hedge funds and mutual funds -  Goldman,Seeking Alpha,https://seekingalpha.com/news/3941168-stocks-most-and-least-liked-by-hedge-funds-and-mutual-funds-goldman?utm_source=businessinsider&utm_medium=referral,positive,0.8097005486488342
2166,2/28/2023 12:20:08 PM,"Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Viatris (VTRS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-biomarin-pharmaceutical-bmrn-eli-lilly-co-lly-and-viatris-vtrs-1032131149,positive,0.9082995653152466
2167,2/28/2023 8:27:27 PM,"Analysts Sees Over 50% Upside Opportunity For This Newly Listed Obesity Player Stock, Participating In Big Pharma Race",Benzinga,/news/stocks/analysts-sees-over-50-upside-opportunity-for-this-newly-listed-obesity-player-stock-participating-in-big-pharma-race-1032133040,negative,0.8847235441207886
2168,3/1/2023 11:39:48 AM,FBI Director says novel coronavirus likely originated from China lab leak,Seeking Alpha,https://seekingalpha.com/news/3942433-fbi-director-says-novel-coronavirus-likely-originated-from-china-lab-leak?utm_source=businessinsider&utm_medium=referral,positive,0.9219886064529419
2169,3/1/2023 2:00:00 PM,Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month,PR Newswire,/news/stocks/lilly-cuts-insulin-prices-by-70-and-caps-patient-insulin-out-of-pocket-costs-at-35-per-month-1032136009,negative,0.5672895908355713
2170,3/1/2023 2:00:08 PM,"Eli Lilly slashes insulin prices by 70%, places $35 monthly out-of-pocket cap",Seeking Alpha,https://seekingalpha.com/news/3942564-eli-lilly-slashes-insulin-prices-by-70-places-35-monthly-out-of-pocket-cap?utm_source=businessinsider&utm_medium=referral,neutral,0.8351263403892517
2171,3/1/2023 2:40:49 PM,Eli Lilly Announces Aggressive Price Cuts For Insulins; Announces Expansion Of Insulin Value Program ,RTTNews,/news/stocks/eli-lilly-announces-aggressive-price-cuts-for-insulins-announces-expansion-of-insulin-value-program-1032136245,negative,0.8214254975318909
2172,3/1/2023 3:51:26 PM,China PMI Surprises To Upside,Benzinga,/news/stocks/china-pmi-surprises-to-upside-1032136732,positive,0.6577954292297363
2173,3/1/2023 4:25:28 PM,Morgan Stanley Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-keeps-their-buy-rating-on-eli-lilly-co-lly-1032137112,positive,0.9107039570808411
2174,3/1/2023 4:38:51 PM,"LLY Stock Alert: Eli Lilly Slashes Insulin Prices, Caps Patient Costs",InvestorPlace,/news/stocks/lly-stock-alert-eli-lilly-slashes-insulin-prices-caps-patient-costs-1032137149,neutral,0.8952714204788208
2175,3/1/2023 8:04:43 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032137520,positive,0.8414194583892822
2176,3/2/2023 1:27:22 PM,Eli Lilly licenses non opioid pain med for $40M upfront,Seeking Alpha,https://seekingalpha.com/news/3943220-eli-lilly-licenses-non-opioid-pain-med-for-40m-upfront?utm_source=businessinsider&utm_medium=referral,negative,0.5620070099830627
2177,3/3/2023 12:20:56 PM,Viatris joins AbbVie and Lilly in protesting against U.K. drug pricing deal,Seeking Alpha,https://seekingalpha.com/news/3943792-viatris-joins-abbvie-and-lilly-in-protesting-against-uk-drug-pricing-deal?utm_source=businessinsider&utm_medium=referral,neutral,0.7959650754928589
2178,3/3/2023 4:30:35 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Innoviva (INVA) and Alector (ALEC)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-innoviva-inva-and-alector-alec-1032144359,neutral,0.8140445947647095
2179,3/3/2023 8:08:25 PM,Wegovy CV risk reduction data in obesity could help both Novo Nordisk and Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3944109-wegovy-cv-risk-reduction-data-in-obesity-could-help-both-novo-nordisk-and-eli-lilly?utm_source=businessinsider&utm_medium=referral,negative,0.9242402911186218
2180,3/3/2023 8:20:28 PM,Eli Lilly wins additional breast cancer indication for Verzenio,Seeking Alpha,https://seekingalpha.com/news/3944114-eli-lilly-wins-additional-breast-cancer-indication-for-verzenio?utm_source=businessinsider&utm_medium=referral,negative,0.8935527801513672
2181,3/3/2023 8:58:00 PM,"U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer",PR Newswire,/news/stocks/u-s-fda-broadens-indication-for-verzenio-abemaciclib-in-hr-her2-node-positive-high-risk-early-breast-cancer-1032144778,negative,0.9044980406761169
2182,3/5/2023 4:19:39 PM,7 High-Growth Stocks for ESG-Oriented Investors,InvestorPlace,/news/stocks/7-high-growth-stocks-for-esg-oriented-investors-1032145717,positive,0.8966245055198669
2183,3/6/2023 11:50:15 AM,"Analysts’ Top Healthcare Picks: Abbott Labs (ABT), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-abbott-labs-abt-eli-lilly-co-lly-1032146876,negative,0.505389392375946
2184,3/6/2023 12:36:50 PM,"US Stocks Could Consolidate As S&P 500, Nasdaq Futures Tick Up Ahead Of Fed Chair Powell's Congressional Testimony",Benzinga,/news/stocks/us-stocks-could-consolidate-as-s-p-500-nasdaq-futures-tick-up-ahead-of-fed-chair-powell-s-congressional-testimony-1032146852,neutral,0.7071163058280945
2185,3/6/2023 4:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-6-2023-1032147650,neutral,0.4970482587814331
2186,3/6/2023 4:30:00 PM,"Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according t...",PR Newswire,/news/stocks/intensive-education-at-clinics-about-multidisciplinary-care-improved-likelihood-that-adults-with-type-2-diabetes-and-cardiovascular-disease-were-receiving-guideline-directed-medicines-according-t-1032147710,negative,0.9475324153900146
2187,3/6/2023 6:50:03 PM,Eli Lilly granted Hold rating at Jefferies as shares look “priced to perfection”,Seeking Alpha,https://seekingalpha.com/news/3944576-eli-lilly-granted-hold-rating-jefferies-shares-look-priced-to-perfection?utm_source=businessinsider&utm_medium=referral,negative,0.8783054351806641
2188,3/6/2023 9:51:01 PM,WW buying telehealth provider Sequence; provides easier access to obesity drugs,Seeking Alpha,https://seekingalpha.com/news/3944657-weight-watchers-buys-telehealth-provider-sequence-provides-easier-access-to-obesity-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.9048106670379639
2189,3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,negative,0.533659815788269
2190,3/7/2023 4:24:57 PM,Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin,Seeking Alpha,https://seekingalpha.com/news/3944959-lexicon-initiated-at-buy-at-jefferies-on-uptake-of-heart-failure-candidate-sotagliflozin?utm_source=businessinsider&utm_medium=referral,positive,0.8048403859138489
2191,3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775,neutral,0.9652082920074463
2192,3/8/2023 2:38:05 PM,"Boehringer, Lilly get FDA review for expanded use of Jardiance in adolescents",Seeking Alpha,https://seekingalpha.com/news/3945363-boehringer-lilly-get-fda-review-for-expanded-use-of-jardiance-in-adolescents?utm_source=businessinsider&utm_medium=referral,negative,0.7527263164520264
2193,3/8/2023 3:00:00 PM,US FDA accepts supplemental New Drug Application for Jardiance® for children 10 years and older with type 2 diabetes,PR Newswire,/news/stocks/us-fda-accepts-supplemental-new-drug-application-for-jardiance-for-children-10-years-and-older-with-type-2-diabetes-1032153748,negative,0.7569578886032104
2194,3/8/2023 3:36:12 PM,Lilly : FDA Accepts SNDA For Jardiance For Children 10 Years & Older With Type 2 Diabetes ,RTTNews,/news/stocks/lilly-fda-accepts-snda-for-jardiance-for-children-10-years-older-with-type-2-diabetes-1032153943,negative,0.7104620933532715
2195,3/8/2023 10:33:01 PM,Lilly ends development of Alzheimer's candidate solanezumab after study failure,Seeking Alpha,https://seekingalpha.com/news/3945692-lilly-ends-development-of-alzheimers-candidate-solanezumab-after-study-failure?utm_source=businessinsider&utm_medium=referral,positive,0.6777191162109375
2196,3/8/2023 11:00:00 PM,Lilly Provides Update on A4 Study of Solanezumab for Preclinical Alzheimer's Disease,PR Newswire,/news/stocks/lilly-provides-update-on-a4-study-of-solanezumab-for-preclinical-alzheimer-s-disease-1032154925,positive,0.8201545476913452
2197,3/9/2023 2:41:44 AM,Lilly's Solanezumab Fails In Alzheimer's Prevention Trial ,RTTNews,/news/stocks/lilly-s-solanezumab-fails-in-alzheimer-s-prevention-trial-1032155097,neutral,0.5240225791931152
2198,3/9/2023 6:07:49 PM,Sanders unveils bill to cap insulin price at $20 per vial,Seeking Alpha,https://seekingalpha.com/news/3946076-sanders-unveils-bill-to-cap-insulin-price-at-20-per-vial?utm_source=businessinsider&utm_medium=referral,positive,0.7633273601531982
2199,3/10/2023 7:10:43 PM,"Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs",Benzinga,/news/stocks/hefty-listing-price-of-new-drugs-for-cancer-rare-diseases-put-pressure-on-annual-hike-for-older-drugs-1032160689,neutral,0.7246754765510559
2200,3/12/2023 5:00:16 PM,New weight loss therapies can burden Medicare - experts,Seeking Alpha,https://seekingalpha.com/news/3946678-new-weight-loss-therapies-can-burden-medicare?utm_source=businessinsider&utm_medium=referral,neutral,0.853018581867218
2201,3/13/2023 9:50:23 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-axsome-therapeutics-axsm-1032162619,positive,0.9135671257972717
2202,3/13/2023 11:55:12 AM,Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows,Benzinga,/news/stocks/nasdaq-futures-climb-solidly-after-past-week-s-rout-analyst-flags-key-s-p-500-support-to-stay-above-october-lows-1032162772,negative,0.8695937991142273
2203,3/13/2023 12:20:01 PM,"3 Stocks to Buy Today, 3/13/2023, According to Top Analysts",TipRanks,/news/stocks/3-stocks-to-buy-today-3-13-2023-according-to-top-analysts-1032163130,positive,0.9016789793968201
2204,3/13/2023 4:00:45 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-13-2023-1032163649,neutral,0.4953747093677521
2205,3/13/2023 4:35:00 PM,Eli Lilly upgraded at Wells Fargo citing opportunity after recent weakness,Seeking Alpha,https://seekingalpha.com/news/3946916-lly-stock-upgraded-wells-fargo-opportunity-weakness?utm_source=businessinsider&utm_medium=referral,negative,0.8932348489761353
2206,3/14/2023 12:38:36 PM,"Eli Lilly, Hewlett Packard Enterprise And 2 Other Stocks Insiders Are Selling",Benzinga,/news/stocks/eli-lilly-hewlett-packard-enterprise-and-2-other-stocks-insiders-are-selling-1032165906,positive,0.9298517107963562
2207,3/14/2023 12:45:58 PM,Novo Nordisk to bring down insulin prices by up to 75% - WSJ,Seeking Alpha,https://seekingalpha.com/news/3947235-novo-nordisk-to-bring-down-insulin-prices-by-up-to-75?utm_source=businessinsider&utm_medium=referral,negative,0.6382297277450562
2208,3/14/2023 9:30:00 PM,Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-2023-american-association-for-cancer-research-aacr-annual-meeting-1032167521,positive,0.9417323470115662
2209,3/15/2023 2:03:35 PM,"Eli Lilly, Novo could make more money on insulin despite price reductions - Bloomberg",Seeking Alpha,https://seekingalpha.com/news/3947677-eli-lilly-novo-could-make-more-money-on-insulin-despite-price-reductions-bloomberg?utm_source=businessinsider&utm_medium=referral,negative,0.6112989783287048
2210,3/16/2023 9:41:10 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Halozyme (HALO) and 9 Meters Biopharma (NMTR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-halozyme-halo-and-9-meters-biopharma-nmtr-1032172053,positive,0.9140462279319763
2211,3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.9513846635818481
2212,3/17/2023 3:26:18 AM,Sanofi To Cut U.S. List Price Of Its Most-prescribed Insulin By 78% ,RTTNews,/news/stocks/sanofi-to-cut-u-s-list-price-of-its-most-prescribed-insulin-by-78-1032174315,neutral,0.8771167993545532
2213,3/19/2023 4:00:30 PM,Pfizer CEO pockets $33M for 2022 after 36% pay hike,Seeking Alpha,https://seekingalpha.com/news/3948694-pfizer-ceo-pockets-33m-for-2022-after-36-percent-pay-hike?utm_source=businessinsider&utm_medium=referral,positive,0.5718112587928772
2214,3/20/2023 10:45:56 AM,Takeda hits main goals in mid-stage trial for plaque psoriasis therapy,Seeking Alpha,https://seekingalpha.com/news/3948751-takeda-hits-main-goals-mid-stage-trial-plaque-psoriasis-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.8746462464332581
2215,3/20/2023 11:15:08 AM,BMO Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032178534,positive,0.49679994583129883
2216,3/21/2023 9:41:13 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Humana (HUM)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-humana-hum-1032181184,positive,0.7804961800575256
2217,3/21/2023 6:58:24 PM,Altimmune leads obesity drug developers lower after data for lead asset,Seeking Alpha,https://seekingalpha.com/news/3949662-altimmune-leads-obesity-drug-developers-lower-after-data-for-lead-asset?utm_source=businessinsider&utm_medium=referral,neutral,0.8946324586868286
2218,3/21/2023 7:34:59 PM,Eli Lilly experiencing shortages of diabetes med Trulicity,Seeking Alpha,https://seekingalpha.com/news/3949668-eli-lilly-experiencing-shortages-diabetes-med-trulicity?utm_source=businessinsider&utm_medium=referral,neutral,0.8791753053665161
2219,3/21/2023 8:13:55 PM,7 Healthcare Stocks to Buy for Long-Term Growth and Stability,InvestorPlace,/news/stocks/7-healthcare-stocks-to-buy-for-long-term-growth-and-stability-1032183221,positive,0.7752803564071655
2220,3/22/2023 7:26:26 AM,"Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease ",RTTNews,/news/stocks/roche-lilly-to-develop-elecsys-amyloid-plasma-panel-to-boost-early-diagnosis-of-alzheimer-s-disease-1032183853,negative,0.6387822031974792
2221,3/22/2023 9:12:23 AM,"Lilly, Roche team up to develop blood test for Alzheimer's disease",Seeking Alpha,https://seekingalpha.com/news/3949789-lilly-roche-team-up-to-develop-blood-test-for-alzheimers-disease?utm_source=businessinsider&utm_medium=referral,positive,0.6968367099761963
2222,3/22/2023 9:51:19 PM,"7 Hot Stocks To Turn $1,000 Into $10,000 By 2030",InvestorPlace,/news/stocks/7-hot-stocks-to-turn-1000-into-10000-by-2030-1032191126,positive,0.6837493777275085
2223,3/23/2023 1:59:14 PM,‘Our Best Long-Term Picks’: Morgan Stanley Suggests 3 High-Quality Stocks to Buy Now,TipRanks,/news/stocks/our-best-long-term-picks-morgan-stanley-suggests-3-high-quality-stocks-to-buy-now-1032188153,positive,0.8172614574432373
2224,3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral,positive,0.6495422124862671
2225,3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.6456917524337769
2226,3/24/2023 7:13:32 PM,California to produce state-label low-cost insulin,Seeking Alpha,https://seekingalpha.com/news/3951103-california-to-produce-state-label-low-cost-insulin?utm_source=businessinsider&utm_medium=referral,positive,0.7595078945159912
2227,3/27/2023 12:20:41 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV), Eli Lilly & Co (LLY) and Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-elevance-health-elv-eli-lilly-co-lly-and-johnson-johnson-jnj-1032193916,neutral,0.9393702149391174
2228,3/28/2023 9:00:00 PM,"Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says",Benzinga,/news/stocks/viking-therapeutics-initial-vk2735-data-resoundingly-beat-expectations-analyst-says-1032198283,negative,0.9534130096435547
2229,3/28/2023 9:53:02 PM,Mid-Cap Monday: ETF Fund Flows,Benzinga,/news/etf/mid-cap-monday-etf-fund-flows-1032198343,positive,0.7068472504615784
2230,3/29/2023 2:50:46 PM,WHO to weigh adding obesity therapies to 'essential' medicines list – Reuters,Seeking Alpha,https://seekingalpha.com/news/3952303-who-to-weigh-adding-obesity-therapies-to-essential-medicines-list-reuters?utm_source=businessinsider&utm_medium=referral,positive,0.9277750253677368
2231,3/30/2023 10:37:24 AM,"Stopping Novo Nordisk's Wegovy, Ozempic may lead to regaining weight - report",Seeking Alpha,https://seekingalpha.com/news/3952594-stopping-novo-nordisks-wegovy-ozempic-may-lead-to-regaining-weight?utm_source=businessinsider&utm_medium=referral,positive,0.5820401310920715
2232,3/31/2023 12:02:14 PM,Lilly's ulcerative colitis drug Omvoh inches closer to EU approval with EMA nod,Seeking Alpha,https://seekingalpha.com/news/3953087-lillys-ulcerative-colitis-drug-omvoh-inches-closer-eu-approval?utm_source=businessinsider&utm_medium=referral,negative,0.9408904910087585
2233,3/31/2023 2:55:02 PM,Eli Lilly says new Alzheimer’s drug showed dose-dependent effect,Seeking Alpha,https://seekingalpha.com/news/3953216-eli-lilly-stock-shows-early-effect-of-alzheimers-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.5145508050918579
2234,4/3/2023 10:15:22 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032210142,positive,0.7920135259628296
2235,4/3/2023 11:31:23 AM,"Analysts’ Top Healthcare Picks: Legend Biotech (LEGN), Y-Mabs Therapeutics (YMAB)",TipRanks,/news/stocks/analysts-top-healthcare-picks-legend-biotech-legn-y-mabs-therapeutics-ymab-1032210419,negative,0.662499189376831
2236,4/3/2023 10:52:51 PM,7 Spectacular Growth Stocks to Buy in April,InvestorPlace,/news/stocks/7-spectacular-growth-stocks-to-buy-in-april-1032212167,positive,0.8473924994468689
2237,4/3/2023 11:01:46 PM,8 Analysts Have This to Say About Eli Lilly,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-eli-lilly-1032212036,positive,0.9264670610427856
2238,4/6/2023 3:09:09 PM,"Morgan Stanley cuts Comcast, adds Becton Dickinson to its model portfolio",Seeking Alpha,https://seekingalpha.com/news/3954991-morgan-stanley-cuts-comcast-adds-becton-dickinson-to-its-model-portfolio?utm_source=businessinsider&utm_medium=referral,positive,0.7136231660842896
2239,4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral,neutral,0.8911572694778442
2240,4/6/2023 9:20:22 PM,What To Expect When Merus Presents Petosemtamab Data Update At AACR,Benzinga,/news/stocks/what-to-expect-when-merus-presents-petosemtamab-data-update-at-aacr-1032219940,positive,0.9483116865158081
2241,4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral,positive,0.9218350052833557
2242,4/7/2023 7:50:36 PM,6 Questions With Rocket Pharma's CEO On World Health Day: How The Biotech Is 'Changing The Narrative',Benzinga,/news/stocks/6-questions-with-rocket-pharma-s-ceo-on-world-health-day-how-the-biotech-is-changing-the-narrative-1032220849,positive,0.8850300908088684
2243,4/9/2023 4:00:00 PM,"Premier cancer research event, AACR is starting this week; Here is what to expect",Seeking Alpha,https://seekingalpha.com/news/3955202-aacr-2023-is-starting-this-week-here-is-what-to-expect?utm_source=businessinsider&utm_medium=referral,positive,0.9468868374824524
2244,4/10/2023 8:05:16 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032221717,negative,0.595212996006012
2245,4/11/2023 2:25:44 AM,U.S. launches $5B program to speed up development of next-gen COVID vaccines,Seeking Alpha,https://seekingalpha.com/news/3955481-us-launches-5b-program-develop-next-gen-covid-vaccines?utm_source=businessinsider&utm_medium=referral,negative,0.8896018862724304
2246,4/11/2023 11:05:05 AM,Eli Lilly & Co (LLY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bmo-capital-1032223998,negative,0.5500200390815735
2247,4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral,neutral,0.7583171725273132
2248,4/12/2023 6:13:04 PM,Bernie Sanders weighs Senate hearing for largest insulin makers – Stat News,Seeking Alpha,https://seekingalpha.com/news/3956054-bernie-sanders--senate-hearing-insulin-makers?utm_source=businessinsider&utm_medium=referral,positive,0.8766098022460938
2249,4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral,positive,0.5150909423828125
2250,4/13/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for First-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-first-quarter-2023-financial-results-announcement-1032230447,positive,0.9416284561157227
2251,4/13/2023 8:51:21 PM,FDA rejects Eli Lilly's license application for ulcerative colitis treatment mirikizumab,Seeking Alpha,https://seekingalpha.com/news/3956434-fda-rejects-eli-lillys-license-application-for-ulcerative-colitis-treatment-mirikizumab?utm_source=businessinsider&utm_medium=referral,neutral,0.7623556852340698
2252,4/13/2023 10:30:00 PM,U.S. Food and Drug Administration Issues Complete Response Letter for Mirikizumab,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-mirikizumab-1032231292,positive,0.8678203225135803
2253,4/14/2023 8:30:53 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-cigna-ci-eli-lilly-co-lly-and-teva-pharmaceutical-teva-1032232189,neutral,0.9291797876358032
2254,4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,negative,0.6195566654205322
2255,4/14/2023 9:35:12 AM,Bank of America Securities Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032232290,positive,0.8028758764266968
2256,4/14/2023 9:45:07 AM,Morgan Stanley Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-remains-a-buy-on-eli-lilly-co-lly-1032232335,positive,0.9360031485557556
2257,4/14/2023 3:28:52 PM,WeightWatchers Latest Strategic Acquisition: Simplify Insurance Reimbursement For Costly Weight-Loss Drugs,Benzinga,/news/stocks/weightwatchers-latest-strategic-acquisition-simplify-insurance-reimbursement-for-costly-weight-loss-drugs-1032232977,negative,0.501233696937561
2258,4/14/2023 4:01:32 PM,"Big Bank's Big Q1 Performance, Florida Gov. Quietly Slips 6-Week Abortion Ban Into Law, Subway Sandwich Seeks $10B Sale: Today's Top Stories",Benzinga,/news/stocks/big-bank-s-big-q1-performance-florida-gov-quietly-slips-6-week-abortion-ban-into-law-subway-sandwich-seeks-10b-sale-today-s-top-stories-1032233074,positive,0.8562995195388794
2259,4/15/2023 12:20:12 AM,"Merus' Petosemtamab Abstract Hits Upside Scenario For Overall Response Rate, Duration Of Response: Analyst",Benzinga,/news/stocks/merus-petosemtamab-abstract-hits-upside-scenario-for-overall-response-rate-duration-of-response-analyst-1032233789,positive,0.8390128016471863
2260,4/16/2023 12:30:06 PM,Get In Now. 3 Stocks That Are Set to Soar.,InvestorPlace,/news/stocks/3-stocks-to-buy-stocks-that-are-set-to-soar-1032234461,positive,0.5334120392799377
2261,4/17/2023 11:45:08 AM,Eli Lilly & Co (LLY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bmo-capital-1032236121,negative,0.49973437190055847
2262,4/17/2023 5:00:00 PM,Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities,PR Newswire,/news/stocks/lilly-to-make-record-breaking-investment-in-indiana-manufacturing-facilities-1032236845,negative,0.8611681461334229
2263,4/17/2023 5:28:30 PM,Eli Lilly to boost investment in Indiana manufacturing facilities,Seeking Alpha,https://seekingalpha.com/news/3956981-eli-lilly-boost-investment-indiana-manufacturing-facilities?utm_source=businessinsider&utm_medium=referral,negative,0.9311884045600891
2264,4/17/2023 6:12:49 PM,"Eli Lilly To Invest Additional $1.6 Bln, Commits 200 New Jobs At LEAP Innovation Park ",RTTNews,/news/stocks/eli-lilly-to-invest-additional-1-6-bln-commits-200-new-jobs-at-leap-innovation-park-1032237074,negative,0.719902753829956
2265,4/17/2023 9:46:12 PM,Nektar Therapeutics up 7% after hours on restructuring plan,Seeking Alpha,https://seekingalpha.com/news/3957126-nektar-therapeutics-up-7-after-hours-on-restructuring-plan?utm_source=businessinsider&utm_medium=referral,negative,0.9306427240371704
2266,4/18/2023 1:20:41 PM,Analyst Says Nektar Therapeutics' Rezpeg Prioritization Likely to Spark Investor Questions,Benzinga,/news/stocks/analyst-says-nektar-therapeutics-rezpeg-prioritization-likely-to-spark-investor-questions-1032239294,negative,0.9083856344223022
2267,4/18/2023 5:23:54 PM,"Teladoc up 8% on expansion into weight management, diabetes",Seeking Alpha,https://seekingalpha.com/news/3957412-teladoc-up-8-expansion-into-weight-management-diabetes?utm_source=businessinsider&utm_medium=referral,negative,0.9532086849212646
2268,4/18/2023 7:19:36 PM,Why Is Teladoc (TDOC) Stock Up 6% Today?,InvestorPlace,/news/stocks/why-is-teladoc-tdoc-stock-up-6-today-1032240941,negative,0.798618733882904
2269,4/21/2023 8:30:57 AM,"Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amerisourcebergen-abc-eli-lilly-co-lly-1032249192,positive,0.8407812118530273
2270,4/21/2023 12:30:10 PM,Eli Lilly expects Medicare coverage for Alzheimer's drugs - Reuters,Seeking Alpha,https://seekingalpha.com/news/3958637-eli-lilly-expects-medicare-coverage-alzheimers-drugs-reuters?utm_source=businessinsider&utm_medium=referral,positive,0.7425058484077454
2271,4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9372532963752747
2272,4/21/2023 7:00:36 PM,"Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut",Seeking Alpha,https://seekingalpha.com/news/3958768-catalyst-watch-earnings-blitz-mobileye-lockup-expiration-and-the-new-one-day-vix-debut?utm_source=businessinsider&utm_medium=referral,positive,0.9063062071800232
2273,4/22/2023 8:00:00 PM,Ulcerative colitis market set to hit $9.6B by 2031,Seeking Alpha,https://seekingalpha.com/news/3958777-ulcerative-colitis-market-set-to-hit-96b-by-2031?utm_source=businessinsider&utm_medium=referral,negative,0.7096775770187378
2274,4/24/2023 9:40:07 AM,Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-procept-biorobotics-prct-and-eli-lilly-co-lly-1032253421,positive,0.9086992144584656
2275,4/24/2023 11:31:21 AM,Eli Lilly to divest diabetes therapy Baqsimi to Amphastar,Seeking Alpha,https://seekingalpha.com/news/3958992-eli-lilly-stock-divest-diabetes-therapy-baqsimi-amphastar?utm_source=businessinsider&utm_medium=referral,positive,0.9132319688796997
2276,4/24/2023 12:45:00 PM,Lilly to Divest BAQSIMI to Amphastar,PR Newswire,/news/stocks/lilly-to-divest-baqsimi-to-amphastar-1032253594,positive,0.9383460283279419
2277,4/24/2023 1:39:39 PM,Lilly To Sell BAQSIMI For At Least $500 Mln In Cash ,RTTNews,/news/stocks/lilly-to-sell-baqsimi-for-at-least-500-mln-in-cash-1032253742,positive,0.9076650738716125
2278,4/24/2023 3:46:03 PM,Eli Lilly to conduct Mounjaro head-to-head trial against Novo Nordisk's Wegovy,Seeking Alpha,https://seekingalpha.com/news/3959125-eli-lilly-conduct-mounjaro-head-to-head-trial-against-novo-nordisk-wegovy?utm_source=businessinsider&utm_medium=referral,positive,0.9017747640609741
2279,4/24/2023 7:37:37 PM,Weight-loss drugmakers push for Medicare coverage,Seeking Alpha,https://seekingalpha.com/news/3959326-weight-loss-drugmakers-push-medicare-coverage?utm_source=businessinsider&utm_medium=referral,positive,0.6653686165809631
2280,4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral,negative,0.8105085492134094
2281,4/25/2023 5:35:06 PM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032259613,positive,0.90191650390625
2282,4/26/2023 3:01:13 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-q1-earnings-preview-1032263654,positive,0.9291529059410095
2283,4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8825733065605164
2284,4/26/2023 3:32:44 PM,Lilly to report Q1 2023 results with pipeline updates in spotlight,Seeking Alpha,https://seekingalpha.com/news/3960530-lilly-stock-report-q1-2023-results-wth-pipeline-updates-focus?utm_source=businessinsider&utm_medium=referral,positive,0.9159575700759888
2285,4/26/2023 8:05:11 PM,Biogen gains as Medicare to cover new Alzheimer’s drug with full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3960780-biogen-stock-gains-medicare-cover-new-alzheimers-drug?utm_source=businessinsider&utm_medium=referral,negative,0.9222493171691895
2286,4/27/2023 10:45:09 AM,7 Healthcare Stocks With Huge Return Potential for Long-Term Investors,InvestorPlace,/news/stocks/7-healthcare-stocks-with-huge-return-potential-for-long-term-investors-1032267993,negative,0.7780923843383789
2287,4/27/2023 10:48:16 AM,"Eli Lilly Non-GAAP EPS of $1.62 misses by $0.11, revenue of $6.96B beats by $90M",Seeking Alpha,https://seekingalpha.com/news/3961164-eli-lilly-non-gaap-eps-of-1_62-misses-0_11-revenue-of-6_96b-beats-90m?utm_source=businessinsider&utm_medium=referral,positive,0.6290218830108643
2288,4/27/2023 10:55:09 AM,Lilly obesity therapy shows ~16% weight loss in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3961177-lilly-stock-obesity-therapy-shows-weight-loss?utm_source=businessinsider&utm_medium=referral,negative,0.5685485601425171
2289,4/27/2023 12:15:00 PM,Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2,PR Newswire,/news/stocks/lilly-s-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-surmount-2-1032267820,negative,0.938769519329071
2290,4/27/2023 12:29:50 PM,Eli Lilly: Tirzepatide Achieves Up To 15.7% Weight Loss In Results From SURMOUNT-2 ,RTTNews,/news/stocks/eli-lilly-tirzepatide-achieves-up-to-15-7-weight-loss-in-results-from-surmount-2-1032267884,negative,0.9455971717834473
2291,4/27/2023 12:45:00 PM,"Lilly Reports First-Quarter 2023 Financial Results, Highlights Continued Core Business Growth and Pipeline Momentum",PR Newswire,/news/stocks/lilly-reports-first-quarter-2023-financial-results-highlights-continued-core-business-growth-and-pipeline-momentum-1032267967,negative,0.9457733035087585
2292,4/27/2023 1:01:01 PM,"Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Eli Lilly & Co (LLY) and Universal Health (UHS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-eli-lilly-co-lly-and-universal-health-uhs-1032269007,positive,0.9226823449134827
2293,4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050,negative,0.7996723055839539
2294,4/27/2023 1:07:20 PM,"Eli Lilly And Co. Q1 Profit Decreases, misses estimates",RTTNews,/news/stocks/eli-lilly-and-co-q1-profit-decreases-misses-estimates-1032268069,neutral,0.9725165963172913
2295,4/27/2023 1:10:44 PM,"Lilly Q1 Profit Down, Misses View; Lifts FY23 Forecast; Stock Up In Pre Market ",RTTNews,/news/stocks/lilly-q1-profit-down-misses-view-lifts-fy23-forecast-stock-up-in-pre-market-1032268066,negative,0.5528221130371094
2296,4/27/2023 1:24:55 PM,Eli Lilly posts Q1 contraction amid hit to COVID sales,Seeking Alpha,https://seekingalpha.com/news/3961359-eli-lilly-stock-posts-q1-contraction-amid-hit-to-covid-sales?utm_source=businessinsider&utm_medium=referral,neutral,0.973946750164032
2297,4/27/2023 2:13:09 PM,LLY Stock Alert: Mounjaro Takes Eli Lilly to the Next Level,InvestorPlace,/news/stocks/lly-stock-alert-mounjaro-takes-eli-lilly-to-the-next-level-1032269314,positive,0.8652186393737793
2298,4/27/2023 2:14:00 PM,Nektar regains rights to atopic dermatitis candidate from Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3961402-nektar-regains-rights-atopic-dermatitis-candidate-rezpeg-eli-lilly?utm_source=businessinsider&utm_medium=referral,positive,0.6779311299324036
2299,4/27/2023 2:53:44 PM,Cathie Wood Doubles Down on Tesla (TSLA) Stock After Earnings,InvestorPlace,/news/stocks/cathie-wood-doubles-down-on-tesla-tsla-stock-after-earnings-1032269413,neutral,0.9042213559150696
2300,4/27/2023 3:12:38 PM,Zura to license autoimmune disease drug from Lilly; plans $80M private offering,Seeking Alpha,https://seekingalpha.com/news/3961450-zura-to-license-autoimmune-disease-drug-lilly-plans-80m-private-offering?utm_source=businessinsider&utm_medium=referral,positive,0.8723292946815491
2301,4/27/2023 3:19:42 PM,Why Are Stocks Up Today?,InvestorPlace,/news/stocks/why-are-stocks-up-today-april-27th-1032269539,positive,0.5933130979537964
2302,4/27/2023 3:46:08 PM,Eli Lilly to use priority review voucher for Mounjaro weight loss indication,Seeking Alpha,https://seekingalpha.com/news/3961462-eli-lilly-priority-review-voucher-mounjaro-weight-loss-indication?utm_source=businessinsider&utm_medium=referral,positive,0.7631650567054749
2303,4/27/2023 5:01:56 PM,"Hot Stocks: TDOC, LLY, ROKU and CMCSA rises on earnings; DBX falls on layoffs; LUV, CAT and BMY slides",Seeking Alpha,https://seekingalpha.com/news/3961499-hot-stocks-tdoc-lly-roku-and-cmcsa-rises-on-earnings-dbx-fallss-on-layoffs-luv-cat-and-bmy-slides?utm_source=businessinsider&utm_medium=referral,neutral,0.907573938369751
2304,4/28/2023 8:15:08 AM,Goldman Sachs Sticks to Their Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-hold-rating-for-eli-lilly-co-lly-1032272692,positive,0.8859421610832214
2305,4/28/2023 8:25:44 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1032272677,positive,0.9309778809547424
2306,4/28/2023 8:59:59 AM,Lilly's blood cancer drug Jaypirca gets EMA greenlight for conditional approval,Seeking Alpha,https://seekingalpha.com/news/3961899-lillys-blood-cancer-drug-jaypirca-gets-ema-greenlight-conditional-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8779113292694092
2307,4/28/2023 9:30:31 AM,"Analysts Conflicted on These Healthcare Names: Baxter International (BAX), Eli Lilly & Co (LLY) and Quest Diagnostics (DGX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-baxter-international-bax-eli-lilly-co-lly-and-quest-diagnostics-dgx-1032272923,neutral,0.7011821866035461
2308,4/28/2023 2:40:41 PM,Mastercard To Rally Over 18%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/mastercard-to-rally-over-18-here-are-10-other-analyst-forecasts-for-friday-1032273736,positive,0.9135242104530334
2309,4/28/2023 4:12:21 PM,ImmunoGen Boosts Annual Guidance On Upbeat Uptake Of Newly Approved Ovarian Cancer Drug,Benzinga,/news/stocks/immunogen-boosts-annual-guidance-on-upbeat-uptake-of-newly-approved-ovarian-cancer-drug-1032274159,negative,0.9465528726577759
2310,4/29/2023 8:00:00 PM,"Pfizer, GSK, AbbVie among pharmas set to rise with May catalysts",Seeking Alpha,https://seekingalpha.com/news/3962345-pfizer-gsk-abbvie-among-pharmas-rise-may-catalysts?utm_source=businessinsider&utm_medium=referral,negative,0.9250966310501099
2311,4/29/2023 11:19:13 PM,Here Are The Best Sector ETFs And Major Sector-Moving Stocks In April,Benzinga,/news/etf/here-are-the-best-sector-etfs-and-major-sector-moving-stocks-in-april-1032275372,positive,0.9359045624732971
2312,5/1/2023 9:25:16 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1032277525,negative,0.595212996006012
2313,5/1/2023 11:10:34 AM,Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immunogen-imgn-and-eli-lilly-co-lly-1032277746,positive,0.9186499714851379
2314,5/1/2023 11:26:37 AM,Eli Lilly posts additional late-stage data for eczema therapy,Seeking Alpha,https://seekingalpha.com/news/3962508-eli-lilly-stock-posts-late-stage-data-eczema-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9106619358062744
2315,5/1/2023 12:45:00 PM,Up to 73% of Atopic Dermatitis Patients Taking Lilly's Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New Analysis,PR Newswire,/news/stocks/up-to-73-of-atopic-dermatitis-patients-taking-lilly-s-lebrikizumab-had-improved-or-cleared-skin-on-face-or-hands-in-new-analysis-1032277699,negative,0.8794214725494385
2316,5/1/2023 1:35:57 PM,Lilly Says Lebrikizumab Improved 'face Or Hand Dermatitis' At 16 Weeks ,RTTNews,/news/stocks/lilly-says-lebrikizumab-improved-face-or-hand-dermatitis-at-16-weeks-1032277786,neutral,0.4815581440925598
2317,5/1/2023 5:26:39 PM,Eli Lilly declares $1.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3962738-eli-lilly-and-company-declares-1_13-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9219610095024109
2318,5/1/2023 7:02:00 PM,Lilly Declares Second-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-second-quarter-2023-dividend-1032278949,positive,0.890753984451294
2319,5/2/2023 5:12:33 PM,"Eli Lilly, Sanofi to cap insulin prices at $35 per month for uninsured New Yorkers",Seeking Alpha,https://seekingalpha.com/news/3963574-lilly-sanofi-cap-monthly-insulin-prices-uninsured-in-new-york?utm_source=businessinsider&utm_medium=referral,positive,0.7450233697891235
2320,5/2/2023 6:25:36 PM,"Eli Lilly, Merck hit new 52-week highs",Seeking Alpha,https://seekingalpha.com/news/3963709-eli-lilly-merck-hit-new-52-week-highs?utm_source=businessinsider&utm_medium=referral,negative,0.82575923204422
2321,5/2/2023 8:09:10 PM,Bipartisan prescription drug price legislation hits snag - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3963865-bipartisan-prescription-drug-price-legislation-hits-snag-bloomberg?utm_source=businessinsider&utm_medium=referral,neutral,0.47859278321266174
2322,5/3/2023 10:00:58 AM,3 Stocks Quietly Hitting All-Time Highs (and Can Continue Higher) ,InvestorPlace,/news/stocks/3-stocks-quietly-hitting-all-time-highs-and-can-continue-higher-1032286732,negative,0.9110158085823059
2323,5/3/2023 10:08:01 AM,"Fentanyl overdose deaths rose 279%, oxycodone deaths fell in 5 years",Seeking Alpha,https://seekingalpha.com/news/3964240-fentanyl-overdose-deaths-rose-279-oxycodone-deaths-fell-in-5-years?utm_source=businessinsider&utm_medium=referral,negative,0.9210435748100281
2324,5/3/2023 11:13:53 AM,"Lilly stock surges after Alzheimer's drug donanemab slows cognitive decline by 35%, brain swelling seen in some",Seeking Alpha,https://seekingalpha.com/news/3964326-lilly-stock-rises-after-alzheimers-drug-donanemab-slows-cognitive-decline?utm_source=businessinsider&utm_medium=referral,negative,0.8118067979812622
2325,5/3/2023 12:19:32 PM,Eli Lilly: Donanemab Meets Primary Endpoint In Phase 3 Study Of Early Alzheimer's Disease ,RTTNews,/news/stocks/eli-lilly-donanemab-meets-primary-endpoint-in-phase-3-study-of-early-alzheimer-s-disease-1032286779,negative,0.5100886821746826
2326,5/3/2023 12:49:51 PM,"Eli Lilly, Livent, Super Micro Computer And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session",Benzinga,/news/stocks/eli-lilly-livent-super-micro-computer-and-other-big-stocks-moving-higher-in-wednesday-s-pre-market-session-1032286905,negative,0.9170119762420654
2327,5/3/2023 1:44:52 PM,LLY Stock Alert: Eli Lilly Announces Positive Alzheimer’s Drug Data,InvestorPlace,/news/stocks/lly-stock-alert-eli-lilly-announces-positive-alzheimers-drug-data-1032288023,negative,0.9226256012916565
2328,5/3/2023 2:04:45 PM,Why Is ImmunoGen (IMGN) Stock Up 125% Today?,InvestorPlace,/news/stocks/why-is-immunogen-imgn-stock-up-125-today-1032288066,negative,0.7452353239059448
2329,5/3/2023 5:13:59 PM,Novo Nordisk to report Q1 2023 results with Wegovy sales in focus,Seeking Alpha,https://seekingalpha.com/news/3964707-novo-nordisk-q1-2023-earnings-preview-wegovy-sales?utm_source=businessinsider&utm_medium=referral,positive,0.4959726631641388
2330,5/3/2023 5:31:14 PM,"Hot Stocks: GOLD rises on earnings; EL, AMCR fall on guidance cut; PSO gains on upgrade; LLY on strong clinical data; IEP slides",Seeking Alpha,https://seekingalpha.com/news/3964740-hot-stocks-gold-rise-on-earnings-el-amcr-fall-on-guidance-cut-pso-gain-on-upgrade-lly-on-strong-clinical-data-iep-slide?utm_source=businessinsider&utm_medium=referral,negative,0.8400464653968811
2331,5/3/2023 7:37:28 PM,Lilly sends Alzheimer’s drug developers higher after trial data,Seeking Alpha,https://seekingalpha.com/news/3964896-lilly-stock-sends-alzheimers-drug-developers-higher-after-trial-data?utm_source=businessinsider&utm_medium=referral,negative,0.8823214173316956
2332,5/4/2023 10:10:46 AM,7 A-Rated Stocks to Buy for May 2023,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-for-may-2023-1032291725,positive,0.9209400415420532
2333,5/4/2023 11:35:13 AM,BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032292212,negative,0.5093250274658203
2334,5/4/2023 12:25:54 PM,Credit Suisse Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/credit-suisse-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032292508,positive,0.7460410594940186
2335,5/4/2023 12:50:30 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), United Therapeutics (UTHR) and Bausch + Lomb Corporation (BLCO)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-united-therapeutics-uthr-and-bausch-+-lomb-corporation-blco-1032292666,neutral,0.7003825902938843
2336,5/4/2023 7:29:16 PM,Which Healthcare Stock Is a Compelling Pick for the Long Haul?,InvestorPlace,/news/stocks/which-healthcare-stock-is-a-compelling-pick-for-the-long-haul-1032294048,positive,0.8750478029251099
2337,5/4/2023 8:34:50 PM,Mastercard To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Thursday,Benzinga,/news/stocks/mastercard-to-rally-around-27-here-are-10-other-analyst-forecasts-for-thursday-1032293945,positive,0.9164426326751709
2338,5/4/2023 9:06:04 PM,"Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen",Benzinga,/news/stocks/analysts-say-eli-lilly-s-donanemab-in-alzheimer-s-is-encouraging-outline-potential-implications-for-biogen-1032294014,negative,0.9320789575576782
2339,5/5/2023 11:46:28 AM,"Dividend Roundup: Apple, PepsiCo, UPS, Visa and more",Seeking Alpha,https://seekingalpha.com/news/3965910-dividend-roundup-pepsico-ups-visa-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9437497854232788
2340,5/6/2023 8:00:00 PM,"Eli Lilly, Humana among best health care names in defensive environment - BofA",Seeking Alpha,https://seekingalpha.com/news/3966792-eli-lilly-humana-among-best-health-care-names-defensive-environment?utm_source=businessinsider&utm_medium=referral,negative,0.6749860644340515
2341,5/7/2023 4:00:27 PM,Spending on weight loss drugs to rise 378% in 2023 – 2027: report,Seeking Alpha,https://seekingalpha.com/news/3966814-spending-weight-loss-drugs-wegovy-mounjaro-2023-2027?utm_source=businessinsider&utm_medium=referral,negative,0.9277639389038086
2342,5/9/2023 10:45:43 AM,3 Dividend Stocks to Buy as the Healthcare Sector Booms in 2023,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-as-the-healthcare-sector-booms-in-2023-1032306053,positive,0.6284603476524353
2343,5/9/2023 11:32:42 AM,Lilly touts more data for ulcerative colitis therapy mirikizumab,Seeking Alpha,https://seekingalpha.com/news/3967871-lilly-touts-more-data-for-ulcerative-colitis-therapy-mirikizumab?utm_source=businessinsider&utm_medium=referral,positive,0.9320084452629089
2344,5/9/2023 12:45:00 PM,"Lilly Discloses First-in-Class, Interim Phase 2 Data in Pediatric Patients and New Analysis from Phase 3 Program in Adult Patients for Mirikizumab in Ulcerative Colitis",PR Newswire,/news/stocks/lilly-discloses-first-in-class-interim-phase-2-data-in-pediatric-patients-and-new-analysis-from-phase-3-program-in-adult-patients-for-mirikizumab-in-ulcerative-colitis-1032306025,positive,0.7624350190162659
2345,5/9/2023 2:13:37 PM,Eli Lilly Reports Interim Results From The Phase 2 Study Of Mirikizumab ,RTTNews,/news/stocks/eli-lilly-reports-interim-results-from-the-phase-2-study-of-mirikizumab-1032306523,positive,0.8914097547531128
2346,5/9/2023 3:00:00 PM,Lilly's Social Impact Venture Capital Portfolio Poised to Grow to $300 Million with New $50 Million Allocation,PR Newswire,/news/stocks/lilly-s-social-impact-venture-capital-portfolio-poised-to-grow-to-300-million-with-new-50-million-allocation-1032307047,negative,0.9143226146697998
2347,5/10/2023 9:25:43 AM,Bank of America Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032311424,positive,0.844591498374939
2348,5/10/2023 9:54:01 AM,"Boehringer, Zealand's drug helps cut weight up to 14.9%, meets phase 2 trial's goal",Seeking Alpha,https://seekingalpha.com/news/3968883-boehringer-zealands-drug-helps-cut-weight-by-149-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.916483461856842
2349,5/10/2023 5:27:29 PM,"Obesity Drug Achieves ~15% Weight Loss - Zealand Pharma-Boehringer Ingelheim Partnered Drug May Compete With Novo Nordisk, Eli Lilly",Benzinga,/news/stocks/obesity-drug-achieves-~15-weight-loss---zealand-pharma-boehringer-ingelheim-partnered-drug-may-compete-with-novo-nordisk-eli-lilly-1032313298,negative,0.826899528503418
2350,5/10/2023 9:47:30 PM,ELi Lilly won't raise prices of its currently marketed insulins - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3969678-eli-lilly-wont-raise-prices-of-currently-marketed-insulin?utm_source=businessinsider&utm_medium=referral,positive,0.8876135945320129
2351,5/11/2023 9:56:21 AM,"Lundbeck, Otsuka's Rexulti wins FDA approval for agitation linked with Alzheimer's",Seeking Alpha,https://seekingalpha.com/news/3969842-lundbeck-otsukas-rexulti-wins-fda-nod-for-alzheimers-agitation?utm_source=businessinsider&utm_medium=referral,negative,0.8899219632148743
2352,5/11/2023 10:09:45 AM,The 3 Best MedTech Stocks to Watch in May 2023,InvestorPlace,/news/stocks/the-3-best-medtech-stocks-to-watch-in-may-2023-1032317056,positive,0.8671631813049316
2353,5/11/2023 4:00:00 PM,Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting,PR Newswire,/news/stocks/loxo-lilly-announces-details-of-presentations-at-2023-european-hematology-association-eha-annual-meeting-1032318365,positive,0.9455694556236267
2354,5/12/2023 8:40:50 AM,Obesity review: World Health Organization weighs in on weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3970649-obesity-review-world-health-organization-weighs-in-on-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.846613347530365
2355,5/12/2023 5:11:43 PM,AI-Run ETF Dumps Apple In Favor Of This Chip Stock And Hints At New Opportunity Brewing In Market,Benzinga,/news/etf/ai-run-etf-dumps-apple-in-favor-of-this-chip-stock-and-hints-at-new-opportunity-brewing-in-market-1032323317,neutral,0.5373362302780151
2356,5/14/2023 4:00:49 PM,Biogen’s new Alzheimer’s drug to raise annual Medicare costs by up to $5B – study,Seeking Alpha,https://seekingalpha.com/news/3971102-biogen-new-alzheimers-drug-leqembi-raise-medicare-costs?utm_source=businessinsider&utm_medium=referral,negative,0.9365440011024475
2357,5/15/2023 1:25:15 PM,Eli Lilly & Co (LLY) Gets a Buy from Morgan Stanley,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-morgan-stanley-1032327631,negative,0.5285465717315674
2358,5/15/2023 7:01:51 PM,What 20 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-20-analyst-ratings-have-to-say-about-eli-lilly-1032328277,positive,0.9423834085464478
2359,5/15/2023 10:03:22 PM,"Druckenmiller's Duquesne adds Microsoft, IQVIA, exits Cenovus Energy, Lennar",Seeking Alpha,https://seekingalpha.com/news/3971810-druckenmillers-duquesne-adds-microsoft-iqvia-exits-cenovus-energy-lennar?utm_source=businessinsider&utm_medium=referral,positive,0.9470711350440979
2360,5/16/2023 1:07:42 PM,"Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront  cash/equity deal",Seeking Alpha,https://seekingalpha.com/news/3972036-lilly-scribe-team-up-for-neuro-diseases-crispr-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.6606525778770447
2361,5/17/2023 12:30:41 AM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Compugen (CGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-compugen-cgen-and-eli-lilly-co-lly-1032332838,positive,0.9251680374145508
2362,5/17/2023 8:47:25 PM,Shhh! 3 Healthcare Stocks Quietly Hitting 52-Week Highs,InvestorPlace,/news/stocks/shhh-3-healthcare-stocks-quietly-hitting-52-week-highs-1032336112,negative,0.6872824430465698
2363,5/18/2023 11:35:07 AM,Lilly's rheumatoid arthritis drug peresolimab shows promise in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3972930-lillys-rheumatoid-arthritis-drug-peresolimab-shows-promise-in-trial?utm_source=businessinsider&utm_medium=referral,negative,0.9213806390762329
2364,5/18/2023 12:45:00 PM,Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine,PR Newswire,/news/stocks/lilly-s-peresolimab-phase-2a-rheumatoid-arthritis-trial-published-in-the-new-england-journal-of-medicine-1032337009,positive,0.8506712913513184
2365,5/18/2023 3:30:11 PM,Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer’s study,Seeking Alpha,https://seekingalpha.com/news/3973090-cognition-stock-rises-after-ct1812-shows-promise-in-alzheimers?utm_source=businessinsider&utm_medium=referral,negative,0.9288967251777649
2366,5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,neutral,0.7930806875228882
2367,5/18/2023 7:30:02 PM,"Sen. Wyden presses HHS, CMS on access to new Alzheimer's therapies",Seeking Alpha,https://seekingalpha.com/news/3973210-sen-ron-wyden-presses-hhs-cms-access-new-alzheimers-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.8973407745361328
2368,5/19/2023 4:51:21 PM,"WHO Recommends New COVID Booster Shots To Target XBB Variants, Despite Slower Uptake",Benzinga,/news/stocks/who-recommends-new-covid-booster-shots-to-target-xbb-variants-despite-slower-uptake-1032340045,negative,0.6635165810585022
2369,5/20/2023 8:00:39 PM,Novo Nordisk Ozempic sales expected to reach $17B in 2029,Seeking Alpha,https://seekingalpha.com/news/3973617-novo-nordisk-ozempic-sales-expected-reach-17b-2029?utm_source=businessinsider&utm_medium=referral,negative,0.6512323021888733
2370,5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.7357143759727478
2371,5/22/2023 10:23:17 AM,Novo Nordisk gains as study shows cardiovascular benefits of obesity drug,Seeking Alpha,https://seekingalpha.com/news/3973701-novo-nordisk-obesity-drug-linked-heart-health?utm_source=businessinsider&utm_medium=referral,negative,0.9317561388015747
2372,5/22/2023 11:25:05 AM,BMO Capital Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-remains-a-buy-on-eli-lilly-co-lly-1032342314,positive,0.9430696964263916
2373,5/22/2023 1:05:48 PM,The 3 Best Momentum Stocks to Buy in May 2023,InvestorPlace,/news/stocks/momentum-stocks-to-buy-1032342750,positive,0.9131151437759399
2374,5/22/2023 4:00:00 PM,Lilly ESG Report Highlights Progress Towards Sustainability Goals,PR Newswire,/news/stocks/lilly-esg-report-highlights-progress-towards-sustainability-goals-1032342887,negative,0.8878563642501831
2375,5/22/2023 4:30:42 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Bausch Health Companies (BHC) and Resmed (RMD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-bausch-health-companies-bhc-and-resmed-rmd-1032343304,positive,0.922945499420166
2376,5/23/2023 3:25:08 AM,Bank of America Securities Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032343912,positive,0.8028758764266968
2377,5/23/2023 1:49:23 PM,Microsoft To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Tuesday,Benzinga,/news/stocks/microsoft-to-rally-around-25-here-are-10-other-analyst-forecasts-for-tuesday-1032345031,positive,0.9144173860549927
2378,5/23/2023 2:51:44 PM,Pfizer stock yet to imply obesity drug’s blockbuster potential – Cantor,Seeking Alpha,https://seekingalpha.com/news/3974223-pfizer-stock-to-imply-obesity-drugs-potential-cantor?utm_source=businessinsider&utm_medium=referral,negative,0.7164328098297119
2379,5/24/2023 12:18:40 AM,7 Stocks That Could Be the Next $2 Trillion-Dollar Companies,InvestorPlace,/news/stocks/7-stocks-that-could-be-the-next-2-trillion-dollar-companies-1032346826,positive,0.939713716506958
2380,5/24/2023 2:00:57 PM,Zura Bio soars 37% as Raymond James starts with Strong Buy,Seeking Alpha,https://seekingalpha.com/news/3974613-zura-bio-stock-soars-raymond-james-strong-buy?utm_source=businessinsider&utm_medium=referral,negative,0.9122418165206909
2381,5/24/2023 8:42:38 PM,"Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside",Benzinga,/news/stocks/zura-bio-s-veteran-leadership-eyes-repeat-success-confident-analyst-sees-150-upside-1032349587,negative,0.9441695213317871
2382,5/25/2023 4:29:40 PM,7 Top Stock Tips for June 2023,InvestorPlace,/news/stocks/7-top-stock-tips-for-june-2023-1032352462,positive,0.9229313731193542
2383,5/26/2023 10:19:56 AM,3 Biotech Stocks Sitting on Huge-Upside Catalysts,InvestorPlace,/news/stocks/3-biotech-stocks-sitting-on-huge-upside-catalysts-1032353942,positive,0.5751631855964661
2384,5/26/2023 10:38:37 AM,Elon Musk's Neuralink gets FDA nod to start human trial of brain implant,Seeking Alpha,https://seekingalpha.com/news/3975338-elon-musks-neuralink-gets-fda-nod-to-start-human-trial-of-brain-implant?utm_source=businessinsider&utm_medium=referral,negative,0.5858262777328491
2385,5/26/2023 12:30:32 PM,"Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-allogene-therapeutics-allo-eli-lilly-co-lly-1032354317,positive,0.7134908437728882
2386,5/26/2023 4:30:27 PM,"Analysts Offer Insights on Healthcare Companies: Centene (CNC), Eli Lilly & Co (LLY) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-centene-cnc-eli-lilly-co-lly-and-sarepta-therapeutics-srpt-1032354885,positive,0.9099828600883484
2387,5/27/2023 6:04:05 PM,3 High-Growth Stocks to Buy Before They Join the Trillion-Dollar Club,InvestorPlace,/news/stocks/3-high-growth-stocks-to-buy-before-they-join-the-trillion-dollar-club-1032355503,positive,0.9199323058128357
2388,5/28/2023 10:27:56 PM,7 Overvalued Value Stocks to Sell Before June 2023,InvestorPlace,/news/stocks/7-overvalued-value-stocks-to-sell-before-june-2023-1032355835,positive,0.9228505492210388
2389,5/29/2023 6:05:36 PM,SVB Securities Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032356756,positive,0.6265906095504761
2390,5/30/2023 2:23:23 AM,"LLY, DXCM, or ISRG: Which Healthcare Stock is the Most Attractive Pick?",TipRanks,/news/stocks/lly-dxcm-or-isrg-which-healthcare-stock-is-the-most-attractive-pick-1032356958,positive,0.9260873198509216
2391,5/30/2023 4:00:00 PM,Lilly to Participate in Goldman Sachs Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-goldman-sachs-global-healthcare-conference-1032358529,positive,0.892741322517395
2392,5/30/2023 7:30:57 PM,Eli Lilly partners with XtalPi on AI drug discovery in up to $250M deal,Seeking Alpha,https://seekingalpha.com/news/3975939-eli-lilly-partners-xtalpi-artificial-intelligence-drug-discovery-250m-deal?utm_source=businessinsider&utm_medium=referral,negative,0.7498099207878113
2393,6/1/2023 2:33:27 PM,Medicare to cover Alzheimer's drugs granted full FDA approval,Seeking Alpha,https://seekingalpha.com/news/3976628-medicare-cover-alzheimers-drugs-granted-full-fda-approval?utm_source=businessinsider&utm_medium=referral,negative,0.8785544037818909
2394,6/1/2023 5:01:15 PM,Eli Lilly beats Johnson & Johnson to become world's most valuable drugmaker,Seeking Alpha,https://seekingalpha.com/news/3976741-lilly-stock-pips-jnj-stock-become-most-valuable-pharma?utm_source=businessinsider&utm_medium=referral,negative,0.8911044597625732
2395,6/2/2023 2:00:00 PM,Lilly Highlights Verzenio® (abemaciclib) and Jaypirca™ (pirtobrutinib) Data at 2023 ASCO® Annual Meeting,PR Newswire,/news/stocks/lilly-highlights-verzenio-abemaciclib-and-jaypirca-pirtobrutinib-data-at-2023-asco-annual-meeting-1032367099,positive,0.8089506030082703
2396,6/3/2023 4:00:00 PM,ASCO 2023: What to look for at oncology's biggest meeting,Seeking Alpha,https://seekingalpha.com/news/3976898-asco-2023-what-look-for-oncology-biggest-meeting?utm_source=businessinsider&utm_medium=referral,positive,0.9382763504981995
2397,6/4/2023 4:00:08 PM,Morgan Stanley sees broader MedTech impact from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3977410-morgan-stanley-sees-medtech-impact-from-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.44781309366226196
2398,6/4/2023 6:53:53 PM,"Novo Nordisk, Lilly facing increased competition in obesity drug market",Seeking Alpha,https://seekingalpha.com/news/3977415-novo-nordisk-lilly-facing-increased-competition-in-obesity-drug-market?utm_source=businessinsider&utm_medium=referral,negative,0.6209858059883118
2399,6/5/2023 9:02:14 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032369720,negative,0.5521676540374756
2400,6/5/2023 11:15:09 AM,BMO Capital Gives a Buy Rating to Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-gives-a-buy-rating-to-eli-lilly-co-lly-1032369990,positive,0.8319082856178284
2401,6/5/2023 11:31:25 AM,Akero gains 15% on potential of liver disease drug and weight loss therapy combo,Seeking Alpha,https://seekingalpha.com/news/3977502-akero-posts-data-liver-disease-drug-glp-1-combo?utm_source=businessinsider&utm_medium=referral,negative,0.9485821723937988
2402,6/6/2023 12:48:16 AM,7 Growth Stocks to Sell in June Before They Crash and Burn,InvestorPlace,/news/stocks/7-growth-stocks-to-sell-in-june-before-they-crash-and-burn-1032371563,positive,0.7631572484970093
2403,6/7/2023 8:45:27 AM,Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bank-of-america-securities-1032375162,positive,0.5223994851112366
2404,6/7/2023 9:55:24 AM,SVB Securities Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032375300,positive,0.7664648294448853
2405,6/7/2023 10:50:17 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Oscar Health (OSCR) and Doximity (DOCS)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-oscar-health-oscr-and-doximity-docs-1032375473,positive,0.9281877279281616
2406,6/7/2023 7:46:56 PM,"Eli Lilly, Takeda must face racketeering claims over Actos diabetes drug, judge rules",Seeking Alpha,https://seekingalpha.com/news/3978336-eli-lilly-takeda-hit-with-racketeering-class-action-lawsuit?utm_source=businessinsider&utm_medium=referral,neutral,0.5738555788993835
2407,6/7/2023 10:30:39 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Guardant Health (GH) and Coya Therapeutics, Inc. (COYA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-guardant-health-gh-and-coya-therapeutics-inc-coya-1032377089,positive,0.9235747456550598
2408,6/9/2023 1:21:31 AM,Want to Invest in Republican or Democratic Stocks? Check Out These 2 ETFs,TipRanks,/news/stocks/want-to-invest-in-republican-or-democratic-stocks-check-out-these-2-etfs-1032379619,positive,0.9269009232521057
2409,6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral,positive,0.5447219014167786
2410,6/11/2023 4:00:02 PM,Alzheimer’s disease market expected to reach $14B globally in 2030,Seeking Alpha,https://seekingalpha.com/news/3979065-biogens-leqembi-drive-alzheimers-market-2030?utm_source=businessinsider&utm_medium=referral,negative,0.863539457321167
2411,6/12/2023 11:50:11 AM,"Analysts Are Bullish on These Healthcare Stocks: Intellia Therapeutics (NTLA), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-intellia-therapeutics-ntla-eli-lilly-co-lly-1032383274,positive,0.7473872900009155
2412,6/14/2023 12:12:36 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032387458,negative,0.5521676540374756
2413,6/15/2023 10:56:49 AM,Verve teams with Lilly to advance vivo gene editing program targeting Lp(a),Seeking Alpha,https://seekingalpha.com/news/3980078-verve-teams-with-lilly-to-advance-vivo-gene-editing-program-targeting-lpa?utm_source=businessinsider&utm_medium=referral,positive,0.6187905669212341
2414,6/16/2023 2:47:23 PM,Eli Lilly diabetes med Mounjaro on intermittent backorder,Seeking Alpha,https://seekingalpha.com/news/3980497-eli-lilly-diabetes-med-mounjaro-intermittent-backorder?utm_source=businessinsider&utm_medium=referral,neutral,0.5999657511711121
2415,6/16/2023 5:21:44 PM,Eli Lilly migraine drug Emgality fails to beat Pfizer's Nurtec,Seeking Alpha,https://seekingalpha.com/news/3980545-eli-lilly-migraine-drug-emgality-fails-beat-pfizer-nurtec?utm_source=businessinsider&utm_medium=referral,neutral,0.5928570032119751
2416,6/16/2023 6:00:00 PM,First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention,PR Newswire,/news/stocks/first-of-its-kind-head-to-head-clinical-trial-reaffirms-the-efficacy-of-emgality-in-episodic-migraine-prevention-1032394793,negative,0.9143361449241638
2417,6/19/2023 11:05:11 AM,BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-eli-lilly-co-lly-1032396626,positive,0.901610255241394
2418,6/20/2023 11:03:12 AM,Eli Lilly to acquire oral drug developer Dice Therapeutics for over $2B,Seeking Alpha,https://seekingalpha.com/news/3980764-eli-lilly-stock-to-buy-dice-therapeutics-for-over-2b?utm_source=businessinsider&utm_medium=referral,positive,0.8286346793174744
2419,6/20/2023 12:45:00 PM,Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology,PR Newswire,/news/stocks/lilly-to-acquire-dice-therapeutics-to-advance-innovation-in-immunology-1032398451,negative,0.6712785363197327
2420,6/20/2023 12:59:48 PM,Eli Lilly To Acquire DICE Therapeutics For $48/share All-cash Deal ,RTTNews,/news/stocks/eli-lilly-to-acquire-dice-therapeutics-for-48-share-all-cash-deal-1032398495,positive,0.912817656993866
2421,6/20/2023 1:21:21 PM,"4 stocks to watch on Tuesday: FedEx, AT&T and more",Seeking Alpha,https://seekingalpha.com/news/3980909-4-stocks-to-watch-on-tuesday-fedex-att-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9272924065589905
2422,6/20/2023 1:31:08 PM,Why Is Dice Therapeutics (DICE) Stock Up 38% Today?,InvestorPlace,/news/stocks/why-is-dice-therapeutics-dice-stock-up-38-today-1032399204,negative,0.8191302418708801
2423,6/20/2023 2:00:00 PM,"Lilly Teams up with the American Diabetes Association and Adam Duvall to Launch ""Tap the Cap""",PR Newswire,/news/stocks/lilly-teams-up-with-the-american-diabetes-association-and-adam-duvall-to-launch-tap-the-cap-1032398651,negative,0.7149317264556885
2424,6/20/2023 2:18:17 PM,"Biggest stock movers today: Nikola, Avis Budget, DICE Therapeutics, Faraday Future and more",Seeking Alpha,https://seekingalpha.com/news/3980740-biggest-stock-movers-today-nikola-arcellx-beam-global-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9031307697296143
2425,6/20/2023 3:16:39 PM,Why DICE Therapeutics Stock Is Soaring Tuesday,Benzinga,/news/stocks/why-dice-therapeutics-stock-is-soaring-tuesday-1032399129,negative,0.8268378973007202
2426,6/20/2023 3:51:59 PM,Eli Lilly To Acquire Small Company DICE Therapeutics Focused On Autoimmune Diseases For $2B,Benzinga,/news/stocks/eli-lilly-to-acquire-small-company-dice-therapeutics-focused-on-autoimmune-diseases-for-2b-1032399256,positive,0.8468834757804871
2427,6/20/2023 4:31:26 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), RegenXBio (RGNX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-regenxbio-rgnx-1032399915,positive,0.6071733236312866
2428,6/20/2023 4:36:03 PM,"Alexandria Research completes sale of five facilities, reiterates 2023 guidance",Seeking Alpha,https://seekingalpha.com/news/3981077-alexandria-research-completes-sale-of-five-facilities-reiterates-2023-guidance?utm_source=businessinsider&utm_medium=referral,positive,0.9287493228912354
2429,6/20/2023 7:37:00 PM,Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association's® 83rd Scientific Sessions,PR Newswire,/news/stocks/lilly-to-present-new-research-in-the-treatment-of-diabetes-and-obesity-at-the-american-diabetes-association-s-83rd-scientific-sessions-1032400003,positive,0.7586247324943542
2430,6/20/2023 9:02:27 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032400114,positive,0.8414194583892822
2431,6/21/2023 4:34:09 AM,FDA Approves Boehringer Ingelheim' Jardiance And Synjardy To Treat Pediatric Type 2 Diabetes ,RTTNews,/news/stocks/fda-approves-boehringer-ingelheim-jardiance-and-synjardy-to-treat-pediatric-type-2-diabetes-1032400467,negative,0.7947174310684204
2432,6/21/2023 11:53:36 AM,Eli Lilly and partner win FDA nod to include children for diabetes drugs,Seeking Alpha,https://seekingalpha.com/news/3981352-eli-lilly-partner-win-fda-nod-childrens-diabetes-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.6755637526512146
2433,6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,neutral,0.9452309608459473
2434,6/21/2023 5:17:16 PM,Key Data On Novo Nordisk's Weight Loss Drug Wegovy Due In July: Biotech Analyst Details Likely Impact On Lilly's Stock,Benzinga,/news/stocks/key-data-on-novo-nordisk-s-weight-loss-drug-wegovy-due-in-july-biotech-analyst-details-likely-impact-on-lilly-s-stock-1032402337,positive,0.6078782677650452
2435,6/21/2023 7:15:00 PM,US FDA approves Jardiance® (empagliflozin) for the treatment of type 2 diabetes in children 10 years and older,PR Newswire,/news/stocks/us-fda-approves-jardiance-empagliflozin-for-the-treatment-of-type-2-diabetes-in-children-10-years-and-older-1032402663,negative,0.8159244060516357
2436,6/22/2023 9:55:37 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032403901,positive,0.90191650390625
2437,6/22/2023 11:03:39 AM,Novo Nordisk falls after safety signal linked to weight loss drug class,Seeking Alpha,https://seekingalpha.com/news/3981844-novo-nordisk-stock-falls-safety-signal-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.938318133354187
2438,6/22/2023 8:54:22 PM,"Terns Pharma Has 35% Upside According To This Analyst, NASH Asset To Drive Valuation",Benzinga,/news/stocks/terns-pharma-has-35-upside-according-to-this-analyst-nash-asset-to-drive-valuation-1032405573,positive,0.8836092352867126
2439,6/24/2023 3:50:00 AM,"Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we...",PR Newswire,/news/stocks/lilly-s-phase-2-results-published-in-the-new-england-journal-of-medicine-show-orforglipron-a-once-daily-oral-nonpeptide-glp-1-receptor-agonist-achieved-up-to-14-7-mean-weight-reduction-at-36-we-1032407804,negative,0.9441550374031067
2440,6/24/2023 11:48:37 AM,Eli Lilly says oral obesity therapy caused up to 15% weight loss,Seeking Alpha,https://seekingalpha.com/news/3982546-eli-lilly-oral-obesity-drug-cut-15-percent-weight?utm_source=businessinsider&utm_medium=referral,positive,0.697614312171936
2441,6/24/2023 5:18:00 PM,Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes,PR Newswire,/news/stocks/lilly-s-surmount-2-results-published-in-the-lancet-show-tirzepatide-achieved-a-mean-weight-reduction-of-15-7-at-the-highest-dose-15-mg-in-adults-with-obesity-or-overweight-and-type-2-diabetes-1032408028,negative,0.9246577620506287
2442,6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral,neutral,0.6917394399642944
2443,6/26/2023 7:10:14 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), MoonLake Immunotherapeutics (MLTX) and Jazz Pharmaceuticals (JAZZ)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-moonlake-immunotherapeutics-mltx-and-jazz-pharmaceuticals-jazz-1032408813,neutral,0.7435212731361389
2444,6/26/2023 9:20:36 AM,Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sanofi-othersnynf-and-eli-lilly-co-lly-1032409063,positive,0.9246612191200256
2445,6/26/2023 10:11:55 AM,Pills for obesity: Novo Nordisk records success in late-stage trials,Seeking Alpha,https://seekingalpha.com/news/3982632-novo-nordisk-high-dose-weight-loss-pills?utm_source=businessinsider&utm_medium=referral,negative,0.855697751045227
2446,6/26/2023 1:01:33 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), CymaBay Therapeutics (CBAY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-cymabay-therapeutics-cbay-1032409777,negative,0.6060064435005188
2447,6/26/2023 1:38:25 PM,ALX Oncology gastric cancer candidate wins orphan drug status from EC,Seeking Alpha,https://seekingalpha.com/news/3982736-alx-oncology-gastric-cancer-candidate-evorpacept-orphan-drug-european-commission?utm_source=businessinsider&utm_medium=referral,negative,0.8955455422401428
2448,6/26/2023 2:28:42 PM,Pfizer to drop studies for weight-loss pill,Seeking Alpha,https://seekingalpha.com/news/3982779-pfizer-stock-falls-plans-discontinue-weight-loss-pill?utm_source=businessinsider&utm_medium=referral,neutral,0.942676305770874
2449,6/26/2023 3:27:00 PM,Eli Lilly declares $1.13 dividend,Seeking Alpha,https://seekingalpha.com/news/3982806-eli-lilly-and-company-declares-1_13-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9219610095024109
2450,6/26/2023 4:36:33 PM,Pfizer wins FDA approval for oral hair loss therapy,Seeking Alpha,https://seekingalpha.com/news/3982832-pfizer-wins-fda-nod-oral-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral,negative,0.899830162525177
2451,6/26/2023 5:06:00 PM,Lilly Declares Third-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-third-quarter-2023-dividend-1032410144,positive,0.9076256155967712
2452,6/26/2023 11:15:58 PM,Lilly says patients saw mean weight reduction of 58 lbs on retatrutide,Seeking Alpha,https://seekingalpha.com/news/3983017-lilly-says-patients-saw-mean-weight-reduction-of-58-lbs-on-retatrutide?utm_source=businessinsider&utm_medium=referral,negative,0.8072904944419861
2453,6/27/2023 12:00:00 AM,Lilly's phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity...,PR Newswire,/news/stocks/lilly-s-phase-2-retatrutide-results-published-in-the-new-england-journal-of-medicine-show-the-investigational-molecule-achieved-up-to-17-5-mean-weight-reduction-at-24-weeks-in-adults-with-obesity-1032410879,negative,0.9430494904518127
2454,6/27/2023 4:27:43 AM,Eli Lilly's Obesity Drug Retatrutide Leads To 24.2% Weight Loss In Phase 2 Trial ,RTTNews,/news/stocks/eli-lilly-s-obesity-drug-retatrutide-leads-to-24-2-weight-loss-in-phase-2-trial-1032410968,negative,0.7496195435523987
2455,6/27/2023 8:50:47 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Amedisys (AMED),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-amedisys-amed-1032411532,positive,0.9241170883178711
2456,6/27/2023 4:25:25 PM,Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032413085,positive,0.7646060585975647
2457,6/27/2023 5:03:37 PM,Eli Lilly highlights weight loss agent’s potential in fatty liver,Seeking Alpha,https://seekingalpha.com/news/3983279-eli-lilly-shows-weight-loss-agents-potential-fatty-liver?utm_source=businessinsider&utm_medium=referral,negative,0.6799625158309937
2458,6/27/2023 8:52:55 PM,Why did Madrigal Pharma stock drop today? Lilly fatty liver data,Seeking Alpha,https://seekingalpha.com/news/3983432-why-did-madrigal-pharma-stock-drop-today-eli-lilly-fatty-liver-data?utm_source=businessinsider&utm_medium=referral,neutral,0.915253758430481
2459,6/27/2023 9:13:52 PM,Here’s 2023’s Best-Performing Actively-Managed ETF,TipRanks,/news/stocks/here-s-2023-s-best-performing-actively-managed-etf-1032413585,negative,0.6680084466934204
2460,6/28/2023 1:45:33 PM,Eli Lilly & Co (LLY) Receives a Buy from SVB Securities,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-svb-securities-1032415335,positive,0.7293986678123474
2461,6/28/2023 8:53:46 PM,"Terns Pharmaceuticals Is ""Attractively Priced"" Despite Pressure From Eli Lilly's Obesity Data, Analyst Says",Benzinga,/news/stocks/terns-pharmaceuticals-is-attractively-priced-despite-pressure-from-eli-lilly-s-obesity-data-analyst-says-1032416121,negative,0.9473310708999634
2462,6/29/2023 1:26:45 AM,Looking for a Market-Beating Growth ETF? Check Out VUG,TipRanks,/news/stocks/looking-for-a-market-beating-growth-etf-check-out-vug-1032416446,positive,0.8317864537239075
2463,6/29/2023 11:11:28 AM,Sigilon stock skyrockets 650% on buyout deal with Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/3984041-sigilon-stock-skyrockets-buyout-deal-eli-lilly?utm_source=businessinsider&utm_medium=referral,negative,0.7789270877838135
2464,6/29/2023 11:27:32 AM,Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday,InvestorPlace,/news/stocks/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-29th-1032417552,neutral,0.48035502433776855
2465,6/29/2023 11:59:44 AM,Why Is Sigilon Therapeutics (SGTX) Stock Up 691% Today?,InvestorPlace,/news/stocks/why-is-sigilon-therapeutics-sgtx-stock-up-691-today-1032417665,negative,0.7440022826194763
2466,6/29/2023 12:45:00 PM,Lilly to Acquire Sigilon Therapeutics,PR Newswire,/news/stocks/lilly-to-acquire-sigilon-therapeutics-1032417388,positive,0.9336897730827332
2467,6/29/2023 1:06:41 PM,Eli Lilly To Acquire Sigilon Therapeutics ,RTTNews,/news/stocks/eli-lilly-to-acquire-sigilon-therapeutics-1032417474,positive,0.9343615174293518
2468,6/29/2023 2:48:14 PM,Viking Therapeutics gains as Street defends after selloff,Seeking Alpha,https://seekingalpha.com/news/3984135-viking-therapeutics-stock-gains-street-defends-post-selloff?utm_source=businessinsider&utm_medium=referral,negative,0.764456033706665
2469,6/29/2023 6:00:35 PM,The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-now-june-2023-1032418755,positive,0.9014137983322144
2470,6/30/2023 10:25:17 AM,3 Dividend Stocks That Have Insiders Running for the Exit,InvestorPlace,/news/stocks/3-dividend-stocks-to-avoid-as-insiders-head-for-the-exits-1032420229,positive,0.8563302755355835
2471,6/30/2023 11:48:19 AM,"Dividend Roundup: General Mills, Mastercard, JPMorgan, Verizon, and more",Seeking Alpha,https://seekingalpha.com/news/3984403-dividend-roundup-general-mills-mastercard-jpmorgan-verizon-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9471454620361328
2472,6/30/2023 4:39:00 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: June 2023,InvestorPlace,/news/stocks/pharma-stocks-to-buy-1032421255,positive,0.9032686352729797
2473,6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.901573121547699
2474,7/1/2023 8:00:00 PM,"Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst",Seeking Alpha,https://seekingalpha.com/news/3984694-lilly-vertex-top-pharma-performers-h1-moderna-pfizer-worst?utm_source=businessinsider&utm_medium=referral,negative,0.6028405427932739
2475,7/3/2023 10:05:15 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032423088,positive,0.8035197257995605
2476,7/3/2023 11:35:08 AM,BMO Capital Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-eli-lilly-co-lly-1032423316,positive,0.901610255241394
2477,7/5/2023 7:38:26 PM,Cassava Sciences (SAVA) Stock Drops Despite Positive Trial Results,InvestorPlace,/news/stocks/cassava-sciences-sava-stock-drops-despite-positive-trial-results-1032428453,neutral,0.965555727481842
2478,7/6/2023 1:45:00 PM,New England Journal of Medicine Publishes BRUIN Phase 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,PR Newswire,/news/stocks/new-england-journal-of-medicine-publishes-bruin-phase-1-2-trial-data-for-pirtobrutinib-in-btk-inhibitor-pre-treated-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-1032429845,positive,0.708109974861145
2479,7/6/2023 6:30:39 PM,Novo Nordisk sues Florida pharmacy for allegedly selling Wegovy copycat,Seeking Alpha,https://seekingalpha.com/news/3986050-novo-nordisk-sues-florida-pharmacy-allegedly-selling-wegovy-copycat?utm_source=businessinsider&utm_medium=referral,neutral,0.9151103496551514
2480,7/7/2023 6:16:21 PM,FDA Approves Biogen's Alzheimer's Drug: Here Are Other Companies With Treatments In The Pipeline,Benzinga,/news/stocks/fda-approves-biogen-s-alzheimer-s-drug-here-are-other-companies-with-treatments-in-the-pipeline-1032432660,positive,0.9400222301483154
2481,7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,negative,0.937191367149353
2482,7/9/2023 7:34:36 PM,The 7 Best Value Stocks to Buy in July,InvestorPlace,/news/stocks/the-7-best-value-stocks-to-buy-in-july-1032433488,positive,0.9127336144447327
2483,7/10/2023 8:20:06 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Syndax Pharmaceuticals (SNDX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-syndax-pharmaceuticals-sndx-1032434231,positive,0.9185888171195984
2484,7/11/2023 4:00:00 PM,Lilly Announces Webcast to Provide Alzheimer's Disease Update at AAIC,PR Newswire,/news/stocks/lilly-announces-webcast-to-provide-alzheimer-s-disease-update-at-aaic-1032438083,positive,0.8906348943710327
2485,7/11/2023 5:31:05 PM,EU expands probe into suicide risk linked to weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3986847-eu-widens-probe-suicide-risk-linked-weight-loss-meds?utm_source=businessinsider&utm_medium=referral,positive,0.7356560826301575
2486,7/11/2023 8:00:37 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032438698,positive,0.8414194583892822
2487,7/12/2023 10:17:56 PM,Eli Lilly sees IPR&D charges negatively impacting Q2 EPS,Seeking Alpha,https://seekingalpha.com/news/3987245-eli-lilly-sees-iprd-charges-negatively-impacting-q2-eps?utm_source=businessinsider&utm_medium=referral,neutral,0.9654667973518372
2488,7/13/2023 7:24:22 AM,"Analysts Are Bullish on Top Healthcare Stocks: Alnylam Pharma (ALNY), Replimune Group (REPL)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-alnylam-pharma-alny-replimune-group-repl-1032443396,positive,0.8545003533363342
2489,7/13/2023 7:25:08 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1032443395,negative,0.6687780618667603
2490,7/14/2023 12:20:11 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Humana (HUM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-humana-hum-1032445940,positive,0.9170433282852173
2491,7/14/2023 12:38:01 PM,Eli Lilly to acquire Versanis Bio in ~$2B deal to boost weight loss franchise,Seeking Alpha,https://seekingalpha.com/news/3987685-eli-lilly-buy-versanis-bio-boost-weight-loss-franchise?utm_source=businessinsider&utm_medium=referral,negative,0.8647894263267517
2492,7/14/2023 2:00:00 PM,Lilly to Acquire Versanis to Improve Patient Outcomes in Cardiometabolic Diseases,PR Newswire,/news/stocks/lilly-to-acquire-versanis-to-improve-patient-outcomes-in-cardiometabolic-diseases-1032447238,negative,0.8217286467552185
2493,7/14/2023 2:09:44 PM,Eli Lilly To Acquire Versanis Bio - Quick Facts ,RTTNews,/news/stocks/eli-lilly-to-acquire-versanis-bio-quick-facts-1032447269,positive,0.925952672958374
2494,7/14/2023 2:29:26 PM,LLY Stock Alert: What to Know as Eli Lilly Acquires Versanis Bio,InvestorPlace,/news/stocks/lly-stock-alert-what-to-know-as-eli-lilly-acquires-versanis-bio-1032447923,positive,0.9495337009429932
2495,7/14/2023 2:48:42 PM,PRGO Stock Alert: Perrigo Climbs on Landmark FDA Birth Control Decision,InvestorPlace,/news/stocks/prgo-stock-alert-perrigo-climbs-on-landmark-fda-birth-control-decision-1032447956,positive,0.5037170648574829
2496,7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974,positive,0.4949893355369568
2497,7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,positive,0.4974316656589508
2498,7/17/2023 12:14:12 AM,"HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna",Seeking Alpha,https://seekingalpha.com/news/3987876-hsbc-bullish-on-roche-lonza-bearish-on-bristol-myers-gsk-moderna?utm_source=businessinsider&utm_medium=referral,negative,0.4802684485912323
2499,7/17/2023 11:20:11 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Apellis Pharmaceuticals (APLS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-apellis-pharmaceuticals-apls-1032450987,positive,0.9174372553825378
2500,7/17/2023 2:42:39 PM,Sangamo Inks Evaluation And Option Agreement With Lilly's Prevail For Adeno-associated Virus Capsids ,RTTNews,/news/stocks/sangamo-inks-evaluation-and-option-agreement-with-lilly-s-prevail-for-adeno-associated-virus-capsids-1032451234,negative,0.9313653111457825
2501,7/17/2023 4:15:00 PM,Results from Lilly's Landmark Phase 3 Trial of Donanemab Presented at Alzheimer's Association Conference and Published in JAMA,PR Newswire,/news/stocks/results-from-lilly-s-landmark-phase-3-trial-of-donanemab-presented-at-alzheimer-s-association-conference-and-published-in-jama-1032451878,positive,0.898383378982544
2502,7/17/2023 5:21:00 PM,Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab,Seeking Alpha,https://seekingalpha.com/news/3988105-eli-lilly-full-phase-3-data-confirms-benefit-alzheimers-donanemab?utm_source=businessinsider&utm_medium=referral,negative,0.6457030177116394
2503,7/18/2023 4:20:07 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), UnitedHealth (UNH) and Caliber Imaging & Diagnostic (OtherLCDX)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-eli-lilly-co-lly-unitedhealth-unh-and-caliber-imaging-diagnostic-otherlcdx-1032453288,neutral,0.8389882445335388
2504,7/18/2023 5:35:12 AM,SVB Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/svb-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1032453528,positive,0.90191650390625
2505,7/18/2023 9:05:11 AM,Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline ,RTTNews,/news/stocks/lilly-says-its-alzheimer-s-drug-significantly-slowed-cognitive-and-functional-decline-1032453676,negative,0.7803897857666016
2506,7/18/2023 9:10:33 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Argenx Se (ARGX) and Alector (ALEC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-argenx-se-argx-and-alector-alec-1032454094,positive,0.9229907393455505
2507,7/18/2023 10:22:03 AM,3 Biotech Stocks for Getting Rich in 2023,InvestorPlace,/news/stocks/3-biotech-stocks-for-getting-rich-in-2023-1032454309,positive,0.7535070776939392
2508,7/18/2023 3:27:28 PM,Sanofi expands collaboration with Scribe on CRISPR genome editing,Seeking Alpha,https://seekingalpha.com/news/3988429-sanofi-expands-collaboration-scribe-crispr-genome-editing?utm_source=businessinsider&utm_medium=referral,negative,0.8825411796569824
2509,7/20/2023 5:58:57 PM,Lawmakers reintroduce bill to offer Medicare coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/3989310-bill-offer-medicare-coverage-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.5810311436653137
2510,7/20/2023 7:36:44 PM,Eli Lilly's Solid Portfolio Alzheimer's & Diabetes Drugs To Aid Sales Growth: Analyst,Benzinga,/news/stocks/eli-lilly-s-solid-portfolio-alzheimer-s-diabetes-drugs-to-aid-sales-growth-analyst-1032463634,negative,0.9318552017211914
2511,7/21/2023 7:31:28 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-july-2023-1032466871,positive,0.9029704332351685
2512,7/21/2023 8:45:52 PM,WINN ETF: Can You Really Win with This ETF?,TipRanks,/news/stocks/winn-etf-can-you-really-win-with-this-etf-1032466949,positive,0.7109965682029724
2513,7/24/2023 11:50:28 AM,"Analysts Are Bullish on These Healthcare Stocks: Thorne HealthTech (THRN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-thorne-healthtech-thrn-eli-lilly-co-lly-1032469817,positive,0.7378103733062744
2514,7/25/2023 12:55:00 PM,Lilly Announces Extension of Tender Offer to Acquire DICE,PR Newswire,/news/stocks/lilly-announces-extension-of-tender-offer-to-acquire-dice-1032473843,positive,0.7585579752922058
2515,7/25/2023 1:30:57 PM,Lilly Extends Tender Offer To Acquire DICE ,RTTNews,/news/stocks/lilly-extends-tender-offer-to-acquire-dice-1032473982,positive,0.733370304107666
2516,7/25/2023 1:33:48 PM,Eli Lilly extends tender offer to acquire Dice,Seeking Alpha,https://seekingalpha.com/news/3990559-eli-lilly-extends-tender-offer-acquire-dice?utm_source=businessinsider&utm_medium=referral,positive,0.6336816549301147
2517,7/25/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Second-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-second-quarter-2023-financial-results-announcement-1032474853,positive,0.9389679431915283
2518,7/25/2023 5:46:10 PM,"Lilly, Novo Nordisk diabetes and weight loss drug shortages persist",Seeking Alpha,https://seekingalpha.com/news/3990724-eli-lilly-novo-nordisk-diabetes-weight-loss-drug-shortages-persist?utm_source=businessinsider&utm_medium=referral,positive,0.9221067428588867
2519,7/26/2023 4:50:29 PM,Probe over suicide risk linked to weight loss drugs expands to U.K. – Reuters,Seeking Alpha,https://seekingalpha.com/news/3991362-uk-probes-suicide-risk-linked-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.7115354537963867
2520,7/26/2023 6:26:37 PM,3 Risky Stocks to Avoid at All Costs in 2023,InvestorPlace,/news/stocks/3-risky-stocks-to-avoid-at-all-costs-in-2023-1032481132,positive,0.9205359220504761
2521,7/27/2023 12:04:51 AM,VTI ETF’s Simple but Powerful Strategy is a Long-Term Winner,TipRanks,/news/stocks/vti-etf-s-simple-but-powerful-strategy-is-a-long-term-winner-1032481766,positive,0.7039119601249695
2522,7/27/2023 11:39:24 AM,Eli Lilly updates Phase 3 data for obesity drug indicating up to 26% of weight loss,Seeking Alpha,https://seekingalpha.com/news/3992014-eli-lilly-obesity-drug-indicates-26-weight-loss?utm_source=businessinsider&utm_medium=referral,negative,0.6901787519454956
2523,7/27/2023 12:48:00 PM,Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies,PR Newswire,/news/stocks/tirzepatide-demonstrated-significant-and-superior-weight-loss-compared-to-placebo-in-two-pivotal-studies-1032483877,negative,0.9355870485305786
2524,7/27/2023 1:42:27 PM,7 Millionaire-Maker Healthcare Stocks to Buy Before the Window Closes,InvestorPlace,/news/stocks/7-millionaire-maker-healthcare-stocks-to-buy-before-the-window-closes-1032484989,positive,0.8679835796356201
2525,7/27/2023 3:48:50 PM,Lilly's Diabetes Drug Tirzepatide Demonstrates Significant And Superior Weight Loss In Two Studies ,RTTNews,/news/stocks/lilly-s-diabetes-drug-tirzepatide-demonstrates-significant-and-superior-weight-loss-in-two-studies-1032484975,negative,0.942653477191925
2526,7/28/2023 9:03:18 AM,Analysts Offer Insights on Healthcare Companies: Laboratory (LH) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-laboratory-lh-and-eli-lilly-co-lly-1032489117,positive,0.9141594767570496
2527,7/31/2023 8:41:24 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-idexx-laboratories-idxx-1032494416,positive,0.7428888082504272
2528,7/31/2023 11:11:04 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-4d-molecular-therapeutics-fdmt-1032494909,positive,0.9105669260025024
2529,7/31/2023 9:50:57 PM,NULG: Check Out This Large-Cap Growth ETF’s Strong Performance,TipRanks,/news/stocks/nulg-check-out-this-large-cap-growth-etf-s-strong-performance-1032497282,negative,0.9344850778579712
2530,8/2/2023 7:35:39 PM,Dice Therapeutics gains amid Nasdaq delisting notice for Eli Lilly deal,Seeking Alpha,https://seekingalpha.com/news/3995698-dice-therapeutics-gains-amid-nasdaq-delisting-notice-for-eli-lilly-deal?utm_source=businessinsider&utm_medium=referral,neutral,0.4159521758556366
2531,8/4/2023 1:45:00 PM,Lilly's Retevmo® (selpercatinib) is the First Targeted Therapy to Demonstrate Superior Progression-Free Survival Compared to a PD-1 Inhibitor Plus Chemotherapy for Adults with Newly-Diagnosed Adva...,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-is-the-first-targeted-therapy-to-demonstrate-superior-progression-free-survival-compared-to-a-pd-1-inhibitor-plus-chemotherapy-for-adults-with-newly-diagnosed-adva-1032517655,negative,0.9527403116226196
2532,8/4/2023 2:54:59 PM,Eli Lilly: LIBRETTO-431 Study Meets Primary Endpoint ,RTTNews,/news/stocks/eli-lilly-libretto-431-study-meets-primary-endpoint-1032517948,positive,0.739386796951294
2533,8/4/2023 6:41:33 PM,"ETF Winners And Losers: Micro-Cap Fund Flows - Innovative AUSF, With Annualized Returns Of 17.19% Over Last 3 Years, Adds $159.87 Million",Benzinga,/news/etf/etf-winners-and-losers-micro-cap-fund-flows---innovative-ausf-with-annualized-returns-of-17-19-over-last-3-years-adds-159-87-million-1032518855,negative,0.8787616491317749
2534,8/4/2023 7:00:42 PM,"Catalyst Watch: Wayfair and Kellogg events, Alibaba earnings and AI hacking test at Def Con",Seeking Alpha,https://seekingalpha.com/news/3997605-catalyst-watch-wayfair-and-kellogg-events-alibaba-earnings-and-ai-hacking-test-at-def-con?utm_source=businessinsider&utm_medium=referral,positive,0.9352651238441467
2535,8/6/2023 4:00:54 PM,Nearly half of U.S. adults want weight-loss drugs – KFF poll,Seeking Alpha,https://seekingalpha.com/news/3997955-nearly-half-of-americans-want-weight-loss-drugs-kff-poll?utm_source=businessinsider&utm_medium=referral,positive,0.856417715549469
2536,8/7/2023 9:16:06 AM,Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-eli-lilly-co-lly-1032523200,positive,0.9004620313644409
2537,8/7/2023 11:20:34 AM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-alnylam-pharma-alny-1032523487,positive,0.5013821125030518
2538,8/7/2023 3:01:13 PM,Eli Lilly and earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-q2-quarterly-earnings-preview-1032524059,positive,0.9387240409851074
2539,8/7/2023 3:20:35 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/3998171-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral,negative,0.8660826683044434
2540,8/7/2023 5:29:20 PM,Nektar reportedly sues Lilly for bungling clinical data on dermo drug,Seeking Alpha,https://seekingalpha.com/news/3998390-nektar-reportedly-sues-lilly-for-bungling-clinical-data-on-dermo-drug?utm_source=businessinsider&utm_medium=referral,neutral,0.95742267370224
2541,8/7/2023 7:08:21 PM,"Eli Lilly, up 24% YTD, looks to Q2 results beats",Seeking Alpha,https://seekingalpha.com/news/3998430-eli-lilly-up-24-ytd-looks-q2-results-beats?utm_source=businessinsider&utm_medium=referral,negative,0.7925102710723877
2542,8/8/2023 1:20:07 AM,"Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-mineralys-therapeutics-inc-mlys-eli-lilly-co-lly-1032525803,positive,0.7570439577102661
2543,8/8/2023 10:18:50 AM,"Eli Lilly, Beyond Meat And 3 Stocks To Watch Heading Into Tuesday",Benzinga,/news/stocks/eli-lilly-beyond-meat-and-3-stocks-to-watch-heading-into-tuesday-1032527715,positive,0.9250320792198181
2544,8/8/2023 10:47:52 AM,Eli Lilly beats Q2 top and bottom line estimates; raises FY23 EPS outlook,Seeking Alpha,https://seekingalpha.com/news/3998862-eli-lilly-beats-q2-top-and-bottom-line-estimates-raises-fy23-eps-outlook?utm_source=businessinsider&utm_medium=referral,negative,0.9299284219741821
2545,8/8/2023 10:52:00 AM,Novo Nordisk weight loss drug cuts heart disease risk by 20%,Seeking Alpha,https://seekingalpha.com/news/3998866-novo-nordisk-weight-loss-drug-cuts-heart-disease-risk?utm_source=businessinsider&utm_medium=referral,negative,0.7697901725769043
2546,8/8/2023 11:28:24 AM,Eli Lilly Q2 beat driven by Mounjaro and growth products,Seeking Alpha,https://seekingalpha.com/news/3998931-eli-lilly-q2-beat-driven-mounjaro-and-growth-products?utm_source=businessinsider&utm_medium=referral,negative,0.805820643901825
2547,8/8/2023 12:45:00 PM,"Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements",PR Newswire,/news/stocks/lilly-reports-second-quarter-2023-financial-results-highlights-accelerating-revenue-growth-and-key-pipeline-advancements-1032528235,negative,0.9508166313171387
2548,8/8/2023 12:50:33 PM,"Eli Lilly And Co. Q2 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q2-profit-increases-beats-estimates-1032528243,negative,0.9398201107978821
2549,8/8/2023 12:59:23 PM,Eli Lilly Boosts FY23 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-boosts-fy23-outlook-update-1032528292,negative,0.7733203768730164
2550,8/8/2023 2:24:46 PM,"Biggest stock movers today: Medical Properties Trust, Novavax, Eli Lilly, Tilray Brands, and more",Seeking Alpha,https://seekingalpha.com/news/3998776-biggest-stock-movers-today-tilray-brands-beyond-meat-and-more?utm_source=businessinsider&utm_medium=referral,positive,0.9152239561080933
2551,8/8/2023 2:26:14 PM,"Lilly reaches all-time high on Q2 results, 2023 guidance boost",Seeking Alpha,https://seekingalpha.com/news/3999097-lilly-reaches-all-time-high-q2-results-2023-guidance-boost?utm_source=businessinsider&utm_medium=referral,negative,0.9195758104324341
2552,8/8/2023 2:47:02 PM,Watch weight loss stocks after cardiovascular data for Wegovy,Seeking Alpha,https://seekingalpha.com/news/3999115-watch-weight-loss-stocks-cardiovascular-data-for-wegovy?utm_source=businessinsider&utm_medium=referral,positive,0.8803889155387878
2553,8/8/2023 3:28:34 PM,"Eli Lilly Up Over 11% In Pre-market After Increased Q2 Profit, Outlook ",RTTNews,/news/stocks/eli-lilly-up-over-11-in-pre-market-after-increased-q2-profit-outlook-1032529321,negative,0.953205406665802
2554,8/8/2023 3:31:32 PM,Eli Lilly Boosts Outlook As Q2 Results Top Estimates; Stock Up 11% ,RTTNews,/news/stocks/eli-lilly-boosts-outlook-as-q2-results-top-estimates-stock-up-11-1032529342,negative,0.9387491345405579
2555,8/8/2023 4:15:25 PM,"Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy",Seeking Alpha,https://seekingalpha.com/news/3999177-stifel-guggenheim-jefferies-wedbush-start-apogee-therapeutics-at-buy?utm_source=businessinsider&utm_medium=referral,positive,0.9403935670852661
2556,8/8/2023 4:35:25 PM,"Fox, Warner Music, Eli Lilly, Chegg And Other Big Stocks Moving Higher On Tuesday",Benzinga,/news/stocks/fox-warner-music-eli-lilly-chegg-and-other-big-stocks-moving-higher-on-tuesday-1032529860,negative,0.9259002208709717
2557,8/8/2023 6:06:59 PM,Dow Falls 1%; Eli Lilly Raises Annual Guidance,Benzinga,/news/stocks/dow-falls-1-eli-lilly-raises-annual-guidance-1032530154,neutral,0.7949767112731934
2558,8/8/2023 6:16:56 PM,Eli Lilly (LLY) Stock Just Reached a New All-Time High,InvestorPlace,/news/stocks/eli-lilly-lly-stock-just-reached-a-new-all-time-high-1032530411,negative,0.79793781042099
2559,8/8/2023 7:13:13 PM,Why Energizer Holdings Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-energizer-holdings-shares-are-trading-lower-by-13-here-are-other-stocks-moving-in-tuesday-s-mid-day-session-1032530289,neutral,0.805759608745575
2560,8/9/2023 4:55:06 AM,Eli Lilly & Co (LLY) Gets a Hold from Goldman Sachs,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-hold-from-goldman-sachs-1032532701,positive,0.9019989967346191
2561,8/9/2023 7:32:29 AM,"Analysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO), Elevance Health (ELV) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sangamo-biosciences-sgmo-elevance-health-elv-and-eli-lilly-co-lly-1032533583,positive,0.910227358341217
2562,8/9/2023 11:41:19 AM,CBOE Volatility Index Increases Ahead Of Inflation Data,Benzinga,/news/stocks/cboe-volatility-index-increases-ahead-of-inflation-data-1032534093,negative,0.4777635633945465
2563,8/9/2023 2:30:03 PM,Eli Lilly upgraded at Jefferies on Mounjaro sales and Wegovy data (update),Seeking Alpha,https://seekingalpha.com/news/4000027-eli-lilly-stock-upgraded-jefferies-mounjaro-sales?utm_source=businessinsider&utm_medium=referral,positive,0.9097924828529358
2564,8/9/2023 3:02:00 PM,Lilly Completes Acquisition of DICE Therapeutics,PR Newswire,/news/stocks/lilly-completes-acquisition-of-dice-therapeutics-1032535172,positive,0.8443690538406372
2565,8/9/2023 4:03:13 PM,"Eli Lilly Analysts Bump Up Forecasts On Q2 Print: Mounjaro, Alzheimer's Franchise Key To Future Growth",Benzinga,/news/stocks/eli-lilly-analysts-bump-up-forecasts-on-q2-print-beyond-mounjaro-alzheimer-s-franchise-remains-a-key-pillar-to-future-growth-1032535647,negative,0.6390405893325806
2566,8/9/2023 5:00:38 PM,"Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-august-9-2023-1032535842,neutral,0.48692119121551514
2567,8/9/2023 9:51:42 PM,3 Growth Stocks to Sell in August Before They Crash and Burn,InvestorPlace,/news/stocks/3-growth-stocks-to-sell-in-august-before-they-crash-and-burn-1032536926,positive,0.8467138409614563
2568,8/9/2023 10:43:54 PM,"Stifel cuts Morphic to hold, doesn't see it as near-term M&A target",Seeking Alpha,https://seekingalpha.com/news/4000665-stifel-cuts-morphic-to-hold-doesnt-see-it-as-near-term-takeover-target?utm_source=businessinsider&utm_medium=referral,positive,0.9199356436729431
2569,8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral,negative,0.8962883353233337
2570,8/10/2023 4:01:10 PM,Expert Ratings for Eli Lilly,Benzinga,/news/stocks/expert-ratings-for-eli-lilly-1032541047,positive,0.8414194583892822
2571,8/10/2023 5:51:32 PM,Novo Nordisk Soars To New High On Weight-Loss Drug Trial Results,Benzinga,/news/stocks/novo-nordisk-soars-to-new-high-on-weight-loss-drug-trial-results-1032541453,negative,0.9335570931434631
2572,8/11/2023 8:52:36 AM,"Uber Crowded, Battleground and Sweet 16 stock portfolios from Jefferies",Seeking Alpha,https://seekingalpha.com/news/3999208-uber-crowded-battleground-and-sweet-16-stock-portfolios-from-jefferies?utm_source=businessinsider&utm_medium=referral,positive,0.8961217403411865
2573,8/11/2023 6:47:04 PM,5 ETFs Responding To PPI Surge And Consumer Sentiment Dip On Friday,Benzinga,/news/etf/5-etfs-responding-to-ppi-surge-and-consumer-sentiment-dip-on-friday-1032547560,neutral,0.7792469263076782
2574,8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.5231574177742004
2575,8/14/2023 1:25:00 PM,Lilly Completes Acquisition of Sigilon Therapeutics,PR Newswire,/news/stocks/lilly-completes-acquisition-of-sigilon-therapeutics-1032550835,positive,0.8466238975524902
2576,8/14/2023 1:30:42 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Y-Mabs Therapeutics (YMAB)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-y-mabs-therapeutics-ymab-1032551662,negative,0.4873918294906616
2577,8/14/2023 2:03:16 PM,"Eli Lilly closes Sigilon, Versanis buyouts boosting diabetes/ obesity franchise",Seeking Alpha,https://seekingalpha.com/news/4002290-eli-lilly-closes-sigilon-versanis-buyouts?utm_source=businessinsider&utm_medium=referral,negative,0.832755446434021
2578,8/14/2023 2:19:11 PM,Eli Lilly Concludes Acquisition Of Sigilon Therapeutics ,RTTNews,/news/stocks/eli-lilly-concludes-acquisition-of-sigilon-therapeutics-1032551055,positive,0.9120097160339355
2579,8/14/2023 3:09:00 PM,Lilly Completes Acquisition of Versanis Bio,PR Newswire,/news/stocks/lilly-completes-acquisition-of-versanis-bio-1032551486,positive,0.8756059408187866
2580,8/14/2023 3:21:40 PM,Eli Lilly Completes Acquisition Of Versanis Bio ,RTTNews,/news/stocks/eli-lilly-completes-acquisition-of-versanis-bio-1032551535,positive,0.8804358839988708
2581,8/14/2023 7:06:48 PM,"Tiger Global reduces holdings in tech, boosts stakes in Grab, Apollo, adds Eli Lilly",Seeking Alpha,https://seekingalpha.com/news/4002479-tiger-global-reduces-holdings-in-tech-boosts-stakes-in-grab-apollo-adds-eli-lilly?utm_source=businessinsider&utm_medium=referral,negative,0.6887014508247375
2582,8/15/2023 7:06:54 PM,"Coatue Management takes new stake in Oracle, exits GameStop, trims Tesla, adds to Amazon",Seeking Alpha,https://seekingalpha.com/news/4003164-coatue-management-takes-new-stake-in-oracle-exits-gamestop-trims-tesla-adds-to-amazon?utm_source=businessinsider&utm_medium=referral,positive,0.9156391620635986
2583,8/16/2023 11:07:03 PM,The 7 Most Undervalued Healthcare Stocks to Buy Now: August 2023,InvestorPlace,/news/stocks/the-7-most-undervalued-healthcare-stocks-to-buy-now-august-2023-1032561356,positive,0.8634922504425049
2584,8/17/2023 10:40:49 AM,7 A-Rated Biotech Stocks for Your August Buy List,InvestorPlace,/news/stocks/7-a-rated-biotech-stocks-for-your-august-buy-list-1032562826,positive,0.9206423759460449
2585,8/17/2023 12:11:53 PM,"Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'",Benzinga,/news/stocks/eli-lilly-s-stock-spikes-yet-team-jim-cramer-holds-back-on-recommending-immediate-buying-wait-for-a-pullback-1032562599,neutral,0.4732588231563568
2586,8/17/2023 6:19:02 PM,Fitch Flags Major Credit Risks Amid Sticky Inflation and High Interest Rates: Bond Market Turmoil Persists,Benzinga,/news/etf/fitch-flags-major-credit-risks-amid-sticky-inflation-and-high-interest-rates-bond-market-turmoil-persists-1032564234,neutral,0.9325469136238098
2587,8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral,positive,0.8961257338523865
2588,8/21/2023 10:20:07 AM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), Brainsway (BWAY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-brainsway-bway-1032569197,positive,0.5898825526237488
2589,8/21/2023 11:26:04 AM,BMO Capital Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032569373,positive,0.7878067493438721
2590,8/21/2023 3:28:18 PM,5 Safe Stocks Under $40 to Buy Immediately,InvestorPlace,/news/stocks/5-safe-stocks-under-40-to-buy-immediately-1032570520,positive,0.8483371734619141
2591,8/21/2023 4:09:36 PM,Insulet downgraded at Baird; upgraded at Citi amid GLP1-linked selloff,Seeking Alpha,https://seekingalpha.com/news/4004840-insulet-downgraded-baird-upgraded-citi-amid-glp1-linked-selloff?utm_source=businessinsider&utm_medium=referral,neutral,0.6823350191116333
2592,8/21/2023 7:53:10 PM,Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed,Benzinga,/news/etf/value-stocks-outshine-growth-amidst-rising-treasury-yields-key-sectors-and-stocks-analyzed-1032570802,positive,0.8104676604270935
2593,8/21/2023 7:58:31 PM,"Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk",Seeking Alpha,https://seekingalpha.com/news/4004913-lillys-market-cap-soared-in-q2-eclipsing-jnj-merck-novo-nordisk?utm_source=businessinsider&utm_medium=referral,negative,0.9460121989250183
2594,8/22/2023 1:28:26 PM,Eli Lilly succeeds in Phase 3 thyroid cancer trial for Retevmo,Seeking Alpha,https://seekingalpha.com/news/4005158-eli-lilly-phase-3-thyroid-cancer-trial-retevmo-succeeds?utm_source=businessinsider&utm_medium=referral,negative,0.8550601601600647
2595,8/22/2023 1:45:00 PM,Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-demonstrates-superior-progression-free-survival-compared-to-approved-multikinase-inhibitors-in-ret-mutant-medullary-thyroid-cancer-1032572662,negative,0.9570281505584717
2596,8/22/2023 1:59:38 PM,Eli Lilly Says LIBRETTO-531 Study Evaluating Retevmo Meets Primary Endpoint ,RTTNews,/news/stocks/eli-lilly-says-libretto-531-study-evaluating-retevmo-meets-primary-endpoint-1032572689,positive,0.6034544110298157
2597,8/23/2023 8:25:24 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032575471,positive,0.8219966292381287
2598,8/24/2023 11:10:36 AM,7 A-Rated Growth Stocks to Grab Up Now,InvestorPlace,/news/stocks/7-a-rated-growth-stocks-to-grab-up-now-1032579326,negative,0.676399827003479
2599,8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,positive,0.9293889403343201
2600,8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.8904427886009216
2601,8/28/2023 9:58:12 AM,Want to Get Rich? 3 Game-Changing Growth Stocks to Buy Right Now,InvestorPlace,/news/stocks/want-to-get-rich-3-game-changing-growth-stocks-to-buy-right-now-1032585368,positive,0.9213942289352417
2602,8/28/2023 10:35:42 AM,Hedge and mutual funds rotate from tech; see the stocks they love and shun,Seeking Alpha,https://seekingalpha.com/news/4006637-hedge-and-mutual-funds-rotate-from-tech-see-the-stocks-they-love-and-shun?utm_source=businessinsider&utm_medium=referral,positive,0.6943780183792114
2603,8/28/2023 12:10:38 PM,The 3 Blue-Chip Stocks Every Investor Needs to Own Today,InvestorPlace,/news/stocks/the-3-blue-chip-stocks-every-investor-needs-to-own-today-1032585783,positive,0.9351764917373657
2604,8/28/2023 1:50:15 PM,"Analysts Offer Insights on Healthcare Companies: Privia Health Group (PRVA), Eli Lilly & Co (LLY) and Alnylam Pharma (ALNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-privia-health-group-prva-eli-lilly-co-lly-and-alnylam-pharma-alny-1032586152,positive,0.9265727996826172
2605,8/28/2023 4:37:09 PM,"Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories",Benzinga,/news/stocks/hawaiian-electric-says-power-lines-not-responsible-for-deadly-lahaina-fire-china-targets-stock-market-revival-ftc-pauses-legal-battle-with-amgen-s-28b-horizon-deal-today-s-top-stories-1032586588,positive,0.9021692872047424
2606,8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral,positive,0.9310519099235535
2607,8/29/2023 4:00:00 PM,Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-morgan-stanley-21st-annual-global-healthcare-conference-1032589333,positive,0.784396231174469
2608,8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral,neutral,0.8554677963256836
2609,8/30/2023 12:58:15 AM,SPLG: The Market’s Lowest-Cost S&P 500 ETF,TipRanks,/news/stocks/splg-the-market-s-lowest-cost-s-p-500-etf-1032590792,positive,0.7738195657730103
2610,8/30/2023 9:20:13 AM,The 3 Most Promising Pharma Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-pharma-stocks-to-own-now-1032591971,positive,0.6068364381790161
2611,8/30/2023 12:54:37 PM,3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of,InvestorPlace,/news/stocks/3-biotech-stocks-that-wall-street-analysts-cant-get-enough-of-1032592710,positive,0.6408605575561523
2612,8/30/2023 11:17:20 PM,7 Stocks Sitting At 52-Week Highs Right Now,InvestorPlace,/news/stocks/stocks-at-52-week-highs-1032594399,positive,0.7168640494346619
2613,8/31/2023 11:10:56 AM,7 A-Rated Blue-Chip Stocks to Secure Your Financial Future,InvestorPlace,/news/stocks/7-a-rated-blue-chip-stocks-to-secure-your-financial-future-1032595839,positive,0.7781670689582825
2614,8/31/2023 8:35:18 PM,"Senators ask Novo Nordisk, Lilly, Sanofi for details on discount insulin programs",Seeking Alpha,https://seekingalpha.com/news/4008203-senators-ask-novo-nordisk-lilly-sanofi-for-details-on-discount-insulin-programs?utm_source=businessinsider&utm_medium=referral,positive,0.946946382522583
2615,8/31/2023 9:18:56 PM,Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects,Benzinga,/news/stocks/why-abcellera-biologics-is-still-a-buy-despite-dropping-royalties-analyst-on-long-term-prospects-1032597681,positive,0.8095165491104126
2616,9/1/2023 1:38:50 AM,"Vanguard Mega Cap Growth ETF (MGK): Go Big, or Go Home",TipRanks,/news/stocks/vanguard-mega-cap-growth-etf -mgk-go-big-or-go-home-1032598019,positive,0.8418961763381958
2617,9/1/2023 10:00:11 PM,The 3 Most Promising Healthcare Stocks to Own Now,InvestorPlace,/news/stocks/the-3-most-promising-healthcare-stocks-to-own-now-1032600808,positive,0.6742458343505859
2618,9/2/2023 6:00:00 PM,"Lilly, Novo Nordisk top pharma performers in August; AstraZeneca, Roche lag",Seeking Alpha,https://seekingalpha.com/news/4008548-lilly-novo-nordisk-top-pharma-performers-august-astrazeneca-roche-lag?utm_source=businessinsider&utm_medium=referral,negative,0.8847639560699463
2619,9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral,positive,0.7872201800346375
2620,9/4/2023 2:47:20 PM,Nestle-partnered weight loss capsule succeeds in pivotal trial,Seeking Alpha,https://seekingalpha.com/news/4008913-nestle-partnered-weight-loss-capsule-succeeds-trial?utm_source=businessinsider&utm_medium=referral,negative,0.8922839760780334
2621,9/5/2023 9:41:15 AM,S&P 500 (SPY) ETF: What’s in the Cards?,TipRanks,/news/stocks/s-p-500-spy-etf-what-s-in-the-cards-1032604500,positive,0.9149129390716553
2622,9/5/2023 11:25:04 AM,BMO Capital Releases a Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bmo-capital-releases-a-buy-rating-on-eli-lilly-co-lly-1032604871,positive,0.9091771245002747
2623,9/5/2023 10:00:25 PM,The Latest Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/the-latest-analyst-ratings-for-eli-lilly-1032606748,positive,0.9401240944862366
2624,9/6/2023 12:26:49 AM,Cantor Fitzgerald Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-eli-lilly-co-lly-1032607024,positive,0.9108292460441589
2625,9/6/2023 5:47:07 PM,DexCom cites rising glucose monitor use amid weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4009594-dexcom-stock-gains-cgm-use-rises-amid-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9152308702468872
2626,9/7/2023 1:55:26 AM,Berenberg Bank Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/berenberg-bank-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032610948,positive,0.7834326028823853
2627,9/7/2023 11:08:02 AM,7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth,InvestorPlace,/news/stocks/7-pharma-stocks-to-buy-for-groundbreaking-treatments-and-robust-revenue-growth-1032612381,negative,0.9394681453704834
2628,9/7/2023 12:41:19 PM,3 Nasdaq Stocks to Sell in September Before They Crash & Burn,InvestorPlace,/news/stocks/3-nasdaq-stocks-to-sell-in-september-before-they-crash-burn-1032612766,positive,0.7616114616394043
2629,9/7/2023 3:04:48 PM,Researchers study weight loss drugs in dementia and addiction,Seeking Alpha,https://seekingalpha.com/news/4009962-researchers-test-weight-loss-drugs-dementia-addiction?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.890235185623169
2630,9/8/2023 11:14:27 AM,Eli Lilly wins U.K. backing for diabetes drug Mounjaro,Seeking Alpha,https://seekingalpha.com/news/4010163-eli-lilly-wins-uk-backing-for-diabetes-drug-mounjaro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9346126317977905
2631,9/10/2023 4:00:00 PM,"Eli Lilly, Novo to lead $100B weight loss drug market in 2030: JPMorgan",Seeking Alpha,https://seekingalpha.com/news/4010426-eli-lilly-novo-lead-weight-loss-drug-market-jpmorgan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5451600551605225
2632,9/12/2023 1:59:15 AM,Pound for Pound: 3 Buzzworthy Drug Stocks Worth Their Weight in Gold,InvestorPlace,/news/stocks/pound-for-pound-3-buzzworthy-drug-stocks-worth-their-weight-in-gold-1032621509,positive,0.8567546606063843
2633,9/13/2023 5:55:35 AM,Eli Lilly & Co (LLY) Gets a Buy from DBS,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-dbs-1032625517,negative,0.6571701169013977
2634,9/15/2023 9:26:39 PM,"VTI ETF: This Diversified Powerhouse Owns Over 3,800 Stocks",TipRanks,/news/stocks/vti-etf-this-diversified-powerhouse-owns-over-3-800-stocks-1032634771,positive,0.9168491959571838
2635,9/18/2023 11:30:27 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Precision BioSciences (DTIL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-precision-biosciences-dtil-1032636638,positive,0.9132342338562012
2636,9/20/2023 2:17:37 PM,Eli Lilly Sues Clinics Over Unauthorized Mounjaro Drug Sale ,RTTNews,/news/stocks/eli-lilly-sues-clinics-over-unauthorized-mounjaro-drug-sale-1032643266,neutral,0.9398147463798523
2637,9/20/2023 5:03:50 PM,The 7 Most Hated Stocks by Institutional Traders,InvestorPlace,/news/stocks/the-7-most-hated-stocks-by-institutional-traders-1032644534,neutral,0.8152946829795837
2638,9/22/2023 2:33:00 PM,US FDA approves Jardiance® for the treatment of adults with chronic kidney disease,PR Newswire,/news/stocks/us-fda-approves-jardiance-for-the-treatment-of-adults-with-chronic-kidney-disease-1032649564,negative,0.8182269930839539
2639,9/22/2023 2:53:39 PM,Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease ,RTTNews,/news/stocks/eli-lilly-fda-approves-jardiance-in-treatment-of-chronic-kidney-disease-1032649637,negative,0.8353199362754822
2640,9/22/2023 4:46:19 PM,'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase,Benzinga,/news/stocks/stocks-in-monopolistic-bull-market-wall-street-analyst-contemplates-a-bright-future-for-next-phase-1032650182,negative,0.7921591997146606
2641,9/22/2023 9:05:52 PM,Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend,InvestorPlace,/news/stocks/immunomics-stocks-3-ways-to-play-this-massive-ai-biotech-megatrend-1032650707,positive,0.9053971767425537
2642,9/23/2023 8:00:05 PM,David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′,InvestorPlace,/news/stocks/david-vs-goliath-3-stocks-poised-to-challenge-the-magnificent-7-1032650929,negative,0.6112227439880371
2643,9/25/2023 11:10:48 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Centessa Pharmaceuticals (CNTA)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-centessa-pharmaceuticals-cnta-1032652558,positive,0.6903237104415894
2644,9/26/2023 5:00:53 PM,Don’t Miss the Boom: 3 Biotech Stocks Set to Explode Higher,InvestorPlace,/news/stocks/dont-miss-the-boom-3-biotech-stocks-set-to-explode-higher-1032657128,positive,0.913301944732666
2645,9/28/2023 12:45:04 PM,3 Biotech Stocks to Watch Ahead of Potential Obesity Drug Approvals,InvestorPlace,/news/stocks/3-biotech-stocks-to-watch-ahead-of-potential-obesity-drug-approvals-1032662925,positive,0.9009644389152527
2646,9/29/2023 1:52:14 AM,SCHX ETF: A Large-Cap ETF for Large Gains,TipRanks,/news/stocks/schx-etf-a-large-cap-etf-for-large-gains-1032664747,positive,0.9166260957717896
2647,10/1/2023 2:32:42 AM,"LLY, ISRG, or JNJ: Which Healthcare Stock Could Generate the Best Returns?",TipRanks,/news/stocks/lly-isrg-or-jnj-which-healthcare-stock-could-generate-the-best-returns-1032668067,positive,0.8824886679649353
2648,10/2/2023 12:45:00 PM,U.S. Food and Drug Administration Issues Complete Response Letter for Lebrikizumab Based on Inspection Findings at Third-Party Manufacturer,PR Newswire,/news/stocks/u-s-food-and-drug-administration-issues-complete-response-letter-for-lebrikizumab-based-on-inspection-findings-at-third-party-manufacturer-1032669811,positive,0.8536917567253113
2649,10/2/2023 12:58:07 PM,Eli Lilly: FDA Issues CRL For Lebrikizumab BLA Related To Third-party Manufacturing Organization ,RTTNews,/news/stocks/eli-lilly-fda-issues-crl-for-lebrikizumab-bla-related-to-third-party-manufacturing-organization-1032669837,positive,0.5365134477615356
2650,10/2/2023 1:20:21 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Abbott Labs (ABT), Eli Lilly & Co (LLY) and Rocket Pharmaceuticals (RCKT)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-abbott-labs-abt-eli-lilly-co-lly-and-rocket-pharmaceuticals-rckt-1032670481,neutral,0.7999124526977539
2651,10/2/2023 3:28:42 PM,Stable Giants: 3 Bigwig Biotech Stocks for Consistent Returns,InvestorPlace,/news/stocks/stable-giants-3-bigwig-biotech-stocks-for-consistent-returns-1032671153,negative,0.6947975158691406
2652,10/2/2023 3:32:07 PM,Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024,InvestorPlace,/news/stocks/q4-stock-predictions-3-pharma-stocks-ready-to-roar-into-2024-1032671152,positive,0.8758504986763
2653,10/2/2023 11:00:46 PM,Analyst Ratings for Eli Lilly,Benzinga,/news/stocks/analyst-ratings-for-eli-lilly-1032671752,positive,0.9140509963035583
2654,10/3/2023 8:25:29 AM,Cantor Fitzgerald Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032672635,positive,0.8345123529434204
2655,10/3/2023 12:45:00 PM,Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies,PR Newswire,/news/stocks/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-1032673889,negative,0.7773271799087524
2656,10/3/2023 12:55:09 PM,Why Is Point Biopharma (PNT) Stock Up 84% Today?,InvestorPlace,/news/stocks/why-is-point-biopharma-pnt-stock-up-84-today-1032674584,negative,0.7867308259010315
2657,10/3/2023 1:23:12 PM,Lilly To Acquire POINT Biopharma For $1.4 Bln In Cash; POINT Up In Pre Market ,RTTNews,/news/stocks/lilly-to-acquire-point-biopharma-for-1-4-bln-in-cash-point-up-in-pre-market-1032674015,negative,0.9156912565231323
2658,10/3/2023 2:58:30 PM,Why Cancer-Focused ALX Oncology Stock Gained Over 100% Today?,Benzinga,/news/stocks/why-cancer-focused-alx-oncology-stock-gained-over-100-today-1032674452,negative,0.6460390686988831
2659,10/3/2023 3:03:07 PM,Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today?,Benzinga,/news/stocks/why-is-cancer-treatment-focused-point-biopharma-stock-trading-higher-today-1032674451,positive,0.6641989350318909
2660,10/3/2023 3:42:06 PM,Dow Falls Over 100 Points; McCormick Sales Miss Views,Benzinga,/news/stocks/dow-falls-over-100-points-mccormick-sales-miss-views-1032674679,neutral,0.9160908460617065
2661,10/3/2023 4:09:54 PM,"Vericity, POINT Biopharma Global, Oddity Tech And Other Big Stocks Moving Higher On Tuesday",Benzinga,/news/stocks/vericity-point-biopharma-global-oddity-tech-and-other-big-stocks-moving-higher-on-tuesday-1032675118,negative,0.9358797073364258
2662,10/3/2023 4:11:21 PM,"'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories",Benzinga,/news/stocks/airbnb-has-foundational-cracks-disney+-follows-netflix-on-subscription-sharing-crackdown-microsoft-s-nadella-criticizes-google-s-exclusive-content-deals-today-s-top-stories-1032675117,neutral,0.9165230989456177
2663,10/3/2023 6:20:54 PM,Nasdaq Down Over 200 Points; US Job Openings Rise In August,Benzinga,/news/stocks/nasdaq-down-over-200-points-us-job-openings-rise-in-august-1032675501,neutral,0.9656189680099487
2664,10/3/2023 7:26:04 PM,"Wall Street Sell-Off Worsens, VIX Spikes As Bond Yields Rise Further, Dollar Strengthens: What's Driving Markets Tuesday?",Benzinga,/news/etf/wall-street-sell-off-worsens-vix-spikes-as-bond-yields-rise-further-dollar-strengthens-what-s-driving-markets-tuesday-1032675610,positive,0.42587387561798096
2665,10/3/2023 7:33:22 PM,Why Getty Images Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session,Benzinga,/news/stocks/why-getty-images-holdings-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-tuesday-s-mid-day-session-1032675609,neutral,0.8524999618530273
2666,10/3/2023 8:36:40 PM,Crude Oil Moves Higher; POINT Biopharma Global Shares Jump,Benzinga,/news/stocks/crude-oil-moves-higher-point-biopharma-global-shares-jump-1032675711,negative,0.9241970777511597
2667,10/4/2023 11:16:07 AM,Strategic Pipeline Progression and Growth Prospects Affirm Buy Rating for Lilly: An Analysis,TipRanks,/news/stocks/strategic-pipeline-progression-and-growth-prospects-affirm-buy-rating-for-lilly-an-analysis-1032677501,positive,0.9164596199989319
2668,10/4/2023 12:45:00 PM,Lilly Announces Leadership Transitions,PR Newswire,/news/stocks/lilly-announces-leadership-transitions-1032677321,positive,0.9331324696540833
2669,10/4/2023 6:05:00 PM,Loxo@Lilly Unveils Three New Oncology Programs at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics,PR Newswire,/news/stocks/loxo-lilly-unveils-three-new-oncology-programs-at-2023-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-1032678907,positive,0.8263180255889893
2670,10/6/2023 11:10:46 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Apellis Pharmaceuticals (APLS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-apellis-pharmaceuticals-apls-1032684257,positive,0.9174372553825378
2671,10/6/2023 1:45:00 PM,Lilly Announces Details of Presentations at ESMO Congress 2023,PR Newswire,/news/stocks/lilly-announces-details-of-presentations-at-esmo-congress-2023-1032684340,positive,0.9482817053794861
2672,10/6/2023 6:23:48 PM,"Eli Lilly's Upcoming Obesity Drugs Highlight Bright Future, Says Optimistic Analyst",Benzinga,/news/stocks/eli-lilly-s-upcoming-obesity-drugs-highlight-bright-future-says-optimistic-analyst-1032685329,negative,0.9164058566093445
2673,10/6/2023 10:01:38 PM,"Snacks In The Ozempic Era: Food, Beverage Stocks Crash With Weight Loss Drugs On The Rise",Benzinga,/news/stocks/snacks-in-the-ozempic-era-food-beverage-stocks-crash-with-weight-loss-drugs-on-the-rise-1032685569,neutral,0.9235928654670715
2674,10/6/2023 10:14:50 PM,"Shutdown Averted, Treasury Yields Flirt With 5%, Strong Payrolls Add to Fed Tightening Risk: The Week In The Markets",Benzinga,/news/etf/shutdown-averted-treasury-yields-flirt-with-5-strong-payrolls-add-to-fed-tightening-risk-the-week-in-the-markets-1032685594,negative,0.5581754446029663
2675,10/7/2023 1:00:48 PM,3 Biotech Stocks Ready to Break Out in 2024,InvestorPlace,/news/stocks/3-biotech-stocks-ready-to-break-out-in-2024-1032685969,positive,0.8537952303886414
2676,10/9/2023 10:42:41 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032688302,negative,0.5521676540374756
2677,10/10/2023 8:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-bristol-myers-squibb-bmy-1032691280,positive,0.9204502701759338
2678,10/10/2023 2:06:15 PM,Obesity Medication Insurance Coverage? Employers Embrace the Inclusion of Novo Nordisk's Wegovy in Health Coverage,Benzinga,/news/stocks/obesity-medication-insurance-coverage-employers-embrace-the-inclusion-of-novo-nordisk-s-wegovy-in-health-coverage-1032692132,negative,0.7595357894897461
2679,10/10/2023 9:06:49 PM,"RayzeBio Is A New Contender in Radiopharmaceutical Arena, Will Attract Prominent Entities: JP Morgan",Benzinga,/news/stocks/rayzebio-is-a-new-contender-in-radiopharmaceutical-arena-will-attract-prominent-entities-jp-morgan-1032693787,negative,0.7121986150741577
2680,10/11/2023 6:16:04 PM,What's Going On With Eli Lilly Stock Wednesday?,Benzinga,/news/stocks/what-s-going-on-with-eli-lilly-stock-wednesday-1032697667,neutral,0.5761770009994507
2681,10/11/2023 7:10:15 PM,"Stocks In The Red, Bonds On The Rise As Investors Brace for FOMC Minutes, Crucial CPI Report: What's Driving Markets Wednesday?",Benzinga,/news/etf/stocks-in-the-red-bonds-on-the-rise-as-investors-brace-for-fomc-minutes-crucial-cpi-report-what-s-driving-markets-wednesday-1032697769,positive,0.6113160252571106
2682,10/12/2023 10:43:42 AM,Could Eli Lilly (NYSE:LLY) Stock Hit $1 Trillion in Market Cap?,TipRanks,/news/stocks/could-eli-lilly-nyse-lly-stock-hit-1-trillion-in-market-cap-1032699932,positive,0.7719424962997437
2683,10/12/2023 12:45:00 PM,Lilly's Mirikizumab Helped Patients with Crohn's Disease Achieve Long-Term Remission in Phase 3 Trial,PR Newswire,/news/stocks/lilly-s-mirikizumab-helped-patients-with-crohn-s-disease-achieve-long-term-remission-in-phase-3-trial-1032699918,negative,0.9032292366027832
2684,10/12/2023 1:29:43 PM,Lilly: Mirikizumab Phase 3 Trial In Adults With Crohn's Disease Meets Coprimary Endpoints ,RTTNews,/news/stocks/lilly-mirikizumab-phase-3-trial-in-adults-with-crohn-s-disease-meets-coprimary-endpoints-1032700070,negative,0.7625361680984497
2685,10/12/2023 10:53:43 PM,7 Stocks to Buy With Your 2024 Social Security Increase,InvestorPlace,/news/stocks/stocks-to-buy-with-social-security-increases-1032702135,positive,0.9351891875267029
2686,10/16/2023 12:00:00 AM,"Lilly's tirzepatide shows additional 21.1% weight loss after 12 weeks of intensive lifestyle intervention, for a total mean weight loss of 26.6% from study entry over 84 weeks",PR Newswire,/news/stocks/lilly-s-tirzepatide-shows-additional-21-1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention-for-a-total-mean-weight-loss-of-26-6-from-study-entry-over-84-weeks-1032706040,neutral,0.8142890334129333
2687,10/16/2023 3:30:31 AM,Lilly's Tirzepatide Shows Addl 21.1% Weight Loss After 12 Weeks Of Intensive Lifestyle Intervention ,RTTNews,/news/stocks/lilly-s-tirzepatide-shows-addl-21-1-weight-loss-after-12-weeks-of-intensive-lifestyle-intervention-1032706077,neutral,0.6738521456718445
2688,10/16/2023 11:30:33 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), AstraZeneca (AZN) and Ultragenyx Pharmaceutical (RARE)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-astrazeneca-azn-and-ultragenyx-pharmaceutical-rare-1032708087,positive,0.9120358824729919
2689,10/16/2023 8:43:28 PM,Food and Beverage Stocks Look Appetizing After Ozempic Selloff,InvestorPlace,/news/stocks/food-and-beverage-stocks-look-appetizing-after-ozempic-selloff-1032709959,negative,0.8848299384117126
2690,10/16/2023 10:16:41 PM,7 Cutting-Edge Stocks That Could Change Humanity as We Know It,InvestorPlace,/news/stocks/7-cutting-edge-stocks-that-could-change-humanity-as-we-know-it-1032710031,positive,0.8706300854682922
2691,10/18/2023 10:51:54 PM,The Next Trillion-Dollar Companies: 3 Stocks to Buy Now,InvestorPlace,/news/stocks/the-next-trillion-dollar-companies-3-stocks-to-buy-now-1032718562,positive,0.9403858780860901
2692,10/19/2023 11:58:05 AM,Optimistic Future for Eli Lilly: Potential Approval and Impact of Mounjaro in Obstructive Sleep Apnea Treatment Landscape,TipRanks,/news/stocks/optimistic-future-for-eli-lilly-potential-approval-and-impact-of-mounjaro-in-obstructive-sleep-apnea-treatment-landscape-1032720635,negative,0.9219902157783508
2693,10/19/2023 8:11:36 PM,7 Healthcare Stocks That Can Cure a Lackluster Portfolio,InvestorPlace,/news/stocks/healthcare-stocks-to-buy-4-1032722294,positive,0.7649615406990051
2694,10/20/2023 3:42:15 AM,"NVO, LLY, AZN: 3 “Strong Buy” Stocks to Bet on Weight-Loss Drugs",TipRanks,/news/stocks/nvo-lly-azn-3-strong-buy-stocks-to-bet-on-weight-loss-drugs-1032722680,negative,0.8043599724769592
2695,10/20/2023 4:25:32 AM,LLY vs. PFE: Which Pharma Stock is the Better Buy?,TipRanks,/news/stocks/lly-vs-pfe-which-pharma-stock-is-the-better-buy-1032722758,positive,0.9144653081893921
2696,10/20/2023 12:45:00 PM,Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years,PR Newswire,/news/stocks/nearly-80-of-patients-with-moderate-to-severe-atopic-dermatitis-maintained-clear-or-almost-clear-skin-with-lilly-s-lebrikizumab-monthly-maintenance-dosing-at-two-years-1032723948,positive,0.5339526534080505
2697,10/20/2023 2:00:00 PM,Landmark 5-Year monarchE Outcome Data Demonstrate Verzenio® (abemaciclib)'s Long-Term Impact on Cancer Recurrence in High-Risk Early Breast Cancer,PR Newswire,/news/stocks/landmark-5-year-monarche-outcome-data-demonstrate-verzenio-abemaciclib-s-long-term-impact-on-cancer-recurrence-in-high-risk-early-breast-cancer-1032724130,negative,0.8641994595527649
2698,10/20/2023 2:24:43 PM,Eli Lilly Reports Five-year Outcomes From Pre-planned Analysis Of Phase 3 MonarchE Study ,RTTNews,/news/stocks/eli-lilly-reports-five-year-outcomes-from-pre-planned-analysis-of-phase-3-monarche-study-1032724188,negative,0.8703002333641052
2699,10/20/2023 4:00:00 PM,Lilly Confirms Date and Conference Call for Third-Quarter 2023 Financial Results Announcement,PR Newswire,/news/stocks/lilly-confirms-date-and-conference-call-for-third-quarter-2023-financial-results-announcement-1032724483,positive,0.939089834690094
2700,10/20/2023 11:00:23 PM,What 23 Analyst Ratings Have To Say About Eli Lilly,Benzinga,/news/stocks/what-23-analyst-ratings-have-to-say-about-eli-lilly-1032725257,positive,0.9401511549949646
2701,10/21/2023 1:42:20 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Intuitive Surgical (ISRG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-intuitive-surgical-isrg-1032725606,positive,0.915465772151947
2702,10/21/2023 4:31:00 PM,Lilly's Retevmo® (selpercatinib) Phase 3 Results in RET Fusion-Positive Non-Small Cell Lung Cancer and RET-Mutant Medullary Thyroid Cancer Both Published in The New England Journal of Medicine and...,PR Newswire,/news/stocks/lilly-s-retevmo-selpercatinib-phase-3-results-in-ret-fusion-positive-non-small-cell-lung-cancer-and-ret-mutant-medullary-thyroid-cancer-both-published-in-the-new-england-journal-of-medicine-and-1032725643,negative,0.5070095062255859
2703,10/26/2023 12:16:41 PM,Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1032746054,positive,0.7053605914115906
2704,10/26/2023 12:19:29 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Alnylam Pharma (ALNY) and Thermo Fisher (TMO)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-alnylam-pharma-alny-and-thermo-fisher-tmo-1032746041,positive,0.9214524030685425
2705,10/26/2023 4:00:00 PM,Lilly to Participate in UBS Biopharma Conference 2023,PR Newswire,/news/stocks/lilly-to-participate-in-ubs-biopharma-conference-2023-1032744299,positive,0.9184742569923401
2706,10/26/2023 11:41:57 PM,CGDG: This New Dividend Growth ETF Looks Promising,TipRanks,/news/stocks/cgdg-this-new-dividend-growth-etf-looks-promising-1032748443,negative,0.8851513862609863
2707,10/27/2023 12:24:00 AM,"FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis",PR Newswire,/news/stocks/fda-approves-lilly-s-omvoh-mirikizumab-mrkz-a-first-in-class-treatment-for-adults-with-moderately-to-severely-active-ulcerative-colitis-1032745805,negative,0.9282107353210449
2708,10/27/2023 5:11:57 AM,FDA Approves Lilly's Omvoh For Ulcerative Colitis Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-omvoh-for-ulcerative-colitis-treatment-1032746241,negative,0.5871227383613586
2709,10/27/2023 10:33:58 PM,"Bears Roam Wall Street As Middle East Conflict, Earnings Outlook Raise Concerns Despite Strong Q3 US Economic Growth: This Week In Markets",Benzinga,/news/etf/bears-roam-wall-street-as-middle-east-conflict-earnings-outlook-raise-concerns-despite-strong-q3-us-economic-growth-this-week-in-markets-1032749881,neutral,0.7046886682510376
2710,10/30/2023 10:02:53 AM,Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1032755904,positive,0.7660669684410095
2711,10/31/2023 1:52:54 PM,Why Beam Therapeutics Stock Is Getting Bought Today,Benzinga,/news/stocks/why-beam-therapeutics-stock-is-getting-bought-today-1032759115,positive,0.8835479021072388
2712,10/31/2023 8:48:26 PM,AI-Powered Investing: 3 Promising Stocks for 2024,InvestorPlace,/news/stocks/ai-powered-investing-3-promising-stocks-for-2024-1032761245,negative,0.7236824035644531
2713,11/1/2023 1:48:01 AM,7 A-Rated Stocks to Buy in Q4,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-in-q4-1032761726,positive,0.8489571213722229
2714,11/1/2023 9:40:00 AM,Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On,InvestorPlace,/news/stocks/inside-cathie-woods-portfolio-3-stocks-she-is-betting-millions-on-1032764221,positive,0.9386062026023865
2715,11/1/2023 11:55:00 AM,Lilly Declares Fourth-Quarter 2023 Dividend,PR Newswire,/news/stocks/lilly-declares-fourth-quarter-2023-dividend-1032764380,positive,0.902026355266571
2716,11/1/2023 1:00:00 PM,"Hip-Hop Classic ""It Takes Two"" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease",PR Newswire,/news/stocks/hip-hop-classic-it-takes-two-takes-on-new-meaning-in-remix-to-elevate-importance-of-testing-for-kidney-disease-1032764655,positive,0.7516829371452332
2717,11/1/2023 3:01:13 PM,Eli Lilly and earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/eli_lilly-q3-earnings-preview-1032765587,positive,0.9291529059410095
2718,11/2/2023 5:31:20 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Amgen (AMGN), Eli Lilly & Co (LLY) and Repligen (RGEN)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-amgen-amgn-eli-lilly-co-lly-and-repligen-rgen-1032771764,neutral,0.9305192828178406
2719,11/2/2023 10:40:00 AM,7 A-Rated Tech Stocks to Buy for November,InvestorPlace,/news/stocks/7-a-rated-tech-stocks-to-buy-for-november-1032769617,positive,0.8813299536705017
2720,11/2/2023 11:30:00 AM,"Lilly Reports Third-Quarter 2023 Financial Results, Highlights Strong Sales Growth and Business Development Activity",PR Newswire,/news/stocks/lilly-reports-third-quarter-2023-financial-results-highlights-strong-sales-growth-and-business-development-activity-1032769525,negative,0.9539510011672974
2721,11/2/2023 11:34:22 AM,Eli Lilly And Co. Q3 Earnings Summary,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-summary-1032769550,positive,0.7800344824790955
2722,11/2/2023 12:25:46 PM,Eli Lilly Cuts Annual Earnings Outlook Below View - Update ,RTTNews,/news/stocks/eli-lilly-cuts-annual-earnings-outlook-below-view-update-1032769848,neutral,0.8831747174263
2723,11/2/2023 2:00:00 PM,Lilly Announces Details of Pirtobrutinib Presentations in B-Cell Malignancies at 2023 ASH Annual Meeting,PR Newswire,/news/stocks/lilly-announces-details-of-pirtobrutinib-presentations-in-b-cell-malignancies-at-2023-ash-annual-meeting-1032770295,positive,0.9264928698539734
2724,11/2/2023 6:24:15 PM,Positive Growth Prospects and Strategic Opportunities Bolster Buy Rating for Eli Lilly & Co: An Analyst’s Perspective,TipRanks,/news/stocks/positive-growth-prospects-and-strategic-opportunities-bolster-buy-rating-for-eli-lilly-co-an-analyst-s-perspective-1032774901,positive,0.507845401763916
2725,11/2/2023 6:58:06 PM,"Green Wave Boosts Stocks, Bonds As Traders Embrace Fed's Stance, Await Apple Earnings: What's Driving Markets Thursday?",Benzinga,/news/etf/green-wave-boosts-stocks-bonds-as-traders-embrace-fed-s-stance-await-apple-earnings-what-s-driving-markets-thursday-1032771843,positive,0.7291427254676819
2726,11/3/2023 3:50:06 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Irhythm Technologies (IRTC) and Seres Therapeutics (MCRB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-irhythm-technologies-irtc-and-seres-therapeutics-mcrb-1032776998,positive,0.920493483543396
2727,11/3/2023 12:32:34 PM,"Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Stryker (SYK) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-moderna-mrna-stryker-syk-and-eli-lilly-co-lly-1032778033,positive,0.9178615808486938
2728,11/3/2023 4:56:15 PM,The Importance of Brand Power: 3 Stocks to Consider,InvestorPlace,/news/stocks/the-importance-of-brand-power-3-stocks-to-consider-1032777152,positive,0.9025685787200928
2729,11/6/2023 1:10:55 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Rani Therapeutics Holdings (RANI) and Crispr Therapeutics AG (CRSP)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-rani-therapeutics-holdings-rani-and-crispr-therapeutics-ag-crsp-1032784199,positive,0.925994873046875
2730,11/8/2023 10:20:12 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Crispr Therapeutics AG (CRSP),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-crispr-therapeutics-ag-crsp-1032796758,positive,0.9151490926742554
2731,11/8/2023 6:22:00 PM,"FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems",PR Newswire,/news/stocks/fda-approves-lilly-s-zepbound-tirzepatide-for-chronic-weight-management-a-powerful-new-option-for-the-treatment-of-obesity-or-overweight-with-weight-related-medical-problems-1032795836,negative,0.8752784132957458
2732,11/8/2023 9:50:07 PM,Wall Street Analysts Are Neutral on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-neutral-on-top-healthcare-picks-1032799748,neutral,0.700346827507019
2733,11/8/2023 10:56:00 PM,Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma,PR Newswire,/news/stocks/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-1032796691,positive,0.7521809935569763
2734,11/9/2023 2:35:46 AM,Buy Rating for Eli Lilly & Co. Driven by Zepbound’s Potential Success in Obesity Market,TipRanks,/news/stocks/buy-rating-for-eli-lilly-co-driven-by-zepbound-s-potential-success-in-obesity-market-1032801132,negative,0.8617950677871704
2735,11/9/2023 4:46:15 AM,"Lilly : FDA Approves Zepbound For Chronic Weight Management, New Option For Treatment Of Obesity ",RTTNews,/news/stocks/lilly-fda-approves-zepbound-for-chronic-weight-management-new-option-for-treatment-of-obesity-1032797295,negative,0.8591799736022949
2736,11/9/2023 4:58:34 AM,Lilly Extends Tender Offer For POINT Biopharma Global Until Nov. 16 ,RTTNews,/news/stocks/lilly-extends-tender-offer-for-point-biopharma-global-until-nov-16-1032797306,positive,0.9009701609611511
2737,11/9/2023 8:25:47 AM,J.P. Morgan Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/j-p-morgan-remains-a-buy-on-eli-lilly-co-lly-1032802437,positive,0.9353289604187012
2738,11/9/2023 1:35:46 PM,"Analysts’ Top Healthcare Picks: Biogen (BIIB), Stryker (SYK)",TipRanks,/news/stocks/analysts-top-healthcare-picks-biogen-biib-stryker-syk-1032803039,negative,0.5827824473381042
2739,11/9/2023 2:16:01 PM,Eli Lilly & Co (LLY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bmo-capital-1032803082,negative,0.5500200390815735
2740,11/10/2023 12:00:00 PM,7 Biotech Stocks to Buy for Big-Time Gains,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-big-time-gains-1032806584,positive,0.8238290548324585
2741,11/10/2023 3:01:42 PM,"'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer",Benzinga,/news/stocks/i-want-you-to-buy-it-and-every-time-it-dips-i-want-you-to-buy-more-cramer-hypes-up-auto-parts-retailer-1032806934,positive,0.8606605529785156
2742,11/10/2023 5:20:06 PM,3 Stocks to Buy for Retirees Looking to Beat Inflation,InvestorPlace,/news/stocks/3-stocks-to-buy-for-retirees-looking-to-beat-inflation-1032807707,positive,0.8725924491882324
2743,11/12/2023 11:50:44 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), BridgeBio Pharma (BBIO) and Boston Scientific (BSX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-bridgebio-pharma-bbio-and-boston-scientific-bsx-1032812570,positive,0.9184757471084595
2744,11/13/2023 8:07:30 AM,"Up 65% YTD, Is Eli Lilly (NYSE:LLY) Stock Worth Buying?  ",TipRanks,/news/stocks/up-65-ytd-is-eli-lilly-nyse-lly-stock-worth-buying- -1032814439,positive,0.5869038105010986
2745,11/13/2023 12:06:31 PM,Eli Lilly & Co’s Stock Earns Buy Rating: Promising Obesity Treatment Results and Cardiovascular Benefits Beyond Weight Loss,TipRanks,/news/stocks/eli-lilly-co-s-stock-earns-buy-rating-promising-obesity-treatment-results-and-cardiovascular-benefits-beyond-weight-loss-1032814856,negative,0.9323914051055908
2746,11/13/2023 12:45:33 PM,Hold Rating for Eli Lilly & Co: A Mixed Outlook Amid Promising Clinical Results and Potential Market Challenges,TipRanks,/news/stocks/hold-rating-for-eli-lilly-co-a-mixed-outlook-amid-promising-clinical-results-and-potential-market-challenges-1032814950,neutral,0.8532143235206604
2747,11/13/2023 1:06:08 PM,Potential Synergies of Combined Treatment for T2D and Albuminuria Drive Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/potential-synergies-of-combined-treatment-for-t2d-and-albuminuria-drive-buy-rating-for-eli-lilly-co-1032814964,positive,0.504519522190094
2748,11/13/2023 1:56:07 PM,The Magnificent Seven: 7 Stocks That Could Make It the ‘Elite Eight’,InvestorPlace,/news/stocks/the-magnificent-seven-7-stocks-that-could-make-it-the-elite-eight-1032813036,positive,0.7947158217430115
2749,11/13/2023 3:06:28 PM,"‘Hold Your Horses,’ Says Goldman Sachs About Eli Lilly Stock",TipRanks,/news/stocks/hold-your-horses-says-goldman-sachs-about-eli-lilly-stock-1032815036,positive,0.7958210706710815
2750,11/13/2023 3:40:17 PM,"Analysts Conflicted on These Healthcare Names: Inogen (INGN), Eli Lilly & Co (LLY) and Celcuity (CELC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-inogen-ingn-eli-lilly-co-lly-and-celcuity-celc-1032815047,neutral,0.6680066585540771
2751,11/13/2023 8:00:11 PM,"Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly",Benzinga,/news/stocks/is-there-room-for-improvement-in-weight-loss-arena-analysts-evaluate-novo-nordisk-data-emphasize-opportunities-for-eli-lilly-1032814358,negative,0.9303251504898071
2752,11/14/2023 12:50:39 AM,"Analysts Conflicted on These Healthcare Names: Vertex (VERX), Eli Lilly & Co (LLY) and Mirum Pharmaceuticals (MIRM)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-vertex-verx-eli-lilly-co-lly-and-mirum-pharmaceuticals-mirm-1032817492,neutral,0.7788253426551819
2753,11/14/2023 2:48:37 AM,Royal Rule: Buy These 3 Dividend Aristocrats on Every. Single. Dip.,InvestorPlace,/news/stocks/royal-rule-buy-these-3-dividend-aristocrats-on-every-single-dip-1032815027,positive,0.9495763778686523
2754,11/14/2023 4:00:00 PM,Lilly to Participate in Evercore ISI HealthCONx Conference,PR Newswire,/news/stocks/lilly-to-participate-in-evercore-isi-healthconx-conference-1032818227,positive,0.8830476999282837
2755,11/14/2023 9:06:08 PM,Why It’s Time to Sell These 3 Hot Stocks,InvestorPlace,/news/stocks/why-its-time-to-sell-these-3-hot-stocks-1032819466,positive,0.9052941799163818
2756,11/14/2023 10:33:00 PM,Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma,PR Newswire,/news/stocks/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma-1032819518,positive,0.862384557723999
2757,11/15/2023 4:33:23 AM,Lilly Receives NRC Consent In Connection With Proposed Acquisition Of POINT Biopharma ,RTTNews,/news/stocks/lilly-receives-nrc-consent-in-connection-with-proposed-acquisition-of-point-biopharma-1032819978,positive,0.7894711494445801
2758,11/16/2023 8:25:29 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1032829152,positive,0.6347510814666748
2759,11/16/2023 9:51:17 PM,Goldman Sachs' 2024 Equity Outlook: Winning Stocks And Sectors To Watch,Benzinga,/news/stocks/goldman-sachs-2024-equity-outlook-winning-stocks-and-sectors-to-watch-1032829179,positive,0.8669686317443848
2760,11/17/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-1-2023-1032830849,positive,0.8586564660072327
2761,11/17/2023 2:00:00 PM,Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany,PR Newswire,/news/stocks/lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-germany-1032831044,negative,0.929612934589386
2762,11/17/2023 2:09:47 PM,"Eli Lilly To Construct A New $2.5 Billion High-tech Manufacturing Site In Alzey, Germany ",RTTNews,/news/stocks/eli-lilly-to-construct-a-new-2-5-billion-high-tech-manufacturing-site-in-alzey-germany-1032831103,negative,0.6663668155670166
2763,11/17/2023 5:23:20 PM,The Relative Strength Index (RSI) Indicator: Does It Work?,InvestorPlace,/news/stocks/the-relative-strength-index-rsi-indicator-does-it-work-1032832168,positive,0.8995361328125
2764,11/19/2023 3:51:26 PM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Karuna Therapeutics (KRTX) and Masimo (MASI)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-karuna-therapeutics-krtx-and-masimo-masi-1032833752,neutral,0.7869997024536133
2765,11/20/2023 12:35:42 PM,"Eli Lilly & Co: A Bullish Outlook Based on Robust Growth Potential, Strong Financial Performance, and Promising Pipeline Strategy",TipRanks,/news/stocks/eli-lilly-co-a-bullish-outlook-based-on-robust-growth-potential-strong-financial-performance-and-promising-pipeline-strategy-1032837224,negative,0.9414153695106506
2766,11/20/2023 8:00:42 PM,Analyst Expectations for Eli Lilly's Future,Benzinga,/news/stocks/analyst-expectations-for-eli-lilly-s-future-1032836776,negative,0.8380778431892395
2767,11/21/2023 8:25:44 AM,Cantor Fitzgerald Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-keeps-their-buy-rating-on-eli-lilly-co-lly-1032840641,positive,0.9108292460441589
2768,11/21/2023 2:55:13 PM,Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?,Benzinga,/news/etf/can-weight-loss-drug-ozempic-tip-the-scales-for-tema-s-new-healthcare-etf-1032839197,positive,0.7884793281555176
2769,11/21/2023 9:16:25 PM,"Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others",Benzinga,/news/stocks/alzheimer-s-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-others-1032840637,negative,0.923071026802063
2770,11/22/2023 6:13:03 PM,3 Healthcare Stocks to Scoop Up as They Change the Medical Landscape,InvestorPlace,/news/stocks/3-healthcare-stocks-to-scoop-up-as-they-change-the-medical-landscape-1032843890,positive,0.8476630449295044
2771,11/26/2023 11:45:31 PM,Robust Demand and Promising Forecasts Reinforce Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/robust-demand-and-promising-forecasts-reinforce-buy-rating-for-eli-lilly-co-1032850866,negative,0.9488939642906189
2772,11/28/2023 2:00:00 PM,"Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego",PR Newswire,/news/stocks/alexandria-real-estate-equities-inc-announces-exclusive-partnership-with-lilly-to-expand-lilly-gateway-labs-to-san-diego-1032854533,negative,0.9054362773895264
2773,11/28/2023 2:00:00 PM,Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego,PR Newswire,/news/stocks/lilly-announces-plans-to-open-its-first-ever-gateway-labs-site-in-san-diego-1032854501,positive,0.7745658755302429
2774,11/28/2023 2:15:03 PM,Lilly To Open New Gateway Labs Location In Partnership With Alexandria Real Estate Equities ,RTTNews,/news/stocks/lilly-to-open-new-gateway-labs-location-in-partnership-with-alexandria-real-estate-equities-1032854638,negative,0.506134033203125
2775,11/30/2023 2:25:31 AM,Truist Financial Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1032862775,positive,0.7646060585975647
2776,12/1/2023 2:10:12 PM,Analysts Offer Insights on Healthcare Companies: Pfizer (PFE) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-and-eli-lilly-co-lly-1032867939,positive,0.9248926639556885
2777,12/1/2023 4:55:50 PM,"Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst",Benzinga,/news/stocks/weight-loss-drugs---novo-nordisk-a-primary-beneficiary-in-obesity-space-currently-controlled-by-two-players-says-analyst-1032867014,positive,0.9152721166610718
2778,12/1/2023 11:22:00 PM,Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Thera...,PR Newswire,/news/stocks/jaypirca-pirtobrutinib-now-approved-by-u-s-fda-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-thera-1032867707,negative,0.7561066150665283
2779,12/2/2023 5:46:20 PM,Lilly's Jaypirca Gets Second Approval From FDA ,RTTNews,/news/stocks/lilly-s-jaypirca-gets-second-approval-from-fda-1032868093,negative,0.8532283306121826
2780,12/4/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-15-2023-1032869940,positive,0.8619575500488281
2781,12/4/2023 12:50:33 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032872254,negative,0.5521676540374756
2782,12/4/2023 1:10:30 PM,"VICI, LLY, ET Stocks: 3 Analyst Favorites with “Strong Buy” Technical Indicators",TipRanks,/news/stocks/vici-lly-et-stocks-3-analyst-favorites-with-strong-buy-technical-indicators-1032872275,negative,0.9285436272621155
2783,12/4/2023 1:17:32 PM,Lilly Says Tender Offer Expiration Extended Related To POINT Biopharma Acquisition ,RTTNews,/news/stocks/lilly-says-tender-offer-expiration-extended-related-to-point-biopharma-acquisition-1032870079,neutral,0.5695321559906006
2784,12/4/2023 10:20:13 PM,"Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market",Benzinga,/news/etf/roche-pfizer-race-to-find-next-ozempic-as-pharma-giants-hustle-to-join-obesity-treatment-market-1032871966,positive,0.8253699541091919
2785,12/5/2023 1:38:00 PM,Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity,PR Newswire,/news/stocks/zepbound-tirzepatide-is-now-available-in-u-s-pharmacies-for-adults-living-with-obesity-1032873874,positive,0.7328212857246399
2786,12/5/2023 2:01:57 PM,Eli Lilly Announces Availability Of Zepbound In U.S. Pharmacies - Quick Facts ,RTTNews,/news/stocks/eli-lilly-announces-availability-of-zepbound-in-u-s-pharmacies-quick-facts-1032874006,positive,0.6919081211090088
2787,12/5/2023 2:15:00 PM,Lilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer S...,PR Newswire,/news/stocks/lilly-to-present-final-overall-survival-analysis-from-the-monarch-3-study-of-verzenio-abemaciclib-and-additional-results-from-its-breast-cancer-portfolio-at-the-2023-san-antonio-breast-cancer-s-1032874088,positive,0.8495013117790222
2788,12/5/2023 3:24:03 PM,Eli Lilly To Present Final Survival Results Of MONARCH 3 Trial Of Verzenio In Breast Cancer ,RTTNews,/news/stocks/eli-lilly-to-present-final-survival-results-of-monarch-3-trial-of-verzenio-in-breast-cancer-1032874543,positive,0.8817851543426514
2789,12/6/2023 5:23:37 PM,"JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities",Benzinga,/news/stocks/jnj-ceo-signals-no-rush-into-weight-loss-drug-realm-emphasizes-different-priorities-1032879077,positive,0.8401648998260498
2790,12/8/2023 10:15:00 AM,Challenging the Magnificent 7: 3 Stocks on the Rise,InvestorPlace,/news/stocks/challenging-the-magnificent-7-3-stocks-on-the-rise-1032885008,negative,0.4912888705730438
2791,12/8/2023 5:25:00 PM,"Lilly Announces 15% Dividend Increase, First-Quarter 2024 Dividend",PR Newswire,/news/stocks/lilly-announces-15-dividend-increase-first-quarter-2024-dividend-1032886280,negative,0.9034234881401062
2792,12/11/2023 12:20:57 PM,"Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Legend Biotech (LEGN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-healthequity-hqy-legend-biotech-legn-and-eli-lilly-co-lly-1032891195,positive,0.9077398180961609
2793,12/11/2023 4:54:00 PM,"Lilly's Zepbound™ (tirzepatide) achieved additional 6.7% weight loss following a 36-week open-label lead-in period, for a total mean weight loss of 26.0% from study entry over 88 weeks",PR Newswire,/news/stocks/lilly-s-zepbound-tirzepatide-achieved-additional-6-7-weight-loss-following-a-36-week-open-label-lead-in-period-for-a-total-mean-weight-loss-of-26-0-from-study-entry-over-88-weeks-1032890271,neutral,0.5782852172851562
2794,12/12/2023 1:30:00 AM,Updated Data from the BRUIN Phase 1/2 Study of Pirtobrutinib in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Presented at the 2023 ASH Annual Meeting,PR Newswire,/news/stocks/updated-data-from-the-bruin-phase-1-2-study-of-pirtobrutinib-in-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-presented-at-the-2023-ash-annual-meeting-1032891215,positive,0.9407691359519958
2795,12/12/2023 12:20:23 PM,"Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Eli Lilly & Co (LLY) and Disc Medicine (IRON)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-centessa-pharmaceuticals-cnta-eli-lilly-co-lly-and-disc-medicine-iron-1032895160,positive,0.9189989566802979
2796,12/12/2023 4:30:26 PM,"Did Eli Lilly Stock Rally Too Far, Too Fast? Goldman Sachs Weighs In",TipRanks,/news/stocks/did-eli-lilly-stock-rally-too-far-too-fast-goldman-sachs-weighs-in-1032895363,positive,0.8018282055854797
2797,12/13/2023 7:13:00 AM,"ABBV, NVO, or LLY: Which Healthcare Stock Could Generate the Highest Returns?",TipRanks,/news/stocks/abbv-nvo-or-lly-which-healthcare-stock-could-generate-the-highest-returns-1032898484,positive,0.9054728150367737
2798,12/14/2023 7:14:00 PM,Billionaire Ken Griffin Bets Big on 2 ‘Strong Buy’ Stocks — Eli Lilly and Microsoft,TipRanks,/news/stocks/billionaire-ken-griffin-bets-big-on-2-strong-buy-stocks-—-eli-lilly-and-microsoft-1032903660,negative,0.9144222736358643
2799,12/15/2023 1:55:17 PM,The New Magnificent 7: 7 Stocks Rising to Prominence,InvestorPlace,/news/stocks/the-new-magnificent-7-stocks-7-more-players-rising-to-prominence-1032904774,negative,0.5082575678825378
2800,12/15/2023 3:51:25 PM,3 Stocks Wall Street Bulls Are Betting On Big-Time,InvestorPlace,/news/stocks/3-stocks-wall-street-bulls-are-betting-on-big-time-1032905400,positive,0.851802408695221
2801,12/17/2023 6:46:58 PM,Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?,InvestorPlace,/news/stocks/are-novembers-3-biggest-stock-losers-worth-snapping-up-now-1032907117,positive,0.5884045362472534
2802,12/18/2023 10:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Elevance Health (ELV) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pfizer-pfe-elevance-health-elv-and-eli-lilly-co-lly-1032910493,positive,0.9175032377243042
2803,12/18/2023 12:25:58 PM,Eli Lilly & Co: A Strong Buy on Robust Diabetes and Oncology Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-diabetes-and-oncology-growth-prospects-1032910579,negative,0.9309746026992798
2804,12/18/2023 12:45:00 PM,"Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 22, 2023",PR Newswire,/news/stocks/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-22-2023-1032908517,positive,0.8492469191551208
2805,12/18/2023 8:39:37 PM,Obesity/Diabetes Drug Class GLP-1s' Cost-Saving Potential: Decoding Impact on Healthcare Spending,Benzinga,/news/stocks/obesity-diabetes-drug-class-glp-1s-cost-saving-potential-decoding-impact-on-healthcare-spending-1032910224,positive,0.8431267738342285
2806,12/19/2023 6:03:48 AM,Goldman Sachs: Eli Lilly's Shares May Surge By 140% With GLP-1 Drug Boom,Benzinga,/news/stocks/goldman-sachs-eli-lilly-s-shares-may-surge-by-140-with-glp-1-drug-boom-1032910837,negative,0.9491458535194397
2807,12/21/2023 2:00:45 PM,What Analysts Are Saying About Eli Lilly Stock,Benzinga,/news/stocks/what-analysts-are-saying-about-eli-lilly-stock-1032919073,positive,0.9332314133644104
2808,12/22/2023 12:51:10 PM,Looking Beyond Tech: 7 High-Growth Stocks for Substantial Returns,InvestorPlace,/news/stocks/looking-beyond-tech-7-high-growth-stocks-for-substantial-returns-1032922090,negative,0.5465737581253052
2809,12/22/2023 9:21:22 PM,7 Small-Cap Stocks That Wall Street Loves for Good Reason ,InvestorPlace,/news/stocks/7-small-cap-stocks-that-analysts-are-upgrading-1032923323,positive,0.7156015038490295
2810,12/26/2023 8:02:49 PM,Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst,Benzinga,/news/stocks/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-karxt-analyst-1032926298,negative,0.8689960837364197
2811,12/27/2023 2:31:00 PM,Lilly Completes Acquisition of POINT Biopharma,PR Newswire,/news/stocks/lilly-completes-acquisition-of-point-biopharma-1032927846,positive,0.8595046997070312
2812,12/27/2023 3:11:10 PM,Lilly Acquires Point Biopharma For Approx. $1.4 Bln ,RTTNews,/news/stocks/lilly-acquires-point-biopharma-for-approx-1-4-bln-1032927941,positive,0.9202510118484497
2813,12/27/2023 6:42:14 PM,"Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned",Benzinga,/news/stocks/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned-1032928584,negative,0.94742351770401
2814,12/28/2023 2:54:49 AM,"Innovent Biologics, Xuanzhu Collaborate On Clinical Trial For Advanced Solid Tumors In China ",RTTNews,/news/stocks/innovent-biologics-xuanzhu-collaborate-on-clinical-trial-for-advanced-solid-tumors-in-china-1032928924,positive,0.6167594194412231
2815,12/28/2023 1:33:14 PM,"Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts",Benzinga,/news/stocks/eli-lilly-johnson-johnson-and-other-health-care-stocks-from-wall-street-s-most-accurate-analysts-1032929866,positive,0.8699533939361572
2816,12/29/2023 12:22:40 AM,Top 3 Large-Cap Growth Stock Picks for the New Year,InvestorPlace,/news/stocks/top-3-large-cap-growth-stock-picks-for-the-new-year-1032931106,positive,0.8463602066040039
2817,12/30/2023 9:00:00 PM,3 Ken Griffin Stocks to Invest Like Citadel,InvestorPlace,/news/stocks/3-ken-griffin-stocks-to-invest-like-citadel-1032933562,positive,0.9105806946754456
2818,1/1/2024 1:56:17 PM,2024’s Power Players: 7 Stocks Racing to a Trillion Valuation,InvestorPlace,/news/stocks/2024s-power-players-7-stocks-racing-to-a-trillion-valuation-1032934899,positive,0.7322298288345337
2819,1/2/2024 2:51:46 PM,"Analysts Conflicted on These Healthcare Names: Staar Surgical (STAA), Venus Concept (VERO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-staar-surgical-staa-venus-concept-vero-and-eli-lilly-co-lly-1032938548,neutral,0.7378684878349304
2820,1/2/2024 4:00:00 PM,Lilly to Participate in J.P. Morgan Healthcare Conference,PR Newswire,/news/stocks/lilly-to-participate-in-j-p-morgan-healthcare-conference-1032937015,positive,0.8359732031822205
2821,1/3/2024 10:42:40 PM,The 7 Best Meme Stocks to Buy Now,InvestorPlace,/news/stocks/best-meme-stocks-1031269612,positive,0.9085869193077087
2822,1/4/2024 2:02:53 PM,"Eli Lilly Launches LillyDirect To Help Patients Manage Health, Access Medicines ",RTTNews,/news/stocks/eli-lilly-launches-lillydirect-to-help-patients-manage-health-access-medicines-1032942973,positive,0.5872573852539062
2823,1/4/2024 8:29:37 PM,"EXCLUSIVE: Buy The Dip — There's A Lot More Upside To Come, Says Marc Chaikin",Benzinga,/news/stocks/exclusive-buy-the-dip-—-there-s-a-lot-more-upside-to-come-says-marc-chaikin-1032944300,negative,0.6770836114883423
2824,1/4/2024 11:53:24 PM,Global Giants: 3 Multinational Corporations to Outperform in 2024,InvestorPlace,/news/stocks/global-giants-3-multinational-corporations-to-outperform-in-2024-1032944623,negative,0.4937356412410736
2825,1/5/2024 3:25:22 PM,Short Sellers' Nightmare: $195B Evaporates In 2023's Market Surge,Benzinga,/news/etf/short-sellers-nightmare-195b-evaporates-in-2023-s-market-surge-1032946074,neutral,0.9086310267448425
2826,1/5/2024 6:20:23 PM,Dry January Investing: Trading Pints For Portfolio Growth,Benzinga,/news/etf/dry-january-investing-trading-pints-for-portfolio-growth-1032946780,positive,0.8352900147438049
2827,1/5/2024 6:30:11 PM,Why Is WeightWatchers (WW) Stock Down 5% Today?,InvestorPlace,/news/stocks/why-is-weightwatchers-ww-stock-down-5-today-1032946887,neutral,0.966195285320282
2828,1/5/2024 9:21:16 PM,3 Stocks to Make You the Millionaire Next Door: 2024 Edition,InvestorPlace,/news/stocks/3-stocks-to-make-you-the-millionaire-next-door-2024-edition-1032947071,positive,0.9336923956871033
2829,1/8/2024 7:28:48 PM,Q1’s Rising Stars: 3 Dividend Stocks with Massive Upside,InvestorPlace,/news/stocks/3-dividend-stocks-to-buy-for-upside-in-2024-1032951464,positive,0.8148317933082581
2830,1/9/2024 6:30:24 AM,"Analysts Offer Insights on Healthcare Companies: Walgreens Boots Alliance (WBA), InflaRx (IFRX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-walgreens-boots-alliance-wba-inflarx-ifrx-and-eli-lilly-co-lly-1032954795,positive,0.9196985363960266
2831,1/9/2024 11:19:15 AM,Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/9/2024,TipRanks,/news/stocks/analysts-and-technical-indicators-agree-these-3-stocks-are-strong-buys-–-1-9-2024-1032955265,negative,0.9279174208641052
2832,1/10/2024 2:05:20 AM,Goldman Sachs Sticks to Its Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/goldman-sachs-sticks-to-its-hold-rating-for-eli-lilly-co-lly-1032956046,positive,0.8661994338035583
2833,1/10/2024 11:00:21 AM,Analysts Offer Insights on Healthcare Companies: Ardelyx (ARDX) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ardelyx-ardx-and-eli-lilly-co-lly-1032957350,positive,0.9189401865005493
2834,1/11/2024 2:15:56 PM,Pfizer’s 2024 Outlook: Is PFE Stock Poised for a Major Rebound?,InvestorPlace,/news/stocks/pfizers-2024-outlook-is-pfe-stock-poised-for-a-major-rebound-1032960713,negative,0.7994892597198486
2835,1/11/2024 5:40:37 PM,"Large Drugmakers Show Enthusiasm To Embrace $100B Obesity Market, Despite Novo And Lilly's Dominance",Benzinga,/news/stocks/large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lilly-s-dominance-1032961467,negative,0.9427829384803772
2836,1/11/2024 9:38:39 PM,3 Stocks to Buy in the Booming Field of Gene Editing,InvestorPlace,/news/stocks/3-gene-editing-stocks-to-profit-from-the-coming-boom-1032962080,positive,0.7116246819496155
2837,1/12/2024 7:21:55 PM,Portfolio Protection: 7 Risky Stocks to Drop Right Now,InvestorPlace,/news/stocks/portfolio-protection-7-risky-stocks-to-drop-right-now-1032964859,neutral,0.9589329957962036
2838,1/19/2024 1:05:15 PM,Senate panel to consider subpoenas for J&J and Merck CEOs,Seeking Alpha,https://seekingalpha.com/news/4056351-sen-bernie-sanders-weighs-subpoenas-jj-merck-ceos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.576749861240387
2839,1/19/2024 4:18:03 PM,Eli Lilly production plant said to be under renewed FDA scrutiny,Seeking Alpha,https://seekingalpha.com/news/4056498-eli-lilly-plant-renewed-fda-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.529183030128479
2840,1/19/2024 10:03:58 PM,S&P 500 Shatters Records: The Top-Performing Stocks In January 2024,Benzinga,/news/etf/s-p-500-shatters-records-the-top-performing-stocks-in-january-2024-1032981017,neutral,0.6330354809761047
2841,1/21/2024 5:00:01 PM,Anti-obesity meds can expand the market for weight loss surgery: Bernstein,Seeking Alpha,https://seekingalpha.com/news/4056663-glp-1s-can-expand-market-weight-loss-surgery-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.820827305316925
2842,1/23/2024 8:31:16 AM,"Analysts Offer Insights on Healthcare Companies: Kineta (KA), Eli Lilly & Co (LLY) and Iovance Biotherapeutics (IOVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-kineta-ka-eli-lilly-co-lly-and-iovance-biotherapeutics-iova-1032987150,positive,0.9106814861297607
2843,1/23/2024 3:00:20 PM,The Latest Analyst Ratings For Eli Lilly,Benzinga,/news/stocks/the-latest-analyst-ratings-for-eli-lilly-1032987935,positive,0.9401240944862366
2844,1/24/2024 4:20:18 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032990859,negative,0.5521676540374756
2845,1/24/2024 6:53:17 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Crispr Therapeutics AG (CRSP) and Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-crispr-therapeutics-ag-crsp-and-gilead-sciences-gild-1032991442,positive,0.9182502627372742
2846,1/24/2024 7:16:06 PM,Eli Lilly gene therapy restores hearing in Phase 1/2 trial,Seeking Alpha,https://seekingalpha.com/news/4058092-eli-lilly-gene-therapy-restores-hearing-phase-12-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6228726506233215
2847,1/25/2024 11:35:07 AM,Eli Lilly's Mounjaro dose available in limited amounts through February,Seeking Alpha,https://seekingalpha.com/news/4058355-eli-lillys-mounjaro-dose-available-in-limited-amounts-through-february?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9147327542304993
2848,1/25/2024 6:01:15 PM,5 Mega-Cap Stocks Ready to Make the Magnificent 7 a Dynamic Dozen,InvestorPlace,/news/stocks/5-mega-cap-stocks-ready-to-make-the-magnificent-7-a-dynamic-dozen-1032998173,positive,0.7444758415222168
2849,1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9376139640808105
2850,1/26/2024 7:15:39 PM,Perspective gains as B. Riley sees over 100% upside on radiopharma prospects,Seeking Alpha,https://seekingalpha.com/news/4059244-perspective-stock-gains-b-riley-starts-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9548143148422241
2851,1/26/2024 8:57:19 PM,3 Biotech Stocks with Potential for Major Medical Breakthroughs in 2024,InvestorPlace,/news/stocks/biotech-breakthroughs-in-2024-and-the-3-stocks-that-can-benefit-1033002304,positive,0.5140779614448547
2852,1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8954368233680725
2853,1/29/2024 11:05:27 AM,Eli Lilly: Expanding Market Reach with KwikPen for Zepbound – A Buy Rating Review,TipRanks,/news/stocks/eli-lilly-expanding-market-reach-with-kwikpen-for-zepbound-–-a-buy-rating-review-1033005772,negative,0.8720732927322388
2854,1/29/2024 12:20:49 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Regeneron (REGN),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-regeneron-regn-1033006315,positive,0.9210485219955444
2855,1/29/2024 3:20:11 PM,Eli Lilly said to be in talks with Germany to win coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4059549-eli-lilly-talks-win-german-coverage-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8329208493232727
2856,1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.735865592956543
2857,1/30/2024 7:30:47 AM,HUTCHMED Announces Marketing Approval For ELUNATE By Pharmacy And Poisons Board Of Hong Kong ,RTTNews,/news/stocks/hutchmed-announces-marketing-approval-for-elunate-by-pharmacy-and-poisons-board-of-hong-kong-1033008450,positive,0.772239089012146
2858,1/30/2024 1:59:38 PM,Eli Lilly wins Canada approval for severe hair loss therapy,Seeking Alpha,https://seekingalpha.com/news/4060020-eli-lilly-wins-canada-approval-for-severe-hair-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8736494183540344
2859,1/30/2024 3:45:12 PM,"Tech Giants' Market Concentration Echoes Dot-Com Bubble Peak, Analysts Warn",Benzinga,/news/stocks/tech-giants-market-concentration-echoes-dot-com-bubble-peak-analysts-warn-1033010437,negative,0.4217306971549988
2860,1/31/2024 3:56:09 PM,Abbott launches nutritional brand for GLP-1 users (update),Seeking Alpha,https://seekingalpha.com/news/4060732-abbott-launches-nutritional-product-brand-for-glp-1-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8129065036773682
2861,1/31/2024 5:03:34 PM,Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-biotech-stocks-with-strong-buy-ratings-for-january-2024-1033016369,negative,0.8527645468711853
2862,1/31/2024 5:32:57 PM,"Lilly, Novo could be first trillion-dollar health stocks: world's largest sovereign wealth fund",Seeking Alpha,https://seekingalpha.com/news/4060795-lilly-novo-first-trillion-dollar-health-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7582072615623474
2863,1/31/2024 11:03:00 PM,"LLY, ABT, CVS: Which Healthcare Stock Do Analysts Prefer?",TipRanks,/news/stocks/lly-abt-cvs-which-healthcare-stock-do-analysts-prefer-1033017434,positive,0.937714159488678
2864,2/1/2024 2:38:18 PM,NeuroBo to begin Phase 1 testing of potential Wegovy rival,Seeking Alpha,https://seekingalpha.com/news/4061296-neurobo-to-begin-phase-1-testing-of-potential-wegovy-rival?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5257337689399719
2865,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49058476090431213
2866,2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49058476090431213
2867,2/1/2024 4:28:24 PM,The Road to a Trillion: 3 Stocks Next in Line for the Mega Milestone,InvestorPlace,/news/stocks/the-road-to-a-trillion-3-stocks-next-in-line-for-the-mega-milestone-1033021784,positive,0.6119634509086609
2868,2/1/2024 6:22:16 PM,"Lilly, Zoetis, Abbott least shorted stocks in S&P 500 health sector in mid-Jan",Seeking Alpha,https://seekingalpha.com/news/4061498-lilly-zoetis-abbott-least-shorted-stocks-in-health-sector-till-mid-jan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7107202410697937
2869,2/2/2024 4:15:43 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033023698,positive,0.6347510814666748
2870,2/2/2024 6:06:23 PM,AbbVie cites tailwinds to Botox business from weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4062286-abbvie-cites-tailwinds-botox-sales-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9681975841522217
2871,2/2/2024 6:29:10 PM,What's Going On With Eli Lilly Stock Today?,Benzinga,/news/stocks/what-s-going-on-with-eli-lilly-stock-today-1033026202,neutral,0.6076439619064331
2872,2/2/2024 7:39:14 PM,3 Pharma Stocks to Sell in February Before They Crash and Burn,InvestorPlace,/news/stocks/3-pharma-stocks-to-sell-in-february-before-they-crash-and-burn-1033026411,positive,0.7678835988044739
2873,2/2/2024 8:00:00 PM,"Catalyst watch: Alibaba earnings, World Defense Show, Fed speakers unleashed and Super Bowl buzz",Seeking Alpha,https://seekingalpha.com/news/4060879-catalyst-watch-alibaba-earnings-world-defense-show-fed-speakers-unleashed-and-super-bowl-buzz?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9349634647369385
2874,2/3/2024 6:49:12 PM,7 Mutual Funds That Will Outperform in Any Market,InvestorPlace,/news/stocks/7-mutual-funds-that-will-outperform-in-any-market-1033026808,negative,0.5209316611289978
2875,2/4/2024 1:45:00 PM,"Earnings week ahead: Alibaba, PepsiCo, Disney, Palantir, McDonalds, Ford and more",Seeking Alpha,https://seekingalpha.com/news/4062246-earnings-week-ahead-alibaba-pepsico-disney-palantir-mcdonalds-philip-morris-ford-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8989530205726624
2876,2/5/2024 8:10:43 AM,"Analysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Eli Lilly & Co (LLY) and Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-roche-holding-ag-otherrhhvf-eli-lilly-co-lly-and-idexx-laboratories-idxx-1033029408,neutral,0.6721388697624207
2877,2/5/2024 11:35:53 AM,Amgen weight loss drug shows promising early data,Seeking Alpha,https://seekingalpha.com/news/4062458-amgen-weight-loss-drug-shows-promising-early-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9441946744918823
2878,2/5/2024 12:59:52 PM,Eli Lilly & Co: A Buy Rating Anchored in Growth Prospects and Innovative Pipeline,TipRanks,/news/stocks/eli-lilly-co-a-buy-rating-anchored-in-growth-prospects-and-innovative-pipeline-1033031053,negative,0.7469039559364319
2879,2/5/2024 3:01:13 PM,Here's what Wall Street expects from Eli Lilly and's earnings report,Markets Insider Automation,/news/stocks/eli_lilly-q4-quarterly-earnings-preview-stock-1033030181,positive,0.9245331287384033
2880,2/5/2024 3:51:44 PM,Eli Lilly sees highest intraday trade since November ahead of earnings,Seeking Alpha,https://seekingalpha.com/news/4062641-eli-lilly-sees-highest-intraday-trade-since-november-ahead-of-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5470156669616699
2881,2/5/2024 4:04:02 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4062654-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8660826683044434
2882,2/5/2024 4:32:52 PM,"Estée Lauder Posts Upbeat Earnings, Joins ON Semiconductor, Tyson Foods And Other Big Stocks Moving Higher On Monday",Benzinga,/news/stocks/estée-lauder-posts-upbeat-earnings-joins-on-semiconductor-tyson-foods-and-other-big-stocks-moving-higher-on-monday-1033030909,negative,0.9348865747451782
2883,2/5/2024 5:38:30 PM,Eli Lilly Q4 results to highlight Zepbound uptake,Seeking Alpha,https://seekingalpha.com/news/4062717-eli-lilly-q4-results-highlight-zepbound-uptake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9195890426635742
2884,2/5/2024 6:56:50 PM,Why Air Products and Chemicals Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-air-products-and-chemicals-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-monday-s-mid-day-session-1033031395,neutral,0.8462857604026794
2885,2/5/2024 7:18:07 PM,"NVO, LLY or AZN: Which Pharma Stock Is the Best Weight-Loss Investment?",InvestorPlace,/news/stocks/nvo-lly-or-azn-which-pharma-stock-is-the-best-weight-loss-investment-1033031555,positive,0.9268656969070435
2886,2/5/2024 9:14:41 PM,3 High-Octane Growth Stocks Not Slowing Down Any Time Soon,InvestorPlace,/news/stocks/3-high-octane-growth-stocks-not-slowing-down-any-time-soon-1033031767,positive,0.5961577892303467
2887,2/6/2024 1:31:38 AM,"Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY), Premier (PINC) and Idexx Laboratories (IDXX)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-premier-pinc-and-idexx-laboratories-idxx-1033032171,neutral,0.6672547459602356
2888,2/6/2024 4:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Vertex Pharmaceuticals (VRTX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-vertex-pharmaceuticals-vrtx-1033033385,positive,0.9126845598220825
2889,2/6/2024 7:05:41 AM,Eli Lilly Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts,Benzinga,/news/stocks/eli-lilly-likely-to-report-higher-q4-earnings-here-are-the-recent-forecast-changes-from-wall-street-s-most-accurate-analysts-1033033240,positive,0.8643459677696228
2890,2/6/2024 11:47:47 AM,Eli Lilly beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4063010-eli-lilly-beats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7632657885551453
2891,2/6/2024 12:25:47 PM,Eli Lilly beats in Q4 as obesity drug sales blow past estimates,Seeking Alpha,https://seekingalpha.com/news/4063037-eli-lilly-stock-gains-q4-beats-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8121507167816162
2892,2/6/2024 12:28:18 PM,"Eli Lilly in charts: Verzenio and Mounjaro drive revenue growth, while Humalog and Trulicity decline",Seeking Alpha,https://seekingalpha.com/news/4063035-eli-lilly-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7921180725097656
2893,2/6/2024 12:49:11 PM,"Eli Lilly And Co. Q4 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q4-profit-increases-beats-estimates-1033034264,negative,0.9386289119720459
2894,2/6/2024 1:03:29 PM,Eli Lilly Guides FY24 Revenues Above Estimates - Update ,RTTNews,/news/stocks/eli-lilly-guides-fy24-revenues-above-estimates-update-1033034314,positive,0.7151403427124023
2895,2/6/2024 2:15:00 PM,"6 stocks to watch on Tuesday: Spotify, Eli Lilly, Chipotle, DocuSign and more",Seeking Alpha,https://seekingalpha.com/news/4063134-6-stocks-to-watch-on-tuesday-spotify-eli-lilly-chipotle-docusign-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9196032285690308
2896,2/6/2024 2:55:15 PM,"Biggest stock movers today: DocuSign, BP, Palantir Technologies, and more",Seeking Alpha,https://seekingalpha.com/news/4062976-biggest-stock-movers-today-palantir-technologies-chegg-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8939441442489624
2897,2/6/2024 3:06:14 PM,Eli Lilly Q4 Results Top Estimates ,RTTNews,/news/stocks/eli-lilly-q4-results-top-estimates-1033035398,positive,0.6614784598350525
2898,2/6/2024 5:58:10 PM,Eli Lilly hurts NASH drug developers after mid-stage win for obesity therapy,Seeking Alpha,https://seekingalpha.com/news/4063338-nash-drug-developers-drop-trial-win-lilly-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5459367632865906
2899,2/6/2024 6:23:49 PM,Lilly reportedly worried about impact of Catalent/Novo deal,Seeking Alpha,https://seekingalpha.com/news/4063363-lilly-reportedly-worried-about-impact-of-catalent-novo-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9060004353523254
2900,2/6/2024 7:48:01 PM,"Eli Lilly, Novo Nordisk Could Be First Trillion-Dollar Drug Stocks",InvestorPlace,/news/stocks/eli-lilly-novo-nordisk-could-be-first-trillion-dollar-drug-stocks-1033036679,positive,0.874981701374054
2901,2/6/2024 8:24:05 PM,"Tech Slides, Chinese Stocks Rebound, New York Community Bancorp Tumbles: What's Driving Markets Tuesday?",Benzinga,/news/etf/tech-slides-chinese-stocks-rebound-new-york-community-bancorp-tumbles-what-s-driving-markets-tuesday-1033036589,neutral,0.8938384652137756
2902,2/6/2024 8:33:01 PM,"Move Over, Tesla: 5 Stocks That Could Take Its Place in the Magnificent Seven",InvestorPlace,/news/stocks/move-over-tesla-5-stocks-that-could-take-its-place-in-the-magnificent-seven-1033036706,positive,0.8855504989624023
2903,2/6/2024 9:16:24 PM,Catalent ticks lower amid report Indiana plant may have quality issues,Seeking Alpha,https://seekingalpha.com/news/4063443-catalent-ticks-lower-amid-report-indiana-plant-may-have-quality-issues?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9090938568115234
2904,2/6/2024 9:31:15 PM,The Top 25 Stocks to Buy Immediately According to AI: February 2024 Edition,InvestorPlace,/news/stocks/the-top-25-stocks-to-buy-immediately-according-to-ai-february-2024-edition-1033036939,positive,0.9487829208374023
2905,2/7/2024 4:15:53 AM,Wells Fargo Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-remains-a-buy-on-eli-lilly-co-lly-1033039021,positive,0.9333938956260681
2906,2/7/2024 10:15:43 AM,Eli Lilly & Co.: A Balanced Outlook with Hold Rating Amid Growth and Uncertainties,TipRanks,/news/stocks/eli-lilly-co-a-balanced-outlook-with-hold-rating-amid-growth-and-uncertainties-1033040694,negative,0.8580012917518616
2907,2/7/2024 10:21:13 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Impedimed Limited (OtherIPDQF)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-exelixis-exel-and-impedimed-limited-otheripdqf-1033040645,positive,0.9171860814094543
2908,2/7/2024 12:21:04 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Exelixis (EXEL),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-exelixis-exel-1033041729,positive,0.9149182438850403
2909,2/7/2024 1:37:02 PM,Eli Lilly: Strong Q4 Performance and Promising Tirzepatide Trials Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-strong-q4-performance-and-promising-tirzepatide-trials-justify-buy-rating-1033042113,negative,0.9519940614700317
2910,2/7/2024 2:34:00 PM,Amgen cut at Leerink on heavy obesity expectations,Seeking Alpha,https://seekingalpha.com/news/4063851-amgen-stock-cut-leerink-obesity-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9227665066719055
2911,2/7/2024 8:49:42 PM,"Analysts Boost Eli Lilly's Forecast With High Hopes On Mounjaro, Zepbound Performance",Benzinga,/news/stocks/analysts-boost-eli-lilly-s-forecast-with-high-hopes-on-mounjaro-zepbound-performance-1033042624,negative,0.9364190697669983
2912,2/7/2024 10:43:49 PM,EU drug regulators to assess potential impact of Catalent-Novo merger,Seeking Alpha,https://seekingalpha.com/news/4064289-eu-drug-regulators-to-assess-potential-impact-of-catalent-novo-merger?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8659239411354065
2913,2/8/2024 3:06:41 AM,"Apple, Chipotle And Eli Lilly Stocks Baffle Jim Cramer With Unusual Moves: 'Authentic Stupidity Is A Perfectly Plausible Explanation'",Benzinga,/news/stocks/apple-chipotle-and-eli-lilly-stocks-baffle-jim-cramer-with-unusual-moves-authentic-stupidity-is-a-perfectly-plausible-explanation-1033043234,positive,0.8150076270103455
2914,2/8/2024 12:41:07 PM,Foghorn says Eli Lilly picked lung cancer candidate for further studies,Seeking Alpha,https://seekingalpha.com/news/4064506-foghorn-stock-gains-eli-lilly-picks-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7014507055282593
2915,2/8/2024 6:15:00 PM,The 3 Most Undervalued Biotech Stocks to Buy in February 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-february-2024-1033047922,positive,0.7355531454086304
2916,2/8/2024 10:33:09 PM,"S&P 500 Hits 5,000 Milestone, Yet Concerns Of Overvaluation Versus Its Equal-Weight Counterpart Mount",Benzinga,/news/etf/s-p-500-hits-5-000-milestone-yet-concerns-of-overvaluation-versus-its-equal-weight-counterpart-mount-1033048271,neutral,0.6252869963645935
2917,2/9/2024 3:39:53 PM,Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies,Benzinga,/news/stocks/is-tesla-still-a-magnificent-7-stock-ev-maker-could-get-bumped-by-these-companies-1033051308,positive,0.5311586260795593
2918,2/9/2024 4:25:25 PM,Eli Lilly & Co: Strong Growth Trajectory Prompts Buy Rating and Raised EPS Forecasts Through 2030,TipRanks,/news/stocks/eli-lilly-co-strong-growth-trajectory-prompts-buy-rating-and-raised-eps-forecasts-through-2030-1033052408,negative,0.9470465779304504
2919,2/9/2024 5:20:31 PM,3 Stocks to Sell Immediately Before the Bubble Bursts: February 2024,InvestorPlace,/news/stocks/3-stocks-to-sell-immediately-before-the-bubble-bursts-february-2024-1033052201,positive,0.9175056219100952
2920,2/9/2024 6:21:35 PM,AstraZeneca looking to ramp up in-house production amid Catalent deal,Seeking Alpha,https://seekingalpha.com/news/4065249-astrazeneca-looking-to-ramp-up-in-house-production-amid-catalent-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9433637261390686
2921,2/9/2024 6:39:14 PM,FTC likely to look at Catalent alternatives in review of Novo deal - report,Seeking Alpha,https://seekingalpha.com/news/4065255-ftc-likely-to-look-at-catalent-alternatives-in-review-of-novo-deal-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8839836716651917
2922,2/9/2024 10:08:19 PM,"S&P 500 Hits 5,000, Magnificent 7 Tops $13 Trillion, Commercial Real Estate Cracks Emerge: The Week In The Markets",Benzinga,/news/etf/s-p-500-hits-5-000-magnificent-7-tops-13-trillion-commercial-real-estate-cracks-emerge-the-week-in-the-markets-1033052503,neutral,0.8241379857063293
2923,2/10/2024 9:16:57 AM,Eli Lilly Secures $6 Billion in Underwritten Notes,TipRanks,/news/stocks/eli-lilly-secures-6-billion-in-underwritten-notes-1033052803,positive,0.7601858973503113
2924,2/11/2024 5:00:03 PM,Booming weight-loss drug market to lift “pick-and-shovel” plays: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4065355-weight-loss-drug-market-lifts-pick-and-shovel-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6393693685531616
2925,2/12/2024 1:41:44 PM,Novo Nordisk’s parent eyes $7B annual investments by 2030: FT,Seeking Alpha,https://seekingalpha.com/news/4065481-novo-nordisks-parent-eyes-7b-annual-investments-2030?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8855694532394409
2926,2/12/2024 3:32:46 PM,Coca-Cola Q4 earnings ahead: Will the beverage giant continue to fizz?,Seeking Alpha,https://seekingalpha.com/news/4065558-coca-cola-q4-earnings-ahead-will-the-beverage-giant-continue-to-fizz?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.4517865478992462
2927,2/12/2024 8:55:20 PM,"Eli Lilly's Weight Loss Drug Tirzepatide Is Expanding Market Share, Analyst Outlines What Lies Ahead (CORRECTED)",Benzinga,/news/stocks/eli-lilly-s-weight-loss-drug-tripeptide-is-expanding-market-share-analyst-outlines-what-lies-ahead-1033058372,positive,0.7526557445526123
2928,2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6178923845291138
2929,2/13/2024 10:36:01 AM,Eli Lilly’s Tirzepatide Poised for Success: Buy Rating Affirmed Amid Anticipated Clinical Advancements,TipRanks,/news/stocks/eli-lilly-s-tirzepatide-poised-for-success-buy-rating-affirmed-amid-anticipated-clinical-advancements-1033060981,negative,0.95086669921875
2930,2/13/2024 10:43:53 AM,Eli Lilly & Co (LLY) Receives a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-jefferies-1033061078,negative,0.591037392616272
2931,2/13/2024 6:07:35 PM,Eli Lilly partner BioAge wins $170M to study Zepbound combo,Seeking Alpha,https://seekingalpha.com/news/4066258-eli-lilly-partner-bioage-wins-170m-zepbound-combo-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8227844834327698
2932,2/13/2024 8:07:53 PM,Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report,InvestorPlace,/news/stocks/kerrisdale-capital-slams-altimmune-alt-stock-in-new-short-report-1033062803,positive,0.8796600699424744
2933,2/14/2024 7:43:49 PM,7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution,InvestorPlace,/news/stocks/7-must-buy-pharma-stocks-amid-the-weight-loss-drug-revolution-1033068096,negative,0.6460100412368774
2934,2/15/2024 12:53:06 PM,Eli Lilly obesity therapy tirzepatide being rolled out in the U.K.,Seeking Alpha,https://seekingalpha.com/news/4067537-eli-lilly-obesity-therapy-launched-uk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6035048961639404
2935,2/15/2024 3:38:38 PM,Meet the Next Trillion-Dollar Companies: Our Top 7 Picks,InvestorPlace,/news/stocks/meet-the-next-trillion-dollar-companies-our-top-7-picks-1033072617,positive,0.9015949368476868
2936,2/16/2024 12:15:34 PM,Could Eli Lilly be the first $1T biopharma stock? Morgan Stanley asks,Seeking Alpha,https://seekingalpha.com/news/4068101-could-eli-lilly-be-first-1t-biopharma-morgan-stanley?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.916292130947113
2937,2/16/2024 3:29:22 PM,Novartis aiming to develop next-generation weight-loss drugs,Seeking Alpha,https://seekingalpha.com/news/4068274-novartis-aiming-to-develop-next-generation-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6095861792564392
2938,2/16/2024 5:13:28 PM,My Top 3 Stock Candidates to Replace Tesla in the Magnificent 7,InvestorPlace,/news/stocks/my-top-3-stock-candidates-to-replace-tesla-in-the-magnificent-7-1033077042,positive,0.9346912503242493
2939,2/16/2024 5:34:51 PM,Viking Therapeutics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4068347-viking-therapeutics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8901377320289612
2940,2/18/2024 11:29:58 PM,Weight-loss drugs cut grocery bills by up to 9% - Morgan Stanley,Seeking Alpha,https://seekingalpha.com/news/4068526-weight-loss-drugs-cut-grocery-bill-by-up-to-9-percent?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6329136490821838
2941,2/19/2024 11:21:00 AM,3 Stocks Primed to Reach Trillion-Dollar Valuation,InvestorPlace,/news/stocks/3-stocks-primed-to-reach-trillion-dollar-valuation-1033079746,negative,0.5553659200668335
2942,2/20/2024 4:39:42 AM,"LLY, CVS, EXAS: Which Strong-Buy-Rated Healthcare Stock Is the Better Buy?",TipRanks,/news/stocks/lly-cvs-exas-which-strong-buy-rated-healthcare-stock-is-the-better-buy-1033081825,positive,0.9178698658943176
2943,2/20/2024 6:54:06 PM,Top 7 Contenders to Join the Trillion-Dollar Club,InvestorPlace,/news/stocks/top-7-contenders-to-join-the-trillion-dollar-club-1033084666,positive,0.8761575818061829
2944,2/20/2024 8:36:00 PM,3 Cheap Dividend Stocks to Snatch Up Now,InvestorPlace,/news/stocks/3-cheap-dividend-stocks-to-snatch-up-now-1033085289,positive,0.7684123516082764
2945,2/20/2024 8:45:00 PM,3 Top Sectors Investment Dollars Are Pouring Into Now: February 2024,InvestorPlace,/news/stocks/3-top-sectors-investment-dollars-are-pouring-into-now-february-2024-1033084786,positive,0.901038408279419
2946,2/21/2024 2:02:21 PM,"Jazz Pharma Names Eli Lilly's Philip Johnson CFO, Effective March 1 ",RTTNews,/news/stocks/jazz-pharma-names-eli-lilly-s-philip-johnson-cfo-effective-march-1-1033087458,positive,0.923880934715271
2947,2/21/2024 4:26:20 PM,Ventyx surges as Piper highlights potential against obesity,Seeking Alpha,https://seekingalpha.com/news/4069678-ventyx-stock-surges-piper-cites-obesity-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.848923921585083
2948,2/21/2024 6:02:57 PM,Health Care Becomes Most Overweighted Sector As Hedge Funds Crowd Into Magnificent 7,Benzinga,/news/stocks/health-care-becomes-most-overweighted-sector-as-hedge-funds-crowd-into-magnificent-7-1033089072,negative,0.4598877429962158
2949,2/21/2024 7:03:43 PM,3 Stocks With the Potential to Knock Tesla Out of the Magnificent 7,InvestorPlace,/news/stocks/3-stocks-with-the-potential-to-knock-tesla-out-of-the-magnificent-7-1033089430,neutral,0.6336219906806946
2950,2/21/2024 7:32:41 PM,Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for February 2024,InvestorPlace,/news/stocks/wall-street-favorites-7-growth-stocks-with-strong-buy-ratings-for-february-2024-1033089466,negative,0.678650438785553
2951,2/22/2024 7:41:34 PM,Obesity drugs to expand U.S. GDP by 1% in the coming years: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/4070545-obesity-drugs-expand-us-gdp-goldman-sachs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8677510023117065
2952,2/23/2024 11:01:36 AM,"Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-c4-therapeutics-cccc-eli-lilly-co-lly-and-irhythm-technologies-irtc-1033097545,neutral,0.5983399152755737
2953,2/23/2024 1:30:26 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Icon (ICLR)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-icon-iclr-1033098488,positive,0.7965855002403259
2954,2/23/2024 4:49:56 PM,Weight Watchers weighed down by fallout from 'GLP-1 House' - report,Seeking Alpha,https://seekingalpha.com/news/4069831-weight-watchers-weighed-down-fallout-from-glp-1-house?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9661034941673279
2955,2/25/2024 5:00:00 PM,Radiopharmaceutical market expected to reach ~$14B by 2032,Seeking Alpha,https://seekingalpha.com/news/4071376-radiopharmaceutical-market-reach-14b-by-2032?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7533724904060364
2956,2/26/2024 8:50:36 AM,"Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Bausch + Lomb Corporation (BLCO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-idexx-laboratories-idxx-bausch-+-lomb-corporation-blco-and-eli-lilly-co-lly-1033101988,positive,0.9225672483444214
2957,2/26/2024 11:55:00 AM,3 Highly Rated Biotech Stocks to Buy for 300% Gains,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-to-buy-for-300-gains-1033102093,negative,0.5116621255874634
2958,2/26/2024 12:30:21 PM,"Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-c4-therapeutics-cccc-halozyme-halo-and-eli-lilly-co-lly-1033103492,positive,0.9102644920349121
2959,2/26/2024 4:29:29 PM,3 Top Pharma Stocks for Investors Betting on a Biotech Boom,InvestorPlace,/news/stocks/3-top-pharma-stocks-for-investors-betting-on-a-biotech-boom-1033103696,positive,0.7925871014595032
2960,2/26/2024 5:31:36 PM,"Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors",Benzinga,/news/etf/eli-lilly-novo-nordisk-s-strategies-against-new-weight-loss-drug-competitors-1033103712,positive,0.8304937481880188
2961,2/26/2024 7:10:07 PM,Future Juggernauts: The Next 7 Trillion Dollar Companies to Buy Now,InvestorPlace,/news/stocks/future-juggernauts-the-next-7-trillion-dollar-companies-to-buy-now-1033104208,positive,0.935997724533081
2962,2/26/2024 7:12:31 PM,The 3 Hottest Healthcare ETFs to Buy in 2024,InvestorPlace,/news/stocks/the-3-hottest-healthcare-etfs-to-buy-in-2024-1033104224,positive,0.9023116230964661
2963,2/26/2024 7:25:33 PM,"Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs",Benzinga,/news/stocks/amgen-s-upcoming-catalysts-in-2024-set-to-unlock-multi-billion-dollar-markets-says-goldman-sachs-1033104128,negative,0.9065037369728088
2964,2/27/2024 1:11:23 PM,Viking Therapeutics surges 80% on phase 2 obesity drug results,Seeking Alpha,https://seekingalpha.com/news/4072194-viking-therapeutics-surges-80-phase-2-obesity-drug-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9485713243484497
2965,2/27/2024 1:52:11 PM,"Novo Nordisk, Lilly fall premarket on Viking's obesity drug gains",Seeking Alpha,https://seekingalpha.com/news/4072227-novo-nordisk-lilly-fall-premarket-viking-obesity-drug-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.697813093662262
2966,2/27/2024 2:10:06 PM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-day-one-biopharmaceuticals-dawn-eli-lilly-co-lly-and-sanofi-othersnynf-1033108809,neutral,0.6944514513015747
2967,2/27/2024 2:19:00 PM,"4 stocks to watch on Tuesday: Viking Therapeutics, Macy's and more",Seeking Alpha,https://seekingalpha.com/news/4072259-4-stocks-to-watch-on-tuesday-viking-therapeutics-macys-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9029208421707153
2968,2/27/2024 5:24:52 PM,Eli Lilly talks with Viking Therapeutics may have stalled - report,Seeking Alpha,https://seekingalpha.com/news/4072391-eli-lilly-talks-with-viking-therapeutics-may-have-stalled-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9397096633911133
2969,2/27/2024 5:45:21 PM,Beam stock jumps as Eli Lilly deal drives Q4 beat,Seeking Alpha,https://seekingalpha.com/news/4072415-beam-stock-jumps-as-eli-lilly-deal-brings-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5264666080474854
2970,2/27/2024 6:22:55 PM,Stock Spotlight: 3 Picks ChatGPT Urges You Not to Miss,InvestorPlace,/news/stocks/stock-spotlight-3-picks-chatgpt-urges-you-not-to-miss-1033109018,positive,0.9093151688575745
2971,2/27/2024 6:34:20 PM,Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect,Benzinga,/news/stocks/beyond-tech-and-ai-why-the-sector-hedge-funds-prefer-is-not-the-one-you-d-expect-1033108902,positive,0.9344183206558228
2972,2/27/2024 9:00:02 PM,"Waters, Moderna most shorted stocks in S&P 500 health sector till Jan-end",Seeking Alpha,https://seekingalpha.com/news/4072568-waters-moderna-most-shorted-stocks-in-sp-500-health-sector-till-jan-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5255063772201538
2973,2/27/2024 9:06:43 PM,"BMO starts Korro at outperform, cites upcoming data for AATD drug",Seeking Alpha,https://seekingalpha.com/news/4072585-bmo-starts-korro-at-outperform-cites-upcoming-data-for-aatd-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5666339993476868
2974,2/28/2024 8:40:26 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ligand Pharma (LGND), Agilent (A) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ligand-pharma-lgnd-agilent-a-and-eli-lilly-co-lly-1033112061,neutral,0.9314587712287903
2975,2/28/2024 10:38:13 AM,Eli Lilly Maintains Strong Market Position Despite Viking’s Phase 2 Data: A Buy Rating,TipRanks,/news/stocks/eli-lilly-maintains-strong-market-position-despite-viking-s-phase-2-data-a-buy-rating-1033112663,negative,0.8948797583580017
2976,2/28/2024 11:51:11 AM,Beam reverses gains after mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/4072881-beam-stock-slips-mixed-shelf-offering?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6624250411987305
2977,2/28/2024 12:40:51 PM,"Analysts’ Top Healthcare Picks: Alphatec Holdings (ATEC), PROCEPT BioRobotics (PRCT)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alphatec-holdings-atec-procept-biorobotics-prct-1033113823,negative,0.6892446875572205
2978,2/28/2024 1:50:24 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Radnet (RDNT),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-radnet-rdnt-1033114205,positive,0.9177764654159546
2979,2/28/2024 6:05:35 PM,"Viking Therapeutics' Weight Loss Study Data Outperformed Novo Nordisk, Eli Lilly Studies, Analysts Say",Benzinga,/news/stocks/viking-therapeutics-weight-loss-study-data-outperformed-novo-nordisk-eli-lilly-studies-analysts-say-1033114321,negative,0.8398277163505554
2980,2/28/2024 10:20:55 PM,Stock Splits Watch: 3 Likely Candidates to Keep on Your Radar in 2024,InvestorPlace,/news/stocks/stock-splits-watch-3-likely-candidates-to-keep-on-your-radar-in-2024-1033115164,positive,0.8309637904167175
2981,2/29/2024 2:34:38 PM,NeuroBo stock jumps 14% on weight-loss drug update,Seeking Alpha,https://seekingalpha.com/news/4073921-neurobo-stock-jumps-on-weight-loss-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8876736164093018
2982,2/29/2024 8:23:07 PM,5 Investors Betting Big on Weight Watchers (WW) Stock as Oprah Backs Out,InvestorPlace,/news/stocks/5-investors-betting-big-on-weight-watchers-ww-stock-as-oprah-backs-out-1033120364,neutral,0.3924632668495178
2983,2/29/2024 11:00:45 PM,Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit),Benzinga,/news/stocks/top-stocks-not-named-nvidia-you-need-to-know-about-in-2024-here-s-what-investors-think-about-them-wall-street-vs-reddit-1033120683,positive,0.9334502816200256
2984,3/1/2024 11:33:35 AM,"Over a billion people worldwide living with obesity, study finds",Seeking Alpha,https://seekingalpha.com/news/4074466-over-a-billion-people-worldwide-living-with-obesity-study-finds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8041467666625977
2985,3/1/2024 11:40:24 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033123671,negative,0.5521676540374756
2986,3/1/2024 12:30:00 PM,The Hot List: 3 AI Stocks Worth Buying on Weakness,InvestorPlace,/news/stocks/the-hot-list-3-ai-stocks-worth-buying-on-weakness-1033123124,positive,0.8718504905700684
2987,3/1/2024 1:19:15 PM,Eli Lilly gains as Bank of America renews bullish narrative,Seeking Alpha,https://seekingalpha.com/news/4074523-lilly-stock-gains-bank-of-america-raises-target?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7495035529136658
2988,3/1/2024 2:03:00 PM,"4 stocks to watch on Friday: Plug Power, Eli Lilly and more",Seeking Alpha,https://seekingalpha.com/news/4074559-4-stocks-to-watch-on-friday-plug-power-eli-lilly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9237481951713562
2989,3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8509966135025024
2990,3/1/2024 9:02:26 PM,A Closer Look at 18 Analyst Recommendations For Eli Lilly and Co,Benzinga,/news/stocks/a-closer-look-at-18-analyst-recommendations-for-eli-lilly-and-co-1033125113,positive,0.9143711924552917
2991,3/1/2024 9:45:00 PM,"Eli Lilly's Commercial Moat, Competitor Landscape: BofA Emphasizes Strength in Incretin Space, Undervalued Assets",Benzinga,/news/stocks/eli-lilly-s-commercial-moat-competitor-landscape-bofa-emphasizes-strength-in-incretin-space-undervalued-assets-1033125178,negative,0.7486532330513
2992,3/1/2024 10:05:12 PM,"Record-High S&P 500 Propels SPY ETF To $500-Billion Milestone, Nvidia Tops $2 Trillion, Broadcom Surpasses Tesla",Benzinga,/news/etf/record-high-s-p-500-propels-spy-etf-to-500-billion-milestone-nvidia-tops-2-trillion-broadcom-surpasses-tesla-1033125195,negative,0.847528874874115
2993,3/2/2024 3:10:00 PM,The $1T club could soon have its first non-tech members: Berkshire Hathaway & Eli Lilly,Seeking Alpha,https://seekingalpha.com/news/4074979-the-1t-club-could-soon-have-its-first-non-tech-members-berkshire-hathaway-eli-lilly?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9019008874893188
2994,3/3/2024 7:08:04 PM,Biggest contributors and detractors to the S&P's run,Seeking Alpha,https://seekingalpha.com/news/4075016-biggest-contributors-and-detractors-to-the-sps-run?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7131364941596985
2995,3/4/2024 12:30:45 PM,"Analysts Offer Insights on Healthcare Companies: Y-Mabs Therapeutics (YMAB), Eli Lilly & Co (LLY) and 4D Molecular Therapeutics (FDMT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-y-mabs-therapeutics-ymab-eli-lilly-co-lly-and-4d-molecular-therapeutics-fdmt-1033129294,positive,0.9086207151412964
2996,3/4/2024 3:06:12 PM,It’s Time! 3 Dodgy Pharma Stocks to Sell in February,InvestorPlace,/news/stocks/its-time-3-dodgy-pharma-stocks-to-sell-in-february-1033129175,positive,0.8289964199066162
2997,3/4/2024 4:07:52 PM,Eli Lilly price target upped at UBS on GLP-1 survey,Seeking Alpha,https://seekingalpha.com/news/4075349-eli-lilly-price-target-upped-ubs-glp-1-survey?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9212498068809509
2998,3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8006861805915833
2999,3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8196350932121277
3000,3/5/2024 12:30:03 PM,"Novo Nordisk slips, dialysis stocks gain after kidney disease data for Ozempic",Seeking Alpha,https://seekingalpha.com/news/4075853-novo-stock-lilly-stock-slip-ozempic-kidney-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9057050943374634
3001,3/5/2024 6:02:26 PM,"Eli Lilly said to have tapped National Resilience, BSP for Zepbound production",Seeking Alpha,https://seekingalpha.com/news/4076137-eli-lilly-taps-national-resilience-bsp-make-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7466343641281128
3002,3/5/2024 7:42:07 PM,Amphastar a new overweight at J.P. Morgan on diverse asset portfolio,Seeking Alpha,https://seekingalpha.com/news/4076207-amphastar-new-overweight-jp-morgan-diverse-asset-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8081136345863342
3003,3/6/2024 4:31:43 PM,"Eli Lilly likely won't meet demand for weight loss, diabetes drugs in 2024",Seeking Alpha,https://seekingalpha.com/news/4076590-eli-lilly-likely-wont-meet-demand-weight-loss-diabetes-drugs-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5880196690559387
3004,3/6/2024 6:12:14 PM,Trillion-Dollar Threshold: The Next 3 Stocks Ready to Rise,InvestorPlace,/news/stocks/trillion-dollar-threshold-the-next-3-stocks-ready-to-rise-1033139066,positive,0.8287705779075623
3005,3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7659493088722229
3006,3/7/2024 11:43:36 AM,"Cigna in pact with Novo, Eli Lilly to widen obesity coverage",Seeking Alpha,https://seekingalpha.com/news/4077029-cigna-pact-novo-eli-lilly-widen-obesity-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9022220373153687
3007,3/7/2024 2:33:18 PM,Labcorp introduces weight loss management portfolio,Seeking Alpha,https://seekingalpha.com/news/4077193-labcorp-introduces-weight-loss-management-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8565091490745544
3008,3/7/2024 2:34:17 PM,Novo Nordisk hits all-time high as oral obesity drug shows promising early results,Seeking Alpha,https://seekingalpha.com/news/4077048-novo-nordisk-stock-jumps-as-experimental-obesity-drug-shows-promising-early-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.946962833404541
3009,3/7/2024 6:43:42 PM,The Top 3 ETFs to Buy in March 2024,InvestorPlace,/news/stocks/the-top-3-etfs-to-buy-in-march-2024-1033143692,positive,0.9182321429252625
3010,3/7/2024 10:45:00 PM,3 Stocks Mario Gabelli Is Betting on Big,InvestorPlace,/news/stocks/3-stocks-mario-gabelli-is-betting-on-big-1033144221,positive,0.9134254455566406
3011,3/8/2024 12:06:31 AM,Novo Nordisk expects Wegovy approval in China this year: report,Seeking Alpha,https://seekingalpha.com/news/4077511-novo-nordisk-expects-wegovy-approval-in-china-this-year-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7831695079803467
3012,3/8/2024 10:21:53 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033146221,negative,0.5521676540374756
3013,3/8/2024 10:41:35 AM,"Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-rapt-therapeutics-rapt-eli-lilly-co-lly-and-sight-sciences-sght-1033146290,neutral,0.6904416680335999
3014,3/8/2024 12:07:44 PM,Eli Lilly slips as FDA delays decision on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4077577-eli-lilly-stock-slips-fda-decision-alzheimers-drug-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9297435879707336
3015,3/8/2024 1:20:04 PM,FDA Delays Decision On Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-delays-decision-on-lilly-s-alzheimer-s-drug-1033146031,neutral,0.7650875449180603
3016,3/8/2024 2:25:22 PM,Eli Lilly & Co. Maintains Hold Rating Amidst Unexpected FDA Scrutiny on Alzheimer’s Drug Donanemab,TipRanks,/news/stocks/eli-lilly-co-maintains-hold-rating-amidst-unexpected-fda-scrutiny-on-alzheimer-s-drug-donanemab-1033147376,neutral,0.9337071180343628
3017,3/8/2024 4:25:31 PM,Novo Nordisk sees launching new obesity drugs before Wegovy patent expires,Seeking Alpha,https://seekingalpha.com/news/4077692-novo-nordisk-sees-launching-new-obesity-drugs-before-wegovy-patent-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7814866900444031
3018,3/8/2024 5:10:25 PM,Novo Nordisk not planning more supply chain acquisitions: report,Seeking Alpha,https://seekingalpha.com/news/4077703-novo-nordisk-not-planning-more-supply-chain-acquisitions-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9289149045944214
3019,3/8/2024 7:28:57 PM,FDA approves Wegovy for reduction of cardiovascular risks,Seeking Alpha,https://seekingalpha.com/news/4077743-fda-approves-wegovy-for-reduction-of-cardiovascular-risks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.833710789680481
3020,3/9/2024 6:00:00 PM,The Top 3 Pharma Stocks to Buy in March 2024,InvestorPlace,/news/stocks/the-top-3-pharma-stocks-to-buy-in-march2024-1033148079,positive,0.9020588397979736
3021,3/11/2024 2:02:22 AM,Lilly: Majority Of People With AD & Skin Of Color Experienced Skin Improvement In Lebrikizumab Study ,RTTNews,/news/stocks/lilly-majority-of-people-with-ad-skin-of-color-experienced-skin-improvement-in-lebrikizumab-study-1033148751,negative,0.5255303978919983
3022,3/11/2024 6:35:09 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033150000,positive,0.7920135259628296
3023,3/11/2024 9:53:32 AM,Eli Lilly eczema drug shows robust efficacy in people of color,Seeking Alpha,https://seekingalpha.com/news/4077872-eli-lilly-eczema-drug-shows-robust-efficacy-in-people-of-color?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.945309042930603
3024,3/11/2024 11:10:33 AM,"Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Merus (MRUS) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ocuphire-pharma-ocup-merus-mrus-and-eli-lilly-co-lly-1033151121,positive,0.9255996942520142
3025,3/11/2024 11:40:36 AM,"Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-moonlake-immunotherapeutics-mltx-eli-lilly-co-lly-1033151280,positive,0.7540016770362854
3026,3/11/2024 5:22:56 PM,Eli Lilly Stock Drops 4% ,RTTNews,/news/stocks/eli-lilly-stock-drops-4-1033151956,neutral,0.9397961497306824
3027,3/12/2024 5:11:55 PM,"Wedbush raises AnaptysBio to outperform, cites upcoming data",Seeking Alpha,https://seekingalpha.com/news/4078536-wedbush-raises-anaptysbio-to-outperform-cites-upcoming-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5813930034637451
3028,3/12/2024 7:48:53 PM,Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers,Benzinga,/news/stocks/skin-disease-focused-anaptysbio-earns-analyst-upgrade-on-positive-outlook-for-clinical-triggers-1033156516,negative,0.9491928815841675
3029,3/13/2024 6:40:07 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Axsome Therapeutics (AXSM),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-axsome-therapeutics-axsm-1033158619,positive,0.9135671257972717
3030,3/13/2024 11:47:31 AM,Eli Lilly in pact with Amazon to deliver Zepbound and other medicines,Seeking Alpha,https://seekingalpha.com/news/4078790-eli-lilly-amazon-pharmacy-deliver-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6835328936576843
3031,3/13/2024 1:26:44 PM,LLY Stock Alert: You Can Now Get Eli Lilly’s Weight Loss Drugs on Amazon,InvestorPlace,/news/stocks/lly-stock-alert-you-can-now-get-eli-lillys-weight-loss-drugs-on-amazon-1033159632,positive,0.8894807696342468
3032,3/13/2024 2:17:18 PM,Why Is MicroCloud Hologram (HOLO) Stock Up 31% Today?,InvestorPlace,/news/stocks/why-is-microcloud-hologram-holo-stock-up-31-today-1033159925,negative,0.8530718088150024
3033,3/13/2024 2:36:34 PM,Why Is Gaxos.ai (GXAI) Stock Up 134% Today?,InvestorPlace,/news/stocks/why-is-gaxos-ai-gxai-stock-up-134-today-1033160005,negative,0.7163758873939514
3034,3/13/2024 3:07:00 PM,Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio,InvestorPlace,/news/stocks/billionaires-biotech-bets-3-stocks-dominating-bill-gates-portfolio-1033161056,positive,0.9177296757698059
3035,3/13/2024 5:29:04 PM,Liver drug developers outperform as U.S. awaits first NASH drug,Seeking Alpha,https://seekingalpha.com/news/4079090-liver-drug-developers-gain-us-awaits-first-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6568204760551453
3036,3/13/2024 5:37:06 PM,Top 7 Biotech Stock Winners As Weight Loss Drug Battle Escalates: Goldman Sachs Names Best Picks,Benzinga,/news/stocks/top-7-biotech-winners-of-novo-nordisk-eli-lilly-s-outsourcing-strategy-for-weight-loss-drugs-goldman-sachs-1033160762,positive,0.8136965036392212
3037,3/13/2024 7:30:57 PM,WW slumps amid report of lenders hiring lawyers for debt talks,Seeking Alpha,https://seekingalpha.com/news/4079134-ww-slumps-amid-report-of-report-lenders-hiring-lawyers-for-debt-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9602104425430298
3038,3/13/2024 9:16:40 PM,Eli Lilly Strikes Deal With Amazon Pharmacy To Deliver Prescription Drugs ,RTTNews,/news/stocks/eli-lilly-strikes-deal-with-amazon-pharmacy-to-deliver-prescription-drugs-1033161271,negative,0.89954674243927
3039,3/14/2024 10:50:00 AM,7 Delightful Dividend Stocks to Put Some Spring in Your Step,InvestorPlace,/news/stocks/7-delightful-dividend-stocks-to-put-some-spring-in-your-step-1033163248,negative,0.5553693175315857
3040,3/14/2024 11:20:30 AM,Biotech group backs anti-China bill; part ways with WuXi AppTec,Seeking Alpha,https://seekingalpha.com/news/4079392-biotech-group-backs-anti-china-bill-splits-wuxi-apptec?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5961117744445801
3041,3/14/2024 1:45:32 PM,Is WW Stock on the Brink of Bankruptcy?,InvestorPlace,/news/stocks/is-ww-stock-on-the-brink-of-bankruptcy-1033164175,neutral,0.8077430129051208
3042,3/14/2024 2:23:45 PM,7 Growth Stocks to Sell in March Before They Crash & Burn,InvestorPlace,/news/stocks/7-growth-stocks-to-sell-in-march-before-they-crash-burn-1033164348,positive,0.7772335410118103
3043,3/14/2024 3:44:36 PM,UBS sees Lilly GLP-1/sleep apnea study falling short of Street estimates,Seeking Alpha,https://seekingalpha.com/news/4079564-ubs-sees-lilly-glp-1sleep-apnea-study-falling-short-of-street-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9086613655090332
3044,3/14/2024 7:45:17 PM,Madrigal granted FDA approval for NASH therapy,Seeking Alpha,https://seekingalpha.com/news/4079638-madrigal-stock-focus-fda-clears-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9019347429275513
3045,3/14/2024 10:49:54 PM,3 Pharma Stocks to Sell in March Before They Crash & Burn,InvestorPlace,/news/stocks/3-pharma-stocks-to-sell-in-march-before-they-crash-burn-1033165973,positive,0.7923381924629211
3046,3/14/2024 11:23:16 PM,Terns to report Phase 1 data on GLP-1 drug in 2H 2024,Seeking Alpha,https://seekingalpha.com/news/4079774-terns-to-report-phase-1-data-on-glp-1-drug-in-2h-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9183884859085083
3047,3/15/2024 9:17:03 AM,Wells Fargo Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033167891,positive,0.7053605914115906
3048,3/15/2024 11:08:11 AM,Truist Financial Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033168311,negative,0.5540192127227783
3049,3/15/2024 12:15:00 PM,3 Weight-Loss Stocks to Buy as GLP-1 Mania Takes Hold,InvestorPlace,/news/stocks/3-weight-loss-stocks-to-buy-as-glp-1-mania-takes-hold-1033167937,positive,0.5437567234039307
3050,3/15/2024 12:19:55 PM,Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades,Seeking Alpha,https://seekingalpha.com/news/4079886-madrigal-stock-climbs-fda-nod-nash-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9023323059082031
3051,3/15/2024 1:29:14 PM,"Johnson & Johnson, Boston Scientific least shorted stocks in S&P 500 healthcare sector for Feb-end",Seeking Alpha,https://seekingalpha.com/news/4079885-johnson-johnson-boston-scientific-least-shorted-stocks-in-sp-500-healthcare-sector-for-feb-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6527519226074219
3052,3/15/2024 7:38:23 PM,Eli Lilly Zepbound prescriptions exceed Novo’s Wegovy for the first time in U.S.,Seeking Alpha,https://seekingalpha.com/news/4080150-eli-lilly-zepbound-prescriptions-exceed-novos-wegovy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9436370730400085
3053,3/16/2024 4:57:30 PM,NASH drug market expected to surpass $48B by 2035,Seeking Alpha,https://seekingalpha.com/news/4080234-nash-drug-market-expected-top-48b-2035?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8953897953033447
3054,3/16/2024 6:00:00 PM,The Trillion-Dollar Crystal Ball: 3 Companies Next in Line for the Market Milestone,InvestorPlace,/news/stocks/the-trillion-dollar-crystal-ball-3-companies-next-in-line-for-the-market-milestone-1033169865,positive,0.7875685095787048
3055,3/17/2024 5:00:00 PM,"The $1 Trillion Question: Will LLY, TSMC or TSLA Be Wall Street’s Next Nvidia?",InvestorPlace,/news/stocks/the-1-trillion-question-will-lly-tsmc-or-tsla-be-wall-streets-next-nvidia-1033170285,positive,0.9417864680290222
3056,3/17/2024 9:09:16 PM,Survey finds GLP-1 users more inclined to get aesthetic procedures,Seeking Alpha,https://seekingalpha.com/news/4080286-survey-finds-glp-1-users-more-inclined-to-get-aesthetic-procedures?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4846843183040619
3057,3/18/2024 7:10:16 AM,"Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA), Eli Lilly & Co (LLY) and Globus Medical (GMED)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-hca-healthcare-hca-eli-lilly-co-lly-and-globus-medical-gmed-1033171716,positive,0.9248663187026978
3058,3/18/2024 4:17:28 PM,AstraZeneca to cap costs of inhalers at $35 per month,Seeking Alpha,https://seekingalpha.com/news/4080619-astrazeneca-to-cap-costs-of-inhalers-at-35-per-month?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6632614731788635
3059,3/18/2024 5:31:24 PM,Oprah expected to endorse WeightWatchers Clinic on ABC special,Seeking Alpha,https://seekingalpha.com/news/4080683-oprah-expected-endorse-weightwatchers-clinic-abc-special?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9058869481086731
3060,3/18/2024 8:10:58 PM,Wall Street’s Favorite Growth Stocks? 7 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-growth-stocks-7-names-that-could-make-you-filthy-rich-1033174061,positive,0.8964772820472717
3061,3/18/2024 9:45:43 PM,Inventiva Phase 2 study for MASH drug meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4080815-inventiva-phase-2-study-for-mash-drug-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6061493754386902
3062,3/19/2024 12:19:47 PM,AstraZeneca-Fusion deal reignites radiopharma space,Seeking Alpha,https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6613726019859314
3063,3/19/2024 2:55:15 PM,"Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'",Benzinga,/news/stocks/cramer-calls-datadog-dynamite-puts-sofi-in-dog-house-what-the-heck-is-going-on-1033176692,neutral,0.7734217643737793
3064,3/19/2024 5:57:51 PM,What Retail Apocalypse? 7 Stocks Proving the Doomsayers Wrong.,InvestorPlace,/news/stocks/what-retail-apocalypse-7-stocks-proving-the-doomsayers-wrong-1033177900,neutral,0.5061988830566406
3065,3/19/2024 9:07:51 PM,3 Juicy Stocks Serving Up 5% Dividends That You Can Snag for $50,InvestorPlace,/news/stocks/3-juicy-stocks-serving-up-5-dividends-that-you-can-snag-for-50-1033178210,positive,0.6467196941375732
3066,3/20/2024 10:00:00 AM,3 Stocks Ready to Ride the Bull Higher,InvestorPlace,/news/stocks/3-stocks-ready-to-ride-the-bull-higher-1033179637,positive,0.7874731421470642
3067,3/20/2024 1:00:32 PM,Labcorp expands Alzheimer's testing portfolio with new diagnostic,Seeking Alpha,https://seekingalpha.com/news/4081545-labcorp-expands-alzheimers-test-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8395878076553345
3068,3/20/2024 5:09:31 PM,Medicare coverage for obesity drugs could strain federal budget: CBO,Seeking Alpha,https://seekingalpha.com/news/4081689-weight-loss-drug-coverage-could-strain-federal-budget-cbo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4960291087627411
3069,3/20/2024 5:38:58 PM,Wall Street’s Favorite Tech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-tech-stocks-3-names-that-could-make-you-filthy-rich-1033181883,positive,0.8905964493751526
3070,3/21/2024 10:25:00 AM,Amazon’s 1-2 Punch: AI-Powered Listings and Eli Lilly Deal Make AMZN a Must-Buy,InvestorPlace,/news/stocks/amazons-1-2-punch-ai-powered-listings-and-eli-lilly-deal-make-amzn-a-must-buy-1033183881,positive,0.6340944766998291
3071,3/21/2024 5:35:23 PM,Medicare expands coverage for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4082299-medicare-expands-coverage-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9262157082557678
3072,3/22/2024 11:10:32 AM,"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-dianthus-therapeutics-dnth-and-eli-lilly-co-lly-1033188793,positive,0.90938800573349
3073,3/22/2024 1:41:41 PM,"Argus cuts Pfizer to hold, cites concerns about topline growth",Seeking Alpha,https://seekingalpha.com/news/4082673-argus-cuts-pfizer-to-hold-cites-concerns-about-topline-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9265572428703308
3074,3/22/2024 9:07:27 PM,Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs,InvestorPlace,/news/stocks/hot-stocks-the-3-best-opportunities-for-investing-in-weight-loss-drugs-1033190216,positive,0.8771572113037109
3075,3/24/2024 7:41:46 PM,Hedge Funds Are Fleeing Tech: 7 Stocks They’re Buying Instead,InvestorPlace,/news/stocks/hedge-funds-are-fleeing-tech-7-stocks-theyre-buying-instead-1033191198,neutral,0.6329663395881653
3076,3/25/2024 7:32:21 AM,Analysts Offer Insights on Healthcare Companies: Sotera Health (SHC) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-sotera-health-shc-and-eli-lilly-co-lly-1033192497,positive,0.9224342703819275
3077,3/25/2024 10:00:00 AM,Amazon’s AI Awakening: Why AMZN Stock Is the Magnificent Seven’s Sleeping Giant,InvestorPlace,/news/stocks/amazons-ai-awakening-why-amzn-stock-is-the-magnificent-sevens-sleeping-giant-1033192426,positive,0.8968842029571533
3078,3/25/2024 2:05:49 PM,"Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'",Benzinga,/news/stocks/cramer-isn-t-knocking-this-pharma-firm-anymore-as-a-matter-of-fact-i-m-going-in-1033193181,positive,0.8706889152526855
3079,3/25/2024 7:00:00 PM,Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich,InvestorPlace,/news/stocks/wall-streets-favorite-biotech-stocks-3-names-that-could-make-you-filthy-rich-1033194514,positive,0.9046082496643066
3080,3/26/2024 11:37:54 AM,Viking Therapeutics gains on early data for oral weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4083623-viking-therapeutics-stock-gains-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8850501775741577
3081,3/26/2024 3:43:00 PM,Biotech Roundtable: Is CRISPR all it's cracked up to be?,Seeking Alpha,https://seekingalpha.com/news/4083198-biotech-roundtable-is-crispr-all-its-cracked-up-to-be?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9258078336715698
3082,3/26/2024 6:01:03 PM,Cytokinetics gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/4083918-cytokinetics-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9322801232337952
3083,3/26/2024 6:15:37 PM,Amazon reportedly leaning on weight loss frenzy to boost pharmacy unit,Seeking Alpha,https://seekingalpha.com/news/4083927-amazon-expects-weight-loss-frenzy-boost-pharmacy-unit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9254492521286011
3084,3/27/2024 9:54:19 AM,The 2025 Double: 3 Stocks Poised to Deliver 100% Gains in Just 12 Months,InvestorPlace,/news/stocks/the-2025-double-3-stocks-poised-to-deliver-100-gains-in-just-12-months-1033200341,negative,0.9273695945739746
3085,3/27/2024 12:26:15 PM,Altimmune falls after Q4 results; obesity drug data released,Seeking Alpha,https://seekingalpha.com/news/4084241-altimmune-stock-falls-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9307665228843689
3086,3/27/2024 12:36:10 PM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033202073,negative,0.6287072896957397
3087,3/27/2024 6:59:41 PM,US Companies In Japan Wary On Market Intervention As Yen Hits 34-Year Low Vs. Dollar,Benzinga,/news/etf/us-companies-in-japan-wary-on-market-intervention-as-yen-hits-34-year-low-vs-dollar-1033202545,neutral,0.954104483127594
3088,3/27/2024 9:02:39 PM,Sen. Sanders goes after Novo Nordisk on a study on Ozempic low manufacture cost,Seeking Alpha,https://seekingalpha.com/news/4084693-sanders-goes-after-novo-nordisk-study-ozempic-low-manufacture-cost?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8823014497756958
3089,3/28/2024 2:00:53 PM,"CVS, Elevance Health to cover Novo Nordisk’s Wegovy: WSJ",Seeking Alpha,https://seekingalpha.com/news/4084965-cvs-elevance-cover-novo-nordisks-wegovy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7505475878715515
3090,3/29/2024 10:40:00 AM,The 3 Best Biotech Stocks to Buy in Q2 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-q2-2024-1033208071,positive,0.7683516144752502
3091,3/30/2024 4:13:00 PM,Eli Lilly tops S&P 500 healthcare sector in Q1 as weight loss frenzy continues,Seeking Alpha,https://seekingalpha.com/news/4084974-eli-lilly-tops-the-growth-chart-for-the-sp-500-index-in-q1-as-the-sector-gains-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6530331969261169
3092,4/1/2024 3:00:49 PM,What Analysts Are Saying About Eli Lilly and Co Stock,Benzinga,/news/stocks/what-analysts-are-saying-about-eli-lilly-and-co-stock-1033210971,positive,0.9172949194908142
3093,4/2/2024 9:07:25 AM,Eli Lilly Poised for Market Dominance Amid Positive orforglipron Trial Results and Legislative Tailwinds,TipRanks,/news/stocks/eli-lilly-poised-for-market-dominance-amid-positive-orforglipron-trial-results-and-legislative-tailwinds-1033214650,negative,0.8696283102035522
3094,4/2/2024 10:00:00 AM,Buy Amazon Stock Now for Continued Growth and Diversification,InvestorPlace,/news/stocks/buy-amazon-stock-now-for-continued-growth-and-diversification-1033214034,positive,0.7612683773040771
3095,4/2/2024 11:34:50 AM,Verve drops after pausing trial enrollments for lead asset,Seeking Alpha,https://seekingalpha.com/news/4086152-verve-stock-drops-setback-lead-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9550532698631287
3096,4/2/2024 4:13:19 PM,Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts,InvestorPlace,/news/stocks/merger-mania-3-potential-takeover-targets-to-watch-for-lucrative-buyouts-1033216143,positive,0.921463668346405
3097,4/2/2024 5:39:43 PM,Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience,Benzinga,/news/stocks/eli-lilly-stock-navigates-weight-loss-drug-competition-with-technical-resilience-1033215940,negative,0.9183506369590759
3098,4/2/2024 8:30:04 PM,5 Healthcare Stocks to Buy for 2024,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-2024-1033216722,positive,0.9175675511360168
3099,4/2/2024 8:41:50 PM,"Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand",Benzinga,/news/stocks/citi-monitors-competitive-threats-to-eli-lilly-says-it-is-positioned-to-maintain-leadership-and-expand-1033216480,negative,0.8663269281387329
3100,4/3/2024 9:40:11 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Glaukos (GKOS) and Omnicell (OMCL)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-glaukos-gkos-and-omnicell-omcl-1033218769,positive,0.9200767874717712
3101,4/3/2024 11:01:03 AM,Novo’s Ozempic to face copycats as Chinese firm seeks biosimilar nod,Seeking Alpha,https://seekingalpha.com/news/4086664-novos-ozempic-face-biosimilar-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8150251507759094
3102,4/3/2024 4:05:29 PM,Zepbound shortage: Eli Lilly's weight-loss drug in limited availability through April-end,Seeking Alpha,https://seekingalpha.com/news/4086918-zepbound-shortage-eli-lillys-weight-loss-drug-in-limited-availability-through-april-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6280438899993896
3103,4/3/2024 8:09:31 PM,The 3 Best Healthcare Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-april-2024-1033220393,positive,0.8723218441009521
3104,4/3/2024 11:03:07 PM,"LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?",TipRanks,/news/stocks/lly-regn-bhvn-which-biotech-stock-offers-the-most-upside-1033220670,positive,0.889915406703949
3105,4/4/2024 10:55:00 AM,7 A-Rated Stocks to Buy in April,InvestorPlace,/news/stocks/7-a-rated-stocks-to-buy-in-april-1033221911,positive,0.8709800243377686
3106,4/4/2024 1:33:00 PM,3 Growth Stocks with Even Greater Potential Than the Magnificent 7,InvestorPlace,/news/stocks/3-growth-stocks-with-even-greater-potential-than-the-magnificent-7-1033222646,negative,0.8899354338645935
3107,4/4/2024 5:15:40 PM,"Baird puts Inspire on top idea list, sees limited impact by GLP-1s",Seeking Alpha,https://seekingalpha.com/news/4087357-baird-puts-inspire-on-top-idea-list-sees-limited-impact-by-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6767430305480957
3108,4/4/2024 11:40:25 PM,"Analysts’ Top Healthcare Picks: Eli Lilly & Co (LLY), UnitedHealth (UNH)",TipRanks,/news/stocks/analysts-top-healthcare-picks-eli-lilly-co-lly-unitedhealth-unh-1033224162,negative,0.5217211246490479
3109,4/5/2024 6:24:15 PM,Wondering Where To Find An Over 7% Annual Return? Check Out These 10 Investment-Grade Corporate Bonds,Benzinga,/news/stocks/wondering-where-to-find-an-over-7-annual-return-check-out-these-10-investment-grade-corporate-bonds-1033226605,positive,0.8957199454307556
3110,4/5/2024 9:58:39 PM,Lilly to record $111M pre-tax IPR&D charges in Q1,Seeking Alpha,https://seekingalpha.com/news/4087706-lilly-to-record-111m-pre-tax-iprd-charges-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6983909010887146
3111,4/5/2024 10:23:33 PM,"Traders Rethink Interest Rate Cuts, Labor Market Heats Up, Oil Prices Quietly Reach 6-Month High: This Week In The Markets",Benzinga,/news/etf/traders-rethink-interest-rate-cuts-labor-market-heats-up-oil-prices-quietly-reach-6-month-high-this-week-in-the-markets-1033226941,neutral,0.4735451638698578
3112,4/6/2024 4:20:25 AM,"Analysts’ Top Healthcare Picks: Pfizer (PFE), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-pfizer-pfe-eli-lilly-co-lly-1033227104,positive,0.5149402618408203
3113,4/8/2024 9:50:54 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Ionis Pharmaceuticals (IONS) and Medtronic (MDT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-ionis-pharmaceuticals-ions-and-medtronic-mdt-1033229651,positive,0.9216921925544739
3114,4/8/2024 5:43:58 PM,ProfoundBio Discovers The Joys Of Having A Wealthy Owner,Benzinga,/news/stocks/profoundbio-discovers-the-joys-of-having-a-wealthy-owner-1033230521,positive,0.8390495777130127
3115,4/8/2024 7:11:44 PM,"EMA to discuss possible link between GLP-1s, suicidal thoughts: report",Seeking Alpha,https://seekingalpha.com/news/4088011-ema-to-discuss-possible-link-between-glp-1s-suicidal-thoughts-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8738497495651245
3116,4/9/2024 11:00:00 AM,3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April,InvestorPlace,/news/stocks/3-high-growth-biotech-stocks-investors-shouldnt-sleep-on-in-april-1033232893,positive,0.8930463790893555
3117,4/9/2024 2:03:48 PM,Madrigal announces US launch of NASH/MASH drug Rezdiffra,Seeking Alpha,https://seekingalpha.com/news/4088257-madrigal-announces-us-launch-of-nashmash-drug-rezdiffra?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7331196069717407
3118,4/9/2024 4:37:13 PM,"Cantor starts Structure at overweight, sees positive data for GLP-1 drug",Seeking Alpha,https://seekingalpha.com/news/4088314-cantor-starts-structure-at-overweight-sees-positive-data-for-glp-1-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9303026795387268
3119,4/9/2024 5:06:07 PM,Eli Lilly launches construction of $2.5B plant to meet obesity drug demand,Seeking Alpha,https://seekingalpha.com/news/4088326-eli-lilly-eyes-25b-plant-make-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6523458957672119
3120,4/9/2024 8:25:52 PM,MarketMasterAI’s Top 500 Stocks: April 2024,InvestorPlace,/news/stocks/marketmasterais-top-500-stocks-april-2024-1033234851,positive,0.9242361187934875
3121,4/10/2024 9:46:07 AM,Eli Lilly & Co: Strong Buy Rating on Robust ‘Diabesity’ Portfolio and Key Product Outperformance,TipRanks,/news/stocks/eli-lilly-co-strong-buy-rating-on-robust-diabesity-portfolio-and-key-product-outperformance-1033237131,negative,0.951643168926239
3122,4/10/2024 6:56:07 PM,Top 10 best performing S&P 500 health care stocks of 2024,Seeking Alpha,https://seekingalpha.com/news/4088691-top-10-best-performing-sp-500-health-care-stocks-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8458035588264465
3123,4/10/2024 7:41:00 PM,3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild,InvestorPlace,/news/stocks/3-obesity-drug-stocks-set-to-skyrocket-as-demand-goes-wild-1033238954,neutral,0.6071718335151672
3124,4/10/2024 9:23:59 PM,Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies,Benzinga,/news/stocks/amphastar-pharmaceuticals-interested-in-potential-acquisitions-in-endocrinology-focused-companies-1033238698,positive,0.6497352123260498
3125,4/11/2024 7:22:29 AM,Roche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection ,RTTNews,/news/stocks/roche-s-elecsys-ptau217-blood-test-receives-fda-breakthrough-designation-for-alzheimer-s-detection-1033239569,negative,0.8970329165458679
3126,4/11/2024 10:20:37 AM,"Roche, Eli Lilly gain FDA breakthrough device tag for Alzheimer's blood test",Seeking Alpha,https://seekingalpha.com/news/4088828-roche-eli-lilly-gain-fda-breakthrough-device-tag-for-alzheimers-blood-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8851044178009033
3127,4/11/2024 7:55:19 PM,Trillion-Dollar Trajectories: 3 Billion-Dollar Stocks With the Potential to Hit the Next Milestone,InvestorPlace,/news/stocks/trillion-dollar-trajectories-3-billion-dollar-stocks-with-the-potential-to-hit-the-next-milestone-1033242439,positive,0.7016460299491882
3128,4/11/2024 8:30:00 PM,Wall Street Favorites: 3 Healthcare Stocks With Strong Buy Ratings for April 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-healthcare-stocks-with-strong-buy-ratings-for-april-2024-1033242568,negative,0.6592323184013367
3129,4/12/2024 10:25:00 AM,"Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027",InvestorPlace,/news/stocks/shed-the-fat-gain-the-profits-3-weight-loss-stocks-to-own-until-2027-1033243810,positive,0.9163532257080078
3130,4/12/2024 10:40:00 AM,7 A-Rated Aggressive Biotech Stocks to Bet On in 2024,InvestorPlace,/news/stocks/7-a-rated-aggressive-biotech-stocks-to-bet-on-in-2024-1033243804,positive,0.7495233416557312
3131,4/12/2024 11:05:43 AM,"No link between weight loss drugs and suicidal thoughts, EU regulator concludes",Seeking Alpha,https://seekingalpha.com/news/4089182-no-link-weight-loss-drugs-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9012607336044312
3132,4/12/2024 4:02:53 PM,GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma,Seeking Alpha,https://seekingalpha.com/news/4089307-glp-1s-benefit-parkinsons-barclays-sees-biopharma-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6429069638252258
3133,4/12/2024 5:17:44 PM,"Short interest in S&P 500 health stocks rises, Moderna among most shorted companies in March",Seeking Alpha,https://seekingalpha.com/news/4089272-short-interest-in-sp-500-healthcare-sector-rises-lilly-least-shorted-industry-at-march-end?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8770027160644531
3134,4/14/2024 9:56:08 PM,"Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down",Seeking Alpha,https://seekingalpha.com/news/4089446-needham-sees-bsx-cnmd-rmd-beating-street-despite-medtech-slow-down?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8204345703125
3135,4/15/2024 8:20:06 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: HCA Healthcare (HCA), PolyPid (PYPD) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-hca-healthcare-hca-polypid-pypd-and-eli-lilly-co-lly-1033248808,neutral,0.9348580241203308
3136,4/15/2024 6:19:53 PM,BTIG Research Predicts Over 118% Rally for These 3 Stocks,InvestorPlace,/news/stocks/btig-research-predicts-over-118-rally-for-these-3-stocks-1033250641,negative,0.8785549402236938
3137,4/16/2024 4:20:14 AM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), McKesson (MCK)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-mckesson-mck-1033251959,positive,0.8101070523262024
3138,4/16/2024 6:35:28 AM,Eli Lilly & Co: A Strong Buy on Robust Incretin Franchise Prospects and Positive Market Trends,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-incretin-franchise-prospects-and-positive-market-trends-1033252465,negative,0.952507495880127
3139,4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.752937912940979
3140,4/16/2024 4:23:16 PM,Bayer dethroned as Germany’s top drugmaker,Seeking Alpha,https://seekingalpha.com/news/4090165-bayer-beaten-top-german-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4228775203227997
3141,4/16/2024 4:38:35 PM,Lexaria gets ethics board okay for oral GLP-1 study,Seeking Alpha,https://seekingalpha.com/news/4090172-lexaria-gets-ethics-board-okay-for-oral-glp-1-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.742171585559845
3142,4/16/2024 5:19:09 PM,These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?,InvestorPlace,/news/stocks/these-3-biotech-stocks-are-up-269-in-2024-is-there-more-to-come-1033254629,positive,0.6992359161376953
3143,4/16/2024 8:25:01 PM,"Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades",Benzinga,/news/stocks/avalo-therapeutics-newly-acquired-ex-eli-lilly-drug-could-stand-out-in-competitive-hidradenitis-suppurativa-market-analyst-upgrades-1033254721,negative,0.9143946170806885
3144,4/16/2024 8:59:57 PM,"Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration",Seeking Alpha,https://seekingalpha.com/news/4090270-eli-lilly-subsidiary-precision-biosciences-end-gene-therapy-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9103291034698486
3145,4/17/2024 8:30:36 AM,3 Weight-Loss ETFs to Profit From the Obesity Drug Boom,InvestorPlace,/news/stocks/3-weight-loss-etfs-to-profit-from-the-obesity-drug-boom-1033256825,positive,0.5709972977638245
3146,4/17/2024 11:04:07 AM,Eli Lilly obesity therapy succeeds in late-stage trials for sleep disorder,Seeking Alpha,https://seekingalpha.com/news/4090375-eli-lilly-stock-gains-zepbound-succeeds-sleep-apnea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9316429495811462
3147,4/17/2024 12:58:25 PM,Lilly's Tirzepatide To Treat Sleep Apnea Meets Primary Goals In Late-stage Studies ,RTTNews,/news/stocks/lilly-s-tirzepatide-to-treat-sleep-apnea-meets-primary-goals-in-late-stage-studies-1033257233,negative,0.79770427942276
3148,4/17/2024 1:22:00 PM,"5 stocks to watch on Wednesday: LLY, ABT and more",Seeking Alpha,https://seekingalpha.com/news/4090463-5-stocks-to-watch-on-wednesday-lly-abt-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.927644670009613
3149,4/17/2024 2:30:28 PM,Inspire Medical rebounds as J.P. Morgan defends after Lilly sleep data,Seeking Alpha,https://seekingalpha.com/news/4090500-inspire-medical-stock-spikes-jp-morgan-defends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.4995500445365906
3150,4/17/2024 4:02:34 PM,"Eli Lilly's Mounjaro, Zepbound to remain in shortage through end of Q2",Seeking Alpha,https://seekingalpha.com/news/4090552-eli-lilly-mounjaro-zepbound-remain-shortage-through-end-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6091738939285278
3151,4/17/2024 7:45:55 PM,Eli Lilly's Weight Loss Drug Zepbound Shows Promise In Reducing Sleep Apnea ,RTTNews,/news/stocks/eli-lilly-s-weight-loss-drug-zepbound-shows-promise-in-reducing-sleep-apnea-1033259201,negative,0.9189623594284058
3152,4/18/2024 9:32:38 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Zoetis (ZTS) and TScan Therapeutics (TCRX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-zoetis-zts-and-tscan-therapeutics-tcrx-1033261988,positive,0.9131087064743042
3153,4/18/2024 10:00:59 AM,"Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), US Physical Therapy (USPH)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-abbott-labs-abt-us-physical-therapy-usph-1033262193,negative,0.5008850693702698
3154,4/18/2024 11:20:37 AM,Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-pacific-biosciences-pacb-and-eli-lilly-co-lly-1033262781,positive,0.9165763854980469
3155,4/18/2024 11:30:18 AM,"Analysts’ Top Healthcare Picks: Inspire Medical Systems (INSP), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-inspire-medical-systems-insp-eli-lilly-co-lly-1033262875,negative,0.5123708248138428
3156,4/18/2024 12:20:54 PM,"Analysts Conflicted on These Healthcare Names: Intra-Cellular Therapies (ITCI), Eli Lilly & Co (LLY) and Sanofi (OtherSNYNF)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-intra-cellular-therapies-itci-eli-lilly-co-lly-and-sanofi-othersnynf-1033263051,neutral,0.6751114130020142
3157,4/18/2024 1:30:39 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), TG Therapeutics (TGTX)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-tg-therapeutics-tgtx-1033263410,positive,0.7144588232040405
3158,4/18/2024 2:23:15 PM,Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.,InvestorPlace,/news/stocks/want-to-double-your-tax-refund-in-2024-7-stocks-to-buy-now-1033262864,positive,0.8406462669372559
3159,4/19/2024 11:30:00 AM,Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now,InvestorPlace,/news/stocks/strong-buy-alert-7-no-brainer-stocks-to-scoop-up-now-1033265717,positive,0.7397273778915405
3160,4/19/2024 9:10:14 PM,Hepion ends Phase 2 study for NASH drug due to cash restraints,Seeking Alpha,https://seekingalpha.com/news/4091671-hepion-ends-phase-2-study-for-nash-drug-due-to-cash-restraints?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8149272203445435
3161,4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9173789024353027
3162,4/22/2024 12:04:07 AM,13 new obesity drugs could hit the market by 2029 amid surging demand,Seeking Alpha,https://seekingalpha.com/news/4091726-13-new-obesity-drugs-could-hit-the-market-by-2029-amid-surging-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8077118992805481
3163,4/22/2024 7:50:34 AM,Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-abbott-labs-abt-and-eli-lilly-co-lly-1033270364,positive,0.9201853275299072
3164,4/22/2024 2:35:45 PM,Eli Lilly buys injectable medicine manufacturing facility in Wisconsin,Seeking Alpha,https://seekingalpha.com/news/4091934-eli-lilly-buys-injectable-medicine-manufacturing-facility-in-wisconsin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7230252027511597
3165,4/22/2024 5:43:04 PM,7 High-Flying Stocks That Are Majorly Overdue for a Pullback,InvestorPlace,/news/stocks/7-high-flying-stocks-that-are-majorly-overdue-for-a-pullback-1033272415,neutral,0.9010204076766968
3166,4/23/2024 11:00:00 AM,3 Stocks With the Potential to Surpass Analyst Expectations for 2024,InvestorPlace,/news/stocks/3-stocks-with-the-potential-to-surpass-analyst-expectations-for-2024-1033275494,negative,0.9248522520065308
3167,4/23/2024 7:23:33 PM,TikTok to restrict weight loss drug promotion (updated),Seeking Alpha,https://seekingalpha.com/news/4092598-tiktok-restrict-weight-loss-drug-promotion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9237021207809448
3168,4/24/2024 10:33:00 AM,3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains,InvestorPlace,/news/stocks/3-speculative-weight-loss-drug-stocks-to-bet-on-for-big-gains-1033280935,positive,0.8868301510810852
3169,4/24/2024 2:27:55 PM,3.6M Medicare patients could qualify for Wegovy coverage: report,Seeking Alpha,https://seekingalpha.com/news/4093197-36m-medicare-patients-could-qualify-for-wegovy-coverage-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9108472466468811
3170,4/24/2024 6:51:49 PM,Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses,InvestorPlace,/news/stocks/which-companies-will-join-the-trillion-dollar-team-in-2024-our-3-best-guesses-1033283869,positive,0.9408359527587891
3171,4/24/2024 7:42:21 PM,Novo Nordisk comes under Senate probe over pricing for weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4093539-novo-nordisk-senate-probe-wegovy-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9437999129295349
3172,4/24/2024 10:40:03 PM,Surprise! These 3 Dividend Giants Are at 52-Week Lows. Buy Them Before They Soar,InvestorPlace,/news/stocks/surprise-these-3-dividend-giants-are-at-52-week-lows-buy-them-before-they-soar-1033284469,neutral,0.5322868824005127
3173,4/25/2024 10:04:00 AM,Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List,InvestorPlace,/news/stocks/dont-miss-out-3-top-tier-blue-chip-growth-stocks-for-your-must-buy-list-1033286956,positive,0.8747630715370178
3174,4/25/2024 4:07:32 PM,Dividend Legends: 3 Stocks With Over 100 Years of Payouts,InvestorPlace,/news/stocks/dividend-legends-3-stocks-with-over-100-years-of-payouts-1033289488,positive,0.9032428860664368
3175,4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6158705353736877
3176,4/26/2024 7:00:06 PM,"Catalyst Watch: Apple earnings, Viking IPO, Chinese EV deliveries and Russell indices' Rank Day",Seeking Alpha,https://seekingalpha.com/news/4094989-catalyst-watch-apple-earnings-viking-ipo-chinese-ev-deliveries-and-russell-indices-rank-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9245423674583435
3177,4/26/2024 7:11:32 PM,More than half of the S&P 500 names that reported results this week beat top and bottom line - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095089-more-than-half-of-the-sp-500-names-that-reported-results-this-week-beat-top-and-bottom-line-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5653102397918701
3178,4/28/2024 12:00:00 PM,"Earnings week ahead: Amazon, Apple, Pfizer, AMD, Coca-Cola, Starbucks and more",Seeking Alpha,https://seekingalpha.com/news/4094953-earnings-week-ahead-amazon-apple-pfizer-amd-qualcomm-coca-cola-starbucks-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9127193093299866
3179,4/28/2024 2:34:47 PM,What do weight-loss drugs mean for the diet industry?,Seeking Alpha,https://seekingalpha.com/news/4095227-what-do-weight-loss-drugs-mean-for-the-diet-industry?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9187130331993103
3180,4/29/2024 9:46:53 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033300080,negative,0.595212996006012
3181,4/29/2024 3:01:13 PM,Eli Lilly and earnings: here's what to expect,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q1-1033300228,positive,0.9447187185287476
3182,4/29/2024 3:15:34 PM,Notable earnings before Tuesday's open,Seeking Alpha,https://seekingalpha.com/news/4095553-notable-earnings-before-tuesdays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8660826683044434
3183,4/29/2024 5:13:13 PM,Eli Lilly Q1 Earnings Preview: Weight loss therapies to drive quarterly growth,Seeking Alpha,https://seekingalpha.com/news/4095722-eli-lilly-q1-earnings-preview-weight-loss-therapies-to-drive-quarterly-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8504507541656494
3184,4/30/2024 10:47:16 AM,"Eli Lilly Non-GAAP EPS of $2.58 beats by $0.09, revenue of $8.77B misses by $160M",Seeking Alpha,https://seekingalpha.com/news/4096067-eli-lilly-non-gaap-eps-of-2_58-beats-0_09-revenue-of-8_77b-misses-160m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5235602855682373
3185,4/30/2024 11:03:41 AM,"Eli Lilly in charts: Mounjaro, Zepbound, Verzenio, and Jardiance drive revenue growth in Q1; Trulicity declines 26%",Seeking Alpha,https://seekingalpha.com/news/4096088-eli-lilly-in-charts-mounjaro-zepbound-verzenio-and-jardiance-drive-revenue-growth-in-q1-trulicity-declines-26?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9249356985092163
3186,4/30/2024 11:31:21 AM,Eli Lilly raises guidance on weight loss momentum,Seeking Alpha,https://seekingalpha.com/news/4096119-eli-lilly-stock-gains-weight-loss-momentum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7849271297454834
3187,4/30/2024 12:48:23 PM,"Eli Lilly And Co. Q1 Profit Increases, beats estimates",RTTNews,/news/stocks/eli-lilly-and-co-q1-profit-increases-beats-estimates-1033305281,negative,0.9377925992012024
3188,4/30/2024 1:02:03 PM,Eli Lilly Boosts FY24 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-boosts-fy24-outlook-update-1033305347,negative,0.8171504139900208
3189,4/30/2024 1:18:00 PM,"5 stocks to watch on Tuesday: KO, MCD, AMZN and more",Seeking Alpha,https://seekingalpha.com/news/4096254-5-stocks-to-watch-on-tuesday-ko-mcd-amzn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9242247939109802
3190,4/30/2024 1:30:01 PM,Bank of America Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1033308261,positive,0.9046719670295715
3191,4/30/2024 1:32:37 PM,"Analysts’ Top Healthcare Picks: Qiagen (QGEN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-qiagen-qgen-eli-lilly-co-lly-1033308254,positive,0.5578196048736572
3192,4/30/2024 2:41:18 PM,"Biggest stock movers today: LLY, NXPI, MSTR, ST, and more",Seeking Alpha,https://seekingalpha.com/news/4095999-biggest-stock-movers-today-nxpi-mstr-st-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9186674356460571
3193,4/30/2024 2:53:01 PM,"LLY Stock Earnings: Eli Lilly Beats EPS, Misses Revenue for Q1 2024",InvestorPlace,/news/stocks/lly-stock-earnings-eli-lilly-for-q1-of-2024-1033307499,neutral,0.5554578304290771
3194,4/30/2024 7:35:14 PM,"Stocks Dive On Fears Of Hawkish Fed; Treasury Yields Rise, Bitcoin Tumbles To $60,000: What's Driving Markets Tuesday?",Benzinga,/news/stocks/stocks-dive-on-fears-of-hawkish-fed-treasury-yields-rise-bitcoin-tumbles-to-60-000-what-s-driving-markets-tuesday-1033308411,neutral,0.8567904829978943
3195,4/30/2024 9:11:33 PM,"Goldman Scrutinizes Hits, Misses, And Growth Trajectory Concerns For Eli Lilly And Its Its Obesity and Diabetes Drugs",Benzinga,/news/stocks/goldman-scrutinizes-hits-misses-and-growth-trajectory-concerns-for-eli-lilly-and-its-its-obesity-and-diabetes-drugs-1033308604,positive,0.9185956120491028
3196,5/1/2024 10:01:13 AM,"Pfizer plans direct-to-consumer platform to sell Covid, migraine drugs - report",Seeking Alpha,https://seekingalpha.com/news/4097035-pfizer-plans-direct-to-consumer-platform-to-sell-covid-migraine-drugs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8115430474281311
3197,5/1/2024 10:14:21 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033313537,negative,0.5521676540374756
3198,5/1/2024 10:42:18 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-exelixis-exel-and-zynex-zyxi-1033313579,positive,0.9123848676681519
3199,5/1/2024 10:50:23 AM,"Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-10x-genomics-txg-axonics-modulation-technologies-axnx-and-eli-lilly-co-lly-1033313676,positive,0.9113795161247253
3200,5/1/2024 11:15:39 AM,Truist Financial Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-eli-lilly-co-lly-1033314141,positive,0.8780941963195801
3201,5/1/2024 2:47:16 PM,3 Healthcare Stocks With the Potential to Triple Your Investment by 2026,InvestorPlace,/news/stocks/3-healthcare-stocks-with-the-potential-to-triple-your-investment-by-2026-1033314236,negative,0.7737095355987549
3202,5/1/2024 3:59:48 PM,Stock Market Crash Alert: 3 Must-Buy Biotech Stocks When Prices Plunge,InvestorPlace,/news/stocks/stock-market-crash-alert-3-must-buy-biotech-stocks-when-prices-plunge-1033314585,positive,0.8044172525405884
3203,5/1/2024 4:01:09 PM,What 23 Analyst Ratings Have To Say About Eli Lilly and Co,Benzinga,/news/stocks/what-23-analyst-ratings-have-to-say-about-eli-lilly-and-co-1033313991,positive,0.92987060546875
3204,5/1/2024 4:38:01 PM,Stock Market Crash Warning: Don’t Get Caught Holding These 3 Consumer Stocks.,InvestorPlace,/news/stocks/stock-market-crash-warning-dont-get-caught-holding-these-3-consumer-stocks-1033314760,neutral,0.5027034282684326
3205,5/1/2024 5:41:56 PM,Profit from the Panic: 3 Stocks to Pounce on When They Become Steals,InvestorPlace,/news/stocks/profit-from-the-panic-3-stocks-to-pounce-on-when-they-become-steals-1033314988,positive,0.9045398831367493
3206,5/1/2024 7:36:03 PM,Q1 Earnings Seasons Picks & Pans: The 4 Biggest Stock Winners (and 3 Losers),InvestorPlace,/news/stocks/q1-earnings-seasons-picks-pans-the-4-biggest-stock-winners-and-3-losers-1033315221,positive,0.8215121030807495
3207,5/1/2024 9:26:50 PM,"Eli Lilly 'On Its Way' To $1 Trillion Market Cap, Analysts Say: It's A 'Have' In A Sea Of 'Have Nots'",Benzinga,/news/stocks/eli-lilly-on-its-way-to-1-trillion-market-cap-analysts-say-it-s-a-have-in-a-sea-of-have-nots-1033315206,positive,0.5240874290466309
3208,5/2/2024 6:31:05 AM,Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-tandem-diabetes-care-tndm-and-eli-lilly-co-lly-1033318536,positive,0.9175443649291992
3209,5/2/2024 8:11:57 AM,"Novo Nordisk lifts guidance as Ozempic, Wegovy sales surge; but stock falls 3%",Seeking Alpha,https://seekingalpha.com/news/4098171-novo-nordisk-stock-guidance-earnings-weight-loss-drug-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7764908075332642
3210,5/2/2024 1:17:44 PM,"Novo Nordisk says prices dropping for Wegovy, Ozempic: report",Seeking Alpha,https://seekingalpha.com/news/4098574-novo-nordisk-says-prices-dropping-for-wegovy-ozempic-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8780768513679504
3211,5/2/2024 1:58:32 PM,"GLP-1 drug prices falling at UK pharmacies, clinics: report",Seeking Alpha,https://seekingalpha.com/news/4098637-glp-1-drug-prices-falling-at-uk-pharmacies-clinics-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9571473598480225
3212,5/2/2024 2:00:00 PM,3 Stocks Gunning for Trillion-Dollar Status: The Players to Own Now,InvestorPlace,/news/stocks/3-stocks-gunning-for-trillion-dollar-status-the-players-to-own-now-1033320626,positive,0.9190177321434021
3213,5/2/2024 6:31:50 PM,Radiopharma stocks higher as sector welcomes the latest M&A deal,Seeking Alpha,https://seekingalpha.com/news/4099035-novartis-mariana-oncology-deal-drives-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9220007658004761
3214,5/2/2024 7:10:06 PM,Palatin gets FDA OK to test weight loss therapy with Eli Lilly’s tirzepatide,Seeking Alpha,https://seekingalpha.com/news/4099046-palatin-stock-spikes-fda-clears-obesity-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8767286539077759
3215,5/2/2024 9:40:21 PM,"Amgen stock rallies 13% amid weight-loss drug updates, tweaked guidance",Seeking Alpha,https://seekingalpha.com/news/4099298-amgen-stock-rallies-on-weight-loss-drug-updates-tweaked-guidanace?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8810361623764038
3216,5/3/2024 2:28:54 PM,Amgen stock rallies 13% on GLP-1 weight-loss drug update,Seeking Alpha,https://seekingalpha.com/news/4099749-amgen-stock-rallies-on-glp-1-weight-loss-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8914835453033447
3217,5/3/2024 6:39:42 PM,3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030,InvestorPlace,/news/stocks/3-under-the-radar-stocks-that-could-be-worth-over-1-trillion-by-2030-1033328193,positive,0.9067659378051758
3218,5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9528807997703552
3219,5/4/2024 8:47:00 PM,16 out of 24 health care companies beat topline numbers this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4099757-16-out-of-24-health-care-companies-beat-topline-numbers-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8876544833183289
3220,5/5/2024 8:08:00 PM,About 79% of the S&P 500 names beat on EPS during the busiest week of Q1 reporting - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4099902-about-79-of-the-sp-500-names-beat-on-eps-during-the-busiest-week-of-q1-reporting-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.648939847946167
3221,5/6/2024 8:37:45 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033332480,positive,0.9309778809547424
3222,5/6/2024 3:38:47 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4100436-eli-lilly-declares-130-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9196907877922058
3223,5/6/2024 6:30:17 PM,3 Biotech Stocks to Double Your Money in the Next 24 Months,InvestorPlace,/news/stocks/3-biotech-stocks-to-double-your-money-in-the-next-24-months-1033334986,negative,0.7702029347419739
3224,5/7/2024 1:38:29 PM,Eli Lilly Alzheimer’s therapy set for June FDA AdCom meeting,Seeking Alpha,https://seekingalpha.com/news/4101160-eli-lilly-alzheimers-drug-set-june-fda-adcom?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9474264979362488
3225,5/7/2024 5:24:47 PM,Fresenius down 6% despite bottom-line beat,Seeking Alpha,https://seekingalpha.com/news/4101564-fresenius-down-6-despite-bottom-line-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9692587852478027
3226,5/7/2024 5:28:03 PM,FDA Advisory Committee To Convene Meeting To Discuss On Eli Lilly's Alzheimer's Drug ,RTTNews,/news/stocks/fda-advisory-committee-to-convene-meeting-to-discuss-on-eli-lilly-s-alzheimer-s-drug-1033340860,positive,0.9387300610542297
3227,5/7/2024 6:04:24 PM,Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare,InvestorPlace,/news/stocks/biotech-breakthroughs-7-stocks-driving-the-next-wave-in-healthcare-1033341676,positive,0.8313630819320679
3228,5/9/2024 5:30:47 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033354744,negative,0.5521676540374756
3229,5/9/2024 2:34:23 PM,7 Weight Loss Drug Stocks Poised for Explosive Growth by 2025,InvestorPlace,/news/stocks/7-weight-loss-drug-stocks-poised-for-explosive-growth-by-2025-1033357058,negative,0.8605071902275085
3230,5/9/2024 4:40:14 PM,Lilly next-generation diabetes drug mazdutide meets primary goal in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/4103883-lilly-next-generation-diabetes-drug-mazdutide-meets-primary-goal-phase-3-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8551706075668335
3231,5/9/2024 4:41:08 PM,A Look at Pharma ETFs Post Q1 Earnings,Benzinga,/news/etf/a-look-at-pharma-etfs-post-q1-earnings-1033357001,positive,0.9325221180915833
3232,5/9/2024 5:22:28 PM,"Novo Nordisk, Flagship to develop next-generation obesity drugs",Seeking Alpha,https://seekingalpha.com/news/4103937-novo-nordisk-flagship-to-develop-next-generation-obesity-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6775999069213867
3233,5/10/2024 10:30:00 AM,3 Biotech Stocks to Sell in May Before They Crash & Burn,InvestorPlace,/news/stocks/3-biotech-stocks-to-sell-in-may-before-they-crash-burn-1033362353,positive,0.8534220457077026
3234,5/10/2024 12:18:46 PM,"Dividend Roundup: Eli Lilly, American Express, Microsoft, Delta Air Lines, and more",Seeking Alpha,https://seekingalpha.com/news/4104536-dividend-roundup-eli-lilly-american-express-microsoft-delta-air-lines-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9436390995979309
3235,5/10/2024 2:16:35 PM,One in eight U.S. adults admits to GLP-1 usage as public awareness climbs,Seeking Alpha,https://seekingalpha.com/news/4104648-one-in-eight-us-adults-admits-glp-1-usage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8346967697143555
3236,5/10/2024 5:01:03 PM,Lilly could partner with Cipla to market GLP-1 drugs in India - report,Seeking Alpha,https://seekingalpha.com/news/4104762-lilly-could-partner-cipla-market-glp-1-drugs-india?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6695333123207092
3237,5/10/2024 6:13:46 PM,AI-discovered drugs have an 80%–90% success rate: study,Seeking Alpha,https://seekingalpha.com/news/4104786-ai-discovered-drugs-have-an-8090-success-rate-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5321410298347473
3238,5/13/2024 7:51:10 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eli-lilly-co-lly-trubridge-tbrg-and-ligand-pharma-lgnd-1033370083,neutral,0.9340864419937134
3239,5/13/2024 11:00:00 AM,The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory,InvestorPlace,/news/stocks/the-must-watch-list-3-stocks-to-snap-up-as-soon-as-they-hit-bargain-territory-1033370214,positive,0.6391982436180115
3240,5/13/2024 3:48:17 PM,BoA raises 2024 Novo Nordisk Wegovy sales estimates on prescription trends,Seeking Alpha,https://seekingalpha.com/news/4105273-boa-raises-2024-novo-nordisk-wegovy-sales-estimates-prescription-trends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8810392022132874
3241,5/14/2024 10:30:00 AM,Biotech Behemoths: 3 Giants Set to Dominate the Health Scene,InvestorPlace,/news/stocks/biotech-behemoths-3-giants-set-to-dominate-the-health-scene-1033375431,positive,0.852258026599884
3242,5/14/2024 2:39:47 PM,"Lilly target price raised at Argus on Mounjaro, Zepbound sales",Seeking Alpha,https://seekingalpha.com/news/4105874-lilly-target-price-raised-argus-mounjaro-zepbound-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.903577446937561
3243,5/15/2024 2:21:25 PM,"Short interest in S&P 500 healthcare sector dips in April, biotechnology companies most shorted",Seeking Alpha,https://seekingalpha.com/news/4106501-short-interest-in-sp-500-healthcare-sector-dips-in-april-biotechnology-companies-most-shorted?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.96722412109375
3244,5/15/2024 5:09:04 PM,Wall Street Favorites: 3 Growth Stocks With Strong Buy Ratings for May 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-growth-stocks-with-strong-buy-ratings-for-may-2024-1033386011,negative,0.6144020557403564
3245,5/15/2024 8:27:14 PM,"Duquesne Family Office top Q1 buys, cuts: Coherent, Eli Lilly, others",Seeking Alpha,https://seekingalpha.com/news/4106936-duquesne-family-office-top-q1-buys-cuts-coherent-eli-lilly-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8549694418907166
3246,5/15/2024 9:43:25 PM,Should You Hold Viking Therapeutics in Your Portfolio?,Benzinga,/news/stocks/should-you-hold-viking-therapeutics-in-your-portfolio-1033386466,positive,0.9406071305274963
3247,5/16/2024 10:15:00 AM,Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade,InvestorPlace,/news/stocks/patent-peril-3-stocks-at-risk-from-the-ftcs-drug-crusade-1033392050,neutral,0.9288397431373596
3248,5/16/2024 10:48:39 AM,Roche obesity therapy leads to ~19% weight loss in Phase 1 trial,Seeking Alpha,https://seekingalpha.com/news/4107185-roche-obesity-therapy-causes-19-weight-loss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8494001626968384
3249,5/16/2024 11:15:00 AM,7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs,InvestorPlace,/news/stocks/7-pharma-stocks-harnessing-ai-brainpower-for-big-breakthroughs-1033392344,negative,0.5881011486053467
3250,5/16/2024 11:21:56 AM,Eli Lilly once-weekly insulin hits main goal in late-stage trials,Seeking Alpha,https://seekingalpha.com/news/4107209-eli-lilly-weekly-insulin-hits-main-goal-late-stage-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5633445382118225
3251,5/16/2024 12:13:38 PM,The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024,InvestorPlace,/news/stocks/the-dividend-investors-playbook-3-stocks-for-consistent-cash-flow-in-2024-1033392689,negative,0.514305055141449
3252,5/16/2024 1:10:28 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-celcuity-celc-and-89bio-etnb-1033394380,positive,0.9200678467750549
3253,5/16/2024 2:30:33 PM,Novo Nordisk falls on reports of fire at construction site (update),Seeking Alpha,https://seekingalpha.com/news/4107388-novo-nordisk-stock-falls-construction-site-fire?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.910983145236969
3254,5/16/2024 3:31:52 PM,Lilly Says Phase 3 Trials Of Once-weekly Insulin In Type 2 Diabetes Meets Primary Endpoint ,RTTNews,/news/stocks/lilly-says-phase-3-trials-of-once-weekly-insulin-in-type-2-diabetes-meets-primary-endpoint-1033393113,negative,0.8505202531814575
3255,5/16/2024 4:40:29 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Arvinas Holding Company (ARVN) and Progyny (PGNY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-arvinas-holding-company-arvn-and-progyny-pgny-1033394933,positive,0.928029477596283
3256,5/16/2024 6:37:18 PM,Viking falls after Roche’s obesity drug data; RayJay upgrades (update),Seeking Alpha,https://seekingalpha.com/news/4107654-viking-stock-falls-roche-obesity-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7845667600631714
3257,5/17/2024 11:10:11 AM,"Analysts Are Bullish on These Healthcare Stocks: Amgen (AMGN), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-amgen-amgn-eli-lilly-co-lly-1033399669,positive,0.8092842698097229
3258,5/17/2024 6:44:34 PM,Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge,InvestorPlace,/news/stocks/rally-rockets-3-stocks-benefitting-from-the-markets-unstoppable-surge-1033400584,negative,0.933208167552948
3259,5/17/2024 7:02:01 PM,Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?,InvestorPlace,/news/stocks/pharma-stocks-outlook-where-are-2024s-top-performers-headed-next-1033400641,positive,0.8749277591705322
3260,5/17/2024 9:04:43 PM,"EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga",Benzinga,/news/etf/exclusive-gamestop-amc-buzz-may-prove-to-be-short-lived-ceo-of-company-behind-meme-etf-tells-benzinga-1033400602,neutral,0.6404998898506165
3261,5/17/2024 9:24:26 PM,"4 Stocks That Could Break Novo Nordisk, Lilly's Obesity Duopoly",Benzinga,/news/stocks/4-stocks-that-could-break-novo-nordisk-lilly-s-obesity-duopoly-1033400634,negative,0.5076711177825928
3262,5/18/2024 5:35:22 AM,AstraZeneca Sharpens Focus on Innovation,TipRanks,/news/stocks/astrazeneca-sharpens-focus-on-innovation-1033400908,positive,0.6908308267593384
3263,5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8400077223777771
3264,5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8515272736549377
3265,5/20/2024 10:02:10 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Johnson & Johnson (JNJ), Eli Lilly & Co (LLY) and Coherus Biosciences (CHRS)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-johnson-johnson-jnj-eli-lilly-co-lly-and-coherus-biosciences-chrs-1033403373,neutral,0.8155579566955566
3266,5/20/2024 2:15:35 PM,Hims & Hers surges on cheap compounded versions of Novo Nordisk's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4108357-hims-hers-surges-cheap-compounded-versions-novo-nordisk-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8916902542114258
3267,5/20/2024 7:16:21 PM,HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections,InvestorPlace,/news/stocks/hims-stock-alert-hims-hers-shares-rocket-on-weight-loss-injections-1033404593,neutral,0.6242539286613464
3268,5/20/2024 7:18:17 PM,Should You Invest in the Vanguard Health Care ETF?,Benzinga,/news/etf/should-you-invest-in-the-vanguard-health-care-etf-1033404417,positive,0.9077762961387634
3269,5/21/2024 10:43:02 AM,Eli Lilly’s tirzepatide cleared for diabetes treatment in China,Seeking Alpha,https://seekingalpha.com/news/4108665-eli-lillys-tirzepatide-cleared-for-diabetes-treatment-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.793947160243988
3270,5/21/2024 11:20:00 AM,3 S&P 500 Stocks to Buy in May Before They Rocket Higher,InvestorPlace,/news/stocks/3-sp-500-stocks-to-buy-in-may-before-they-rocket-higher-1033406733,positive,0.8815874457359314
3271,5/21/2024 12:06:41 PM,Eli Lilly & Co.: A Strong Buy on Robust Pipeline and Financial Health,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-financial-health-1033408148,negative,0.9482333660125732
3272,5/21/2024 1:13:41 PM,Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis,Seeking Alpha,https://seekingalpha.com/news/4108774-eli-lilly-inks-radiopharma-deal-aktis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8129591941833496
3273,5/21/2024 1:21:57 PM,Microcap Mangoceuticals doubles on plan to sell cheap oral GLP-1 weight loss meds,Seeking Alpha,https://seekingalpha.com/news/4108784-microcap-mangoceuticals-doubles-on-plan-to-sell-cheap-oral-glp-1-weight-loss-meds?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7297839522361755
3274,5/21/2024 1:44:06 PM,7 Reliable Blue-Chip Stocks That Cannot Miss,InvestorPlace,/news/stocks/7-reliable-blue-chip-stocks-that-cannot-miss-1033407489,positive,0.7943858504295349
3275,5/21/2024 2:29:09 PM,Roundhill Investment launches GLP-1 & Weight Loss ETF,Seeking Alpha,https://seekingalpha.com/news/4108849-roundhill-investment-launches-glp-1-weight-loss-etf?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9234378337860107
3276,5/21/2024 3:13:11 PM,Lilly Reports Positive Phase 3 Trial Results Of Mirikizumab In Crohn's Disease ,RTTNews,/news/stocks/lilly-reports-positive-phase-3-trial-results-of-mirikizumab-in-crohn-s-disease-1033407307,negative,0.9344110488891602
3277,5/21/2024 3:50:45 PM,Novo Nordisk unsure when it will meet obesity drug demand: report,Seeking Alpha,https://seekingalpha.com/news/4108910-novo-nordisk-unsure-when-it-will-meet-obesity-drug-demand-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.937421977519989
3278,5/21/2024 6:06:23 PM,"Study finds 30% of Wegovy, Saxenda users quit within 4 weeks",Seeking Alpha,https://seekingalpha.com/news/4108986-study-finds-30-percent-of-wegovy-saxenda-users-quit-within-4-weeks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9170540571212769
3279,5/21/2024 6:36:28 PM,3 Growth Stocks That Could Be Millionaire-Makers: May Edition,InvestorPlace,/news/stocks/3-growth-stocks-that-could-be-millionaire-makers-may-edition-1033408725,positive,0.9056154489517212
3280,5/21/2024 10:35:00 PM,EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic,Benzinga,/news/stocks/exclusive-roundhill-investments-launches-weight-loss-etf-for-exposure-to-blockbuster-drugs-like-ozempic-1033408932,positive,0.8658260703086853
3281,5/22/2024 11:14:37 AM,Australia to ban copycat versions of weight loss drugs like Ozempic,Seeking Alpha,https://seekingalpha.com/news/4109205-australia-ban-compounded-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5926664471626282
3282,5/22/2024 1:58:49 PM,Retire Rich: 3 Game-Changing Stocks to Own for the Next 10 Years,InvestorPlace,/news/stocks/retire-rich-3-game-changing-stocks-to-own-for-the-next-10-years-1033412253,positive,0.901934027671814
3283,5/22/2024 3:11:31 PM,"The 500 Top Stocks to Buy in May, According to AI",InvestorPlace,/news/stocks/the-500-top-stocks-to-buy-in-may-according-to-ai-1033412478,positive,0.9145966172218323
3284,5/22/2024 3:25:25 PM,FDA reviewers voice concerns over hypoglycemia with Novo Nordisk weekly insulin,Seeking Alpha,https://seekingalpha.com/news/4109381-fda-reviewers-voice-concerns-hypoglycemia-novo-nordisk-weekly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7478130459785461
3285,5/23/2024 10:50:00 AM,Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.,InvestorPlace,/news/stocks/move-over-ozempic-3-new-glp-1-drugs-and-products-coming-soon-1033415366,positive,0.6933512091636658
3286,5/23/2024 1:03:35 PM,"Analysts’ Top Healthcare Picks: Silk Road Medical (SILK), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-silk-road-medical-silk-eli-lilly-co-lly-1033416866,negative,0.5106465816497803
3287,5/23/2024 6:01:14 PM,3 Biotech Stocks to Buy on the Dip: May 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-may-2024-1033417162,positive,0.8900653719902039
3288,5/23/2024 6:07:59 PM,SA Asks: Is Eli Lilly or Novo Nordisk a better investment?,Seeking Alpha,https://seekingalpha.com/news/4109962-sa-asks-is-eli-lilly-or-novo-nordisk-a-better-investment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8848584890365601
3289,5/24/2024 10:00:00 AM,7 Stocks to Buy if the Market Ends Up Plunging,InvestorPlace,/news/stocks/7-stocks-to-buy-if-the-market-ends-up-plunging-1033419330,positive,0.9035343527793884
3290,5/24/2024 11:00:00 AM,Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now,InvestorPlace,/news/stocks/stocks-to-buy-7-undeniable-dow-darlings-to-pile-into-now-1033419440,positive,0.8567739129066467
3291,5/24/2024 11:06:38 AM,Novo weight loss therapy cuts mortality risk in kidney disease,Seeking Alpha,https://seekingalpha.com/news/4110177-novo-ozempic-cuts-death-risk-kidney-patient?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6845099925994873
3292,5/24/2024 2:10:36 PM,"Eli Lilly to spend another $5.3B on production site for Mounjaro, Zepbound",Seeking Alpha,https://seekingalpha.com/news/4110256-eli-lilly-spend-another-53b-production-site-mounjaro-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7117814421653748
3293,5/24/2024 2:40:44 PM,Zealand Pharma releases top-line phase 2 results on weight loss asset dapiglutide,Seeking Alpha,https://seekingalpha.com/news/4110248-zealand-pharma-releases-top-line-phase-1-results-weight-loss-asset-dapiglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.92645263671875
3294,5/24/2024 4:06:22 PM,"Lilly Increases Investment In Indiana-Based Unit To Enhance Production Of Zepbound, Mounjaro ",RTTNews,/news/stocks/lilly-increases-investment-in-indiana-based-unit-to-enhance-production-of-zepbound-mounjaro-1033420251,negative,0.9305979609489441
3295,5/24/2024 8:16:00 PM,Novo Nordisk once weekly insulin fails to get thumbs up from majority of FDA advisors,Seeking Alpha,https://seekingalpha.com/news/4110352-novo-nordisk-once-weekly-insulin-fails-get-thumbs-up-majority-fda-advisors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9168346524238586
3296,5/25/2024 12:41:46 PM,Novo Nordisk’s Wegovy improves kidney health in addition to weight loss: study,Seeking Alpha,https://seekingalpha.com/news/4110469-novo-nordisks-wegovy-kidney-health-in-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9113202095031738
3297,5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9204940795898438
3298,5/26/2024 5:36:00 PM,SA Asks: Who will launch the next big weight-loss drug?,Seeking Alpha,https://seekingalpha.com/news/4110093-sa-asks-who-will-launch-the-next-big-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9171247482299805
3299,5/27/2024 6:56:31 PM,The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop,InvestorPlace,/news/stocks/the-penny-stock-prophecy-3-overlooked-stocks-primed-to-pop-1033424976,positive,0.8789829611778259
3300,5/28/2024 9:41:05 AM,Analysts Conflicted on These Healthcare Names: Eli Lilly & Co (LLY) and Veeva Systems (VEEV),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-eli-lilly-co-lly-and-veeva-systems-veev-1033426901,neutral,0.5815162658691406
3301,5/28/2024 11:50:00 AM,The Dividend Acceleration Squad: 3 Stocks With Rapidly Rising Yields,InvestorPlace,/news/stocks/the-dividend-acceleration-squad-3-stocks-with-rapidly-rising-yields-1033426687,negative,0.7991143465042114
3302,5/28/2024 3:32:01 PM,OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF,InvestorPlace,/news/stocks/ozem-etf-7-things-to-know-about-the-new-roundhill-glp-1-weight-loss-etf-1033427842,positive,0.92902672290802
3303,5/29/2024 10:30:00 AM,"If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-in-may-it-better-be-one-of-these-3-names-1033431002,positive,0.9427831172943115
3304,5/29/2024 2:01:00 PM,3 Sorry Pharma Stocks to Sell in May While You Still Can,InvestorPlace,/news/stocks/3-sorry-pharma-stocks-to-sell-in-may-while-you-still-can-1033433603,positive,0.8258687257766724
3305,5/29/2024 4:11:20 PM,"Ro provides supply tracking feature for Lilly, Novo Nordisk weight loss drugs",Seeking Alpha,https://seekingalpha.com/news/4111188-ro-provides-supply-tracking-feature-lilly-novo-nordisk-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9021850824356079
3306,5/29/2024 4:32:44 PM,Lilly's Retevmo gains approval for children as young as two with thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4111200-lilly-retevmo-gains-approval-children-as-young-as-two-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9469336867332458
3307,5/29/2024 11:56:12 PM,"Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker",Benzinga,/news/stocks/nvidia-is-up-186-from-a-year-ago-yet-these-7-stocks-have-more-than-doubled-their-returns-over-the-ai-chipmaker-1033433492,negative,0.9522829055786133
3308,5/30/2024 11:30:00 AM,Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit,InvestorPlace,/news/stocks/blue-chip-bubble-trouble-7-stocks-to-short-as-valuations-stretch-to-the-limit-1033435720,neutral,0.9286768436431885
3309,5/30/2024 11:31:44 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and VolitionRX (VNRX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-volitionrx-vnrx-1033436798,positive,0.9119063019752502
3310,5/30/2024 11:55:49 AM,Biotech Stocks Facing FDA Decision In June 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2024-1033435348,positive,0.9173391461372375
3311,5/30/2024 3:22:06 PM,Goldman Sachs raises obesity drug market estimate to $130B,Seeking Alpha,https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6894457936286926
3312,5/30/2024 5:17:07 PM,"Weight Loss Drug Market To Rocket To $130B By 2030 With Eli Lilly, Novo Nordisk In Lead: Goldman Sachs",Benzinga,/news/stocks/weight-loss-drug-market-to-rocket-to-130b-by-2030-with-eli-lilly-novo-nordisk-in-lead-goldman-sachs-1033436939,negative,0.5986940264701843
3313,5/30/2024 7:03:57 PM,Should You Invest in the iShares U.S. Healthcare ETF?,Benzinga,/news/stocks/should-you-invest-in-the-ishares-u-s-healthcare-etf-1033437375,positive,0.9228521585464478
3314,5/30/2024 9:36:44 PM,"New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk",Benzinga,/news/etf/new-weight-loss-etf-is-essentially-a-play-on-eli-lilly-novo-nordisk-1033437704,positive,0.9129385352134705
3315,5/30/2024 9:37:15 PM,Institutional Bets: 7 Stocks the Big Money Will Send Higher This Year,InvestorPlace,/news/stocks/institutional-bets-7-stocks-the-big-money-will-send-higher-this-year-1033437969,positive,0.6835368871688843
3316,5/31/2024 1:01:10 AM,"ZTS, SYK, LLY: Which Healthcare Stock Is the Best Buy?",TipRanks,/news/stocks/zts-syk-lly-which-healthcare-stock-is-the-best-buy-1033438317,positive,0.9380984902381897
3317,5/31/2024 3:04:41 AM,Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033439807,positive,0.7660669684410095
3318,5/31/2024 10:00:00 AM,Aristocrats in Disguise: 3 Blue-Chip Stocks With Stealth Growth Potential,InvestorPlace,/news/stocks/aristocrats-in-disguise-3-blue-chip-stocks-with-stealth-growth-potential-1033440553,positive,0.8323235511779785
3319,5/31/2024 10:00:00 AM,Unearthing Unknown Stocks: 3 Picks That Could Be the Next Big Thing,InvestorPlace,/news/stocks/unearthing-unknown-stocks-3-picks-that-could-be-the-next-big-thing-1033440550,positive,0.9218350648880005
3320,5/31/2024 2:02:26 PM,Summit pares gains as ‘China-only’ trial beats Merck’s Keytruda (update),Seeking Alpha,https://seekingalpha.com/news/4111919-summit-stock-falls-despite-data-beating-merck?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5685202479362488
3321,5/31/2024 7:00:19 PM,"Catalyst Watch: Nvidia stock split buzz, COMPUTEX, Walmart's annual meeting, and REITs on display",Seeking Alpha,https://seekingalpha.com/news/4111995-catalyst-watch-nvidia-stock-split-buzz-computex-walmarts-annual-meeting-and-reits-on-display?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9244751334190369
3322,6/1/2024 3:53:31 PM,Lilly Announces Updated Data From Phase 1/2 Study Of Olomorasib In Advanced Solid Tumors ,RTTNews,/news/stocks/lilly-announces-updated-data-from-phase-1-2-study-of-olomorasib-in-advanced-solid-tumors-1033442941,positive,0.8631588816642761
3323,6/1/2024 6:44:45 PM,FDA oncology chief says international clinical trials should be priority,Seeking Alpha,https://seekingalpha.com/news/4112136-fda-oncology-chief-international-clinical-trials-priority?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7988932728767395
3324,6/2/2024 2:00:00 PM,SA Asks: Which weight-loss stocks should investors be watching?,Seeking Alpha,https://seekingalpha.com/news/4112116-sa-asks-which-weight-loss-stocks-should-investors-be-watching?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9329712986946106
3325,6/3/2024 8:41:06 AM,"Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Eli Lilly & Co (LLY) and Envista Holdings (NVST)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-werewolf-therapeutics-howl-eli-lilly-co-lly-and-envista-holdings-nvst-1033445307,positive,0.9169474840164185
3326,6/3/2024 11:29:07 AM,Eli Lilly: A Strong Buy on Oncology Overhaul and Expanding Pipeline,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-oncology-overhaul-and-expanding-pipeline-1033446442,negative,0.9304869771003723
3327,6/3/2024 2:41:18 PM,Eli Lilly granted exclusive license to QurAlis candidate for neurodegenerative diseases,Seeking Alpha,https://seekingalpha.com/news/4112353-eli-lilly-granted-exclusive-license-quralis-candidate-neurodegenerative-diseases?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8146026134490967
3328,6/3/2024 9:15:12 PM,"Structure Therapeutics Obesity Candidate Is 'Very Competitive' To Eli Lilly's Orforglipron, Analyst Says",Benzinga,/news/stocks/structure-therapeutics-obesity-candidate-is-very-competitive-to-eli-lilly-s-orforglipron-analyst-says-1033447122,negative,0.8111833930015564
3329,6/4/2024 11:40:13 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Eledon Pharmaceuticals (ELDN), BioNTech SE (BNTX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-eledon-pharmaceuticals-eldn-biontech-se-bntx-and-eli-lilly-co-lly-1033450204,neutral,0.9308317303657532
3330,6/4/2024 12:46:53 PM,"Largest companies in the Russell 3000 Index by size: NVDA, LLY, AVGO make huge leaps",Seeking Alpha,https://seekingalpha.com/news/4112667-largest-companies-in-the-russell-3000-index-by-size-nvda-lly-avgo-make-huge-leaps?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9025338292121887
3331,6/4/2024 2:37:18 PM,Eli Lilly sees improving availability of GLP-1 drugs Mounjaro and Zepbound,Seeking Alpha,https://seekingalpha.com/news/4112744-eli-lilly-sees-improving-availability-of-glp-1-drugs-mounjaro-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9499258399009705
3332,6/4/2024 6:57:26 PM,Eli Lilly wins favorable terms for obesity drug use in U.K.,Seeking Alpha,https://seekingalpha.com/news/4112822-eli-lilly-obesity-drug-recommended-use-uk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9498683214187622
3333,6/4/2024 7:40:11 PM,Viking falls despite positive mid-stage data for liver drug,Seeking Alpha,https://seekingalpha.com/news/4112830-viking-stock-falls-positive-nash-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8973859548568726
3334,6/5/2024 10:13:00 AM,AMZN Buy Alert: Why Amazon Stock Is a Bargain Hiding in Plain Sight,InvestorPlace,/news/stocks/amzn-buy-alert-why-amazon-stock-is-a-bargain-hiding-in-plain-sight-1033452716,positive,0.7472556829452515
3335,6/5/2024 12:00:24 PM,Eli Lilly CFO Anat Ashkenazi to resign,Seeking Alpha,https://seekingalpha.com/news/4113047-eli-lilly-cfo-anat-ashkenazi-to-resign?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.834854006767273
3336,6/5/2024 12:10:19 PM,Eli Lilly details NASH effects of weight loss drug,Seeking Alpha,https://seekingalpha.com/news/4113054-eli-lilly-details-nash-effects-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8723682761192322
3337,6/5/2024 12:21:51 PM,Alphabet taps Eli Lilly executive as new CFO,Seeking Alpha,https://seekingalpha.com/news/4113065-alphabet-taps-eli-lilly-executive-as-new-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9276266098022461
3338,6/5/2024 1:20:09 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), LENSAR (LNSR)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-lensar-lnsr-1033454760,positive,0.5501919984817505
3339,6/5/2024 2:12:36 PM,Eli Lilly CFO Anat Ashkenazi Resigns ,RTTNews,/news/stocks/eli-lilly-cfo-anat-ashkenazi-resigns-1033453239,neutral,0.6859180927276611
3340,6/5/2024 5:10:12 PM,Biogen favored at RBC as Eli Lilly awaits FDA AdCom on Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113279-biogen-stock-favored-rbc-lilly-awaits-alzheimers-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7142057418823242
3341,6/5/2024 5:44:31 PM,LifeMD gains as KeyBanc issues bullish view on weight loss program,Seeking Alpha,https://seekingalpha.com/news/4113285-lifemd-stock-gains-keybanc-bullish-view?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8910759091377258
3342,6/6/2024 10:00:00 AM,Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition,InvestorPlace,/news/stocks/growth-stock-goliaths-7-picks-that-will-tower-over-the-competition-1033456766,positive,0.8746131658554077
3343,6/6/2024 10:00:00 AM,Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half,InvestorPlace,/news/stocks/mid-year-momentum-plays-7-stocks-to-buy-for-the-second-half-1033456769,positive,0.7957617044448853
3344,6/6/2024 2:09:40 PM,FDA suggests safety warning for Eli Lilly Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4113676-eli-lilly-alzheimers-drug-should-come-safety-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5038935542106628
3345,6/6/2024 9:23:47 PM,The 3 Most Undervalued Pharma Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-june-2024-1033459382,positive,0.75202476978302
3346,6/6/2024 9:36:29 PM,Halozyme's ENHANZE Product Gets New Patent Grant in EU,Benzinga,/news/stocks/halozyme-s-enhanze-product-gets-new-patent-grant-in-eu-1033459113,negative,0.7392569780349731
3347,6/7/2024 12:10:56 PM,"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Qiagen (QGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-amgen-amgn-qiagen-qgen-and-eli-lilly-co-lly-1033461868,positive,0.9212010502815247
3348,6/7/2024 2:53:19 PM,Kroger follows Costco to offer GLP-1s as part of weight loss program,Seeking Alpha,https://seekingalpha.com/news/4114154-kroger-follows-costco-offer-glp-1-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7474575042724609
3349,6/7/2024 4:42:12 PM,"ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential",Benzinga,/news/etf/etfs-bet-high-on-weight-loss-drugs-but-industry-observers-question-long-term-potential-1033461767,negative,0.5535902976989746
3350,6/7/2024 4:50:53 PM,Wall Street Reacts To Hot Jobs Report: Stocks Swing As Traders Abandon July Rate Cut Hopes,Benzinga,/news/etf/wall-street-reacts-to-hot-jobs-report-stocks-swing-as-traders-abandon-july-rate-cut-hopes-1033461780,neutral,0.9293622970581055
3351,6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8829660415649414
3352,6/8/2024 11:40:00 AM,Profiting from the Crowd: 3 Stocks Set to Surge on Retail Investor Enthusiasm,InvestorPlace,/news/stocks/profiting-from-the-crowd-3-stocks-set-to-surge-on-retail-investor-enthusiasm-1033462715,negative,0.8485677242279053
3353,6/8/2024 6:00:00 PM,"Lilly's donanemab, remternetug set to dominate Alzheimer's treatment by 2030",Seeking Alpha,https://seekingalpha.com/news/4114265-lillys-donanemeb-remternetug-set-dominate-alzheimers-treatment-2030?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7012606859207153
3354,6/10/2024 10:45:00 AM,7 Blue-Chip Stocks to Add to Your June Buy List ,InvestorPlace,/news/stocks/7-blue-chip-stocks-to-add-to-your-june-buy-list-1033465204,positive,0.9101737141609192
3355,6/10/2024 10:45:28 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033465783,negative,0.595212996006012
3356,6/10/2024 1:26:01 PM,Bank of America Securities Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bank-of-america-securities-keeps-their-buy-rating-on-eli-lilly-co-lly-1033466595,positive,0.9046719670295715
3357,6/10/2024 4:09:47 PM,"Biogen, Eisai get January 2025 FDA action date for monthly Leqembi",Seeking Alpha,https://seekingalpha.com/news/4114537-biogen-eisai-get-january-2025-fda-action-date-monthly-leqembi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9272090792655945
3358,6/10/2024 6:38:05 PM,Weight loss drugs other benefits could convince more men to use them - report,Seeking Alpha,https://seekingalpha.com/news/4114576-weight-loss-drugs-other-benefits-could-convince-more-men-use-them?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6708354949951172
3359,6/10/2024 7:01:31 PM,7 Over-Hyped Stocks to Sell Before They Plunge: June Edition,InvestorPlace,/news/stocks/7-over-hyed-stocks-to-sell-before-they-plunge-june-edition-1033466884,positive,0.7690200805664062
3360,6/10/2024 7:35:10 PM,"Lilly's donanemab effective for Alzheimer's disease, FDA advisors say (updated)",Seeking Alpha,https://seekingalpha.com/news/4114590-lilly-donanemab-effective-alzheimers-disease-fda-advisors-say?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8593549728393555
3361,6/11/2024 11:13:14 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1033469525,negative,0.5521676540374756
3362,6/11/2024 11:33:22 AM,"Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Dianthus Therapeutics (DNTH) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-addus-homecare-adus-dianthus-therapeutics-dnth-and-eli-lilly-co-lly-1033469621,positive,0.9139556884765625
3363,6/11/2024 2:49:50 PM,Eli Lilly Stock Hits New 52-Week High as FDA Panel Recommends Alzheimer’s Drug,InvestorPlace,/news/stocks/eli-lilly-stock-hits-new-52-week-high-as-fda-panel-recommends-alzheimers-drug-1033469655,negative,0.7121654748916626
3364,6/11/2024 3:23:45 PM,Why Are Stocks Down Today?,InvestorPlace,/news/stocks/why-are-stocks-down-today-june-11th-1033469755,neutral,0.9098419547080994
3365,6/11/2024 5:25:29 PM,"Wall Street’s most overbought stocks include NVDA, COST, LLY, and others",Seeking Alpha,https://seekingalpha.com/news/4114919-wall-streets-most-overbought-stocks-include-nvda-cost-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7165610790252686
3366,6/11/2024 8:19:11 PM,"Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst",Benzinga,/news/stocks/eli-lilly-s-donanemab-gains-favorable-fda-advisory-verdict-boosting-stock-potential-says-bofa-analyst-1033470262,negative,0.9560290575027466
3367,6/12/2024 6:26:26 AM,Eli Lilly: Strong Buy on Diverse Portfolio and Promising Alzheimer’s Pipeline Despite Donanemab’s Challenges,TipRanks,/news/stocks/eli-lilly-strong-buy-on-diverse-portfolio-and-promising-alzheimer-s-pipeline-despite-donanemab-s-challenges-1033471819,negative,0.9495922923088074
3368,6/12/2024 10:30:00 AM,3 Must-Buy Stocks Before the Third Quarter,InvestorPlace,/news/stocks/3-must-buy-stocks-before-the-third-quarter-1033472099,positive,0.9296216368675232
3369,6/12/2024 10:43:00 AM,7 Trending Stocks With Momentum on Their Side,InvestorPlace,/news/stocks/7-trending-stocks-with-momentum-on-their-side-1033472098,negative,0.682360053062439
3370,6/12/2024 2:00:00 PM,3 Stocks Quietly Preparing for a 10X Surge: June Edition,InvestorPlace,/news/stocks/3-stocks-quietly-preparing-for-a-10x-surge-june-edition-1033473227,negative,0.46577024459838867
3371,6/12/2024 2:27:30 PM,Palatin starts Phase 2 obesity study of bremelanotide with Zepbound,Seeking Alpha,https://seekingalpha.com/news/4115213-palatin-starts-phase-2-obesity-study-of-bremelanotide-with-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8054700493812561
3372,6/12/2024 4:33:43 PM,GLP-1 obesity drug coverage dropped by Blue Cross Michigan: report,Seeking Alpha,https://seekingalpha.com/news/4115246-glp-1-drug-coverage-dropped-by-blue-cross-michigan-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9600133299827576
3373,6/12/2024 6:24:16 PM,4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024,InvestorPlace,/news/stocks/4-best-stocks-to-buy-and-3-best-stocks-to-sell-june-2024-1033474011,positive,0.9411122798919678
3374,6/12/2024 6:39:17 PM,Lilly's Retevmo gains traditional approval in thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4115326-lilly-retevmo-gains-traditional-approval-in-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.949586033821106
3375,6/12/2024 11:00:19 PM,Eli Lilly and Co Stock: A Deep Dive Into Analyst Perspectives (17 Ratings),Benzinga,/news/stocks/eli-lilly-and-co-stock-a-deep-dive-into-analyst-perspectives-17-ratings-1033474278,positive,0.8610808253288269
3376,6/13/2024 10:15:00 AM,3 Stocks to Buy as Ozempic Surges in Popularity,InvestorPlace,/news/stocks/3-stocks-to-buy-as-ozempic-surges-in-popularity-1033475495,negative,0.49994802474975586
3377,6/13/2024 10:30:00 AM,"3 Stocks to Buy if You Want to Turn Your $1,000 into $10,000 Within 2 Years",InvestorPlace,/news/stocks/3-stocks-to-buy-if-you-want-to-turn-your-1000-into-10000-within-2-years-2-1033475586,positive,0.9427772164344788
3378,6/13/2024 11:40:34 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Cardinal Health (CAH),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-cardinal-health-cah-1033476821,positive,0.9259130954742432
3379,6/13/2024 1:49:40 PM,J.P. Morgan Private Capital raises over $500M for life sciences fund,Seeking Alpha,https://seekingalpha.com/news/4115629-jp-morgan-private-capital-raises-over-500m-for-life-sciences-fund?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7398619651794434
3380,6/14/2024 10:37:00 AM,3 Stocks to Sell as Ozempic Surges in Popularity,InvestorPlace,/news/stocks/3-stocks-to-sell-as-ozempic-surges-in-popularity-1033479269,negative,0.7905429601669312
3381,6/14/2024 11:15:00 AM,7 A-Rated Biotech Stocks Worth Betting on in June,InvestorPlace,/news/stocks/7-a-rated-biotech-stocks-worth-betting-on-in-june-1033479361,positive,0.8425543308258057
3382,6/14/2024 12:01:46 PM,Employer coverage for GLP-1s rising amid FDA label expansions: survey,Seeking Alpha,https://seekingalpha.com/news/4116127-employer-coverage-for-glp-1s-rising-survey?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9466157555580139
3383,6/14/2024 4:31:42 PM,U.S. sector and stock leaders and laggards as first half winds down,Seeking Alpha,https://seekingalpha.com/news/4116288-us-sector-and-stock-leaders-and-laggards-as-h1-winds-down?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9126456379890442
3384,6/14/2024 7:39:10 PM,"Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails",Benzinga,/news/stocks/pharma-stock-roundup-fda-panel-endorses-lly-s-donanemab-pfe-s-dmd-therapy-study-fails-1033480819,positive,0.6571053266525269
3385,6/14/2024 10:24:23 PM,Employee benefits survey finds marked increase in GLP-1 coverage,Seeking Alpha,https://seekingalpha.com/news/4116449-employee-benefits-survey-finds-marked-increase-in-glp-1-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.949941873550415
3386,6/15/2024 10:12:00 AM,Exit Alert: 3 Stocks to Offload Before the Downturn,InvestorPlace,/news/stocks/exit-alert-3-stocks-to-offload-before-the-downturn-1033481227,neutral,0.6021974086761475
3387,6/15/2024 3:19:01 PM,U.S. drug shortages worsen to reach a decade high: report,Seeking Alpha,https://seekingalpha.com/news/4116477-us-drug-shortages-reach-decade-high?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.37639614939689636
3388,6/16/2024 4:33:31 PM,"Ozempic drives more demand for smaller clothes, WSJ reports",Seeking Alpha,https://seekingalpha.com/news/4116505-ozempic-drives-more-demand-for-smaller-clothes-wsj-reports?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.509763240814209
3389,6/17/2024 9:26:49 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033483419,positive,0.9309778809547424
3390,6/18/2024 10:00:45 AM,"Analysts Offer Insights on Healthcare Companies: Acadia Healthcare (ACHC), Qiagen (QGEN) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-acadia-healthcare-achc-qiagen-qgen-and-eli-lilly-co-lly-1033487105,positive,0.919328510761261
3391,6/18/2024 2:34:48 PM,Least shorted S&P 500 stocks in May,Seeking Alpha,https://seekingalpha.com/news/4117019-least-shorted-sp-500-stocks-in-may?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7336819767951965
3392,6/18/2024 5:49:28 PM,Eli Lilly oral weight-loss candidate orforglipron is potential winner: SA Investing Summit,Seeking Alpha,https://seekingalpha.com/news/4117103-eli-lilly-oral-weight-loss-candidate-orfoglipron-potential-winner-sa-summit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6652898788452148
3393,6/20/2024 1:02:55 PM,Eli Lilly ramps up efforts against fake weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4117468-eli-lilly-ramps-up-efforts-against-fake-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7178519368171692
3394,6/20/2024 3:58:22 PM,Wall Street Favorites: 7 Growth Stocks With Strong Buy Ratings for June 2024 ,InvestorPlace,/news/stocks/wall-street-favorites-7-growth-stocks-with-strong-buy-ratings-for-june-2024-1033493767,negative,0.5750938653945923
3395,6/21/2024 4:25:41 AM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033494967,positive,0.6347510814666748
3396,6/21/2024 10:22:00 AM,Hype Busters: 3 Overvalued Stocks Ready for a Reality Check,InvestorPlace,/news/stocks/hype-busters-3-overvalued-stocks-ready-for-a-reality-check-1033495538,positive,0.7739607691764832
3397,6/21/2024 12:20:43 PM,Zealand Pharma extends gains on early-stage data for weight loss drug,Seeking Alpha,https://seekingalpha.com/news/4117889-zealand-pharma-stock-gains-weight-loss-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9178835153579712
3398,6/21/2024 1:44:16 PM,Hims & Hers defended at BofA as Lilly fights compounded GLP-1s,Seeking Alpha,https://seekingalpha.com/news/4117935-hims-stock-defended-lilly-fights-compounded-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9466885328292847
3399,6/21/2024 2:12:29 PM,"Move Aside Ozempic, WeGovy: Denmark's New Drug Just Showed Positive Results For Weightloss",Benzinga,/news/etf/move-aside-ozempic-wegovy-denmark-s-new-drug-just-showed-positive-results-for-weightloss-1033495776,negative,0.9400413036346436
3400,6/21/2024 6:00:00 PM,3 Biotech Stocks to Buy Now: June 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-now-june-2024-1033497074,positive,0.9347099661827087
3401,6/21/2024 8:24:19 PM,Lilly weight loss drug tirzepatide meets primary endpoint in sleep apnea study,Seeking Alpha,https://seekingalpha.com/news/4118034-lilly-weight-loss-drug-tirzepatide-meets-primary-endpoint-sleep-apnea-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5938119292259216
3402,6/21/2024 8:33:06 PM,Takeda gets EU approval for Fruzaqla for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4118039-takeda-gets-eu-approval-for-fruzaqla-for-colorectal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.825551450252533
3403,6/21/2024 9:31:14 PM,"The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly",Benzinga,/news/stocks/the-zacks-analyst-blog-highlights-pfizer-johnson-johnson-and-eli-lilly-1033497156,positive,0.9443087577819824
3404,6/22/2024 12:27:42 PM,"ResMed, Philips under pressure as Eli Lilly seeks sleep indication for weight loss drug",Seeking Alpha,https://seekingalpha.com/news/4118134-resmed-philips-stocks-fall-osa-potential-zepbound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8846768140792847
3405,6/22/2024 1:36:54 PM,"Eli Lilly’s Tirzepatide Shows Promising Results in Sleep Apnea Treatment, Justifying a Buy Rating",TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promising-results-in-sleep-apnea-treatment-justifying-a-buy-rating-1033497576,negative,0.9499663710594177
3406,6/22/2024 1:50:11 PM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Vertex Pharmaceuticals (VRTX),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-vertex-pharmaceuticals-vrtx-1033497585,positive,0.9126845598220825
3407,6/22/2024 2:00:36 PM,"Analysts Are Bullish on Top Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-vertex-pharmaceuticals-vrtx-eli-lilly-co-lly-1033497592,positive,0.5018159747123718
3408,6/22/2024 3:00:00 PM,GLP-1 drugs linked to reduced dementia risk: study,Seeking Alpha,https://seekingalpha.com/news/4118147-glp-1-drugs-linked-reduced-dementia-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6400054693222046
3409,6/23/2024 6:00:00 PM,"Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit",Seeking Alpha,https://seekingalpha.com/news/4118072-lilly-novo-nordisk-dominate-weight-loss-therapy-sa-investing-summit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7935812473297119
3410,6/24/2024 7:43:56 AM,Australian Stocks: ResMed Shares Tumble on Rival’s Weight-Loss Drug Results,TipRanks,/news/stocks/australian-stocks-resmed-shares-tumble-on-rival-s-weight-loss-drug-results-1033499433,neutral,0.9678093791007996
3411,6/24/2024 10:18:49 AM,Buy Rating Affirmed for Eli Lilly on Tirzepatide’s Promise in OSA and Obesity Treatment,TipRanks,/news/stocks/buy-rating-affirmed-for-eli-lilly-on-tirzepatide-s-promise-in-osa-and-obesity-treatment-1033500010,negative,0.9398912191390991
3412,6/24/2024 11:55:51 AM,Eli Lilly & Co (LLY) Receives a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-jefferies-1033500655,negative,0.591037392616272
3413,6/24/2024 12:26:03 PM,Eli Lilly & Co (LLY) Gets a Buy from Cantor Fitzgerald,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-cantor-fitzgerald-1033500767,positive,0.6347510814666748
3414,6/24/2024 1:21:19 PM,Altimmune jumps 13% on phase 2 pemvidutide results for obesity,Seeking Alpha,https://seekingalpha.com/news/4118343-altimmune-jumps-13-phase-2-pemvidutide-results-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9389580488204956
3415,6/24/2024 2:56:49 PM,ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings,InvestorPlace,/news/stocks/alt-stock-alert-altimmune-pops-on-weight-loss-drug-findings-1033500759,positive,0.7489796876907349
3416,6/24/2024 3:14:09 PM,Top 10 performing S&P 500 names as first half looks to close out this week,Seeking Alpha,https://seekingalpha.com/news/4118379-top-10-performing-sp-500-names-as-h1-looks-to-close-out-this-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.681973934173584
3417,6/24/2024 3:38:22 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4118430-eli-lilly-and-company-declares-1_30-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9196907877922058
3418,6/24/2024 6:51:58 PM,Novo Nordisk to spend $4.1B to build new plant for obesity drugs in N.C.,Seeking Alpha,https://seekingalpha.com/news/4118545-novo-nordisk-spend-41b-build-new-plant-obesity-drugs-nc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7023594379425049
3419,6/24/2024 7:17:13 PM,"Inspire Medical, ResMed decline following Lilly tirzepatide sleep apnea data",Seeking Alpha,https://seekingalpha.com/news/4118548-inspire-medical-resmed-decline-following-lilly-tirzepatide-sleep-apnea-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9622578620910645
3420,6/24/2024 7:56:56 PM,"Market shifting focus to softening growth from inflation, Morgan Stanley and BofA say",Seeking Alpha,https://seekingalpha.com/news/4118556-market-shifting-focus-to-softening-growth-from-inflation-morgan-stanley-and-bofa-say?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5658198595046997
3421,6/25/2024 11:26:24 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033504439,positive,0.7503917217254639
3422,6/25/2024 1:29:33 PM,NVO Stock: Novo Nordisk Pops as China Approves Wegovy Weight Loss Drug,InvestorPlace,/news/stocks/nvo-stock-novo-nordisk-pops-as-china-approves-wegovy-weight-loss-drug-1033503921,negative,0.6670786738395691
3423,6/25/2024 3:08:09 PM,Eli Lilly collaborates with OpenAI for medicines against drug-resistant bacteria,Seeking Alpha,https://seekingalpha.com/news/4119028-eli-lilly-collaborates-with-openai-for-medicines-against-drug-resistant-bacteria?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5459283590316772
3424,6/25/2024 4:12:34 PM,Lilly gains approval of lebrikizumab in Canada for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4119066-lilly-gains-approval-lebrikizumab-canada-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9391080737113953
3425,6/25/2024 4:14:48 PM,Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials ,RTTNews,/news/stocks/eli-lilly-collaborates-with-openai-to-use-generative-ai-to-invent-novel-antimicrobials-1033504398,negative,0.6287410259246826
3426,6/25/2024 5:15:54 PM,GLP-1 weight loss meds + exercise seen preserving bone health,Seeking Alpha,https://seekingalpha.com/news/4119100-glp-1-weight-loss-meds-exercise-seen-preserving-bone-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.4975476861000061
3427,6/25/2024 5:37:45 PM,ResMed cut at Oppenheimer after Eli Lilly’s tirzepatide sleep apnea data,Seeking Alpha,https://seekingalpha.com/news/4119106-resmed-cut-at-oppenheimer-after-eli-lillys-tirzepatide-sleep-apnea-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8452447056770325
3428,6/26/2024 7:33:34 AM,Augustine Therapeutics raises €17M in series A first closing,Seeking Alpha,https://seekingalpha.com/news/4119241-augustine-therapeutics-raises-17m-in-series-a-first-closing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6058535575866699
3429,6/26/2024 11:50:00 AM,The Next 7 Trillion-Dollar Stocks to Buy: June 2024 Edition,InvestorPlace,/news/stocks/the-next-7-trillion-dollar-stocks-to-buy-june-2024-edition-1033507334,positive,0.9523062705993652
3430,6/26/2024 1:26:08 PM,Augustine Therapeutics raises EUR 17M in Series A first closing,Seeking Alpha,https://seekingalpha.com/news/4119532-augustine-therapeutics-raises-eur-17m-in-series-a-first-closing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5857742428779602
3431,6/27/2024 10:02:20 AM,3 Valuable Stocks That Are Worth the Expensive Price Tag,InvestorPlace,/news/stocks/3-valuable-stocks-that-are-worth-the-expensive-price-tag-1033510649,positive,0.8979343771934509
3432,6/27/2024 10:50:00 AM,7 A-Rated Stocks for Your June Buy List,InvestorPlace,/news/stocks/7-a-rated-stocks-for-your-june-buy-list-1033510905,positive,0.9382988810539246
3433,6/27/2024 11:15:00 AM,3 Promising Stocks That Can Turn $10K Into $1 Million,InvestorPlace,/news/stocks/3-promising-stocks-that-can-turn-10k-into-1-million-1033510940,positive,0.656855583190918
3434,6/27/2024 1:36:33 PM,Hims & Hers down 6% following report on weight loss drug (updated),Seeking Alpha,https://seekingalpha.com/news/4120028-him-hers-down-6-following-report-shady-supplier-for-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9586833715438843
3435,6/27/2024 6:21:43 PM,You’ve Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.,InvestorPlace,/news/stocks/youve-been-warned-3-biotech-stocks-to-buy-now-or-regret-forever-1033512850,positive,0.8179779648780823
3436,6/28/2024 10:00:00 AM,The Top 3 Weight Loss Drug Stocks to Buy for Huge Gains,InvestorPlace,/news/stocks/the-top-3-weight-loss-drug-stocks-to-buy-for-huge-gains-1033514451,positive,0.7380595803260803
3437,6/28/2024 11:55:34 AM,"Dividend Roundup: Kroger, AT&T, Pfizer, JPMorgan, and more",Seeking Alpha,https://seekingalpha.com/news/4120524-dividend-roundup-kroger-att-pfizer-jpmorgan-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9469661712646484
3438,6/28/2024 2:00:00 PM,The 3 Smartest Healthcare Stocks to Buy With $1K Right Now,InvestorPlace,/news/stocks/the-3-smartest-healthcare-stocks-to-buy-with-1k-right-now-1033515560,positive,0.8209035992622375
3439,6/28/2024 2:09:51 PM,The 3 Smartest Biotech Stocks to Buy With $5K Right Now,InvestorPlace,/news/stocks/the-3-smartest-biotech-stocks-to-buy-with-5k-right-now-1033515559,positive,0.8349236249923706
3440,6/29/2024 10:30:00 AM,3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt,InvestorPlace,/news/stocks/3-sectors-that-could-get-slammed-by-attempts-to-reduce-u-s-debt-1033516833,neutral,0.9460068345069885
3441,6/29/2024 1:00:00 PM,Sound Investments: 3 Stocks to Buy for a Good Night’s Rest,InvestorPlace,/news/stocks/sound-investments-3-stocks-to-buy-for-a-good-nights-rest-1033516864,positive,0.7977286577224731
3442,6/29/2024 3:35:00 PM,Insulet tops S&P 500 growth chart for Q2 as it gains market share in the diabetes space,Seeking Alpha,https://seekingalpha.com/news/4120025-insulet-tops-sp-500-growth-chart-for-q2-as-it-gains-market-share-in-the-diabetes-space?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9450204372406006
3443,6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7290322184562683
3444,7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.770165741443634
3445,7/1/2024 7:45:19 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033519052,positive,0.8035197257995605
3446,7/1/2024 5:36:30 PM,Lilly in deal with Radionetics Oncology on radiopharmaceuticals development,Seeking Alpha,https://seekingalpha.com/news/4121300-lilly-deal-radionetics-oncology-radiopharmaceuticals-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8006486296653748
3447,7/2/2024 12:25:20 AM,Cantor Fitzgerald Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033521213,positive,0.8219966292381287
3448,7/2/2024 10:24:00 AM,3 Under-the-Radar Biotech Stocks With Blockbuster Potential,InvestorPlace,/news/stocks/3-under-the-radar-biotech-stocks-with-blockbuster-potential-1033522419,positive,0.6027738451957703
3449,7/2/2024 1:17:30 PM,"Eli Lilly, Novo under pressure as Biden urges lower drug prices",Seeking Alpha,https://seekingalpha.com/news/4121664-eli-lilly-novo-stocks-fall-biden-urges-lower-drug-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.938783586025238
3450,7/2/2024 5:54:29 PM,Eli Lilly wins FDA approval of donanemab for Alzheimer's,Seeking Alpha,https://seekingalpha.com/news/4121800-eli-lilly-wins-fda-approval-donanemab-alzheimers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9159002900123596
3451,7/2/2024 7:11:24 PM,AMZN Stock Outlook: Amazon’s Next Growth Wave Could Make Early Investors Rich,InvestorPlace,/news/stocks/amzn-stock-outlook-amazons-next-growth-wave-could-make-early-investors-rich-1033524370,negative,0.5130443572998047
3452,7/3/2024 3:01:50 AM,FDA Approves Lilly's Kisunla To Treat Early Symptomatic Alzheimer's Disease ,RTTNews,/news/stocks/fda-approves-lilly-s-kisunla-to-treat-early-symptomatic-alzheimer-s-disease-1033524684,negative,0.8340345025062561
3453,7/3/2024 11:07:14 AM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033527076,negative,0.6287072896957397
3454,7/3/2024 11:15:37 AM,Eli Lilly’s Kisunla Approval Spurs Buy Rating Amid Anticipated Revenue Boost and Alzheimer’s Treatment Paradigm Shift,TipRanks,/news/stocks/eli-lilly-s-kisunla-approval-spurs-buy-rating-amid-anticipated-revenue-boost-and-alzheimer-s-treatment-paradigm-shift-1033527131,negative,0.9514122009277344
3455,7/3/2024 12:16:06 PM,Eli Lilly’s Promising Alzheimer’s Treatment: A Buy Rating on Kisunla’s Market Potential and Clinical Benefits,TipRanks,/news/stocks/eli-lilly-s-promising-alzheimer-s-treatment-a-buy-rating-on-kisunla-s-market-potential-and-clinical-benefits-1033527318,negative,0.8354491591453552
3456,7/3/2024 12:55:31 PM,Eli Lilly & Co (LLY) Gets a Hold from Evercore ISI,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-hold-from-evercore-isi-1033527415,positive,0.8697418570518494
3457,7/3/2024 4:01:53 PM,"Novo Nordisk’s Ozempic, Wegovy linked to eye disorder in small study",Seeking Alpha,https://seekingalpha.com/news/4122130-novo-nordisks-ozempic-linked-eye-disorder?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5821840167045593
3458,7/3/2024 5:09:17 PM,Lilly's new Alzheimer's drug could generate $7.1B in sales: analyst,Seeking Alpha,https://seekingalpha.com/news/4122161-lillys-new-alzheimers-drug-could-generate-7b-in-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.523905336856842
3459,7/3/2024 6:13:19 PM,Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst,Benzinga,/news/stocks/eli-lilly-s-alzheimer-s-therapy-s-broad-label-reflects-regulatory-confidence-in-anti-amyloid-antibodies-analyst-1033527516,negative,0.5806208252906799
3460,7/3/2024 7:04:02 PM,"S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?",Benzinga,/news/etf/s-p-500-nasdaq-100-climb-to-record-highs-as-data-fosters-rate-cut-optimism-ahead-of-fed-minutes-gold-bonds-rally-what-s-driving-markets-wednesday-1033527636,positive,0.7391337752342224
3461,7/4/2024 7:05:46 AM,Eli Lilly’s Kisunla Launch: A Cautious Hold Amid Competitive and Logistical Uncertainties,TipRanks,/news/stocks/eli-lilly-s-kisunla-launch-a-cautious-hold-amid-competitive-and-logistical-uncertainties-1033529084,neutral,0.9235165119171143
3462,7/4/2024 10:35:00 AM,The 3 Best Healthcare Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-july-2024-1033529151,positive,0.878911018371582
3463,7/4/2024 7:45:11 PM,7 High Priced Stocks That Would Benefit From a Stock Split,InvestorPlace,/news/stocks/7-high-priced-stocks-that-would-benefit-from-a-stock-split-1033530303,positive,0.8075976371765137
3464,7/5/2024 10:20:00 AM,3 Highly Rated Biotech Stocks for Your July Buy List,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-for-your-july-buy-list-1033531559,positive,0.9089598059654236
3465,7/5/2024 7:04:46 PM,"Study links GLP-1 drugs, metformin to lower risk of certain cancers",Seeking Alpha,https://seekingalpha.com/news/4122404-study-links-glp-1-drugs-metformin-to-lower-risk-of-certain-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8924569487571716
3466,7/6/2024 12:00:00 PM,The 7 Best Under $10 Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-7-best-under-10-stocks-to-buy-in-july-2024-1033533214,positive,0.9001163244247437
3467,7/6/2024 6:00:00 PM,"Small, mid-size biotechs could see M&A action in H2 - PwC",Seeking Alpha,https://seekingalpha.com/news/4122402-small-mid-size-biotechs-could-see-ma-action-h2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5447043180465698
3468,7/7/2024 3:39:52 PM,"EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO",Benzinga,/news/stocks/exclusive-glp-1-weight-loss-drugs-could-become-a-trillion-dollar-market-predicts-tema-etfs-ceo-1033533664,positive,0.6258196830749512
3469,7/8/2024 7:55:31 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033535320,positive,0.9309778809547424
3470,7/8/2024 11:05:08 AM,Eli Lilly to acquire Morphic for $57 a share in cash,Seeking Alpha,https://seekingalpha.com/news/4122514-eli-lilly-to-acquire-morphic-for-57-a-share-in-cash?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9285153746604919
3471,7/8/2024 12:53:48 PM,Lilly To Acquire Morphic In Approx. $3.2 Bln Deal - Quick Facts ,RTTNews,/news/stocks/lilly-to-acquire-morphic-in-approx-3-2-bln-deal-quick-facts-1033535308,positive,0.8879647850990295
3472,7/8/2024 1:45:25 PM,"Biggest stock movers today: LCID, PARA, GRFS, and more",Seeking Alpha,https://seekingalpha.com/news/4122483-biggest-stock-movers-today-para-and-grfs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9269736409187317
3473,7/8/2024 4:32:20 PM,3 Overlooked Giants-in-the-Making for Patient Investors,InvestorPlace,/news/stocks/3-overlooked-giants-in-the-making-for-patient-investors-1033536832,positive,0.8439481854438782
3474,7/8/2024 11:11:55 PM,Study finds patients lost more weight on Mounjaro than Ozempic,Seeking Alpha,https://seekingalpha.com/news/4122749-study-finds-patients-lost-more-weight-on-mounjaro-than-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5533037781715393
3475,7/9/2024 9:27:08 AM,Eli Lilly’s Strategic Acquisition of MORF Bolsters Buy Rating Amid IBD Market Growth Opportunities,TipRanks,/news/stocks/eli-lilly-s-strategic-acquisition-of-morf-bolsters-buy-rating-amid-ibd-market-growth-opportunities-1033539140,negative,0.9539880752563477
3476,7/9/2024 10:42:00 AM,7 Bullish Stock Picks With the Potential to Turn $5K Into $50K,InvestorPlace,/news/stocks/7-bullish-stock-picks-with-the-potential-to-turn-5k-into-50k-1033538881,negative,0.8631351590156555
3477,7/9/2024 11:15:25 AM,Eli Lilly’s Strategic Expansion and Acquisition Synergy: A Buy Rating Analysis,TipRanks,/news/stocks/eli-lilly-s-strategic-expansion-and-acquisition-synergy-a-buy-rating-analysis-1033540059,positive,0.769422173500061
3478,7/9/2024 6:24:24 PM,Hot Stocks: 3 Sleeping Giants About to Dominate Their Sectors,InvestorPlace,/news/stocks/hot-stocks-3-sleeping-giants-about-to-dominate-their-sectors-1033540831,positive,0.872383177280426
3479,7/9/2024 7:00:45 PM,"BMO sees BMRN, LEGN, SLN as attractive M&A targets",Seeking Alpha,https://seekingalpha.com/news/4123073-bmo-sees-bmrn-legn-sln-as-attractive-ma-targets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7297300100326538
3480,7/9/2024 9:00:47 PM,"Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst",Benzinga,/news/stocks/eli-lilly-s-3-2b-morphic-deal-is-crucial-has-strategic-merit-despite-investor-attention-on-obesity-analyst-1033540871,negative,0.8405292630195618
3481,7/10/2024 12:19:40 PM,"Most patients discontinue Novo’s Wegovy, Ozempic within two years: report",Seeking Alpha,https://seekingalpha.com/news/4123250-most-patients-stop-wegovy-ozempic-two-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8697760105133057
3482,7/10/2024 1:05:53 PM,Eli Lilly names Gordon Brooks as interim CFO,Seeking Alpha,https://seekingalpha.com/news/4123281-eli-lilly-names-gordon-brooks-as-interim-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9195154309272766
3483,7/10/2024 1:10:28 PM,"Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Catalyst Pharma (CPRX) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-intuitive-surgical-isrg-catalyst-pharma-cprx-and-eli-lilly-co-lly-1033544298,positive,0.9078484773635864
3484,7/10/2024 6:34:38 PM,3 Pharma Stocks That Could Make Your Grandchildren Rich,InvestorPlace,/news/stocks/3-pharma-stocks-that-could-make-your-grandchildren-rich-1033544623,positive,0.8934544324874878
3485,7/11/2024 5:25:50 AM,Eli Lilly & Co (LLY) Receives a Buy from Berenberg Bank,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-berenberg-bank-1033546156,positive,0.5040807127952576
3486,7/11/2024 9:39:42 AM,Eli Lilly & Co: A Strong Buy on Robust Pipeline and Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-growth-prospects-1033546921,negative,0.9479568004608154
3487,7/11/2024 11:18:20 AM,Pfizer advances development of once-daily weight-loss pill,Seeking Alpha,https://seekingalpha.com/news/4123562-pfizer-advances-development-of-once-daily-weight-loss-pill?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.496343195438385
3488,7/11/2024 11:56:06 AM,SA subscribers pitch stocks that could potentially replace Tesla in Magnificent 7,Seeking Alpha,https://seekingalpha.com/news/4123564-sa-subscribers-pitch-stocks-that-could-potentially-replace-tesla-in-magnificent-7?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7484980225563049
3489,7/11/2024 1:00:20 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Biodesix (BDSX) and CVRx (CVRX)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-biodesix-bdsx-and-cvrx-cvrx-1033548147,positive,0.9181200861930847
3490,7/11/2024 2:10:00 PM,3 Future Blue-Chip Stocks That Could Make You Rich,InvestorPlace,/news/stocks/3-future-blue-chip-stocks-that-could-make-you-rich-1033547734,positive,0.8907219171524048
3491,7/11/2024 3:17:00 PM,"Lilly, DaVita, Illumina among top healthcare Quant picks ahead of Q2 earnings",Seeking Alpha,https://seekingalpha.com/news/4123344-lilly-davita-illumina-among-top-healthcare-quant-picks-for-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5734253525733948
3492,7/12/2024 8:12:28 AM,"This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment",Seeking Alpha,https://seekingalpha.com/news/4123754-weight-loss-amgen-stock-obesity-plays?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7048126459121704
3493,7/12/2024 10:08:00 AM,The 3 Most Undervalued Biotech Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-july-2024-1033549932,positive,0.7703022360801697
3494,7/12/2024 2:27:31 PM,Novo’s Ozempic linked to improved brain health: study,Seeking Alpha,https://seekingalpha.com/news/4123974-novos-ozempic-linked-to-improved-brain-health-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8598303198814392
3495,7/12/2024 6:26:43 PM,"With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence - Goldman Sachs",Benzinga,/news/stocks/with-oral-anti-obesity-candidate-development-pfizer-seeks-relevant-and-competitive-presence---goldman-sachs-1033551299,negative,0.7830184102058411
3496,7/12/2024 7:57:37 PM,The Next Trillion-Dollar Stocks? 3 Top Contenders to Buy Now,InvestorPlace,/news/stocks/the-next-trillion-dollar-stocks-3-top-contenders-to-buy-now-1033551548,positive,0.894043505191803
3497,7/12/2024 8:55:48 PM,Lilly expecting Q2 IPR&D pre-tax charge of around $0.14 per share: report,Seeking Alpha,https://seekingalpha.com/news/4124073-lilly-expecting-q2-iprd-pre-tax-charge-of-around-014-per-share-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6311385631561279
3498,7/13/2024 11:30:00 AM,3 Powerful Stocks Worthy of Magnificent 7 Status,InvestorPlace,/news/stocks/3-powerful-stocks-worthy-of-magnificent-7-status-1033551774,negative,0.5202926993370056
3499,7/13/2024 1:00:00 PM,The 7 Most Important Stocks to Watch as Q2 Earnings Season Kicks Off,InvestorPlace,/news/stocks/the-7-most-important-stocks-to-watch-as-q2-earnings-season-kicks-off-1033551795,positive,0.8596351742744446
3500,7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8902468085289001
3501,7/13/2024 7:34:06 PM,Eli Lilly’s GLP-1 impact on ResMed is overblown: Barron’s,Seeking Alpha,https://seekingalpha.com/news/4124110-resmed-stock-a-buy-despite-lilly-impact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8680447340011597
3502,7/14/2024 7:00:00 PM,3 Stocks for Patient Investors Looking to Build Generational Wealth,InvestorPlace,/news/stocks/3-stocks-for-patient-investors-looking-to-build-generational-wealth-1033552534,positive,0.8010954260826111
3503,7/15/2024 7:56:10 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033554852,negative,0.595212996006012
3504,7/15/2024 10:58:00 AM,7 Billion-Dollar Stocks That Deserve a Spot in Your Portfolio,InvestorPlace,/news/stocks/7-billion-dollar-stocks-that-deserve-a-spot-in-your-portfolio-1033554910,positive,0.8276141881942749
3505,7/15/2024 5:00:00 PM,7 Top-Quality Stocks to Buy Now: July 2024,InvestorPlace,/news/stocks/7-top-quality-stocks-to-buy-now-july-2024-1033556432,positive,0.9312219023704529
3506,7/15/2024 7:13:12 PM,"This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges",Benzinga,/news/stocks/this-analyst-sees-potential-downside-in-eli-lilly-adjusts-model-for-acquired-ipr-d-charges-1033556441,neutral,0.5873618721961975
3507,7/16/2024 5:01:00 PM,"Incyte, Moderna among most shorted S&P 500 healthcare stocks in June",Seeking Alpha,https://seekingalpha.com/news/4124310-incyte-moderna-among-most-shorted-sp-500-healthcare-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8085744976997375
3508,7/16/2024 5:33:42 PM,3 Biotech Stocks to Buy in Case of Another Pandemic,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-in-case-of-another-pandemic-1033560541,positive,0.8967233896255493
3509,7/17/2024 5:43:26 AM,Aclaris Sells OLUMIANT Royalties & Milestones To OMERS For Up To $31.5 Mln; Stock Up In After-hours ,RTTNews,/news/stocks/aclaris-sells-olumiant-royalties-milestones-to-omers-for-up-to-31-5-mln-stock-up-in-after-hours-1033561114,negative,0.9269789457321167
3510,7/17/2024 10:06:00 AM,3 Moonshot Stocks With the Potential to Turn $10K Into $100K,InvestorPlace,/news/stocks/3-moonshot-stocks-with-the-potential-to-turn-10k-into-1-million-1033540783,negative,0.6585848331451416
3511,7/17/2024 11:36:37 AM,"Eli Lilly, Novo slip as Roche posts early-stage data for oral weight loss drug",Seeking Alpha,https://seekingalpha.com/news/4124932-eli-lilly-novo-slip-as-roche-posts-early-stage-data-for-oral-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9135512113571167
3512,7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5109472870826721
3513,7/17/2024 6:25:18 PM,Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio,InvestorPlace,/news/stocks/forget-boring-diversification-3-wild-card-stocks-to-spice-up-your-portfolio-1033565172,positive,0.8800460696220398
3514,7/18/2024 9:16:57 AM,Eli Lilly & Co: A Strong Buy on Orforglipron’s Market Lead and Promising Pipeline,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-orforglipron-s-market-lead-and-promising-pipeline-1033568222,negative,0.9523249864578247
3515,7/18/2024 9:25:17 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033568212,positive,0.7503917217254639
3516,7/18/2024 10:16:52 AM,Eli Lilly’s Market Position Challenged by Roche’s CT996: A Hold Rating Justified,TipRanks,/news/stocks/eli-lilly-s-market-position-challenged-by-roche-s-ct996-a-hold-rating-justified-1033568632,neutral,0.9343175888061523
3517,7/18/2024 12:10:00 PM,"3 Reliable Blue-Chip Stocks to Buy, Hold and Never Let Go",InvestorPlace,/news/stocks/3-reliable-blue-chip-stocks-to-buy-hold-and-never-let-go-1033568295,positive,0.8773118853569031
3518,7/18/2024 1:33:46 PM,3 High-Flying Stocks That Show No Signs of Slowing Down,InvestorPlace,/news/stocks/3-high-flying-stocks-that-show-no-signs-of-slowing-down-1033568680,positive,0.4162900745868683
3519,7/18/2024 2:06:53 PM,Least shorted S&P 500 stocks in June,Seeking Alpha,https://seekingalpha.com/news/4125485-least-shorted-sp-500-stocks-in-june?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6751642227172852
3520,7/18/2024 5:05:34 PM,"Eli Lilly, Novo extend muti-day decline in rare selloff",Seeking Alpha,https://seekingalpha.com/news/4125589-eli-lilly-stock-novo-stock-rare-selloff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9236568212509155
3521,7/18/2024 8:05:29 PM,"VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?",Benzinga,/news/etf/vix-stages-double-digit-spike-as-risk-off-takes-over-chipmakers-fail-to-rebound-weight-loss-giants-eli-lilly-novo-tumble-what-s-driving-markets-thursday-1033569954,neutral,0.5287970304489136
3522,7/18/2024 8:51:35 PM,"Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst",Benzinga,/news/stocks/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-says-analyst-1033569993,negative,0.9231750965118408
3523,7/18/2024 10:59:13 PM,"EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'",Benzinga,/news/stocks/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-won-t-be-dominated-by-just-2-players-1033570253,positive,0.5957275629043579
3524,7/19/2024 11:21:36 AM,Eli Lilly weight loss drug approved in China,Seeking Alpha,https://seekingalpha.com/news/4125778-lilly-stock-gains-obesity-drug-cleared-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5662219524383545
3525,7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7739253044128418
3526,7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49974918365478516
3527,7/22/2024 7:52:23 PM,Don’t Delay! 3 Stocks to Buy BEFORE Q2 Earnings.,InvestorPlace,/news/stocks/dont-delay-3-stocks-to-buy-before-q2-earnings-1033579281,positive,0.8867826461791992
3528,7/22/2024 8:53:08 PM,AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst,Benzinga,/news/stocks/anaptysbio-investigational-arthritis-drug-might-have-better-efficacy-profile-than-eli-lilly-s-analyst-1033579146,negative,0.8645511269569397
3529,7/23/2024 3:11:23 PM,U.K. regulators approve Wegovy for prevention of cardiac events,Seeking Alpha,https://seekingalpha.com/news/4126846-uk-regulators-approve-wegovy-for-prevention-of-cardiac-events?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8138608932495117
3530,7/24/2024 7:40:28 PM,3 Fabulous Growth Stocks to Buy and Hold Forever,InvestorPlace,/news/stocks/3-fabulous-growth-stocks-to-buy-and-hold-forever-1033590657,positive,0.9336369037628174
3531,7/24/2024 10:00:33 PM,Expert Outlook: Eli Lilly and Co Through The Eyes Of 25 Analysts,Benzinga,/news/stocks/expert-outlook-eli-lilly-and-co-through-the-eyes-of-25-analysts-1033590670,positive,0.7770355939865112
3532,7/25/2024 10:08:00 AM,Morgan Stanley Predicts Triple-Digit Rally for These 3 Stocks,InvestorPlace,/news/stocks/morgan-stanley-predicts-triple-digit-rally-for-these-3-stocks-1033593798,negative,0.929273247718811
3533,7/25/2024 11:01:43 AM,"Viking sends Lilly, Novo lower as obesity drug enters late-stage program",Seeking Alpha,https://seekingalpha.com/news/4128191-viking-stock-climbs-obesity-drug-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7345916032791138
3534,7/25/2024 12:20:55 PM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Gilead Sciences (GILD)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-gilead-sciences-gild-1033595679,positive,0.7208800911903381
3535,7/25/2024 3:58:18 PM,3 Companies Gearing Up for a Stock Split,InvestorPlace,/news/stocks/3-companies-gearing-up-for-a-stock-split-1033595895,positive,0.8961323499679565
3536,7/25/2024 6:29:01 PM,3 Top-Performing Stocks Beating the Big Names in 2024,InvestorPlace,/news/stocks/3-top-performing-stocks-beating-the-big-names-in-2024-1033596309,negative,0.7216567993164062
3537,7/25/2024 9:17:16 PM,7 Explosive Growth Stocks Set to Soar in 2024,InvestorPlace,/news/stocks/7-explosive-growth-stocks-set-to-soar-in-2024-1033596726,negative,0.5944820642471313
3538,7/26/2024 11:22:32 AM,Biogen-partnered Alzheimer’s therapy fails to clear EU hurdle,Seeking Alpha,https://seekingalpha.com/news/4128882-biogen-stock-slips-lecanemab-rebuffed-eu?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8742020726203918
3539,7/26/2024 3:18:45 PM,AbbVie exits Alzheimer’s program on lack of differentiation,Seeking Alpha,https://seekingalpha.com/news/4129035-abbvie-axes-alzheimers-drug-mid-stage-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7185733914375305
3540,7/26/2024 6:13:09 PM,FDA issues warning on compounded versions of Novo Nordisk's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4129096-fda-issues-warning-compounded-versions-novo-nordisk-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8343082070350647
3541,7/28/2024 2:00:00 PM,Most U.S. pharmas don't pay any U.S. income tax,Seeking Alpha,https://seekingalpha.com/news/4129257-most-us-pharmas-dont-pay-any-us-income-tax?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9261671304702759
3542,7/28/2024 5:00:41 PM,7 Smart Stocks to Buy BEFORE They Report Q2 Earnings,InvestorPlace,/news/stocks/7-smart-stocks-to-buy-before-they-report-q2-earnings-1033602806,positive,0.9329637289047241
3543,7/29/2024 8:16:46 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033605623,negative,0.595212996006012
3544,7/29/2024 10:11:23 AM,Roche to fast-track weight loss drugs to compete with rivals - report,Seeking Alpha,https://seekingalpha.com/news/4129338-roche-to-fast-track-weight-loss-drugs-to-compete-with-rivals-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8725601434707642
3545,7/29/2024 6:53:38 PM,3 Overlooked Stocks Poised for a Breakout Very Soon,InvestorPlace,/news/stocks/3-overlooked-stocks-poised-for-a-breakout-very-soon-1033607686,negative,0.37615349888801575
3546,7/30/2024 6:23:50 AM,"Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Eli Lilly & Co (LLY) and Owens & Minor (OMI)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-aquestive-therapeutics-aqst-eli-lilly-co-lly-and-owens-minor-omi-1033610702,neutral,0.7839441299438477
3547,7/30/2024 9:18:45 AM,Eli Lilly & Co Faces European Market Challenges; Analyst Maintains Hold Rating,TipRanks,/news/stocks/eli-lilly-co-faces-european-market-challenges-analyst-maintains-hold-rating-1033611546,neutral,0.9211882948875427
3548,7/30/2024 10:50:00 AM,Healthy Profits: 7 Healthcare Stocks to Build a Lifetime of Wealth,InvestorPlace,/news/stocks/healthy-profits-7-healthcare-stocks-to-build-a-lifetime-of-wealth-1033611118,negative,0.7569751739501953
3549,7/30/2024 11:45:00 AM,Unlocking the Next 3 Trillion-Dollar Stock Opportunities,InvestorPlace,/news/stocks/unlocking-the-next-3-trillion-dollar-stock-opportunities-1033611478,positive,0.8936878442764282
3550,7/30/2024 3:03:36 PM,Novo’s older obesity drug benefits Alzheimer’s patients in small trial,Seeking Alpha,https://seekingalpha.com/news/4130198-novos-obesity-drug-benefits-alzheimers-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8379793167114258
3551,7/30/2024 3:54:32 PM,Fractyl gets FDA breakthrough device status for Revita,Seeking Alpha,https://seekingalpha.com/news/4130253-fractyl-gets-fda-breakthrough-device-status-for-revita?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9024529457092285
3552,7/30/2024 7:07:52 PM,3 Biotech Stocks That Could Make Your Summer Unforgettable,InvestorPlace,/news/stocks/3-biotech-stocks-that-could-make-your-summer-unforgettable-1033613685,positive,0.8535476922988892
3553,7/31/2024 11:00:00 AM,The Top 3 Healthcare Stocks to Buy Now: Summer 2024,InvestorPlace,/news/stocks/the-top-3-healthcare-stocks-to-buy-now-summer-2024-1033617324,positive,0.9356123805046082
3554,7/31/2024 2:54:40 PM,Vaccinex stock plunges 24% on mixed results for Alzheimer's study,Seeking Alpha,https://seekingalpha.com/news/4131127-vaccinex-stock-plunges-on-mixed-results-for-alzheimers-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9643994569778442
3555,8/1/2024 11:31:41 AM,Eli Lilly stock rises as weight loss drug tirzepatide reduces heart failure risks in study,Seeking Alpha,https://seekingalpha.com/news/4132068-eli-lillys-weight-loss-drug-tirzepatide-reduces-heart-failure-risks-in-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9348021745681763
3556,8/1/2024 1:40:27 PM,WW International shares crash as GLP-1 popularity weighs on Q2 profits,Seeking Alpha,https://seekingalpha.com/news/4132311-ww-international-shares-crash-glp-1-popularity-weighs-q2-profits?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9496130347251892
3557,8/1/2024 2:26:09 PM,Lilly Reports Positive Topline Results From SUMMIT Phase 3 Study Of Tirzepatide ,RTTNews,/news/stocks/lilly-reports-positive-topline-results-from-summit-phase-3-study-of-tirzepatide-1033626313,negative,0.9493457674980164
3558,8/1/2024 4:19:01 PM,Morphic Holding ticks higher after HSR waiting period for Eli Lilly deal expires,Seeking Alpha,https://seekingalpha.com/news/4132424-morphic-holding-ticks-higher-after-hsr-waiting-period-for-eli-lilly-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5466545820236206
3559,8/1/2024 5:06:01 PM,Eli Lilly CEO says weight loss drug shortage is ending,Seeking Alpha,https://seekingalpha.com/news/4132434-eli-lilly-weight-loss-drug-shortage-ending?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9418289065361023
3560,8/1/2024 7:20:05 PM,What Are the Hottest Weight Loss Stocks Right Now? 3 Top Picks.,InvestorPlace,/news/stocks/what-are-the-hottest-weight-loss-stocks-right-now-3-top-picks-1033628715,positive,0.9202921986579895
3561,8/2/2024 11:49:39 AM,Eli Lilly & Co (LLY) Receives a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-truist-financial-1033633007,negative,0.6287072896957397
3562,8/2/2024 12:29:02 PM,Eli Lilly & Co: Set for Rebound as Analyst Maintains Buy Rating Amidst Potential Turnaround,TipRanks,/news/stocks/eli-lilly-co-set-for-rebound-as-analyst-maintains-buy-rating-amidst-potential-turnaround-1033633273,neutral,0.6246082186698914
3563,8/2/2024 7:00:00 PM,"Catalyst Watch: Disney earnings, Costco sales update, MicroStrategy split, and eyes on AI patents",Seeking Alpha,https://seekingalpha.com/news/4132451-catalyst-watch-disney-earnings-costco-sales-update-microstrategy-split-and-eyes-on-ai-patents?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6060433983802795
3564,8/2/2024 7:15:31 PM,Eli Lilly weight loss drug shortage is officially over,Seeking Alpha,https://seekingalpha.com/news/4133557-eli-lillys-zepbound-shortage-is-officially-over?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5238044261932373
3565,8/3/2024 3:12:23 PM,Viking obesity drug could become direct rival to Eli Lilly’s: report,Seeking Alpha,https://seekingalpha.com/news/4133672-viking-obesity-drug-could-become-direct-rival-to-eli-lillys-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.796725869178772
3566,8/4/2024 11:00:05 AM,"Weekly Biotech Buzz: FGEN Cuts Jobs, FDA OKs ADAP's Groundbreaking Cell Therapy, ME Rebuffs CEO Bid ",RTTNews,/news/stocks/weekly-biotech-buzz-fgen-cuts-jobs-fda-oks-adap-s-groundbreaking-cell-therapy-me-rebuffs-ceo-bid-1033634796,positive,0.5439757108688354
3567,8/4/2024 12:00:00 PM,"Earnings week ahead: Disney, Duke Energy, Palantir, Shopify, Uber and more",Seeking Alpha,https://seekingalpha.com/news/4133349-earnings-week-ahead-disney-duke-energy-palantir-shopify-uber-plug-power-nikola-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9215457439422607
3568,8/5/2024 6:22:24 AM,Eli Lilly Buy Rating Affirmed Amid Promising Alzheimer’s Treatment Advances,TipRanks,/news/stocks/eli-lilly-buy-rating-affirmed-amid-promising-alzheimer-s-treatment-advances-1033637852,negative,0.9413331151008606
3569,8/5/2024 7:40:51 AM,"Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Eli Lilly & Co (LLY) and Teva Pharmaceutical (TEVA)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-eli-lilly-co-lly-and-teva-pharmaceutical-teva-1033638187,positive,0.9125890731811523
3570,8/5/2024 8:28:26 AM,Eli Lilly & Co.: Balancing Tirzepatide’s Supply Challenges with Fundamental Growth Prospects,TipRanks,/news/stocks/eli-lilly-co-balancing-tirzepatide-s-supply-challenges-with-fundamental-growth-prospects-1033638495,negative,0.832855224609375
3571,8/5/2024 8:26:07 PM,"FDA indicates Lilly, Novo weight-loss drug shortages easing",Seeking Alpha,https://seekingalpha.com/news/4134422-fda-indicates-lilly-novo-weight-loss-drug-shortages-easing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8872135877609253
3572,8/6/2024 10:21:22 PM,Novo Nordisk's Wegovy no longer in shortage,Seeking Alpha,https://seekingalpha.com/news/4135595-novo-nordisk-wegovy-no-longer-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9116225242614746
3573,8/7/2024 12:18:15 PM,Amgen cut at Wells Fargo; says obesity success is already priced in,Seeking Alpha,https://seekingalpha.com/news/4135878-amgen-stock-cut-wells-fargo-maritide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.545423686504364
3574,8/7/2024 1:50:00 PM,Novo Nordisk stock falls as Wegovy Q2 sales miss the mark,Seeking Alpha,https://seekingalpha.com/news/4135735-novo-nordisk-boosts-sales-outlook-on-soaring-demand-for-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9658468961715698
3575,8/7/2024 3:01:13 PM,Eli Lilly and is about to announce its earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/eli_lilly-stock-price-quarter-earnings-preview-q2-1033652826,positive,0.9319095611572266
3576,8/7/2024 3:46:20 PM,Eli Lilly Q2 2024 Earnings Preview: Overseas obesity drug approvals could boost guidance,Seeking Alpha,https://seekingalpha.com/news/4136157-eli-lilly-q2-2024-earnings-preview-overseas-obesity-drug-approvals-could-boost-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9539210200309753
3577,8/8/2024 10:46:13 AM,"Eli Lilly Non-GAAP EPS of $3.92 beats by $1.16, revenue of $11.3B beats by $1.33B",Seeking Alpha,https://seekingalpha.com/news/4136972-eli-lilly-non-gaap-eps-of-3_92-beats-1_16-revenue-of-11_3b-beats-1_33b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7246772646903992
3578,8/8/2024 11:02:02 AM,"Earnings Summary: Eli Lilly reports strong Q2, further boosts FY2024 outlook",Seeking Alpha,https://seekingalpha.com/news/4136996-earnings-summary-eli-lilly-reports-strong-q2-further-boosts-fy2024-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9506128430366516
3579,8/8/2024 11:22:50 AM,Eli Lilly jumps after guidance raise on weight loss momentum,Seeking Alpha,https://seekingalpha.com/news/4137050-eli-lilly-stock-jumps-after-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5661223530769348
3580,8/8/2024 11:32:12 AM,Eli Lilly Poised for Growth Amidst Sector Challenges: A Buy Rating Analysis,TipRanks,/news/stocks/eli-lilly-poised-for-growth-amidst-sector-challenges-a-buy-rating-analysis-1033661473,positive,0.6158701181411743
3581,8/8/2024 11:45:55 AM,"Eli Lilly in charts: Mounjaro, Zepbound, Verzenio, and Jardiance power Q2 performance",Seeking Alpha,https://seekingalpha.com/news/4137087-eli-lilly-in-charts-mounjaro-zepbound-verzenio-and-jardiance-power-q2-performance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8171442151069641
3582,8/8/2024 12:50:27 PM,"Eli Lilly And Co. Q2 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/eli-lilly-and-co-q2-profit-increases-beats-estimates-1033659815,negative,0.9398201107978821
3583,8/8/2024 12:59:49 PM,Eli Lilly Again Boosts FY24 Outlook - Update ,RTTNews,/news/stocks/eli-lilly-again-boosts-fy24-outlook-update-1033659870,negative,0.9026731252670288
3584,8/8/2024 1:24:00 PM,"4 stocks to watch on Thursday: LLY, HOOD and more",Seeking Alpha,https://seekingalpha.com/news/4137228-4-stocks-to-watch-on-thursday-lly-hood-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9154744744300842
3585,8/8/2024 1:28:17 PM,LLY Stock Alert: Why Are Eli Lilly Shares Surging Today?,InvestorPlace,/news/stocks/lly-stock-alert-why-are-eli-lilly-shares-surging-today-1033660905,positive,0.5905771851539612
3586,8/8/2024 2:26:51 PM,"Biggest stock movers today: UAA, WBD, MNST, and more",Seeking Alpha,https://seekingalpha.com/news/4136848-biggest-stock-movers-today-wbd-mnst-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9233841300010681
3587,8/8/2024 3:52:37 PM,"Volume Leaders: MCK, UAA, HOOD, LLY, and more",Seeking Alpha,https://seekingalpha.com/news/4137378-volume-leaders-mck-uaa-hood-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9507187604904175
3588,8/8/2024 4:05:07 PM,Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook ,RTTNews,/news/stocks/eli-lilly-q2-results-top-estimates-boosts-fy24-outlook-1033661265,negative,0.9207143187522888
3589,8/8/2024 6:02:29 PM,Lilly Alzheimer's asset targeting tau protein fails in phase 2,Seeking Alpha,https://seekingalpha.com/news/4137445-lilly-alzheimers-asset-targeting-tau-protein-fails-phase-2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6790547966957092
3590,8/9/2024 7:52:31 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1033668437,negative,0.6687780618667603
3591,8/9/2024 10:00:39 AM,Eli Lilly & Co (LLY) Buy Rating Affirmed on Strong HFpEF Data and Competitive Edge Over Novo Nordisk (NVO),TipRanks,/news/stocks/eli-lilly-co-lly-buy-rating-affirmed-on-strong-hfpef-data-and-competitive-edge-over-novo-nordisk-nvo-1033669036,negative,0.9535939693450928
3592,8/9/2024 12:05:01 PM,"Dividend Roundup: Prudential Financial, Progressive, Alcoa, Eli Lilly, and more",Seeking Alpha,https://seekingalpha.com/news/4138000-dividend-roundup-prudential-financial-progressive-alcoa-eli-lilly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9484832882881165
3593,8/9/2024 12:39:49 PM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033670004,positive,0.7503917217254639
3594,8/9/2024 12:46:04 PM,Eli Lilly & Co: Hold Recommendation Amid Robust Performance and Market Uncertainties,TipRanks,/news/stocks/eli-lilly-co-hold-recommendation-amid-robust-performance-and-market-uncertainties-1033670178,neutral,0.9596976637840271
3595,8/9/2024 12:51:09 PM,"Analysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-crinetics-pharmaceuticals-crnx-eli-lilly-co-lly-1033670140,positive,0.810860812664032
3596,8/9/2024 1:28:46 PM,Jefferies Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/jefferies-remains-a-buy-on-eli-lilly-co-lly-1033670514,positive,0.9421079158782959
3597,8/9/2024 3:13:39 PM,Eli Lilly & Co: A Balanced Hold Rating Amid Growth and Competitive Challenges,TipRanks,/news/stocks/eli-lilly-co-a-balanced-hold-rating-amid-growth-and-competitive-challenges-1033670887,negative,0.8081282377243042
3598,8/9/2024 4:02:42 PM,3 Healthcare Stocks to Sell in August Before They Crash & Burn,InvestorPlace,/news/stocks/3-healthcare-stocks-to-sell-in-august-before-they-crash-burn-1033670345,positive,0.7787308096885681
3599,8/9/2024 7:19:52 PM,Eli Lilly a new 'top pick' at Morgan Stanley following strong Q2 results,Seeking Alpha,https://seekingalpha.com/news/4138313-eli-lilly-new-top-pick-morgan-stanley-following-strong-q2-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9285979270935059
3600,8/10/2024 10:32:00 AM,3 Stocks to Load-Up On Before Autumn Arrives,InvestorPlace,/news/stocks/3-stocks-to-load-up-on-before-autumn-arrives-2-1033671324,positive,0.6926835775375366
3601,8/11/2024 11:57:04 AM,About 73% of the S&P 500 names beat on EPS during the week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4138410-about-73-of-the-sp-500-names-beat-on-eps-during-the-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7882164120674133
3602,8/12/2024 7:50:47 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033676436,positive,0.9309778809547424
3603,8/12/2024 1:58:15 PM,Deutsche Bank calls Eli Lilly a ‘high growth unicorn’ in upgrade to Buy,Seeking Alpha,https://seekingalpha.com/news/4138646-deutsche-bank-calls-eli-lilly-high-growth-unicorn-in-upgrade-to-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.605514407157898
3604,8/13/2024 12:09:50 PM,Eli Lilly opens R&D center in Boston Seaport,Seeking Alpha,https://seekingalpha.com/news/4139071-eli-lilly-opens-rd-center-in-boston-seaport?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7804363965988159
3605,8/13/2024 2:08:54 PM,3 Stocks on the Rise After Stellar Q2 Earnings Results,InvestorPlace,/news/stocks/3-stocks-on-the-rise-after-stellar-q2-earnings-results-1033682606,negative,0.7949806451797485
3606,8/13/2024 6:17:41 PM,Eli Lilly & Co: A Strong Buy on Robust Pipeline and Market Leadership,TipRanks,/news/stocks/eli-lilly-co-a-strong-buy-on-robust-pipeline-and-market-leadership-1033684030,negative,0.9471184015274048
3607,8/14/2024 5:16:22 AM,Berenberg Bank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/berenberg-bank-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033687043,positive,0.8078015446662903
3608,8/14/2024 10:01:18 PM,"Bridgewater adds to Amazon, Microsoft, exits Intel, Devon, others in Q2",Seeking Alpha,https://seekingalpha.com/news/4140130-bridgewater-adds-to-amazon-microsoft-exits-intel-devon-others-in-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9406663179397583
3609,8/15/2024 1:31:20 AM,"LLY, NVO: Which GLP-1 Stock Is the Better Bet?",TipRanks,/news/stocks/lly-nvo-which-glp-1-stock-is-the-better-bet-1033692804,positive,0.9259721040725708
3610,8/15/2024 10:00:00 AM,3 Biotech Stocks to Buy on the Dip: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-to-buy-on-the-dip-august-2024-1033694134,positive,0.899672269821167
3611,8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9052250385284424
3612,8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.802365779876709
3613,8/15/2024 5:47:22 PM,Moderna was the most shorted S&P 500 healthcare stock in July,Seeking Alpha,https://seekingalpha.com/news/4139953-moderna-was-the-most-shorted-sp-500-healthcare-stock-in-july?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5078945755958557
3614,8/15/2024 9:21:59 PM,Philippe Laffont's Coatue Management ups Nvidia stake by nearly tenfold among top Q2 moves,Seeking Alpha,https://seekingalpha.com/news/4140822-philippe-laffonts-coatue-management-ups-nvidia-stake-by-nearly-tenfold-among-top-q2-moves?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9319825172424316
3615,8/17/2024 6:00:44 PM,"J&J, Roche come out on top in S&P ratings of strongest pharma companies",Seeking Alpha,https://seekingalpha.com/news/4141255-johnson-johnson-roche-come-out-top-in-ratings-strongest-pharma-companies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8499211668968201
3616,8/17/2024 6:31:00 PM,"Notable analyst calls this week: WBD, Medtronic and Dell among top picks",Seeking Alpha,https://seekingalpha.com/news/4141124-notable-analyst-calls-this-week-wbd-medtronic-and-dell-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6270737051963806
3617,8/19/2024 12:16:42 PM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033704774,positive,0.9309778809547424
3618,8/20/2024 11:12:49 AM,Eli Lilly’s tirzepatide cuts risk of diabetes by 94% in obese patients,Seeking Alpha,https://seekingalpha.com/news/4141781-lillys-tirzepatide-cuts-risk-of-diabetes-by-94-in-obese-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9365927577018738
3619,8/20/2024 12:45:37 PM,"Eli Lilly, Organon expand distribution deal for migraine drug",Seeking Alpha,https://seekingalpha.com/news/4141846-eli-lilly-organon-expand-distribution-deal-for-migraine-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.640842616558075
3620,8/20/2024 1:09:27 PM,Eli Lilly: Tirzepatide Lowers Risk Of Developing Type 2 Diabetes By 94% In 3-yr Study ,RTTNews,/news/stocks/eli-lilly-tirzepatide-lowers-risk-of-developing-type-2-diabetes-by-94-in-3-yr-study-1033706827,negative,0.9445046782493591
3621,8/20/2024 1:28:00 PM,"4 stocks to watch on Tuesday: LOW, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4141885-4-stocks-to-watch-on-tuesday-low-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5385611057281494
3622,8/20/2024 1:50:43 PM,"Biggest stock movers today: LLY, PANW, FN, and more",Seeking Alpha,https://seekingalpha.com/news/4141719-biggest-stock-movers-today-panw-fn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.910239040851593
3623,8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5784038305282593
3624,8/20/2024 7:01:10 PM,Eli Lilly to examine weight loss med Zepbound for immune disorders -- report,Seeking Alpha,https://seekingalpha.com/news/4142053-eli-lilly-weight-loss-med-zepbound-under-investigation-immune-disorders-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8558581471443176
3625,8/20/2024 7:59:30 PM,Novo Nordisk weight loss med semaglutide linked to suicidal thoughts,Seeking Alpha,https://seekingalpha.com/news/4142061-novo-nordisk-weight-loss-med-semaglutide-linked-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6349399089813232
3626,8/21/2024 11:45:55 AM,Eli Lilly’s Tirzepatide Shows Promising Efficacy in T2D Prevention and Weight Loss: Buy Rating Justified,TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promising-efficacy-in-t2d-prevention-and-weight-loss-buy-rating-justified-1033711639,negative,0.9025887250900269
3627,8/22/2024 4:37:22 AM,"Eli Lilly’s Tirzepatide Shows Promise in Preventing Type 2 Diabetes, Earns Buy Rating",TipRanks,/news/stocks/eli-lilly-s-tirzepatide-shows-promise-in-preventing-type-2-diabetes-earns-buy-rating-1033713534,negative,0.9096934199333191
3628,8/24/2024 5:16:09 PM,Eli Lilly Alzheimer’s drug set to face same fate as Biogen’s in U.K.: report,Seeking Alpha,https://seekingalpha.com/news/4143531-eli-lilly-alzheimers-drug-face-uk-rejection?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8033483028411865
3629,8/25/2024 6:00:00 PM,"Eli Lilly, Novo Nordisk to maintain 'two horse race' in GLP-1 weight loss market",Seeking Alpha,https://seekingalpha.com/news/4143506-eli-lilly-novo-nordisk-maintain-two-horse-race-glp-1-weight-loss-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7960001826286316
3630,8/26/2024 7:45:11 AM,Eli Lilly & Co (LLY) Receives a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-barclays-1033721511,negative,0.6687780618667603
3631,8/27/2024 11:14:45 AM,"Pfizer launches direct sales website for common vaccines, medicines",Seeking Alpha,https://seekingalpha.com/news/4144069-pfizer-launches-direct-sales-website-for-common-vaccines-medicines?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8609997630119324
3632,8/27/2024 11:35:14 AM,Eli Lilly Zepbound prices slashed by 50% for lowest doses,Seeking Alpha,https://seekingalpha.com/news/4144077-eli-lilly-zepbound-low-dose-price-cut-50?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8293975591659546
3633,8/27/2024 12:55:26 PM,Eli Lilly’s Strategic Initiatives in Drug Accessibility Prompts Buy Rating,TipRanks,/news/stocks/eli-lilly-s-strategic-initiatives-in-drug-accessibility-prompts-buy-rating-1033726211,negative,0.9355955719947815
3634,8/27/2024 1:28:29 PM,Lilly Releases 2.5 Mg And 5 Mg Vials Of Obesity Drug Zepbound ,RTTNews,/news/stocks/lilly-releases-2-5-mg-and-5-mg-vials-of-obesity-drug-zepbound-1033725035,positive,0.8753790855407715
3635,8/27/2024 6:20:34 PM,"Walgreens, Hims stocks drop as Lilly rolls out cheap weight-loss drugs",Seeking Alpha,https://seekingalpha.com/news/4144270-walgreens-hims-stocks-drop-as-lilly-rolls-out-cheap-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8896263241767883
3636,8/27/2024 7:00:55 PM,Weight loss drug developers slump as Eli Lilly slashes cost of some Zepbound doses,Seeking Alpha,https://seekingalpha.com/news/4144285-weight-loss-drug-developers-slump-eli-lilly-slashes-cost-some-zepbound-doses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.969231903553009
3637,8/27/2024 9:12:01 PM,FDA approves Illumina's TruSight Oncology biomarker test,Seeking Alpha,https://seekingalpha.com/news/4144349-fda-approves-illumina-trusight-oncology-biomarker-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6170622110366821
3638,8/27/2024 10:52:39 PM,Medicare coverage of Novo Nordisk's Wegovy could cost up to $145B annually,Seeking Alpha,https://seekingalpha.com/news/4144361-medicare-coverage-novo-nordisk-wegovy-could-cost-145b-annually?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8380087018013
3639,8/28/2024 12:05:54 PM,Eli Lilly & Co: Strategic Pricing and Market Expansion Fuel Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strategic-pricing-and-market-expansion-fuel-buy-rating-1033729591,positive,0.8243778944015503
3640,8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8434954881668091
3641,8/29/2024 6:27:02 PM,Eli Lilly’s Zepbound price cut comes with shocker for those on patient assistance,Seeking Alpha,https://seekingalpha.com/news/4145247-eli-lilly-zepbound-price-cut-comes-with-shocker?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9488165974617004
3642,9/3/2024 9:01:28 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033743264,negative,0.595212996006012
3643,9/3/2024 9:02:35 AM,"Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-alnylam-pharma-alny-eli-lilly-co-lly-1033743259,positive,0.5932162404060364
3644,9/3/2024 11:14:01 AM,Novo Nordisk warns of continued Ozempic shortage in Q4,Seeking Alpha,https://seekingalpha.com/news/4146035-novo-nordisk-warns-of-continued-ozempic-shortage-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9646046161651611
3645,9/4/2024 11:01:23 AM,Eli Lilly inks licensing deal to expand Olumiant access in Africa,Seeking Alpha,https://seekingalpha.com/news/4146624-eli-lilly-inks-licensing-deal-to-expand-olumiant-access-in-africa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9432264566421509
3646,9/4/2024 12:34:09 PM,Lilly And EVA Pharma To Expand Access To Baricitinib In Low-to Middle-income Countries In Africa ,RTTNews,/news/stocks/lilly-and-eva-pharma-to-expand-access-to-baricitinib-in-low-to-middle-income-countries-in-africa-1033746475,negative,0.9034985303878784
3647,9/4/2024 12:56:11 PM,Novartis expands U.S. radiopharma production amid rising competition,Seeking Alpha,https://seekingalpha.com/news/4146729-novartis-expands-us-radiopharma-production-amid-rising-competition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9449089765548706
3648,9/4/2024 2:55:22 PM,Eli Lilly’s quest for obesity drugs leads to $1B bet on dark genome,Seeking Alpha,https://seekingalpha.com/news/4146895-eli-lilly-bets-up-1b-haya-deal-obesity?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5832173228263855
3649,9/4/2024 6:21:24 PM,"UK regulators find no link between certain GLP-1 drugs, suicidal thoughts",Seeking Alpha,https://seekingalpha.com/news/4147000-uk-regulators-find-no-link-between-certain-glp-1-drugs-suicidal-thoughts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7860089540481567
3650,9/4/2024 6:36:05 PM,Inspire Medical gains on GLP-1 prospects,Seeking Alpha,https://seekingalpha.com/news/4147002-inspire-medical-stock-gains-glp-1-prospects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9453884959220886
3651,9/4/2024 9:28:01 PM,"QIAGEN, Lilly to develop Alzheimer's risk detection test",Seeking Alpha,https://seekingalpha.com/news/4147100-qiagen-lilly-to-develop-alzheimers-risk-detection-test?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7123450040817261
3652,9/5/2024 5:15:51 AM,"QIAGEN, Lilly To Develop QIAstat-Dx IVD Panel For Early Alzheimer's Disease Risk Identification ",RTTNews,/news/stocks/qiagen-lilly-to-develop-qiastat-dx-ivd-panel-for-early-alzheimer-s-disease-risk-identification-1033749015,positive,0.6897459030151367
3653,9/5/2024 11:27:49 AM,Eli Lilly marks late-stage trial win for once weekly insulin,Seeking Alpha,https://seekingalpha.com/news/4147209-eli-lilly-marks-trial-win-once-weekly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7577200531959534
3654,9/5/2024 11:55:59 AM,Evercore ISI Keeps Their Hold Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-keeps-their-hold-rating-on-eli-lilly-co-lly-1033751427,positive,0.9096813797950745
3655,9/5/2024 1:16:27 PM,"Lilly's QWINT-1, QWINT-3 Phase 3 Studies In Once Weekly Insulin Efsitora Alfa Meet Primary Goals ",RTTNews,/news/stocks/lilly-s-qwint-1-qwint-3-phase-3-studies-in-once-weekly-insulin-efsitora-alfa-meet-primary-goals-1033750183,positive,0.6566445827484131
3656,9/5/2024 5:16:14 PM,Perspective gets FDA fast track status for radiopharmaceutical VMT101,Seeking Alpha,https://seekingalpha.com/news/4147405-perspective-gets-fda-fast-track-status-for-radiopharmaceutical-vmt101?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.828557550907135
3657,9/5/2024 5:16:14 PM,Perspective gets FDA fast track status for radiopharmaceutical VMT01,Seeking Alpha,https://seekingalpha.com/news/4147405-perspective-gets-fda-fast-track-status-for-radiopharmaceutical-vmt01?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8212451934814453
3658,9/5/2024 6:41:56 PM,Eli Lilly bets $409M for AI-focused drug discovery,Seeking Alpha,https://seekingalpha.com/news/4147427-eli-lilly-bets-409m-for-ai-focused-drug-discovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.60256427526474
3659,9/5/2024 9:25:20 PM,Eli Lilly: A Strong Buy on Promising Once-Weekly Insulin Efsitora and Positive Market Outlook,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-promising-once-weekly-insulin-efsitora-and-positive-market-outlook-1033752261,negative,0.9542498588562012
3660,9/9/2024 7:55:38 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033756800,positive,0.8035197257995605
3661,9/9/2024 10:55:02 AM,Eli Lilly taps veteran Lucas Montarce as new CFO,Seeking Alpha,https://seekingalpha.com/news/4147932-eli-lilly-taps-veteran-lucas-montarce-as-new-cfo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.906466543674469
3662,9/9/2024 12:47:33 PM,Terns stock jumps as weight loss drug succeeds in early trial,Seeking Alpha,https://seekingalpha.com/news/4147984-terns-stock-jumps-as-weight-loss-drug-succeeds-in-early-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.791333794593811
3663,9/9/2024 1:04:53 PM,Lilly Names Lucas Montarce EVP And CFO With Immediate Effect ,RTTNews,/news/stocks/lilly-names-lucas-montarce-evp-and-cfo-with-immediate-effect-1033756824,positive,0.8458409309387207
3664,9/10/2024 2:58:30 PM,Global stocks with the highest Triple Momentum analysis – BofA,Seeking Alpha,https://seekingalpha.com/news/4148393-global-stocks-with-the-highest-triple-momentum-analysis-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8304357528686523
3665,9/10/2024 7:21:12 PM,UBS updates its ‘election watch’ stocks to match new winning probabilities,Seeking Alpha,https://seekingalpha.com/news/4148454-ubs-updates-its-election-watch-stocks-to-match-new-winning-probabilities?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6845300793647766
3666,9/10/2024 7:47:02 PM,Altimmune spikes after presenting data for obesity drug,Seeking Alpha,https://seekingalpha.com/news/4148457-altimmune-stock-spikes-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7764471173286438
3667,9/10/2024 10:56:30 PM,16 new GLP-1 weight-loss drugs could be launched by 2029: report,Seeking Alpha,https://seekingalpha.com/news/4148522-16-new-glp-1-weight-loss-drugs-could-be-launched-by-2029-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8558949828147888
3668,9/11/2024 3:40:22 AM,Lilly's Weekly Efsitora Alfa Insulin Delivers A1C Reduction Consistent With Daily Insulin ,RTTNews,/news/stocks/lilly-s-weekly-efsitora-alfa-insulin-delivers-a1c-reduction-consistent-with-daily-insulin-1033762075,negative,0.7998132705688477
3669,9/11/2024 12:36:23 PM,Evercore ISI Reaffirms Their Hold Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-reaffirms-their-hold-rating-on-eli-lilly-co-lly-1033764711,positive,0.8414214849472046
3670,9/11/2024 12:40:10 PM,Viking spikes as J.P. Morgan recommends ahead of key obesity drug readout,Seeking Alpha,https://seekingalpha.com/news/4148645-viking-stock-spikes-jp-morgan-recommends?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6181726455688477
3671,9/11/2024 5:28:48 PM,"Roche falls while Novo, Lilly gain on weight-loss drug report",Seeking Alpha,https://seekingalpha.com/news/4148758-roche-falls-while-novo-lilly-gain-on-weight-loss-drug-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.628801167011261
3672,9/12/2024 9:58:56 AM,Eli Lilly invests $1.8B to boost manufacturing footprint in Ireland,Seeking Alpha,https://seekingalpha.com/news/4148911-eli-lilly-invests-18b-to-boost-manufacturing-footprint-in-ireland?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9437265396118164
3673,9/12/2024 12:00:35 PM,Eli Lilly Lifts Manufacturing Investment In Limerick By $1 Bln - Quick Facts ,RTTNews,/news/stocks/eli-lilly-lifts-manufacturing-investment-in-limerick-by-1-bln-quick-facts-1033766242,negative,0.9294262528419495
3674,9/12/2024 4:57:26 PM,Each U.S. state has at least 20% of adults living with obesity: CDC,Seeking Alpha,https://seekingalpha.com/news/4149176-each-us-state-has-at-least-20-of-adults-living-with-obesity-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8782730102539062
3675,9/12/2024 5:57:26 PM,Noom launches cheaper compounded version of Novo's semaglutide,Seeking Alpha,https://seekingalpha.com/news/4149198-noom-launches-cheaper-compounded-version-of-semaglutide?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5642961859703064
3676,9/13/2024 8:56:39 AM,Eli Lilly & Co (LLY) Gets a Buy from Citi,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-citi-1033769922,negative,0.6344325542449951
3677,9/13/2024 12:43:38 PM,Eli Lilly wins buy as Citi resumes coverage on obesity prospects,Seeking Alpha,https://seekingalpha.com/news/4149428-eli-lilly-stock-gains-citi-resumes-at-buy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5571725368499756
3678,9/13/2024 12:56:51 PM,Eli Lilly & Co (LLY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-bank-of-america-securities-1033771009,positive,0.5223994851112366
3679,9/13/2024 8:38:21 PM,Lilly gains FDA approval for lebrikizumab for atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4149730-lilly-gains-fda-approval-for-lebrikizumab-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.938184916973114
3680,9/15/2024 1:36:00 PM,Least shorted S&P 500 stocks in August,Seeking Alpha,https://seekingalpha.com/news/4149788-least-shorted-sp-500-stocks-in-august?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.590275764465332
3681,9/15/2024 2:07:52 PM,Do queasy side effects mean the end of weight-loss drug stock hype?,Seeking Alpha,https://seekingalpha.com/news/4149819-do-nauseating-side-effects-mean-the-end-of-weight-loss-drug-stock-hype?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6545578837394714
3682,9/16/2024 7:25:20 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033773603,positive,0.8035197257995605
3683,9/16/2024 2:49:45 PM,Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month,Seeking Alpha,https://seekingalpha.com/news/4149983-moderna-was-most-shorted-sp-500-healthcare-stock-in-august-for-second-consecutive-month?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8436502814292908
3684,9/17/2024 5:20:43 PM,Rhythm Pharma draws bullish view at JMP on opportunity in rare genetic obesities,Seeking Alpha,https://seekingalpha.com/news/4150393-rhythm-pharma-stock-draws-bullish-view-at-jmp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9045266509056091
3685,9/18/2024 4:56:58 PM,Sanders says generic drugmakers could sell Novo Nordisk Ozempic for less than $100,Seeking Alpha,https://seekingalpha.com/news/4150792-sen-sanders-claims-generic-drugmakers-sell-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9026581645011902
3686,9/18/2024 6:05:40 PM,ResMed slips as Wolfe downgrades on GLP-1 threat from Lilly,Seeking Alpha,https://seekingalpha.com/news/4150858-resmed-stock-cut-wolfe-lilly-glp-1-threat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9504061937332153
3687,9/19/2024 11:54:21 AM,Vanda slips as FDA rejects therapy for stomach condition,Seeking Alpha,https://seekingalpha.com/news/4151038-vanda-stock-slips-fda-snub-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9478214979171753
3688,9/19/2024 3:15:37 PM,Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO,Seeking Alpha,https://seekingalpha.com/news/4151220-obesity-drug-developer-bioage-sets-ipo-terms?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7500146627426147
3689,9/19/2024 4:42:16 PM,Tandem Diabetes rises as insulin pump cleared for use in EU with Lilly insulin,Seeking Alpha,https://seekingalpha.com/news/4151269-tandem-diabetes-rises-insulin-pump-cleared-use-eu-lilly-insulin?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9277583360671997
3690,9/20/2024 2:21:41 PM,Lilly asks people who took compounded tirzepatide for their medical records,Seeking Alpha,https://seekingalpha.com/news/4151567-lilly-asks-people-took-compounded-tirzepatide-medical-records?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8526512384414673
3691,9/20/2024 3:35:17 PM,Eli Lilly’s Competitive Edge in Weight Loss Medication Market Bolstered by Orforglipron’s Promising Trial Results,TipRanks,/news/stocks/eli-lilly-s-competitive-edge-in-weight-loss-medication-market-bolstered-by-orforglipron-s-promising-trial-results-1033787597,negative,0.9535208344459534
3692,9/20/2024 3:49:22 PM,Novo Nordisk down 6% on data for oral weight loss drug onlunabant,Seeking Alpha,https://seekingalpha.com/news/4151646-novo-nordisk-down-6-data-oral-weight-loss-drug-onlunabant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9696282744407654
3693,9/20/2024 4:09:55 PM,Novo Nordisk down 6% on data for oral weight loss drug monlunabant,Seeking Alpha,https://seekingalpha.com/news/4151646-novo-nordisk-down-6-data-oral-weight-loss-drug-monlunabant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9708143472671509
3694,9/20/2024 5:17:34 PM,"UnitedHealth, Cigna, CVS PBMs targeted by FTC over inflated insulin prices",Seeking Alpha,https://seekingalpha.com/news/4151680-unitedhealth-cigna-cvs-pbms-targeted-ftc-inflated-insulin-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8741910457611084
3695,9/21/2024 11:45:40 AM,Eli Lilly & Co: Maintaining Market Dominance with Orforglipron Amid Competitor Challenges,TipRanks,/news/stocks/eli-lilly-co-maintaining-market-dominance-with-orforglipron-amid-competitor-challenges-1033787883,negative,0.9302734732627869
3696,9/21/2024 11:55:57 AM,Eli Lilly: A Strong Buy Amidst Obesity Treatment Market Dominance and Expanding Pipeline,TipRanks,/news/stocks/eli-lilly-a-strong-buy-amidst-obesity-treatment-market-dominance-and-expanding-pipeline-1033787873,negative,0.9026267528533936
3697,9/21/2024 8:00:07 PM,Novartis' Pluvicto expected to dominate prostate cancer radiopharmaceutical market,Seeking Alpha,https://seekingalpha.com/news/4151752-novartis-pluvicto-expected-dominate-prostate-cancer-radiopharmaceutical-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6771224141120911
3698,9/23/2024 1:22:37 PM,Mizuho recommends buying Corbus following its drop post-Novo's obesity data,Seeking Alpha,https://seekingalpha.com/news/4151904-mizuho-recommends-buying-corbus-following-its-drop-post-novos-obesity-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5276878476142883
3699,9/23/2024 5:30:12 PM,"Analysts Are Bullish on These Healthcare Stocks: Eli Lilly & Co (LLY), Aura Biosciences Inc (AURA)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-eli-lilly-co-lly-aura-biosciences-inc-aura-1033791834,positive,0.7810783386230469
3700,9/23/2024 5:47:31 PM,Morgan Stanley starts Structure Therapeutics at overweight,Seeking Alpha,https://seekingalpha.com/news/4152192-morgan-stanley-starts-structure-therapeutics-at-overweight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8926413059234619
3701,9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9338517189025879
3702,9/23/2024 8:26:47 PM,Senate HELP Committee hearing could get heated as Novo Nordisk CEO testifies,Seeking Alpha,https://seekingalpha.com/news/4152285-senate-help-committee-hearing-could-get-heated-novo-nordisk-ceo-testifies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6947923898696899
3703,9/24/2024 10:22:45 AM,Eli Lilly's Alzheimer's therapy approved in Japan,Seeking Alpha,https://seekingalpha.com/news/4152449-eli-lillys-alzheimers-therapy-approved-in-japan?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.838262677192688
3704,9/24/2024 12:35:13 PM,Lilly Gets Approval For Its Alzheimer's Disease Drug Kisunla In Japan ,RTTNews,/news/stocks/lilly-gets-approval-for-its-alzheimer-s-disease-drug-kisunla-in-japan-1033793048,negative,0.9198224544525146
3705,9/24/2024 4:07:15 PM,Roche narrows pipeline to 11 disease areas amidst weight loss push - WSJ,Seeking Alpha,https://seekingalpha.com/news/4152759-roche-narrows-pipeline-11-disease-areas-amidst-weight-loss-push?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.3527926206588745
3706,9/25/2024 1:50:13 PM,Lilly Reports New Long-term Data For Its Atopic Dermatitis Treatment Ebglyss ,RTTNews,/news/stocks/lilly-reports-new-long-term-data-for-its-atopic-dermatitis-treatment-ebglyss-1033796465,positive,0.7915801405906677
3707,9/25/2024 2:48:47 PM,Lilly Ebglyss demonstrates durable disease control in atopic dermatitis,Seeking Alpha,https://seekingalpha.com/news/4153146-lilly-ebglyss-demonstrates-durable-disease-control-in-atopic-dermatitis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8630761504173279
3708,9/25/2024 3:47:35 PM,"Novo Nordisk, Lilly weight loss drugs poised for price reductions: Cantor's Louise Chen",Seeking Alpha,https://seekingalpha.com/news/4153231-novo-nordisk-lilly-weight-loss-drugs-poised--price-reductions-cantor-louise-chen?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5277031660079956
3709,9/25/2024 4:45:53 PM,Novo Nordisk's Ozempic could have another benefit: reducing opioid overdoses,Seeking Alpha,https://seekingalpha.com/news/4153287-novo-nordisk-ozempic-could-have-another-benefit-reducing-opioid-overdoses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6300478577613831
3710,9/25/2024 5:06:51 PM,"BioAge, obesity drug developer, upsizes proposed IPO",Seeking Alpha,https://seekingalpha.com/news/4153310-bioage-obesity-drug-developer-upsizes-proposed-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8964921832084656
3711,9/25/2024 6:29:49 PM,Amgen stock slides 5% as analysts weigh in on drug study results,Seeking Alpha,https://seekingalpha.com/news/4153393-amgen-stock-slides-as-analysts-weigh-in-on-drug-study-results?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.941432535648346
3712,9/25/2024 6:55:41 PM,Next frontier in anti-obesity landscape: oral GLP-1s with potential OTC switch,Seeking Alpha,https://seekingalpha.com/news/4153415-next-frontier-in-anti-obesity-drugs-oral-glp-1s-with-otc-switch?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5640956163406372
3713,9/26/2024 4:35:56 PM,BioAge stock rallies 29% following upsized $198M IPO,Seeking Alpha,https://seekingalpha.com/news/4153819-bioage-stock-rallies-following-upsized-198m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9264777898788452
3714,9/26/2024 9:30:32 PM,"Investigation Discloses Safety, Efficacy Concerns About Eli Lilly's Donanemab ",RTTNews,/news/stocks/investigation-discloses-safety-efficacy-concerns-about-eli-lilly-s-donanemab-1033801945,positive,0.8143149614334106
3715,9/27/2024 5:59:43 PM,"Bristol Cobenfy approval draws optimism from Street, though with caveats",Seeking Alpha,https://seekingalpha.com/news/4154179-bristol-cobenfy-approval-draws-optimism-from-street-though-with-caveats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.862154483795166
3716,9/27/2024 10:03:02 PM,Lilly gets traditional FDA approval for Retevmo for thyroid cancer,Seeking Alpha,https://seekingalpha.com/news/4154298-lilly-gets-traditional-fda-approval-for-retevmo-for-thyroid-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8556911945343018
3717,9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.941364049911499
3718,9/30/2024 7:15:25 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033806917,negative,0.595212996006012
3719,9/30/2024 11:05:34 AM,Eli Lilly & Co: Strong Buy Rating Amid Robust Product Growth and Promising Pipeline,TipRanks,/news/stocks/eli-lilly-co-strong-buy-rating-amid-robust-product-growth-and-promising-pipeline-1033808038,negative,0.9517382979393005
3720,9/30/2024 3:25:11 PM,Roche sees Carmot obesity drugs' potential peak sales at $3.6B+: report,Seeking Alpha,https://seekingalpha.com/news/4154563-roche-sees-carmot-obesity-drugs-potential-peak-sales-at-4b-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8101692199707031
3721,9/30/2024 7:23:25 PM,Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset,Seeking Alpha,https://seekingalpha.com/news/4154703-nektar-rises-11-btig-initiates-buy-rating-autoimmune-disorders-asset?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9049825072288513
3722,10/1/2024 2:22:33 PM,Lilly looking to test Zepbound as health maintenance drug: report,Seeking Alpha,https://seekingalpha.com/news/4155026-lilly-looking-to-test-zepbound-as-health-maintenance-drug-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7170921564102173
3723,10/1/2024 7:35:29 PM,U.S. port strike expected to have limited impact on healthcare supply chain: HHS,Seeking Alpha,https://seekingalpha.com/news/4155196-us-port-strike-have-limited-impact-medical-supplies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9400646090507507
3724,10/2/2024 11:55:06 AM,Eli Lilly announces $4.5B production/R&D site in Indiana,Seeking Alpha,https://seekingalpha.com/news/4155415-eli-lilly-announces-45b-site-indiana?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.538658857345581
3725,10/2/2024 12:25:59 PM,Cantor Fitzgerald Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/cantor-fitzgerald-remains-a-buy-on-eli-lilly-co-lly-1033815972,positive,0.9399490356445312
3726,10/2/2024 1:40:27 PM,Eli Lilly To Create Indiana Medicine Foundry For Advanced Manufacturing And Drug Development ,RTTNews,/news/stocks/eli-lilly-to-create-indiana-medicine-foundry-for-advanced-manufacturing-and-drug-development-1033814674,positive,0.770210325717926
3727,10/2/2024 2:07:00 PM,Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3,Seeking Alpha,https://seekingalpha.com/news/4155316-bristol-myers-tops-growth-chart-among-sp-500-healthcare-stocks-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9400187730789185
3728,10/3/2024 10:25:28 AM,Eli Lilly & Co: Resolution of Tirzepatide Supply Issue Bolsters Buy Rating,TipRanks,/news/stocks/eli-lilly-co-resolution-of-tirzepatide-supply-issue-bolsters-buy-rating-1033818218,negative,0.945502758026123
3729,10/3/2024 11:16:47 AM,Eli Lilly & Co (LLY) Gets a Buy from Truist Financial,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-truist-financial-1033818716,negative,0.5010780692100525
3730,10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7824940085411072
3731,10/3/2024 12:59:00 PM,"4 stocks to watch on Thursday: STZ, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4155935-4-stocks-to-watch-on-thursday-stz-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9153627157211304
3732,10/3/2024 1:46:03 PM,"Eli Lilly GLP-1 shortage officially ends, hurting Hims & Hers",Seeking Alpha,https://seekingalpha.com/news/4155847-eli-lillys-weight-loss-drug-no-longer-in-shortage-fda-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9672737121582031
3733,10/3/2024 2:15:33 PM,Eli Lilly weight loss therapy on track for NHS rollout in England,Seeking Alpha,https://seekingalpha.com/news/4156017-eli-lilly-zepbound-track-nhs-rollout?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.49599337577819824
3734,10/3/2024 6:40:10 PM,Is Hims & Hers rally at risk as GLP-1 shortages ease?,Seeking Alpha,https://seekingalpha.com/news/4156219-can-hims-hers-stock-rally-glp-1-shortages?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7250548005104065
3735,10/5/2024 5:45:56 PM,"Can Novo, Lilly take credit for U.S. obesity rate decline?",Seeking Alpha,https://seekingalpha.com/news/4156593-did-novo-lilly-cause-us-obesity-rate-decline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8252951502799988
3736,10/7/2024 7:26:37 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033824084,positive,0.7920135259628296
3737,10/7/2024 2:03:41 PM,Pfizer stock climbs 4% amid reports Starboard has taken $1B stake,Seeking Alpha,https://seekingalpha.com/news/4156751-pfizer-stock-climbs-amid-reports-starboard-has-taken-1b-stake?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7593421936035156
3738,10/8/2024 7:51:12 AM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Abivax SA Sponsored ADR (ABVX) and Aquestive Therapeutics (AQST)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-abivax-sa-sponsored-adr-abvx-and-aquestive-therapeutics-aqst-1033827450,positive,0.9178206324577332
3739,10/8/2024 12:00:54 PM,Eli Lilly obesity drug shortage ends fueling lawsuit against FDA,Seeking Alpha,https://seekingalpha.com/news/4156953-fda-sued-over-end-eli-lilly-zepbound-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.931894838809967
3740,10/8/2024 1:30:53 PM,"Lilly to take Q3 IPR&D charge of $2.83B, or $3.08 per share",Seeking Alpha,https://seekingalpha.com/news/4157008-lilly-to-take-q3-iprd-charge-of-283b-or-308-per-share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8702637553215027
3741,10/8/2024 8:47:03 PM,"LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?",TipRanks,/news/stocks/lly-nvs-or-isrg-which-healthcare-stock-scores-wall-street-s-strong-buy-rating-1033829481,positive,0.855743944644928
3742,10/9/2024 10:21:02 AM,Medicare coverage of obesity drugs could raise federal spending by $35B through 2034 - CBO,Seeking Alpha,https://seekingalpha.com/news/4157187-weight-loss-drugs-medicare-spending-cbo-analysis?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9300304651260376
3743,10/9/2024 5:43:52 PM,CBO report on projected Medicare spending on obesity drugs could jeopardize coverage,Seeking Alpha,https://seekingalpha.com/news/4157358-cbo-report-projected-medicare-spending-obesity-drugs-could-jeopardize-coverage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9674368500709534
3744,10/9/2024 7:25:20 PM,Weight-loss drugs: How much should investors worry about side effects?,Seeking Alpha,https://seekingalpha.com/news/4157105-weight-loss-drugs-how-much-should-investors-worry-about-side-effects?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8704334497451782
3745,10/10/2024 2:16:51 PM,Lilly threatens legal action against copycat Zepbound providers: report,Seeking Alpha,https://seekingalpha.com/news/4157606-lilly-threatens-legal-action-against-copycat-zepbound-providers-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6972971558570862
3746,10/10/2024 5:40:34 PM,Eli Lilly widens obesity reach with $1.4B KeyBioscience deal,Seeking Alpha,https://seekingalpha.com/news/4157666-eli-lilly-widens-obesity-reach-with-new-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8463173508644104
3747,10/10/2024 6:20:58 PM,"WW surges after GLP-1 compounding announcement not justified after study, Barclays says",Seeking Alpha,https://seekingalpha.com/news/4157677-ww-surge-after-glp-1-compounding-announcement-not-justified-after-study-barclay-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6269592642784119
3748,10/10/2024 7:39:30 PM,Will Pfizer transform in response to Starboard’s activism?,Seeking Alpha,https://seekingalpha.com/news/4157703-will-pfizer-transform-amid-starboards-activism?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8450762629508972
3749,10/11/2024 8:56:04 AM,Eli Lilly & Co: Buy Rating Justified Despite Short-Term Sales Miss,TipRanks,/news/stocks/eli-lilly-co-buy-rating-justified-despite-short-term-sales-miss-1033838297,negative,0.9373795986175537
3750,10/11/2024 12:36:05 PM,Morgan Stanley Sticks to Their Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-buy-rating-for-eli-lilly-co-lly-1033839280,positive,0.8390757441520691
3751,10/11/2024 3:09:50 PM,Lilly expects Zepbound approval in Japan by mid-2025: report,Seeking Alpha,https://seekingalpha.com/news/4157926-lilly-expects-zepbound-approval-in-japan-by-mid-2025-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.77531898021698
3752,10/12/2024 11:55:08 AM,FDA to review removal of Eli Lilly weight loss drug from shortage list,Seeking Alpha,https://seekingalpha.com/news/4158052-fda-to-review-decison-end-of-zepbound-shortage?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6778935790061951
3753,10/12/2024 5:58:03 PM,Weight loss drugs have one big issue; these companies want to fix it,Seeking Alpha,https://seekingalpha.com/news/4158061-these-companies-address-muscle-loss-glp-1s?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8579020500183105
3754,10/14/2024 8:05:43 AM,Barclays Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033842579,positive,0.8035197257995605
3755,10/14/2024 1:24:40 PM,Lilly Reports 1-year Histologic Data From Phase 3 VIVID-1 Study Of Mirikizumab In Crohn's Disease ,RTTNews,/news/stocks/lilly-reports-1-year-histologic-data-from-phase-3-vivid-1-study-of-mirikizumab-in-crohn-s-disease-1033842600,positive,0.7915599346160889
3756,10/14/2024 2:37:06 PM,Lilly reports positive data for Omvoh versus Stelara in Crohn's,Seeking Alpha,https://seekingalpha.com/news/4158237-lilly-reports-positive-data-for-omvoh-versus-stelara-in-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.922605037689209
3757,10/14/2024 3:04:13 PM,Hims & Hers up 10% as FDA reconsiders taking Lilly weight loss drug off shortage list,Seeking Alpha,https://seekingalpha.com/news/4158246-hims-hers-up-10-fda-reconsiders-taking-lilly-weight-loss-drugs-off-shortage-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8942139148712158
3758,10/14/2024 3:56:46 PM,Eli Lilly & Co (LLY) Gets a Buy from TD Cowen,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-td-cowen-1033844066,positive,0.5125682950019836
3759,10/14/2024 5:20:25 PM,Eli Lilly To Invest $364 Mln In UK's Biotech Segment To Tackle Health Challenges ,RTTNews,/news/stocks/eli-lilly-to-invest-364-mln-in-uk-s-biotech-segment-to-tackle-health-challenges-1033843604,negative,0.8059725165367126
3760,10/15/2024 9:28:06 AM,Eli Lilly: A Strong Buy on Robust Revenue Growth and Expanding Market Potential,TipRanks,/news/stocks/eli-lilly-a-strong-buy-on-robust-revenue-growth-and-expanding-market-potential-1033846639,negative,0.9518333077430725
3761,10/15/2024 6:35:59 PM,Moderna continues to be the most shorted S&P 500 healthcare stock in September,Seeking Alpha,https://seekingalpha.com/news/4162080-moderna-continues-to-be-the-most-shorted-sp-500-healthcare-stock-in-september?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.48144128918647766
3762,10/16/2024 4:21:34 PM,Least shorted S&P 500 stocks in September,Seeking Alpha,https://seekingalpha.com/news/4166027-least-shorted-sp-500-stocks-in-september?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6412530541419983
3763,10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7325470447540283
3764,10/19/2024 1:37:00 PM,"Notable analyst calls this week: Etsy, Zoom and Enphase among top picks",Seeking Alpha,https://seekingalpha.com/news/4175781-notable-analyst-calls-this-week-etsy-zoom-and-enphase-among-top-picks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6625578999519348
3765,10/21/2024 9:17:01 AM,Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1033864152,positive,0.7920135259628296
3766,10/21/2024 2:42:58 PM,Novo Nordisk semaglutide cut cardio risks by 14% in diabetics: study,Seeking Alpha,https://seekingalpha.com/news/4184024-novo-nordisk-semaglutide-cut-cardio-risks-by-14-percent-in-diabetics-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9342092871665955
3767,10/21/2024 4:50:44 PM,"Goldman Sachs, Morgan Stanley bullish on BioAge, cite Lilly relationship",Seeking Alpha,https://seekingalpha.com/news/4185381-goldman-sachs-morgan-stanley-bullish-on-bioage-cite-lilly-relationship?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7477417588233948
3768,10/21/2024 7:05:25 PM,"Lilly sues companies selling compounded Zepbound, Mounjaro",Seeking Alpha,https://seekingalpha.com/news/4186465-lilly-sues-companies-selling-compounded-zepbound-mounjaro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.913723349571228
3769,10/21/2024 8:35:44 PM,Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data,TipRanks,/news/stocks/morgan-stanley-names-amgen-catalyst-driven-idea-into-phase-2-maritide-data-1033866771,positive,0.7655250430107117
3770,10/21/2024 9:15:37 PM,Mangoceuticals ‘refutes’ claims by Eli Lilly regarding sale of tirzepatide,TipRanks,/news/stocks/mangoceuticals-refutes-claims-by-eli-lilly-regarding-sale-of-tirzepatide-1033866869,neutral,0.423432856798172
3771,10/21/2024 11:12:34 PM,Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit,Seeking Alpha,https://seekingalpha.com/news/4187735-mangoceuticals-refutes-claims-made-by-lilly-in-weight-loss-drug-lawsuit?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.36695200204849243
3772,10/22/2024 5:31:19 AM,Mangoceuticals To Defend Against Eli Lilly's Lawsuit Over Alleged Copying Of Weight-Loss Drugs ,RTTNews,/news/stocks/mangoceuticals-to-defend-against-eli-lilly-s-lawsuit-over-alleged-copying-of-weight-loss-drugs-1033867111,neutral,0.47537165880203247
3773,10/22/2024 1:25:54 PM,"Pfizer, Lilly pressed about telehealth prescriber relationships, STAT reports",TipRanks,/news/stocks/pfizer-lilly-pressed-about-telehealth-prescriber-relationships-stat-reports-1033872465,positive,0.9403422474861145
3774,10/22/2024 4:01:16 PM,"GE Aerospace, GM report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/ge-aerospace-gm-report-quarterly-earnings-beats-morning-buzz-1033873047,positive,0.8467079997062683
3775,10/22/2024 5:19:03 PM,"Pfizer, Lilly relationships with telehealth platforms draw Sen. Durbin's attention",Seeking Alpha,https://seekingalpha.com/news/4190392-pfizer-lilly-relationships-telehealth-platforms-draw-sen-durbin-attention?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8783955574035645
3776,10/22/2024 10:48:32 PM,Lilly Alzheimer's drug not to be covered by U.K.'s NHS: report,Seeking Alpha,https://seekingalpha.com/news/4192946-lilly-alzheimers-drug-not-to-be-covered-by-uks-nhs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9389773011207581
3777,10/23/2024 9:10:26 AM,Eli Lilly announces MHRA grants marketing authorization for donanemab,TipRanks,/news/stocks/eli-lilly-announces-mhra-grants-marketing-authorization-for-donanemab-1033877923,negative,0.652707576751709
3778,10/23/2024 10:05:20 AM,"Eli Lilly Alzheimer’s drug rejected as too expensive by UK’s NHS, FT reports",TipRanks,/news/stocks/eli-lilly-alzheimer-s-drug-rejected-as-too-expensive-by-uk-s-nhs-ft-reports-1033878329,neutral,0.861038863658905
3779,10/23/2024 10:08:26 AM,Eli Lilly’s Alzheimer’s drug donanemab rejected for NHS use,Seeking Alpha,https://seekingalpha.com/news/4193722-eli-lillys-alzheimers-drug-donanemab-rejected-for-nhs-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5665565729141235
3780,10/23/2024 1:28:16 PM,Novo tells FDA compounded semaglutide too difficult to make,Seeking Alpha,https://seekingalpha.com/news/4194796-novo-tells-fda-compounded-semaglutide-too-difficult-to-make?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8356778621673584
3781,10/23/2024 4:06:12 PM,More states considering Medicaid coverage of GLP-1 weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4196032-more-states-considering-medicaid-coverage-glp-1-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.765507161617279
3782,10/23/2024 4:26:42 PM,Roche CEO says antitrust regulators should block Catalent sale to Novo Holdings (update),Seeking Alpha,https://seekingalpha.com/news/4195690-roche-ceo-says-antitrust-regulators-should-block-catalent-sale-to-novo-foundation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7209324240684509
3783,10/23/2024 7:49:55 PM,"Him & Hers, WW down on Novo attempt to restrict compounded semaglutide",Seeking Alpha,https://seekingalpha.com/news/4196990-hims-and-hers-ww-down-novo-attempt-restrict-compounded-semagluti?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8423635959625244
3784,10/24/2024 3:26:50 PM,Viking Therapeutics jumps as obesity updates outshine Q3 beat,Seeking Alpha,https://seekingalpha.com/news/4200535-viking-therapeutics-stock-jumps-post-q-3-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8254027962684631
3785,10/24/2024 4:54:00 PM,Lilly to launch Mounjaro in rival Novo Nordisk's home country: report,Seeking Alpha,https://seekingalpha.com/news/4201290-lilly-to-launch-mounjaro-in-rival-novo-nordisks-home-country-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8747895359992981
3786,10/24/2024 6:40:34 PM,"Study finds high costs, few benefits associated with GLP-1 weight loss drugs",Seeking Alpha,https://seekingalpha.com/news/4201472-study-finds-high-costs-few-benefits-associated-glp-1-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.4716617465019226
3787,10/25/2024 10:20:32 AM,"Eli Lilly price target raised to $1,250 from $1,060 at Citi",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-250-from-1-060-at-citi-1033892717,negative,0.9406459331512451
3788,10/25/2024 10:56:31 AM,Eli Lilly presents new Ebglyss data at FCD Conference,TipRanks,/news/stocks/eli-lilly-presents-new-ebglyss-data-at-fcd-conference-1033892927,positive,0.9236413836479187
3789,10/25/2024 2:19:09 PM,Lilly's Ebglyss shown to be effective in former Dupixent users,Seeking Alpha,https://seekingalpha.com/news/4204992-lillys-ebglyss-shown-to-be-effective-in-former-dupixent-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9465171098709106
3790,10/25/2024 7:00:00 PM,"Catalyst Watch: Eyes on tech with Apple, Amazon, Alphabet, and Meta reporting",Seeking Alpha,https://seekingalpha.com/news/4201499-catalyst-watch-eyes-on-tech-with-apple-amazon-alphabet-and-meta-reporting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9125537276268005
3791,10/26/2024 5:46:00 PM,About 75% of companies that reported earnings this week delivered EPS wins-Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4205854-about-75-of-companies-that-reported-earnings-this-week-delivered-eps-wins-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8234386444091797
3792,10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9362694025039673
3793,10/28/2024 7:10:55 AM,Eli Lilly gets nod to sell weight-loss drug in Hong Kong by year-end - report,Seeking Alpha,https://seekingalpha.com/news/4212378-eli-lilly-gets-nod-to-sell-weight-loss-drug-in-hong-kong-by-year-end-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7836210131645203
3794,10/28/2024 8:51:14 AM,"Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), Eli Lilly & Co (LLY) and Ligand Pharma (LGND)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-eli-lilly-co-lly-and-ligand-pharma-lgnd-1033901057,positive,0.9199034571647644
3795,10/28/2024 10:56:43 AM,"Eli Lilly announces results from two, multi-year mirikizumab studies",TipRanks,/news/stocks/eli-lilly-announces-results-from-two-multi-year-mirikizumab-studies-1033901827,positive,0.7254481315612793
3796,10/28/2024 11:36:44 AM,"Eli Lilly’s Omvoh shows long-term effectiveness against UC, Crohn’s disease",Seeking Alpha,https://seekingalpha.com/news/4212961-eli-lillys-omvoh-shows-long-term-effectiveness-against-uc-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9025084972381592
3797,10/28/2024 12:00:46 PM,Apogee Therapeutics price target raised to $100 from $81 at BTIG,TipRanks,/news/stocks/apogee-therapeutics-price-target-raised-to-100-from-81-at-btig-1033902665,negative,0.9480775594711304
3798,10/28/2024 12:15:19 PM,"Eli Lilly, ViaNautis sign collaboration agreement for polyNaut platform",TipRanks,/news/stocks/eli-lilly-vianautis-sign-collaboration-agreement-for-polynaut-platform-1033902742,negative,0.9140368700027466
3799,10/28/2024 12:17:03 PM,Eli Lilly’s Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients,TipRanks,/news/stocks/eli-lilly-s-ebglyss-a-promising-alternative-for-dupixent-resistant-atopic-dermatitis-patients-1033902726,negative,0.7101114392280579
3800,10/28/2024 12:24:42 PM,Investors eye earnings data volatility movements as it reflects highest levels in 15 years,Seeking Alpha,https://seekingalpha.com/news/4213053-investors-eye-earnings-data-as-volatility-movements-reflects-highest-levels-in-15-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5034686923027039
3801,10/28/2024 12:46:03 PM,Eli Lilly tells Bloomberg approval received to launch Mounjaro in Hong Kong,TipRanks,/news/stocks/eli-lilly-tells-bloomberg-approval-received-to-launch-mounjaro-in-hong-kong-1033902907,positive,0.5053568482398987
3802,10/28/2024 1:58:49 PM,"ViaNautis Bio, Lilly Partner For ViaNautis' Drug Delivery Platform PolyNaut ",RTTNews,/news/stocks/vianautis-bio-lilly-partner-for-vianautis-drug-delivery-platform-polynaut-1033901523,positive,0.8265492916107178
3803,10/28/2024 2:03:34 PM,Evoke stock rockets 90% on study of Gimoti in GLP-1 users,Seeking Alpha,https://seekingalpha.com/news/4213544-evok-stock-rockets-on-study-of-gimoti-in-glp-1-users?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6594215631484985
3804,10/28/2024 3:38:58 PM,Eli Lilly declares $1.30 dividend,Seeking Alpha,https://seekingalpha.com/news/4214160-eli-lilly-declares-130-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9196907877922058
3805,10/28/2024 4:10:30 PM,"Boeing to offer 90M common shares, Philips reports mixed Q3: Morning Buzz",TipRanks,/news/stocks/boeing-to-offer-90m-common-shares-philips-reports-mixed-q3-morning-buzz-1033903631,negative,0.5231991410255432
3806,10/28/2024 6:45:12 PM,"Eli Lilly touts long-term data on Omvoh for ulcerative colitis, Crohn's",Seeking Alpha,https://seekingalpha.com/news/4215117-eli-lilly-touts-long-term-data-omvoh-ulcerative-colitis-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9032479524612427
3807,10/29/2024 4:20:15 PM,Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients,TipRanks,/news/stocks/eli-lilly-says-donanemab-redudced-aria-e-in-early-alzheimer-s-patients-1033911491,negative,0.7337510585784912
3808,10/29/2024 5:40:37 PM,Lilly reports positive Phase 3 results for modified Kisunla dosing,Seeking Alpha,https://seekingalpha.com/news/4220053-lilly-reports-positive-phase-3-results-for-modified-kisunla-dosing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9444435238838196
3809,10/29/2024 6:00:55 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033911969,positive,0.9220908284187317
3810,10/29/2024 7:19:04 PM,"Eli Lilly Q3 2024 Earnings Preview: Focus on exit rate, fear of revenue miss on the horizon",Seeking Alpha,https://seekingalpha.com/news/4220488-eli-lilly-q3-2024-earnings-preview-focus-on-exit-rate-fear-of-revenue-miss-on-the-horizon?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.812300443649292
3811,10/30/2024 10:46:08 AM,"Eli Lilly Non-GAAP EPS of $1.18 misses by $0.29, revenue of $11.44B misses by $680M",Seeking Alpha,https://seekingalpha.com/news/4222385-eli-lilly-non-gaap-eps-of-1_18-misses-0_29-revenue-of-11_44b-misses-680m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6011213064193726
3812,10/30/2024 10:51:16 AM,"Eli Lilly reports Q3 EPS $1.18, consensus $1.47",TipRanks,/news/stocks/eli-lilly-reports-q3-eps-1-18-consensus-1-47-1033917917,positive,0.5409896969795227
3813,10/30/2024 10:57:34 AM,Eli Lilly cuts FY24 EPS view to $13.02-$13.52 from $16.10-$16.60,TipRanks,/news/stocks/eli-lilly-cuts-fy24-eps-view-to-13-02--13-52-from-16-10--16-60-1033917881,neutral,0.8502643704414368
3814,10/30/2024 11:00:46 AM,"Earnings Snapshot: Eli Lilly falls short in Q3 results, lowers FY2024 outlook",Seeking Alpha,https://seekingalpha.com/news/4222460-earnings-snapshot-eli-lilly-falls-short-in-q3-results-lowers-fy2024-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9665657877922058
3815,10/30/2024 11:17:23 AM,"Eli Lilly in charts: Mounjaro, Zepbound, and Humalog fuel Q3 sales growth",Seeking Alpha,https://seekingalpha.com/news/4222510-eli-lilly-in-charts-mounjaro-zepbound-and-humalog-fuel-q3-sales-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6595225930213928
3816,10/30/2024 11:23:40 AM,"Eli Lilly drops, sending Novo lower after Q3 miss",Seeking Alpha,https://seekingalpha.com/news/4222515-eli-lilly-stock-drops-hurting-novo-after-q-3-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9661661386489868
3817,10/30/2024 11:51:36 AM,Eli Lilly And Co. Q3 Earnings Summary ,RTTNews,/news/stocks/eli-lilly-and-co-q3-earnings-summary-1033916334,positive,0.7800344824790955
3818,10/30/2024 12:18:04 PM,"Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan",TipRanks,/news/stocks/eli-lilly-core-thesis-remains-intact-despite-q3-miss-says-jpmorgan-1033919156,negative,0.943489134311676
3819,10/30/2024 12:18:05 PM,"Lilly Cuts FY24 Earnings, Revenue Outlook After Q3 Misses Street; Stock Down In Pre-market - Update ",RTTNews,/news/stocks/lilly-cuts-fy24-earnings-revenue-outlook-after-q3-misses-street-stock-down-in-pre-market-update-1033916486,neutral,0.9708213210105896
3820,10/30/2024 12:46:43 PM,AnaptysBio plunges as Eli Lilly drops arthritis drug from pipeline,Seeking Alpha,https://seekingalpha.com/news/4222747-anaptys-bio-stock-falls-lilly-updates-pipeline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9550563097000122
3821,10/30/2024 12:50:24 PM,AnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulled,TipRanks,/news/stocks/anaptysbio-sinks-30-after-lilly-slides-show-pd-1-agonist-pulled-1033919388,neutral,0.9358559846878052
3822,10/30/2024 12:55:28 PM,"AnaptysBio to be weak on Lilly pulling peresolimab from pipeline, says Stifel",TipRanks,/news/stocks/anaptysbio-to-be-weak-on-lilly-pulling-peresolimab-from-pipeline-says-stifel-1033919373,neutral,0.8792111277580261
3823,10/30/2024 1:01:23 PM,Morning Movers: Caterpillar and Eli Lilly sink following quarterly reports,TipRanks,/news/stocks/morning-movers-caterpillar-and-eli-lilly-sink-following-quarterly-reports-1033919565,positive,0.9493290185928345
3824,10/30/2024 1:20:00 PM,"5 stocks to watch on Wednesday: MSFT, META, LLY and more",Seeking Alpha,https://seekingalpha.com/news/4223018-5-stocks-to-watch-on-wednesday-msft-meta-lly-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9399659037590027
3825,10/30/2024 1:50:35 PM,Eli Lilly falls -12.0%,TipRanks,/news/stocks/eli-lilly-falls--12-0-1033919816,neutral,0.9214510321617126
3826,10/30/2024 2:00:35 PM,Eli Lilly falls -13.5%,TipRanks,/news/stocks/eli-lilly-falls--13-5-1033919999,neutral,0.8825502991676331
3827,10/30/2024 2:15:22 PM,"Biggest stock movers Wednesday: SMCI, LLY, GOOG, SNAP, and more",Seeking Alpha,https://seekingalpha.com/news/4221935-biggest-stock-movers-wednesday-goog-snap-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9198371767997742
3828,10/30/2024 2:20:13 PM,"AnaptysBio weakness on competitor news a buying opportunity, says Guggenheim",TipRanks,/news/stocks/anaptysbio-weakness-on-competitor-news-a-buying-opportunity-says-guggenheim-1033920029,negative,0.8543053865432739
3829,10/30/2024 3:45:40 PM,H.C. Wainwright still ‘optimistic’ on Phase 2 data for AnaptysBio’s rosnilimab,TipRanks,/news/stocks/h-c-wainwright-still-optimistic-on-phase-2-data-for-anaptysbio-s-rosnilimab-1033920348,positive,0.5444656014442444
3830,10/30/2024 4:15:41 PM,"Alphabet, AMD report Q3 earnings beats: Morning Buzz",TipRanks,/news/stocks/alphabet-amd-report-q3-earnings-beats-morning-buzz-1033920421,positive,0.8454447984695435
3831,10/30/2024 5:43:56 PM,"Eli Lilly had a strong Q3, so why is its stock falling?",Seeking Alpha,https://seekingalpha.com/news/4224905-eli-lilly-had-strong-q-3-so-why-is-its-stock-falling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.947363018989563
3832,10/30/2024 5:55:24 PM,Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update),Seeking Alpha,https://seekingalpha.com/news/4224998-hims-hers-stock-falls-after-novo-semaglutide-taken-off-shortage-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.943552553653717
3833,10/31/2024 8:46:06 AM,Eli Lilly & Co: Buy Rating Affirmed Amidst U.S. Market Challenges and International Growth Potential,TipRanks,/news/stocks/eli-lilly-co-buy-rating-affirmed-amidst-u-s-market-challenges-and-international-growth-potential-1033927429,negative,0.899936318397522
3834,10/31/2024 8:47:49 AM,Eli Lilly & Co (LLY) Gets a Buy from Barclays,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-barclays-1033927409,negative,0.595212996006012
3835,10/31/2024 9:56:08 AM,Eli Lilly’s Resilient Outlook: Buy Rating Affirmed Despite Q3 Challenges,TipRanks,/news/stocks/eli-lilly-s-resilient-outlook-buy-rating-affirmed-despite-q3-challenges-1033927923,negative,0.9443700909614563
3836,10/31/2024 12:37:07 PM,"Eli Lilly earnings selloff brings buying opportunity, says JPMorgan",TipRanks,/news/stocks/eli-lilly-earnings-selloff-brings-buying-opportunity-says-jpmorgan-1033929826,negative,0.9134694337844849
3837,10/31/2024 1:11:01 PM,"Analysts Offer Insights on Healthcare Companies: Bausch + Lomb Corporation (BLCO), Ginkgo Bioworks Holdings (DNA) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bausch-+-lomb-corporation-blco-ginkgo-bioworks-holdings-dna-and-eli-lilly-co-lly-1033930018,positive,0.9286145567893982
3838,10/31/2024 1:26:00 PM,Jefferies Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/jefferies-remains-a-buy-on-eli-lilly-co-lly-1033930133,positive,0.9421079158782959
3839,11/1/2024 12:50:42 PM,Novo Nordisk posts Phase 3 win for obesity drug in MASH,Seeking Alpha,https://seekingalpha.com/news/4233438-novo-nordisk-wegovy-hits-main-goal-mash-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9359320402145386
3840,11/1/2024 3:45:22 PM,"Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-015-from-1-025-at-deutsche-bank-1033938576,neutral,0.8471223711967468
3841,11/1/2024 7:00:45 PM,"Catalyst Watch: Eyes on election bets, FOMC meeting, drug data, and NXP Semiconductors event",Seeking Alpha,https://seekingalpha.com/news/4234423-catalyst-watch-eyes-on-election-bets-fomc-meeting-drug-data-and-nxp-semiconductors-event?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9366456866264343
3842,11/2/2024 7:36:20 PM,New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity,Seeking Alpha,https://seekingalpha.com/news/4238084-novo-nordisk’s-wegovy-can-heal-joint-pain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.836555004119873
3843,11/4/2024 9:17:24 AM,Barclays Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-remains-a-buy-on-eli-lilly-co-lly-1033943537,positive,0.9309778809547424
3844,11/4/2024 10:00:03 AM,"Viking shares jump after positive early data on oral obesity pill; Lilly, Novo drop",Seeking Alpha,https://seekingalpha.com/news/4241430-viking-shares-jump-after-positive-early-data-on-oral-obesity-pill-lilly-novo-drop?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6452763676643372
3845,11/4/2024 10:40:34 AM,Viking Therapeutics surges after presenting ‘promising’ obesity drug data,TipRanks,/news/stocks/viking-therapeutics-surges-after-presenting-promising-obesity-drug-data-1033943945,negative,0.9454663991928101
3846,11/4/2024 2:07:37 PM,"Eli Lilly price target lowered to $1,015 from $1,025 at Deutsche Bank",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-015-from-1-025-at-deutsche-bank-1033945960,neutral,0.8471223711967468
3847,11/4/2024 4:26:04 PM,"AstraZeneca says experimental obesity pill ‘competitive,’ Bloomberg reports",TipRanks,/news/stocks/astrazeneca-says-experimental-obesity-pill-competitive-bloomberg-reports-1033946485,negative,0.6369112133979797
3848,11/4/2024 6:41:14 PM,New study reveals another benefit in using Novo Nordisk’s Wegovy in obesity,Seeking Alpha,https://seekingalpha.com/news/4238084-novo-nordisk-wegovy-can-heal-joint-pain?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.836555004119873
3849,11/4/2024 6:50:17 PM,"AstraZeneca oral GLP1 looks to be trailing Eli Lilly’s, says Deutsche Bank",TipRanks,/news/stocks/astrazeneca-oral-glp1-looks-to-be-trailing-eli-lilly-s-says-deutsche-bank-1033947020,positive,0.4620845317840576
3850,11/4/2024 8:40:58 PM,Viking stock drops 13% after jumping 9% on obesity drug data,Seeking Alpha,https://seekingalpha.com/news/4245047-viking-stock-drops-after-jumping-on-obesity-drug-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9600344300270081
3851,11/4/2024 8:42:07 PM,"How does Viking's weight loss med compare to ones from Novo, Eli Lilly?",Seeking Alpha,https://seekingalpha.com/news/4244507-how-viking-weight-loss-med-compares-ones-novo-eli-lilly?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8481084108352661
3852,11/6/2024 2:32:58 AM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1033957098,positive,0.7503917217254639
3853,11/6/2024 12:48:12 PM,Novo beats Eli Lilly in Q3 sales for obesity drug,Seeking Alpha,https://seekingalpha.com/news/4254529-novo-beats-eli-lilly-in-q3-sales-for-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8794840574264526
3854,11/6/2024 3:29:57 PM,"Tango stock plunges 28% amid pipeline updates, Q3 earnings report",Seeking Alpha,https://seekingalpha.com/news/4255539-tango-stock-plunges-amid-pipeline-updates-q3-earnings-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9618350863456726
3855,11/6/2024 8:17:19 PM,SA Asks: How will the U.S. election results impact healthcare stocks?,Seeking Alpha,https://seekingalpha.com/news/4257322-sa-asks-how-will-the-us-election-results-impact-healthcare-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7067018747329712
3856,11/7/2024 9:01:04 PM,Eli Lilly snaps six straight sessions of losses,Seeking Alpha,https://seekingalpha.com/news/4262015-eli-lilly-set-to-snap-six-straight-sessions-of-losses?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5055035948753357
3857,11/8/2024 4:45:14 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1033984770,negative,0.9105142951011658
3858,11/11/2024 8:10:20 AM,"Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), Radnet (RDNT) and Eli Lilly & Co (LLY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-jazz-pharmaceuticals-jazz-radnet-rdnt-and-eli-lilly-co-lly-1033991070,positive,0.9197514653205872
3859,11/11/2024 7:15:37 PM,Tectonic Therapeutic price target raised to $69 from $49 at Leerink,TipRanks,/news/stocks/tectonic-therapeutic-price-target-raised-to-69-from-49-at-leerink-1033994544,negative,0.9487611055374146
3860,11/11/2024 9:21:12 PM,Needham biotech analysts hold an analyst/industry conference call,TipRanks,/news/stocks/needham-biotech-analysts-hold-an-analyst-industry-conference-call-1033994780,positive,0.9411064386367798
3861,11/12/2024 1:22:50 PM,Bristol-Myers upgraded at Leerink after AbbVie setback,Seeking Alpha,https://seekingalpha.com/news/4279606-bristol-myers-stock-upgraded-leerink?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7898422479629517
3862,11/12/2024 8:32:02 PM,Amgen slips as Cantor cites safety concerns linked to obesity candidate,Seeking Alpha,https://seekingalpha.com/news/4281785-amgen-stock-slips-amid-risk-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9452197551727295
3863,11/13/2024 7:13:36 PM,Hims & Hers launches GLP-1 drug shortage tracker,Seeking Alpha,https://seekingalpha.com/news/4286579-hims-hers-launches-glp-1-drug-shortage-tracker?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8115925788879395
3864,11/13/2024 10:10:11 PM,Eli Lilly announces results from Phase 3 SURMOUNT-1 three-year study,TipRanks,/news/stocks/eli-lilly-announces-results-from-phase-3-surmount-1-three-year-study-1034011943,positive,0.7739806175231934
3865,11/13/2024 10:45:18 PM,"Lilly three-year tirzepatide results show sustained weight loss, diabetes benefits",Seeking Alpha,https://seekingalpha.com/news/4287466-lilly-three-year-tirzepatide-results-show-sustained-weight-loss-diabetes-benefits?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7911891341209412
3866,11/14/2024 4:46:23 PM,Global increase in diabetes indicates more room for GLP-1 meds to grow,Seeking Alpha,https://seekingalpha.com/news/4290949-global-increase-diabetes-indicates-more-room-for-glp-1-meds-grow?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9435994029045105
3867,11/14/2024 8:30:19 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1034021054,negative,0.9105142951011658
3868,11/14/2024 9:15:11 PM,Eli Lilly initiated with an Outperform at Wolfe Research,TipRanks,/news/stocks/eli-lilly-initiated-with-an-outperform-at-wolfe-research-1034021192,neutral,0.550254225730896
3869,11/14/2024 10:48:03 PM,"Renaissance Tech adds Micron, exits Broadcom, among Q3 trades",Seeking Alpha,https://seekingalpha.com/news/4292581-renaissance-tech-adds-micron-exits-broadcom-among-q3-trades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8644103407859802
3870,11/14/2024 11:27:00 PM,"Coatue Management top Q3 moves: cuts Nvidia, exits CRM & UNH, piles into Chinese stocks",Seeking Alpha,https://seekingalpha.com/news/4292784-coatue-management-top-q3-moves-cuts-nvidia-exits-crm-unh-piles-into-chinese-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8305882215499878
3871,11/14/2024 11:45:10 PM,"Wolfe sees attractive Eli Lilly opportunity on price drop, starts at Outperform",TipRanks,/news/stocks/wolfe-sees-attractive-eli-lilly-opportunity-on-price-drop-starts-at-outperform-1034021615,neutral,0.6822795271873474
3872,11/15/2024 12:19:45 PM,Eli Lilly follows JNJ in suing govt. over 340B drug-discount program,Seeking Alpha,https://seekingalpha.com/news/4294034-eli-lilly-follows-jnj-suing-over-340-b-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.39144593477249146
3873,11/15/2024 3:32:00 PM,Least shorted S&P 500 stocks in October,Seeking Alpha,https://seekingalpha.com/news/4294512-least-shorted-sp-500-stocks-in-october?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5993219614028931
3874,11/15/2024 5:26:07 PM,"Eli Lilly sues to change hospital drug discount payments, WSJ reports",TipRanks,/news/stocks/eli-lilly-sues-to-change-hospital-drug-discount-payments-wsj-reports-1034026316,neutral,0.7439976930618286
3875,11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9049097299575806
3876,11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9230126738548279
3877,11/17/2024 3:30:13 AM,"Lilly' Tirzepatide Reduces Heart Failure Risk, Improves Symptoms In HFpEF Patients With Obesity ",RTTNews,/news/stocks/lilly-tirzepatide-reduces-heart-failure-risk-improves-symptoms-in-hfpef-patients-with-obesity-1034027157,negative,0.9457692503929138
3878,11/18/2024 9:05:36 AM,Barclays Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/barclays-keeps-their-buy-rating-on-eli-lilly-co-lly-1034029862,positive,0.9004620313644409
3879,11/18/2024 11:45:58 AM,"Eli Lilly’s tirzepatide cuts risk of worsening heart failure in HFpEF, obese patients",Seeking Alpha,https://seekingalpha.com/news/4301465-eli-lillys-tirzepatide-cuts-risk-of-worsening-heart-failure-in-hfpef-obese-patients?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9135088920593262
3880,11/18/2024 12:55:48 PM,Eli Lilly & Co (LLY) Receives a Hold from Evercore ISI,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-hold-from-evercore-isi-1034031547,positive,0.8884941339492798
3881,11/18/2024 2:02:31 PM,"Incyclix Bio And Eli Lilly To Evaluate INX-315, Verzenio, And Fulvestrant In HR+/HER2- Breast Cancer ",RTTNews,/news/stocks/incyclix-bio-and-eli-lilly-to-evaluate-inx-315-verzenio-and-fulvestrant-in-hr-her2-breast-cancer-1034030088,negative,0.5498902201652527
3882,11/18/2024 6:26:46 PM,"Lilly, Incyclix to work on Verzenio combo treatment for breast cancer",Seeking Alpha,https://seekingalpha.com/news/4303653-lilly-incyclix-work-verzenio-combo-treatment-breast-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5955973267555237
3883,11/18/2024 6:46:20 PM,Novo Nordisk reportedly launches Wegovy in China,Seeking Alpha,https://seekingalpha.com/news/4303757-novo-nordisk-reportedly-launches-wegovy-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.904471218585968
3884,11/18/2024 7:55:17 PM,Lilly’s muvalaplin lowered lipoprotein(a) levels in adults in Phase 2 trial,TipRanks,/news/stocks/lilly-s-muvalaplin-lowered-lipoprotein-a-levels-in-adults-in-phase-2-trial-1034033013,neutral,0.4828703999519348
3885,11/18/2024 9:30:43 PM,Lilly heart drug muvalaplin significantly reduces lipoprotein(a) levels,Seeking Alpha,https://seekingalpha.com/news/4304285-lilly-heart-drug-muvalaplin-significantly-reduces-lipoprotein-levels?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9084609150886536
3886,11/19/2024 6:55:56 AM,Eli Lilly’s Promising Prospects and New Product Pipeline Drive Buy Rating,TipRanks,/news/stocks/eli-lilly-s-promising-prospects-and-new-product-pipeline-drive-buy-rating-1034034992,negative,0.91873699426651
3887,11/19/2024 5:50:15 PM,Eli Lilly Canada ‘disappointed’ by CDA-AMC’s Final Recommendation for Ebglyss,TipRanks,/news/stocks/eli-lilly-canada-disappointed-by-cda-amc-s-final-recommendation-for-ebglyss-1034038706,neutral,0.963230550289154
3888,11/19/2024 9:35:33 PM,Eli Lilly appoints Jon Moeller to board of directors,TipRanks,/news/stocks/eli-lilly-appoints-jon-moeller-to-board-of-directors-1034039124,positive,0.9217750430107117
3889,11/19/2024 10:20:38 PM,Eli Lilly & Co Appoints Procter & Gamble CEO to Board,TipRanks,/news/stocks/eli-lilly-co-appoints-procter-gamble-ceo-to-board-1034039234,positive,0.8550156354904175
3890,11/20/2024 10:15:31 AM,"Eli Lilly, Verge announce milestones in ALS collaboration",TipRanks,/news/stocks/eli-lilly-verge-announce-milestones-in-als-collaboration-1034041942,positive,0.5053374171257019
3891,11/20/2024 3:11:06 PM,Oppenheimer biotech analyst holds an analyst/industry conference call,TipRanks,/news/stocks/oppenheimer-biotech-analyst-holds-an-analyst-industry-conference-call-1034044058,positive,0.939740002155304
3892,11/20/2024 4:14:55 PM,More companies covering weight loss drugs for their employees,Seeking Alpha,https://seekingalpha.com/news/4312209-more-companies-covering-weight-loss-drugs-employees?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.810773491859436
3893,11/20/2024 5:45:21 PM,"Tectonic started at outperform by Raymond James, TX45 cited",Seeking Alpha,https://seekingalpha.com/news/4313083-tectonic-started-at-outperform-by-raymond-james-tx45-cited?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8459581136703491
3894,11/20/2024 7:28:07 PM,Eli Lilly in pact with Chinese biotech for novel weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4313537-eli-lilly-in-pact-novel-weight-loss-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7571631073951721
3895,11/20/2024 8:30:19 PM,Eli Lilly and China-based biotech Laekna team on obesity drug,TipRanks,/news/stocks/eli-lilly-and-china-based-biotech-laekna-team-on-obesity-drug-1034044779,positive,0.8624977469444275
3896,11/21/2024 11:06:58 AM,"Eli Lilly & Co: Buy Rating Amid Valuation, Growth Prospects, and IPI Concerns",TipRanks,/news/stocks/eli-lilly-co-buy-rating-amid-valuation-growth-prospects-and-ipi-concerns-1034048729,negative,0.7155217528343201
3897,11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7575292587280273
3898,11/21/2024 8:40:08 PM,Hims & Hers jumps as status report says patients unable to obtain branded GLP-1s,TipRanks,/news/stocks/hims-hers-jumps-as-status-report-says-patients-unable-to-obtain-branded-glp-1s-1034051586,neutral,0.9341992735862732
3899,11/21/2024 9:00:09 PM,"FDA tirzepatide status report ‘moderately positive’ for Hims & Hers, says Citi",TipRanks,/news/stocks/fda-tirzepatide-status-report-moderately-positive-for-hims-hers-says-citi-1034051677,negative,0.9327324628829956
3900,11/21/2024 9:09:46 PM,Hims & Hers closes up 10% as Lilly tirzepatide compounding dispute resolution delayed,Seeking Alpha,https://seekingalpha.com/news/4318664-hims-hers-health-closes-up-10-lilly-tirzepatide-compounding-dispute-resolution-delayed?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9121193885803223
3901,11/22/2024 12:25:48 PM,Protagonist Therapeutics price target raised to $67 from $51 at BTIG,TipRanks,/news/stocks/protagonist-therapeutics-price-target-raised-to-67-from-51-at-btig-1034055542,negative,0.9484549760818481
3902,11/22/2024 12:31:46 PM,Novo Nordisk said to have contracted Ypsomed to make next gen obesity drug’s pens,Seeking Alpha,https://seekingalpha.com/news/4320724-novo-nordisk-contracts-ypsomed-to-make-cagrisema-pens?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5252244472503662
3903,11/22/2024 4:35:10 PM,"Sanofi planning changes to 340B hospital drug discount plan, WSJ reports",TipRanks,/news/stocks/sanofi-planning-changes-to-340b-hospital-drug-discount-plan-wsj-reports-1034056551,positive,0.9313058257102966
3904,11/22/2024 4:50:49 PM,Sanofi becomes latest drugmaker to challenge HHS over 340B drug-discount program,Seeking Alpha,https://seekingalpha.com/news/4322264-sanofi-becomes-latest-drugmakert-challenge-hhs-340-b-drug-discount-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8740205764770508
3905,11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9368929862976074
3906,11/24/2024 12:05:06 PM,"Eli Lilly, others to buy after RFK-inspired drop, Barron’s says",TipRanks,/news/stocks/eli-lilly-others-to-buy-after-rfk-inspired-drop-barron-s-says-1034057659,neutral,0.6806352138519287
3907,11/25/2024 5:46:13 PM,Hims & Hers up 18% amid optimism for compounders with Makary FDA pick,Seeking Alpha,https://seekingalpha.com/news/4330979-hims-hers-up-18-optimism-compounders-makary-fda-pick?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9297050833702087
3908,11/26/2024 11:15:49 AM,"Biden admin proposes obesity drugs covered by Medicare, Medicaid, NYTimes says",TipRanks,/news/stocks/biden-admin-proposes-obesity-drugs-covered-by-medicare-medicaid-nytimes-says-1034065988,positive,0.8880847692489624
3909,11/26/2024 11:30:59 AM,"Biden administration proposes expanded obesity drug coverage under Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/4334040-biden-administration-proposes-expanded-obesity-drug-coverage-under-medicare-medicaid?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8528860807418823
3910,11/26/2024 12:18:47 PM,Amgen posts mid-stage data for weight loss therapy,Seeking Alpha,https://seekingalpha.com/news/4334405-amgen-stock-slips-on-data-weight-loss-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4569445550441742
3911,11/26/2024 1:55:40 PM,Anavex gains after seeking EU marketing nod for Alzheimer’s drug,Seeking Alpha,https://seekingalpha.com/news/4335176-anavex-gains-seeking-eu-marketing-nod-alzheimer-s-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9270050525665283
3912,11/26/2024 2:00:20 PM,White House proposes Medicare and Medicaid cover weight loss drugs,TipRanks,/news/stocks/white-house-proposes-medicare-and-medicaid-cover-weight-loss-drugs-1034067371,positive,0.8904197812080383
3913,11/26/2024 2:20:33 PM,"Amgen’s MariTide only differentiation seems to be dosing frequency, says Leerink",TipRanks,/news/stocks/amgen-s-maritide-only-differentiation-seems-to-be-dosing-frequency-says-leerink-1034067414,positive,0.9105874300003052
3914,11/26/2024 2:20:51 PM,"Amgen weight loss data ‘underwhelms,’ says Deutsche Bank",TipRanks,/news/stocks/amgen-weight-loss-data-underwhelms-says-deutsche-bank-1034067412,negative,0.9363100528717041
3915,11/26/2024 2:55:12 PM,Early notable gainers among liquid option names on November 26th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-26th-1034067491,negative,0.9009581804275513
3916,11/26/2024 3:10:15 PM,"Trump Trade: Carmakers slip after 25% tariff threat on Mexico, Canada",TipRanks,/news/stocks/trump-trade-carmakers-slip-after-25-tariff-threat-on-mexico-canada-1034067545,neutral,0.9696193933486938
3917,11/26/2024 3:13:10 PM,"Biggest stock movers Tuesday: PSTX, ARWR, KSS, ALEC, AMGN, EMBC, and more",Seeking Alpha,https://seekingalpha.com/news/4333610-biggest-stock-movers-tuesday-pstx-smtc-alec-lesl-wwd-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9275177717208862
3918,11/26/2024 3:40:24 PM,Weight loss drugmakers in spotlight as White House proposes coverage,TipRanks,/news/stocks/weight-loss-drugmakers-in-spotlight-as-white-house-proposes-coverage-1034067621,positive,0.6365492939949036
3919,11/26/2024 5:05:29 PM,"Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/trump-threatens-tariffs-zoom-reports-q3-beat-morning-buzz-1034067844,positive,0.8744351863861084
3920,11/26/2024 6:05:25 PM,RBC sees little cause for concern over CMS’ proposed part D GLP-1 coverage rule,TipRanks,/news/stocks/rbc-sees-little-cause-for-concern-over-cms-proposed-part-d-glp-1-coverage-rule-1034067980,positive,0.7087421417236328
3921,11/27/2024 10:25:48 AM,Eli Lilly’s Stock Poised for Growth Amid Potential CMS Coverage for Zepbound,TipRanks,/news/stocks/eli-lilly-s-stock-poised-for-growth-amid-potential-cms-coverage-for-zepbound-1034071154,negative,0.9463464617729187
3922,11/27/2024 11:20:19 AM,Eli Lilly downgraded to Hold from Buy at Erste Group,TipRanks,/news/stocks/eli-lilly-downgraded-to-hold-from-buy-at-erste-group-1034071477,positive,0.5807015299797058
3923,11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8861560225486755
3924,11/27/2024 5:16:04 PM,Short stock ideas from each sector with Earnings Quality in the bottom 20%,Seeking Alpha,https://seekingalpha.com/news/4340651-short-stock-ideas-from-each-sector-with-earnings-quality-in-the-bottom-20?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9181330800056458
3925,12/2/2024 12:47:11 PM,Eli Lilly’s Growth Driven by Strong Prescription Trends for Mounjaro and Zepbound,TipRanks,/news/stocks/eli-lilly-s-growth-driven-by-strong-prescription-trends-for-mounjaro-and-zepbound-1034087114,negative,0.9289973974227905
3926,12/2/2024 1:16:09 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034087325,positive,0.505634069442749
3927,12/3/2024 7:24:14 PM,BeiGene started at overweight at Morgan Stanley on Brukinsa market share growth,Seeking Alpha,https://seekingalpha.com/news/4360565-beigene-started-overweight-morgan-stanley-on-brukinsa-market-share-growth?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7217849493026733
3928,12/3/2024 7:40:10 PM,Truist biopharma analyst to hold an analyst/industry conference call,TipRanks,/news/stocks/truist-biopharma-analyst-to-hold-an-analyst-industry-conference-call-1034094073,positive,0.9468002915382385
3929,12/4/2024 11:50:40 AM,Lilly says Zepbound superior to Novo’s Wegovy weight loss in head-to-head trial,TipRanks,/news/stocks/lilly-says-zepbound-superior-to-novo-s-wegovy-weight-loss-in-head-to-head-trial-1034097098,negative,0.9460451602935791
3930,12/4/2024 12:00:13 PM,Eli Lilly announces topline results from SURMOUNT-5 trial,TipRanks,/news/stocks/eli-lilly-announces-topline-results-from-surmount-5-trial-1034097513,positive,0.7092171907424927
3931,12/4/2024 1:53:43 PM,Eli Lilly in deal with Rondo to develop bispecific antibodies for tumors,Seeking Alpha,https://seekingalpha.com/news/4362518-eli-lilly-deal-rondo-develop-bispecific-antibodies-tumors?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.569618284702301
3932,12/4/2024 1:57:04 PM,Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial,Seeking Alpha,https://seekingalpha.com/news/4362474-eli-lillys-zepbound-outperforms-novo-wegovy-for-weight-loss-in-head-to-head-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9393749237060547
3933,12/4/2024 2:04:21 PM,Lilly Says Zepbound Provided 47% Higher Relative Weight Loss Compared To Wegovy In SURMOUNT-5 Study ,RTTNews,/news/stocks/lilly-says-zepbound-provided-47-higher-relative-weight-loss-compared-to-wegovy-in-surmount-5-study-1034096430,negative,0.9500263333320618
3934,12/4/2024 2:05:51 PM,"Morning Movers: Salesforce jumps after Q3, Foot Locker sinks after guidance cut",TipRanks,/news/stocks/morning-movers-salesforce-jumps-after-q3-foot-locker-sinks-after-guidance-cut-1034098167,neutral,0.8903068900108337
3935,12/4/2024 3:06:14 PM,"Lilly, Rondo to collaborate on CD28 bispecific antibody development",Seeking Alpha,https://seekingalpha.com/news/4362608-lilly-rondo-to-collaborate-on-cd28-bispecific-antibody-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5640133619308472
3936,12/4/2024 5:15:25 PM,"Salesforce up after Q3, GM outlines $5B in China business charges: Morning Buzz",TipRanks,/news/stocks/salesforce-up-after-q3-gm-outlines-5b-in-china-business-charges-morning-buzz-1034098728,positive,0.49498313665390015
3937,12/4/2024 6:45:28 PM,"Viking’s VK2735 likely ‘even better’ than Lilly’s Zepbound, says BTIG",TipRanks,/news/stocks/viking-s-vk2735-likely-even-better-than-lilly-s-zepbound-says-btig-1034098997,negative,0.890566349029541
3938,12/5/2024 11:20:48 AM,"Eli Lilly CEO says he will fight for FDA , challenge Kennedy’s stance, NYT says",TipRanks,/news/stocks/eli-lilly-ceo-says-he-will-fight-for-fda-challenge-kennedy-s-stance-nyt-says-1034101935,positive,0.7392287254333496
3939,12/5/2024 2:40:47 PM,"U.K. to limit Eli Lilly’s Mounjaro to patients with greatest need, STAT reports",TipRanks,/news/stocks/u-k-to-limit-eli-lilly-s-mounjaro-to-patients-with-greatest-need-stat-reports-1034103374,positive,0.6965945959091187
3940,12/5/2024 3:00:18 PM,Trump Trade: Fiserv shares slip as CEO set to join new administration,TipRanks,/news/stocks/trump-trade-fiserv-shares-slip-as-ceo-set-to-join-new-administration-1034103525,neutral,0.9613490700721741
3941,12/5/2024 5:08:21 PM,"Dollar General reports mixed Q3, American Air raises Q4 outlook: Morning Buzz",TipRanks,/news/stocks/dollar-general-reports-mixed-q3-american-air-raises-q4-outlook-morning-buzz-1034104341,neutral,0.5476245284080505
3942,12/5/2024 5:49:19 PM,"Pfizer, Lilly CEOs have dinner at Mar-a-Lago with Trump, RFK Jr. - report",Seeking Alpha,https://seekingalpha.com/news/4367278-pfizer-lilly-ceos-dinner-mar-a-lago-trump-rfk-jr?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9428231716156006
3943,12/5/2024 8:35:17 PM,Eli Lilly announces $3B expansion to Wisconsin manufacturing facility,TipRanks,/news/stocks/eli-lilly-announces-3b-expansion-to-wisconsin-manufacturing-facility-1034105275,negative,0.8156383633613586
3944,12/5/2024 10:19:31 PM,Lilly planning $3B expansion of Wisconsin plant to boost production,Seeking Alpha,https://seekingalpha.com/news/4368316-lilly-planning-3b-expansion-of-wisconsin-plant-to-boost-production?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.927589476108551
3945,12/6/2024 2:47:01 AM,Lilly Announces $3 Bln Expansion Of Manufacturing Facility In Wisconsin ,RTTNews,/news/stocks/lilly-announces-3-bln-expansion-of-manufacturing-facility-in-wisconsin-1034105621,negative,0.8543768525123596
3946,12/6/2024 5:59:14 AM,"Eli Lilly’s Zepbound Outperforms Competitor in Weight Loss Trial, Supporting Buy Rating",TipRanks,/news/stocks/eli-lilly-s-zepbound-outperforms-competitor-in-weight-loss-trial-supporting-buy-rating-1034106749,negative,0.9530174136161804
3947,12/6/2024 9:21:18 PM,Lilly tops Morgan Stanley's biopharma pick list for 2025,Seeking Alpha,https://seekingalpha.com/news/4372587-lilly-tops-morgan-stanleys-biopharma-pick-list-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6062930822372437
3948,12/6/2024 10:44:19 PM,BioAge stock craters 70% on obesity drug study halt (update),Seeking Alpha,https://seekingalpha.com/news/4372757-bioage-stock-craters-on-obesity-drug-study-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7281392216682434
3949,12/8/2024 8:45:14 AM,Eli Lilly & Co’s Promising Growth Driven by Mounjaro and Zepbound Performance,TipRanks,/news/stocks/eli-lilly-co-s-promising-growth-driven-by-mounjaro-and-zepbound-performance-1034110840,negative,0.9117692708969116
3950,12/9/2024 9:20:38 PM,"Eli Lilly announces $15B share repurchase program, 15% dividend increase",TipRanks,/news/stocks/eli-lilly-announces-15b-share-repurchase-program-15-dividend-increase-1034116292,positive,0.51095050573349
3951,12/9/2024 10:50:07 PM,Eli Lilly to present Phase 3 results for Jaypirca at ASH meeting,TipRanks,/news/stocks/eli-lilly-to-present-phase-3-results-for-jaypirca-at-ash-meeting-1034116514,positive,0.9325240850448608
3952,12/9/2024 11:43:56 PM,Lilly reports positive Phase 3 data for Jaypirca in CLL/SLL,Seeking Alpha,https://seekingalpha.com/news/4380289-lilly-reports-positive-phase-3-data-for-jaypirca-in-cllsll?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9476233124732971
3953,12/10/2024 1:25:00 AM,Lilly Board Approves New $15 Bln Share Repurchase Program; Hikes Dividend ,RTTNews,/news/stocks/lilly-board-approves-new-15-bln-share-repurchase-program-hikes-dividend-1034116266,negative,0.5889288783073425
3954,12/10/2024 5:23:49 AM,Eli Lilly hikes dividend by 15.4% to $1.50 a share; approves $15B share repurchase program,Seeking Alpha,https://seekingalpha.com/news/4380695-eli-lilly-hikes-dividend-by-154-to-150-a-share-approves-15b-share-repurchase-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8840935230255127
3955,12/10/2024 11:55:27 AM,Eli Lilly reinstated with a Buy at BofA,TipRanks,/news/stocks/eli-lilly-reinstated-with-a-buy-at-bofa-1034119249,positive,0.7240385413169861
3956,12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,positive,0.8453127145767212
3957,12/10/2024 9:55:29 PM,Cantor Fitzgerald biotech analysts hold an analyst/industry conference call,TipRanks,/news/stocks/cantor-fitzgerald-biotech-analysts-hold-an-analyst-industry-conference-call-1034121668,positive,0.9425137639045715
3958,12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8290336728096008
3959,12/11/2024 1:20:18 PM,Eli Lilly announces results from the Phase 3 EMBER-3 study,TipRanks,/news/stocks/eli-lilly-announces-results-from-the-phase-3-ember-3-study-1034125730,positive,0.8477444052696228
3960,12/11/2024 1:31:17 PM,Eli Lilly announces results from EMBER-3 study of imlunestrant,TipRanks,/news/stocks/eli-lilly-announces-results-from-ember-3-study-of-imlunestrant-1034125835,positive,0.6768890023231506
3961,12/11/2024 2:15:11 PM,BofA views news of Lilly selling Zepbound through Ro as ‘mixed’ for Hims & Hers,TipRanks,/news/stocks/bofa-views-news-of-lilly-selling-zepbound-through-ro-as-mixed-for-hims-hers-1034126124,neutral,0.8728288412094116
3962,12/11/2024 2:15:31 PM,"Ro, Eli Lilly to streamline patient access to Zepbound single-dose vials",TipRanks,/news/stocks/ro-eli-lilly-to-streamline-patient-access-to-zepbound-single-dose-vials-1034126121,positive,0.6582628488540649
3963,12/11/2024 2:55:17 PM,Lilly Reports Positive Phase 3 EMBER-3 Study Data In Advanced Breast Cancer ,RTTNews,/news/stocks/lilly-reports-positive-phase-3-ember-3-study-data-in-advanced-breast-cancer-1034124249,negative,0.9486002922058105
3964,12/11/2024 3:14:21 PM,Lilly to sell Zepbound through telehealth platform Ro,Seeking Alpha,https://seekingalpha.com/news/4385605-lilly-to-sell-zepbound-through-telehealth-platform-ro?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8845642805099487
3965,12/11/2024 3:37:18 PM,Lilly reports positive Phase 3 breast cancer data for imlunestrant,Seeking Alpha,https://seekingalpha.com/news/4385611-lilly-reports-positive-phase-3-breast-cancer-data-for-imlunestrant?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9421737194061279
3966,12/11/2024 5:50:44 PM,"Ro, Lilly partnership creates volatility for Hims & Hers shares, says Leerink",TipRanks,/news/stocks/ro-lilly-partnership-creates-volatility-for-hims-hers-shares-says-leerink-1034126630,neutral,0.9121209979057312
3967,12/11/2024 7:45:11 PM,"Arvinas down on investors’ read of Lilly data, says BTIG",TipRanks,/news/stocks/arvinas-down-on-investors-read-of-lilly-data-says-btig-1034126879,neutral,0.8594420552253723
3968,12/12/2024 6:05:08 PM,TD Cowen Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/td-cowen-keeps-their-buy-rating-on-eli-lilly-co-lly-1034132070,positive,0.8985071182250977
3969,12/13/2024 12:51:26 PM,"Lilly's Mounjaro does not need separate indication for sleep apnea, EMA panel determines",Seeking Alpha,https://seekingalpha.com/news/4386252-lillys-mounjaro-does-not-need-separate-approval-for-sleep-apnea-ema-panel-determines?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9291504621505737
3970,12/13/2024 1:15:32 PM,Eli Lilly’s Omvoh recommended by CHMP for approval in EU,TipRanks,/news/stocks/eli-lilly-s-omvoh-recommended-by-chmp-for-approval-in-eu-1034136087,negative,0.563335657119751
3971,12/13/2024 1:16:10 PM,Buy Rating for Eli Lilly & Co: Strategic Developments and Promising Oncology Pipeline Drive Optimism,TipRanks,/news/stocks/buy-rating-for-eli-lilly-co-strategic-developments-and-promising-oncology-pipeline-drive-optimism-1034136077,negative,0.944744348526001
3972,12/13/2024 2:40:22 PM,Lilly Gets Positive CHMP Opinion For Omvoh In Crohn's Disease ,RTTNews,/news/stocks/lilly-gets-positive-chmp-opinion-for-omvoh-in-crohn-s-disease-1034134783,negative,0.9202357530593872
3973,12/13/2024 3:13:08 PM,Lilly gets positive EU regulatory opinion for Omvoh for Crohn's,Seeking Alpha,https://seekingalpha.com/news/4386294-lilly-gets-positive-eu-regulatory-opinion-for-omvoh-for-crohns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9445919990539551
3974,12/13/2024 4:05:35 PM,"Study confirms semaglutide link to increased, but ‘low,’ risk of NAION",TipRanks,/news/stocks/study-confirms-semaglutide-link-to-increased-but-low-risk-of-naion-1034136623,negative,0.9331089854240417
3975,12/16/2024 12:16:34 PM,Foghorn to discontinue independent development of FHD-286 with decitabine in AML,TipRanks,/news/stocks/foghorn-to-discontinue-independent-development-of-fhd-286-with-decitabine-in-aml-1034141324,positive,0.8336782455444336
3976,12/16/2024 6:05:00 PM,Moderna remains the most shorted among S&P 500 healthcare stocks in November,Seeking Alpha,https://seekingalpha.com/news/4386556-moderna-remains-the-most-shorted-among-sp-500-healthcare-stocks-in-november?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9052240252494812
3977,12/17/2024 11:10:44 AM,Eli Lilly announces regulatory approval for insulin manufactured in Egypt,TipRanks,/news/stocks/eli-lilly-announces-regulatory-approval-for-insulin-manufactured-in-egypt-1034145789,positive,0.6587994694709778
3978,12/17/2024 12:15:11 PM,Eli Lilly: Egyptian Drug Authority Approves Insulin Glargine Injection Manufactured By EVA Pharma ,RTTNews,/news/stocks/eli-lilly-egyptian-drug-authority-approves-insulin-glargine-injection-manufactured-by-eva-pharma-1034144962,negative,0.6626660227775574
3979,12/18/2024 1:05:07 AM,Eli Lilly’s Kisunla approved in China for Alzheimer’s Disease treatment,TipRanks,/news/stocks/eli-lilly-s-kisunla-approved-in-china-for-alzheimer-s-disease-treatment-1034148679,negative,0.8176589012145996
3980,12/18/2024 2:26:46 AM,China Approves Lilly's Kisunla For Early Symptomatic Alzheimer's Disease Treatment ,RTTNews,/news/stocks/china-approves-lilly-s-kisunla-for-early-symptomatic-alzheimer-s-disease-treatment-1034148446,negative,0.6118074655532837
3981,12/18/2024 12:00:22 PM,Eli Lilly Alzheimer's therapy approved in China,Seeking Alpha,https://seekingalpha.com/news/4387585-eli-lilly-alzheimers-therapy-approved-in-china?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5417214632034302
3982,12/18/2024 12:19:45 PM,Merck enters obesity drug race in pact with Chinese pharma Hansoh,Seeking Alpha,https://seekingalpha.com/news/4387598-merck-enters-obesity-drug-race-in-pact-with-hansoh?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8321036100387573
3983,12/18/2024 1:36:20 PM,Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug,TipRanks,/news/stocks/viking-therapeutics-lower-after-merck-signs-pact-with-hansoh-for-glp-1-drug-1034152180,neutral,0.9337723255157471
3984,12/18/2024 3:25:59 PM,Lilly rival gets FDA okay for Phase 2 study of obesity drug,Seeking Alpha,https://seekingalpha.com/news/4387649-lilly-rival-gets-fda-okay-for-phase-2-study-of-obesity-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8052337765693665
3985,12/18/2024 3:37:04 PM,Least shorted S&P 500 stocks in November,Seeking Alpha,https://seekingalpha.com/news/4387575-least-shorted-sp-500-stocks-in-november?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6016121506690979
3986,12/18/2024 3:49:06 PM,Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers,Seeking Alpha,https://seekingalpha.com/news/4387714-merck-hansoh-deal-hurts-obesity-drug-developers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6005010008811951
3987,12/18/2024 7:02:38 PM,"BioAge, Novartis team up to discover age-related disease targets",Seeking Alpha,https://seekingalpha.com/news/4387789-bioage-novartis-team-up-to-discover-age-related-disease-targets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6699015498161316
3988,12/19/2024 2:46:52 PM,Hims & Hers Health falls as FDA issues unfavorable compounded GLP-1 decision,Seeking Alpha,https://seekingalpha.com/news/4388119-hims-hers-health-falls-fda-issues-unfavorable-compounded-glp-1-decision?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9697248935699463
3989,12/19/2024 3:20:17 PM,Hims & Hers falls after FDA ends shortage of Lilly weight loss drug,TipRanks,/news/stocks/hims-hers-falls-after-fda-ends-shortage-of-lilly-weight-loss-drug-1034157985,neutral,0.9399290084838867
3990,12/19/2024 3:40:18 PM,"End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink",TipRanks,/news/stocks/end-to-tirzepatide-shortage-has-read-on-hims-glp-1-trajectory-says-leerink-1034158026,neutral,0.8011038899421692
3991,12/19/2024 8:43:24 PM,U.S. healthcare spending climbs 7.5% in 2023,Seeking Alpha,https://seekingalpha.com/news/4388656-us-healthcare-spending-accelerates-in-2023?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9225358366966248
3992,12/20/2024 11:31:34 AM,"Novo Nordisk crashes after data for next gen obesity drug, Eli Lilly spikes",Seeking Alpha,https://seekingalpha.com/news/4389022-novo-nordisk-stock-crashes-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9503294229507446
3993,12/20/2024 12:25:25 PM,"Weight loss seen with Novo’s CagriSema weaker than expected, says BofA",TipRanks,/news/stocks/weight-loss-seen-with-novo-s-cagrisema-weaker-than-expected-says-bofa-1034162421,neutral,0.6897014379501343
3994,12/20/2024 12:30:43 PM,"Novo obesity data positive for Eli Lilly and Amgen, says UBS",TipRanks,/news/stocks/novo-obesity-data-positive-for-eli-lilly-and-amgen-says-ubs-1034162520,negative,0.9249807596206665
3995,12/20/2024 12:45:26 PM,BofA says Hims’ semaglutide compounding opportunity may be shorter than expected,TipRanks,/news/stocks/bofa-says-hims-semaglutide-compounding-opportunity-may-be-shorter-than-expected-1034162572,positive,0.5776761770248413
3996,12/20/2024 1:50:33 PM,"Novo obesity data ‘nearly a best-case’ for Eli Lilly, says Citi",TipRanks,/news/stocks/novo-obesity-data-nearly-a-best-case-for-eli-lilly-says-citi-1034162913,negative,0.749415934085846
3997,12/20/2024 2:15:18 PM,"Morning Movers: Lilly rises, Novo Nordisk falls following CagriSema trial data",TipRanks,/news/stocks/morning-movers-lilly-rises-novo-nordisk-falls-following-cagrisema-trial-data-1034163121,neutral,0.786128044128418
3998,12/20/2024 2:55:14 PM,Early notable gainers among liquid option names on December 20th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-december-20th-1034163229,negative,0.9055624604225159
3999,12/20/2024 2:55:22 PM,Eli Lilly rises 6.3%,TipRanks,/news/stocks/eli-lilly-rises-6-3-1034163228,negative,0.7532682418823242
4000,12/20/2024 3:18:36 PM,Why is Novo Nordisk crashing after data for next-gen weight loss drug?,Seeking Alpha,https://seekingalpha.com/news/4389278-novo-nordisk-stock-down-lilly-up-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8379318118095398
4001,12/20/2024 4:30:27 PM,J.P. Morgan’s top Healthcare stocks for 2025,Seeking Alpha,https://seekingalpha.com/news/4389333-jp-morgans-top-healthcare-stocks-for-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9314796924591064
4002,12/20/2024 5:37:36 PM,Eli Lilly & Co: Strategic Expansion and Tactical DTC Advertising Bolster Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strategic-expansion-and-tactical-dtc-advertising-bolster-buy-rating-1034163710,negative,0.9472535252571106
4003,12/20/2024 6:20:47 PM,Bernstein Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/bernstein-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034163996,positive,0.7758182287216187
4004,12/20/2024 7:30:26 PM,"BMO lowers Novo Nordisk price target to $105, says reaction to data ‘overdone’",TipRanks,/news/stocks/bmo-lowers-novo-nordisk-price-target-to-105-says-reaction-to-data-overdone-1034164259,neutral,0.9345114231109619
4005,12/20/2024 8:36:52 PM,Pfizer gets FDA accelerated approval for Braftovi,Seeking Alpha,https://seekingalpha.com/news/4389412-pfizer-gets-fda-accelerated-approval-for-braftovi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8788320422172546
4006,12/20/2024 8:38:54 PM,"Biggest stock movers Friday: RGTI, CCL, NVO, DXCM and more",Seeking Alpha,https://seekingalpha.com/news/4388947-biggest-stock-movers-friday-fdx-x-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9151267409324646
4007,12/20/2024 9:35:24 PM,Eli Lilly announces FDA approval for Zepbound,TipRanks,/news/stocks/eli-lilly-announces-fda-approval-for-zepbound-1034164381,positive,0.7439264059066772
4008,12/20/2024 9:50:31 PM,Eli Lilly announces FDA approval for Zepbound for obstructive sleep apnea,TipRanks,/news/stocks/eli-lilly-announces-fda-approval-for-zepbound-for-obstructive-sleep-apnea-1034164425,negative,0.7907832860946655
4009,12/20/2024 10:00:25 PM,Eli Lilly's Zepbound gains sleep apnea indication,Seeking Alpha,https://seekingalpha.com/news/4389472-eli-lilly-zepbound-gains-sleep-apnea-indication?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5263479351997375
4010,12/21/2024 2:08:17 AM,FDA Approves Lilly's Zepbound To Treat Obstructive Sleep Apnea In Adults With Obesity ,RTTNews,/news/stocks/fda-approves-lilly-s-zepbound-to-treat-obstructive-sleep-apnea-in-adults-with-obesity-1034164435,negative,0.8236700296401978
4011,12/21/2024 3:03:30 PM,Novo Nordisk raises expectations for Eli Lilly after CagriSema slipup,Seeking Alpha,https://seekingalpha.com/news/4389541-novo-nordisk-raises-eli-lilly-post-cagrisema-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8777886033058167
4012,12/21/2024 3:58:23 PM,Trending stocks in bearish pre-holiday week for U.S. stock market,Seeking Alpha,https://seekingalpha.com/news/4389543-trending-stocks-in-bearish-pre-holiday-week-for-us-stock-market?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8949296474456787
4013,12/23/2024 2:32:49 PM,"Biggest stock movers Monday: HMC, XRX, RUM, and more",Seeking Alpha,https://seekingalpha.com/news/4389714-biggest-stock-movers-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9131941795349121
4014,12/23/2024 5:35:08 PM,FDA revokes EUAs for some antibody treatments for COVID-19,TipRanks,/news/stocks/fda-revokes-euas-for-some-antibody-treatments-for-covid-19-1034169449,neutral,0.8177931904792786
4015,12/23/2024 6:45:16 PM,Eli Lilly ‘commends’ ITC ruling cracking down on unlawful tirzepatide imports,TipRanks,/news/stocks/eli-lilly-commends-itc-ruling-cracking-down-on-unlawful-tirzepatide-imports-1034169599,neutral,0.7030711770057678
4016,12/23/2024 7:28:23 PM,Anavex stock rallies 30% on business updates,Seeking Alpha,https://seekingalpha.com/news/4390016-anavex-stock-rallies-30-on-business-updates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9171409010887146
4017,12/24/2024 4:35:44 PM,Eli Lilly's weight loss med tirzepatide gets endorsement from U.K.'s NICE,Seeking Alpha,https://seekingalpha.com/news/4390750-eli-lilly-weight-loss-med-tirzepatide-gets-endorsement-uk-nice?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.878330409526825
4018,12/26/2024 1:03:42 PM,Elon Musk says he prefers Lilly’s Mounjaro over Novo’s Ozempic,Seeking Alpha,https://seekingalpha.com/news/4390958-elon-musk-prefers-lilly-mounjaro-over-novo-ozempic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8898862600326538
4019,12/28/2024 2:05:56 PM,Eli Lilly to end 2024 among best in Big Pharma; Novo among worst,Seeking Alpha,https://seekingalpha.com/news/4391294-eli-lilly-among-best-big-pharma-2024-novo-among-worst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9020727276802063
4020,1/2/2025 3:20:56 PM,"Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Kymera Therapeutics (KYMR) and Sarepta Therapeutics (SRPT)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-kymera-therapeutics-kymr-and-sarepta-therapeutics-srpt-1034187927,positive,0.9144662022590637
4021,1/2/2025 4:27:35 PM,Weight loss drugs can cut grocery spending by up to 9%: study,Seeking Alpha,https://seekingalpha.com/news/4392036-weight-loss-drugs-can-cut-grocery-spending?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5267760753631592
4022,1/2/2025 8:57:35 PM,Lilly seeking to join lawsuit over compounded GLP-1 drugs,Seeking Alpha,https://seekingalpha.com/news/4392105-lilly-seeking-to-join-lawsuit-over-compounded-glp-1-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9414380788803101
4023,1/3/2025 4:21:15 PM,Viking Therapeutics among potential buyout candidates: Oppenheimer,Seeking Alpha,https://seekingalpha.com/news/4392377-viking-stock-among-buyout-targets-oppenheimer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9071784019470215
4024,1/3/2025 11:54:07 PM,Novo Nordisk seeks to block compounded Victoza,Seeking Alpha,https://seekingalpha.com/news/4392489-novo-nordisk-seeks-to-block-compounded-victoza?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7638496160507202
4025,1/6/2025 11:36:10 AM,Eli Lilly & Co.: Strategic Growth Driven by Mounjaro and Zepbound with Attractive Entry Point,TipRanks,/news/stocks/eli-lilly-co-strategic-growth-driven-by-mounjaro-and-zepbound-with-attractive-entry-point-1034194767,negative,0.8973453044891357
4026,1/6/2025 3:00:02 PM,"Healthcare sector's 2024 gainers and losers: Intuitive Surgical, Boston Scientific tops chart",Seeking Alpha,https://seekingalpha.com/news/4392667-healthcare-sectors-2024-gainers-and-losers-intuitive-surgical-boston-scientific-tops-chart?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7643327116966248
4027,1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9278177618980408
4028,1/7/2025 11:37:44 AM,Eli Lilly & Co (LLY) Receives a Buy from Morgan Stanley,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-morgan-stanley-1034200150,negative,0.6065289378166199
4029,1/7/2025 4:25:17 PM,Eli Lilly call volume above normal and directionally bullish,TipRanks,/news/stocks/eli-lilly-call-volume-above-normal-and-directionally-bullish-1034201969,negative,0.9105142951011658
4030,1/7/2025 4:53:02 PM,FDA issues draft guidance on developing weight loss drugs,Seeking Alpha,https://seekingalpha.com/news/4393123-fda-issues-draft-guidance-developing-weight-loss-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9205100536346436
4031,1/8/2025 6:30:03 AM,Truist Financial Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034203919,negative,0.5540192127227783
4032,1/8/2025 8:35:29 PM,CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea,TipRanks,/news/stocks/cms-confirms-to-cnbc-medicare-plans-can-now-cover-zepbound-for-sleep-apnea-1034207692,positive,0.7818804979324341
4033,1/8/2025 9:02:40 PM,Lilly's Zepbound to be covered by Medicare for sleep apnea,Seeking Alpha,https://seekingalpha.com/news/4393567-lillys-zepbound-to-be-covered-by-medicare-for-sleep-apnea?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8330132961273193
4034,1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6913239359855652
4035,1/9/2025 4:35:33 PM,Drugs not selected for Medicare negotiations saw prices nearly double - report,Seeking Alpha,https://seekingalpha.com/news/4393809-drugs-not-selected-medicare-price-negotiation-nearly-doubled-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5023412108421326
4036,1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9193293452262878
4037,1/10/2025 1:56:38 PM,"HIMS downgraded, agilon upgraded at Citi in 2025 Health Tech review",Seeking Alpha,https://seekingalpha.com/news/4394065-hims-stock-downgraded-agilon-stock-upgraded-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.630949854850769
4038,1/10/2025 2:25:26 PM,Argus reveals top stock picks for 2025,TipRanks,/news/stocks/argus-reveals-top-stock-picks-for-2025-1034215881,positive,0.9244880676269531
4039,1/10/2025 6:35:25 PM,"Lilly in advanced talks to buy cancer biotech Scorpion for up to $2.5B, FT says",TipRanks,/news/stocks/lilly-in-advanced-talks-to-buy-cancer-biotech-scorpion-for-up-to-2-5b-ft-says-1034216558,negative,0.5154830813407898
4040,1/10/2025 6:44:22 PM,"Eli Lilly in talks to acquire Scorpion Therapeutics, FT says; Relay Therapeutics seesaws",Seeking Alpha,https://seekingalpha.com/news/4394211-eli-lilly-in-talks-to-acquire-scorpion-therapeutics-ft-says-relay-therapeutics-surges?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9018837809562683
4041,1/10/2025 7:01:52 PM,Lilly signs licensing deal with Mediar for IPF drug,Seeking Alpha,https://seekingalpha.com/news/4394217-lilly-signs-licensing-deal-with-mediar-for-ipf-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7783915996551514
4042,1/11/2025 3:40:17 PM,Bernstein Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/bernstein-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034217251,positive,0.8502117395401001
4043,1/11/2025 7:25:15 PM,"Potential acquisition of Scorpion positive for Relay, says Barclays",TipRanks,/news/stocks/potential-acquisition-of-scorpion-positive-for-relay-says-barclays-1034217338,negative,0.5869601368904114
4044,1/11/2025 7:36:00 PM,"Key deals this week: FuboTV - Disney, Constellation Energy, Eli Lilly, Phillips 66, Intercontinental Exchange and more",Seeking Alpha,https://seekingalpha.com/news/4393975-key-deals-this-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9313321113586426
4045,1/11/2025 8:06:44 PM,Can 2025 J.P. Morgan Healthcare Conference spark biotech M&A?,Seeking Alpha,https://seekingalpha.com/news/4394318-can-2025-jp-morgan-healthcare-conference-spark-biotech-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8774529099464417
4046,1/13/2025 7:51:35 AM,"Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Sagimet Biosciences, Inc. Class A (SGMT)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-eli-lilly-co-lly-sagimet-biosciences-inc-class-a-sgmt-1034219557,positive,0.650074303150177
4047,1/13/2025 12:40:51 PM,Verve Therapeutics announces anticipated 2025 milestones,TipRanks,/news/stocks/verve-therapeutics-announces-anticipated-2025-milestones-1034221397,negative,0.5759974122047424
4048,1/13/2025 2:05:44 PM,Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B,TipRanks,/news/stocks/eli-lilly-to-acquire-scorpion-therapeutics-stx-478-program-for-up-to-2-5b-1034222120,positive,0.8534896969795227
4049,1/13/2025 2:45:15 PM,Eli Lilly to acquire Scorpion for up to $2.5B,Seeking Alpha,https://seekingalpha.com/news/4394548-eli-lilly-to-acquire-scorpion-for-up-to-2_5b?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8736960887908936
4050,1/13/2025 4:41:04 PM,Lilly oral obesity drug could get FDA okay in early 2026: report,Seeking Alpha,https://seekingalpha.com/news/4394612-lilly-oral-obesity-drug-could-get-fda-okay-in-early-2026-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8237103819847107
4051,1/13/2025 5:49:50 PM,Eli Lilly To Buy Scorpion Therapeutics' Experimental Cancer Therapy For Up To $2.5 Bln In Cash ,RTTNews,/news/stocks/eli-lilly-to-buy-scorpion-therapeutics-experimental-cancer-therapy-for-up-to-2-5-bln-in-cash-1034221909,positive,0.7580963373184204
4052,1/13/2025 6:20:20 PM,Eli Lilly CEO tells Bloomberg TV company sees weight loss pill approval in 2026,TipRanks,/news/stocks/eli-lilly-ceo-tells-bloomberg-tv-company-sees-weight-loss-pill-approval-in-2026-1034222788,positive,0.7389505505561829
4053,1/13/2025 6:49:49 PM,Lilly asked Feds to pause drug pricing negotiations: report,Seeking Alpha,https://seekingalpha.com/news/4394665-lilly-asked-feds-to-pause-drug-pricing-negotiations-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8260691165924072
4054,1/13/2025 10:54:17 PM,Obesity drug developer Metsera files for $100M IPO,Seeking Alpha,https://seekingalpha.com/news/4394524-obesity-drug-developer-metsera-files-for-100m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9014841318130493
4055,1/14/2025 2:05:21 PM,"Eli Lilly sees Q4 worldwide revenue ~$13.5B, consensus $13.95B",TipRanks,/news/stocks/eli-lilly-sees-q4-worldwide-revenue-~-13-5b-consensus-13-95b-1034226875,positive,0.5060122013092041
4056,1/14/2025 2:06:01 PM,"Eli Lilly sees FY25 revenue $58B-$61B, consensus $58.48B",TipRanks,/news/stocks/eli-lilly-sees-fy25-revenue-58b--61b-consensus-58-48b-1034226863,positive,0.894740879535675
4057,1/14/2025 2:06:15 PM,"Eli Lilly cuts FY24 revenue view to ~$45B from $45.4B-$46B, consensus $45.55B",TipRanks,/news/stocks/eli-lilly-cuts-fy24-revenue-view-to-~-45b-from-45-4b--46b-consensus-45-55b-1034226859,neutral,0.909692645072937
4058,1/14/2025 2:11:09 PM,Eli Lilly sees growth in 2025 from new medicines,TipRanks,/news/stocks/eli-lilly-sees-growth-in-2025-from-new-medicines-1034226833,negative,0.8990680575370789
4059,1/14/2025 2:26:34 PM,Eli Lilly issues Q4 2024 revenue guidance below consensus,Seeking Alpha,https://seekingalpha.com/news/4394918-eli-lilly-issues-q4-2024-revenue-guidance-below-consensus?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8914006948471069
4060,1/14/2025 2:36:59 PM,"Biggest stock movers Tuesday: LLY, HEES, KBH, CHGG, and more",Seeking Alpha,https://seekingalpha.com/news/4394789-biggest-stock-movers-tuesday-kbh-chgg-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9056359529495239
4061,1/14/2025 2:40:39 PM,"Drugmakers to push Trump to pause price negotiations, Bloomberg reports",TipRanks,/news/stocks/drugmakers-to-push-trump-to-pause-price-negotiations-bloomberg-reports-1034226968,neutral,0.7503699064254761
4062,1/14/2025 3:06:07 PM,Eli Lilly falls -6.5%,TipRanks,/news/stocks/eli-lilly-falls--6-5-1034227045,neutral,0.8770724534988403
4063,1/14/2025 3:29:45 PM,"Lilly Cuts Q4 Revenue View Below Market, Lifts FY24 Outlook; Sees Growth In FY25 ",RTTNews,/news/stocks/lilly-cuts-q4-revenue-view-below-market-lifts-fy24-outlook-sees-growth-in-fy25-1034225485,negative,0.9159832000732422
4064,1/14/2025 4:45:16 PM,Hims & Hers in focus as Eli Lilly obesity drug sales disappoint,Seeking Alpha,https://seekingalpha.com/news/4394979-hims-hers-stock-up-eli-lilly-glp-1-sales-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8273652195930481
4065,1/14/2025 4:50:26 PM,European markets ended mixed ahead of crucial economic data,Seeking Alpha,https://seekingalpha.com/news/4394774-european-markets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8586024641990662
4066,1/14/2025 5:00:54 PM,"Lilly cuts FY24 outlook, United Rentals to acquire H&E: Morning Buzz",TipRanks,/news/stocks/lilly-cuts-fy24-outlook-united-rentals-to-acquire-h-e-morning-buzz-1034227251,positive,0.7771710157394409
4067,1/14/2025 6:00:33 PM,Leerink remains bullish on Eli Lilly despite lower Q4 revenue guidance,TipRanks,/news/stocks/leerink-remains-bullish-on-eli-lilly-despite-lower-q4-revenue-guidance-1034227342,neutral,0.8466333150863647
4068,1/14/2025 7:10:33 PM,ETF earnings: Biggest weeks for major funds as holdings report,Seeking Alpha,https://seekingalpha.com/news/4394999-etf-earnings-biggest-weeks-for-major-funds-as-holdings-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5929394960403442
4069,1/14/2025 11:35:23 PM,Eli Lilly & Co: Strong Growth Prospects and Strategic Investments Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-growth-prospects-and-strategic-investments-justify-buy-rating-1034227794,negative,0.777991533279419
4070,1/14/2025 11:35:47 PM,Eli Lilly & Co: Strong Long-Term Growth Prospects Amid Q4 Revenue Shortfall Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-long-term-growth-prospects-amid-q4-revenue-shortfall-justify-buy-rating-1034227791,negative,0.947081983089447
4071,1/15/2025 9:35:14 AM,Eli Lilly & Co.: Positive Long-Term Outlook Despite Recent Setbacks – Buy Rating Affirmed,TipRanks,/news/stocks/eli-lilly-co-positive-long-term-outlook-despite-recent-setbacks-–-buy-rating-affirmed-1034230028,negative,0.947309672832489
4072,1/15/2025 10:45:57 AM,Eli Lilly & Co: Strong Growth Prospects and Strategic Positioning Justify Buy Rating,TipRanks,/news/stocks/eli-lilly-co-strong-growth-prospects-and-strategic-positioning-justify-buy-rating-1034230334,negative,0.824228823184967
4073,1/15/2025 12:01:55 PM,"European markets gain, UK inflation unexpectedly slows while yields dip",Seeking Alpha,https://seekingalpha.com/news/4395140-european-markets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9196608066558838
4074,1/15/2025 12:05:14 PM,"Eli Lilly Q4 miss brings buying opportunity, says JPMorgan",TipRanks,/news/stocks/eli-lilly-q4-miss-brings-buying-opportunity-says-jpmorgan-1034231153,negative,0.9209551811218262
4075,1/15/2025 1:16:27 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034231557,positive,0.505634069442749
4076,1/15/2025 3:00:00 PM,Moderna remains the most shorted stock among S&P 500 healthcare stocks in the last month of 2024,Seeking Alpha,https://seekingalpha.com/news/4395003-moderna-remains-the-most-shorted-stock-among-sp-500-healthcare-stocks-in-the-last-month-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.78468257188797
4077,1/15/2025 8:25:19 PM,Balanced Outlook with Long-Term Optimism: Steve Scala Maintains Buy Rating for Eli Lilly & Co,TipRanks,/news/stocks/balanced-outlook-with-long-term-optimism-steve-scala-maintains-buy-rating-for-eli-lilly-co-1034232627,negative,0.6441650390625
4078,1/15/2025 8:25:50 PM,TD Cowen Sticks to Its Buy Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/td-cowen-sticks-to-its-buy-rating-for-eli-lilly-co-lly-1034232622,positive,0.6004976034164429
4079,1/15/2025 9:16:24 PM,Eli Lilly’s Omvoh for Crohn’s disease approved by FDA,TipRanks,/news/stocks/eli-lilly-s-omvoh-for-crohn-s-disease-approved-by-fda-1034232692,negative,0.5681324601173401
4080,1/15/2025 9:31:33 PM,Lilly gets FDA approval for Omvoh for Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4395443-lilly-gets-fda-approval-for-omvoh-for-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6709202527999878
4081,1/16/2025 4:35:50 AM,FDA Approves Lilly's Omvoh For Crohn's Disease Treatment ,RTTNews,/news/stocks/fda-approves-lilly-s-omvoh-for-crohn-s-disease-treatment-1034232823,positive,0.6051004528999329
4082,1/16/2025 9:50:52 AM,"Eli Lilly price target lowered to $970 from $1,050 at Berenberg",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-970-from-1-050-at-berenberg-1034234957,neutral,0.7433925271034241
4083,1/16/2025 11:46:02 AM,"Insulin prices have dropped but some poor patients are paying more, NYT says",TipRanks,/news/stocks/insulin-prices-have-dropped-but-some-poor-patients-are-paying-more-nyt-says-1034235801,neutral,0.953491747379303
4084,1/16/2025 4:30:04 PM,Least shorted S&P 500 stocks in December,Seeking Alpha,https://seekingalpha.com/news/4395791-least-shorted-sp-500-stocks-in-december?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5818331837654114
4085,1/17/2025 12:21:15 PM,Eli Lilly price target lowered to $973 from $995 at Guggenheim,TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-973-from-995-at-guggenheim-1034240597,neutral,0.7659290432929993
4086,1/17/2025 12:42:16 PM,Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4396073-novo-nordisk-stock-slips-data-higher-wegovy-dose?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8949782848358154
4087,1/17/2025 2:20:46 PM,Novo Nordisk price target lowered to $110 from $140 at Argus,TipRanks,/news/stocks/novo-nordisk-price-target-lowered-to-110-from-140-at-argus-1034241161,neutral,0.8159228563308716
4088,1/17/2025 4:23:17 PM,Hims & Hers Health down 3% after BoA says Q4 revenue could be a miss,Seeking Alpha,https://seekingalpha.com/news/4396179-hims-hers-health-down-3-after-boa-says-q4-revenue-could-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.97135329246521
4089,1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.826055109500885
4090,1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,positive,0.4902459383010864
4091,1/18/2025 4:31:23 PM,Trending stocks as Wall Street bounces back with strong week,Seeking Alpha,https://seekingalpha.com/news/4396381-trending-stocks-as-wall-street-bounces-back-with-strong-week?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8051233887672424
4092,1/18/2025 8:56:17 PM,Chinese biotech dominance in R&D is on the rise,Seeking Alpha,https://seekingalpha.com/news/4396390-chinese-biotech-dominance-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7791072726249695
4093,1/21/2025 12:47:53 PM,Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch,Seeking Alpha,https://seekingalpha.com/news/4396624-sanofi-trial-cialis-otc-no-longer-under-fda-hold?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7521585822105408
4094,1/21/2025 2:15:58 PM,Eli Lilly & Co (LLY) Receives a Buy from Bank of America Securities,TipRanks,/news/stocks/eli-lilly-co-lly-receives-a-buy-from-bank-of-america-securities-1034250898,negative,0.5799316763877869
4095,1/21/2025 4:06:24 PM,GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study,Seeking Alpha,https://seekingalpha.com/news/4396883-glp-1-weight-loss-drugs-linked-new-risks-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8988829255104065
4096,1/21/2025 9:10:23 PM,Kyverna appoints Naji Gehchan as Chief Medical and Development Officer,TipRanks,/news/stocks/kyverna-appoints-naji-gehchan-as-chief-medical-and-development-officer-1034251781,positive,0.9170289635658264
4097,1/22/2025 4:44:48 PM,Top SA Quant-rated medical devices stocks as technicals look strong,Seeking Alpha,https://seekingalpha.com/news/4397413-top-sa-quant-rated-medical-devices-stocks-as-technicals-look-strong?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.921491801738739
4098,1/23/2025 9:56:43 AM,Evercore ISI Sticks to Their Hold Rating for Eli Lilly & Co (LLY),TipRanks,/news/stocks/evercore-isi-sticks-to-their-hold-rating-for-eli-lilly-co-lly-1034259293,positive,0.7573175430297852
4099,1/23/2025 10:36:05 AM,Eli Lilly & Co’s Promising Growth: Accelerated Revenue and Drug Pipeline Advances,TipRanks,/news/stocks/eli-lilly-co-s-promising-growth-accelerated-revenue-and-drug-pipeline-advances-1034259549,negative,0.9382439255714417
4100,1/23/2025 10:55:09 AM,"Datadog, Booz Allen added to US 1 list at BofA, Lilly removed",TipRanks,/news/stocks/datadog-booz-allen-added-to-us-1-list-at-bofa-lilly-removed-1034259620,positive,0.854050874710083
4101,1/23/2025 1:16:08 PM,Eli Lilly & Co: Buy Rating Backed by Promising Orfoglipron Trials and Strong Pharmaceutical Pipeline,TipRanks,/news/stocks/eli-lilly-co-buy-rating-backed-by-promising-orfoglipron-trials-and-strong-pharmaceutical-pipeline-1034261002,negative,0.9217420220375061
4102,1/23/2025 2:25:41 PM,Argus Research Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/argus-research-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034261371,positive,0.8353907465934753
4103,1/23/2025 11:07:44 PM,Allurion stock soars 70% on weight-loss therapy update,Seeking Alpha,https://seekingalpha.com/news/4398176-allurion-stock-soars-on-weight-loss-therapy-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9079923629760742
4104,1/24/2025 11:42:31 AM,Novo Nordisk spikes as novel obesity drug causes up to 22% of weight loss,Seeking Alpha,https://seekingalpha.com/news/4398289-novo-nordisk-stock-spikes-new-weight-loss-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8171150088310242
4105,1/24/2025 3:24:51 PM,"Biggest stock movers Friday: DAN, NVO, TXN, and more",Seeking Alpha,https://seekingalpha.com/news/4398236-biggest-stock-movers-friday-twlo-txn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9113549590110779
4106,1/25/2025 8:36:19 PM,Pfizer succeeds in late-stage trial for colorectal cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4398681-pfizer-posts-trial-win-colorectal-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8531913161277771
4107,1/27/2025 12:01:47 PM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1034272479,negative,0.5521676540374756
4108,1/27/2025 12:01:51 PM,Eli Lilly & Co (LLY) Gets a Buy from Citi,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-citi-1034272478,negative,0.6344325542449951
4109,1/27/2025 12:16:18 PM,Morgan Stanley Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034272593,positive,0.825495719909668
4110,1/27/2025 5:58:21 PM,Novo Nordisk settles Minnesota insulin pricing case: report,Seeking Alpha,https://seekingalpha.com/news/4398943-novo-nordisk-settles-minnesota-insulin-pricing-case-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9001592993736267
4111,1/27/2025 10:39:46 PM,Obesity drug developer Metsera sets terms for $275M IPO,Seeking Alpha,https://seekingalpha.com/news/4398987-obesity-drug-developer-metsera-sets-terms-for-275m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9284818768501282
4112,1/28/2025 9:50:26 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Eli Lilly & Co (LLY),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-nanosonics-limited-othernncsf-and-eli-lilly-co-lly-1034276496,neutral,0.9382395148277283
4113,1/28/2025 11:25:45 AM,"Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-970-from-1-000-at-wells-fargo-1034277033,neutral,0.6818366646766663
4114,1/28/2025 11:36:26 AM,"Eli Lilly price target lowered to $1,190 from $1,250 at Citi",TipRanks,/news/stocks/eli-lilly-price-target-lowered-to-1-190-from-1-250-at-citi-1034277158,neutral,0.8558527231216431
4115,1/28/2025 12:10:43 PM,BeyondSpring to sell portion of equity interest in SEED for $35.4MEli Lilly,TipRanks,/news/stocks/beyondspring-to-sell-portion-of-equity-interest-in-seed-for-35-4meli-lilly-1034277709,positive,0.9295004606246948
4116,1/28/2025 12:55:16 PM,Eli Lilly & Co. Receives Buy Rating from David Risinger Due to Promising Tirzepatide Trial Results and Competitive Tolerability,TipRanks,/news/stocks/eli-lilly-co-receives-buy-rating-from-david-risinger-due-to-promising-tirzepatide-trial-results-and-competitive-tolerability-1034277953,negative,0.9540191292762756
4117,1/28/2025 7:50:14 PM,Leerink says Eli Lilly news causes concern about Tectonic’s TX45 success,TipRanks,/news/stocks/leerink-says-eli-lilly-news-causes-concern-about-tectonic-s-tx45-success-1034279450,neutral,0.9410226345062256
4118,1/28/2025 8:15:30 PM,Novo Nordisk's Ozempic gets FDA approval for kidney disease,Seeking Alpha,https://seekingalpha.com/news/4399631-novo-nordisk-ozempic-gets-fda-approval-for-kidney-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8510880470275879
4119,1/28/2025 8:31:08 PM,Eli Lilly trial update on kidney drug hurts Tectonic,Seeking Alpha,https://seekingalpha.com/news/4399630-tectonic-stock-plunges-eli-lilly-trial-update?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8803558349609375
4120,1/28/2025 9:20:22 PM,OnKure Therapeutics initiated with a Buy at JonesResearch,TipRanks,/news/stocks/onkure-therapeutics-initiated-with-a-buy-at-jonesresearch-1034279558,positive,0.8342844843864441
4121,1/29/2025 3:48:40 PM,Vaccine stocks in focus as RFK Jr. faces confirmation hearing,Seeking Alpha,https://seekingalpha.com/news/4400073-vaccine-stocks-in-focus-as-rfk-jr-faces-confirmation-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.79876708984375
4122,1/29/2025 6:55:13 PM,"RFK Jr. comments contradict anti-vaccine legacy, says Truist",TipRanks,/news/stocks/rfk-jr-comments-contradict-anti-vaccine-legacy-says-truist-1034284331,positive,0.638435423374176
4123,1/29/2025 8:54:46 PM,HHS Secretary nominee RFK Jr. faces contentious Senate hearing,Seeking Alpha,https://seekingalpha.com/news/4400271-hhs-secretary-nominee-rfk-jr_-faces-contentious-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8407506346702576
4124,1/30/2025 10:20:18 AM,Wells downgrades Vertex to Equal Weight on lack of catalysts,TipRanks,/news/stocks/wells-downgrades-vertex-to-equal-weight-on-lack-of-catalysts-1034287994,neutral,0.8586761355400085
4125,1/30/2025 5:05:46 PM,Foghorn Therapeutics a new buy at B Riley on tumor fighting technology,Seeking Alpha,https://seekingalpha.com/news/4400869-foghorn-therapeutics-new-buy-b-riley-tumor-fighting-technology?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6609562635421753
4126,1/30/2025 5:46:44 PM,RFK Jr. hails GLP-1 weight loss meds as 'miracle drugs',Seeking Alpha,https://seekingalpha.com/news/4400916-rfk-jr-hails-glp-1-weight-loss-meds-miracle-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8047659993171692
4127,1/31/2025 6:08:16 PM,Metsera sees stock rally 54% following $275M IPO,Seeking Alpha,https://seekingalpha.com/news/4401417-metsera-sees-stock-rally-54-following-275m-ipo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9370744228363037
4128,1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9292561411857605
4129,2/1/2025 12:53:24 PM,Are healthcare stocks on the rebound?,Seeking Alpha,https://seekingalpha.com/news/4401695-are-healthcare-stocks-rebound?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7119130492210388
4130,2/1/2025 11:30:00 PM,Over 75% of companies beat EPS estimates this week - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4401476-over-75-of-companies-beat-eps-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.873219907283783
4131,2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9316384792327881
4132,2/3/2025 12:15:43 PM,Truist Financial Remains a Buy on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-eli-lilly-co-lly-1034303088,positive,0.9244024157524109
4133,2/3/2025 2:25:45 PM,"Eli Lilly price target raised to $1,038 from $1,029 at Truist",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-038-from-1-029-at-truist-1034303923,negative,0.9435745477676392
4134,2/3/2025 5:30:39 PM,SA Asks: What's the most attractive weight-loss stock right now?,Seeking Alpha,https://seekingalpha.com/news/4401656-sa-asks-whats-the-most-attractive-weight-loss-stock-right-now?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9177672266960144
4135,2/3/2025 5:44:37 PM,"Sens. Wyden, Warren press RFK Jr. on conflicts of interest ahead of vote",Seeking Alpha,https://seekingalpha.com/news/4402094-senators-wyden-warren-press-rfk-jr-conflicts-of-interest-ahead-vote?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7472131252288818
4136,2/4/2025 3:52:32 PM,RFK Jr. HHS nomination advances out of Senate Finance Committee,Seeking Alpha,https://seekingalpha.com/news/4402747-rfk-jr-hhs-nomination-advances-out-senate-finance-committee?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8293061852455139
4137,2/5/2025 9:17:26 AM,Eli Lilly (LLY) Stock Eyes Price Breakout as Q4 Results Loom,TipRanks,/news/stocks/eli-lilly-lly-stock-eyes-price-breakout-as-q4-results-loom-1034314164,neutral,0.8732064366340637
4138,2/5/2025 11:19:20 AM,NVO Earnings: Novo Nordisk Jumps on Healthy Sales Beat Driven by Wegovy,TipRanks,/news/stocks/nvo-earnings-novo-nordisk-jumps-on-healthy-sales-beat-driven-by-wegovy-1034314594,negative,0.9485867619514465
4139,2/5/2025 12:18:51 PM,Novo Nordisk beats in Q4 as Wegovy sales more than double,Seeking Alpha,https://seekingalpha.com/news/4403367-novo-nordisk-stock-higher-q4-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9459999203681946
4140,2/5/2025 12:36:27 PM,Are thinner people harming the environment? Novo emissions rise on Wegovy demand,Seeking Alpha,https://seekingalpha.com/news/4403390-are-thinner-people-harming-the-environment-novo-emissions-rise-on-wegovy-demand?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5251489877700806
4141,2/5/2025 1:35:28 PM,Eli Lilly & Co (LLY) Gets a Buy from Jefferies,TipRanks,/news/stocks/eli-lilly-co-lly-gets-a-buy-from-jefferies-1034315685,positive,0.505634069442749
4142,2/5/2025 6:23:46 PM,Eli Lilly Q4 2024 Earnings Preview: All eyes on stronger 2025,Seeking Alpha,https://seekingalpha.com/news/4403802-eli-lilly-q4-2024-earnings-preview-all-eyes-on-stronger-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8857295513153076
4143,2/5/2025 6:40:19 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034317367,positive,0.9220908284187317
4144,2/5/2025 7:37:48 PM,Novo doubles down on next-gen weight loss therapy despite early setback,Seeking Alpha,https://seekingalpha.com/news/4403823-novo-nordisk-stock-new-plans-cagrisema?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8904004693031311
4145,2/5/2025 8:40:24 PM,Eli Lilly upgraded to Buy from Hold at Erste Group,TipRanks,/news/stocks/eli-lilly-upgraded-to-buy-from-hold-at-erste-group-1034317565,positive,0.7939285039901733
4146,2/6/2025 11:46:37 AM,"Eli Lilly Non-GAAP EPS of $5.32 beats by $0.24, revenue of $13.53B beats by $100M",Seeking Alpha,https://seekingalpha.com/news/4404290-eli-lilly-non-gaap-eps-of-5_51-beats-by-0_43-revenue-of-13_53b-beats-by-100m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5681511759757996
4147,2/6/2025 12:05:36 PM,"Options Volatility and Implied Earnings Moves Today, February 06, 2025",TipRanks,/news/stocks/options-volatility-and-implied-earnings-moves-today-february-06-2025-1034322024,positive,0.9175546169281006
4148,2/6/2025 12:11:16 PM,"Eli Lilly reports Q4 EPS $5.32, consensus $5.08",TipRanks,/news/stocks/eli-lilly-reports-q4-eps-5-32-consensus-5-08-1034321961,neutral,0.4108746647834778
4149,2/6/2025 12:18:20 PM,"Eli Lilly sees FY25 EPS $22.50-$24.00, consensus $22.69",TipRanks,/news/stocks/eli-lilly-sees-fy25-eps-22-50--24-00-consensus-22-69-1034322169,positive,0.48897016048431396
4150,2/6/2025 12:24:20 PM,"Eli Lilly in charts: Mounjaro, Zepbound, and Jardiance drive sales growth in Q4",Seeking Alpha,https://seekingalpha.com/news/4404336-eli-lilly-in-charts-mounjaro-zepbound-and-jardiance-drive-sales-growth-in-q4?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9014810919761658
4151,2/6/2025 12:36:04 PM,LLY Earnings: Weight Loss Drug Demand Drives Eli Lilly Sales as Investors Eye Next-Gen Treatments,TipRanks,/news/stocks/lly-earnings-weight-loss-drug-demand-drives-eli-lilly-sales-as-investors-eye-next-gen-treatments-1034322370,neutral,0.9416545629501343
4152,2/6/2025 12:39:18 PM,Truist Financial Reaffirms Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-eli-lilly-co-lly-1034322329,positive,0.7503917217254639
4153,2/6/2025 12:48:40 PM,"Eli Lilly And Co. Q4 Profit Increases, Beats Estimates ",RTTNews,/news/stocks/eli-lilly-and-co-q4-profit-increases-beats-estimates-1034321794,negative,0.9386289119720459
4154,2/6/2025 1:00:13 PM,Eli Lilly records over twofold rise in diabetes/ obesity drugs in Q4,Seeking Alpha,https://seekingalpha.com/news/4404294-eli-lilly-stock-rises-q4-2024-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9168859720230103
4155,2/6/2025 1:08:03 PM,Eli Lilly Guides FY25 In Line With Estimates - Update ,RTTNews,/news/stocks/eli-lilly-guides-fy25-in-line-with-estimates-update-1034321922,positive,0.7733147740364075
4156,2/6/2025 1:57:03 PM,Morning Movers: Roblox sinks following fourth quarter results and guidance,TipRanks,/news/stocks/morning-movers-roblox-sinks-following-fourth-quarter-results-and-guidance-1034322920,positive,0.9285986423492432
4157,2/6/2025 2:03:42 PM,"4 stocks to watch on Thursday: HON, AMZN and more",Seeking Alpha,https://seekingalpha.com/news/4404375-4-stocks-to-watch-on-thursday-hon-amzn-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9185230135917664
4158,2/6/2025 5:06:03 PM,"Qualcomm, Eli Lilly report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/qualcomm-eli-lilly-report-quarterly-earnings-beats-morning-buzz-1034324189,positive,0.8575502634048462
4159,2/6/2025 5:36:07 PM,Eli Lilly (NYSE:LLY) Speeds Up Weight Loss Drug Data Release,TipRanks,/news/stocks/eli-lilly-nyse-lly-speeds-up-weight-loss-drug-data-release-1034324309,negative,0.4898521900177002
4160,2/6/2025 6:35:50 PM,"White House readying order to fire thousands of federal health workers, WSJ says",TipRanks,/news/stocks/white-house-readying-order-to-fire-thousands-of-federal-health-workers-wsj-says-1034324421,neutral,0.9388383626937866
4161,2/6/2025 6:40:55 PM,S&P 500 Gains Today Alongside Earnings Reports,TipRanks,/news/stocks/s-p-500-gains-today-alongside-earnings-reports-1034324418,negative,0.8871886134147644
4162,2/7/2025 11:38:52 AM,Citi Keeps Their Buy Rating on Eli Lilly & Co (LLY),TipRanks,/news/stocks/citi-keeps-their-buy-rating-on-eli-lilly-co-lly-1034326728,positive,0.9026976823806763
4163,2/7/2025 11:55:51 AM,Eli Lilly announces results from VIVID-2 study,TipRanks,/news/stocks/eli-lilly-announces-results-from-vivid-2-study-1034326794,positive,0.8652532696723938
4164,2/7/2025 1:30:44 PM,Viking Therapeutics price target lowered to $70 from $120 at Maxim,TipRanks,/news/stocks/viking-therapeutics-price-target-lowered-to-70-from-120-at-maxim-1034327597,neutral,0.47655218839645386
4165,2/7/2025 1:32:58 PM,"Eli Lilly price target raised to $1,000 from $997 at BofA",TipRanks,/news/stocks/eli-lilly-price-target-raised-to-1-000-from-997-at-bofa-1034327580,negative,0.939868688583374
4166,2/7/2025 2:58:59 PM,Lilly reports positive results for Omvoh in Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4405158-lilly-reports-positive-results-for-omvoh-in-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9403334856033325
4167,2/7/2025 3:21:13 PM,Trump Trade: President advocates to close carried interest tax loophole,TipRanks,/news/stocks/trump-trade-president-advocates-to-close-carried-interest-tax-loophole-1034328479,positive,0.6031154990196228
4168,2/7/2025 5:20:21 PM,Hims & Hers jumps ahead of controversial Super Bowl ad airing,TipRanks,/news/stocks/hims-hers-jumps-ahead-of-controversial-super-bowl-ad-airing-1034328929,positive,0.7626093029975891
4169,2/8/2025 9:04:00 PM,18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8692342042922974
